<SEC-DOCUMENT>0001628280-21-017022.txt : 20210813
<SEC-HEADER>0001628280-21-017022.hdr.sgml : 20210813
<ACCEPTANCE-DATETIME>20210813170819
ACCESSION NUMBER:		0001628280-21-017022
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		53
CONFORMED PERIOD OF REPORT:	20210630
FILED AS OF DATE:		20210813
DATE AS OF CHANGE:		20210813

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CUMBERLAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001087294
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33637
		FILM NUMBER:		211173267

	BUSINESS ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE,
		STATE:			TN
		ZIP:			37203
		BUSINESS PHONE:		615-255-0068

	MAIL ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE
		STATE:			TN
		ZIP:			37203
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>cpix-20210630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:976bbab0-2784-42fd-860c-1897d99c723d,g:5df55cfc-81cf-4a6f-b91d-2b22fdc37eaa,d:d0faa06a8909446fa2394f59c1490a03--><html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:cpix="http://www.cumberlandpharma.com/20210630" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>cpix-20210630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180L2ZyYWc6M2FmZWJiOGVkZDVlNDNiY2I5NmJjZDFlNGJlZmMxNWQvdGFibGU6MmYzOWM4ZmJiNGU0NGEyMTkxN2IyMTA1MTllY2Q2ZWMvdGFibGVyYW5nZToyZjM5YzhmYmI0ZTQ0YTIxOTE3YjIxMDUxOWVjZDZlY181LTEtMS0xLTA_9690d087-941b-4e11-bfea-bdf2c2cb1e08">2021</ix:nonNumeric><ix:nonNumeric contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180L2ZyYWc6M2FmZWJiOGVkZDVlNDNiY2I5NmJjZDFlNGJlZmMxNWQvdGFibGU6MmYzOWM4ZmJiNGU0NGEyMTkxN2IyMTA1MTllY2Q2ZWMvdGFibGVyYW5nZToyZjM5YzhmYmI0ZTQ0YTIxOTE3YjIxMDUxOWVjZDZlY182LTEtMS0xLTA_3fbfee24-977e-4338-ab9c-e5fb07a88f8a">Q2</ix:nonNumeric><ix:nonNumeric contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180L2ZyYWc6M2FmZWJiOGVkZDVlNDNiY2I5NmJjZDFlNGJlZmMxNWQvdGFibGU6MmYzOWM4ZmJiNGU0NGEyMTkxN2IyMTA1MTllY2Q2ZWMvdGFibGVyYW5nZToyZjM5YzhmYmI0ZTQ0YTIxOTE3YjIxMDUxOWVjZDZlY183LTEtMS0xLTA_872613f0-2a3d-4e7e-8bef-db14770f3422">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180L2ZyYWc6M2FmZWJiOGVkZDVlNDNiY2I5NmJjZDFlNGJlZmMxNWQvdGV4dHJlZ2lvbjozYWZlYmI4ZWRkNWU0M2JjYjk2YmNkMWU0YmVmYzE1ZF83OA_127e60e9-9aaf-4b96-b550-192db0c28852">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180L2ZyYWc6M2FmZWJiOGVkZDVlNDNiY2I5NmJjZDFlNGJlZmMxNWQvdGV4dHJlZ2lvbjozYWZlYmI4ZWRkNWU0M2JjYjk2YmNkMWU0YmVmYzE1ZF83OQ_ad8098cc-3a36-4468-8378-74add67f5dae">0001087294</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="cpix-20210630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i85957d50b58d4241a665bd7848aa809d_I20210809"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-08-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="iba716d2d6c004c9c85738b68d83bc0b7_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie36ac2d370b44b7b850f453251764d25_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0932967c9c90454494cbf245d9fa585d_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffc2a4291a32445fb79072f7fe43a870_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53d85ca5dcbd44ba870830f97461a800_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i166678b245754127b39f5e9c73e8cf2d_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie98ab83b91d54ad0aa13294fe0c3bdb6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4860200ab8134ae18446101822694027_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d6d3147bec94616bcf72690b2be296a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83e7ecfbf2a84991a8389944813821f5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i114a57733d5043469e08faf40e0cd3f8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i466ef04c404e4ac6a59e26ee7fd0c3cf_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab72c368dd2d4ce9a791ab677393c6a5_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if884adb91afc4270896a5966ea47d7aa_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba53f6b880994dffa4c65f2e2602560a_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifcedca0bf3ff4536974d961a488fc053_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e77b9f22c1042519f6f27f64401d843_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb9ba2c0e442481695058478aea8e7d6_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic49b798ae420415688228a42789077ba_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a150324b9d0427e89459a576fa87284_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4067952523e04c2eb44fce178eac9c45_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58fc83ab5ccd43ce857e2367d7e167ac_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i757638cd1ac54400a7212a39551700fa_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2543a120857490e9cdf7ff91a0a636a_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1721669d68794a37916477190e8866d2_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i851f7a722da048d59591d314f36aabc7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9f59f7e0e644c3e9406612323559f4b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a6e35b8c49547efba40d6119ccf44be_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id451c947a6d945de824fde928e9539b8_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8613f3fef30a4cf99a52244890006824_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b5aa580bb2d4a5f8f2914acb615a1e1_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46f84339676244a68c635efc3276aab8_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2444510ac2f491e93494d3efc1d3f10_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bfadd4b687f465caceadefb291b8a5a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i236298ea92174d4481784e6bae4c0605_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i759d312796b74964bece38516542bb38_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9737d5fe1a1a4b64a348bd61bcd44e8b_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i625473b616364e838b15588a276d254c_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4378e699a13493b8e84114b0815eeb1_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2772008cf324e93b9ddec0ec4490b6e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b884d549e1f475999a61e98b2694ba2_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9809a8bcb7eb490aa76cb00858c80e7c_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>cpix:Segment</xbrli:measure></xbrli:unit><xbrli:context id="ia5edd42c5f134552b215b0303905dc64_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf76e1a947e34b99bf20371f1394bc94_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b7593836c514ab7ae6235e51053a4d3_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i165e5c5a2d664922aea782b5ec2beaa1_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifad013eb9e344ea389599dff33e69ac5_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb72b6c62fb3497caec435b11f56df5b_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie99d1326bbe74354aa379ee065b7c800_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if75eedbbeb5a4ee7b41a92f8a8b0fb07_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9e93a7211e0479a81c8bd344131c4e7_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76b0812334e5493ba0a8152f3015bf4a_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabe2fb0732864cfb86e1ccecbb610f34_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i857d42211e8846b8ae37d954dc44d6a5_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8bb9cad97f943fca7a044ed530e9867_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2de112b4b874426a53bf6ed84e287a5_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54cb558d5ce44437ad69a746dc9c0d82_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2dc8e2802e642b5b94cadd517394321_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e418762fd0d400aa38934d9baef2d1f_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief1b47cbad4647fdb4c761fccef2aa59_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9fecc8c7c5546288fd7851d2d94e26c_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic88623cc09cd42dfa613a0b3710040a3_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibaa9e52c4cd5496c898ae44c5f71a2f6_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if58606b340b94db39d3ecaa02a4573ed_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16a80924d1204bd0b90b95ff2356a104_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic02c2f75924e441689c5ffc79ba729b8_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifca6a00e3fc6401ab98a098751461284_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:RediTrexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2c40ebe0b7f44769ff470354a3fe426_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:RediTrexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb0eee768e294f599281385f4a3835f6_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:RediTrexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6095f924cf50491b815b0dfba23349fd_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:RediTrexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb0ee00056ff487ca51af9d696aa113b_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c43803cc80549529c2ba24144989e73_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic93c6aab3bcf4cda8e32399f9d56970e_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice06f3366d2249119a9109b31bb8f7d2_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6172287cab0745339de538f8ae5b507b_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15931d26dd6041dfa28287b72ffd540a_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6742997b2ea4497a8b57f546e21e37aa_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifaa5fd674df1464290cfa2809fea1eaf_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i339d4531f62d4de7929176842fce1307_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">cpix:IfetrobanClinicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8de84d46a4b4f1288caecd9e279f91c_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">cpix:IfetrobanClinicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i5d1ec29c3e7d45128f2daec3011f8ff5_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfffd86898e74da5b26d2c9090d7aef5_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">srt:OfficeBuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="iea5110fd579441d385d9a44cd82a7b57_I20100513"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2010-05-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e44f0e8ba3a437db0695f10422fa49b_I20160131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2016-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i569ae37ae6bd451aba5271c09e866dd6_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51df30cfe8df40d49c632283258bef9d_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84950ce31a9648138dca94d14b435ecc_D20171101-20171130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-01</xbrli:startDate><xbrli:endDate>2017-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6837db1dd6864c6f9523c35e88733824_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7809f262685d483280e68e02e89f4262_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6eaa74b46ec44f199aa9dfd669c1664f_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f5feacbf7384a1087c1db7cf1ec114c_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cpix:IncentiveStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifadcff6052794ad7afbe6463edf069fc_I20201007"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cpix:FourthAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7949c2029147408c82a03b03371c2934_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id63b8386c6dd4a9096c2f08b1caa166d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec72b3e70c5e4d5b9f0a256af0a2e6eb_D20200814-20200814"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-14</xbrli:startDate><xbrli:endDate>2020-08-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42c0403c56e842038637f32dfa213083_D20200814-20200814"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-14</xbrli:startDate><xbrli:endDate>2020-08-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4487ea5e24834d4bb26ece0c7fc05f81_D20200814-20200814"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-14</xbrli:startDate><xbrli:endDate>2020-08-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1ff553c5d964f12b7361c40d75ba752_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22d029b9f8fc4612bd2da5c75672b40a_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ea7837abdfa48999669b93f02fe29d4_D20200420-20200420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-20</xbrli:startDate><xbrli:endDate>2020-04-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3738112144924be8b7ed4df49c530139_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:WinHealthInvestmentSingaporeLtdDomain</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5161e91b97f647a1a447fe4ae410abff_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:WinHealthInvestmentSingaporeLtdDomain</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93503f9d933448f182c19f672ad05ba9_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfbdaba777624b8b96b3800f1e5753bf_D20181101-20181130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-01</xbrli:startDate><xbrli:endDate>2018-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i666e3ad219a249f69a70f9d7525a1f8b_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieca5d4731d90438e81ee926eb9a44d99_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i543d802ba6254fea92215d118fe3fb4e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f48945eef8d4b2d820f10f38c6f7a00_D20161101-20161130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-11-01</xbrli:startDate><xbrli:endDate>2016-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib90d441c6774404295b76ceae446e40d_D20161101-20161130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-11-01</xbrli:startDate><xbrli:endDate>2016-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i537c330f50e745f197afdd484a2730ec_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b8a1a744ec04c1d913f27f1efc5efa2_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e8de0e06633438faeea349c72c801a5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i452c4da6ebcf4c4ebc44e66aaa120e9b_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f2247edd8fd4841affbe5d013f55977_D20191001-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="id0faa06a8909446fa2394f59c1490a03_1"></div><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xL2ZyYWc6ZjI4NWRkNTBmZGMxNDMyNmJmNDRjNDgyNWZhOTBhNGIvdGV4dHJlZ2lvbjpmMjg1ZGQ1MGZkYzE0MzI2YmY0NGM0ODI1ZmE5MGE0Yl8yMDMy_ba758f3c-4572-46c3-b15e-ebd69ddabe6e">10-Q</ix:nonNumeric> </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" format="ixt:booleantrue" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xL2ZyYWc6ZjI4NWRkNTBmZGMxNDMyNmJmNDRjNDgyNWZhOTBhNGIvdGFibGU6Yzc0MWQ5YjA3MjBmNDc5YmIyM2M2M2YxNGVhNWMyODMvdGFibGVyYW5nZTpjNzQxZDliMDcyMGY0NzliYjIzYzYzZjE0ZWE1YzI4M18wLTAtMS0xLTA_01b2f31a-db6e-473d-a006-afc0f5b25af7">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xL2ZyYWc6ZjI4NWRkNTBmZGMxNDMyNmJmNDRjNDgyNWZhOTBhNGIvdGV4dHJlZ2lvbjpmMjg1ZGQ1MGZkYzE0MzI2YmY0NGM0ODI1ZmE5MGE0Yl8yNzQ4Nzc5MDcxNzA5_100568a1-3de8-46ac-90dd-6cd65c7edfb1">June 30, 2021</ix:nonNumeric> </span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" format="ixt:booleanfalse" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xL2ZyYWc6ZjI4NWRkNTBmZGMxNDMyNmJmNDRjNDgyNWZhOTBhNGIvdGFibGU6YWJiNjNmODcxYWI0NGYxN2E0OTljYzNhZjMxNDMxNmEvdGFibGVyYW5nZTphYmI2M2Y4NzFhYjQ0ZjE3YTQ5OWNjM2FmMzE0MzE2YV8wLTAtMS0xLTA_7d56cb17-5d2e-4642-8a0d-808a2c989e69">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;.</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number: <ix:nonNumeric contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xL2ZyYWc6ZjI4NWRkNTBmZGMxNDMyNmJmNDRjNDgyNWZhOTBhNGIvdGV4dHJlZ2lvbjpmMjg1ZGQ1MGZkYzE0MzI2YmY0NGM0ODI1ZmE5MGE0Yl8yMDI5_12a6b018-42d4-4c7b-a93d-dfcda3380c56">001-33637</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xL2ZyYWc6ZjI4NWRkNTBmZGMxNDMyNmJmNDRjNDgyNWZhOTBhNGIvdGV4dHJlZ2lvbjpmMjg1ZGQ1MGZkYzE0MzI2YmY0NGM0ODI1ZmE5MGE0Yl8yMDMw_ab5ea1c5-a891-47cd-aba1-76a0d77e8441">Cumberland Pharmaceuticals Inc.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified In Its Charter)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:48.532%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xL2ZyYWc6ZjI4NWRkNTBmZGMxNDMyNmJmNDRjNDgyNWZhOTBhNGIvdGFibGU6YzE5ZWQ4MWU2ZDQxNDljYjgwZmZmNDYyODJhYWZkZDUvdGFibGVyYW5nZTpjMTllZDgxZTZkNDE0OWNiODBmZmY0NjI4MmFhZmRkNV8wLTAtMS0xLTA_5fee8bb7-3375-4fd3-a440-c35ecb1f5c26">Tennessee</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xL2ZyYWc6ZjI4NWRkNTBmZGMxNDMyNmJmNDRjNDgyNWZhOTBhNGIvdGFibGU6YzE5ZWQ4MWU2ZDQxNDljYjgwZmZmNDYyODJhYWZkZDUvdGFibGVyYW5nZTpjMTllZDgxZTZkNDE0OWNiODBmZmY0NjI4MmFhZmRkNV8wLTItMS0xLTA_163e9beb-b80c-4c2e-9620-b63c6ef47429">62-1765329</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or Other Jurisdiction of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporation or Organization)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Identification No.)</span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xL2ZyYWc6ZjI4NWRkNTBmZGMxNDMyNmJmNDRjNDgyNWZhOTBhNGIvdGFibGU6YzE5ZWQ4MWU2ZDQxNDljYjgwZmZmNDYyODJhYWZkZDUvdGFibGVyYW5nZTpjMTllZDgxZTZkNDE0OWNiODBmZmY0NjI4MmFhZmRkNV8zLTAtMS0xLTAvdGV4dHJlZ2lvbjpjOTFkYzI3ZGU1Zjg0NTIwOTVkZjQzNTMxY2NmNTAyYV81_65758720-a630-4ea5-83b9-1e7e89eb3e1f">2525 West End Avenue</ix:nonNumeric>, <ix:nonNumeric contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xL2ZyYWc6ZjI4NWRkNTBmZGMxNDMyNmJmNDRjNDgyNWZhOTBhNGIvdGFibGU6YzE5ZWQ4MWU2ZDQxNDljYjgwZmZmNDYyODJhYWZkZDUvdGFibGVyYW5nZTpjMTllZDgxZTZkNDE0OWNiODBmZmY0NjI4MmFhZmRkNV8zLTAtMS0xLTAvdGV4dHJlZ2lvbjpjOTFkYzI3ZGU1Zjg0NTIwOTVkZjQzNTMxY2NmNTAyYV85_345b656a-d49e-4b0a-9044-52651df55d9e">Suite 950</ix:nonNumeric>,</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xL2ZyYWc6ZjI4NWRkNTBmZGMxNDMyNmJmNDRjNDgyNWZhOTBhNGIvdGFibGU6YzE5ZWQ4MWU2ZDQxNDljYjgwZmZmNDYyODJhYWZkZDUvdGFibGVyYW5nZTpjMTllZDgxZTZkNDE0OWNiODBmZmY0NjI4MmFhZmRkNV8zLTAtMS0xLTAvdGV4dHJlZ2lvbjpjOTFkYzI3ZGU1Zjg0NTIwOTVkZjQzNTMxY2NmNTAyYV8xMw_f7dfc5b3-9566-4466-8972-56894ce0bec0">Nashville</ix:nonNumeric>, <ix:nonNumeric contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xL2ZyYWc6ZjI4NWRkNTBmZGMxNDMyNmJmNDRjNDgyNWZhOTBhNGIvdGFibGU6YzE5ZWQ4MWU2ZDQxNDljYjgwZmZmNDYyODJhYWZkZDUvdGFibGVyYW5nZTpjMTllZDgxZTZkNDE0OWNiODBmZmY0NjI4MmFhZmRkNV8zLTAtMS0xLTAvdGV4dHJlZ2lvbjpjOTFkYzI3ZGU1Zjg0NTIwOTVkZjQzNTMxY2NmNTAyYV8xNw_682a491b-2dc3-41b6-9079-1b7e2f8c3d92">Tennessee</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xL2ZyYWc6ZjI4NWRkNTBmZGMxNDMyNmJmNDRjNDgyNWZhOTBhNGIvdGFibGU6YzE5ZWQ4MWU2ZDQxNDljYjgwZmZmNDYyODJhYWZkZDUvdGFibGVyYW5nZTpjMTllZDgxZTZkNDE0OWNiODBmZmY0NjI4MmFhZmRkNV8zLTItMS0xLTA_4799f669-1e4a-4b4e-b610-d03bf98fcd1e">37203</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of Principal Executive Offices)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></div></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xL2ZyYWc6ZjI4NWRkNTBmZGMxNDMyNmJmNDRjNDgyNWZhOTBhNGIvdGV4dHJlZ2lvbjpmMjg1ZGQ1MGZkYzE0MzI2YmY0NGM0ODI1ZmE5MGE0Yl8yMDMx_3aed4f37-f13c-411c-a7d8-dc704e4171f6">615</ix:nonNumeric>) <ix:nonNumeric contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xL2ZyYWc6ZjI4NWRkNTBmZGMxNDMyNmJmNDRjNDgyNWZhOTBhNGIvdGV4dHJlZ2lvbjpmMjg1ZGQ1MGZkYzE0MzI2YmY0NGM0ODI1ZmE5MGE0Yl8yMDM0_f67a3d00-3cbe-4252-9c88-36d1089becf4">255-0068</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s Telephone Number, Including Area Code)</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.269%"><tr><td style="width:1.0%"></td><td style="width:31.774%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.585%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities registered pursuant to Section 12(b) of the Act:</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xL2ZyYWc6ZjI4NWRkNTBmZGMxNDMyNmJmNDRjNDgyNWZhOTBhNGIvdGFibGU6MDg2YmZlODJmMDZkNDVlYzg5YWU0NTQzYjE4M2NkYWEvdGFibGVyYW5nZTowODZiZmU4MmYwNmQ0NWVjODlhZTQ1NDNiMTgzY2RhYV8yLTAtMS0xLTE5NTg_7a9a191e-6fe3-42bc-9557-6fe939d42390">Common stock, no par value</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xL2ZyYWc6ZjI4NWRkNTBmZGMxNDMyNmJmNDRjNDgyNWZhOTBhNGIvdGFibGU6MDg2YmZlODJmMDZkNDVlYzg5YWU0NTQzYjE4M2NkYWEvdGFibGVyYW5nZTowODZiZmU4MmYwNmQ0NWVjODlhZTQ1NDNiMTgzY2RhYV8yLTItMS0xLTE5NTg_19eb3b67-722c-43ce-953b-bec798a6248c">CPIX</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xL2ZyYWc6ZjI4NWRkNTBmZGMxNDMyNmJmNDRjNDgyNWZhOTBhNGIvdGFibGU6MDg2YmZlODJmMDZkNDVlYzg5YWU0NTQzYjE4M2NkYWEvdGFibGVyYW5nZTowODZiZmU4MmYwNmQ0NWVjODlhZTQ1NDNiMTgzY2RhYV8yLTQtMS0xLTE5NTg_3773c0c9-9f73-4320-b350-d5147d3918b8">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xL2ZyYWc6ZjI4NWRkNTBmZGMxNDMyNmJmNDRjNDgyNWZhOTBhNGIvdGV4dHJlZ2lvbjpmMjg1ZGQ1MGZkYzE0MzI2YmY0NGM0ODI1ZmE5MGE0Yl8yMDM1_0af5933d-63dd-4e8a-aecf-ae3678a38c99">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files.)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xL2ZyYWc6ZjI4NWRkNTBmZGMxNDMyNmJmNDRjNDgyNWZhOTBhNGIvdGV4dHJlZ2lvbjpmMjg1ZGQ1MGZkYzE0MzI2YmY0NGM0ODI1ZmE5MGE0Yl8yMDM2_edd9457f-f8ff-47d5-8e74-49c024fa7caf">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.431%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.923%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.434%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Large&#160;accelerated&#160;filer</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xL2ZyYWc6ZjI4NWRkNTBmZGMxNDMyNmJmNDRjNDgyNWZhOTBhNGIvdGFibGU6ZWVhNDQxOGE2Yzc0NDI2ZmJlYjQ5OThhYjQ0MDQ2NjMvdGFibGVyYW5nZTplZWE0NDE4YTZjNzQ0MjZmYmViNDk5OGFiNDQwNDY2M18xLTAtMS0xLTA_87f13264-a45c-4672-905c-f43f70e446e7">Non-accelerated filer</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" format="ixt:booleantrue" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xL2ZyYWc6ZjI4NWRkNTBmZGMxNDMyNmJmNDRjNDgyNWZhOTBhNGIvdGFibGU6ZWVhNDQxOGE2Yzc0NDI2ZmJlYjQ5OThhYjQ0MDQ2NjMvdGFibGVyYW5nZTplZWE0NDE4YTZjNzQ0MjZmYmViNDk5OGFiNDQwNDY2M18xLTUtMS0xLTA_a31549c1-fb5e-4fa0-b7af-112099a9f36e">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Emerging growth company</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xL2ZyYWc6ZjI4NWRkNTBmZGMxNDMyNmJmNDRjNDgyNWZhOTBhNGIvdGFibGU6ZWVhNDQxOGE2Yzc0NDI2ZmJlYjQ5OThhYjQ0MDQ2NjMvdGFibGVyYW5nZTplZWE0NDE4YTZjNzQ0MjZmYmViNDk5OGFiNDQwNDY2M18yLTItMS0xLTA_1b206b25-3db5-4d1d-8887-bfccfc06a50f">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to&#160;Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" format="ixt:booleanfalse" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xL2ZyYWc6ZjI4NWRkNTBmZGMxNDMyNmJmNDRjNDgyNWZhOTBhNGIvdGV4dHJlZ2lvbjpmMjg1ZGQ1MGZkYzE0MzI2YmY0NGM0ODI1ZmE5MGE0Yl8yMDM3_160b35b9-b1f3-4c0c-9cf1-7e29c464289f">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate the number of shares outstanding of each of the issuer&#8217;s classes of common stock, as of the latest practicable date: <ix:nonFraction unitRef="shares" contextRef="i85957d50b58d4241a665bd7848aa809d_I20210809" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xL2ZyYWc6ZjI4NWRkNTBmZGMxNDMyNmJmNDRjNDgyNWZhOTBhNGIvdGV4dHJlZ2lvbjpmMjg1ZGQ1MGZkYzE0MzI2YmY0NGM0ODI1ZmE5MGE0Yl8xOTMx_3ff28572-e5c8-451f-9958-9f56ff9c8784">14,879,599</ix:nonFraction> shares of common stock as of August&#160;9, 2021.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="margin-top:9pt"><span><br/></span></div><div id="id0faa06a8909446fa2394f59c1490a03_7"></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:82.331%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.469%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id0faa06a8909446fa2394f59c1490a03_10">PART I &#8211; FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id0faa06a8909446fa2394f59c1490a03_10">1</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;padding-right:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id0faa06a8909446fa2394f59c1490a03_13">Item&#160;1. Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id0faa06a8909446fa2394f59c1490a03_13">1</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id0faa06a8909446fa2394f59c1490a03_16">Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id0faa06a8909446fa2394f59c1490a03_16">1</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id0faa06a8909446fa2394f59c1490a03_19">Condensed Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id0faa06a8909446fa2394f59c1490a03_19">2</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id0faa06a8909446fa2394f59c1490a03_22">Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id0faa06a8909446fa2394f59c1490a03_22">3</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id0faa06a8909446fa2394f59c1490a03_25">Condensed Consolidated Statements of Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id0faa06a8909446fa2394f59c1490a03_25">4</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id0faa06a8909446fa2394f59c1490a03_28">Notes to the Unaudited Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id0faa06a8909446fa2394f59c1490a03_28">5</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id0faa06a8909446fa2394f59c1490a03_58">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id0faa06a8909446fa2394f59c1490a03_58">15</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id0faa06a8909446fa2394f59c1490a03_76">Item&#160;3. Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id0faa06a8909446fa2394f59c1490a03_76">28</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id0faa06a8909446fa2394f59c1490a03_79">Item&#160;4. Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id0faa06a8909446fa2394f59c1490a03_79">28</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id0faa06a8909446fa2394f59c1490a03_82">PART II &#8211; OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id0faa06a8909446fa2394f59c1490a03_82">29</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id0faa06a8909446fa2394f59c1490a03_85">Item&#160;1. Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id0faa06a8909446fa2394f59c1490a03_85">29</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id0faa06a8909446fa2394f59c1490a03_88">Item&#160;1A. Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id0faa06a8909446fa2394f59c1490a03_88">29</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id0faa06a8909446fa2394f59c1490a03_91">Item&#160;2. Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id0faa06a8909446fa2394f59c1490a03_91">29</a></span></div></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id0faa06a8909446fa2394f59c1490a03_94">Item&#160;6. Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id0faa06a8909446fa2394f59c1490a03_94">30</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id0faa06a8909446fa2394f59c1490a03_97">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id0faa06a8909446fa2394f59c1490a03_97">31</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="id0faa06a8909446fa2394f59c1490a03_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I &#8211; FINANCIAL INFORMATION</span></div><div id="id0faa06a8909446fa2394f59c1490a03_13"></div><div style="-sec-extract:summary;margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1. Financial Statements (Unaudited)</span></div><div id="id0faa06a8909446fa2394f59c1490a03_16"></div><div style="-sec-extract:summary;margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:58.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.518%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMy0xLTEtMS0w_8d2f314e-a4aa-45e5-adda-da0c4cae2777">25,670,462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMy0zLTEtMS0w_c8612fbd-00f3-4846-8890-139f721c2ec7">24,753,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfNS0xLTEtMS0w_5e60e14f-4c02-427f-ad17-0b9fbd14dcd5">9,147,493</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfNS0zLTEtMS0w_afcb5590-3f89-45e5-9e71-6aba8800dd5a">12,377,713</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfNi0xLTEtMS0w_46622e68-e6a2-4f5b-80b8-4b60db3e88b8">10,104,219</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfNi0zLTEtMS0w_43a04b71-55fa-4efc-8df7-921018bb7631">10,638,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfNy0xLTEtMS0w_c2b994a8-f681-4cd1-8880-a8e9dc658d03">1,758,332</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfNy0zLTEtMS0w_8363468a-5e76-4ef3-99ee-0e6353d96351">2,199,926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfOC0xLTEtMS0w_0bf186fb-ed07-43a5-92b0-e05c225f4569">46,680,506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfOC0zLTEtMS0w_683e235a-4de9-435b-b711-7adb67654606">49,969,592</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfOS0xLTEtMS0w_bbaf57d8-e010-4045-b3eb-b148d7e3cd62">9,880,766</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfOS0zLTEtMS0w_2489393c-0446-4f13-9ec0-d14bf0fca410">11,656,742</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMTAtMS0xLTEtMA_ae62976f-9667-4a20-b962-3f8e484327f9">493,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMTAtMy0xLTEtMA_8d7fe9b0-7158-428d-ac59-b285f02ad94a">574,169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMTEtMS0xLTEtMA_cc8e0661-7664-40b6-a5a8-9111a0023948">25,888,622</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMTEtMy0xLTEtMA_f9660c5b-ebe4-43d4-917e-2b959543f346">28,118,316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMTItMS0xLTEtMA_667dff7a-79f1-4a16-8354-23b7828ba06d">882,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMTItMy0xLTEtMA_9dc389b6-5966-471a-855a-4923b1fae01a">882,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMTMtMS0xLTEtMA_2e05e7f0-60a9-432f-b689-714e14aa54d6">1,535,556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMTMtMy0xLTEtMA_53309c83-57d8-4782-995c-5783f3665269">2,028,148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMTQtMS0xLTEtMA_2d3f8d8d-e206-4e0c-8d32-2f326123287f">3,490,768</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMTQtMy0xLTEtMA_eb1d6912-a35b-4b52-868b-c3c5bf19d145">3,234,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMTUtMS0xLTEtMA_4c1163de-4522-4992-9d97-d0f46c4424fb">88,851,474</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMTUtMy0xLTEtMA_261bf230-c8bd-4e2d-839a-a0e26e6fd5e8">96,463,305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND EQUITY</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMTgtMS0xLTEtMA_6f916c4b-28f8-4767-923c-14dc047bd503">8,962,916</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMTgtMy0xLTEtMA_cac2316e-4d09-4993-adea-8835e3bd500c">13,396,286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMTktMS0xLTEtMA_76cf164b-f512-47ff-9598-0ce24a62b161">1,067,880</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMTktMy0xLTEtMA_9cf1e8d6-554c-40d5-8761-2fc00629e997">1,016,779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMjAtMS0xLTEtMA_3bbd1746-681f-4ee9-8507-50b3b2dd6b2f">8,615,995</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMjAtMy0xLTEtMA_1aca0fcc-b8f1-4107-9c7e-5343ceba81f4">11,254,381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMjEtMS0xLTEtMA_769e13d2-4180-457d-975c-dae98ebb5b64">18,646,791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMjEtMy0xLTEtMA_c2664694-ee79-4c56-b755-30fc0bed1943">25,667,446</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolving line of credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermLineOfCredit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMjItMS0xLTEtMA_104889ae-44ad-4962-b63b-9ae24450108d">14,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermLineOfCredit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMjItMy0xLTEtMA_1e22ec19-a5e4-4d6f-ad7f-8d26e266f7ac">15,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMjMtMS0xLTEtMA_27314676-eaef-4b08-b629-1bd57f9cb72d">512,324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMjMtMy0xLTEtMA_2365ee51-2da6-4722-864a-e0100f76ed91">1,059,693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630" decimals="0" format="ixt:numdotdecimal" name="cpix:OtherLongTermObligationsExcludingCurrentPortion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMjQtMS0xLTEtMA_b7bcc86c-7659-40e4-a1fe-5c641aa1571f">7,883,952</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231" decimals="0" format="ixt:numdotdecimal" name="cpix:OtherLongTermObligationsExcludingCurrentPortion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMjQtMy0xLTEtMA_fc3a1203-88a2-427f-ab6d-9eaee68bbc66">7,862,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMjUtMS0xLTEtMA_d8bad717-c04f-41d6-84ca-dc8fd49c642b">41,043,067</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMjUtMy0xLTEtMA_7c10d1de-63ba-4f3d-acfe-7a2824714570">49,589,911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMjYtMS0xLTEtMA_0943f11b-8206-433f-b37e-9577c92e2868"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMjYtMy0xLTEtMA_55aaae7b-a5a9-4d07-b9bf-56652eead23a"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock&#8212;<ix:nonFraction unitRef="usdPerShare" contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:CommonStockNoParValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmFhYThiODQ3Y2Q2MTQ2MzA4MDRlZWJkZWFkZjM4YWNlXzE3_9e77537b-c588-40ff-a2a6-400cec234149"><ix:nonFraction unitRef="usdPerShare" contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:CommonStockNoParValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmFhYThiODQ3Y2Q2MTQ2MzA4MDRlZWJkZWFkZjM4YWNlXzE3_ba8fef5e-002f-48c7-b490-b93943b548c2">no</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmFhYThiODQ3Y2Q2MTQ2MzA4MDRlZWJkZWFkZjM4YWNlXzMx_1f1229f8-81f3-4cb0-8b7a-9c8eba94b67e"><ix:nonFraction unitRef="shares" contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmFhYThiODQ3Y2Q2MTQ2MzA4MDRlZWJkZWFkZjM4YWNlXzMx_c19e2d18-900c-4d57-88d8-28d1d8976efd">100,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmFhYThiODQ3Y2Q2MTQ2MzA4MDRlZWJkZWFkZjM4YWNlXzUz_088ac56d-aca6-4940-970c-a94af63c3c48"><ix:nonFraction unitRef="shares" contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmFhYThiODQ3Y2Q2MTQ2MzA4MDRlZWJkZWFkZjM4YWNlXzUz_5c8f8f95-d951-4ec4-8adf-8b7158ff57f0">14,926,059</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmFhYThiODQ3Y2Q2MTQ2MzA4MDRlZWJkZWFkZjM4YWNlXzYw_8aff7bee-6fe0-4718-81c9-8aaed874e0d7"><ix:nonFraction unitRef="shares" contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmFhYThiODQ3Y2Q2MTQ2MzA4MDRlZWJkZWFkZjM4YWNlXzYw_aadd4dd1-57d2-4b72-9bb7-8618d0f93709">14,988,429</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMjktMS0xLTEtMA_b45a4686-a266-45e9-bbf4-1d23225cfe23">48,688,384</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMjktMy0xLTEtMA_109ee336-1067-4371-ae21-46895568bcd2">49,121,523</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings (deficit)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMzAtMS0xLTEtMA_d6b208f2-f575-4ad5-88b2-8f3a5e1dd90e">735,625</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMzAtMy0xLTEtMA_f45a004a-831a-4b14-936f-8ecd0bd3c406">2,131,013</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total shareholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMzEtMS0xLTEtMA_8d7d2a57-c1fa-45ec-81bf-83c12a24f6fe">47,952,759</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMzEtMy0xLTEtMA_2fb44e57-1612-41a5-a841-7bbbc11ced18">46,990,510</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:MinorityInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMzItMS0xLTEtMA_198da7c9-35ca-44b0-836e-339bd55088db">144,352</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:MinorityInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMzItMy0xLTEtMA_f720cadb-1c86-4274-9ebd-8c9bd95a235a">117,116</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMzMtMS0xLTEtMA_d761dd63-9c17-4b2f-8948-42064e559ab0">47,808,407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMzMtMy0xLTEtMA_7c79ca6f-ebc9-4589-86d3-84ee837f4c9b">46,873,394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMzQtMS0xLTEtMA_2b5b19f0-24bd-44b2-bf93-12785dfef94b">88,851,474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMzQtMy0xLTEtMA_406594fa-bea6-452a-8930-e7c7af80ddd3">96,463,305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying Notes to Unaudited Condensed Consolidated Financial Statements. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="id0faa06a8909446fa2394f59c1490a03_19"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.333%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMi0xLTEtMS0w_43c14d3c-5e73-420c-8691-da04c351d460">9,055,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMi0zLTEtMS0w_f926022a-c432-40ae-91ff-49f270f64eb5">9,598,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMi01LTEtMS0w_98fb81f8-ba3f-4c21-92c9-c8cef7867be5">19,592,642</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMi03LTEtMS0w_7866b9b9-31f9-4dc8-883e-3ec2193a9625">17,928,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfNC0xLTEtMS0w_30bf56db-8819-4131-8c81-f5ad73b048ee">1,740,649</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfNC0zLTEtMS0w_7b3b5bcd-d334-4d5a-80ce-410e08e71c67">2,609,982</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfNC01LTEtMS0w_400faead-c1e1-4315-91e9-0a8e8d51f5db">4,157,978</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfNC03LTEtMS0w_43bd455d-74d0-421d-901a-adfd18b6198f">4,244,163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling and marketing</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SellingAndMarketingExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfNS0xLTEtMS0w_06d9718d-93d2-442a-b46c-97fcf09565ce">4,121,817</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SellingAndMarketingExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfNS0zLTEtMS0w_b3c62998-7ed4-4258-8d2d-e428f55cfcb9">3,865,406</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SellingAndMarketingExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfNS01LTEtMS0w_b1e38330-db68-4bce-a66c-750c396e59c2">7,909,157</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SellingAndMarketingExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfNS03LTEtMS0w_245fdf4a-c89b-49bc-a0e5-cf6dd63e6e3b">7,573,082</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfNi0xLTEtMS0w_a68220ec-d5a7-481c-8b0e-06cc3233f9a9">1,360,398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfNi0zLTEtMS0w_df6a19c7-6ab7-4c24-89f9-715ab89839c3">1,421,502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfNi01LTEtMS0w_b611ffe6-37f2-458f-9b32-55425b54c477">2,617,765</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfNi03LTEtMS0w_00607ed0-835c-4897-a315-d74ad5ef4e07">3,144,057</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfNy0xLTEtMS0w_0af888b3-5ad6-4232-81ac-8af03fac5baa">2,097,130</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfNy0zLTEtMS0w_851ed82c-5e31-4a64-8de4-05018f4a6144">2,190,764</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfNy01LTEtMS0w_e7bf2be7-579f-4ae0-8469-dc6f4d00b6f7">4,327,639</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfNy03LTEtMS0w_6a56f486-2a34-4d46-8d61-54788f739be3">4,227,048</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfOC0xLTEtMS0w_add048c2-1343-453f-99eb-a0f67b1d9521">1,171,218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfOC0zLTEtMS0w_ab50613a-dad2-4459-b36e-3f4dfb003e6e">1,091,485</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfOC01LTEtMS0w_3c2f9590-0412-497a-96ec-2f791f14597c">2,340,132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfOC03LTEtMS0w_bfb6de10-c4a9-4a52-9bd2-4b98f56a1153">2,167,524</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfOS0xLTEtMS0w_7b02229c-6b19-4d99-9a50-e3ca8bcd1d6f">10,491,212</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfOS0zLTEtMS0w_8c5e592b-ce59-491a-b4e3-959eb6ba0e8c">11,179,139</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfOS01LTEtMS0w_12482a8b-d44d-4f56-b899-13decf3317b1">21,352,671</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfOS03LTEtMS0w_ac3eb413-efc4-48b8-a547-bfcf0f3f5783">21,355,874</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTAtMS0xLTEtMA_1387e406-65fb-45ae-9d1f-4e562f72aa89">1,435,729</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTAtMy0xLTEtMA_0ae2d962-c7c9-4109-aa07-94778977c56f">1,580,962</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTAtNS0xLTEtMA_21b694aa-c8ca-4ccc-86d9-db2a5c9aedba">1,760,029</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTAtNy0xLTEtMA_6c61448c-e459-4928-aaf7-f3649334888e">3,426,963</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTEtMS0xLTEtMA_3bbcedc4-38ef-4f2b-b843-6efbcd7ebb34">6,591</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTEtMy0xLTEtMA_008dd6c6-905d-4a83-9a47-05dc6fae93ef">28,661</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTEtNS0xLTEtMA_23a82b58-ed6a-4d12-9667-ea5e8c3d34b9">12,017</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTEtNy0xLTEtMA_437cdcda-7875-46a8-bef5-5d71f5a311a5">58,549</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherIncome" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTItMS0xLTEtMTY_1ac8f5cc-7397-4f6b-99be-b2e27b619bab">2,187,140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630" decimals="0" format="ixt:zerodash" name="us-gaap:OtherIncome" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTItMy0xLTEtMTY_a616ae82-8c26-4bbb-bcd9-854fb787ff1d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherIncome" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTItNS0xLTEtNDQ_33b7d1ef-4672-4af2-babe-a9f8152703dc">2,187,140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630" decimals="0" format="ixt:zerodash" name="us-gaap:OtherIncome" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTItNy0xLTEtNDA_62f26054-b64b-45e1-a627-1fc78eeee253">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTItMS0xLTEtMA_805e04bd-ab99-44a5-baf6-5e70fcb57464">25,859</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTItMy0xLTEtMA_5538e440-f580-4aca-83f8-a49fdba3765d">119,455</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTItNS0xLTEtMA_d09862a4-0c84-4cd6-8362-e1a634552a14">50,276</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTItNy0xLTEtMA_030a05d3-8a2b-4c61-80d4-86abca5ec29f">152,520</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from continuing operations before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTMtMS0xLTEtMA_300fc29f-1399-4e26-9d74-0cc63ca58793">732,143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTMtMy0xLTEtMA_217ad10d-4d0f-4b3a-931b-572e476382d5">1,671,756</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTMtNS0xLTEtMA_d44cf48a-fa1b-43fe-be6b-971f02eef115">388,852</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTMtNy0xLTEtMA_31067390-fa60-4be1-a047-ac5aedc5c5cb">3,520,934</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (expense) benefit</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTQtMS0xLTEtMA_d8fd549a-1d72-4cb7-b89a-7d2ea0ff1ae4">7,459</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTQtMy0xLTEtMA_5ed24682-4f39-4a7b-82c8-f5be96d317a8">7,455</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTQtNS0xLTEtMA_a01ba25a-005d-46ad-ac30-471ad8081705">14,917</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTQtNy0xLTEtMA_028be3e3-26bc-4faf-bc47-e6c6b6361845">41,695</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTUtMS0xLTEtMA_761328f0-deef-47f7-9f51-604c18a2e233">724,684</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTUtMy0xLTEtMA_d81f4724-54a3-4bf0-afb3-205bc093c40b">1,679,211</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTUtNS0xLTEtMA_a63db8bb-8ef8-4664-9c16-a1c90b7c2460">373,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTUtNy0xLTEtMA_edf48b93-5a80-48fd-b726-5a6b729875c2">3,562,629</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0932967c9c90454494cbf245d9fa585d_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTYtMS0xLTEtMA_33139f42-0425-4d08-841a-9ae006c66914">498,807</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffc2a4291a32445fb79072f7fe43a870_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTYtMy0xLTEtMA_cf0ce557-4fdd-47c1-9191-c917bd799f4a">738,622</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53d85ca5dcbd44ba870830f97461a800_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTYtNS0xLTEtMA_1bcf2509-7467-4c5c-b800-3d442a6bcef9">994,217</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i166678b245754127b39f5e9c73e8cf2d_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTYtNy0xLTEtMA_72de53a1-48b1-4c79-aa3d-faa22b8da99b">1,556,895</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTctMS0xLTEtMA_38da6285-7070-402f-b837-0f3086a49f75">1,223,491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTctMy0xLTEtMA_dcb401ca-38e5-45c6-95be-49953c1e7e9e">940,589</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTctNS0xLTEtMA_38cb88e6-86a6-4d02-81c9-6ac76b42e377">1,368,152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTctNy0xLTEtMA_7826b7b4-b91b-4335-a18c-a35cbf70f406">2,005,734</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (income) loss at subsidiary attributable to noncontrolling interests</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTgtMS0xLTEtMA_ad9cdbb0-35e4-4783-875f-a33b803b750c">5,069</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTgtMy0xLTEtMA_47af32b2-36dc-48d1-ae83-7216b2cc2889">22,314</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTgtNS0xLTEtMA_3132eb79-3ac2-46ef-b108-4ed939312a07">27,236</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTgtNy0xLTEtMA_16452e5d-8d67-4eab-b11e-724dc4efa96b">31,839</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTktMS0xLTEtMA_b8dfc5cf-c6a5-4f7c-9c61-6a80b153a842">1,228,560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTktMy0xLTEtMA_334f259a-7999-4f1a-857c-595692c065d0">918,275</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTktNS0xLTEtMA_c4f19629-5882-4929-89aa-d989770a2c78">1,395,388</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTktNy0xLTEtMA_461cc6b8-bca3-4299-be42-5d55162be78f">1,973,895</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings (loss) per share attributable to common shareholders</span></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- Continuing operations - basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMjEtMS0xLTEtMA_2a8ede92-0da7-4fc4-bccb-641e06e375c9">0.05</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMjEtMy0xLTEtMA_f113112f-72e5-4fee-8d1d-72109c1935c3">0.11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMjEtNS0xLTEtMA_3ed3949f-e6e1-4fdf-a405-900344e298d5">0.02</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMjEtNy0xLTEtMA_54e90f0a-4fff-4305-8614-3c6bc6cd1698">0.23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- Discontinued operations - basic</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMjItMS0xLTEtMA_bf0076e8-2ef4-4178-8412-323e5c33171d">0.03</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMjItMy0xLTEtMA_38fb56c4-5d5f-40ca-803e-1175fad896af">0.05</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMjItNS0xLTEtMA_e2ad922a-cef8-4623-91a0-4986b6daf631">0.07</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMjItNy0xLTEtMA_46a02ac7-e916-484e-b0b1-e01c4d6fa6ff">0.10</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMjMtMS0xLTEtMA_83c569a8-15d9-42eb-9285-667fb502455a">0.08</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMjMtMy0xLTEtMA_d98ecdea-22dc-4e7b-93e0-d279e57d5694">0.06</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMjMtNS0xLTEtMA_148c7eab-edab-49e7-9555-4e09a44ae4c3">0.09</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMjMtNy0xLTEtMA_5d98fc53-f6cf-4236-9386-49c02fdb3649">0.13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- Continuing operations - diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMjUtMS0xLTEtMA_0f500a0c-8d4d-44f1-ba73-0e451c8e451f">0.05</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMjUtMy0xLTEtMA_df2301ab-921f-4113-94e1-1c7d25285dc6">0.11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMjUtNS0xLTEtMA_8ca9685c-2555-4e95-ad9e-260beaecc625">0.02</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMjUtNy0xLTEtMA_e78f0b20-3cf0-4ed3-8c5a-f0afabd2aad2">0.23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- Discontinued operations - diluted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMjYtMS0xLTEtMA_66cfa766-1e1c-44b4-b330-7d514228ec5c">0.03</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMjYtMy0xLTEtMA_ad2e8087-31c8-4b9c-926d-01fa1db330eb">0.05</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMjYtNS0xLTEtMA_57d43691-d252-4a15-9b9d-ca0d93f74203">0.07</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMjYtNy0xLTEtMA_8e97a492-d312-4906-ae51-bf6ef8acad7a">0.10</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMjctMS0xLTEtMA_532a0445-d941-4f4a-9574-95b69bf182bc">0.08</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMjctMy0xLTEtMA_b7027d9d-7985-497f-9d48-74f9e75ddcd8">0.06</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMjctNS0xLTEtMA_2bca3d5c-cf8d-4c0b-a351-7036fb54be79">0.09</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMjctNy0xLTEtMA_16cc53be-5f87-4ea6-930b-c0dfad689b07">0.13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMjktMS0xLTEtMA_c2df2a85-063d-4e72-8cc0-f113580e1ac4">14,976,034</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMjktMy0xLTEtMA_3df73b08-d9bc-4067-b6c3-56fa9ffd698a">15,241,463</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMjktNS0xLTEtMA_90bf369c-59f5-475e-bb5e-dc29a315c526">14,970,241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMjktNy0xLTEtMA_34d5a1e5-220b-41a6-8215-a9b0c1b42040">15,241,020</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- diluted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMzAtMS0xLTEtMA_2cc9f5cb-2fc2-45a0-a213-fabe436ff549">15,109,246</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMzAtMy0xLTEtMA_64d8a77f-6e7d-4077-8194-074fafdb8a68">15,241,463</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMzAtNS0xLTEtMA_c14f7212-bbfa-4857-84b0-5aa8c727c9ef">15,171,589</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMzAtNy0xLTEtMA_65f2f002-432e-4d27-b6d3-2268b01e4d04">15,241,020</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying Notes to Unaudited Condensed Consolidated Financial Statements.</span></div><div style="margin-bottom:17pt;margin-top:17pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="id0faa06a8909446fa2394f59c1490a03_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMy0xLTEtMS0w_642afdcd-46f9-4c19-a167-43040be50bf0">1,368,152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMy0zLTEtMS0w_b1e7ec1d-6fd5-4ce1-9c97-4417accf6f1b">2,005,734</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfNC0xLTEtMS0w_53b31483-cda3-4cc1-a8e4-e06397e34e25">994,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfNC0zLTEtMS0w_7d8306ad-1422-4f4f-97fe-1a8c9686fd61">1,556,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfNS0xLTEtMS0w_24eea12d-4d46-462c-94c6-604ce1e3cde1">373,935</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfNS0zLTEtMS0w_6d888c8a-c33b-4042-82b3-2ed8d2b3e292">3,562,629</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net income (loss) from continuing operations to net cash provided by (used in) operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfNy0xLTEtMS0w_93ac9757-3fec-4344-9d27-e05f57e0532d">2,455,576</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfNy0zLTEtMS0w_b7edd077-5d16-4ffa-96fc-086471a27be2">2,334,669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfOC0xLTEtMS0w_ecf88537-947d-4c24-8567-b4a73fbfc8f0">354,914</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfOC0zLTEtMS0w_c055897d-2037-43e2-b0c9-bf5b72584e99">542,923</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in non-cash contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfOS0xLTEtMS0w_f2f5ce0c-975c-46ee-bcc9-3fcec763e72d">180,110</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfOS0zLTEtMS0w_4d9e291e-2f0f-4555-8ad3-a6586353e561">645,571</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease (increase) in cash surrender value of life insurance policies over premiums paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="cpix:IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMTAtMS0xLTEtMA_ed642114-bf1e-4c19-9d7c-22332f8a8ca4">226,897</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="cpix:IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMTAtMy0xLTEtMA_d8735c7e-34de-43e8-bcd9-e7f9773958a2">215,116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncash interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMTEtMS0xLTEtMA_85c3751f-c19a-4700-b5b4-0e0ae5454c33">27,666</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMTEtMy0xLTEtMA_e8a67e53-6157-4328-ae6c-32b90c1f1062">22,973</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on forgiveness of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:UnrealizedGainLossOnInvestments" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMTItMS0xLTEtNTM_4f111ca0-7e8c-4350-890c-f6e183e4b29f">2,187,140</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630" decimals="0" format="ixt:zerodash" name="us-gaap:UnrealizedGainLossOnInvestments" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMTItMy0xLTEtNTM_b9b8e0db-1857-46f0-bb4c-599c14e59895">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net changes in assets and liabilities affecting operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMTMtMS0xLTEtMA_41edc7d0-d2de-4eb5-85b8-bb5f40559cb3">3,230,220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMTMtMy0xLTEtMA_1c4b7547-7ef4-4c0f-bd17-5fcf24b51ae4">80,421</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMTQtMS0xLTEtMA_cbfd967f-f119-4ebb-a2d8-416b981ae72a">2,309,914</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMTQtMy0xLTEtMA_ea0e8766-0762-4c01-b277-c8bcc7852f43">1,158,916</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMTUtMS0xLTEtMA_e56bd93a-dfc7-40a4-9729-5e10e7db7007">866,987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMTUtMy0xLTEtMA_cfd5120e-0fda-4a06-91b3-12f31c7b5c12">802,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" decimals="0" sign="-" format="ixt:numdotdecimal" name="cpix:IncreaseDecreaseInCurrentOperatingLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMTYtMS0xLTEtMA_98bab84a-96ab-4f88-8ba0-0161943d4bc7">3,008,323</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="cpix:IncreaseDecreaseInCurrentOperatingLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMTYtMy0xLTEtMA_1b6eff17-dd79-48ca-8ce6-278c583ebb8d">2,413,768</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMTctMS0xLTEtMA_493ba5e9-7b25-411f-b6d6-fab9b822524f">526,189</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMTctMy0xLTEtMA_21f251e4-64ee-4217-b467-d43f629a96ff">869,644</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) operating activities from continuing operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMTgtMS0xLTEtMA_2fc44eac-7dda-4b19-adf7-c87e4a011e1d">3,490,553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMTgtMy0xLTEtMA_ff0dc61c-038e-4f40-a1ac-8075480d9292">2,332,634</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMTktMS0xLTEtMA_aa0eea8a-b57b-4f52-8a91-57d1d16460cd">994,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMTktMy0xLTEtMA_4ba1577a-2dae-4279-9849-c7888d7aab06">1,371,437</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMjAtMS0xLTEtMA_821d029f-ef00-4828-bf0e-9b14acc7e271">4,484,770</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMjAtMy0xLTEtMA_fa5d3d03-3121-4a64-8938-ae84f1c4ecf5">3,704,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions to property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMjItMS0xLTEtMA_f44b2557-10f9-4e93-bac3-783b69b1ed0d">34,531</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMjItMy0xLTEtMA_c7963437-e83f-46f1-bd48-501e85ed46ff">50,883</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note receivable investment funding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMjMtMS0xLTEtMA_133669a0-0727-4fc3-8b92-2de7885ee88e">200,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630" decimals="0" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMjMtMy0xLTEtMA_f21a799c-844c-462a-99f7-66e5145948dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions to intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMjQtMS0xLTEtMA_48e93d70-128b-445d-bbb6-85e62235d484">132,323</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMjQtMy0xLTEtMA_f259694b-bd37-420b-9696-d864956f2235">722,131</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMjUtMS0xLTEtMA_b32a99f2-7f55-4d1b-8f49-2c1a3e2f97f2">366,854</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMjUtMy0xLTEtMA_bfd6274d-9913-441a-8903-3c8113ba5699">773,014</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Borrowings on line of credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromRepaymentsOfLinesOfCredit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMjgtMS0xLTEtMA_83608c38-ca81-4b64-a7dc-de88210236bf">29,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromRepaymentsOfLinesOfCredit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMjgtMy0xLTEtMA_5afd82af-82aa-48f0-93ae-1b655f747c12">35,500,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayments on line of credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfNotesPayable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMjktMS0xLTEtMA_3cff173c-ebd9-4271-b6d5-9eaf7599eea9">30,000,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfNotesPayable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMjktMy0xLTEtMA_a3ce262c-d7fc-447e-85e9-292e3e2e6aba">37,000,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment of contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMzAtMS0xLTEtMA_b3507769-327f-406a-976d-60b478c2d7d8">1,423,586</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMzAtMy0xLTEtMA_70177a1d-0cde-40a7-a23c-1a46cbe03f70">260,735</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of subsidiary shares from noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" decimals="0" format="ixt:zerodash" name="us-gaap:PaymentsForRepurchaseOfRedeemableNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMzEtMS0xLTEtMA_a3fa1ec6-0388-4197-b886-75fb22bf5016">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfRedeemableNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMzEtMy0xLTEtMA_f4db0bf7-868e-4600-8f45-f8d714eabf70">800,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMzItMS0xLTEtMA_a884db7a-954f-45fb-a57f-d18076f910f3">777,664</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMzItMy0xLTEtMA_3238029f-9388-4a11-82c9-8a17b430dc0d">1,209,220</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMzMtMS0xLTEtMA_03f034f9-d3f2-459a-b5c5-f0b58214ed2a">3,201,250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMzMtMy0xLTEtMA_eb27c94c-fe43-4551-91c3-c505de79525d">3,769,955</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMzQtMS0xLTEtMA_f10bd4aa-c83c-4207-8cdf-35f7d64dd2d9">916,666</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMzQtMy0xLTEtMA_53935b95-ac64-48b8-bad0-5dc9078bc8ac">838,898</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMzUtMS0xLTEtMA_893d9c8f-6d2f-4717-a91e-06076e566dd2">24,753,796</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98ab83b91d54ad0aa13294fe0c3bdb6_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMzUtMy0xLTEtMA_e08c36f3-9326-4bae-a41e-5f218cf3ce38">28,212,635</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMzYtMS0xLTEtMA_8f192b10-1f32-41d3-b1a5-64fe3c151f85">25,670,462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4860200ab8134ae18446101822694027_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMzYtMy0xLTEtMA_42bb130f-4249-481b-886c-44d8f14d847d">27,373,737</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying Notes to Unaudited Condensed Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="id0faa06a8909446fa2394f59c1490a03_25"></div><hr style="page-break-after:always"/><div style="min-height:33.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:31.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.757%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retained earnings (deficit)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total equity</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3d6d3147bec94616bcf72690b2be296a_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjk4M2M0NGFhMTU2YjRhMDg4NDg3YjMyMDJmZTM1YmU5L3RhYmxlcmFuZ2U6OTgzYzQ0YWExNTZiNGEwODg0ODdiMzIwMmZlMzViZTlfMi0xLTEtMS0w_f6f3df32-0091-4d14-8522-cc47eff6bb4b">15,263,555</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d6d3147bec94616bcf72690b2be296a_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjk4M2M0NGFhMTU2YjRhMDg4NDg3YjMyMDJmZTM1YmU5L3RhYmxlcmFuZ2U6OTgzYzQ0YWExNTZiNGEwODg0ODdiMzIwMmZlMzViZTlfMi0zLTEtMS0w_acef6610-95d6-402c-8afb-4e189b122b68">49,914,478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83e7ecfbf2a84991a8389944813821f5_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjk4M2M0NGFhMTU2YjRhMDg4NDg3YjMyMDJmZTM1YmU5L3RhYmxlcmFuZ2U6OTgzYzQ0YWExNTZiNGEwODg0ODdiMzIwMmZlMzViZTlfMi01LTEtMS0w_b1e7fcdc-c912-4b2f-ac85-45fe72454eec">1,208,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i114a57733d5043469e08faf40e0cd3f8_I20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjk4M2M0NGFhMTU2YjRhMDg4NDg3YjMyMDJmZTM1YmU5L3RhYmxlcmFuZ2U6OTgzYzQ0YWExNTZiNGEwODg0ODdiMzIwMmZlMzViZTlfMi03LTEtMS0w_d88f8c60-2f47-417d-b2d2-ae81330e62db">37,620</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98ab83b91d54ad0aa13294fe0c3bdb6_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjk4M2M0NGFhMTU2YjRhMDg4NDg3YjMyMDJmZTM1YmU5L3RhYmxlcmFuZ2U6OTgzYzQ0YWExNTZiNGEwODg0ODdiMzIwMmZlMzViZTlfMi05LTEtMS0w_c8ea0ce2-dc9b-42f0-bca5-3c8cf77a2533">51,085,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i466ef04c404e4ac6a59e26ee7fd0c3cf_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjk4M2M0NGFhMTU2YjRhMDg4NDg3YjMyMDJmZTM1YmU5L3RhYmxlcmFuZ2U6OTgzYzQ0YWExNTZiNGEwODg0ODdiMzIwMmZlMzViZTlfMy0xLTEtMS0w_827c0712-d898-4e40-bd25-234ee4400bed">219,850</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i466ef04c404e4ac6a59e26ee7fd0c3cf_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjk4M2M0NGFhMTU2YjRhMDg4NDg3YjMyMDJmZTM1YmU5L3RhYmxlcmFuZ2U6OTgzYzQ0YWExNTZiNGEwODg0ODdiMzIwMmZlMzViZTlfMy0zLTEtMS0w_0b907adb-9c1f-4c82-80ef-b00f6f80f36b">264,574</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab72c368dd2d4ce9a791ab677393c6a5_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjk4M2M0NGFhMTU2YjRhMDg4NDg3YjMyMDJmZTM1YmU5L3RhYmxlcmFuZ2U6OTgzYzQ0YWExNTZiNGEwODg0ODdiMzIwMmZlMzViZTlfMy05LTEtMS0w_b5f3e386-b298-4839-b7ad-853bc8f0768c">264,574</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i466ef04c404e4ac6a59e26ee7fd0c3cf_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjk4M2M0NGFhMTU2YjRhMDg4NDg3YjMyMDJmZTM1YmU5L3RhYmxlcmFuZ2U6OTgzYzQ0YWExNTZiNGEwODg0ODdiMzIwMmZlMzViZTlfNC0xLTEtMS0w_74482229-ae44-4c9f-90a8-b9768c47de10">164,866</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i466ef04c404e4ac6a59e26ee7fd0c3cf_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjk4M2M0NGFhMTU2YjRhMDg4NDg3YjMyMDJmZTM1YmU5L3RhYmxlcmFuZ2U6OTgzYzQ0YWExNTZiNGEwODg0ODdiMzIwMmZlMzViZTlfNC0zLTEtMS0w_521bb0a2-fa17-4ec1-a900-1fd01b086225">441,624</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab72c368dd2d4ce9a791ab677393c6a5_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjk4M2M0NGFhMTU2YjRhMDg4NDg3YjMyMDJmZTM1YmU5L3RhYmxlcmFuZ2U6OTgzYzQ0YWExNTZiNGEwODg0ODdiMzIwMmZlMzViZTlfNC05LTEtMS0w_b6e85ecf-32d5-4d7f-88dd-7ef4cafb9ab3">441,624</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if884adb91afc4270896a5966ea47d7aa_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjk4M2M0NGFhMTU2YjRhMDg4NDg3YjMyMDJmZTM1YmU5L3RhYmxlcmFuZ2U6OTgzYzQ0YWExNTZiNGEwODg0ODdiMzIwMmZlMzViZTlfNS01LTEtMS0w_826b5d16-43a0-4c51-bade-b304659278ed">1,055,620</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba53f6b880994dffa4c65f2e2602560a_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjk4M2M0NGFhMTU2YjRhMDg4NDg3YjMyMDJmZTM1YmU5L3RhYmxlcmFuZ2U6OTgzYzQ0YWExNTZiNGEwODg0ODdiMzIwMmZlMzViZTlfNS03LTEtMS0w_8b6e0df7-cc20-498b-975a-f5eed4a4df5c">9,525</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab72c368dd2d4ce9a791ab677393c6a5_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjk4M2M0NGFhMTU2YjRhMDg4NDg3YjMyMDJmZTM1YmU5L3RhYmxlcmFuZ2U6OTgzYzQ0YWExNTZiNGEwODg0ODdiMzIwMmZlMzViZTlfNS05LTEtMS0w_bc5dc888-2b66-4c59-915e-ae20b2925f81">1,065,145</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifcedca0bf3ff4536974d961a488fc053_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjk4M2M0NGFhMTU2YjRhMDg4NDg3YjMyMDJmZTM1YmU5L3RhYmxlcmFuZ2U6OTgzYzQ0YWExNTZiNGEwODg0ODdiMzIwMmZlMzViZTlfNi0xLTEtMS0w_abd03d34-1937-4945-abe0-709dee247ed1">15,318,539</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcedca0bf3ff4536974d961a488fc053_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjk4M2M0NGFhMTU2YjRhMDg4NDg3YjMyMDJmZTM1YmU5L3RhYmxlcmFuZ2U6OTgzYzQ0YWExNTZiNGEwODg0ODdiMzIwMmZlMzViZTlfNi0zLTEtMS0w_f65a66ed-74d9-48ab-a465-4ae4befd97a0">49,737,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e77b9f22c1042519f6f27f64401d843_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjk4M2M0NGFhMTU2YjRhMDg4NDg3YjMyMDJmZTM1YmU5L3RhYmxlcmFuZ2U6OTgzYzQ0YWExNTZiNGEwODg0ODdiMzIwMmZlMzViZTlfNi01LTEtMS0w_a5a5d4fd-2c95-41a7-bef0-6149239fb8b7">152,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifb9ba2c0e442481695058478aea8e7d6_I20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjk4M2M0NGFhMTU2YjRhMDg4NDg3YjMyMDJmZTM1YmU5L3RhYmxlcmFuZ2U6OTgzYzQ0YWExNTZiNGEwODg0ODdiMzIwMmZlMzViZTlfNi03LTEtMS0w_c80360b2-64f8-41ce-b571-f3a91fb2b38b">47,145</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic49b798ae420415688228a42789077ba_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjk4M2M0NGFhMTU2YjRhMDg4NDg3YjMyMDJmZTM1YmU5L3RhYmxlcmFuZ2U6OTgzYzQ0YWExNTZiNGEwODg0ODdiMzIwMmZlMzViZTlfNi05LTEtMS0w_625fd4e3-ff6a-4d3a-ba6d-267b907b6dbc">49,843,058</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:31.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.757%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifcedca0bf3ff4536974d961a488fc053_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjc2YmIwODkwZjljMzQyNmZiNTNhZDRiMDM2MWU3ZjljL3RhYmxlcmFuZ2U6NzZiYjA4OTBmOWMzNDI2ZmI1M2FkNGIwMzYxZTdmOWNfMS0xLTEtMS0w_66cb66b5-ef64-4341-90cf-1a4c722e6e7b">15,318,539</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcedca0bf3ff4536974d961a488fc053_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjc2YmIwODkwZjljMzQyNmZiNTNhZDRiMDM2MWU3ZjljL3RhYmxlcmFuZ2U6NzZiYjA4OTBmOWMzNDI2ZmI1M2FkNGIwMzYxZTdmOWNfMS0zLTEtMS0w_12db626e-c3f0-4b99-a4ac-8a029ecc2a8e">49,737,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e77b9f22c1042519f6f27f64401d843_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjc2YmIwODkwZjljMzQyNmZiNTNhZDRiMDM2MWU3ZjljL3RhYmxlcmFuZ2U6NzZiYjA4OTBmOWMzNDI2ZmI1M2FkNGIwMzYxZTdmOWNfMS01LTEtMS0w_e2b75297-7af8-4f25-8674-aa970ee9911d">152,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifb9ba2c0e442481695058478aea8e7d6_I20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjc2YmIwODkwZjljMzQyNmZiNTNhZDRiMDM2MWU3ZjljL3RhYmxlcmFuZ2U6NzZiYjA4OTBmOWMzNDI2ZmI1M2FkNGIwMzYxZTdmOWNfMS03LTEtMS0w_121cbf8b-3f23-4ca2-8405-340d3dac9eb9">47,145</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic49b798ae420415688228a42789077ba_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjc2YmIwODkwZjljMzQyNmZiNTNhZDRiMDM2MWU3ZjljL3RhYmxlcmFuZ2U6NzZiYjA4OTBmOWMzNDI2ZmI1M2FkNGIwMzYxZTdmOWNfMS05LTEtMS0w_f0938152-59b4-474c-90ae-ce59b21a4fa5">49,843,058</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8a150324b9d0427e89459a576fa87284_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjc2YmIwODkwZjljMzQyNmZiNTNhZDRiMDM2MWU3ZjljL3RhYmxlcmFuZ2U6NzZiYjA4OTBmOWMzNDI2ZmI1M2FkNGIwMzYxZTdmOWNfMi0xLTEtMS0w_7170b2f8-c5c6-49f4-b9b5-d823978aaa6d">4,200</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a150324b9d0427e89459a576fa87284_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjc2YmIwODkwZjljMzQyNmZiNTNhZDRiMDM2MWU3ZjljL3RhYmxlcmFuZ2U6NzZiYjA4OTBmOWMzNDI2ZmI1M2FkNGIwMzYxZTdmOWNfMi0zLTEtMS0w_f3602cbb-05c5-4594-8808-18b9044921f5">278,349</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjc2YmIwODkwZjljMzQyNmZiNTNhZDRiMDM2MWU3ZjljL3RhYmxlcmFuZ2U6NzZiYjA4OTBmOWMzNDI2ZmI1M2FkNGIwMzYxZTdmOWNfMi05LTEtMS0w_9ee71383-af42-4753-a1ab-f3030cefbdd4">278,349</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i8a150324b9d0427e89459a576fa87284_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodShares" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjc2YmIwODkwZjljMzQyNmZiNTNhZDRiMDM2MWU3ZjljL3RhYmxlcmFuZ2U6NzZiYjA4OTBmOWMzNDI2ZmI1M2FkNGIwMzYxZTdmOWNfNC0xLTEtMS0w_442fb05c-6e76-4c58-a86d-61829041b538">141,463</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a150324b9d0427e89459a576fa87284_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjc2YmIwODkwZjljMzQyNmZiNTNhZDRiMDM2MWU3ZjljL3RhYmxlcmFuZ2U6NzZiYjA4OTBmOWMzNDI2ZmI1M2FkNGIwMzYxZTdmOWNfNC0zLTEtMS0w_f5e8212d-a078-4f53-8c5c-08a568b57b13">769,648</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjc2YmIwODkwZjljMzQyNmZiNTNhZDRiMDM2MWU3ZjljL3RhYmxlcmFuZ2U6NzZiYjA4OTBmOWMzNDI2ZmI1M2FkNGIwMzYxZTdmOWNfNC05LTEtMS0w_6cdf6310-57ea-4a6f-a9c7-b03e68ca8290">769,648</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4067952523e04c2eb44fce178eac9c45_D20200401-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjc2YmIwODkwZjljMzQyNmZiNTNhZDRiMDM2MWU3ZjljL3RhYmxlcmFuZ2U6NzZiYjA4OTBmOWMzNDI2ZmI1M2FkNGIwMzYxZTdmOWNfNS01LTEtMS0w_023fd88b-feca-442b-b200-f7b22871aa84">918,275</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i58fc83ab5ccd43ce857e2367d7e167ac_D20200401-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjc2YmIwODkwZjljMzQyNmZiNTNhZDRiMDM2MWU3ZjljL3RhYmxlcmFuZ2U6NzZiYjA4OTBmOWMzNDI2ZmI1M2FkNGIwMzYxZTdmOWNfNS03LTEtMS0w_5abf9643-4af2-48dc-a619-f36e56eb1bf1">22,314</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjc2YmIwODkwZjljMzQyNmZiNTNhZDRiMDM2MWU3ZjljL3RhYmxlcmFuZ2U6NzZiYjA4OTBmOWMzNDI2ZmI1M2FkNGIwMzYxZTdmOWNfNS05LTEtMS0w_73c2a219-2836-401d-9cf4-47d000a77b58">940,589</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, June 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i757638cd1ac54400a7212a39551700fa_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjc2YmIwODkwZjljMzQyNmZiNTNhZDRiMDM2MWU3ZjljL3RhYmxlcmFuZ2U6NzZiYjA4OTBmOWMzNDI2ZmI1M2FkNGIwMzYxZTdmOWNfNi0xLTEtMS0w_f3ab345e-5f40-4444-83c2-d8b57db302bf">15,181,276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i757638cd1ac54400a7212a39551700fa_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjc2YmIwODkwZjljMzQyNmZiNTNhZDRiMDM2MWU3ZjljL3RhYmxlcmFuZ2U6NzZiYjA4OTBmOWMzNDI2ZmI1M2FkNGIwMzYxZTdmOWNfNi0zLTEtMS0w_c0923a71-b604-4100-b6b6-9d2aaa93efa4">49,246,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2543a120857490e9cdf7ff91a0a636a_I20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjc2YmIwODkwZjljMzQyNmZiNTNhZDRiMDM2MWU3ZjljL3RhYmxlcmFuZ2U6NzZiYjA4OTBmOWMzNDI2ZmI1M2FkNGIwMzYxZTdmOWNfNi01LTEtMS0w_758c169e-56e7-4677-b4db-b97a3fda4851">765,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1721669d68794a37916477190e8866d2_I20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjc2YmIwODkwZjljMzQyNmZiNTNhZDRiMDM2MWU3ZjljL3RhYmxlcmFuZ2U6NzZiYjA4OTBmOWMzNDI2ZmI1M2FkNGIwMzYxZTdmOWNfNi03LTEtMS0w_b9c659a8-22bd-47f5-aa3c-e7fed5df9373">69,459</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4860200ab8134ae18446101822694027_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjc2YmIwODkwZjljMzQyNmZiNTNhZDRiMDM2MWU3ZjljL3RhYmxlcmFuZ2U6NzZiYjA4OTBmOWMzNDI2ZmI1M2FkNGIwMzYxZTdmOWNfNi05LTEtMS0w_956f9628-ea97-4656-a0a5-c418e9071a40">48,411,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:31.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.757%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:31.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.757%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:31.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.757%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retained earnings (deficit)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total equity</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i851f7a722da048d59591d314f36aabc7_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjMwMmY0NmFlODQ2YzQ5MjFhYTQ1Y2JmMGRkY2E1YWU1L3RhYmxlcmFuZ2U6MzAyZjQ2YWU4NDZjNDkyMWFhNDVjYmYwZGRjYTVhZTVfMi0xLTEtMS0w_d3f27e6d-fb00-4d5e-ab87-1bd63e59f113">14,988,429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i851f7a722da048d59591d314f36aabc7_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjMwMmY0NmFlODQ2YzQ5MjFhYTQ1Y2JmMGRkY2E1YWU1L3RhYmxlcmFuZ2U6MzAyZjQ2YWU4NDZjNDkyMWFhNDVjYmYwZGRjYTVhZTVfMi0zLTEtMS0w_2ed1e463-c97b-4820-984f-9cfef0433fdc">49,121,523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9f59f7e0e644c3e9406612323559f4b_I20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjMwMmY0NmFlODQ2YzQ5MjFhYTQ1Y2JmMGRkY2E1YWU1L3RhYmxlcmFuZ2U6MzAyZjQ2YWU4NDZjNDkyMWFhNDVjYmYwZGRjYTVhZTVfMi01LTEtMS0w_2a697983-f4e2-4de3-ad3f-3cc704a99831">2,131,013</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a6e35b8c49547efba40d6119ccf44be_I20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjMwMmY0NmFlODQ2YzQ5MjFhYTQ1Y2JmMGRkY2E1YWU1L3RhYmxlcmFuZ2U6MzAyZjQ2YWU4NDZjNDkyMWFhNDVjYmYwZGRjYTVhZTVfMi03LTEtMS0w_36d7c36a-bf88-4232-847c-f683065e2e54">117,116</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjMwMmY0NmFlODQ2YzQ5MjFhYTQ1Y2JmMGRkY2E1YWU1L3RhYmxlcmFuZ2U6MzAyZjQ2YWU4NDZjNDkyMWFhNDVjYmYwZGRjYTVhZTVfMi05LTEtMS0w_36ce383f-ba95-462c-a37e-11bb80fd6675">46,873,394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id451c947a6d945de824fde928e9539b8_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjMwMmY0NmFlODQ2YzQ5MjFhYTQ1Y2JmMGRkY2E1YWU1L3RhYmxlcmFuZ2U6MzAyZjQ2YWU4NDZjNDkyMWFhNDVjYmYwZGRjYTVhZTVfMy0xLTEtMS0w_294b783b-962a-4f2a-b5eb-6c2a6b491511">187,759</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id451c947a6d945de824fde928e9539b8_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjMwMmY0NmFlODQ2YzQ5MjFhYTQ1Y2JmMGRkY2E1YWU1L3RhYmxlcmFuZ2U6MzAyZjQ2YWU4NDZjNDkyMWFhNDVjYmYwZGRjYTVhZTVfMy0zLTEtMS0w_bb58027f-a3aa-46bb-a471-8d21146d271d">162,960</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8613f3fef30a4cf99a52244890006824_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjMwMmY0NmFlODQ2YzQ5MjFhYTQ1Y2JmMGRkY2E1YWU1L3RhYmxlcmFuZ2U6MzAyZjQ2YWU4NDZjNDkyMWFhNDVjYmYwZGRjYTVhZTVfMy05LTEtMS0w_f3d3d0ed-9ba5-4139-a2a2-a058530c29bc">162,960</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="id451c947a6d945de824fde928e9539b8_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodShares" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjMwMmY0NmFlODQ2YzQ5MjFhYTQ1Y2JmMGRkY2E1YWU1L3RhYmxlcmFuZ2U6MzAyZjQ2YWU4NDZjNDkyMWFhNDVjYmYwZGRjYTVhZTVfNC0xLTEtMS0w_846ea41b-34ee-4ece-a81c-ac6b4eb5d70f">91,724</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id451c947a6d945de824fde928e9539b8_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjMwMmY0NmFlODQ2YzQ5MjFhYTQ1Y2JmMGRkY2E1YWU1L3RhYmxlcmFuZ2U6MzAyZjQ2YWU4NDZjNDkyMWFhNDVjYmYwZGRjYTVhZTVfNC0zLTEtMS0w_3cf49f0a-7e96-4d9b-94cb-eb85b0761db7">303,088</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8613f3fef30a4cf99a52244890006824_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjMwMmY0NmFlODQ2YzQ5MjFhYTQ1Y2JmMGRkY2E1YWU1L3RhYmxlcmFuZ2U6MzAyZjQ2YWU4NDZjNDkyMWFhNDVjYmYwZGRjYTVhZTVfNC05LTEtMS0w_3d8670d2-a7c4-4062-b2a1-5f7f5daabb55">303,088</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b5aa580bb2d4a5f8f2914acb615a1e1_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjMwMmY0NmFlODQ2YzQ5MjFhYTQ1Y2JmMGRkY2E1YWU1L3RhYmxlcmFuZ2U6MzAyZjQ2YWU4NDZjNDkyMWFhNDVjYmYwZGRjYTVhZTVfNS01LTEtMS0w_b2fa6259-c128-4817-9bb8-3c1106904c9b">166,828</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46f84339676244a68c635efc3276aab8_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjMwMmY0NmFlODQ2YzQ5MjFhYTQ1Y2JmMGRkY2E1YWU1L3RhYmxlcmFuZ2U6MzAyZjQ2YWU4NDZjNDkyMWFhNDVjYmYwZGRjYTVhZTVfNS03LTEtMS0w_14bcb590-1b8b-4277-aacc-26fc485bff58">22,167</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8613f3fef30a4cf99a52244890006824_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjMwMmY0NmFlODQ2YzQ5MjFhYTQ1Y2JmMGRkY2E1YWU1L3RhYmxlcmFuZ2U6MzAyZjQ2YWU4NDZjNDkyMWFhNDVjYmYwZGRjYTVhZTVfNS05LTEtMS0w_c399b7fe-50fa-48e4-b52b-58736b55aa86">144,661</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic2444510ac2f491e93494d3efc1d3f10_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjMwMmY0NmFlODQ2YzQ5MjFhYTQ1Y2JmMGRkY2E1YWU1L3RhYmxlcmFuZ2U6MzAyZjQ2YWU4NDZjNDkyMWFhNDVjYmYwZGRjYTVhZTVfNi0xLTEtMS0w_d79ca5b2-82e2-49e6-bb28-4f43b8c65899">15,084,464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2444510ac2f491e93494d3efc1d3f10_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjMwMmY0NmFlODQ2YzQ5MjFhYTQ1Y2JmMGRkY2E1YWU1L3RhYmxlcmFuZ2U6MzAyZjQ2YWU4NDZjNDkyMWFhNDVjYmYwZGRjYTVhZTVfNi0zLTEtMS0w_89e1f86c-a5f3-4439-827e-de11e4d28ac6">48,981,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bfadd4b687f465caceadefb291b8a5a_I20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjMwMmY0NmFlODQ2YzQ5MjFhYTQ1Y2JmMGRkY2E1YWU1L3RhYmxlcmFuZ2U6MzAyZjQ2YWU4NDZjNDkyMWFhNDVjYmYwZGRjYTVhZTVfNi01LTEtMS0w_702e9a7c-0adf-49e3-a03e-e0bfc69451eb">1,964,185</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i236298ea92174d4481784e6bae4c0605_I20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjMwMmY0NmFlODQ2YzQ5MjFhYTQ1Y2JmMGRkY2E1YWU1L3RhYmxlcmFuZ2U6MzAyZjQ2YWU4NDZjNDkyMWFhNDVjYmYwZGRjYTVhZTVfNi03LTEtMS0w_d337694f-5c8e-4a86-aefe-2ab839583084">139,283</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i759d312796b74964bece38516542bb38_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjMwMmY0NmFlODQ2YzQ5MjFhYTQ1Y2JmMGRkY2E1YWU1L3RhYmxlcmFuZ2U6MzAyZjQ2YWU4NDZjNDkyMWFhNDVjYmYwZGRjYTVhZTVfNi05LTEtMS0w_af12deae-840d-4f63-a7ed-b0510a72b054">46,877,927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:31.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.757%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic2444510ac2f491e93494d3efc1d3f10_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjI1ZWZiZDVhOWQ4ZDRjNmE4YjNhNjhkOTI5YjViNWYzL3RhYmxlcmFuZ2U6MjVlZmJkNWE5ZDhkNGM2YThiM2E2OGQ5MjliNWI1ZjNfMS0xLTEtMS0w_d79ca5b2-82e2-49e6-bb28-4f43b8c65899">15,084,464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2444510ac2f491e93494d3efc1d3f10_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjI1ZWZiZDVhOWQ4ZDRjNmE4YjNhNjhkOTI5YjViNWYzL3RhYmxlcmFuZ2U6MjVlZmJkNWE5ZDhkNGM2YThiM2E2OGQ5MjliNWI1ZjNfMS0zLTEtMS0w_89e1f86c-a5f3-4439-827e-de11e4d28ac6">48,981,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bfadd4b687f465caceadefb291b8a5a_I20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjI1ZWZiZDVhOWQ4ZDRjNmE4YjNhNjhkOTI5YjViNWYzL3RhYmxlcmFuZ2U6MjVlZmJkNWE5ZDhkNGM2YThiM2E2OGQ5MjliNWI1ZjNfMS01LTEtMS0w_702e9a7c-0adf-49e3-a03e-e0bfc69451eb">1,964,185</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i236298ea92174d4481784e6bae4c0605_I20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjI1ZWZiZDVhOWQ4ZDRjNmE4YjNhNjhkOTI5YjViNWYzL3RhYmxlcmFuZ2U6MjVlZmJkNWE5ZDhkNGM2YThiM2E2OGQ5MjliNWI1ZjNfMS03LTEtMS0w_d337694f-5c8e-4a86-aefe-2ab839583084">139,283</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i759d312796b74964bece38516542bb38_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjI1ZWZiZDVhOWQ4ZDRjNmE4YjNhNjhkOTI5YjViNWYzL3RhYmxlcmFuZ2U6MjVlZmJkNWE5ZDhkNGM2YThiM2E2OGQ5MjliNWI1ZjNfMS05LTEtMS0w_af12deae-840d-4f63-a7ed-b0510a72b054">46,877,927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9737d5fe1a1a4b64a348bd61bcd44e8b_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjI1ZWZiZDVhOWQ4ZDRjNmE4YjNhNjhkOTI5YjViNWYzL3RhYmxlcmFuZ2U6MjVlZmJkNWE5ZDhkNGM2YThiM2E2OGQ5MjliNWI1ZjNfMi0zLTEtMS0w_efccb2d6-b872-4cb6-a15b-a562ff5809b6">191,954</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjI1ZWZiZDVhOWQ4ZDRjNmE4YjNhNjhkOTI5YjViNWYzL3RhYmxlcmFuZ2U6MjVlZmJkNWE5ZDhkNGM2YThiM2E2OGQ5MjliNWI1ZjNfMi05LTEtMS0w_a2fb7dc2-4286-475c-9652-e87bb150d831">191,954</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i9737d5fe1a1a4b64a348bd61bcd44e8b_D20210401-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjI1ZWZiZDVhOWQ4ZDRjNmE4YjNhNjhkOTI5YjViNWYzL3RhYmxlcmFuZ2U6MjVlZmJkNWE5ZDhkNGM2YThiM2E2OGQ5MjliNWI1ZjNfMy0xLTEtMS0w_c7669d4c-e0b5-48fe-b2ae-84925cd1cbe5">158,405</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9737d5fe1a1a4b64a348bd61bcd44e8b_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjI1ZWZiZDVhOWQ4ZDRjNmE4YjNhNjhkOTI5YjViNWYzL3RhYmxlcmFuZ2U6MjVlZmJkNWE5ZDhkNGM2YThiM2E2OGQ5MjliNWI1ZjNfMy0zLTEtMS0w_f15af3c3-c051-4948-9785-3ec1b56f9889">484,965</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjI1ZWZiZDVhOWQ4ZDRjNmE4YjNhNjhkOTI5YjViNWYzL3RhYmxlcmFuZ2U6MjVlZmJkNWE5ZDhkNGM2YThiM2E2OGQ5MjliNWI1ZjNfMy05LTEtMS0w_202d18a3-594f-485c-9759-a34bd8b0dc0b">484,965</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i625473b616364e838b15588a276d254c_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjI1ZWZiZDVhOWQ4ZDRjNmE4YjNhNjhkOTI5YjViNWYzL3RhYmxlcmFuZ2U6MjVlZmJkNWE5ZDhkNGM2YThiM2E2OGQ5MjliNWI1ZjNfNC01LTEtMS0w_6ce42412-e3fe-46e8-885f-ca9f524e15de">1,228,560</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4378e699a13493b8e84114b0815eeb1_D20210401-20210630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjI1ZWZiZDVhOWQ4ZDRjNmE4YjNhNjhkOTI5YjViNWYzL3RhYmxlcmFuZ2U6MjVlZmJkNWE5ZDhkNGM2YThiM2E2OGQ5MjliNWI1ZjNfNC03LTEtMS0w_d3034095-4741-4f18-8158-0ab8f17ef52d">5,069</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjI1ZWZiZDVhOWQ4ZDRjNmE4YjNhNjhkOTI5YjViNWYzL3RhYmxlcmFuZ2U6MjVlZmJkNWE5ZDhkNGM2YThiM2E2OGQ5MjliNWI1ZjNfNC05LTEtMS0w_1ee195d7-afa7-4d9b-8c99-6376ac4d999d">1,223,491</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie2772008cf324e93b9ddec0ec4490b6e_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjI1ZWZiZDVhOWQ4ZDRjNmE4YjNhNjhkOTI5YjViNWYzL3RhYmxlcmFuZ2U6MjVlZmJkNWE5ZDhkNGM2YThiM2E2OGQ5MjliNWI1ZjNfNS0xLTEtMS0w_b4d14566-8c4b-4bed-930d-3dcf8562bae2">14,926,059</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2772008cf324e93b9ddec0ec4490b6e_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjI1ZWZiZDVhOWQ4ZDRjNmE4YjNhNjhkOTI5YjViNWYzL3RhYmxlcmFuZ2U6MjVlZmJkNWE5ZDhkNGM2YThiM2E2OGQ5MjliNWI1ZjNfNS0zLTEtMS0w_41be566a-3f40-4262-8ca2-60c6b2c7ec41">48,688,384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8b884d549e1f475999a61e98b2694ba2_I20210630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjI1ZWZiZDVhOWQ4ZDRjNmE4YjNhNjhkOTI5YjViNWYzL3RhYmxlcmFuZ2U6MjVlZmJkNWE5ZDhkNGM2YThiM2E2OGQ5MjliNWI1ZjNfNS01LTEtMS0w_32760054-18bc-41e5-8d47-3276db4df161">735,625</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9809a8bcb7eb490aa76cb00858c80e7c_I20210630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjI1ZWZiZDVhOWQ4ZDRjNmE4YjNhNjhkOTI5YjViNWYzL3RhYmxlcmFuZ2U6MjVlZmJkNWE5ZDhkNGM2YThiM2E2OGQ5MjliNWI1ZjNfNS03LTEtMS0w_e672b0f0-8f27-4af0-9e4a-414224e492ac">144,352</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjI1ZWZiZDVhOWQ4ZDRjNmE4YjNhNjhkOTI5YjViNWYzL3RhYmxlcmFuZ2U6MjVlZmJkNWE5ZDhkNGM2YThiM2E2OGQ5MjliNWI1ZjNfNS05LTEtMS0w_a364857c-93f4-408c-b2b8-522b1f6c34a3">47,808,407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:31.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.757%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:31.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.757%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="30" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">See accompanying Notes to Unaudited Condensed Consolidated Financial Statements.</span></div></td></tr></table></div><div><span><br/></span></div><div style="height:24.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="id0faa06a8909446fa2394f59c1490a03_28"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div id="id0faa06a8909446fa2394f59c1490a03_31"></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1) <ix:nonNumeric contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zMS9mcmFnOjY1MWQ4MjUzMDhmMzRiNGY4Njc2N2U0MjYxMTM1N2YwL3RleHRyZWdpb246NjUxZDgyNTMwOGYzNGI0Zjg2NzY3ZTQyNjExMzU3ZjBfMTAwMjk_f997184d-8ed0-4952-9708-e57b9702b26d" continuedAt="i282bb79c37c147468f9a72d0f5101349" escape="true">ORGANIZATION AND BASIS OF PRESENTATION</ix:nonNumeric></span></div><ix:continuation id="i282bb79c37c147468f9a72d0f5101349" continuedAt="iebc2e909dc4742e7a11434590a68f8e7"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland Pharmaceuticals Inc. (&#8220;Cumberland,&#8221; the &#8220;Company,&#8221; or as used in the context of &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products.  The Company's primary target markets are hospital acute care, gastroenterology and rheumatology. These medical specialties are characterized by relatively concentrated prescriber bases that the Company believes can be penetrated effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve quality of care for patients and address unmet or poorly met medical needs.  The Company promotes its approved products through its hospital and field sales forces in the United States and is establishing a network of international partners to bring its medicines to patients in their countries.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland focuses its resources on maximizing the commercial potential of its products, as well as developing new product candidates, and has both internal development and commercial capabilities. The Company&#8217;s products are manufactured by third parties, which are overseen by Cumberland&#8217;s quality control and manufacturing professionals. The Company works closely with its third-party distribution partners to make its products available in the United States.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, the accompanying unaudited condensed consolidated financial statements of the Company have been prepared on a basis consistent with the December 31, 2020, audited consolidated financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly present the information set forth herein. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements have been prepared in accordance with the regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;), and certain information and disclosures have been condensed or omitted as permitted by the SEC for interim period presentation. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December 31, 2020 (the &#8220;2020 Annual Report on Form 10-K&#8221;). The results of operations for the three and six months ended June 30, 2021, are not necessarily indicative of the results to be expected for the entire fiscal year or any future period.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Discontinued Operations</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed further in Note 9, during May 2019, Cumberland entered into a Dissolution Agreement  ("Dissolution Agreement") with Clinigen Healthcare Limited ("Clinigen") in which the Company returned the exclusive rights to commercialize Ethyol</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Totect</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States to Clinigen. Under the terms of the Dissolution Agreement, Cumberland is no longer involved directly or indirectly with the distribution, marketing and promotion of either Ethyol or Totect or any competing products following December 31, 2019. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's exit from Ethyol and Totect meets the accounting criteria to be reported as discontinued operations and the discontinued operating results have been presented in the financial statements and footnotes to reflect the discontinued status of Ethyol and Totect. Refer to Note 9, for additional information.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revision of prior period condensed consolidated statement of cash flows presentation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has made a revision to prior period amounts to conform to the current year presentation of the cash surrender value of life insurance policies over premiums paid on the condensed consolidated statement of cash flows.  The revised amounts were previously included as net changes in assets affecting operating activities.  These revisions have no net effect on the reported net cash provided by operating activities nor any impact on the reported operating results or balance sheet for the 2020 period presented.  </span></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Pandemic </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the U.S. declared a health care emergency following the outbreak of the SARS-CoV-2, a novel strain of coronavirus that causes COVID-19, a respiratory illness.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has remained open for business, as the Company is considered to be essential by the United States Department of Homeland Security. The Company has implemented measures to address the impact of the novel coronavirus on the business and taken appropriate action to protect its employees, secure the supply chain, and support the patients who can benefit from its medicines.  All of the Company's employees have been given the opportunity to work remotely, and those that wish to work from Cumberland's office and laboratories are encouraged to practice the behaviors outlined by the Centers for Disease Control.  </span></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><ix:continuation id="iebc2e909dc4742e7a11434590a68f8e7" continuedAt="ib5c4759b5a054ef19c923acfc2a35e75"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout the pandemic, Cumberland has faced the same headwinds affecting other companies that rely on hospital admissions and patient visits to drive revenue.  Our business and our clinical studies were impacted as less patients sought elective surgeries and our access to medical facilities was substantially limited.  During 2020 and 2021, we carefully monitored our supply chain during the pandemic including the flow of raw materials into the plants that manufacture our products as well as the batches of finished product emerging from those facilities. Several of our brands were negatively impacted by the lockdowns and postponement of physician office visits and elective procedures. However, we are fortunate to have a diversified product portfolio, with other brands delivering a strong performance.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland relies on third-party organizations around the world to supply components, manufacture and distribute its products. The Company is aware that it may experience revenue loss, supply interruptions, time delays and incur unplanned expenses as a result of the impact of the ongoing COVID-19 pandemic.   The Company continues to monitor the COVID-19 pandemic situation both in the U.S. and internationally in order to maintain its employees&#8217; safety and well-being, while also keeping its business operating.  Given the uncertainty, magnitude and impact of such changes, the Company is unable to quantify the impact on the future results as of the date of this filing.</span></div><ix:nonNumeric contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zMS9mcmFnOjY1MWQ4MjUzMDhmMzRiNGY4Njc2N2U0MjYxMTM1N2YwL3RleHRyZWdpb246NjUxZDgyNTMwOGYzNGI0Zjg2NzY3ZTQyNjExMzU3ZjBfMTAwMzI_1d494f0f-a948-4e60-b352-faa6463f2879" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Guidance</span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements - Not Yet Adopted</span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board ("FASB") issued ASU No. 2016-13, &#8220;Financial Instruments-Credit Losses,&#8221; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#8220;expected loss&#8221; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose additional information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the ASU&#8217;s provisions as a cumulative-effect adjustment, if any, to retained earnings as of the beginning of the first reporting period in which the guidance is adopted.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related to ASU No. 2016-13 discussed above, in May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably elect the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met and the election must be applied on an instrument-by-instrument basis. The election is not available for either available-for-sale or held-to-maturity debt securities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will adopt both ASU 2016-13 and ASU 2019-05 on January 1, 2023. The adoption of ASU 2016-13 and ASU 2019-05 are not expected to have a material impact on the Company&#8217;s consolidated financial statements.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Policies:</span></div><ix:nonNumeric contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zMS9mcmFnOjY1MWQ4MjUzMDhmMzRiNGY4Njc2N2U0MjYxMTM1N2YwL3RleHRyZWdpb246NjUxZDgyNTMwOGYzNGI0Zjg2NzY3ZTQyNjExMzU3ZjBfMTAwMjU_2a30d72e-1f6b-4ae1-b899-96926ec8aca0" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Use of Estimates</span></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates under different assumptions and conditions.  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns, (2) the allowances for obsolescent or unmarketable inventory and (3) valuation of a contingent consideration liability associated with a business combination.</span></div></ix:nonNumeric><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zMS9mcmFnOjY1MWQ4MjUzMDhmMzRiNGY4Njc2N2U0MjYxMTM1N2YwL3RleHRyZWdpb246NjUxZDgyNTMwOGYzNGI0Zjg2NzY3ZTQyNjExMzU3ZjBfMTAwMjg_e7d7cf66-94c8-4929-af5c-2534db8c10fc" continuedAt="if109c376246b4de392900264b45a5879" escape="true">Operating Segments</ix:nonNumeric></span></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib5c4759b5a054ef19c923acfc2a35e75"><ix:continuation id="if109c376246b4de392900264b45a5879">The Company has <ix:nonFraction unitRef="segment" contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zMS9mcmFnOjY1MWQ4MjUzMDhmMzRiNGY4Njc2N2U0MjYxMTM1N2YwL3RleHRyZWdpb246NjUxZDgyNTMwOGYzNGI0Zjg2NzY3ZTQyNjExMzU3ZjBfOTIxOQ_1cfac7b6-9dc8-4721-b576-99c71896f153">one</ix:nonFraction> operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#8217;s assets are located in the United States and total revenues are primarily attributable to U.S.&#160;customers.</ix:continuation></ix:continuation> </span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="id0faa06a8909446fa2394f59c1490a03_34"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(2) <ix:nonNumeric contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RleHRyZWdpb246Yzg3MDM5YjJjZDE2NGFhMDhhNDYxMjg1MDI2YjIyMDZfNDE1_b0e1a26a-86b0-4a53-9bc6-12f8b07b95ac" continuedAt="i46f864346af6453f8c3f4b1011f659be" escape="true">EARNINGS (LOSS) PER SHARE</ix:nonNumeric></span></div><ix:continuation id="i46f864346af6453f8c3f4b1011f659be"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RleHRyZWdpb246Yzg3MDM5YjJjZDE2NGFhMDhhNDYxMjg1MDI2YjIyMDZfNDE4_ce674444-875f-4353-bd10-25290019cffc" continuedAt="ice0eae757c544111a1b63ba6b1c30734" escape="true">The following table reconciles the numerator and denominator used to calculate diluted earnings (loss) per share for the three and six months ended June 30, 2021 and 2020:</ix:nonNumeric></span></div><div style="text-align:justify"><ix:continuation id="ice0eae757c544111a1b63ba6b1c30734"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RhYmxlOjM5Y2E3ZWIwOTM4YTQ1ZjFhNjkxNzgzYWQyOTI0YzFiL3RhYmxlcmFuZ2U6MzljYTdlYjA5MzhhNDVmMWE2OTE3ODNhZDI5MjRjMWJfMy0xLTEtMS0w_761328f0-deef-47f7-9f51-604c18a2e233">724,684</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RhYmxlOjM5Y2E3ZWIwOTM4YTQ1ZjFhNjkxNzgzYWQyOTI0YzFiL3RhYmxlcmFuZ2U6MzljYTdlYjA5MzhhNDVmMWE2OTE3ODNhZDI5MjRjMWJfMy0zLTEtMS0w_d81f4724-54a3-4bf0-afb3-205bc093c40b">1,679,211</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0932967c9c90454494cbf245d9fa585d_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RhYmxlOjM5Y2E3ZWIwOTM4YTQ1ZjFhNjkxNzgzYWQyOTI0YzFiL3RhYmxlcmFuZ2U6MzljYTdlYjA5MzhhNDVmMWE2OTE3ODNhZDI5MjRjMWJfNC0xLTEtMS0w_33139f42-0425-4d08-841a-9ae006c66914">498,807</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffc2a4291a32445fb79072f7fe43a870_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RhYmxlOjM5Y2E3ZWIwOTM4YTQ1ZjFhNjkxNzgzYWQyOTI0YzFiL3RhYmxlcmFuZ2U6MzljYTdlYjA5MzhhNDVmMWE2OTE3ODNhZDI5MjRjMWJfNC0zLTEtMS0w_cf0ce557-4fdd-47c1-9191-c917bd799f4a">738,622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RhYmxlOjM5Y2E3ZWIwOTM4YTQ1ZjFhNjkxNzgzYWQyOTI0YzFiL3RhYmxlcmFuZ2U6MzljYTdlYjA5MzhhNDVmMWE2OTE3ODNhZDI5MjRjMWJfNS0xLTEtMS0w_1cf241d4-6bf5-4bad-bea5-208a40f95dc7">1,223,491</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RhYmxlOjM5Y2E3ZWIwOTM4YTQ1ZjFhNjkxNzgzYWQyOTI0YzFiL3RhYmxlcmFuZ2U6MzljYTdlYjA5MzhhNDVmMWE2OTE3ODNhZDI5MjRjMWJfNS0zLTEtMS0w_f7a6eeb6-48b4-480a-b905-3cdff1cdd39b">940,589</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (income) loss at subsidiary attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RhYmxlOjM5Y2E3ZWIwOTM4YTQ1ZjFhNjkxNzgzYWQyOTI0YzFiL3RhYmxlcmFuZ2U6MzljYTdlYjA5MzhhNDVmMWE2OTE3ODNhZDI5MjRjMWJfNi0xLTEtMS0w_ad9cdbb0-35e4-4783-875f-a33b803b750c">5,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RhYmxlOjM5Y2E3ZWIwOTM4YTQ1ZjFhNjkxNzgzYWQyOTI0YzFiL3RhYmxlcmFuZ2U6MzljYTdlYjA5MzhhNDVmMWE2OTE3ODNhZDI5MjRjMWJfNi0zLTEtMS0w_47af32b2-36dc-48d1-ae83-7216b2cc2889">22,314</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RhYmxlOjM5Y2E3ZWIwOTM4YTQ1ZjFhNjkxNzgzYWQyOTI0YzFiL3RhYmxlcmFuZ2U6MzljYTdlYjA5MzhhNDVmMWE2OTE3ODNhZDI5MjRjMWJfNy0xLTEtMS0w_b8dfc5cf-c6a5-4f7c-9c61-6a80b153a842">1,228,560</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RhYmxlOjM5Y2E3ZWIwOTM4YTQ1ZjFhNjkxNzgzYWQyOTI0YzFiL3RhYmxlcmFuZ2U6MzljYTdlYjA5MzhhNDVmMWE2OTE3ODNhZDI5MjRjMWJfNy0zLTEtMS0w_334f259a-7999-4f1a-857c-595692c065d0">918,275</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; basic</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RhYmxlOjM5Y2E3ZWIwOTM4YTQ1ZjFhNjkxNzgzYWQyOTI0YzFiL3RhYmxlcmFuZ2U6MzljYTdlYjA5MzhhNDVmMWE2OTE3ODNhZDI5MjRjMWJfOS0xLTEtMS0w_c2df2a85-063d-4e72-8cc0-f113580e1ac4">14,976,034</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RhYmxlOjM5Y2E3ZWIwOTM4YTQ1ZjFhNjkxNzgzYWQyOTI0YzFiL3RhYmxlcmFuZ2U6MzljYTdlYjA5MzhhNDVmMWE2OTE3ODNhZDI5MjRjMWJfOS0zLTEtMS0w_3df73b08-d9bc-4067-b6c3-56fa9ffd698a">15,241,463</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of other securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RhYmxlOjM5Y2E3ZWIwOTM4YTQ1ZjFhNjkxNzgzYWQyOTI0YzFiL3RhYmxlcmFuZ2U6MzljYTdlYjA5MzhhNDVmMWE2OTE3ODNhZDI5MjRjMWJfMTAtMS0xLTEtMA_7cff8ac9-0ed5-4b11-8e7a-cea2ff1c999d">133,212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630" decimals="0" format="ixt:zerodash" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RhYmxlOjM5Y2E3ZWIwOTM4YTQ1ZjFhNjkxNzgzYWQyOTI0YzFiL3RhYmxlcmFuZ2U6MzljYTdlYjA5MzhhNDVmMWE2OTE3ODNhZDI5MjRjMWJfMTAtMy0xLTEtMA_9446fe7b-8c2e-4b10-932d-d37ebd418003">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; diluted</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RhYmxlOjM5Y2E3ZWIwOTM4YTQ1ZjFhNjkxNzgzYWQyOTI0YzFiL3RhYmxlcmFuZ2U6MzljYTdlYjA5MzhhNDVmMWE2OTE3ODNhZDI5MjRjMWJfMTEtMS0xLTEtMA_2cc9f5cb-2fc2-45a0-a213-fabe436ff549">15,109,246</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RhYmxlOjM5Y2E3ZWIwOTM4YTQ1ZjFhNjkxNzgzYWQyOTI0YzFiL3RhYmxlcmFuZ2U6MzljYTdlYjA5MzhhNDVmMWE2OTE3ODNhZDI5MjRjMWJfMTEtMy0xLTEtMA_64d8a77f-6e7d-4077-8194-074fafdb8a68">15,241,463</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:58.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.518%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RhYmxlOmMyMzhjNTkyMThkMzQ4NTQ5M2ZlOTU5ZDY2MWNiNjg1L3RhYmxlcmFuZ2U6YzIzOGM1OTIxOGQzNDg1NDkzZmU5NTlkNjYxY2I2ODVfNC0xLTEtMS0w_a63db8bb-8ef8-4664-9c16-a1c90b7c2460">373,935</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RhYmxlOmMyMzhjNTkyMThkMzQ4NTQ5M2ZlOTU5ZDY2MWNiNjg1L3RhYmxlcmFuZ2U6YzIzOGM1OTIxOGQzNDg1NDkzZmU5NTlkNjYxY2I2ODVfNC0zLTEtMS0w_edf48b93-5a80-48fd-b726-5a6b729875c2">3,562,629</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53d85ca5dcbd44ba870830f97461a800_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RhYmxlOmMyMzhjNTkyMThkMzQ4NTQ5M2ZlOTU5ZDY2MWNiNjg1L3RhYmxlcmFuZ2U6YzIzOGM1OTIxOGQzNDg1NDkzZmU5NTlkNjYxY2I2ODVfNS0xLTEtMS0w_1bcf2509-7467-4c5c-b800-3d442a6bcef9">994,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i166678b245754127b39f5e9c73e8cf2d_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RhYmxlOmMyMzhjNTkyMThkMzQ4NTQ5M2ZlOTU5ZDY2MWNiNjg1L3RhYmxlcmFuZ2U6YzIzOGM1OTIxOGQzNDg1NDkzZmU5NTlkNjYxY2I2ODVfNS0zLTEtMS0w_72de53a1-48b1-4c79-aa3d-faa22b8da99b">1,556,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RhYmxlOmMyMzhjNTkyMThkMzQ4NTQ5M2ZlOTU5ZDY2MWNiNjg1L3RhYmxlcmFuZ2U6YzIzOGM1OTIxOGQzNDg1NDkzZmU5NTlkNjYxY2I2ODVfNi0xLTEtMS0xOTEw_6aa1b4ee-aaf7-4bfd-bd7a-dcff090035e3">1,368,152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RhYmxlOmMyMzhjNTkyMThkMzQ4NTQ5M2ZlOTU5ZDY2MWNiNjg1L3RhYmxlcmFuZ2U6YzIzOGM1OTIxOGQzNDg1NDkzZmU5NTlkNjYxY2I2ODVfNi0zLTEtMS0xOTEw_86ca889e-63e3-4465-be34-caf967ed5d0e">2,005,734</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) at subsidiary attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RhYmxlOmMyMzhjNTkyMThkMzQ4NTQ5M2ZlOTU5ZDY2MWNiNjg1L3RhYmxlcmFuZ2U6YzIzOGM1OTIxOGQzNDg1NDkzZmU5NTlkNjYxY2I2ODVfNi0xLTEtMS0w_3132eb79-3ac2-46ef-b108-4ed939312a07">27,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RhYmxlOmMyMzhjNTkyMThkMzQ4NTQ5M2ZlOTU5ZDY2MWNiNjg1L3RhYmxlcmFuZ2U6YzIzOGM1OTIxOGQzNDg1NDkzZmU5NTlkNjYxY2I2ODVfNi0zLTEtMS0w_16452e5d-8d67-4eab-b11e-724dc4efa96b">31,839</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RhYmxlOmMyMzhjNTkyMThkMzQ4NTQ5M2ZlOTU5ZDY2MWNiNjg1L3RhYmxlcmFuZ2U6YzIzOGM1OTIxOGQzNDg1NDkzZmU5NTlkNjYxY2I2ODVfNy0xLTEtMS0w_c4f19629-5882-4929-89aa-d989770a2c78">1,395,388</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RhYmxlOmMyMzhjNTkyMThkMzQ4NTQ5M2ZlOTU5ZDY2MWNiNjg1L3RhYmxlcmFuZ2U6YzIzOGM1OTIxOGQzNDg1NDkzZmU5NTlkNjYxY2I2ODVfNy0zLTEtMS0w_461cc6b8-bca3-4299-be42-5d55162be78f">1,973,895</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; basic</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RhYmxlOmMyMzhjNTkyMThkMzQ4NTQ5M2ZlOTU5ZDY2MWNiNjg1L3RhYmxlcmFuZ2U6YzIzOGM1OTIxOGQzNDg1NDkzZmU5NTlkNjYxY2I2ODVfOS0xLTEtMS0w_90bf369c-59f5-475e-bb5e-dc29a315c526">14,970,241</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RhYmxlOmMyMzhjNTkyMThkMzQ4NTQ5M2ZlOTU5ZDY2MWNiNjg1L3RhYmxlcmFuZ2U6YzIzOGM1OTIxOGQzNDg1NDkzZmU5NTlkNjYxY2I2ODVfOS0zLTEtMS0w_34d5a1e5-220b-41a6-8215-a9b0c1b42040">15,241,020</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of other securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RhYmxlOmMyMzhjNTkyMThkMzQ4NTQ5M2ZlOTU5ZDY2MWNiNjg1L3RhYmxlcmFuZ2U6YzIzOGM1OTIxOGQzNDg1NDkzZmU5NTlkNjYxY2I2ODVfMTAtMS0xLTEtMA_0166a493-6c22-41f5-a106-006b3518215a">201,348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630" decimals="0" format="ixt:zerodash" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RhYmxlOmMyMzhjNTkyMThkMzQ4NTQ5M2ZlOTU5ZDY2MWNiNjg1L3RhYmxlcmFuZ2U6YzIzOGM1OTIxOGQzNDg1NDkzZmU5NTlkNjYxY2I2ODVfMTAtMy0xLTEtMA_678521a4-269b-4b08-b750-3d06bd336ba4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; diluted</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RhYmxlOmMyMzhjNTkyMThkMzQ4NTQ5M2ZlOTU5ZDY2MWNiNjg1L3RhYmxlcmFuZ2U6YzIzOGM1OTIxOGQzNDg1NDkzZmU5NTlkNjYxY2I2ODVfMTEtMS0xLTEtMA_c14f7212-bbfa-4857-84b0-5aa8c727c9ef">15,171,589</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RhYmxlOmMyMzhjNTkyMThkMzQ4NTQ5M2ZlOTU5ZDY2MWNiNjg1L3RhYmxlcmFuZ2U6YzIzOGM1OTIxOGQzNDg1NDkzZmU5NTlkNjYxY2I2ODVfMTEtMy0xLTEtMA_65f2f002-432e-4d27-b6d3-2268b01e4d04">15,241,020</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021 and 2020, restricted stock awards and options to purchase <ix:nonFraction unitRef="shares" contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RleHRyZWdpb246Yzg3MDM5YjJjZDE2NGFhMDhhNDYxMjg1MDI2YjIyMDZfMjM4_ca9751be-b0ee-4ce2-9cf0-0899b1802915">198,300</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RleHRyZWdpb246Yzg3MDM5YjJjZDE2NGFhMDhhNDYxMjg1MDI2YjIyMDZfMjQ1_9c9feaa0-7ef4-48ab-b20a-df0c15335590">13,500</ix:nonFraction> shares of common stock, respectively, were outstanding but were not included in the computation of diluted earnings per share because the effect would be antidilutive.</span></div></ix:continuation><div id="id0faa06a8909446fa2394f59c1490a03_37"></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(3) <ix:nonNumeric contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RleHRyZWdpb246NTEwNDc5MDRkNjM5NDZkMDhhNjJmMTU5OTUyNmVhMTBfMjU2NQ_0f07d3cc-6496-41eb-8b5d-e4b28ad9a2dd" continuedAt="if416ecc7fa5e4057a0e4b9c6dc1dd226" escape="true">REVENUES</ix:nonNumeric></span></div><ix:continuation id="if416ecc7fa5e4057a0e4b9c6dc1dd226" continuedAt="i7f09aa165d1b4b3e9a791f3b0c96b6f2"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Revenues</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for revenues from contracts with customers under ASC 606, which became effective January 1, 2018. </span></div><div style="margin-top:8pt;text-align:justify"><ix:nonNumeric contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RleHRyZWdpb246NTEwNDc5MDRkNjM5NDZkMDhhNjJmMTU5OTUyNmVhMTBfMjU2Ng_da483623-8a1f-47d8-ab43-e6644e364301" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s net revenues consisted of the following for the three and six months ended June 30, 2021 and 2020:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristalose</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5edd42c5f134552b215b0303905dc64_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfMy0xLTEtMS0w_0edb5017-f321-40d0-ab64-886ee654563b">5,275,065</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf76e1a947e34b99bf20371f1394bc94_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfMy0zLTEtMS0w_ea09c2ad-ac24-4841-a454-e342c765fcea">3,477,471</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b7593836c514ab7ae6235e51053a4d3_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfMy01LTEtMS0w_67d7ff69-71cc-42c4-a565-308d376ee726">8,269,443</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i165e5c5a2d664922aea782b5ec2beaa1_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfMy03LTEtMS0w_d7da85d3-2eaf-4da3-b76b-5002a9cdde5d">6,771,433</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifad013eb9e344ea389599dff33e69ac5_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfNC0xLTEtMS0w_63ff5608-d229-4f94-ba7f-c1cfed41d2a0">1,844,936</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb72b6c62fb3497caec435b11f56df5b_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfNC0zLTEtMS0w_022d405d-1685-4a94-a749-a335c7fe209a">3,299,507</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie99d1326bbe74354aa379ee065b7c800_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfNC01LTEtMS0w_5e729359-cf7c-44fa-bc9c-353f131687ac">6,897,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if75eedbbeb5a4ee7b41a92f8a8b0fb07_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfNC03LTEtMS0w_d6be61cd-17aa-499c-ad48-852288e7bde5">5,721,708</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9e93a7211e0479a81c8bd344131c4e7_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfNS0xLTEtMS0w_6bad5f86-2c6c-42f4-a92e-a03e77b21888">938,328</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76b0812334e5493ba0a8152f3015bf4a_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfNS0zLTEtMS0w_e3d3c205-690e-4462-88ba-c5a4370ef53c">1,166,569</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabe2fb0732864cfb86e1ccecbb610f34_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfNS01LTEtMS0w_b6111921-6cfc-4576-88c1-9892cbdd3d84">2,477,824</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857d42211e8846b8ae37d954dc44d6a5_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfNS03LTEtMS0w_c5fd03ca-36d6-46aa-8819-a445d6cb40e5">2,261,286</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaprisol</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8bb9cad97f943fca7a044ed530e9867_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfNi0xLTEtMS0xNjI5_ec1e972a-4ca3-4bad-a00b-c3154e0a998d">399,952</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2de112b4b874426a53bf6ed84e287a5_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfNi0zLTEtMS0xNjI5_092f5490-34c4-4ded-bb2f-cacec2dac859">174,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54cb558d5ce44437ad69a746dc9c0d82_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfNi01LTEtMS0xNjI5_f29d3cf5-d215-46cc-943c-9dab0d997aeb">1,534,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2dc8e2802e642b5b94cadd517394321_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfNi03LTEtMS0xNjI5_d4b1e529-87b8-4394-8823-69ac9d8a34f1">382,016</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acetadote</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e418762fd0d400aa38934d9baef2d1f_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfNi0xLTEtMS0w_eb2e6dc7-5485-4f3c-91e4-310483a913f5">152,781</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief1b47cbad4647fdb4c761fccef2aa59_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfNi0zLTEtMS0w_576280e5-6943-4343-8c9f-2734feca9c59">595,310</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9fecc8c7c5546288fd7851d2d94e26c_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfNi01LTEtMS0w_9c40ec14-05ae-4ac4-9a92-cf70ad5df573">269,972</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic88623cc09cd42dfa613a0b3710040a3_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfNi03LTEtMS0w_d05304ab-654a-4c3b-ad9c-0a359768c1ce">1,308,711</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Omeclamox-Pak</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibaa9e52c4cd5496c898ae44c5f71a2f6_D20210401-20210630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfNy0xLTEtMS0w_e5d867ad-489f-45bc-ae33-6e8fce793b17">24,109</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if58606b340b94db39d3ecaa02a4573ed_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfNy0zLTEtMS0w_c44228fd-e1a8-431e-b015-7ff9fd4e2a51">10,948</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16a80924d1204bd0b90b95ff2356a104_D20210101-20210630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfNy01LTEtMS0w_cd2ff1c6-9fe5-4e90-81c2-85dcfc7361a2">474,371</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic02c2f75924e441689c5ffc79ba729b8_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfNy03LTEtMS0w_7c8c2cc3-b0a3-4351-bd81-ac3e33a2af95">124,371</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RediTrex</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca6a00e3fc6401ab98a098751461284_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfOS0xLTEtMS0w_e0f19739-1e72-4e9e-8127-041ecee527d5">7,382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2c40ebe0b7f44769ff470354a3fe426_D20200401-20200630" decimals="0" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfOS0zLTEtMS0w_815d6a56-f553-4c47-91a2-578243e5fc0f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb0eee768e294f599281385f4a3835f6_D20210101-20210630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfOS01LTEtMS00MDM_ecaf8c8e-b5ef-42f6-9cb8-6dccc1a20c67">24,870</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6095f924cf50491b815b0dfba23349fd_D20200101-20200630" decimals="0" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfOS03LTEtMS00MDk_2828e277-3674-45e9-9f20-45200e60e9bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb0ee00056ff487ca51af9d696aa113b_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfMTAtMS0xLTEtMA_4edf9b34-5201-4759-bf5d-9a43aa793f78">461,148</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c43803cc80549529c2ba24144989e73_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfMTAtMy0xLTEtMA_dc972368-5ea2-4f21-97d8-fdab556fd21f">874,213</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic93c6aab3bcf4cda8e32399f9d56970e_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfMTAtNS0xLTEtMA_e316daa1-74d0-4e15-ac5a-3b48acd7ddb3">643,249</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice06f3366d2249119a9109b31bb8f7d2_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfMTAtNy0xLTEtMA_9ded4987-d4c4-4878-b8de-6a956de9c3fa">1,359,386</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfMTEtMS0xLTEtMA_9bf99773-3e3e-4aa9-b4c5-26ed00af32f2">9,055,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfMTEtMy0xLTEtMA_7fd6bd5e-76a9-40c1-8ee0-574e20ed2c43">9,598,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfMTEtNS0xLTEtMA_3497de80-568a-4545-b64f-6fa67ca9cfe8">19,592,642</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfMTEtNy0xLTEtMA_a3de6319-3953-49e8-9cb8-174973c31f68">17,928,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Omeclamox-Pak revenue for the first and second quarter of 2021 was the result of Cumberland currently being out of commercial inventory of this product.  The packager for our Omeclamox-Pak product encountered financial difficulties due to the impact of COVID-19.  They are under new management and are in the process of a reorganization. Discussions with the packager are ongoing.  Net revenue was also negatively impacted by product returns during the periods. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Revenues</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has agreements with international partners for commercialization of the Company's products with associated payments included in other revenues. Those agreements provide that each of the partners are responsible for seeking regulatory approvals for the product, and following approval, each partner will be responsible for the ongoing distribution and sales in the respective international territories. The Company provides a dossier for product registration and maintains responsibility for the relevant intellectual property. Cumberland is typically entitled to receive a non-refundable, up-front payment at the time each agreement is executed as consideration for the product dossier and for the rights to the distinct intellectual property rights in the respective international territory. These agreements also typically provide for additional payments upon a partner&#8217;s achievement of a defined regulatory approval and sales milestones. The Company may also be entitled to receive royalties on future sales of the products and a transfer price on supplies.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual payments associated with the partner&#8217;s achievement of regulatory approvals, sales milestones and royalties on future sales are recognized as revenue upon occurrence, or at such time that the Company has a high degree of confidence that the revenue would not be reversed in a subsequent period.</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7f09aa165d1b4b3e9a791f3b0c96b6f2">Other revenues also include funding from federal grant programs including those secured by CET through the Small Business Administration as well as lease income generated by CET&#8217;s Life Sciences Center. The Life Sciences Center is a research center that provides scientists with access to flexible lab space and other resources to develop biomedical products. Grant revenue from these programs totaled approximately $<ix:nonFraction unitRef="usd" contextRef="i6172287cab0745339de538f8ae5b507b_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RleHRyZWdpb246NTEwNDc5MDRkNjM5NDZkMDhhNjJmMTU5OTUyNmVhMTBfMjUwMw_8e1501bc-ba94-497c-bc51-ea3af6d8ecbd">0.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i15931d26dd6041dfa28287b72ffd540a_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RleHRyZWdpb246NTEwNDc5MDRkNjM5NDZkMDhhNjJmMTU5OTUyNmVhMTBfMjUxMA_d1acc996-5fb5-4ff3-b49f-d409563cf8cd">0.5</ix:nonFraction> million for the three months ended June 30, 2021 and 2020</ix:continuation>, respectively.</span></div><div id="id0faa06a8909446fa2394f59c1490a03_40"></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(4) <ix:nonNumeric contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180MC9mcmFnOjk4M2EzMDk1MjI5ZTQwYzQ4M2Q4MjUyMjMwMDdlNzA5L3RleHRyZWdpb246OTgzYTMwOTUyMjllNDBjNDgzZDgyNTIyMzAwN2U3MDlfMjI0Mw_f0af525f-b17f-4290-a0f0-64c2413b6708" continuedAt="i9ffcd98130ab41bd85bf934b3d33c001" escape="true">INVENTORIES</ix:nonNumeric></span></div><ix:continuation id="i9ffcd98130ab41bd85bf934b3d33c001" continuedAt="ibaa75fde29f94370bf891bdd65dc176e"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company works closely with third parties to manufacture and package finished goods for sale.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the arrangements with the manufacturer or packager, the Company will either take title to the finished goods at the time of shipment or at the time of arrival at the Company&#8217;s warehouses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company then holds such goods in inventory until distribution and sale. These finished goods inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually evaluates inventory for potential losses due to excess, obsolete or slow-moving goods by comparing sales history and projections to the inventory on hand. When evidence indicates that the carrying value may not be recoverable, a charge is taken to reduce the inventory to its current net realizable value.  At June 30, 2021 and December 31, 2020, the </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><ix:continuation id="ibaa75fde29f94370bf891bdd65dc176e"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company had recognized and maintained cumulative net realizable value charges for potential obsolescence and discontinuance losses of approximately $<ix:nonFraction unitRef="usd" contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryValuationReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180MC9mcmFnOjk4M2EzMDk1MjI5ZTQwYzQ4M2Q4MjUyMjMwMDdlNzA5L3RleHRyZWdpb246OTgzYTMwOTUyMjllNDBjNDgzZDgyNTIyMzAwN2U3MDlfMTAzOA_f4c7b9ae-163b-4cbc-8c0c-ee24275cdc57">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryValuationReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180MC9mcmFnOjk4M2EzMDk1MjI5ZTQwYzQ4M2Q4MjUyMjMwMDdlNzA5L3RleHRyZWdpb246OTgzYTMwOTUyMjllNDBjNDgzZDgyNTIyMzAwN2U3MDlfMTA0NQ_a7b05c43-fa7a-4473-8072-de3f04e667e7">0.2</ix:nonFraction> million, respectively.  </span></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is responsible for the purchase of the active pharmaceutical ingredient (&#8220;API&#8221;) for Kristalose and maintains the inventory at third-party packagers. As that API is consumed in production, the value of the API is transferred from raw materials to finished goods.  API for the Company's Vaprisol brand is also included in the raw materials inventory at June 30, 2021 and December 31, 2020.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consigned inventory represents Authorized Generic inventory stored with Perrigo until shipment.   </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Vibativ acquisition, Cumberland acquired API and work in process inventories of $<ix:nonFraction unitRef="usd" contextRef="i6742997b2ea4497a8b57f546e21e37aa_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180MC9mcmFnOjk4M2EzMDk1MjI5ZTQwYzQ4M2Q4MjUyMjMwMDdlNzA5L3RleHRyZWdpb246OTgzYTMwOTUyMjllNDBjNDgzZDgyNTIyMzAwN2U3MDlfMTcyOA_d44273dd-74ad-48bc-b686-287d752fe32a">15.6</ix:nonFraction> million that were all initially classified as non-current inventories at the date of acquisition.  At June 30, 2021 and December 31, 2020, total non-current inventory, including Vibativ and ifetroban, was $<ix:nonFraction unitRef="usd" contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180MC9mcmFnOjk4M2EzMDk1MjI5ZTQwYzQ4M2Q4MjUyMjMwMDdlNzA5L3RleHRyZWdpb246OTgzYTMwOTUyMjllNDBjNDgzZDgyNTIyMzAwN2U3MDlfMTkwMg_12b171a1-ae21-4162-8668-207fde0d6c92">9.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180MC9mcmFnOjk4M2EzMDk1MjI5ZTQwYzQ4M2Q4MjUyMjMwMDdlNzA5L3RleHRyZWdpb246OTgzYTMwOTUyMjllNDBjNDgzZDgyNTIyMzAwN2U3MDlfMTkwOQ_8ff38ed3-53f7-40a5-aced-0e8dc95a9c4b">11.7</ix:nonFraction>&#160;million, respectively. The Company had $<ix:nonFraction unitRef="usd" contextRef="ifaa5fd674df1464290cfa2809fea1eaf_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoods" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180MC9mcmFnOjk4M2EzMDk1MjI5ZTQwYzQ4M2Q4MjUyMjMwMDdlNzA5L3RleHRyZWdpb246OTgzYTMwOTUyMjllNDBjNDgzZDgyNTIyMzAwN2U3MDlfMTk0Mw_4875a249-9c02-42ff-8cf6-d5bbcd598ba8">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6742997b2ea4497a8b57f546e21e37aa_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoods" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180MC9mcmFnOjk4M2EzMDk1MjI5ZTQwYzQ4M2Q4MjUyMjMwMDdlNzA5L3RleHRyZWdpb246OTgzYTMwOTUyMjllNDBjNDgzZDgyNTIyMzAwN2U3MDlfMTk1MA_9871b433-1a29-4abd-ab43-4c8c11147484">2.1</ix:nonFraction> million of Vibativ finished goods included in non-current inventory at June 30, 2021 and December 31, 2020, respectively.  The Company also has obtained $<ix:nonFraction unitRef="usd" contextRef="i339d4531f62d4de7929176842fce1307_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180MC9mcmFnOjk4M2EzMDk1MjI5ZTQwYzQ4M2Q4MjUyMjMwMDdlNzA5L3RleHRyZWdpb246OTgzYTMwOTUyMjllNDBjNDgzZDgyNTIyMzAwN2U3MDlfMjA1OA_3e8e1c70-40c3-4cec-8037-1079a3621250"><ix:nonFraction unitRef="usd" contextRef="ic8de84d46a4b4f1288caecd9e279f91c_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180MC9mcmFnOjk4M2EzMDk1MjI5ZTQwYzQ4M2Q4MjUyMjMwMDdlNzA5L3RleHRyZWdpb246OTgzYTMwOTUyMjllNDBjNDgzZDgyNTIyMzAwN2U3MDlfMjA1OA_89f3981c-2f7d-48ce-ba1e-49e91b94f38a">0.4</ix:nonFraction></ix:nonFraction>&#160;million of finished goods in non-current inventory for API related to its ifetroban clinical initiatives at June 30, 2021 and December 31, 2020. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><ix:nonNumeric contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180MC9mcmFnOjk4M2EzMDk1MjI5ZTQwYzQ4M2Q4MjUyMjMwMDdlNzA5L3RleHRyZWdpb246OTgzYTMwOTUyMjllNDBjNDgzZDgyNTIyMzAwN2U3MDlfMjI0Ng_f2edaa20-b3bf-407e-a5b4-b01fa55e4a97" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June 30, 2021 and December 31, 2020 the Company's net inventories consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:57.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.681%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and work in process</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180MC9mcmFnOjk4M2EzMDk1MjI5ZTQwYzQ4M2Q4MjUyMjMwMDdlNzA5L3RhYmxlOmNiYjI2M2FjMjIwYzRkMGI5ZmNlZDc0ODQ1YTA0OTc1L3RhYmxlcmFuZ2U6Y2JiMjYzYWMyMjBjNGQwYjlmY2VkNzQ4NDVhMDQ5NzVfMi0yLTEtMS0w_e599f474-e5c9-41ab-84a0-5c689d88ae6c">14,156,248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180MC9mcmFnOjk4M2EzMDk1MjI5ZTQwYzQ4M2Q4MjUyMjMwMDdlNzA5L3RhYmxlOmNiYjI2M2FjMjIwYzRkMGI5ZmNlZDc0ODQ1YTA0OTc1L3RhYmxlcmFuZ2U6Y2JiMjYzYWMyMjBjNGQwYjlmY2VkNzQ4NDVhMDQ5NzVfMi00LTEtMS0w_21ecfeaa-7eca-4ddc-93c1-f1a23a13e93d"><ix:nonFraction unitRef="usd" contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180MC9mcmFnOjk4M2EzMDk1MjI5ZTQwYzQ4M2Q4MjUyMjMwMDdlNzA5L3RhYmxlOmNiYjI2M2FjMjIwYzRkMGI5ZmNlZDc0ODQ1YTA0OTc1L3RhYmxlcmFuZ2U6Y2JiMjYzYWMyMjBjNGQwYjlmY2VkNzQ4NDVhMDQ5NzVfMi00LTEtMS0w_7fa538f3-b811-4ab9-a876-03f910965528">16,223,162</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consigned inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180MC9mcmFnOjk4M2EzMDk1MjI5ZTQwYzQ4M2Q4MjUyMjMwMDdlNzA5L3RhYmxlOmNiYjI2M2FjMjIwYzRkMGI5ZmNlZDc0ODQ1YTA0OTc1L3RhYmxlcmFuZ2U6Y2JiMjYzYWMyMjBjNGQwYjlmY2VkNzQ4NDVhMDQ5NzVfMy0yLTEtMS0w_5734324b-528f-4597-a664-5249f3f7631e">189,141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180MC9mcmFnOjk4M2EzMDk1MjI5ZTQwYzQ4M2Q4MjUyMjMwMDdlNzA5L3RhYmxlOmNiYjI2M2FjMjIwYzRkMGI5ZmNlZDc0ODQ1YTA0OTc1L3RhYmxlcmFuZ2U6Y2JiMjYzYWMyMjBjNGQwYjlmY2VkNzQ4NDVhMDQ5NzVfMy00LTEtMS0w_1d022e68-1567-4fe8-8b21-fcf571a5d758"><ix:nonFraction unitRef="usd" contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180MC9mcmFnOjk4M2EzMDk1MjI5ZTQwYzQ4M2Q4MjUyMjMwMDdlNzA5L3RhYmxlOmNiYjI2M2FjMjIwYzRkMGI5ZmNlZDc0ODQ1YTA0OTc1L3RhYmxlcmFuZ2U6Y2JiMjYzYWMyMjBjNGQwYjlmY2VkNzQ4NDVhMDQ5NzVfMy00LTEtMS0w_58b0239d-21fd-416a-ac22-1becaa71e82b">128,005</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180MC9mcmFnOjk4M2EzMDk1MjI5ZTQwYzQ4M2Q4MjUyMjMwMDdlNzA5L3RhYmxlOmNiYjI2M2FjMjIwYzRkMGI5ZmNlZDc0ODQ1YTA0OTc1L3RhYmxlcmFuZ2U6Y2JiMjYzYWMyMjBjNGQwYjlmY2VkNzQ4NDVhMDQ5NzVfNC0yLTEtMS0w_22d93e61-9b5f-4829-901e-1719afd053de">5,639,596</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180MC9mcmFnOjk4M2EzMDk1MjI5ZTQwYzQ4M2Q4MjUyMjMwMDdlNzA5L3RhYmxlOmNiYjI2M2FjMjIwYzRkMGI5ZmNlZDc0ODQ1YTA0OTc1L3RhYmxlcmFuZ2U6Y2JiMjYzYWMyMjBjNGQwYjlmY2VkNzQ4NDVhMDQ5NzVfNC00LTEtMS0w_04b35f85-4703-4559-a801-e64470646b4e"><ix:nonFraction unitRef="usd" contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180MC9mcmFnOjk4M2EzMDk1MjI5ZTQwYzQ4M2Q4MjUyMjMwMDdlNzA5L3RhYmxlOmNiYjI2M2FjMjIwYzRkMGI5ZmNlZDc0ODQ1YTA0OTc1L3RhYmxlcmFuZ2U6Y2JiMjYzYWMyMjBjNGQwYjlmY2VkNzQ4NDVhMDQ5NzVfNC00LTEtMS0w_bc034471-fa1b-4442-ab51-0150f419b078">5,943,732</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180MC9mcmFnOjk4M2EzMDk1MjI5ZTQwYzQ4M2Q4MjUyMjMwMDdlNzA5L3RhYmxlOmNiYjI2M2FjMjIwYzRkMGI5ZmNlZDc0ODQ1YTA0OTc1L3RhYmxlcmFuZ2U6Y2JiMjYzYWMyMjBjNGQwYjlmY2VkNzQ4NDVhMDQ5NzVfNS0yLTEtMS0w_af0b302a-3ee1-4705-84ce-e102922e4790">19,984,985</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180MC9mcmFnOjk4M2EzMDk1MjI5ZTQwYzQ4M2Q4MjUyMjMwMDdlNzA5L3RhYmxlOmNiYjI2M2FjMjIwYzRkMGI5ZmNlZDc0ODQ1YTA0OTc1L3RhYmxlcmFuZ2U6Y2JiMjYzYWMyMjBjNGQwYjlmY2VkNzQ4NDVhMDQ5NzVfNS00LTEtMS0w_6cc7177a-af26-4188-ab49-4beb937aef7f">22,294,899</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">less non-current inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180MC9mcmFnOjk4M2EzMDk1MjI5ZTQwYzQ4M2Q4MjUyMjMwMDdlNzA5L3RhYmxlOmNiYjI2M2FjMjIwYzRkMGI5ZmNlZDc0ODQ1YTA0OTc1L3RhYmxlcmFuZ2U6Y2JiMjYzYWMyMjBjNGQwYjlmY2VkNzQ4NDVhMDQ5NzVfNi0yLTEtMS0w_89509102-cb6f-48fd-abc2-82a2ed2ae841">9,880,766</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180MC9mcmFnOjk4M2EzMDk1MjI5ZTQwYzQ4M2Q4MjUyMjMwMDdlNzA5L3RhYmxlOmNiYjI2M2FjMjIwYzRkMGI5ZmNlZDc0ODQ1YTA0OTc1L3RhYmxlcmFuZ2U6Y2JiMjYzYWMyMjBjNGQwYjlmY2VkNzQ4NDVhMDQ5NzVfNi00LTEtMS0w_d5cde96e-f801-4bb8-b627-2140833d82b4">11,656,742</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories classified as current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180MC9mcmFnOjk4M2EzMDk1MjI5ZTQwYzQ4M2Q4MjUyMjMwMDdlNzA5L3RhYmxlOmNiYjI2M2FjMjIwYzRkMGI5ZmNlZDc0ODQ1YTA0OTc1L3RhYmxlcmFuZ2U6Y2JiMjYzYWMyMjBjNGQwYjlmY2VkNzQ4NDVhMDQ5NzVfNy0yLTEtMS0w_a61f8262-9943-47bc-a6b1-804b212190aa">10,104,219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180MC9mcmFnOjk4M2EzMDk1MjI5ZTQwYzQ4M2Q4MjUyMjMwMDdlNzA5L3RhYmxlOmNiYjI2M2FjMjIwYzRkMGI5ZmNlZDc0ODQ1YTA0OTc1L3RhYmxlcmFuZ2U6Y2JiMjYzYWMyMjBjNGQwYjlmY2VkNzQ4NDVhMDQ5NzVfNy00LTEtMS0w_0b3821d5-b799-4d72-a5eb-c513ec38fb5a">10,638,157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div id="id0faa06a8909446fa2394f59c1490a03_43"></div><div style="margin-top:8pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(5) <ix:nonNumeric contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180My9mcmFnOmU1ZmQ2MDUyZGJjZjQwNDdhMTFiNGE2NThiZGY0NTIyL3RleHRyZWdpb246ZTVmZDYwNTJkYmNmNDA0N2ExMWI0YTY1OGJkZjQ1MjJfMTk3Nw_253eff07-8abd-4c94-a9f0-5cbc3862b4c0" continuedAt="i54a7608cb0bc4b07b2080cb90f5bad12" escape="true">LEASES</ix:nonNumeric></span></div><ix:continuation id="i54a7608cb0bc4b07b2080cb90f5bad12"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland&#8217;s significant operating leases include the lease of approximately <ix:nonFraction unitRef="sqft" contextRef="i5d1ec29c3e7d45128f2daec3011f8ff5_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180My9mcmFnOmU1ZmQ2MDUyZGJjZjQwNDdhMTFiNGE2NThiZGY0NTIyL3RleHRyZWdpb246ZTVmZDYwNTJkYmNmNDA0N2ExMWI0YTY1OGJkZjQ1MjJfMjc0ODc3OTA3MTQ3MA_a8375541-6385-4184-875a-38aa36db9874">25,500</ix:nonFraction> square feet of office space in Nashville, Tennessee for its corporate headquarters.  This lease currently expires in October 2022.  The Company's operating leases also include the lease of approximately <ix:nonFraction unitRef="sqft" contextRef="idfffd86898e74da5b26d2c9090d7aef5_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180My9mcmFnOmU1ZmQ2MDUyZGJjZjQwNDdhMTFiNGE2NThiZGY0NTIyL3RleHRyZWdpb246ZTVmZDYwNTJkYmNmNDA0N2ExMWI0YTY1OGJkZjQ1MjJfMjc0ODc3OTA3MTQ2Mg_c7827861-55c5-4d39-84ee-f6dab6073913">14,200</ix:nonFraction> square feet of wet laboratory and office space in Nashville, Tennessee by CET, our majority-owned subsidiary, where it operates the CET Life Sciences Center.  This lease currently expires in April 2023. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities are recorded as the present value of remaining lease payments not yet paid for the lease term discounted using the incremental borrowing rate associated with each lease. Operating lease right-of-use assets represent operating lease liabilities adjusted for lease incentives and initial direct costs. As Cumberland&#8217;s leases do not contain implicit borrowing rates, the incremental borrowing rates were calculated based on information available at January 1, 2019. Incremental borrowing rates reflect the Company&#8217;s estimated interest rates for collateralized borrowings over similar lease terms.  The weighted-average incremental borrowing rate used to discount the present value of the remaining lease payments is <ix:nonFraction unitRef="number" contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180My9mcmFnOmU1ZmQ2MDUyZGJjZjQwNDdhMTFiNGE2NThiZGY0NTIyL3RleHRyZWdpb246ZTVmZDYwNTJkYmNmNDA0N2ExMWI0YTY1OGJkZjQ1MjJfMTI0Ng_cf18bda7-b6b7-4e6a-9100-e57a48752131">7.42</ix:nonFraction>%. The weighted-average remaining lease term at June 30, 2021 is <ix:nonNumeric contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180My9mcmFnOmU1ZmQ2MDUyZGJjZjQwNDdhMTFiNGE2NThiZGY0NTIyL3RleHRyZWdpb246ZTVmZDYwNTJkYmNmNDA0N2ExMWI0YTY1OGJkZjQ1MjJfMTMwMQ_fd997387-c7dd-42a8-b0a5-6cbf62e36614">1.5</ix:nonNumeric> years.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lease Position</span></div><ix:nonNumeric contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" name="cpix:AssetsAndLiabilitiesLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180My9mcmFnOmU1ZmQ2MDUyZGJjZjQwNDdhMTFiNGE2NThiZGY0NTIyL3RleHRyZWdpb246ZTVmZDYwNTJkYmNmNDA0N2ExMWI0YTY1OGJkZjQ1MjJfMTk3OA_2c08834d-f8ef-42de-8368-82cb041bfefd" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June 30, 2021 and December 31, 2020 , the Company's lease assets and liabilities were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Right-of-Use Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180My9mcmFnOmU1ZmQ2MDUyZGJjZjQwNDdhMTFiNGE2NThiZGY0NTIyL3RhYmxlOmMzYTAwNGJhZjZlNDQyNjQ5NTQ4ZWMzZWUzMzE1NWE1L3RhYmxlcmFuZ2U6YzNhMDA0YmFmNmU0NDI2NDk1NDhlYzNlZTMzMTU1YTVfMS0yLTEtMS0w_2e05e7f0-60a9-432f-b689-714e14aa54d6">1,535,556</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180My9mcmFnOmU1ZmQ2MDUyZGJjZjQwNDdhMTFiNGE2NThiZGY0NTIyL3RhYmxlOmMzYTAwNGJhZjZlNDQyNjQ5NTQ4ZWMzZWUzMzE1NWE1L3RhYmxlcmFuZ2U6YzNhMDA0YmFmNmU0NDI2NDk1NDhlYzNlZTMzMTU1YTVfMS00LTEtMS0w_87914a4b-997d-48db-bfce-a1cf0934844f">2,028,148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180My9mcmFnOmU1ZmQ2MDUyZGJjZjQwNDdhMTFiNGE2NThiZGY0NTIyL3RhYmxlOjdiMWZiYjFhODVkMjRiYWNhZTY5NmRhNDg3MTNlMTU3L3RhYmxlcmFuZ2U6N2IxZmJiMWE4NWQyNGJhY2FlNjk2ZGE0ODcxM2UxNTdfMS0yLTEtMS0w_76cf164b-f512-47ff-9598-0ce24a62b161">1,067,880</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180My9mcmFnOmU1ZmQ2MDUyZGJjZjQwNDdhMTFiNGE2NThiZGY0NTIyL3RhYmxlOjdiMWZiYjFhODVkMjRiYWNhZTY5NmRhNDg3MTNlMTU3L3RhYmxlcmFuZ2U6N2IxZmJiMWE4NWQyNGJhY2FlNjk2ZGE0ODcxM2UxNTdfMS00LTEtMS0w_a32dda76-901f-4c26-817a-d2e6ddfe2cc3">1,016,779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease noncurrent liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180My9mcmFnOmU1ZmQ2MDUyZGJjZjQwNDdhMTFiNGE2NThiZGY0NTIyL3RhYmxlOjdiMWZiYjFhODVkMjRiYWNhZTY5NmRhNDg3MTNlMTU3L3RhYmxlcmFuZ2U6N2IxZmJiMWE4NWQyNGJhY2FlNjk2ZGE0ODcxM2UxNTdfMy0yLTEtMS0w_27314676-eaef-4b08-b629-1bd57f9cb72d">512,324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180My9mcmFnOmU1ZmQ2MDUyZGJjZjQwNDdhMTFiNGE2NThiZGY0NTIyL3RhYmxlOjdiMWZiYjFhODVkMjRiYWNhZTY5NmRhNDg3MTNlMTU3L3RhYmxlcmFuZ2U6N2IxZmJiMWE4NWQyNGJhY2FlNjk2ZGE0ODcxM2UxNTdfMy00LTEtMS0w_6799f033-aab7-4267-8e75-e285b68d2ef6">1,059,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630" decimals="0" format="ixt:numdotdecimal" name="cpix:LeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180My9mcmFnOmU1ZmQ2MDUyZGJjZjQwNDdhMTFiNGE2NThiZGY0NTIyL3RhYmxlOjdiMWZiYjFhODVkMjRiYWNhZTY5NmRhNDg3MTNlMTU3L3RhYmxlcmFuZ2U6N2IxZmJiMWE4NWQyNGJhY2FlNjk2ZGE0ODcxM2UxNTdfNC0yLTEtMS0w_68131312-3580-4549-8bff-c24271148b4f">1,580,204</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231" decimals="0" format="ixt:numdotdecimal" name="cpix:LeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180My9mcmFnOmU1ZmQ2MDUyZGJjZjQwNDdhMTFiNGE2NThiZGY0NTIyL3RhYmxlOjdiMWZiYjFhODVkMjRiYWNhZTY5NmRhNDg3MTNlMTU3L3RhYmxlcmFuZ2U6N2IxZmJiMWE4NWQyNGJhY2FlNjk2ZGE0ODcxM2UxNTdfNC00LTEtMS0w_6745505a-b30c-444c-9c49-09283de29782">2,076,472</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumulative future minimum sublease income under non-cancelable operating subleases totals approximately $<ix:nonFraction unitRef="usd" contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180My9mcmFnOmU1ZmQ2MDUyZGJjZjQwNDdhMTFiNGE2NThiZGY0NTIyL3RleHRyZWdpb246ZTVmZDYwNTJkYmNmNDA0N2ExMWI0YTY1OGJkZjQ1MjJfMTUwOA_5b000c8b-7668-43d5-bc82-f35d78f90d1b">0.2</ix:nonFraction> million and will be paid through the leases ending in October 2022 and April 2023. Future minimum lease payments under non-cancelable operating leases (with initial or remaining lease terms in excess of one year) are as follows:</span></div></ix:nonNumeric><div style="margin-bottom:6pt"><ix:nonNumeric contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180My9mcmFnOmU1ZmQ2MDUyZGJjZjQwNDdhMTFiNGE2NThiZGY0NTIyL3RleHRyZWdpb246ZTVmZDYwNTJkYmNmNDA0N2ExMWI0YTY1OGJkZjQ1MjJfMTk3OQ_ccd504fe-9d7a-4ba6-b8d5-5273ca24c343" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.554%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity of Lease Liabilities at June 30, 2021</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180My9mcmFnOmU1ZmQ2MDUyZGJjZjQwNDdhMTFiNGE2NThiZGY0NTIyL3RhYmxlOjQxNTA0MGFhYzQ0YTRjOGNhMGYwNzk2MWVlMTljN2NmL3RhYmxlcmFuZ2U6NDE1MDQwYWFjNDRhNGM4Y2EwZjA3OTYxZWUxOWM3Y2ZfMS0yLTEtMS0w_7b57d960-891f-4c2e-b842-87f92178d907">579,183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180My9mcmFnOmU1ZmQ2MDUyZGJjZjQwNDdhMTFiNGE2NThiZGY0NTIyL3RhYmxlOjQxNTA0MGFhYzQ0YTRjOGNhMGYwNzk2MWVlMTljN2NmL3RhYmxlcmFuZ2U6NDE1MDQwYWFjNDRhNGM4Y2EwZjA3OTYxZWUxOWM3Y2ZfMi0yLTEtMS0w_3a154e76-5901-4f17-a896-774d8fff8905">1,019,313</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180My9mcmFnOmU1ZmQ2MDUyZGJjZjQwNDdhMTFiNGE2NThiZGY0NTIyL3RhYmxlOjQxNTA0MGFhYzQ0YTRjOGNhMGYwNzk2MWVlMTljN2NmL3RhYmxlcmFuZ2U6NDE1MDQwYWFjNDRhNGM4Y2EwZjA3OTYxZWUxOWM3Y2ZfMy0yLTEtMS0w_56dbd299-8c56-442f-ab12-fff1f30e8f75">92,478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630" decimals="0" format="ixt:zerodash" name="cpix:LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180My9mcmFnOmU1ZmQ2MDUyZGJjZjQwNDdhMTFiNGE2NThiZGY0NTIyL3RhYmxlOjQxNTA0MGFhYzQ0YTRjOGNhMGYwNzk2MWVlMTljN2NmL3RhYmxlcmFuZ2U6NDE1MDQwYWFjNDRhNGM4Y2EwZjA3OTYxZWUxOWM3Y2ZfNC0yLTEtMS0w_91952288-a75e-44bd-b82c-20405d4d4406">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180My9mcmFnOmU1ZmQ2MDUyZGJjZjQwNDdhMTFiNGE2NThiZGY0NTIyL3RhYmxlOjQxNTA0MGFhYzQ0YTRjOGNhMGYwNzk2MWVlMTljN2NmL3RhYmxlcmFuZ2U6NDE1MDQwYWFjNDRhNGM4Y2EwZjA3OTYxZWUxOWM3Y2ZfNS0yLTEtMS0w_b45b66d3-118d-414f-8bd1-894ea5e2dd91">1,690,974</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180My9mcmFnOmU1ZmQ2MDUyZGJjZjQwNDdhMTFiNGE2NThiZGY0NTIyL3RhYmxlOjQxNTA0MGFhYzQ0YTRjOGNhMGYwNzk2MWVlMTljN2NmL3RhYmxlcmFuZ2U6NDE1MDQwYWFjNDRhNGM4Y2EwZjA3OTYxZWUxOWM3Y2ZfNi0yLTEtMS0w_a78c679b-a921-44ad-a9ca-a638d4e9b4f4">110,770</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180My9mcmFnOmU1ZmQ2MDUyZGJjZjQwNDdhMTFiNGE2NThiZGY0NTIyL3RhYmxlOjQxNTA0MGFhYzQ0YTRjOGNhMGYwNzk2MWVlMTljN2NmL3RhYmxlcmFuZ2U6NDE1MDQwYWFjNDRhNGM4Y2EwZjA3OTYxZWUxOWM3Y2ZfNy0yLTEtMS0w_e897ea14-fd16-4e13-9409-5a0787da5322">1,580,204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense is recognized over the expected term of the lease, including renewal option periods, if applicable, on a straight-line basis as a component of general and administrative expense. <ix:nonNumeric contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" name="cpix:ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180My9mcmFnOmU1ZmQ2MDUyZGJjZjQwNDdhMTFiNGE2NThiZGY0NTIyL3RleHRyZWdpb246ZTVmZDYwNTJkYmNmNDA0N2ExMWI0YTY1OGJkZjQ1MjJfMTk3Ng_05073709-a3a8-4c91-8b95-de1c6fa0670b" continuedAt="id1ec109cf0f54b7a9bb1ab26df5d3cc0" escape="true">Rent expense and sublease income were as follows:</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><ix:continuation id="id1ec109cf0f54b7a9bb1ab26df5d3cc0"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rent expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LeaseAndRentalExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180My9mcmFnOmU1ZmQ2MDUyZGJjZjQwNDdhMTFiNGE2NThiZGY0NTIyL3RhYmxlOmYxNTc2YjFlZmMxOTQ4NGFiYTg3NGU2ODg0OWI1ZjBkL3RhYmxlcmFuZ2U6ZjE1NzZiMWVmYzE5NDg0YWJhODc0ZTY4ODQ5YjVmMGRfMy0yLTEtMS0w_5a35dd65-e535-4026-b334-809328906ac7">605,130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LeaseAndRentalExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180My9mcmFnOmU1ZmQ2MDUyZGJjZjQwNDdhMTFiNGE2NThiZGY0NTIyL3RhYmxlOmYxNTc2YjFlZmMxOTQ4NGFiYTg3NGU2ODg0OWI1ZjBkL3RhYmxlcmFuZ2U6ZjE1NzZiMWVmYzE5NDg0YWJhODc0ZTY4ODQ5YjVmMGRfMy00LTEtMS0w_e5ece971-1cab-4df6-993c-c6265166be4b">571,399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesRentExpenseSubleaseRentals1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180My9mcmFnOmU1ZmQ2MDUyZGJjZjQwNDdhMTFiNGE2NThiZGY0NTIyL3RhYmxlOmYxNTc2YjFlZmMxOTQ4NGFiYTg3NGU2ODg0OWI1ZjBkL3RhYmxlcmFuZ2U6ZjE1NzZiMWVmYzE5NDg0YWJhODc0ZTY4ODQ5YjVmMGRfNS0yLTEtMS0w_bcac05d7-b051-44b9-9b40-7da60efa6fcd">348,411</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesRentExpenseSubleaseRentals1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180My9mcmFnOmU1ZmQ2MDUyZGJjZjQwNDdhMTFiNGE2NThiZGY0NTIyL3RhYmxlOmYxNTc2YjFlZmMxOTQ4NGFiYTg3NGU2ODg0OWI1ZjBkL3RhYmxlcmFuZ2U6ZjE1NzZiMWVmYzE5NDg0YWJhODc0ZTY4ODQ5YjVmMGRfNS00LTEtMS0w_2d64c735-50bc-4a23-9d7e-52ed5444cd72">323,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div id="id0faa06a8909446fa2394f59c1490a03_46"></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(6) <ix:nonNumeric contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180Ni9mcmFnOjc2MjExMDY0NDEzNTRjODE4YmMzOTA3MTA3MTQ3MDk5L3RleHRyZWdpb246NzYyMTEwNjQ0MTM1NGM4MThiYzM5MDcxMDcxNDcwOTlfODIxOQ_eaaf3461-646b-4e8c-bbbc-7e628ac06925" continuedAt="ice8cc680a53e408f9eb19edce952896b" escape="true">SHAREHOLDERS&#8217; EQUITY AND DEBT</ix:nonNumeric></span></div><ix:continuation id="ice8cc680a53e408f9eb19edce952896b" continuedAt="ifeaa54e3afba48a795f6dea4aba3ec23"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share repurchases</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland currently has a share repurchase program to repurchase up to $<ix:nonFraction unitRef="usd" contextRef="iea5110fd579441d385d9a44cd82a7b57_I20100513" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180Ni9mcmFnOjc2MjExMDY0NDEzNTRjODE4YmMzOTA3MTA3MTQ3MDk5L3RleHRyZWdpb246NzYyMTEwNjQ0MTM1NGM4MThiYzM5MDcxMDcxNDcwOTlfMTMz_8d20ba3d-dc13-4a46-ba8e-8a65a4837578">10</ix:nonFraction> million of its common stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934. In January 2019, the Company's Board of Directors established the current $<ix:nonFraction unitRef="usd" contextRef="i1e44f0e8ba3a437db0695f10422fa49b_I20160131" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180Ni9mcmFnOjc2MjExMDY0NDEzNTRjODE4YmMzOTA3MTA3MTQ3MDk5L3RleHRyZWdpb246NzYyMTEwNjQ0MTM1NGM4MThiYzM5MDcxMDcxNDcwOTlfMjk0_07fb81db-30b5-460d-9044-f851b8fde08e">10</ix:nonFraction> million repurchase program to replace the prior authorizations.  During the six months ended June 30, 2021 and June 30, 2020, the Company repurchased <ix:nonFraction unitRef="shares" contextRef="i569ae37ae6bd451aba5271c09e866dd6_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180Ni9mcmFnOjc2MjExMDY0NDEzNTRjODE4YmMzOTA3MTA3MTQ3MDk5L3RleHRyZWdpb246NzYyMTEwNjQ0MTM1NGM4MThiYzM5MDcxMDcxNDcwOTlfNDAw_ec7726eb-0eab-45f6-8d7b-f3380c2e3c03">250,129</ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="i51df30cfe8df40d49c632283258bef9d_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180Ni9mcmFnOjc2MjExMDY0NDEzNTRjODE4YmMzOTA3MTA3MTQ3MDk5L3RleHRyZWdpb246NzYyMTEwNjQ0MTM1NGM4MThiYzM5MDcxMDcxNDcwOTlfNDE0_0645e95f-f610-4aff-9995-24fe9235b1e5">306,329</ix:nonFraction> shares, respectively, of common stock for approximately $<ix:nonFraction unitRef="usd" contextRef="i569ae37ae6bd451aba5271c09e866dd6_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180Ni9mcmFnOjc2MjExMDY0NDEzNTRjODE4YmMzOTA3MTA3MTQ3MDk5L3RleHRyZWdpb246NzYyMTEwNjQ0MTM1NGM4MThiYzM5MDcxMDcxNDcwOTlfNDcz_eb0318c0-5d56-4ade-b57c-19946e3a7f06">0.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i51df30cfe8df40d49c632283258bef9d_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180Ni9mcmFnOjc2MjExMDY0NDEzNTRjODE4YmMzOTA3MTA3MTQ3MDk5L3RleHRyZWdpb246NzYyMTEwNjQ0MTM1NGM4MThiYzM5MDcxMDcxNDcwOTlfNDgw_848face6-4fc4-459d-a069-7f1557baeb49">1.2</ix:nonFraction> million, respectively.  At June 30, 2021, approximately $5.4 million of common shares was left to repurchase under this program.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share purchases and sales</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the Company's March 2021 trading window, several members of Cumberland's Board of Directors entered into share purchase agreements of the Company's stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934. These purchases are designed to increase ownership in the Company by the members of the Board.  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share Sales</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, Cumberland filed a Shelf Registration on Form S-3 with the SEC associated with the sale of up to $<ix:nonFraction unitRef="usd" contextRef="i84950ce31a9648138dca94d14b435ecc_D20171101-20171130" decimals="-6" format="ixt:numdotdecimal" name="cpix:StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180Ni9mcmFnOjc2MjExMDY0NDEzNTRjODE4YmMzOTA3MTA3MTQ3MDk5L3RleHRyZWdpb246NzYyMTEwNjQ0MTM1NGM4MThiYzM5MDcxMDcxNDcwOTlfOTcz_5cb765e1-b9ab-4819-9e76-1f8887ef6821">100</ix:nonFraction> million in corporate securities. The Shelf Registration was declared effective in January 2018. It also included an At the Market ("ATM") feature that allowed the Company to sell common shares at market prices, along with an agreement with B. Riley FBR Inc. to support such a placement of shares. The Company filed an updated Form S-3 with the SEC in December 2020, which was declared effective in January 2021. The Company does not currently have an ATM feature in place.  Cumberland plans to continue to evaluate the market for its common shares, and if favorable, will further evaluate whether or not to enter into an ATM feature through B. Riley FBR, Inc. that would allow the Company to issue shares of its common stock.  The Company did not issue any shares under an ATM during the six months ended June 30, 2021 or June 30, 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Share Grants and Incentive Stock Options</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June 30, 2021 and June 30, 2020, the Company issued <ix:nonFraction unitRef="shares" contextRef="i6837db1dd6864c6f9523c35e88733824_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180Ni9mcmFnOjc2MjExMDY0NDEzNTRjODE4YmMzOTA3MTA3MTQ3MDk5L3RleHRyZWdpb246NzYyMTEwNjQ0MTM1NGM4MThiYzM5MDcxMDcxNDcwOTlfMTg1OA_9b194600-ee1e-46a0-8109-4e5c0c09f812">36,850</ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="i7809f262685d483280e68e02e89f4262_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180Ni9mcmFnOjc2MjExMDY0NDEzNTRjODE4YmMzOTA3MTA3MTQ3MDk5L3RleHRyZWdpb246NzYyMTEwNjQ0MTM1NGM4MThiYzM5MDcxMDcxNDcwOTlfMTg3Mg_811e1773-0fdd-4c35-aa54-f9d7e1debe63">229,141</ix:nonFraction> shares of restricted stock to employees and directors, respectively. Restricted stock issued to employees generally cliff-vests on the fourth anniversary of the date of grant and for directors on the <ix:nonNumeric contextRef="i6eaa74b46ec44f199aa9dfd669c1664f_D20210101-20210630" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180Ni9mcmFnOjc2MjExMDY0NDEzNTRjODE4YmMzOTA3MTA3MTQ3MDk5L3RleHRyZWdpb246NzYyMTEwNjQ0MTM1NGM4MThiYzM5MDcxMDcxNDcwOTlfODIyMQ_6771156a-0489-4b37-9f0b-fd0b46bfbfa8">one-year</ix:nonNumeric> anniversary of the date of grant.  During the six months ended June 30, 2021, the Company also issued <ix:nonFraction unitRef="shares" contextRef="i4f5feacbf7384a1087c1db7cf1ec114c_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180Ni9mcmFnOjc2MjExMDY0NDEzNTRjODE4YmMzOTA3MTA3MTQ3MDk5L3RleHRyZWdpb246NzYyMTEwNjQ0MTM1NGM4MThiYzM5MDcxMDcxNDcwOTlfMjE1Nw_9a336b6f-b61f-4cb4-b43f-646f851f08e7">173,350</ix:nonFraction> incentive stock options to employees that cliff-vest on the fourth anniversary of the date of grant, that are set to expire in March and May 2031. Stock compensation expense is presented as a component of general and administrative expense in the condensed consolidated statements of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 7, 2020, the Company entered into a Third Amendment to the Revolving Credit Note and Fourth Amendment (&#8220;Fourth Amendment&#8221;) to the Revolving Credit Loan Agreement with Pinnacle Bank (the &#8220;Pinnacle Agreement&#8221;). The original Pinnacle Agreement was dated July 2017. The Fourth Amendment provides for a principal available for borrowing of up to $<ix:nonFraction unitRef="usd" contextRef="ifadcff6052794ad7afbe6463edf069fc_I20201007" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180Ni9mcmFnOjc2MjExMDY0NDEzNTRjODE4YmMzOTA3MTA3MTQ3MDk5L3RleHRyZWdpb246NzYyMTEwNjQ0MTM1NGM4MThiYzM5MDcxMDcxNDcwOTlfMjgxNQ_822a9130-9034-4aab-a51c-3afb2f7391b4">15</ix:nonFraction>&#160;million and Cumberland has the ability to request an increase of up to an additional $<ix:nonFraction unitRef="usd" contextRef="ifadcff6052794ad7afbe6463edf069fc_I20201007" decimals="INF" format="ixt:numdotdecimal" name="cpix:LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180Ni9mcmFnOjc2MjExMDY0NDEzNTRjODE4YmMzOTA3MTA3MTQ3MDk5L3RleHRyZWdpb246NzYyMTEwNjQ0MTM1NGM4MThiYzM5MDcxMDcxNDcwOTlfMjg5NQ_b0c7eda1-00b7-4bdc-84b0-be49f02f1eef">5</ix:nonFraction>&#160;million, upon the satisfaction of certain conditions and approval by Pinnacle Bank. If fully expanded, the Fourth Amendment would provide a maximum principal available for borrowing of up to $<ix:nonFraction unitRef="usd" contextRef="ifadcff6052794ad7afbe6463edf069fc_I20201007" decimals="INF" format="ixt:numdotdecimal" name="cpix:LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180Ni9mcmFnOjc2MjExMDY0NDEzNTRjODE4YmMzOTA3MTA3MTQ3MDk5L3RleHRyZWdpb246NzYyMTEwNjQ0MTM1NGM4MThiYzM5MDcxMDcxNDcwOTlfMzA4MQ_85055d96-acf2-49ef-840b-a454bc31c501">20</ix:nonFraction>&#160;million.  The Fourth Amendment extended the maturity date of the Pinnacle Agreement through October 1, 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 10, 2019, the Company entered into a third amendment ("Third Amendment") to the Pinnacle Agreement, which extended the term of the Pinnacle Agreement through July 31, 2021 as well as modified certain definitions and terms of the existing financial covenants, including the definition of the Funded Debt Ratio and the compliance target of the Tangible Capital Ratio. Both Third Amendment modifications were related to the Vibativ transaction.  Under the Pinnacle Agreement, Cumberland was initially subject to one financial covenant, the maintenance of a Funded Debt Ratio, as such term is defined in the agreement and determined on a quarterly basis.  On August 14, 2018, the Company amended the Pinnacle Agreement ("First Amendment") to replace the single financial covenant with the maintenance of either the Funded Debt Ratio or a Tangible Capital Ratio, as defined in the First Amendment.  The Company was in compliance with the Tangible Capital Ratio financial covenant as of June 30, 2021.  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021 and December 31, 2020, the Company had $<ix:nonFraction unitRef="usd" contextRef="i7949c2029147408c82a03b03371c2934_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermLineOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180Ni9mcmFnOjc2MjExMDY0NDEzNTRjODE4YmMzOTA3MTA3MTQ3MDk5L3RleHRyZWdpb246NzYyMTEwNjQ0MTM1NGM4MThiYzM5MDcxMDcxNDcwOTlfNDIxMg_da91aace-079d-477e-b7c4-97ca4fd58910">14.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id63b8386c6dd4a9096c2f08b1caa166d_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermLineOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180Ni9mcmFnOjc2MjExMDY0NDEzNTRjODE4YmMzOTA3MTA3MTQ3MDk5L3RleHRyZWdpb246NzYyMTEwNjQ0MTM1NGM4MThiYzM5MDcxMDcxNDcwOTlfMTA5OTUxMTYzNjAxMQ_969c1ec4-1f66-4a99-944f-303b3a195a79">15.0</ix:nonFraction> million in borrowings outstanding under its revolving credit facility.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate on the Pinnacle Agreement is based on LIBOR plus an interest rate spread. The pricing under the Fourth Amendment provides for an interest rate spread of <ix:nonFraction unitRef="number" contextRef="iec72b3e70c5e4d5b9f0a256af0a2e6eb_D20200814-20200814" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180Ni9mcmFnOjc2MjExMDY0NDEzNTRjODE4YmMzOTA3MTA3MTQ3MDk5L3RleHRyZWdpb246NzYyMTEwNjQ0MTM1NGM4MThiYzM5MDcxMDcxNDcwOTlfNDQ0OQ_e0c77484-8a00-44bd-bdf7-73cd9bec44e3">1.75</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i42c0403c56e842038637f32dfa213083_D20200814-20200814" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180Ni9mcmFnOjc2MjExMDY0NDEzNTRjODE4YmMzOTA3MTA3MTQ3MDk5L3RleHRyZWdpb246NzYyMTEwNjQ0MTM1NGM4MThiYzM5MDcxMDcxNDcwOTlfNDQ1NQ_ebad8dd5-c833-4ed5-bd00-fc8b001af034">2.75</ix:nonFraction>% above LIBOR with a minimum LIBOR of <ix:nonFraction unitRef="number" contextRef="i4487ea5e24834d4bb26ece0c7fc05f81_D20200814-20200814" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180Ni9mcmFnOjc2MjExMDY0NDEzNTRjODE4YmMzOTA3MTA3MTQ3MDk5L3RleHRyZWdpb246NzYyMTEwNjQ0MTM1NGM4MThiYzM5MDcxMDcxNDcwOTlfNDQ5NA_1fa55020-43e2-4daa-b374-194e9d37a2cc">0.90</ix:nonFraction>%. The applicable interest rate under the Pinnacle Agreement was <ix:nonFraction unitRef="number" contextRef="ic1ff553c5d964f12b7361c40d75ba752_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180Ni9mcmFnOjc2MjExMDY0NDEzNTRjODE4YmMzOTA3MTA3MTQ3MDk5L3RleHRyZWdpb246NzYyMTEwNjQ0MTM1NGM4MThiYzM5MDcxMDcxNDcwOTlfNDU2MA_cc2ff146-3f97-45c3-8071-bf45f2acad89">3.65</ix:nonFraction>% at June 30, 2021.  In addition, a fee of <ix:nonFraction unitRef="number" contextRef="i22d029b9f8fc4612bd2da5c75672b40a_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180Ni9mcmFnOjc2MjExMDY0NDEzNTRjODE4YmMzOTA3MTA3MTQ3MDk5L3RleHRyZWdpb246NzYyMTEwNjQ0MTM1NGM4MThiYzM5MDcxMDcxNDcwOTlfNDU5Mw_23fd2a7e-b13d-4a96-a729-795ae48b89e4">0.25</ix:nonFraction>% per year is charged on the unused line of credit.  Interest and the unused line fee are payable quarterly.  </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><ix:continuation id="ifeaa54e3afba48a795f6dea4aba3ec23" continuedAt="if0d9c75bd331455b8eda164b7f47ee96"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the line of credit are collateralized by substantially all of the Company's assets. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Paycheck Protection Program Loan</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 20, 2020, Cumberland received the funding of a loan from Pinnacle Bank in the amount of $<ix:nonFraction unitRef="usd" contextRef="i3ea7837abdfa48999669b93f02fe29d4_D20200420-20200420" decimals="0" format="ixt:numdotdecimal" name="cpix:TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180Ni9mcmFnOjc2MjExMDY0NDEzNTRjODE4YmMzOTA3MTA3MTQ3MDk5L3RleHRyZWdpb246NzYyMTEwNjQ0MTM1NGM4MThiYzM5MDcxMDcxNDcwOTlfNDkyNw_f573256b-2007-4b99-8426-1baedc046de1">2,187,140</ix:nonFraction> pursuant to the Paycheck Protection Program (the &#8220;PPP&#8221;) under the Federal Coronavirus Aid, Relief, and Economic Security Act ("CARES Act"), which was enacted March 27, 2020.  The PPP is administered by the U.S. Small Business Administration ("SBA").</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the PPP requirements, loan funds were used to maintain payroll, continue group health care benefits, and pay for rent and utilities during the pandemic. We applied for this loan after carefully considering, with our bank, the eligibility criteria to participate in this program, and determining that Cumberland met those criteria. We evaluated and provided information on our payroll and other qualifying expenses to determine the amount of PPP funds to apply for. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the PPP, certain amounts of the loan may be forgiven if they are used for qualifying expenses as described in the CARES Act. Cumberland used the PPP loan funds for such qualifying expenses. Due to assistance from our PPP loan, the Company did not lay off or furlough any employees as a result of the COVID-19 pandemic.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland elected to account for the proceeds of the loan as a government grant under </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">International Accounting Standard 20 ("IAS 20"), Accounting for Government Grants and Disclosure of Government Assistance. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The permitted analogous use of  IAS 20 outlines a model for the accounting for government assistance, including forgivable loans. As a result, the Company recorded the $<ix:nonFraction unitRef="usd" contextRef="i3ea7837abdfa48999669b93f02fe29d4_D20200420-20200420" decimals="0" format="ixt:numdotdecimal" name="cpix:TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180Ni9mcmFnOjc2MjExMDY0NDEzNTRjODE4YmMzOTA3MTA3MTQ3MDk5L3RleHRyZWdpb246NzYyMTEwNjQ0MTM1NGM4MThiYzM5MDcxMDcxNDcwOTlfNjE4OA_c5a60c6b-d7ae-4370-be14-81bf410cfa98">2,187,140</ix:nonFraction> as a deferred income liability, which was included as a component of other current liabilities on the condensed consolidated balance sheet at December 31, 2020. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, Cumberland submitted a request for the loan&#8217;s forgiveness. On June 11, 2021, the Company received a formal notice from the SBA that the full amount of the loan was forgiven. The Company accounted for the forgiveness of the PPP loan under IAS 20 and recorded the $<ix:nonFraction unitRef="usd" contextRef="i3ea7837abdfa48999669b93f02fe29d4_D20200420-20200420" decimals="0" format="ixt:numdotdecimal" name="cpix:TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180Ni9mcmFnOjc2MjExMDY0NDEzNTRjODE4YmMzOTA3MTA3MTQ3MDk5L3RleHRyZWdpb246NzYyMTEwNjQ0MTM1NGM4MThiYzM5MDcxMDcxNDcwOTlfMTA5OTUxMTYzOTkwMw_c5a60c6b-d7ae-4370-be14-81bf410cfa98">2,187,140</ix:nonFraction> as other income.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Joint Venture Agreement</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><ix:continuation id="if0d9c75bd331455b8eda164b7f47ee96" continuedAt="i08fd98db1b3e4656babed6a3300aebc3"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, Cumberland entered into an agreement with WinHealth Investment (Singapore) Ltd creating </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">WHC Biopharmaceuticals, Pte. Ltd</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i08fd98db1b3e4656babed6a3300aebc3">. The joint venture, as a limited liability company, will focus on acquiring, developing, registering, and commercializing development stage and commercial stage biopharmaceuticals for China, Hong Kong and other Asian markets.  The agreement provides for initial investment from WinHealth in the form of a $<ix:nonFraction unitRef="usd" contextRef="i3738112144924be8b7ed4df49c530139_I20200831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180Ni9mcmFnOjc2MjExMDY0NDEzNTRjODE4YmMzOTA3MTA3MTQ3MDk5L3RleHRyZWdpb246NzYyMTEwNjQ0MTM1NGM4MThiYzM5MDcxMDcxNDcwOTlfNzgwOA_6804d17c-515c-4b03-bca9-488fca64b373">0.2</ix:nonFraction>&#160;million equity contribution and an initial investment from Cumberland in the form of a $<ix:nonFraction unitRef="usd" contextRef="i5161e91b97f647a1a447fe4ae410abff_I20200831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180Ni9mcmFnOjc2MjExMDY0NDEzNTRjODE4YmMzOTA3MTA3MTQ3MDk5L3RleHRyZWdpb246NzYyMTEwNjQ0MTM1NGM4MThiYzM5MDcxMDcxNDcwOTlfNzg5MA_c8634ac8-9926-4544-a554-060fc670655d">0.2</ix:nonFraction>&#160;million convertible note, which was funded during the first quarter 2021. The joint venture will seek additional future capital from additional investors and has entered into exclusive option agreements to license intellectual property from both Cumberland Pharmaceuticals Inc. and Cumberland Emerging Technologies.</ix:continuation>   </span></div><div id="id0faa06a8909446fa2394f59c1490a03_49"></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(7) <ix:nonNumeric contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180OS9mcmFnOjQyYjc2MDI0M2I4OTRjOTBhZjUxODJmNWUyY2M3YmVlL3RleHRyZWdpb246NDJiNzYwMjQzYjg5NGM5MGFmNTE4MmY1ZTJjYzdiZWVfNjM1_233052a4-666a-40b6-9d50-487746ca1fa7" continuedAt="i32f0f0bf7bac4c64bbb55ed98eefdd21" escape="true">INCOME TAXES</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i32f0f0bf7bac4c64bbb55ed98eefdd21" continuedAt="id311d4a8a5f04f3595af1091e0cddce9">As of June 30, 2021, the Company has approximately $<ix:nonFraction unitRef="usd" contextRef="i93503f9d933448f182c19f672ad05ba9_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180OS9mcmFnOjQyYjc2MDI0M2I4OTRjOTBhZjUxODJmNWUyY2M3YmVlL3RleHRyZWdpb246NDJiNzYwMjQzYjg5NGM5MGFmNTE4MmY1ZTJjYzdiZWVfNjI_6f83c77d-1126-4646-94ab-666940c0b9d0">56.5</ix:nonFraction> million in federal net operating loss carryforwards including approximately $<ix:nonFraction unitRef="usd" contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180OS9mcmFnOjQyYjc2MDI0M2I4OTRjOTBhZjUxODJmNWUyY2M3YmVlL3RleHRyZWdpb246NDJiNzYwMjQzYjg5NGM5MGFmNTE4MmY1ZTJjYzdiZWVfMTMz_f0fa9450-52b5-460b-8899-8aec8f26c58f">44.1</ix:nonFraction> million of net operating loss carryforwards resulting from the exercise of nonqualified stock options. These have historically been used to significantly offset income tax obligations. The Company expects it will continue to pay minimal income taxes during 2021 and beyond, through the continued utilization of these net operating loss carryforwards, on any taxable income generated from our operations. </ix:continuation></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id311d4a8a5f04f3595af1091e0cddce9">The Company does not allocate any portion of its income tax expense (benefit) to discontinued operations.</ix:continuation> </span></div><div id="id0faa06a8909446fa2394f59c1490a03_52"></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(8) <ix:nonNumeric contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181Mi9mcmFnOjcyZmEyMTJmMzU2YTQyZWY5NmEwMzRhNTRiODNiZWYxL3RleHRyZWdpb246NzJmYTIxMmYzNTZhNDJlZjk2YTAzNGE1NGI4M2JlZjFfMTAyNw_9880cefd-cdf8-4622-9c12-a8f8252b1655" continuedAt="ifea6c864b1b54207850190f9de569d7c" escape="true">COLLABORATIVE AGREEMENTS</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><ix:continuation id="ifea6c864b1b54207850190f9de569d7c"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland is a party to several collaborative arrangements with research institutions to identify and pursue promising pharmaceutical product candidates. The funding for these programs is primarily provided through Federal Small Business Administration (SBIR/STTR) and other grant awards. The Company has determined that these collaborative agreements, with the exception of the collaborative payment received related to RediTrex, do not meet the criteria for accounting under ASC Topic 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The agreements do not specifically designate each party&#8217;s rights and obligations to each other under the collaborative arrangements. Except for patent defense costs, expenses incurred by one party are not required to be reimbursed by the other party.  Expenses incurred under these collaborative agreements are included in research and development expenses and funding received from grants are recorded as net revenues in the condensed consolidated statements of operations.</span></ix:continuation></div><div id="id0faa06a8909446fa2394f59c1490a03_55"></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(9) <ix:nonNumeric contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RleHRyZWdpb246MGZlYjk3NjIxNmQ3NGJiNzlhYmM0YjZhZjNhZGRiMWRfNTg0MQ_0b247c2d-cbd5-4fb2-b689-32ecb9b56b21" continuedAt="i5388414a26294224a77126cb32edadd9" escape="true">ADDITIONS AND RETURN OF PRODUCT RIGHTS</ix:nonNumeric></span></div><ix:continuation id="i5388414a26294224a77126cb32edadd9" continuedAt="i4e28d618d3a14a0495ead9ee311f65ca"><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vibativ</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During November 2018, the Company closed on an agreement with Theravance Biopharma ("Theravance") to acquire the global responsibility for Vibativ including the marketing, distribution, manufacturing and regulatory activities associated with the brand.  Vibativ is a patented, Food and Drug Administration ("FDA") approved injectable anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has accounted for the transaction as a business combination in accordance with ASC 805 and the product sales are included in the results of operations subsequent to the acquisition date. The Company made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="idfbdaba777624b8b96b3800f1e5753bf_D20181101-20181130" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RleHRyZWdpb246MGZlYjk3NjIxNmQ3NGJiNzlhYmM0YjZhZjNhZGRiMWRfOTY3_6f80e612-e4b8-44f2-96aa-9489c8ab84c7">20.0</ix:nonFraction>&#160;million at the closing of the transaction and a $<ix:nonFraction unitRef="usd" contextRef="idfbdaba777624b8b96b3800f1e5753bf_D20181101-20181130" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherPaymentsToAcquireBusinesses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RleHRyZWdpb246MGZlYjk3NjIxNmQ3NGJiNzlhYmM0YjZhZjNhZGRiMWRfMTAxMA_fd23de30-4d82-481f-9279-146703059160">5.0</ix:nonFraction>&#160;million milestone payment in early April 2019. In addition, Cumberland has agreed to pay a royalty of up to <ix:nonFraction unitRef="number" contextRef="idfbdaba777624b8b96b3800f1e5753bf_D20181101-20181130" decimals="2" name="cpix:TieredRoyaltyPaymentsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RleHRyZWdpb246MGZlYjk3NjIxNmQ3NGJiNzlhYmM0YjZhZjNhZGRiMWRfMTExMw_9763332d-33f5-4424-b95c-a5658171c968">20</ix:nonFraction>% of on-going net sales of the product.  The future royalty payments were required to be recognized at their acquisition-date fair value as a contingent consideration liability, as part of the contingent consideration transferred in the business combination. Cumberland prepared the valuations of the contingent consideration liability utilizing significant unobservable inputs.  As a result, the valuation is classified as Level 3 fair value measurement. </span></div><div style="margin-top:6pt;text-align:justify"><ix:nonNumeric contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RleHRyZWdpb246MGZlYjk3NjIxNmQ3NGJiNzlhYmM0YjZhZjNhZGRiMWRfNTg0Mw_e38e2e17-30e8-4370-903f-d63d88f56734" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis.  The contingent consideration earned and accrued in operating expenses is paid to Theravance quarterly.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.345%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6742997b2ea4497a8b57f546e21e37aa_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RhYmxlOmZlNTllYmZmOTk4OTQ2ZDY5YmUyYzk0MDliOWUwZjZiL3RhYmxlcmFuZ2U6ZmU1OWViZmY5OTg5NDZkNjliZTJjOTQwOWI5ZTBmNmJfOS0xLTEtMS0w_4e2164eb-eddb-4017-b250-361e039a32e7">8,200,552</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment of royalty during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i666e3ad219a249f69a70f9d7525a1f8b_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRoyalties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RhYmxlOmZlNTllYmZmOTk4OTQ2ZDY5YmUyYzk0MDliOWUwZjZiL3RhYmxlcmFuZ2U6ZmU1OWViZmY5OTg5NDZkNjliZTJjOTQwOWI5ZTBmNmJfMTAtMS0xLTEtMA_322a0500-f232-4d8d-8ece-894c02e0f2b3">1,423,586</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration included in operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i666e3ad219a249f69a70f9d7525a1f8b_D20210101-20210630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RhYmxlOmZlNTllYmZmOTk4OTQ2ZDY5YmUyYzk0MDliOWUwZjZiL3RhYmxlcmFuZ2U6ZmU1OWViZmY5OTg5NDZkNjliZTJjOTQwOWI5ZTBmNmJfMTEtMS0xLTEtMA_6968bc16-09fe-4b20-8fc1-d4297de74fc7">180,110</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration earned and accrued in operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i666e3ad219a249f69a70f9d7525a1f8b_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RhYmxlOmZlNTllYmZmOTk4OTQ2ZDY5YmUyYzk0MDliOWUwZjZiL3RhYmxlcmFuZ2U6ZmU1OWViZmY5OTg5NDZkNjliZTJjOTQwOWI5ZTBmNmJfMTItMS0xLTEtMA_a2fa170d-1a86-4b9e-bafd-ebaed3183a0d">760,225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifaa5fd674df1464290cfa2809fea1eaf_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RhYmxlOmZlNTllYmZmOTk4OTQ2ZDY5YmUyYzk0MDliOWUwZjZiL3RhYmxlcmFuZ2U6ZmU1OWViZmY5OTg5NDZkNjliZTJjOTQwOWI5ZTBmNmJfMTMtMS0xLTEtMA_f2799e1d-4ec4-4e05-8098-196351808896">7,357,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr></table></ix:nonNumeric></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration liability of $<ix:nonFraction unitRef="usd" contextRef="ifaa5fd674df1464290cfa2809fea1eaf_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RleHRyZWdpb246MGZlYjk3NjIxNmQ3NGJiNzlhYmM0YjZhZjNhZGRiMWRfMTg1OA_01dc136d-39ec-417b-849f-2c8efa3add9d">7.4</ix:nonFraction>&#160;million was classified as other current liabilities of $<ix:nonFraction unitRef="usd" contextRef="ieca5d4731d90438e81ee926eb9a44d99_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RleHRyZWdpb246MGZlYjk3NjIxNmQ3NGJiNzlhYmM0YjZhZjNhZGRiMWRfMTkwOA_fbd7acaf-f43e-47b1-9367-0a28d48b0c21">2.9</ix:nonFraction>&#160;million and other long-term liabilities of $<ix:nonFraction unitRef="usd" contextRef="i543d802ba6254fea92215d118fe3fb4e_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RleHRyZWdpb246MGZlYjk3NjIxNmQ3NGJiNzlhYmM0YjZhZjNhZGRiMWRfMTk0Ng_4d13ca46-540e-4391-9291-6bc5c38955de">4.5</ix:nonFraction>&#160;million on the condensed consolidated balance sheet as of June 30, 2021.  </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RediTrex</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2016, the Company announced an agreement with the Nordic Group B.V. ("Nordic") to acquire the exclusive U.S. rights to Nordic&#8217;s injectable methotrexate product line designed for the treatment of active rheumatoid arthritis, juvenile idiopathic arthritis, severe psoriatic arthritis, and severe disabling psoriasis. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As consideration for the license Cumberland paid a deposit of $<ix:nonFraction unitRef="usd" contextRef="i1f48945eef8d4b2d820f10f38c6f7a00_D20161101-20161130" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RleHRyZWdpb246MGZlYjk3NjIxNmQ3NGJiNzlhYmM0YjZhZjNhZGRiMWRfMjQwNA_73e67b2a-30a5-40c5-a3a4-47a7f1742857">100,000</ix:nonFraction> at closing.  The Company provided $<ix:nonFraction unitRef="usd" contextRef="i1f48945eef8d4b2d820f10f38c6f7a00_D20161101-20161130" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RleHRyZWdpb246MGZlYjk3NjIxNmQ3NGJiNzlhYmM0YjZhZjNhZGRiMWRfMjQ0MQ_2069b6c9-e3b5-4c25-8370-81ee33a0c2c6">0.9</ix:nonFraction>&#160;million in consideration through a grant of <ix:nonFraction unitRef="shares" contextRef="ib90d441c6774404295b76ceae446e40d_D20161101-20161130" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RleHRyZWdpb246MGZlYjk3NjIxNmQ3NGJiNzlhYmM0YjZhZjNhZGRiMWRfMjQ4MA_1cfe0deb-3154-498d-9f70-c6567b7fd2b8">180,000</ix:nonFraction> restricted shares of Cumberland common stock to be vested upon the FDA approval of the first Nordic product. Cumberland also agreed to provide Nordic a series of payments tied to the products&#8217; FDA approval, launch and achievement of certain sales milestones. Under the terms of the agreement, Cumberland is responsible for the product registration and commercialization in the U.S. Nordic is responsible for product manufacturing and supply.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 27, 2019, Cumberland received FDA approval for the first Nordic injectable product and authorization to market them under the RediTrex brand name.  The <ix:nonFraction unitRef="shares" contextRef="ib90d441c6774404295b76ceae446e40d_D20161101-20161130" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RleHRyZWdpb246MGZlYjk3NjIxNmQ3NGJiNzlhYmM0YjZhZjNhZGRiMWRfMzA5MQ_4e8ae41f-37d0-4ddc-bc84-a96197380fb3">180,000</ix:nonFraction> shares of restricted Cumberland common stock previously provided to Nordic vested upon approval and were valued at $<ix:nonFraction unitRef="usd" contextRef="i537c330f50e745f197afdd484a2730ec_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RleHRyZWdpb246MGZlYjk3NjIxNmQ3NGJiNzlhYmM0YjZhZjNhZGRiMWRfMzIwOQ_31a509b7-41db-4a46-96e3-047b0af5b99c">0.9</ix:nonFraction>&#160;million on the vesting date. The FDA approval also resulted in a $<ix:nonFraction unitRef="usd" contextRef="i0b8a1a744ec04c1d913f27f1efc5efa2_I20200731" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RleHRyZWdpb246MGZlYjk3NjIxNmQ3NGJiNzlhYmM0YjZhZjNhZGRiMWRfMzI2OQ_7e973f0a-fe66-42bd-a3fe-d5f2ed709b02">1.0</ix:nonFraction>&#160;million milestone payment due to Nordic.  During December 2020, Cumberland introduced RediTrex and the launch that will take place in late 2021 will result in a $<ix:nonFraction unitRef="usd" contextRef="i9e8de0e06633438faeea349c72c801a5_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RleHRyZWdpb246MGZlYjk3NjIxNmQ3NGJiNzlhYmM0YjZhZjNhZGRiMWRfMjc0ODc3OTA3NTYwNQ_ce0078b9-0b87-4071-b828-a377b958d239">1.0</ix:nonFraction>&#160;million milestone payment due to Nordic.  This milestone payment will be paid during 2022 and is being reported as a current liability at June 30, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has approximately $<ix:nonFraction unitRef="usd" contextRef="i452c4da6ebcf4c4ebc44e66aaa120e9b_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RleHRyZWdpb246MGZlYjk3NjIxNmQ3NGJiNzlhYmM0YjZhZjNhZGRiMWRfMzU4NA_47f96630-1062-49a1-a2e4-c438f6b17154">2.7</ix:nonFraction>&#160;million in net intangible assets related to RediTrex at June 30, 2021.  </span></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><ix:continuation id="i4e28d618d3a14a0495ead9ee311f65ca"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ethyol and Totect </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, Cumberland entered into an agreement with Clinigen for the rights and responsibilities associated with the commercialization of Ethyol in the United States.  In 2017, the Company entered into another agreement with Clinigen for the rights and responsibilities associated with the commercialization of Totect in the United States.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Early in 2019, Cumberland announced a strategic review of the Company's brands, capabilities, and international partners. This review followed an accelerated business development initiative, which resulted in a series of transactions. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During May 2019, Cumberland entered into the Dissolution Agreement with Clinigen in which the Company returned the exclusive rights to commercialize Ethyol and Totect</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the United States to Clinigen. Under the final terms of the Dissolution Agreement, Cumberland was no longer responsible for the distribution, marketing and promotion of either Ethyol or Totect or any competing products after December 31, 2019.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In exchange for the return of these product license rights and the non-compete provisions of the Dissolution Agreement, Cumberland is receiving $<ix:nonFraction unitRef="usd" contextRef="i8f2247edd8fd4841affbe5d013f55977_D20191001-20210930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RleHRyZWdpb246MGZlYjk3NjIxNmQ3NGJiNzlhYmM0YjZhZjNhZGRiMWRfNDc5Ng_f54f9166-1fff-4242-8cc6-c6bc3d120bca">5</ix:nonFraction>&#160;million in financial consideration paid in quarterly installments over the two-years following the transition date. Cumberland recorded the first four quarterly installments totaling $<ix:nonFraction unitRef="usd" contextRef="i8613f3fef30a4cf99a52244890006824_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="cpix:ProceedsFromSaleOfIntangibleAssetsInstallmentPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RleHRyZWdpb246MGZlYjk3NjIxNmQ3NGJiNzlhYmM0YjZhZjNhZGRiMWRfNDk3NA_ec0d0e86-6808-4cac-b2b3-7cd453fb8aa9">3.0</ix:nonFraction> million during 2020 and the next two installments totaling $<ix:nonFraction unitRef="usd" contextRef="i53d85ca5dcbd44ba870830f97461a800_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RleHRyZWdpb246MGZlYjk3NjIxNmQ3NGJiNzlhYmM0YjZhZjNhZGRiMWRfMTA5OTUxMTYzMzY2Ng_38c2c8f4-0913-4445-a238-2d1934f0c714">1.0</ix:nonFraction> million during the six months ended June 30, 2021, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as discontinued operations.  The Company will record the remaining two quarterly installments during the balance of 2021.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exit from Ethyol and Totect meets the accounting criteria to be reported as discontinued operations. December 31, 2019, as the transition date, was the final day Cumberland was responsible for the products. Cumberland was responsible for the products through December 31, 2019 and beginning on January 1, 2020, the products' rights transitioned back to Clinigen. As a result, January 1, 2020, was the first day of discontinued operations for the Ethyol and Totect products.</span></div><ix:nonNumeric contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630" name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RleHRyZWdpb246MGZlYjk3NjIxNmQ3NGJiNzlhYmM0YjZhZjNhZGRiMWRfNTg0NA_a50756f2-8640-467c-af56-6a46cf244a29" escape="true"><div style="margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The dissolution payments from Clinigen are reflected as revenue from discontinued operations.  The Company does not </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">incur expenses associated with these payments from Clinigen. </span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.499%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three months ended June 30,</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0932967c9c90454494cbf245d9fa585d_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RhYmxlOmI0ZDgzZDVmYmQ0ZjQzYWI5YWIxMjFiZmMyNjAxZDQxL3RhYmxlcmFuZ2U6YjRkODNkNWZiZDRmNDNhYjlhYjEyMWJmYzI2MDFkNDFfMy0yLTEtMS02Nzc_33139f42-0425-4d08-841a-9ae006c66914">498,807</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffc2a4291a32445fb79072f7fe43a870_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RhYmxlOmI0ZDgzZDVmYmQ0ZjQzYWI5YWIxMjFiZmMyNjAxZDQxL3RhYmxlcmFuZ2U6YjRkODNkNWZiZDRmNDNhYjlhYjEyMWJmYzI2MDFkNDFfMy00LTEtMS02ODA_cf0ce557-4fdd-47c1-9191-c917bd799f4a">738,622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53d85ca5dcbd44ba870830f97461a800_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RhYmxlOmI0ZDgzZDVmYmQ0ZjQzYWI5YWIxMjFiZmMyNjAxZDQxL3RhYmxlcmFuZ2U6YjRkODNkNWZiZDRmNDNhYjlhYjEyMWJmYzI2MDFkNDFfMi0yLTEtMS0w_1bcf2509-7467-4c5c-b800-3d442a6bcef9">994,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i166678b245754127b39f5e9c73e8cf2d_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RhYmxlOmI0ZDgzZDVmYmQ0ZjQzYWI5YWIxMjFiZmMyNjAxZDQxL3RhYmxlcmFuZ2U6YjRkODNkNWZiZDRmNDNhYjlhYjEyMWJmYzI2MDFkNDFfMi00LTEtMS0w_72de53a1-48b1-4c79-aa3d-faa22b8da99b">1,556,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs of products sold</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0932967c9c90454494cbf245d9fa585d_D20210401-20210630" decimals="0" format="ixt:zerodash" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RhYmxlOmI0ZDgzZDVmYmQ0ZjQzYWI5YWIxMjFiZmMyNjAxZDQxL3RhYmxlcmFuZ2U6YjRkODNkNWZiZDRmNDNhYjlhYjEyMWJmYzI2MDFkNDFfNC0yLTEtMS0xOTMy_73e3971e-9ede-43ec-a884-d62e3d3ee54d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffc2a4291a32445fb79072f7fe43a870_D20200401-20200630" decimals="0" format="ixt:zerodash" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RhYmxlOmI0ZDgzZDVmYmQ0ZjQzYWI5YWIxMjFiZmMyNjAxZDQxL3RhYmxlcmFuZ2U6YjRkODNkNWZiZDRmNDNhYjlhYjEyMWJmYzI2MDFkNDFfNC00LTEtMS0xOTMy_1586e2f5-0081-4c1c-9682-66cbd4db029d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53d85ca5dcbd44ba870830f97461a800_D20210101-20210630" decimals="0" format="ixt:zerodash" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RhYmxlOmI0ZDgzZDVmYmQ0ZjQzYWI5YWIxMjFiZmMyNjAxZDQxL3RhYmxlcmFuZ2U6YjRkODNkNWZiZDRmNDNhYjlhYjEyMWJmYzI2MDFkNDFfMy0yLTEtMS0w_c6231f1b-81ff-41ca-87cd-8167c4dfb7c1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i166678b245754127b39f5e9c73e8cf2d_D20200101-20200630" decimals="0" format="ixt:zerodash" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RhYmxlOmI0ZDgzZDVmYmQ0ZjQzYWI5YWIxMjFiZmMyNjAxZDQxL3RhYmxlcmFuZ2U6YjRkODNkNWZiZDRmNDNhYjlhYjEyMWJmYzI2MDFkNDFfMy00LTEtMS0w_cf7336e0-920d-409c-b057-e4f14bfcab55">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, Marketing and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0932967c9c90454494cbf245d9fa585d_D20210401-20210630" decimals="0" format="ixt:zerodash" name="us-gaap:SellingAndMarketingExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RhYmxlOmI0ZDgzZDVmYmQ0ZjQzYWI5YWIxMjFiZmMyNjAxZDQxL3RhYmxlcmFuZ2U6YjRkODNkNWZiZDRmNDNhYjlhYjEyMWJmYzI2MDFkNDFfNS0yLTEtMS0xOTMy_0ded215b-1970-4e65-82ee-aab2661aaa70">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffc2a4291a32445fb79072f7fe43a870_D20200401-20200630" decimals="0" format="ixt:zerodash" name="us-gaap:SellingAndMarketingExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RhYmxlOmI0ZDgzZDVmYmQ0ZjQzYWI5YWIxMjFiZmMyNjAxZDQxL3RhYmxlcmFuZ2U6YjRkODNkNWZiZDRmNDNhYjlhYjEyMWJmYzI2MDFkNDFfNS00LTEtMS0xOTMy_f002396c-2013-481d-8d86-1381b0958c78">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53d85ca5dcbd44ba870830f97461a800_D20210101-20210630" decimals="0" format="ixt:zerodash" name="us-gaap:SellingAndMarketingExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RhYmxlOmI0ZDgzZDVmYmQ0ZjQzYWI5YWIxMjFiZmMyNjAxZDQxL3RhYmxlcmFuZ2U6YjRkODNkNWZiZDRmNDNhYjlhYjEyMWJmYzI2MDFkNDFfNC0yLTEtMS0w_da98a761-aded-447e-bea5-e45be2b6c435">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i166678b245754127b39f5e9c73e8cf2d_D20200101-20200630" decimals="0" format="ixt:zerodash" name="us-gaap:SellingAndMarketingExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RhYmxlOmI0ZDgzZDVmYmQ0ZjQzYWI5YWIxMjFiZmMyNjAxZDQxL3RhYmxlcmFuZ2U6YjRkODNkNWZiZDRmNDNhYjlhYjEyMWJmYzI2MDFkNDFfNC00LTEtMS0w_08b0d6a7-6055-4baa-a480-0f544d9b0569">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0932967c9c90454494cbf245d9fa585d_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RhYmxlOmI0ZDgzZDVmYmQ0ZjQzYWI5YWIxMjFiZmMyNjAxZDQxL3RhYmxlcmFuZ2U6YjRkODNkNWZiZDRmNDNhYjlhYjEyMWJmYzI2MDFkNDFfNi0yLTEtMS0xOTMy_9c49a1ee-6ffb-4239-938f-58eb8cd99fd1">498,807</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffc2a4291a32445fb79072f7fe43a870_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RhYmxlOmI0ZDgzZDVmYmQ0ZjQzYWI5YWIxMjFiZmMyNjAxZDQxL3RhYmxlcmFuZ2U6YjRkODNkNWZiZDRmNDNhYjlhYjEyMWJmYzI2MDFkNDFfNi00LTEtMS0xOTMy_8a8d90d1-b209-4db6-83bd-e6da9e3763cb">738,622</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53d85ca5dcbd44ba870830f97461a800_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RhYmxlOmI0ZDgzZDVmYmQ0ZjQzYWI5YWIxMjFiZmMyNjAxZDQxL3RhYmxlcmFuZ2U6YjRkODNkNWZiZDRmNDNhYjlhYjEyMWJmYzI2MDFkNDFfNS0yLTEtMS0w_73a58345-6061-4cea-815c-c24f309a2f82">994,217</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i166678b245754127b39f5e9c73e8cf2d_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RhYmxlOmI0ZDgzZDVmYmQ0ZjQzYWI5YWIxMjFiZmMyNjAxZDQxL3RhYmxlcmFuZ2U6YjRkODNkNWZiZDRmNDNhYjlhYjEyMWJmYzI2MDFkNDFfNS00LTEtMS0w_6439f0f5-4367-45f6-bc88-8c80fbf93e63">1,556,895</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><div id="id0faa06a8909446fa2394f59c1490a03_58"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disclosure regarding forward-looking statements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion contains certain forward-looking statements which reflect management&#8217;s current views of future events and operations. These statements involve certain risks and uncertainties, and actual results may differ materially from them. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ significantly from the results discussed in these forward-looking statements. Some important factors which may cause results to differ from expectations include: availability of additional debt and equity capital; market conditions at the time additional capital is required; our ability to continue to acquire branded products; product sales; management of our growth and integration of our acquisitions and impacts on our business as well as national and international markets and economies resulting from the COVID-19 pandemic. While forward-looking statements reflect our beliefs and best judgment based upon current information, they are not guarantees of future performance. Other important factors that may cause actual results to differ materially from forward-looking statements are discussed in the sections entitled &#8220;Risk Factors&#8221; and &#8220;Special Note Regarding Forward-Looking Statements&#8221; of our Annual Report on Form 10-K for the year ended December 31, 2020, and our other filings with the SEC.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not undertake to publicly update or revise any of our forward-looking statements, even in the event that experience or future changes indicate that the anticipated results will not be realized. The following presentation of management&#8217;s discussion and analysis of financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and related notes included in this report on Form 10-Q.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div><span><br/></span></div><div id="id0faa06a8909446fa2394f59c1490a03_61"></div><div style="-sec-extract:summary;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OVERVIEW</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Business</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland Pharmaceuticals Inc. (&#8220;Cumberland,&#8221; the &#8220;Company,&#8221; or as used in the context of &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;), is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. We are dedicated to providing innovative products that improve the quality of care for patients and address poorly met medical needs. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary target markets are hospital acute care, gastroenterology and rheumatology. These medical specialties are characterized by relatively concentrated prescriber bases that we believe can be served effectively by small, targeted sales forces. We promote our approved products through our hospital and field sales forces in the United States and are establishing a network of international partners to register and provide our medicines to patients in their countries.</span></div><div style="margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of FDA approved brands include:</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Acetadote</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">acetylcysteine</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) Injection, for the treatment of acetaminophen poisoning; </span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Caldolor</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ibuprofen</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) Injection, for the treatment of pain and fever;</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Kristalose</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">lactulose</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) for Oral Solution, a prescription laxative, for the treatment of chronic and acute constipation;</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Omeclamox</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">-Pak</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">omeprazole, clarithromycin, and amoxicillin</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) for the treatment of Helicobacter pylori (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">H. pylori</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) infection and related duodenal ulcer disease;</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">RediTrex</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">methotrexate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) Injection,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the treatment of active rheumatoid, juvenile idiopathic and severe psoriatic arthritis, as well as disabling psoriasis;</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Vaprisol</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">conivaptan</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) Injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Vibativ</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">telavancin</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) Injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to these commercial brands, we have Phase II clinical programs underway evaluating our ifetroban product candidates being used by patients with cardiomyopathy associated with Duchenne Muscular Dystrophy (&#8220;DMD&#8221;), a degenerative disease, Systemic Sclerosis (&#8220;SSc&#8221;), a deadly autoimmune condition, and Aspirin-Exacerbated Respiratory Disease (&#8220;AERD&#8221;), a severe form of asthma.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has built core competencies in both the development and commercialization of pharmaceutical products. We have established the capabilities needed to acquire, develop and commercialize branded pharmaceuticals in the U.S. and believe we can leverage this existing infrastructure to support our expected growth. Our management team consists of pharmaceutical industry veterans experienced in business development, product development, regulatory, manufacturing, sales, marketing and finance. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business development team identifies, evaluates, and negotiates product acquisition, licensing and co-promotion agreements. Our product development team creates proprietary product formulations, manages our clinical studies, prepares all regulatory submissions and staffs our medical call center. Our quality and manufacturing professionals oversee the manufacturing, release and shipment of our products. Our marketing and sales team is responsible for our commercial activities, and we work closely with our distribution partners to ensure availability and delivery of our products.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Growth Strategy</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland's growth strategy involves maximizing the potential of our existing brands while continuing to build a portfolio of differentiated products. We currently feature seven FDA products approved for sale in the United States.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through our international partners, we are working to bring our medicines to patients in their countries. We also look for opportunities to expand our products into additional patient populations through clinical trials, new presentations and our support for select, investigator-initiated studies. We actively pursue opportunities to acquire additional marketed products, as well as late-stage development product candidates in our target medical specialties. Our clinical team is developing a pipeline of new product candidates largely to address poorly met medical needs.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are supplementing these activities with the earlier stage drug development at Cumberland Emerging Technologies (&#8220;CET&#8221;), our majority-owned subsidiary. CET partners with academic research institutions to identify and support the progress of promising new product candidates, which Cumberland has the opportunity to further develop and commercialize.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, we are seeking long-term sustainable growth by:</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Supporting and expanding the use of our marketed products </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to evaluate our products following their FDA approval to determine if additional clinical data could expand their market and use. We will continue to explore opportunities for label expansion to bring our products to new patient populations. As examples, we have secured pediatric approval, expanding the labeling for both our Acetadote and Caldolor brands. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selectively adding complementary brands - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our product development activities, we are also seeking to acquire products or late-stage development product candidates to continue building a portfolio of complementary brands. We focus on under-promoted, FDA-approved drugs as well as late-stage development products that address poorly met medical needs. We will continue to target product acquisition candidates that are competitively differentiated, have valuable intellectual property or other protective features, and allow us to leverage our existing infrastructure. Our acquisition of Vibativ is an example of this strategy.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Progressing our clinical pipeline and incubating future product opportunities at CET -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We believe it is important to build a pipeline of innovative new product opportunities, such as we are doing through our ifetroban Phase II development programs. We are also supplementing our acquisition and late-stage development activities with early-stage drug development activities at CET. CET partners with universities and other research organizations to develop promising, early-stage product candidates, which Cumberland has the opportunity to further develop and commercialize. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leveraging our infrastructure through co-promotion partnerships - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our commercial infrastructure can help drive prescription volume and product sales. We look for strategic partners that can complement our capabilities and enhance opportunities for our brands. For example, our co-promotion partnership with Poly Pharmaceuticals, Inc. and Foxland Pharmaceuticals, Inc. has allowed us to expand support for Kristalose across the United States.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">     </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Building an international market -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We have established our own commercial capabilities, including two sales divisions, to cover the U.S. market for our products. We are also building a network of select international partners to register our products and make them available to patients in their countries. We will continue to develop and expand our network of international partners while supporting our partners&#8217; registration and commercialization efforts in their respective territories. The acquisition of Vibativ resulted in several new international partners and market opportunities.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Managing our operations with financial discipline -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We continually work to manage our expenses in line with our revenues in order to deliver positive cash flow from operations. We remain in a strong financial position, with favorable gross margins and a strong balance sheet. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated in 1999 and have been headquartered in Nashville, Tennessee since inception. During 2009, we completed an initial public offering of our common shares and listing on the Nasdaq stock exchange. Our website address is www.cumberlandpharma.com. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make available through our website our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and all material press releases and other reports as soon as reasonably practicable after their filing with the U.S. Securities and Exchange Commission, (&#8220;SEC&#8221;). These filings are also available to the public at </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">www.sec.gov</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RECENT DEVELOPMENTS</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Pandemic </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the U.S. declared a health care emergency following the outbreak of SARS-CoV-2, a novel strain of coronavirus that causes COVID-19, a respiratory illness. The Company has managed through the COVID-19 pandemic, continuing to operate our business &#8211; keeping facilities open and our organization intact. We also maintained our ongoing compliance with the many laws and regulations that apply to us as a publicly traded pharmaceutical company.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout the pandemic, Cumberland faced the same challenges affecting other companies that rely on hospital admissions and patient visits to drive revenue. Our business and our clinical studies were impacted, as fewer patients sought elective surgeries and our access to medical facilities was substantially limited. Throughout the pandemic, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we carefully monitored our supply chain, including the flow of raw materials into the plants that manufacture our products, as well as the batches of finished products emerging from those facilities. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several of our brands were negatively impacted by the lockdowns and postponement of physician office visits and elective procedures. However, we are fortunate to have a diversified product portfolio that includes other brands, such as Vaprisol, that delivered a strong performance during the pandemic.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have responded to the pandemic with a fast and coordinated approach to ensure the health and safety of our team. We were also able to continue the delivery of our products, while addressing the interests of our shareholders, employees, partners and community.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ESG Report</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, we released our second annual Sustainability Report ("ESG Report"), which details Cumberland&#8217;s activities pertaining to environmental, social and governance (&#8220;ESG&#8221;) matters. After issuing our inaugural ESG report last year, we remain committed to sustainability and to maintaining transparency of our corporate operations. As the largest biopharmaceutical company founded and headquartered in the Mid-South, we hold ourselves to the highest standards of ethical practices and understand the importance of recognizing and addressing our impact on our constituents, the community and the environment.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ESG Report notes that in 2020 we provided nearly 2.5 million patient doses of our products, safely disposed of over 4,000 pounds of expired and damaged products and had no product recalls. We also had no Company brands that were listed on the FDA&#8217;s MedWatch Safety Alerts for Human Medical Products, no Company product issues that were identified by FDA from their Adverse Event Reporting System and no clinical trials that were terminated due to failure to practice good clinical standards.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ESG Report also highlights several initiatives we implemented as part of our commitment to delivering high-quality pharmaceutical products to improve patient care. For example, we continued a program to serialize all commercial products sold in the United States, allowing us to track every unit distributed, which helps to prevent counterfeit drugs from entering the market under the Cumberland brand. In addition, through our coupon program, Cumberland covers up to 90% of patient prescription costs for our gastrointestinal products.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ESG Report also highlights our investment in our employees through our continuing education programs, employee development initiatives and employee recognition awards. Cumberland&#8217;s workforce is 46% women &#8211; and 18% of our employees are minorities.</span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Chief Financial Officer Appointment</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 17, 2021, Cumberland appointed John Hamm as the new Senior Director Finance &amp; Accounting and Chief Financial Officer. In this role, he will manage all of the Company&#8217;s finance and accounting activities while continuing to oversee corporate development and legal matters. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Hamm has more than 25 years of finance and accounting experience, including 20 years in health care. He previously held the positions of Chief Operating Officer and Chief Financial Officer, Pharmacy at HealthSpring, Inc., a managed care organization now operating as Cigna-HealthSpring. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">He was also the Vice President Finance at Emdeon Business Services. Emdeon Inc., a healthcare technology firm now operates as Change Healthcare Inc., a NASDAQ listed company with over $3 billion in annual revenue.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Hamm holds a Bachelor of Science in Business Administration with a minor in Accounting from Wheeling University. He earned his Master&#8217;s in Business Administration with an emphasis in Accounting from West Virginia University. He is a Certified Management Accountant (CMA) and Certified Financial Manager (CFM).</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to this new appointment, Mr. Hamm served as Cumberland&#8217;s Director Corporate Development. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Paycheck Protection Program</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 20, 2020, Cumberland received the funding of a loan from Pinnacle Bank in the aggregate amount of $2,187,140 pursuant to the Paycheck Protection Program (the &#8220;PPP&#8221;) under the Federal Coronavirus Aid, Relief and Economic Security Act (&#8220;CARES Act&#8221;), which was enacted March 27, 2020. The PPP is administered by the U.S. Small Business Administration (&#8220;SBA&#8221;). </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the PPP requirements, loan funds were used to maintain payroll, continue group health care benefits, and pay for rent and utilities during the pandemic. We applied for this loan after carefully considering, with our bank, the eligibility criteria to participate in this program, and determining that Cumberland met those criteria. We evaluated and provided information on our payroll and other qualifying expenses to determine the amount of PPP funds to apply for. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the PPP, certain amounts of the loan may be forgiven if they are used for qualifying expenses as described in the CARES Act. Cumberland used the PPP loan funds for such qualifying expenses. Due to assistance from our PPP loan, the Company did not lay off or furlough any employees as a result of the COVID-19 pandemic.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, Cumberland submitted a request for the loan&#8217;s forgiveness. On June 11, 2021, the Company received a formal notice from the SBA that the full amount of the loan was forgiven. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RediTrex Launch</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During late 2018, we completed the submission of and filed with the U.S. Food and Drug Administration (&#8220;FDA&#8221;) a New Drug Application for RediTrex, our methotrexate products. RediTrex is a new line of pre-filled syringes specifically designed for ease of handling and dosing accuracy for the subcutaneous administration of methotrexate in patients with arthritis and psoriasis.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, we received FDA approval for RediTrex and began planning for the launch of the product line. We provided initial shipments of RediTrex to select accounts in November 2020 and we are planning to launch the product line nationally in late September 2021. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ifetroban Phase II Studies</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been evaluating our ifetroban product candidate in a series of clinical studies. We are sponsoring Phase II clinical programs to evaluate our ifetroban product candidates in 1) patients with cardiomyopathy associated with Duchenne Muscular Dystrophy, a rare, fatal, genetic neuromuscular disease that results in deterioration of the skeletal, heart and lung muscles, 2) Systemic Sclerosis or scleroderma, a debilitating autoimmune disorder characterized by diffuse fibrosis of the skin and internal organs and 3) Aspirin-Exacerbated Respiratory Disease, a severe form of asthma. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have completed two pilot Phase II studies involving 1) patients suffering from Hepatorenal Syndrome, a life-threatening condition involving liver and kidney failure and 2) patients with Portal Hypertension that is associated with chronic liver disease.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional pilot preclinical and clinical studies of ifetroban are underway, including several investigator-initiated trials. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Enrollment in our clinical studies was interrupted due to the COVID-19 pandemic. While enrollment of new patients has been limited, many of our clinical study sites have reopened and resumed screening of patients for potential enrollment into our studies. We are awaiting results from the studies underway before deciding on the best development path for the registration of ifetroban, our first new chemical entity.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Hospital Product Candidate</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland was responsible for the formulation, development and FDA approval of both Acetadote and Caldolor. Our Medical Advisory Board has helped us identify additional opportunities that address unmet or poorly met medical needs. As a result, Cumberland has successfully designed, formulated and completed the preclinical studies for a cholesterol-reducing agent for use in the hospital setting. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We completed a Phase I study which defined the pharmacokinetic properties and provided a favorable safety profile for this new product candidate. The study results and a proposed clinical development plan were discussed with the FDA.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also completed a Phase II study to further evaluate administration, dosing and pharmacokinetics of the product. We are now evaluating the next steps for this product development program.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Omeclamox-Pak Supply Update</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has partnered with a select group of FDA-approved facilities to manufacture its line of branded pharmaceutical products and has been carefully monitoring its supply chain during the pandemic. The packager for our Omeclamox-Pak product encountered financial difficulties, and their operations are currently suspended. We are awaiting the resumption of those operations, while also exploring other alternatives to restart the product&#8217;s packaging.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Meanwhile, we informed the FDA of a shortage of the Omeclamox-Pak effective October 14, 2020 and have not provided a date for the availability of new inventory.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Generic IV Acetaminophen</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Four generic companies have launched acetaminophen for injection products that provide an alternative to our Caldolor product for the treatment of acute surgical pain.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite the challenges of operating during a pandemic, Cumberland remains committed to our mission of providing innovative products that improve the quality of care for patients and address poorly met medical needs. We are working to fulfill this mission by building a portfolio of innovative and differentiated products through a multifaceted strategy that includes development of new candidates and acquisition of established brands. Our resulting, diversified product line has enabled us to weather external challenges, while our team has remained responsive to the evolving medical market. We are prepared for and look forward to future opportunities to carry out our mission.</span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div id="id0faa06a8909446fa2394f59c1490a03_64"></div><div style="margin-top:8pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CRITICAL ACCOUNTING POLICIES AND SIGNIFICANT JUDGMENTS AND ESTIMATES</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see a discussion of our critical accounting policies and significant judgments and estimates in Note 1 to the Company's Condensed Consolidated Financial Statements accompanying this report and the section entitled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in our 2020 Annual Report on Form 10-K.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting Estimates and Judgments</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. We base our estimates on past experience and on other factors we deem reasonable given the circumstances. Past results help form the basis of our judgments about the carrying value of assets and liabilities that cannot be determined from other sources. Actual results could differ from these estimates. These estimates, judgments and assumptions are most critical with respect to our accounting for revenue recognition, inventories, fair value of contingent consideration liability associated with a business combination, share-based compensation and intangible assets.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><div id="id0faa06a8909446fa2394f59c1490a03_67"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three months ended June 30, 2021 compared to the three months ended June 30, 2020 </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the unaudited interim statements of operations for continuing operations for the three months ended June 30, 2021 and 2020:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.753%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,055,483&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,598,177&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(542,694)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,740,649&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,609,982&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(869,333)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling and marketing</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,121,817&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,865,406&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,411&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,360,398&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,421,502&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61,104)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,097,130&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,190,764&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93,634)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,171,218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091,485&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,733&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,491,212&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,179,139&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(687,927)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,435,729)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,580,962)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,233&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,591&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,661&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,070)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,187,140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,187,140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,859)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119,455)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,596&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from continuing operations before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">732,143&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,671,756)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,403,899&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (expense) benefit</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,459)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,455)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">724,684&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,679,211)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,403,895&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes net revenues by product for the periods presented: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.753%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristalose</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,275,065&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,477,471&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,797,594&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,844,936&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,299,507&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,454,571)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938,328&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,166,569&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(228,241)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaprisol</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399,952&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,793&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acetadote</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,781&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">595,310&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(442,529)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Omeclamox-Pak</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,109)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,948&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,057)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RediTrex</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,382&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,382&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">461,148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">874,213&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(413,065)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenues</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,055,483&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,598,177&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(542,694)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net revenues.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Net revenues for the three months ended June 30, 2021, were $9.1 million compared to $9.6 million for the three months ended June 30, 2020.  As detailed in the table above, net revenue increased for two of our marketed products: Kristalose and Vaprisol during the quarter.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kristalose revenue increased by 51.7% during the second quarter of 2021 to $5.3 million, when compared to the prior year period.  The increase was primarily the result of growth in shipments of the product to our wholesale customers.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vaprisol revenue was $0.4 million for the second quarter of 2021, an increase of $0.2 million. This increase of net sales compared to the second quarter of 2020 is primarily due to increased utilization in supporting patients impacted by COVID-19 infections. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Caldolor revenue was $0.9 million for the second quarter of 2021, a decrease of $0.2 million compared to the same period last year. The decrease was the result of lower international shipments of the product, due to order timing.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vibativ revenue was $1.8 million for the three months ended June 30, 2021, compared to $3.3 million the same period last year.  The decrease was a result of decreased domestic and international sales volumes during the period due to order timing.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Omeclamox-Pak had no sales for the second quarter of 2021, as Cumberland is currently out of commercial inventory of this product. The packager for our Omeclamox-Pak product encountered financial difficulties, and currently is under new management and a reorganization. We are in discussions about the resumption of packaging the product.  Net revenue for the second quarter of 2021 was negatively impacted by product returns during the period.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acetadote revenue includes net sales of our Acetadote brand and our share of net sales from our Authorized Generic. During the quarter, there was a decrease of $0.4 million in the product's revenue when compared to the prior year period as a result of lower sales volumes during the period, impacted by generic competition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of products sold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Co</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">st of products sold for the second quarter of 2021 and 2020 were $1.7 million and $2.6 million, respectively. Cost of products sold, as a percentage of net revenues, were 19.2% during the three months ended June 30, 2021, compared to 27.2% during the three months ended June 30, 2020.  This change in costs of products sold as a percentage of revenue was attributable to a change in the product sales mix, particularly the decrease in sales of Vibativ.  The Vibativ inventory sold during the period was acquired and paid for by Cumberland as part of the acquisition of the brand during 2018.  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling and marketing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Selling and marketing expense for the second quarter of 2021 increased $0.3 million compared to the prior year period.  This increase is primarily attributable to an increase in marketing spending for RediTrex and Vibativ.  Lower royalty costs were partially offset by an increase in direct promotional spending, meeting costs and travel expenses during the second quarter of 2021. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Research and development costs were $1.4 million for the second quarter of 2021 and approximately the same as for the same period last year.  A portion of our research and development costs is variable based on the number of trials, study sites, number of patients and the cost per patient in each of our clinical programs. We continue to fund our ongoing clinical initiatives associated with our pipeline products.     </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  General and administrative expense for the second quarter of 2021 were $2.1 million, consistent with the second quarter of 2020. There were increases in professional, legal and insurance costs which were offset by decreases in non-cash stock based compensation during the second quarter of 2021.  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the statements of operations discussed above reflect the following impacts from Vibativ:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Impact of Vibativ</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended June 30,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,844,936&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,299,507&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">678,146&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,220,054&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty and operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">767,813&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">834,395&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ contribution</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398,977&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,245,058&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> The Vibativ inventory included in the costs of product sold during the period was acquired and paid for by Cumberland as part of the acquisition of the brand during 2018.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortization.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Amortization expense is the ratable use of our capitalized intangible assets including product and license rights, patents, trademarks and patent defense costs.  Amortization for the three months ended June 30, 2021, and three months ended June 30, 2020, totaled approximately $1.2 million and $1.1 million, respectively. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Income tax expense for the three months ended June 30, 2021, was comparable to the income tax expense for the three months ended June 30, 2020.  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021, we had approximately $44 million of net operating loss carryforwards resulting from the exercise of nonqualified stock options that have historically been used to significantly offset income tax obligations.  We expect to continue to pay minimal income taxes during 2021 and beyond, through the continued utilization of these net operating loss carryforwards, on any taxable income generated from our operations. </span></div><div id="id0faa06a8909446fa2394f59c1490a03_504"></div><div><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Six months ended June 30, 2021 compared to the six months ended June 30, 2020 </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the unaudited interim statements of operations for continuing operations for the six months ended June 30, 2021 and 2020:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,592,642&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,928,911&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,663,731&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,157,978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,244,163&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86,185)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling and marketing</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,909,157&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,573,082&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336,075&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,617,765&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,144,057&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(526,292)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,327,639&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,227,048&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,591&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,340,132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,167,524&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,608&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,352,671&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,355,874&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,203)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,760,029)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,426,963)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,666,934&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,017&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,549&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46,532)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,187,140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,187,140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,276)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(152,520)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from continuing operations before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388,852&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,520,934)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,909,786&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (expense) benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,917)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,695)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,778&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373,935&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,562,629)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,936,564&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes net revenues by product for the periods presented: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.680%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.154%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristalose</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,269,443&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,771,433&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,498,010&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,897,179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,721,708&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,175,471&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,477,824&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,261,286&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216,538&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaprisol</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,534,216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382,016&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,152,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acetadote</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269,972&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,308,711&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,038,739)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Omeclamox-Pak</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(474,371)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,371&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(598,742)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RediTrex</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,870)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,870)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">643,249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,359,386&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(716,137)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,592,642&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,928,911&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,663,731&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net revenues.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Net revenues for the six months ended June 30, 2021, were $19.6 million compared to $17.9 million for the six months ended June 30, 2020.  As detailed in the table above, net revenue increased for our marketed products:  Kristalose, Vibativ, Caldolor and Vaprisol during the first six months of 2021 resulting in an overall 9.3% revenue increase.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kristalose revenue was $8.3 million during the first six months of 2021, an increase of $1.5 million when compared with the prior year period.  Revenue increased due to continued strong sales volume from our Foxland distributor and other wholesalers.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vibativ revenue was $6.9 million for the six months ended June 30, 2021, an increase of $1.2 million over the same period last year.  The 20.5% increase in net revenue was a result of improved sales volume for the product during the first quarter 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vaprisol revenue was $1.5 million for the first six months of 2021, which is an increase of net sales of $1.2 million compared to the first six months of 2020 primarily due to increased sales volumes which is the result of increased utilization in supporting patients impacted by COVID-19 infections.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Omeclamox-Pak had no sales for the six months ended June 30, 2021, as Cumberland is currently out of commercial inventory of this product. The packager for our Omeclamox-Pak product encountered financial difficulties and currently is under new management and a reorganization. We are in discussions about the resumption of packaging the product.  Net revenue for the first two quarters of 2021 was negatively impacted by product returns during the period.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acetadote revenue includes net sales of our Acetadote brand and our share of net sales from our Authorized Generic. There was a decrease of $1.0 million in the product's year to date revenue for the six months ended June 30, 2021, when compared to the prior year period as a result of lower sales volumes for our Authorized Generic.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Caldolor revenue was $2.5 million for the first two quarters of 2021, an increase of $0.2 million compared to the same period last year. Domestic shipments of the product increased in the second quarter of 2021.  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of products sold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Co</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">st of products sold for the first six months of 2021 and 2020 were both $4.2 million remaining consistent. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling and marketing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Selling and marketing expense for the six months ended June 30, 2021, increased $0.3 million compared to the prior year period.  This increase is primarily attributable to increases in royalty costs as well as an increase in salaries and dispensing fees.  These increases were partially offset by decreases in direct sales promotion costs and travel expenses.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Research and development costs were $2.6 million for the first six months of  2021 compared to  $3.1 million for the same period last year.  A portion of our research and development costs is variable based on the number of trials, study sites, cost of the per patient study protocol and patients involved in the development of our new product candidates. We continue to fund our ongoing clinical initiatives associated with our pipeline products.  We experienced a decrease in study activity and salaries offset by an increase in our consulting fees.      </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  General and administrative expense for the six months ended June 30, 2021, remained consistent with $4.3 million from $4.2 million during the six months ended June 30, 2020.  Although we experienced increases in advisory, legal and professional fees, we also had a reduction in non-cash stock based compensation and other benefits during the period. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the statements of operations discussed above reflect the following impacts from Vibativ:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:57.767%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.721%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Impact of Vibativ</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,897,179&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,721,708&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,134,962&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,820,745&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty and operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,170,165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">753,177&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ contribution</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,592,052&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,147,786&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> The Vibativ inventory included in the costs of product sold during the period was acquired and paid for by Cumberland as part of the acquisition of the brand during 2018.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortization.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Amortization expense is the ratable use of our capitalized intangible assets including product and license rights, patents, trademarks and patent defense costs.  Amortization for the six months ended June 30, 2021, and six months ended June 30, 2020, totaled approximately $2.3 million and $2.2 million, respectively. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Income tax expense (benefit) for the six months ended June 30, 2021, as a percentage of income (loss) from continuing operations before income taxes, was (3.8)% compared to (1.2)% for the six months ended June 30, 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div><span><br/></span></div><div id="id0faa06a8909446fa2394f59c1490a03_70"></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIQUIDITY AND CAPITAL RESOURCES</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Working Capital</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary sources of liquidity are cash equivalents, cash flows from operations and the amounts borrowed and available under our line of credit. We believe that our internally generated cash flows, existing working capital and our line of credit will be adequate to finance internal growth, finance business development initiatives, and fund capital expenditures for the foreseeable future. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our liquidity and working capital as of June 30, 2021 and December 31, 2020:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:58.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.458%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.461%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:7pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,670,462&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,753,796&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working capital (current assets less current liabilities)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,033,715&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,302,146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current ratio (multiple of current assets to current liabilities)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolving line of credit availability</span></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:11pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our net changes in cash and cash equivalents for the six months ended June 30, 2021 and June 30, 2020:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:58.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.458%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.461%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,484,770&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,704,071&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(366,854)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(773,014)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,201,250)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,769,955)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">916,666&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(838,898)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net $0.9 million increase in cash and cash equivalents for the six months ended June 30, 2021, was primarily attributable to cash provided by operating activities, partially offset by cash used in investing and financing activities.  Cash provided by operating activities of $4.5 million was positively impacted by decreases in inventory of $2.3 million and accounts receivable of $3.2 million, as well as the add back of non-cash expenses of depreciation, amortization and share-based compensation expense totaling $2.8 million.  Operating activities were also offset by the decrease in accounts payable of $3.0 million and the forgiveness of our PPP Loan of $2.2 million.  Cash used in investing activities was the result of additions to intangibles of $0.1 million and the payment of $0.2 million to the WHC JV.  Our financing activities included the $0.8 million in cash used to repurchase shares of our common stock as well as the $1.4 million used for the payment of royalties to Theravance for sales of Vibativ. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net $0.8 million decrease in cash and cash equivalents for the six months ended June 30, 2020, was primarily attributable to cash used in investing and financing activities.  Cash provided by operating activities of $3.7 million was positively impacted by decreases in  inventory of $1.2 million, as well as the add back of non-cash expenses of depreciation, amortization and share-based compensation expense totaling $2.9 million.  Cash used in investing activities was the result of additions to intangibles of $0.7 million and equipment of $0.1 million.  Our financing activities included the net repayment of $1.5 million on our revolving line of credit, the $1.2 million in cash used to repurchase shares of our common stock as well as the $0.8 million used for the repurchase of subsidiary shares. </span></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Debt Agreement</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 7, 2020, we entered into a Fourth Amendment (&#8220;Fourth Amendment&#8221;) to the Revolving Credit Loan Agreement, dated July 28, 2017, with Pinnacle Bank (the &#8220;Pinnacle Agreement&#8221;). The Fourth Amendment extends the maturity date of the Pinnacle Agreement through October 1, 2022 and provides for a principal available for borrowing of up to $15 million.  We also have the ability to request an increase of up to an additional $5 million, upon the satisfaction of certain conditions and approval by Pinnacle Bank. If fully expanded, the Fourth Amendment would provide a maximum principal available for borrowing of up to $20 million. On May 10, 2019, we entered into a third amendment ("Third Amendment") to the Pinnacle Agreement. The Third Amendment extended the term of the Pinnacle Agreement through July 31, 2021, as well as modified certain definitions and terms of the existing financial covenants.  For a summary of the material terms of the Pinnacle Agreement, as amended, see Note 6 to the accompanying unaudited condensed consolidated financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Pinnacle Agreement, we were initially subject to one financial covenant, the maintenance of a Funded Debt Ratio. On August 14, 2018, we amended the Pinnacle Agreement ("First Amendment") to replace the single financial covenant with the maintenance of either the Funded Debt Ratio or a Tangible Capital Ratio, as defined in the First Amendment.  The Third Amendment modified the definition of the Funded Debt Ratio and the compliance target of the Tangible Capital Ratio. Both Third Amendment modifications were related to the Vibativ transaction.  We were in compliance with the Tangible Capital Ratio financial covenant as of June 30, 2021. We expect to maintain compliance with the Tangible Capital Ratio financial covenant in future periods. </span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Paycheck Protection Program Loan</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 20, 2020, Cumberland received the funding of a loan from Pinnacle Bank in the aggregate amount of $2,187,140 pursuant to the Paycheck Protection Program (the &#8220;PPP&#8221;) under the Federal Coronavirus Aid, Relief, and Economic Security Act ("CARES Act"), which was enacted March 27, 2020. For a summary of the material terms of the Paycheck Protection Program loan, see Note 6 to the accompanying unaudited condensed consolidated financial statements.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the terms of the PPP, certain amounts of the loan may be forgiven if they are used for qualifying expenses as described in the CARES Act, including qualifying payroll costs, covered rent payments, and covered utilities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cumberland used the PPP loan funds for such qualifying expenses. Due to assistance from our PPP loan, the Company did not lay off or furlough any employees as a result of the COVID-19 pandemic.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, Cumberland submitted a request for the loan&#8217;s forgiveness. On June 11, 2021, the Company received a formal notice from the SBA that the full amount of the loan was forgiven. </span></div><div id="id0faa06a8909446fa2394f59c1490a03_73"></div><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OFF-BALANCE SHEET ARRANGEMENTS</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June 30, 2021 and 2020, we did not engage in any off-balance sheet arrangements.</span></div><div id="id0faa06a8909446fa2394f59c1490a03_76"></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3. Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risk related to changes in interest rates on our cash on deposit in highly-liquid money market accounts and our revolving credit facility. We do not utilize derivative financial instruments or other market risk-sensitive instruments to manage exposure to interest rate changes. The main objective of our cash investment activities is to preserve principal while maximizing interest income through low-risk investments. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our interest rate risk related to our cash and cash equivalents is not material. The risk related to interest rates for these accounts would produce less income than expected if market interest rates fall. Based on current interest rates, we do not believe we are exposed to significant downside risk related to a change in interest on our money market accounts at June 30, 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate risk related to borrowings under our line of credit is based on LIBOR plus an interest rate spread.  The pricing under the Fourth Amendment of the Pinnacle Agreement provides for an interest rate spread of 1.75% to 2.75% above LIBOR with a minimum LIBOR of 0.90%. The applicable interest rate under the Pinnacle Agreement was 3.65% at June 30, 2021.   As of June 30, 2021, we had $14.0 million in borrowings outstanding under our revolving credit facility. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exchange Rate Risk</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we operate primarily in the United States, we are exposed to foreign currency risk.  Currently, we do not utilize financial instruments to hedge exposure to foreign currency fluctuations.  We believe our exposure to foreign currency fluctuation is minimal as our purchases in foreign currency have a maximum exposure of 90 days based on invoice terms with a portion of the exposure being limited to 30 days based on the due date of the invoice.  Foreign currency exchange gains and losses were immaterial for the six months ended June 30, 2021 and 2020.  Neither a five percent increase nor decrease from current exchange rates would have a material effect on our operating results or financial condition.</span></div><div id="id0faa06a8909446fa2394f59c1490a03_79"></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4. Controls and Procedures</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management, with the participation of the Company&#8217;s Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company&#8217;s disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on such evaluation, the Company&#8217;s Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of such period, the Company&#8217;s disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms and is accumulated and communicated to the Company&#8217;s management, including its Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June 30, 2021, there has not been any change in our internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><div id="id0faa06a8909446fa2394f59c1490a03_82"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II &#8211; OTHER INFORMATION</span></div><div id="id0faa06a8909446fa2394f59c1490a03_85"></div><div style="-sec-extract:summary;margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1. Legal Proceedings</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="id0faa06a8909446fa2394f59c1490a03_88"></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1A. Risk Factors</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to the other information set forth in this quarterly report, an investor should consider the risk factors included in the Company's Annual Report on Form 10-K for the year ended December 31, 2020.</span></div><div id="id0faa06a8909446fa2394f59c1490a03_91"></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchases of Equity Securities</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have a share repurchase program to purchase up to $10 million of our common stock pursuant to Rule 10b-18 of the Exchange Act. In January 2019, our Board of Directors established the current $10 million repurchase program to replace the prior authorizations for repurchases of our outstanding common stock.  </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity, by month, during the three months ended June 30, 2021:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:37.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.574%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.598%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.207%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.577%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Period</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number&#160;of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares or Units</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Purchased, which were also Part of the Publicly Announced Plans or Programs</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price&#160;Paid</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">per&#160;Share</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(or Unit)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maximum&#160;Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(or Approximate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollar Value) of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares&#160;(or&#160;Units)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">that May Yet Be</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Purchased&#160;Under</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">the Plans or</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Programs</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,977</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.03&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,808,276&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,459</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.84&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,698,887&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,969</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,402,064&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158,405</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Of this amount, 66,321 shares were repurchased directly through private purchases at the then-current fair market value of common stock.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><div id="id0faa06a8909446fa2394f59c1490a03_94"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6. Exhibits</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.617%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.722%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000162828021010388/a8-kexhibit1016.htm">Employment Agreement, dated May 14, 2021, effective as of May 17, 2021, by and between John Hamm and Cumberland Pharmaceuticals Inc., incorporated herein by reference to Exhibit 10.16 of the Registrant&#8217;s Current Report on Form 8-K (File No. 001-33637) as filed with the SEC on May 14, 2021</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2021q2-exhibit311.htm">Certification of Chief Executive Officer Pursuant to Rule 13-14(a) of the Securities Exchange Act of 1934 as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2021q2-exhibit312.htm">Certification of Chief Financial Officer Pursuant to Rule 13-14(a) of the Securities Exchange Act of 1934 as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2021q2-exhibit321.htm">Certification of Chief Executive and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INLINE XBRL INSTANCE DOCUMENT - THE INSTANCE DOCUMENT DOES NOT APPEAR IN THE INTERACTIVE DATA FILE BECAUSE ITS XBRL TAGS ARE EMBEDDED WITHIN THE INLINE XBRL DOCUMENT.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INLINE XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COVER PAGE INTERACTIVE DATA FILE (FORMATTED AS INLINE XBRL AND CONTAINED IN EXHIBIT 101)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furnished herewith.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><div id="id0faa06a8909446fa2394f59c1490a03_97"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:8.288%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.980%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.184%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.669%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.207%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.072%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.184%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.416%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumberland Pharmaceuticals Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 13, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ John Hamm</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John Hamm</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer and Duly Authorized Officer</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>a2021q2-exhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="id8020ea0742a42f188565b3d0b48af47_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION&#160;302 OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, A.J. Kazimi, certify that&#58;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I have reviewed this Form 10-Q of Cumberland Pharmaceuticals Inc.&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div></td></tr></table></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div></td></tr></table></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:50.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.164%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 13, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; A.J. Kazimi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A.J. Kazimi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>a2021q2-exhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ibfe4670213dd4318a45f231392510a32_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION&#160;302 OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, John Hamm, certify that&#58;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I have reviewed this Form 10-Q of Cumberland Pharmaceuticals Inc.&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div></td></tr></table></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div></td></tr></table></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:50.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.158%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.164%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 13, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; John Hamm</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John Hamm</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>a2021q2-exhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i69c1fa675cc546148f3e71c7d1189363_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE AND</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION&#160;1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION&#160;906</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form&#160;10-Q for the fiscal quarter ended June 30, 2021 of Cumberland Pharmaceuticals Inc. (the &#8220;Company&#8221;), as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, A.J. Kazimi, Chief Executive Officer and John Hamm, Chief Financial Officer of the Company, certify, pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. section 1350), that&#58;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Report fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934&#59; and</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:38.888%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; A. J. Kazimi</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A.J. Kazimi</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 13, 2021</font></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; John Hamm</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John Hamm</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 13, 2021</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:right"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>cpix-20210630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:976bbab0-2784-42fd-860c-1897d99c723d,g:5df55cfc-81cf-4a6f-b91d-2b22fdc37eaa-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cpix="http://www.cumberlandpharma.com/20210630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.cumberlandpharma.com/20210630">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20210630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20210630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20210630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20210630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.cumberlandpharma.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperations" roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>1004005 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementofEquity" roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity">
        <link:definition>1005006 - Statement - Condensed Consolidated Statement of Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentation" roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation">
        <link:definition>2101101 - Disclosure - Organization and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentationPolicies" roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies">
        <link:definition>2202201 - Disclosure - Organization and Basis of Presentation (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentationOrganizationDetails" roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails">
        <link:definition>2403401 - Disclosure - Organization and Basis of Presentation Organization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerShare" roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShare">
        <link:definition>2104102 - Disclosure - Earnings (Loss) Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerShareTables" roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables">
        <link:definition>2305301 - Disclosure - Earnings (Loss) Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerShareDetails" roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails">
        <link:definition>2406402 - Disclosure - Earnings (Loss) Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerShareDetailsTextual" roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual">
        <link:definition>2407403 - Disclosure - Earnings (Loss) Per Share (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenues" roleURI="http://www.cumberlandpharma.com/role/Revenues">
        <link:definition>2108103 - Disclosure - Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesTables" roleURI="http://www.cumberlandpharma.com/role/RevenuesTables">
        <link:definition>2309302 - Disclosure - Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesDetails" roleURI="http://www.cumberlandpharma.com/role/RevenuesDetails">
        <link:definition>2410404 - Disclosure - Revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://www.cumberlandpharma.com/role/Inventories">
        <link:definition>2111104 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://www.cumberlandpharma.com/role/InventoriesTables">
        <link:definition>2312303 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails">
        <link:definition>2413405 - Disclosure - Inventories (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesScheduleofInventoriesDetails" roleURI="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails">
        <link:definition>2414406 - Disclosure - Inventories (Schedule of Inventories) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.cumberlandpharma.com/role/Leases">
        <link:definition>2115105 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.cumberlandpharma.com/role/LeasesTables">
        <link:definition>2316304 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails">
        <link:definition>2417407 - Disclosure - Leases (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeasePositionDetails" roleURI="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails">
        <link:definition>2418408 - Disclosure - Leases (Lease Position) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails">
        <link:definition>2419409 - Disclosure - Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1" roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1">
        <link:definition>2419409 - Disclosure - Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesRentExpenseDetails" roleURI="http://www.cumberlandpharma.com/role/LeasesRentExpenseDetails">
        <link:definition>2420410 - Disclosure - Leases - Rent Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityandDebt" roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt">
        <link:definition>2121106 - Disclosure - Shareholders' Equity and Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityandDebtShareholdersEquityDetails" roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails">
        <link:definition>2422411 - Disclosure - Shareholders' Equity and Debt (Shareholders' Equity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityandDebtDebtDetails" roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails">
        <link:definition>2423412 - Disclosure - Shareholders' Equity and Debt (Debt) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.cumberlandpharma.com/role/IncomeTaxes">
        <link:definition>2124107 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetailsTextual" roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual">
        <link:definition>2425413 - Disclosure - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAgreements" roleURI="http://www.cumberlandpharma.com/role/CollaborativeAgreements">
        <link:definition>2126108 - Disclosure - Collaborative Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionsandReturnsofProductRights" roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights">
        <link:definition>2127109 - Disclosure - Additions and Returns of Product Rights</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionsandReturnsofProductRightsTables" roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables">
        <link:definition>2328305 - Disclosure - Additions and Returns of Product Rights (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionsandReturnsofProductRightsNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails">
        <link:definition>2429414 - Disclosure - Additions and Returns of Product Rights - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionsandReturnsofProductRightsChangeinConsiderationDetails" roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails">
        <link:definition>2430415 - Disclosure - Additions and Returns of Product Rights - Change in Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionsandReturnsofProductRightsDissolutionPaymentsDetails" roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails">
        <link:definition>2431416 - Disclosure - Additions and Returns of Product Rights - Dissolution Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity" abstract="false" name="LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" abstract="false" name="TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_MethotrexateMember" abstract="true" name="MethotrexateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_IfetrobanClinicalMember" abstract="true" name="IfetrobanClinicalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_EquityAndDebtAbstract" abstract="true" name="EquityAndDebtAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_FourthAmendmentMember" abstract="true" name="FourthAmendmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount" abstract="false" name="LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_CaldolorMember" abstract="true" name="CaldolorMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_TieredRoyaltyPaymentsPercentage" abstract="false" name="TieredRoyaltyPaymentsPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" abstract="false" name="StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_NumeratorAbstract" abstract="true" name="NumeratorAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" abstract="false" name="IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_IncentiveStockOptionsMember" abstract="true" name="IncentiveStockOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_WinHealthInvestmentSingaporeLtdDomain" abstract="true" name="WinHealthInvestmentSingaporeLtdDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_ProductsAbstract" abstract="true" name="ProductsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_OtherLongTermObligationsExcludingCurrentPortion" abstract="false" name="OtherLongTermObligationsExcludingCurrentPortion" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" abstract="false" name="ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" abstract="false" name="BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_LeaseLiability" abstract="false" name="LeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_PinnacleBankMember" abstract="true" name="PinnacleBankMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_ClinigenHealthcareLimitedMember" abstract="true" name="ClinigenHealthcareLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_AcetadoteMember" abstract="true" name="AcetadoteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_ShareholdersEquityTextualAbstract" abstract="true" name="ShareholdersEquityTextualAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_OtherProductsMember" abstract="true" name="OtherProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_DenominatorAbstract" abstract="true" name="DenominatorAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_OmeclamoxPakMember" abstract="true" name="OmeclamoxPakMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_VIBATIVMember" abstract="true" name="VIBATIVMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment" abstract="false" name="ProceedsFromSaleOfIntangibleAssetsInstallmentPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_KristaloseMember" abstract="true" name="KristaloseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_RediTrexMember" abstract="true" name="RediTrexMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_IncreaseDecreaseInCurrentOperatingLiabilities" abstract="false" name="IncreaseDecreaseInCurrentOperatingLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="cpix_VaprisolMember" abstract="true" name="VaprisolMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>cpix-20210630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:976bbab0-2784-42fd-860c-1897d99c723d,g:5df55cfc-81cf-4a6f-b91d-2b22fdc37eaa-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cpix-20210630.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_4419b1a8-043f-4581-9ca7-7a0bd06b5d20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_a15c8c3b-f7a7-4cc3-ade6-7244e96f1637" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4419b1a8-043f-4581-9ca7-7a0bd06b5d20" xlink:to="loc_us-gaap_LongTermLineOfCredit_a15c8c3b-f7a7-4cc3-ade6-7244e96f1637" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_725fa221-a414-4b0e-aafe-61ec6b9e551a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4419b1a8-043f-4581-9ca7-7a0bd06b5d20" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_725fa221-a414-4b0e-aafe-61ec6b9e551a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_673448a0-6f1d-43dd-93aa-87da88ccd031" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4419b1a8-043f-4581-9ca7-7a0bd06b5d20" xlink:to="loc_us-gaap_LiabilitiesCurrent_673448a0-6f1d-43dd-93aa-87da88ccd031" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion_894b33ae-9e51-4ba2-ba3a-f58eab128cdd" xlink:href="cpix-20210630.xsd#cpix_OtherLongTermObligationsExcludingCurrentPortion"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4419b1a8-043f-4581-9ca7-7a0bd06b5d20" xlink:to="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion_894b33ae-9e51-4ba2-ba3a-f58eab128cdd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_2b2e92e4-bd3b-4d3c-8b96-0f1f0fc4ff09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_d6ab17ad-7eff-4627-87db-5af8c66deb49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2b2e92e4-bd3b-4d3c-8b96-0f1f0fc4ff09" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_d6ab17ad-7eff-4627-87db-5af8c66deb49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_96273bb9-82b5-4951-85fa-575b47fd381f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2b2e92e4-bd3b-4d3c-8b96-0f1f0fc4ff09" xlink:to="loc_us-gaap_Goodwill_96273bb9-82b5-4951-85fa-575b47fd381f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_05be1829-14b0-4f21-ac0b-e176b0e6efc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2b2e92e4-bd3b-4d3c-8b96-0f1f0fc4ff09" xlink:to="loc_us-gaap_InventoryNoncurrent_05be1829-14b0-4f21-ac0b-e176b0e6efc4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_798f88ad-fafb-432f-970a-b8c807dd0a13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2b2e92e4-bd3b-4d3c-8b96-0f1f0fc4ff09" xlink:to="loc_us-gaap_AssetsCurrent_798f88ad-fafb-432f-970a-b8c807dd0a13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_1009bfbb-0572-46c0-be64-70791f20d17c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2b2e92e4-bd3b-4d3c-8b96-0f1f0fc4ff09" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_1009bfbb-0572-46c0-be64-70791f20d17c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_dea7258f-d2cf-460f-a55c-9e97ec35c5da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2b2e92e4-bd3b-4d3c-8b96-0f1f0fc4ff09" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_dea7258f-d2cf-460f-a55c-9e97ec35c5da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_e702e161-939c-4a7a-8262-acbfbdc02b55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2b2e92e4-bd3b-4d3c-8b96-0f1f0fc4ff09" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_e702e161-939c-4a7a-8262-acbfbdc02b55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_9c1728b9-d0f2-4b44-8c80-3748eaa07755" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_dab9b635-a0ae-4038-9ff1-897b45330e82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9c1728b9-d0f2-4b44-8c80-3748eaa07755" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_dab9b635-a0ae-4038-9ff1-897b45330e82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_3d17547d-253c-4c1d-af41-13dc012beeaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9c1728b9-d0f2-4b44-8c80-3748eaa07755" xlink:to="loc_us-gaap_AccountsPayableCurrent_3d17547d-253c-4c1d-af41-13dc012beeaf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_74a72ecd-1ee4-4764-a21b-eb520f5ac620" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9c1728b9-d0f2-4b44-8c80-3748eaa07755" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_74a72ecd-1ee4-4764-a21b-eb520f5ac620" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_4dfb8ec5-0808-4c03-9bb4-86de9911a51b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_3df46c4c-d761-4f61-86e1-6fee919d5a5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_4dfb8ec5-0808-4c03-9bb4-86de9911a51b" xlink:to="loc_us-gaap_Liabilities_3df46c4c-d761-4f61-86e1-6fee919d5a5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_73b3a96b-68cb-4104-87f3-96387e77cc84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_4dfb8ec5-0808-4c03-9bb4-86de9911a51b" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_73b3a96b-68cb-4104-87f3-96387e77cc84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_020b2fa9-0fbf-4f3c-b33d-84ddb325cfc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_4dfb8ec5-0808-4c03-9bb4-86de9911a51b" xlink:to="loc_us-gaap_CommitmentsAndContingencies_020b2fa9-0fbf-4f3c-b33d-84ddb325cfc1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ff98e6f4-b098-40f8-a891-dfebe8991515" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_f84a82c3-60e1-48da-98c8-a57b0a26165e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ff98e6f4-b098-40f8-a891-dfebe8991515" xlink:to="loc_us-gaap_CommonStockValue_f84a82c3-60e1-48da-98c8-a57b0a26165e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_683d1959-05ee-49d9-a2b7-32251d5140d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ff98e6f4-b098-40f8-a891-dfebe8991515" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_683d1959-05ee-49d9-a2b7-32251d5140d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_ac9eaafb-d563-4509-8983-f5fa38d91f21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_dd479a4b-38be-47a1-8fb0-16a0e7253590" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ac9eaafb-d563-4509-8983-f5fa38d91f21" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_dd479a4b-38be-47a1-8fb0-16a0e7253590" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_924d16f9-6f3f-491b-9631-a572ba37707d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ac9eaafb-d563-4509-8983-f5fa38d91f21" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_924d16f9-6f3f-491b-9631-a572ba37707d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_e6a6c26e-ee6c-47d1-8135-e09b101cbe74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ac9eaafb-d563-4509-8983-f5fa38d91f21" xlink:to="loc_us-gaap_OtherAssetsCurrent_e6a6c26e-ee6c-47d1-8135-e09b101cbe74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_0df30418-01dc-4643-bb6a-7510a803945e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ac9eaafb-d563-4509-8983-f5fa38d91f21" xlink:to="loc_us-gaap_InventoryNet_0df30418-01dc-4643-bb6a-7510a803945e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_aee92e55-95b5-42d8-806c-9de3ef0266aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9db05461-1652-4f46-b4c3-a797dc5ca2b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_aee92e55-95b5-42d8-806c-9de3ef0266aa" xlink:to="loc_us-gaap_StockholdersEquity_9db05461-1652-4f46-b4c3-a797dc5ca2b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_32f7241c-086a-4bd5-a050-541142c1eb6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_aee92e55-95b5-42d8-806c-9de3ef0266aa" xlink:to="loc_us-gaap_MinorityInterest_32f7241c-086a-4bd5-a050-541142c1eb6f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="cpix-20210630.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_d16f1ec4-353a-4e7d-8c5b-cc91c3e9fd6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_7c5b2dba-78d5-420a-9cc4-1bcc59e6d830" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_d16f1ec4-353a-4e7d-8c5b-cc91c3e9fd6a" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_7c5b2dba-78d5-420a-9cc4-1bcc59e6d830" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_abbe1001-c57f-4ee3-b142-19ce8afc3e66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_d16f1ec4-353a-4e7d-8c5b-cc91c3e9fd6a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_abbe1001-c57f-4ee3-b142-19ce8afc3e66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_6509e257-f2d5-461c-84f9-48d1976146c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c939134e-8a32-4e95-a110-800e6a1f4f1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_6509e257-f2d5-461c-84f9-48d1976146c7" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c939134e-8a32-4e95-a110-800e6a1f4f1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_51576981-0125-43af-a845-d68fee1960a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_6509e257-f2d5-461c-84f9-48d1976146c7" xlink:to="loc_us-gaap_CostsAndExpenses_51576981-0125-43af-a845-d68fee1960a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_aba9fdea-8125-4824-aacc-03c179f7ffe4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_3664ce86-39d3-423a-b8bb-46ca47cc9211" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_aba9fdea-8125-4824-aacc-03c179f7ffe4" xlink:to="loc_us-gaap_ProfitLoss_3664ce86-39d3-423a-b8bb-46ca47cc9211" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_ece7c14f-79fc-411c-932d-e17ca28a1723" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_aba9fdea-8125-4824-aacc-03c179f7ffe4" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_ece7c14f-79fc-411c-932d-e17ca28a1723" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_32734a23-30a2-423e-acc0-7c49111c62ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_7a2d7a21-a02c-4e0c-be14-6a684712e30d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_32734a23-30a2-423e-acc0-7c49111c62ab" xlink:to="loc_us-gaap_OperatingIncomeLoss_7a2d7a21-a02c-4e0c-be14-6a684712e30d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncome_fc26746b-ab8c-46cc-b6f3-707b1bb5e5b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_32734a23-30a2-423e-acc0-7c49111c62ab" xlink:to="loc_us-gaap_OtherIncome_fc26746b-ab8c-46cc-b6f3-707b1bb5e5b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_e31cb3d0-82e5-46e3-918b-d9147d189f29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_32734a23-30a2-423e-acc0-7c49111c62ab" xlink:to="loc_us-gaap_InvestmentIncomeInterest_e31cb3d0-82e5-46e3-918b-d9147d189f29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_5e079422-d9eb-4deb-803d-df1e7314f400" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_32734a23-30a2-423e-acc0-7c49111c62ab" xlink:to="loc_us-gaap_InterestExpense_5e079422-d9eb-4deb-803d-df1e7314f400" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_21d69b4b-0f3d-4ed3-9831-a3f95c95a0ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_d889b504-84ae-4e3b-b02d-cae3918663ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_21d69b4b-0f3d-4ed3-9831-a3f95c95a0ac" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_d889b504-84ae-4e3b-b02d-cae3918663ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_cecfa284-aec9-46fb-acf6-7a283fd3f3cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_21d69b4b-0f3d-4ed3-9831-a3f95c95a0ac" xlink:to="loc_us-gaap_SellingAndMarketingExpense_cecfa284-aec9-46fb-acf6-7a283fd3f3cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_85760a67-7cb5-469b-a5ed-154f347b3869" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_21d69b4b-0f3d-4ed3-9831-a3f95c95a0ac" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_85760a67-7cb5-469b-a5ed-154f347b3869" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_1bbb2717-a783-4084-bc41-d7a119f76d9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_21d69b4b-0f3d-4ed3-9831-a3f95c95a0ac" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_1bbb2717-a783-4084-bc41-d7a119f76d9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_be863ae2-fb82-4b2b-8272-dae87821214e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_21d69b4b-0f3d-4ed3-9831-a3f95c95a0ac" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_be863ae2-fb82-4b2b-8272-dae87821214e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_04f5e720-d228-4cdf-8bdb-0fa65136c35f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_fc349eb5-e10f-43eb-8963-20b32b885163" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_04f5e720-d228-4cdf-8bdb-0fa65136c35f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_fc349eb5-e10f-43eb-8963-20b32b885163" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b7077ff4-b0d4-4984-94d4-4baf4be4cee0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_04f5e720-d228-4cdf-8bdb-0fa65136c35f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_b7077ff4-b0d4-4984-94d4-4baf4be4cee0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cpix-20210630.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f4a56a45-fddc-4b85-b7cf-a91ab83eb0d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_f6117cc3-b111-4bf3-ac16-242cc06ebf19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f4a56a45-fddc-4b85-b7cf-a91ab83eb0d5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_f6117cc3-b111-4bf3-ac16-242cc06ebf19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_baf2efe4-9a7f-4cc8-bee3-b0490a7aea47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f4a56a45-fddc-4b85-b7cf-a91ab83eb0d5" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_baf2efe4-9a7f-4cc8-bee3-b0490a7aea47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c4b2f5e5-e06b-44a9-8a20-ec37344dc449" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9628a3a9-10fc-49d5-a875-522a453ad7a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c4b2f5e5-e06b-44a9-8a20-ec37344dc449" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9628a3a9-10fc-49d5-a875-522a453ad7a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d4cd3d28-8388-481f-be98-87d5b2b87997" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c4b2f5e5-e06b-44a9-8a20-ec37344dc449" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d4cd3d28-8388-481f-be98-87d5b2b87997" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_636a4f2d-60c8-4570-8064-c2f34f7ef789" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c4b2f5e5-e06b-44a9-8a20-ec37344dc449" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_636a4f2d-60c8-4570-8064-c2f34f7ef789" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_abf6bc61-c46f-4239-a4e4-26124b0800dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_caeaed32-d2a5-4d9f-a988-d72d286541fb" xlink:href="cpix-20210630.xsd#cpix_IncreaseDecreaseInCurrentOperatingLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_abf6bc61-c46f-4239-a4e4-26124b0800dd" xlink:to="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_caeaed32-d2a5-4d9f-a988-d72d286541fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy_5f638787-8d6c-4d4a-b962-0c64e7f88df2" xlink:href="cpix-20210630.xsd#cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_abf6bc61-c46f-4239-a4e4-26124b0800dd" xlink:to="loc_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy_5f638787-8d6c-4d4a-b962-0c64e7f88df2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_600020da-0a5f-41bf-ac33-774b04eb9b67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_abf6bc61-c46f-4239-a4e4-26124b0800dd" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_600020da-0a5f-41bf-ac33-774b04eb9b67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_55657718-d4a2-49ae-b0b6-8712bae80f20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_abf6bc61-c46f-4239-a4e4-26124b0800dd" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_55657718-d4a2-49ae-b0b6-8712bae80f20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_dbb41af5-f311-4615-acad-b4263b0ca5d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_abf6bc61-c46f-4239-a4e4-26124b0800dd" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_dbb41af5-f311-4615-acad-b4263b0ca5d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_5f36b3cb-4521-4b76-bd1f-674663821e29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_abf6bc61-c46f-4239-a4e4-26124b0800dd" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_5f36b3cb-4521-4b76-bd1f-674663821e29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_8215e79a-4e6c-4569-8271-d86e97bcd84d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_abf6bc61-c46f-4239-a4e4-26124b0800dd" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_8215e79a-4e6c-4569-8271-d86e97bcd84d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_45c96b81-41ab-4597-a4fe-3e4c6011507a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_abf6bc61-c46f-4239-a4e4-26124b0800dd" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_45c96b81-41ab-4597-a4fe-3e4c6011507a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_a3b131ad-e646-4218-ae99-eeed09496a4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_abf6bc61-c46f-4239-a4e4-26124b0800dd" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_a3b131ad-e646-4218-ae99-eeed09496a4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_e7ad50dd-2561-48bd-aa65-fc14c320389b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_abf6bc61-c46f-4239-a4e4-26124b0800dd" xlink:to="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_e7ad50dd-2561-48bd-aa65-fc14c320389b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_b00cb58b-abe1-41e3-8a9c-a9b70462a13f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_abf6bc61-c46f-4239-a4e4-26124b0800dd" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_b00cb58b-abe1-41e3-8a9c-a9b70462a13f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_efc0db98-c1df-48de-9231-72318d584a09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_abf6bc61-c46f-4239-a4e4-26124b0800dd" xlink:to="loc_us-gaap_ShareBasedCompensation_efc0db98-c1df-48de-9231-72318d584a09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_05a5f844-9c61-4134-bd61-f158dc8c54f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_60e89b93-a073-412f-83fc-e279b2f12961" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_05a5f844-9c61-4134-bd61-f158dc8c54f9" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_60e89b93-a073-412f-83fc-e279b2f12961" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_01214c5d-16aa-4d03-99f4-6a07f60b83c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_05a5f844-9c61-4134-bd61-f158dc8c54f9" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_01214c5d-16aa-4d03-99f4-6a07f60b83c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_d6ca73f1-4fdb-4fd7-a0fa-d6462cd5bb24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_05a5f844-9c61-4134-bd61-f158dc8c54f9" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_d6ca73f1-4fdb-4fd7-a0fa-d6462cd5bb24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ab2a0e87-3040-4e89-92c0-6da16c3e0d0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_4f3b48ae-4be2-4a8a-8e30-11883dad305e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ab2a0e87-3040-4e89-92c0-6da16c3e0d0d" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_4f3b48ae-4be2-4a8a-8e30-11883dad305e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_3116be78-a983-440e-bc97-2858e2a040cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ab2a0e87-3040-4e89-92c0-6da16c3e0d0d" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_3116be78-a983-440e-bc97-2858e2a040cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_1fc5e600-99e5-483b-97b3-a94d9592e140" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ab2a0e87-3040-4e89-92c0-6da16c3e0d0d" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_1fc5e600-99e5-483b-97b3-a94d9592e140" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_e0162e62-ce42-4aa3-ac67-fd21148b1002" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ab2a0e87-3040-4e89-92c0-6da16c3e0d0d" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_e0162e62-ce42-4aa3-ac67-fd21148b1002" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest_8418a470-4861-4129-9a3f-90a918cba986" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ab2a0e87-3040-4e89-92c0-6da16c3e0d0d" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest_8418a470-4861-4129-9a3f-90a918cba986" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" xlink:type="simple" xlink:href="cpix-20210630.xsd#EarningsLossPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d02d220a-7432-4777-9286-190536507e53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3fa5861d-cd17-4c69-bf34-fdd35a632e33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d02d220a-7432-4777-9286-190536507e53" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3fa5861d-cd17-4c69-bf34-fdd35a632e33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_c34fbea0-9ca3-45d9-9660-059b889bc181" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d02d220a-7432-4777-9286-190536507e53" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_c34fbea0-9ca3-45d9-9660-059b889bc181" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="simple" xlink:href="cpix-20210630.xsd#InventoriesScheduleofInventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_7eeefc23-efc9-4ef9-9289-99f74ca40499" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_22492912-dd32-4ba5-a19b-d57525e61880" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_7eeefc23-efc9-4ef9-9289-99f74ca40499" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_22492912-dd32-4ba5-a19b-d57525e61880" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_0e43cb8b-98c8-43df-b6a0-05f4b39428fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_7eeefc23-efc9-4ef9-9289-99f74ca40499" xlink:to="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_0e43cb8b-98c8-43df-b6a0-05f4b39428fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_f0a63da1-34b4-4128-a5f7-0d519d21c4a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_7eeefc23-efc9-4ef9-9289-99f74ca40499" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_f0a63da1-34b4-4128-a5f7-0d519d21c4a8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" xlink:type="simple" xlink:href="cpix-20210630.xsd#LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f42b88a9-130c-457b-a55c-eff4a1c77c90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d7e07f0a-2924-4034-8c3e-3f50d054f55f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f42b88a9-130c-457b-a55c-eff4a1c77c90" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d7e07f0a-2924-4034-8c3e-3f50d054f55f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_26aaed52-136c-4be2-8407-44a90e11c74d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f42b88a9-130c-457b-a55c-eff4a1c77c90" xlink:to="loc_us-gaap_OperatingLeaseLiability_26aaed52-136c-4be2-8407-44a90e11c74d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1" xlink:type="simple" xlink:href="cpix-20210630.xsd#LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_50acaf2f-c2b6-4322-aacd-38b91380c262" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_fc362e3f-06b1-41fb-a3c7-f05a17605d22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_50acaf2f-c2b6-4322-aacd-38b91380c262" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_fc362e3f-06b1-41fb-a3c7-f05a17605d22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_57356fa0-bc85-44e0-ab6c-f29be9867080" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_50acaf2f-c2b6-4322-aacd-38b91380c262" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_57356fa0-bc85-44e0-ab6c-f29be9867080" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_5cf68bb0-82fb-40af-ac53-cb10476e4b4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_50acaf2f-c2b6-4322-aacd-38b91380c262" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_5cf68bb0-82fb-40af-ac53-cb10476e4b4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree_edae4962-5e2e-40f5-82e0-8f72dc9b6f2b" xlink:href="cpix-20210630.xsd#cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_50acaf2f-c2b6-4322-aacd-38b91380c262" xlink:to="loc_cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree_edae4962-5e2e-40f5-82e0-8f72dc9b6f2b" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>cpix-20210630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:976bbab0-2784-42fd-860c-1897d99c723d,g:5df55cfc-81cf-4a6f-b91d-2b22fdc37eaa-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" xlink:type="simple" xlink:href="cpix-20210630.xsd#CondensedConsolidatedStatementofEquity"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" xlink:type="extended" id="i1f530855a93d460e9a38053c7872e963_CondensedConsolidatedStatementofEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f07d455b-2f6b-4a24-8027-0b27e69ead44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5512c361-45f1-4506-b99e-f245bef4eb5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f07d455b-2f6b-4a24-8027-0b27e69ead44" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5512c361-45f1-4506-b99e-f245bef4eb5d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c2840c25-d2a1-4094-85e1-fa32c924ad65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5512c361-45f1-4506-b99e-f245bef4eb5d" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c2840c25-d2a1-4094-85e1-fa32c924ad65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4f4656a6-730d-43b9-80c9-3e8ebda1e6e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5512c361-45f1-4506-b99e-f245bef4eb5d" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_4f4656a6-730d-43b9-80c9-3e8ebda1e6e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_01d9d7cd-72df-45b8-bb4b-a31d1018968e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5512c361-45f1-4506-b99e-f245bef4eb5d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_01d9d7cd-72df-45b8-bb4b-a31d1018968e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_1e685c27-6638-4fa6-9d7b-6b0223d2c451" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5512c361-45f1-4506-b99e-f245bef4eb5d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_1e685c27-6638-4fa6-9d7b-6b0223d2c451" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_9ba6c5d7-9878-456f-ac30-646a9bc41ac5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5512c361-45f1-4506-b99e-f245bef4eb5d" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_9ba6c5d7-9878-456f-ac30-646a9bc41ac5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_48f5ee04-ecaf-492c-9976-c4d48533b3d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5512c361-45f1-4506-b99e-f245bef4eb5d" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_48f5ee04-ecaf-492c-9976-c4d48533b3d7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_4b268c83-3417-4ca6-ab8a-b7ca676bbc96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5512c361-45f1-4506-b99e-f245bef4eb5d" xlink:to="loc_us-gaap_ProfitLoss_4b268c83-3417-4ca6-ab8a-b7ca676bbc96" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_23d4dacf-46c0-4c4f-8849-e3e3faff0689" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_52801704-b2da-4ddc-a77b-5f150770b06a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_05b7dec8-5b91-47d5-979e-844c1fb95712" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_f07d455b-2f6b-4a24-8027-0b27e69ead44" xlink:to="loc_us-gaap_StatementTable_05b7dec8-5b91-47d5-979e-844c1fb95712" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_ab0a6e93-67e8-49f6-9e59-b8b917ff9a04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_05b7dec8-5b91-47d5-979e-844c1fb95712" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_ab0a6e93-67e8-49f6-9e59-b8b917ff9a04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ab0a6e93-67e8-49f6-9e59-b8b917ff9a04_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ab0a6e93-67e8-49f6-9e59-b8b917ff9a04" xlink:to="loc_us-gaap_EquityComponentDomain_ab0a6e93-67e8-49f6-9e59-b8b917ff9a04_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a14d2e77-c7da-4561-880d-54ee0e45d7ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ab0a6e93-67e8-49f6-9e59-b8b917ff9a04" xlink:to="loc_us-gaap_EquityComponentDomain_a14d2e77-c7da-4561-880d-54ee0e45d7ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_07d9a040-b410-4e9b-84c8-dc70d5937e50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a14d2e77-c7da-4561-880d-54ee0e45d7ac" xlink:to="loc_us-gaap_CommonStockMember_07d9a040-b410-4e9b-84c8-dc70d5937e50" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_030ca2c0-db98-4d69-9309-e55c64498f9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a14d2e77-c7da-4561-880d-54ee0e45d7ac" xlink:to="loc_us-gaap_RetainedEarningsMember_030ca2c0-db98-4d69-9309-e55c64498f9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_9dda376b-9dcb-4617-b3d2-87a8067be63a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a14d2e77-c7da-4561-880d-54ee0e45d7ac" xlink:to="loc_us-gaap_NoncontrollingInterestMember_9dda376b-9dcb-4617-b3d2-87a8067be63a" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesDetails" xlink:type="simple" xlink:href="cpix-20210630.xsd#RevenuesDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesDetails" xlink:type="extended" id="id38e676afff24f7a8a1dd51e03e8a248_RevenuesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_e7b164ff-3bd2-43e9-90f9-fec70855ec55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_a7caafe2-eb17-4071-8643-f9444e0695f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_e7b164ff-3bd2-43e9-90f9-fec70855ec55" xlink:to="loc_us-gaap_RevenuesAbstract_a7caafe2-eb17-4071-8643-f9444e0695f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductsAbstract_bdeed07f-8012-4ea3-aede-7e57c9194037" xlink:href="cpix-20210630.xsd#cpix_ProductsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_a7caafe2-eb17-4071-8643-f9444e0695f4" xlink:to="loc_cpix_ProductsAbstract_bdeed07f-8012-4ea3-aede-7e57c9194037" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ee46d480-1747-47ea-b8d9-b47f05c257aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ProductsAbstract_bdeed07f-8012-4ea3-aede-7e57c9194037" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ee46d480-1747-47ea-b8d9-b47f05c257aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_0259c23d-598c-43e7-9ba4-3a129e913c8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_e7b164ff-3bd2-43e9-90f9-fec70855ec55" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_0259c23d-598c-43e7-9ba4-3a129e913c8f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0d33a87d-6d76-4dd0-8b74-f0dac68fc6ad" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_0259c23d-598c-43e7-9ba4-3a129e913c8f" xlink:to="loc_srt_ProductOrServiceAxis_0d33a87d-6d76-4dd0-8b74-f0dac68fc6ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0d33a87d-6d76-4dd0-8b74-f0dac68fc6ad_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_0d33a87d-6d76-4dd0-8b74-f0dac68fc6ad" xlink:to="loc_srt_ProductsAndServicesDomain_0d33a87d-6d76-4dd0-8b74-f0dac68fc6ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d3fbf0bb-6076-4957-8039-0d53b4c42a1f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_0d33a87d-6d76-4dd0-8b74-f0dac68fc6ad" xlink:to="loc_srt_ProductsAndServicesDomain_d3fbf0bb-6076-4957-8039-0d53b4c42a1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AcetadoteMember_ebeaf36f-cd30-470d-9243-acfbf6195604" xlink:href="cpix-20210630.xsd#cpix_AcetadoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d3fbf0bb-6076-4957-8039-0d53b4c42a1f" xlink:to="loc_cpix_AcetadoteMember_ebeaf36f-cd30-470d-9243-acfbf6195604" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OmeclamoxPakMember_1fc274d6-7fc4-402e-8a72-96dbbdc2e6e3" xlink:href="cpix-20210630.xsd#cpix_OmeclamoxPakMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d3fbf0bb-6076-4957-8039-0d53b4c42a1f" xlink:to="loc_cpix_OmeclamoxPakMember_1fc274d6-7fc4-402e-8a72-96dbbdc2e6e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_KristaloseMember_5abdb4f0-906f-4058-b419-b5898af772e2" xlink:href="cpix-20210630.xsd#cpix_KristaloseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d3fbf0bb-6076-4957-8039-0d53b4c42a1f" xlink:to="loc_cpix_KristaloseMember_5abdb4f0-906f-4058-b419-b5898af772e2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VaprisolMember_8848c34d-09e6-4f48-af08-f564bdb742f4" xlink:href="cpix-20210630.xsd#cpix_VaprisolMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d3fbf0bb-6076-4957-8039-0d53b4c42a1f" xlink:to="loc_cpix_VaprisolMember_8848c34d-09e6-4f48-af08-f564bdb742f4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CaldolorMember_127d7581-551a-4d83-8992-065e639927ba" xlink:href="cpix-20210630.xsd#cpix_CaldolorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d3fbf0bb-6076-4957-8039-0d53b4c42a1f" xlink:to="loc_cpix_CaldolorMember_127d7581-551a-4d83-8992-065e639927ba" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_075315ac-e440-4543-8030-347812e16f60" xlink:href="cpix-20210630.xsd#cpix_VIBATIVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d3fbf0bb-6076-4957-8039-0d53b4c42a1f" xlink:to="loc_cpix_VIBATIVMember_075315ac-e440-4543-8030-347812e16f60" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RediTrexMember_e4d61221-0bc5-4fe9-8caf-95ab2045d037" xlink:href="cpix-20210630.xsd#cpix_RediTrexMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d3fbf0bb-6076-4957-8039-0d53b4c42a1f" xlink:to="loc_cpix_RediTrexMember_e4d61221-0bc5-4fe9-8caf-95ab2045d037" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherProductsMember_a5571674-4554-49c4-9435-878b974cf197" xlink:href="cpix-20210630.xsd#cpix_OtherProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d3fbf0bb-6076-4957-8039-0d53b4c42a1f" xlink:to="loc_cpix_OtherProductsMember_a5571674-4554-49c4-9435-878b974cf197" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_66bec454-c310-4222-9c25-addd8e1f2505" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d3fbf0bb-6076-4957-8039-0d53b4c42a1f" xlink:to="loc_us-gaap_GrantMember_66bec454-c310-4222-9c25-addd8e1f2505" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20210630.xsd#InventoriesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="extended" id="ia666645c4a404a1f8cc11fa4ea35e25d_InventoriesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_22456984-f261-4000-9dd6-ce85df139fef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_0891d467-b059-4382-a6a6-8897a28f158e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_22456984-f261-4000-9dd6-ce85df139fef" xlink:to="loc_us-gaap_InventoryValuationReserves_0891d467-b059-4382-a6a6-8897a28f158e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_0cd54360-0528-4077-beae-de0433fe9bb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_22456984-f261-4000-9dd6-ce85df139fef" xlink:to="loc_us-gaap_InventoryNoncurrent_0cd54360-0528-4077-beae-de0433fe9bb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_a8955473-4943-4664-b56c-7007516d70a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_22456984-f261-4000-9dd6-ce85df139fef" xlink:to="loc_us-gaap_InventoryFinishedGoods_a8955473-4943-4664-b56c-7007516d70a0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_dbd78eff-28c5-4138-a565-f8c90ddbaab7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_22456984-f261-4000-9dd6-ce85df139fef" xlink:to="loc_us-gaap_InventoryCurrentTable_dbd78eff-28c5-4138-a565-f8c90ddbaab7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_daa3b86f-b626-44dc-98f4-d138caf278b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_dbd78eff-28c5-4138-a565-f8c90ddbaab7" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_daa3b86f-b626-44dc-98f4-d138caf278b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_daa3b86f-b626-44dc-98f4-d138caf278b1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_daa3b86f-b626-44dc-98f4-d138caf278b1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_daa3b86f-b626-44dc-98f4-d138caf278b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e55912b3-ea83-4776-a0cf-08b51cecfd35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_daa3b86f-b626-44dc-98f4-d138caf278b1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e55912b3-ea83-4776-a0cf-08b51cecfd35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IfetrobanClinicalMember_6cb53e50-f60a-4794-a0b8-6d4e337e9087" xlink:href="cpix-20210630.xsd#cpix_IfetrobanClinicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e55912b3-ea83-4776-a0cf-08b51cecfd35" xlink:to="loc_cpix_IfetrobanClinicalMember_6cb53e50-f60a-4794-a0b8-6d4e337e9087" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_bcdaa1f4-f38b-4cba-aa07-855bddfe517b" xlink:href="cpix-20210630.xsd#cpix_VIBATIVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e55912b3-ea83-4776-a0cf-08b51cecfd35" xlink:to="loc_cpix_VIBATIVMember_bcdaa1f4-f38b-4cba-aa07-855bddfe517b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_ff4d8255-86f4-4bd4-ba4c-c641774bfa91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_dbd78eff-28c5-4138-a565-f8c90ddbaab7" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_ff4d8255-86f4-4bd4-ba4c-c641774bfa91" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_ff4d8255-86f4-4bd4-ba4c-c641774bfa91_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_ff4d8255-86f4-4bd4-ba4c-c641774bfa91" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_ff4d8255-86f4-4bd4-ba4c-c641774bfa91_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_837d2757-628d-4aa6-9676-5c367ea7fb42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_ff4d8255-86f4-4bd4-ba4c-c641774bfa91" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_837d2757-628d-4aa6-9676-5c367ea7fb42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IfetrobanClinicalMember_0cf60287-beaa-4f4e-a07f-4b8fb9a003c8" xlink:href="cpix-20210630.xsd#cpix_IfetrobanClinicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_837d2757-628d-4aa6-9676-5c367ea7fb42" xlink:to="loc_cpix_IfetrobanClinicalMember_0cf60287-beaa-4f4e-a07f-4b8fb9a003c8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20210630.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="extended" id="ice95ffd5a04945f9a0c44bdfd3d11b81_LeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_ff631491-a4ed-4652-91cf-ac5c5441f1db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_a5c45c58-c501-4341-80b5-267303f9166a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ff631491-a4ed-4652-91cf-ac5c5441f1db" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_a5c45c58-c501-4341-80b5-267303f9166a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_4bdaa34c-1bee-4637-8824-8f544452f298" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ff631491-a4ed-4652-91cf-ac5c5441f1db" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_4bdaa34c-1bee-4637-8824-8f544452f298" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_20c4180c-a333-489e-a224-010e77ad7e99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ff631491-a4ed-4652-91cf-ac5c5441f1db" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_20c4180c-a333-489e-a224-010e77ad7e99" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals_2e52eebf-74a9-4f32-971b-08d5e5b71ff4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ff631491-a4ed-4652-91cf-ac5c5441f1db" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals_2e52eebf-74a9-4f32-971b-08d5e5b71ff4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_d16a3b3b-d827-4486-9551-de184c47c7bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ff631491-a4ed-4652-91cf-ac5c5441f1db" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_d16a3b3b-d827-4486-9551-de184c47c7bc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8d9cf30f-1ff9-434c-b5b5-bda89935756e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_d16a3b3b-d827-4486-9551-de184c47c7bc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8d9cf30f-1ff9-434c-b5b5-bda89935756e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8d9cf30f-1ff9-434c-b5b5-bda89935756e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8d9cf30f-1ff9-434c-b5b5-bda89935756e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8d9cf30f-1ff9-434c-b5b5-bda89935756e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_933500e1-33a8-4cab-b147-5965f477ae46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8d9cf30f-1ff9-434c-b5b5-bda89935756e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_933500e1-33a8-4cab-b147-5965f477ae46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_a0020784-9274-4675-8095-5b8078d925cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_933500e1-33a8-4cab-b147-5965f477ae46" xlink:to="loc_us-gaap_BuildingMember_a0020784-9274-4675-8095-5b8078d925cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OfficeBuildingMember_de9366d5-28ab-4846-bfe5-face0e9ec17c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OfficeBuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_933500e1-33a8-4cab-b147-5965f477ae46" xlink:to="loc_srt_OfficeBuildingMember_de9366d5-28ab-4846-bfe5-face0e9ec17c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" xlink:type="simple" xlink:href="cpix-20210630.xsd#ShareholdersEquityandDebtShareholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" xlink:type="extended" id="i18289e7fb2934a6fbb4aab04c2b4b69a_ShareholdersEquityandDebtShareholdersEquityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3ed7d3ee-4ba1-43d0-8981-6b6bcc8821f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareholdersEquityTextualAbstract_98b76d16-04da-47b4-b741-60979fdff07f" xlink:href="cpix-20210630.xsd#cpix_ShareholdersEquityTextualAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3ed7d3ee-4ba1-43d0-8981-6b6bcc8821f3" xlink:to="loc_cpix_ShareholdersEquityTextualAbstract_98b76d16-04da-47b4-b741-60979fdff07f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_31807f65-dec2-4764-af93-0e301b8e194a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_98b76d16-04da-47b4-b741-60979fdff07f" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_31807f65-dec2-4764-af93-0e301b8e194a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_a314613a-1dcd-4f3b-a50e-ecca3c07d952" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_98b76d16-04da-47b4-b741-60979fdff07f" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_a314613a-1dcd-4f3b-a50e-ecca3c07d952" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_af6a4b6b-2bd8-4d08-9866-b4966faf1b2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_98b76d16-04da-47b4-b741-60979fdff07f" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_af6a4b6b-2bd8-4d08-9866-b4966faf1b2f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_9a24b73a-8b5c-43a2-8c04-4d5a8779316f" xlink:href="cpix-20210630.xsd#cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_98b76d16-04da-47b4-b741-60979fdff07f" xlink:to="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_9a24b73a-8b5c-43a2-8c04-4d5a8779316f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_958b9336-8d0a-4706-9144-f8bbc452b0be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_98b76d16-04da-47b4-b741-60979fdff07f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_958b9336-8d0a-4706-9144-f8bbc452b0be" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b1602609-74c5-42de-b0ba-1692f4dbdbc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_98b76d16-04da-47b4-b741-60979fdff07f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b1602609-74c5-42de-b0ba-1692f4dbdbc1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1f5e0319-6c10-477b-9481-808f90578979" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3ed7d3ee-4ba1-43d0-8981-6b6bcc8821f3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1f5e0319-6c10-477b-9481-808f90578979" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4a78742f-1bc2-4950-b3ff-1458e05e981c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1f5e0319-6c10-477b-9481-808f90578979" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4a78742f-1bc2-4950-b3ff-1458e05e981c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4a78742f-1bc2-4950-b3ff-1458e05e981c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4a78742f-1bc2-4950-b3ff-1458e05e981c" xlink:to="loc_us-gaap_EquityComponentDomain_4a78742f-1bc2-4950-b3ff-1458e05e981c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_88abdcab-9f4e-46ad-ab10-ba6b1e32f201" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4a78742f-1bc2-4950-b3ff-1458e05e981c" xlink:to="loc_us-gaap_EquityComponentDomain_88abdcab-9f4e-46ad-ab10-ba6b1e32f201" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_fcf2d4cf-16df-4cf4-be1d-30deca29381e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_88abdcab-9f4e-46ad-ab10-ba6b1e32f201" xlink:to="loc_us-gaap_CommonStockMember_fcf2d4cf-16df-4cf4-be1d-30deca29381e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_e6dcf714-fa9d-43af-a974-51d7501632b8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1f5e0319-6c10-477b-9481-808f90578979" xlink:to="loc_srt_TitleOfIndividualAxis_e6dcf714-fa9d-43af-a974-51d7501632b8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e6dcf714-fa9d-43af-a974-51d7501632b8_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_e6dcf714-fa9d-43af-a974-51d7501632b8" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e6dcf714-fa9d-43af-a974-51d7501632b8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5db0969f-6c9e-4bbe-8913-9518e1628c3c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_e6dcf714-fa9d-43af-a974-51d7501632b8" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5db0969f-6c9e-4bbe-8913-9518e1628c3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_1450522c-d046-405e-9ab4-779ad39c3716" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5db0969f-6c9e-4bbe-8913-9518e1628c3c" xlink:to="loc_srt_DirectorMember_1450522c-d046-405e-9ab4-779ad39c3716" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_59123591-880f-4ff6-ae12-c25d024f179e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1f5e0319-6c10-477b-9481-808f90578979" xlink:to="loc_us-gaap_AwardTypeAxis_59123591-880f-4ff6-ae12-c25d024f179e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_59123591-880f-4ff6-ae12-c25d024f179e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_59123591-880f-4ff6-ae12-c25d024f179e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_59123591-880f-4ff6-ae12-c25d024f179e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3b96def8-580a-4b13-bff1-9ca719bf321c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_59123591-880f-4ff6-ae12-c25d024f179e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3b96def8-580a-4b13-bff1-9ca719bf321c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_43fb9620-87f7-43bb-b6cd-a30677cb68bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3b96def8-580a-4b13-bff1-9ca719bf321c" xlink:to="loc_us-gaap_RestrictedStockMember_43fb9620-87f7-43bb-b6cd-a30677cb68bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncentiveStockOptionsMember_96db1504-bbb8-46ab-b7eb-860f985ee5ed" xlink:href="cpix-20210630.xsd#cpix_IncentiveStockOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3b96def8-580a-4b13-bff1-9ca719bf321c" xlink:to="loc_cpix_IncentiveStockOptionsMember_96db1504-bbb8-46ab-b7eb-860f985ee5ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_b42b0f6c-457a-4baa-a6e6-b2a20d4ef7c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1f5e0319-6c10-477b-9481-808f90578979" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_b42b0f6c-457a-4baa-a6e6-b2a20d4ef7c7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_b42b0f6c-457a-4baa-a6e6-b2a20d4ef7c7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_b42b0f6c-457a-4baa-a6e6-b2a20d4ef7c7" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_b42b0f6c-457a-4baa-a6e6-b2a20d4ef7c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_c2e03cb6-0634-4f5f-b5dc-a9e868c516b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_b42b0f6c-457a-4baa-a6e6-b2a20d4ef7c7" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_c2e03cb6-0634-4f5f-b5dc-a9e868c516b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PinnacleBankMember_49aff30f-0a44-4380-9a56-847bfb0e6727" xlink:href="cpix-20210630.xsd#cpix_PinnacleBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_c2e03cb6-0634-4f5f-b5dc-a9e868c516b1" xlink:to="loc_cpix_PinnacleBankMember_49aff30f-0a44-4380-9a56-847bfb0e6727" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" xlink:type="simple" xlink:href="cpix-20210630.xsd#ShareholdersEquityandDebtDebtDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" xlink:type="extended" id="i78e1a0347f994951ab6a8d0084e3c623_ShareholdersEquityandDebtDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_214e5821-564c-4f2d-a0fd-cd7f63008c53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_e3ee3d97-8b78-42ed-93f4-dacdb4142bcb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_214e5821-564c-4f2d-a0fd-cd7f63008c53" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_e3ee3d97-8b78-42ed-93f4-dacdb4142bcb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount_8f3b8422-e6ae-4e56-89c9-438580665a54" xlink:href="cpix-20210630.xsd#cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_214e5821-564c-4f2d-a0fd-cd7f63008c53" xlink:to="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount_8f3b8422-e6ae-4e56-89c9-438580665a54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity_acd5d256-e168-403d-a22b-95e1d79fb249" xlink:href="cpix-20210630.xsd#cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_214e5821-564c-4f2d-a0fd-cd7f63008c53" xlink:to="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity_acd5d256-e168-403d-a22b-95e1d79fb249" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_3f90f5d0-baa5-49ff-8476-314a3d07f5de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_214e5821-564c-4f2d-a0fd-cd7f63008c53" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_3f90f5d0-baa5-49ff-8476-314a3d07f5de" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_d2f08cdb-6163-4f1b-aa11-9194df3934a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_214e5821-564c-4f2d-a0fd-cd7f63008c53" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_d2f08cdb-6163-4f1b-aa11-9194df3934a1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_9af08c69-dcf1-4a75-b6cc-b17784dd5af0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_214e5821-564c-4f2d-a0fd-cd7f63008c53" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_9af08c69-dcf1-4a75-b6cc-b17784dd5af0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived_df101c15-132a-43d0-b1b0-58637448bcde" xlink:href="cpix-20210630.xsd#cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_214e5821-564c-4f2d-a0fd-cd7f63008c53" xlink:to="loc_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived_df101c15-132a-43d0-b1b0-58637448bcde" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_febe9688-690f-49fc-9c8f-98fdaf8d2c76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_214e5821-564c-4f2d-a0fd-cd7f63008c53" xlink:to="loc_us-gaap_LongTermLineOfCredit_febe9688-690f-49fc-9c8f-98fdaf8d2c76" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_63bd9ff0-8259-45eb-816f-f1c6640bda95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_214e5821-564c-4f2d-a0fd-cd7f63008c53" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_63bd9ff0-8259-45eb-816f-f1c6640bda95" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_abac43a1-972f-4bc3-929d-4486522439c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_214e5821-564c-4f2d-a0fd-cd7f63008c53" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_abac43a1-972f-4bc3-929d-4486522439c7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_dd279bb3-7b50-4cbb-b4a2-8fb267b48e43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_214e5821-564c-4f2d-a0fd-cd7f63008c53" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_dd279bb3-7b50-4cbb-b4a2-8fb267b48e43" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_c5873076-010d-4bd4-bb5f-d53ed67bb2ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_dd279bb3-7b50-4cbb-b4a2-8fb267b48e43" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_c5873076-010d-4bd4-bb5f-d53ed67bb2ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_c5873076-010d-4bd4-bb5f-d53ed67bb2ac_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_c5873076-010d-4bd4-bb5f-d53ed67bb2ac" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_c5873076-010d-4bd4-bb5f-d53ed67bb2ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_5572dfa7-9789-4161-b01d-37ea2f1a28b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_c5873076-010d-4bd4-bb5f-d53ed67bb2ac" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_5572dfa7-9789-4161-b01d-37ea2f1a28b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PinnacleBankMember_87edd50f-39f3-4ebb-9330-a881dcda3653" xlink:href="cpix-20210630.xsd#cpix_PinnacleBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_5572dfa7-9789-4161-b01d-37ea2f1a28b3" xlink:to="loc_cpix_PinnacleBankMember_87edd50f-39f3-4ebb-9330-a881dcda3653" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d94143d1-8e3e-4741-9786-2eeb76993c69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_dd279bb3-7b50-4cbb-b4a2-8fb267b48e43" xlink:to="loc_us-gaap_DebtInstrumentAxis_d94143d1-8e3e-4741-9786-2eeb76993c69" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d94143d1-8e3e-4741-9786-2eeb76993c69_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_d94143d1-8e3e-4741-9786-2eeb76993c69" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d94143d1-8e3e-4741-9786-2eeb76993c69_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_86f0a42e-ea7e-45c9-bdc7-7f25712bf2c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_d94143d1-8e3e-4741-9786-2eeb76993c69" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_86f0a42e-ea7e-45c9-bdc7-7f25712bf2c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FourthAmendmentMember_b4870271-a3a5-4a5e-88da-9d3327c1aa3c" xlink:href="cpix-20210630.xsd#cpix_FourthAmendmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_86f0a42e-ea7e-45c9-bdc7-7f25712bf2c9" xlink:to="loc_cpix_FourthAmendmentMember_b4870271-a3a5-4a5e-88da-9d3327c1aa3c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_96a69636-29b6-4213-8caf-2dee4a93fab5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_86f0a42e-ea7e-45c9-bdc7-7f25712bf2c9" xlink:to="loc_us-gaap_LineOfCreditMember_96a69636-29b6-4213-8caf-2dee4a93fab5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_4debb1a4-1c2b-430c-840d-c9db9d15e967" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_dd279bb3-7b50-4cbb-b4a2-8fb267b48e43" xlink:to="loc_us-gaap_CreditFacilityAxis_4debb1a4-1c2b-430c-840d-c9db9d15e967" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_4debb1a4-1c2b-430c-840d-c9db9d15e967_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_4debb1a4-1c2b-430c-840d-c9db9d15e967" xlink:to="loc_us-gaap_CreditFacilityDomain_4debb1a4-1c2b-430c-840d-c9db9d15e967_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_1e30a2af-813d-4176-93fb-990619aa2cb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_4debb1a4-1c2b-430c-840d-c9db9d15e967" xlink:to="loc_us-gaap_CreditFacilityDomain_1e30a2af-813d-4176-93fb-990619aa2cb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_1979b08a-f314-46fd-bc49-126b799d13ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_1e30a2af-813d-4176-93fb-990619aa2cb4" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_1979b08a-f314-46fd-bc49-126b799d13ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8f8c12e1-cc6d-4b87-a50f-97f6bdd07dcb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_dd279bb3-7b50-4cbb-b4a2-8fb267b48e43" xlink:to="loc_srt_RangeAxis_8f8c12e1-cc6d-4b87-a50f-97f6bdd07dcb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8f8c12e1-cc6d-4b87-a50f-97f6bdd07dcb_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_8f8c12e1-cc6d-4b87-a50f-97f6bdd07dcb" xlink:to="loc_srt_RangeMember_8f8c12e1-cc6d-4b87-a50f-97f6bdd07dcb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_38a255cd-067a-43fa-b13f-709f1aa43e30" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_8f8c12e1-cc6d-4b87-a50f-97f6bdd07dcb" xlink:to="loc_srt_RangeMember_38a255cd-067a-43fa-b13f-709f1aa43e30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_59041581-8a17-4bb4-b95a-057499034192" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_38a255cd-067a-43fa-b13f-709f1aa43e30" xlink:to="loc_srt_MinimumMember_59041581-8a17-4bb4-b95a-057499034192" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7d4339fb-0e03-49a9-b724-1ef7499db133" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_38a255cd-067a-43fa-b13f-709f1aa43e30" xlink:to="loc_srt_MaximumMember_7d4339fb-0e03-49a9-b724-1ef7499db133" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_df3223fd-8180-4342-99d0-8aa18c20f34a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_dd279bb3-7b50-4cbb-b4a2-8fb267b48e43" xlink:to="loc_us-gaap_VariableRateAxis_df3223fd-8180-4342-99d0-8aa18c20f34a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_df3223fd-8180-4342-99d0-8aa18c20f34a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_df3223fd-8180-4342-99d0-8aa18c20f34a" xlink:to="loc_us-gaap_VariableRateDomain_df3223fd-8180-4342-99d0-8aa18c20f34a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_69ba2bc0-d471-430f-be65-328878fb3eb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_df3223fd-8180-4342-99d0-8aa18c20f34a" xlink:to="loc_us-gaap_VariableRateDomain_69ba2bc0-d471-430f-be65-328878fb3eb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_991c8031-ae78-48d7-9228-040c772273be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_69ba2bc0-d471-430f-be65-328878fb3eb7" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_991c8031-ae78-48d7-9228-040c772273be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1e162a2f-8152-4086-921b-c40dec12568d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_dd279bb3-7b50-4cbb-b4a2-8fb267b48e43" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1e162a2f-8152-4086-921b-c40dec12568d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1e162a2f-8152-4086-921b-c40dec12568d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1e162a2f-8152-4086-921b-c40dec12568d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1e162a2f-8152-4086-921b-c40dec12568d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2ef9735f-120e-463e-a005-973045d24732" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1e162a2f-8152-4086-921b-c40dec12568d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2ef9735f-120e-463e-a005-973045d24732" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_6147715c-55df-4191-b4ac-e7fe6f83f708" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2ef9735f-120e-463e-a005-973045d24732" xlink:to="loc_us-gaap_ConvertibleDebtMember_6147715c-55df-4191-b4ac-e7fe6f83f708" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c3e30c75-091c-489c-86d6-dc4564514887" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_dd279bb3-7b50-4cbb-b4a2-8fb267b48e43" xlink:to="loc_srt_CounterpartyNameAxis_c3e30c75-091c-489c-86d6-dc4564514887" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c3e30c75-091c-489c-86d6-dc4564514887_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_c3e30c75-091c-489c-86d6-dc4564514887" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c3e30c75-091c-489c-86d6-dc4564514887_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_311704f5-39ba-4a50-af4c-9db11ff866d8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_c3e30c75-091c-489c-86d6-dc4564514887" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_311704f5-39ba-4a50-af4c-9db11ff866d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_WinHealthInvestmentSingaporeLtdDomain_dd32eac0-475c-4a6e-b4b4-e116102aeefa" xlink:href="cpix-20210630.xsd#cpix_WinHealthInvestmentSingaporeLtdDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_311704f5-39ba-4a50-af4c-9db11ff866d8" xlink:to="loc_cpix_WinHealthInvestmentSingaporeLtdDomain_dd32eac0-475c-4a6e-b4b4-e116102aeefa" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual" xlink:type="simple" xlink:href="cpix-20210630.xsd#IncomeTaxesDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual" xlink:type="extended" id="ic1de9142135a4e10a34ee3c63421a050_IncomeTaxesDetailsTextual">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_ff26ccfc-3bb6-4e79-95bd-5b51b49805b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_6fcdc13e-b89c-41a7-a618-969504327e04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_ff26ccfc-3bb6-4e79-95bd-5b51b49805b7" xlink:to="loc_us-gaap_OperatingLossCarryforwards_6fcdc13e-b89c-41a7-a618-969504327e04" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_dd763eb3-96c2-4863-96ec-17d14ef66619" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_ff26ccfc-3bb6-4e79-95bd-5b51b49805b7" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_dd763eb3-96c2-4863-96ec-17d14ef66619" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_5ed1f2b2-2a2f-44f7-99dd-5fc977c903ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_dd763eb3-96c2-4863-96ec-17d14ef66619" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_5ed1f2b2-2a2f-44f7-99dd-5fc977c903ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_5ed1f2b2-2a2f-44f7-99dd-5fc977c903ed_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_5ed1f2b2-2a2f-44f7-99dd-5fc977c903ed" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_5ed1f2b2-2a2f-44f7-99dd-5fc977c903ed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_f174c5aa-fa0d-4b6d-9f98-d3cc753727d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_5ed1f2b2-2a2f-44f7-99dd-5fc977c903ed" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_f174c5aa-fa0d-4b6d-9f98-d3cc753727d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_29015967-7582-45a5-a506-d1769e49456b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_f174c5aa-fa0d-4b6d-9f98-d3cc753727d2" xlink:to="loc_us-gaap_DomesticCountryMember_29015967-7582-45a5-a506-d1769e49456b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" xlink:type="simple" xlink:href="cpix-20210630.xsd#AdditionsandReturnsofProductRightsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" xlink:type="extended" id="ie78f82653de649b785dbe6d4405d67b7_AdditionsandReturnsofProductRightsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_3c2b281c-232a-4fb4-b79e-bc53f48c5a03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_e89b1186-4874-4e2c-9acc-01a22c84739f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3c2b281c-232a-4fb4-b79e-bc53f48c5a03" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_e89b1186-4874-4e2c-9acc-01a22c84739f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_980a172d-b2f0-4850-af09-83ba91aa75d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3c2b281c-232a-4fb4-b79e-bc53f48c5a03" xlink:to="loc_us-gaap_OtherPaymentsToAcquireBusinesses_980a172d-b2f0-4850-af09-83ba91aa75d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TieredRoyaltyPaymentsPercentage_37bbc9c4-3291-4ad5-8fc8-5b0a9282ddde" xlink:href="cpix-20210630.xsd#cpix_TieredRoyaltyPaymentsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3c2b281c-232a-4fb4-b79e-bc53f48c5a03" xlink:to="loc_cpix_TieredRoyaltyPaymentsPercentage_37bbc9c4-3291-4ad5-8fc8-5b0a9282ddde" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_10ab573e-47c3-4d42-a7ca-8d40d187b616" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3c2b281c-232a-4fb4-b79e-bc53f48c5a03" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_10ab573e-47c3-4d42-a7ca-8d40d187b616" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_ec7fbd3c-51ea-4c35-ac72-e83648835e40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3c2b281c-232a-4fb4-b79e-bc53f48c5a03" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_ec7fbd3c-51ea-4c35-ac72-e83648835e40" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_98ac7a2f-fab0-467a-9345-7e97c7abe221" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3c2b281c-232a-4fb4-b79e-bc53f48c5a03" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_98ac7a2f-fab0-467a-9345-7e97c7abe221" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_28097e33-db2e-45e2-bc1f-ec6cb7e593d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3c2b281c-232a-4fb4-b79e-bc53f48c5a03" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_28097e33-db2e-45e2-bc1f-ec6cb7e593d5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_539cbe87-09d5-42e8-b09b-8f6ce0e3f176" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3c2b281c-232a-4fb4-b79e-bc53f48c5a03" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_539cbe87-09d5-42e8-b09b-8f6ce0e3f176" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_0ad62a25-ae16-4682-8550-4cc5e5e2b452" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3c2b281c-232a-4fb4-b79e-bc53f48c5a03" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_0ad62a25-ae16-4682-8550-4cc5e5e2b452" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment_10af34ef-16ae-4fdd-8ed6-9e92b835fb98" xlink:href="cpix-20210630.xsd#cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3c2b281c-232a-4fb4-b79e-bc53f48c5a03" xlink:to="loc_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment_10af34ef-16ae-4fdd-8ed6-9e92b835fb98" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_88922ef2-de6b-47d8-b6c5-4b36a235acb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3c2b281c-232a-4fb4-b79e-bc53f48c5a03" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_88922ef2-de6b-47d8-b6c5-4b36a235acb9" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1fb820d6-5c8e-481a-a913-e91e60d80994" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3c2b281c-232a-4fb4-b79e-bc53f48c5a03" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1fb820d6-5c8e-481a-a913-e91e60d80994" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_592c068f-b9e7-402b-9339-a159c5f7f92b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1fb820d6-5c8e-481a-a913-e91e60d80994" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_592c068f-b9e7-402b-9339-a159c5f7f92b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_592c068f-b9e7-402b-9339-a159c5f7f92b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_592c068f-b9e7-402b-9339-a159c5f7f92b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_592c068f-b9e7-402b-9339-a159c5f7f92b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bb8ecac6-da71-4143-b930-f2c4683c4428" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_592c068f-b9e7-402b-9339-a159c5f7f92b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bb8ecac6-da71-4143-b930-f2c4683c4428" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_d7c68325-a5b7-4888-be3f-67b7ad96eb36" xlink:href="cpix-20210630.xsd#cpix_VIBATIVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bb8ecac6-da71-4143-b930-f2c4683c4428" xlink:to="loc_cpix_VIBATIVMember_d7c68325-a5b7-4888-be3f-67b7ad96eb36" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_MethotrexateMember_dd3a0af9-ca29-4ece-94dc-7b64934b0d89" xlink:href="cpix-20210630.xsd#cpix_MethotrexateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bb8ecac6-da71-4143-b930-f2c4683c4428" xlink:to="loc_cpix_MethotrexateMember_dd3a0af9-ca29-4ece-94dc-7b64934b0d89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ece6feb5-d75c-42e3-a978-0075ad96706d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1fb820d6-5c8e-481a-a913-e91e60d80994" xlink:to="loc_srt_CounterpartyNameAxis_ece6feb5-d75c-42e3-a978-0075ad96706d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ece6feb5-d75c-42e3-a978-0075ad96706d_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_ece6feb5-d75c-42e3-a978-0075ad96706d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ece6feb5-d75c-42e3-a978-0075ad96706d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3e98799b-d677-43f3-82d1-371ce91bb145" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_ece6feb5-d75c-42e3-a978-0075ad96706d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3e98799b-d677-43f3-82d1-371ce91bb145" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ClinigenHealthcareLimitedMember_5d5e46ce-d8ec-4c08-9f7f-7e5a4e4f4a94" xlink:href="cpix-20210630.xsd#cpix_ClinigenHealthcareLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3e98799b-d677-43f3-82d1-371ce91bb145" xlink:to="loc_cpix_ClinigenHealthcareLimitedMember_5d5e46ce-d8ec-4c08-9f7f-7e5a4e4f4a94" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_d2842b8c-1a64-4c9c-a505-dc3769a8e9e9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1fb820d6-5c8e-481a-a913-e91e60d80994" xlink:to="loc_srt_StatementScenarioAxis_d2842b8c-1a64-4c9c-a505-dc3769a8e9e9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_d2842b8c-1a64-4c9c-a505-dc3769a8e9e9_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_d2842b8c-1a64-4c9c-a505-dc3769a8e9e9" xlink:to="loc_srt_ScenarioUnspecifiedDomain_d2842b8c-1a64-4c9c-a505-dc3769a8e9e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_b0d2740b-4caf-4b44-a49f-9fa0dc117d0e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_d2842b8c-1a64-4c9c-a505-dc3769a8e9e9" xlink:to="loc_srt_ScenarioUnspecifiedDomain_b0d2740b-4caf-4b44-a49f-9fa0dc117d0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_110cdbda-60b0-41fd-9334-4b29612111a8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_b0d2740b-4caf-4b44-a49f-9fa0dc117d0e" xlink:to="loc_srt_ScenarioForecastMember_110cdbda-60b0-41fd-9334-4b29612111a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d2b0deda-c858-4cca-b3e0-83d89b573ab4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1fb820d6-5c8e-481a-a913-e91e60d80994" xlink:to="loc_us-gaap_AwardTypeAxis_d2b0deda-c858-4cca-b3e0-83d89b573ab4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d2b0deda-c858-4cca-b3e0-83d89b573ab4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_d2b0deda-c858-4cca-b3e0-83d89b573ab4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d2b0deda-c858-4cca-b3e0-83d89b573ab4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_067f0aa3-4c90-4e78-9fa8-ac303aa70335" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_d2b0deda-c858-4cca-b3e0-83d89b573ab4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_067f0aa3-4c90-4e78-9fa8-ac303aa70335" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_55ad34fe-576f-46d9-abac-487764329abb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_067f0aa3-4c90-4e78-9fa8-ac303aa70335" xlink:to="loc_us-gaap_RestrictedStockMember_55ad34fe-576f-46d9-abac-487764329abb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_9e0959d1-485d-4985-897b-644c6180e4c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1fb820d6-5c8e-481a-a913-e91e60d80994" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_9e0959d1-485d-4985-897b-644c6180e4c6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_9e0959d1-485d-4985-897b-644c6180e4c6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_9e0959d1-485d-4985-897b-644c6180e4c6" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_9e0959d1-485d-4985-897b-644c6180e4c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_9aba2864-127f-4fee-a168-8a72eaf3bcce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_9e0959d1-485d-4985-897b-644c6180e4c6" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_9aba2864-127f-4fee-a168-8a72eaf3bcce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_d9a1707f-6b61-462c-b1bb-cda6e80b5717" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_9aba2864-127f-4fee-a168-8a72eaf3bcce" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_d9a1707f-6b61-462c-b1bb-cda6e80b5717" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_2318bf6a-0ae5-4cca-821b-d19343528a17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_9aba2864-127f-4fee-a168-8a72eaf3bcce" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_2318bf6a-0ae5-4cca-821b-d19343528a17" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails" xlink:type="simple" xlink:href="cpix-20210630.xsd#AdditionsandReturnsofProductRightsChangeinConsiderationDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails" xlink:type="extended" id="i9ada367922aa4d96baa1710d59f94314_AdditionsandReturnsofProductRightsChangeinConsiderationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_f8ca68ff-1616-45dc-8419-6d3e2a5c634a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualRollForward_03559210-8578-4bf5-aab3-1090efda1370" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8ca68ff-1616-45dc-8419-6d3e2a5c634a" xlink:to="loc_us-gaap_LossContingencyAccrualRollForward_03559210-8578-4bf5-aab3-1090efda1370" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_5a2f77e2-517e-42dc-9439-184bef21a6bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_03559210-8578-4bf5-aab3-1090efda1370" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_5a2f77e2-517e-42dc-9439-184bef21a6bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties_0c097a2c-3763-46ea-bb7a-2cf621dff67b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_03559210-8578-4bf5-aab3-1090efda1370" xlink:to="loc_us-gaap_PaymentsForRoyalties_0c097a2c-3763-46ea-bb7a-2cf621dff67b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_063ced27-322f-4b75-9a95-8ec1d311b961" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_03559210-8578-4bf5-aab3-1090efda1370" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_063ced27-322f-4b75-9a95-8ec1d311b961" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_7c13dd3d-8625-4d41-9e48-e42da816ec2e" xlink:href="cpix-20210630.xsd#cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_03559210-8578-4bf5-aab3-1090efda1370" xlink:to="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_7c13dd3d-8625-4d41-9e48-e42da816ec2e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_2601148a-e8eb-4bc5-9d82-f9151b48161a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_dc4efe6b-2b49-4a51-8db3-c4bc759f3db6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8ca68ff-1616-45dc-8419-6d3e2a5c634a" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_dc4efe6b-2b49-4a51-8db3-c4bc759f3db6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_48232c98-1090-47a0-a64d-40407f83fb18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_dc4efe6b-2b49-4a51-8db3-c4bc759f3db6" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_48232c98-1090-47a0-a64d-40407f83fb18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_48232c98-1090-47a0-a64d-40407f83fb18_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_48232c98-1090-47a0-a64d-40407f83fb18" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_48232c98-1090-47a0-a64d-40407f83fb18_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1c54ff7d-29cd-4312-b13a-c8f396c39052" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_48232c98-1090-47a0-a64d-40407f83fb18" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1c54ff7d-29cd-4312-b13a-c8f396c39052" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_980dedfc-7d32-4ddd-99e1-54a5294ebcc7" xlink:href="cpix-20210630.xsd#cpix_VIBATIVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1c54ff7d-29cd-4312-b13a-c8f396c39052" xlink:to="loc_cpix_VIBATIVMember_980dedfc-7d32-4ddd-99e1-54a5294ebcc7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails" xlink:type="simple" xlink:href="cpix-20210630.xsd#AdditionsandReturnsofProductRightsDissolutionPaymentsDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails" xlink:type="extended" id="i7e74f2bf6cb243a3ad2c171655a0318c_AdditionsandReturnsofProductRightsDissolutionPaymentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_b52d5fd7-3659-456f-9e74-e6316c02c9f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_68a78744-bbd2-438a-9b57-350e8d977876" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b52d5fd7-3659-456f-9e74-e6316c02c9f3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_68a78744-bbd2-438a-9b57-350e8d977876" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_64290789-4d75-4dc1-892e-f3dbd9747752" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b52d5fd7-3659-456f-9e74-e6316c02c9f3" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_64290789-4d75-4dc1-892e-f3dbd9747752" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_88cc9708-5630-4fe2-a3bf-836bd7b0702e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b52d5fd7-3659-456f-9e74-e6316c02c9f3" xlink:to="loc_us-gaap_SellingAndMarketingExpense_88cc9708-5630-4fe2-a3bf-836bd7b0702e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_9d5c9c62-bd6a-41f4-8648-595435bfafc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b52d5fd7-3659-456f-9e74-e6316c02c9f3" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_9d5c9c62-bd6a-41f4-8648-595435bfafc6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2562284e-a27d-4235-9903-488e3c7c0c18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b52d5fd7-3659-456f-9e74-e6316c02c9f3" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2562284e-a27d-4235-9903-488e3c7c0c18" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_97be0449-83a0-4ee2-b467-db7c79fdaf66" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2562284e-a27d-4235-9903-488e3c7c0c18" xlink:to="loc_srt_CounterpartyNameAxis_97be0449-83a0-4ee2-b467-db7c79fdaf66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_97be0449-83a0-4ee2-b467-db7c79fdaf66_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_97be0449-83a0-4ee2-b467-db7c79fdaf66" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_97be0449-83a0-4ee2-b467-db7c79fdaf66_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9ebf09a3-41c7-4f4f-878d-8e83f51154e3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_97be0449-83a0-4ee2-b467-db7c79fdaf66" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9ebf09a3-41c7-4f4f-878d-8e83f51154e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ClinigenHealthcareLimitedMember_4582fa3f-e27e-4c1c-833a-4c90bd167d15" xlink:href="cpix-20210630.xsd#cpix_ClinigenHealthcareLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9ebf09a3-41c7-4f4f-878d-8e83f51154e3" xlink:to="loc_cpix_ClinigenHealthcareLimitedMember_4582fa3f-e27e-4c1c-833a-4c90bd167d15" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>cpix-20210630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:976bbab0-2784-42fd-860c-1897d99c723d,g:5df55cfc-81cf-4a6f-b91d-2b22fdc37eaa-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_5becee81-3eb7-4c4c-a6d7-d625566ca2f3_terseLabel_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Square feet of office space</link:label>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_label_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of Real Estate Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfRealEstateProperty" xlink:to="lab_us-gaap_AreaOfRealEstateProperty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_07fdec1d-74dd-4ea5-b1fe-226c118495ea_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock granted in period, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_85fedc8b-251e-4b06-8388-2f7bafb04634_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_6852ec0a-d8fc-4dc3-818c-93fb7cb7d204_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEASES</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_b73a2528-414a-48ff-ad5c-a43b816ede9f_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_IfetrobanClinicalMember_16b0c4d6-ac9c-4227-b551-1c51c5ef297b_terseLabel_en-US" xlink:label="lab_cpix_IfetrobanClinicalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ifetroban Clinical</link:label>
    <link:label id="lab_cpix_IfetrobanClinicalMember_label_en-US" xlink:label="lab_cpix_IfetrobanClinicalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ifetroban Clinical [Member]</link:label>
    <link:label id="lab_cpix_IfetrobanClinicalMember_documentation_en-US" xlink:label="lab_cpix_IfetrobanClinicalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ifetroban Clinical</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IfetrobanClinicalMember" xlink:href="cpix-20210630.xsd#cpix_IfetrobanClinicalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_IfetrobanClinicalMember" xlink:to="lab_cpix_IfetrobanClinicalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree_7b31f036-a93e-4aeb-b982-4630c04fe2c7_terseLabel_en-US" xlink:label="lab_cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After 2023</link:label>
    <link:label id="lab_cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree_label_en-US" xlink:label="lab_cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Three</link:label>
    <link:label id="lab_cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree_documentation_en-US" xlink:label="lab_cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" xlink:href="cpix-20210630.xsd#cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" xlink:to="lab_cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_d91ce565-401b-4c21-ae3e-987232621a68_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of products sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_8f881448-de3e-470e-a41f-4f5a18debc3b_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs of products sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_870dfeda-0edf-4b89-bc78-20238a904a9e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from discontinued operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_86333cc8-ebc6-4a28-afed-c1bf2be9006f_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_a01e9767-b082-41d7-a85c-1c9c73c12f19_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_9b5adbd4-9d41-4854-8834-455030029543_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_696876cc-11d9-480f-b09d-276515e22c02_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy_fbc88591-2d91-4d6c-af2a-7dba4fab1b18_negatedTerseLabel_en-US" xlink:label="lab_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Cash Surrender Value Of Life Insurance Policy</link:label>
    <link:label id="lab_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy_label_en-US" xlink:label="lab_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Cash Surrender Value Of Life Insurance Policy</link:label>
    <link:label id="lab_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy_documentation_en-US" xlink:label="lab_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Cash Surrender Value Of Life Insurance Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" xlink:href="cpix-20210630.xsd#cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" xlink:to="lab_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_a2d12bd8-5668-4276-9e7a-daefac47335f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_c4ae8217-9597-4866-9246-e442d040dc71_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings on line of credit</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Repayments of) Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_6453b14a-2f45-47c1-96a8-e2d09a2e3eff_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_eaebaabc-8707-48bb-93e8-88c4d5ebff52_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_0ecf1073-c32f-440e-9e06-1ff7870f7544_negatedLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of shares (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_9ea45b57-e9cc-492b-bfde-404cb5f2011f_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of shares (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_f3efa02f-018c-4a45-8213-85d99709a53e_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_c6705d72-0c0c-4735-a10d-4771644172cc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments on line of credit</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfNotesPayable" xlink:to="lab_us-gaap_RepaymentsOfNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_cf6aa6bb-7d0d-4690-abf8-c1013d6ba7c7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease current liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_AcetadoteMember_b8bc1e55-c431-4341-b18d-bffa8874b429_terseLabel_en-US" xlink:label="lab_cpix_AcetadoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kristalose</link:label>
    <link:label id="lab_cpix_AcetadoteMember_label_en-US" xlink:label="lab_cpix_AcetadoteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acetadote [Member]</link:label>
    <link:label id="lab_cpix_AcetadoteMember_documentation_en-US" xlink:label="lab_cpix_AcetadoteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acetadote</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AcetadoteMember" xlink:href="cpix-20210630.xsd#cpix_AcetadoteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_AcetadoteMember" xlink:to="lab_cpix_AcetadoteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_NumeratorAbstract_84e67bfb-bd7b-49b8-8d1d-f98265c39c55_verboseLabel_en-US" xlink:label="lab_cpix_NumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_cpix_NumeratorAbstract_label_en-US" xlink:label="lab_cpix_NumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator [Abstract]</link:label>
    <link:label id="lab_cpix_NumeratorAbstract_documentation_en-US" xlink:label="lab_cpix_NumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NumeratorAbstract" xlink:href="cpix-20210630.xsd#cpix_NumeratorAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_NumeratorAbstract" xlink:to="lab_cpix_NumeratorAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_48c90346-34e2-412b-9586-4d3e4befdea5_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ea250092-6d8d-4b76-bc14-5b2629a4bc25_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_96021dba-c320-455b-9f3f-a08363972133_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_b145700c-ec82-4086-8e35-be172652f500_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_19c0bb17-2c02-4b70-9416-0ecbcff5b20d_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (income) loss at subsidiary attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d5b31e58-37e3-450e-8629-46bdcf6eb98d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_94607eeb-b908-4e68-8d6d-6fe01bbee2b3_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_1dc46f99-f67c-468c-a07b-a54f81c6741f_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_8f3ccb7d-8226-4b3c-9488-e37c20c795b2_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Revenues</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_185b21f8-db3c-4298-96f1-4f2d6b1ec4d1_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_82f20c5d-1674-4726-b5ea-8b0b79aaa090_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_513679c8-406a-434d-ba78-aca828208772_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SHAREHOLDERS' EQUITY AND DEBT</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_f9e7fab3-ba18-4048-8fdb-2ebe3133d5b4_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income (loss)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_4b92a558-6819-4d30-80ba-ba3055342c77_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_f7d7c3ee-d79d-45cc-9e7d-9bd47d769aaa_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_bb823d9b-79d1-47fd-8df6-05448eae309a_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_c38930d2-030b-4fd0-88bb-3630cde97e2b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ProductsAbstract_a133e211-7bd3-4829-9e53-80a56f899516_verboseLabel_en-US" xlink:label="lab_cpix_ProductsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products:</link:label>
    <link:label id="lab_cpix_ProductsAbstract_label_en-US" xlink:label="lab_cpix_ProductsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products [Abstract]</link:label>
    <link:label id="lab_cpix_ProductsAbstract_documentation_en-US" xlink:label="lab_cpix_ProductsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductsAbstract" xlink:href="cpix-20210630.xsd#cpix_ProductsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ProductsAbstract" xlink:to="lab_cpix_ProductsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_27e3b05a-b96d-4234-8a0c-f630965049d5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of remaining lease payments, percent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_38604772-7843-4b6e-b39e-eb87f4861bcc_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_f829b868-c329-41d0-a6bb-0d415495dba2_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) operating activities from continuing operations</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_d07d5754-63dd-42f4-8668-9d0963263acd_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0a3fb114-30be-4f76-a329-d9d527702c13_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_270550cc-ae60-48cd-b368-28d2fbd62244_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrantMember_f9b566be-fa4c-4ab5-ba02-4a715ca77924_terseLabel_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant</link:label>
    <link:label id="lab_us-gaap_GrantMember_label_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantMember" xlink:to="lab_us-gaap_GrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_3085552a-5403-49b4-8f70-affb4fdce0c4_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common shares</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_ef47bc29-3bfd-4c3d-bce6-2bebf4ffbbbb_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_7c6737b2-8291-4240-a6e2-34fd4dc30e5a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock awards, vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_bfe5b8b5-31c9-4f30-baa4-c2748b123f63_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration included in operating expenses</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_2b83d6a8-537f-4f1a-b199-3edb4d758321_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_6cd8a6a1-1ba6-4e9b-94fe-24e45e144823_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_d2e7d4c8-c4e7-495a-b882-93061ba6e8e0_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_VIBATIVMember_d29f93a8-2482-44ac-a984-80d61d0aa60f_terseLabel_en-US" xlink:label="lab_cpix_VIBATIVMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaprisol</link:label>
    <link:label id="lab_cpix_VIBATIVMember_label_en-US" xlink:label="lab_cpix_VIBATIVMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VIBATIV [Member]</link:label>
    <link:label id="lab_cpix_VIBATIVMember_documentation_en-US" xlink:label="lab_cpix_VIBATIVMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VIBATIV</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember" xlink:href="cpix-20210630.xsd#cpix_VIBATIVMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_VIBATIVMember" xlink:to="lab_cpix_VIBATIVMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_c8a24c7c-5867-4988-9611-30a4e8f0b219_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings (deficit)</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment_5701f425-f514-4b3c-9391-36a21d5d5202_terseLabel_en-US" xlink:label="lab_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial consideration received in exchange for product license rights, installment payments</link:label>
    <link:label id="lab_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment_label_en-US" xlink:label="lab_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Intangible Assets, Installment Payment</link:label>
    <link:label id="lab_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment_documentation_en-US" xlink:label="lab_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Intangible Assets, Installment Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment" xlink:href="cpix-20210630.xsd#cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment" xlink:to="lab_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_99a7f83c-88b5-456b-a65a-6b628c3e5c01_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_bed67133-9d13-4edb-b6c6-a8b07a4f9b37_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_bea0e045-5e73-4c26-8714-7c354357bef5_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_a8bb9293-b953-4793-9055-e8907273ac9f_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_73338bfc-f224-4f87-a369-d4917355e856_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_DenominatorAbstract_77d05bb9-f20a-4eb5-a906-ff9ae6ea5d2a_verboseLabel_en-US" xlink:label="lab_cpix_DenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_cpix_DenominatorAbstract_label_en-US" xlink:label="lab_cpix_DenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator [Abstract]</link:label>
    <link:label id="lab_cpix_DenominatorAbstract_documentation_en-US" xlink:label="lab_cpix_DenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DenominatorAbstract" xlink:href="cpix-20210630.xsd#cpix_DenominatorAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_DenominatorAbstract" xlink:to="lab_cpix_DenominatorAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ClinigenHealthcareLimitedMember_95701bf5-9d1d-4d23-a671-d7838aaecb41_terseLabel_en-US" xlink:label="lab_cpix_ClinigenHealthcareLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinigen</link:label>
    <link:label id="lab_cpix_ClinigenHealthcareLimitedMember_label_en-US" xlink:label="lab_cpix_ClinigenHealthcareLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinigen Healthcare Limited [Member]</link:label>
    <link:label id="lab_cpix_ClinigenHealthcareLimitedMember_documentation_en-US" xlink:label="lab_cpix_ClinigenHealthcareLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinigen Healthcare Limited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ClinigenHealthcareLimitedMember" xlink:href="cpix-20210630.xsd#cpix_ClinigenHealthcareLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ClinigenHealthcareLimitedMember" xlink:to="lab_cpix_ClinigenHealthcareLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c1d87d13-e618-4d5d-a773-58dc682b3da1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualRollForward_226d939d-a20b-4807-8675-766679ab944d_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualRollForward_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward" xlink:to="lab_us-gaap_LossContingencyAccrualRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_bede8a22-6fd4-4880-9521-888136324276_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_9c0efff5-d021-4c08-9d0d-393490eac6cf_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease income</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Rent Expense, Sublease Rentals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesRentExpenseSubleaseRentals1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:to="lab_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_d5069790-897c-43a0-9754-d3d52f7bdccd_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OfficeBuildingMember_7c6d69c4-8f8e-41a9-819f-008aa5b35108_terseLabel_en-US" xlink:label="lab_srt_OfficeBuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wet Laboratory and Office Space</link:label>
    <link:label id="lab_srt_OfficeBuildingMember_label_en-US" xlink:label="lab_srt_OfficeBuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OfficeBuildingMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OfficeBuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OfficeBuildingMember" xlink:to="lab_srt_OfficeBuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_4b84eb70-8e1d-44e6-a3c0-5d21538e7330_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to common shareholders - Continuing operations - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_efa9d4ab-9122-474d-96dd-ded591a9d929_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets_7a7dfbdc-8ee4-4581-828f-19a6b239a716_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial consideration received in exchange for product license rights</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:to="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_3f120467-a746-4f8f-8697-c6dac222c142_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to common shareholders - Discontinued operations - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingMember_33fffcbf-316d-4c21-bf36-2a0b18018a85_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Space</link:label>
    <link:label id="lab_us-gaap_BuildingMember_label_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember" xlink:to="lab_us-gaap_BuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_1603adee-bf20-44bc-b050-f79c4a8e26dc_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_471726eb-c1a2-4369-8efa-60937e4b31bd_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_7f015ab6-68b4-487d-8c42-b1c8f233a0ef_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible note</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_LeaseLiability_edf5686f-2d19-4981-bfc1-2fc752c2a716_terseLabel_en-US" xlink:label="lab_cpix_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_cpix_LeaseLiability_label_en-US" xlink:label="lab_cpix_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability</link:label>
    <link:label id="lab_cpix_LeaseLiability_documentation_en-US" xlink:label="lab_cpix_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LeaseLiability" xlink:href="cpix-20210630.xsd#cpix_LeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_LeaseLiability" xlink:to="lab_cpix_LeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_f74317f1-143a-4c6c-ba83-db936c4038b1_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_OtherProductsMember_2c229e9a-5cc4-4e44-a09d-aeb0424f1ed3_terseLabel_en-US" xlink:label="lab_cpix_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenue</link:label>
    <link:label id="lab_cpix_OtherProductsMember_label_en-US" xlink:label="lab_cpix_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products [Member]</link:label>
    <link:label id="lab_cpix_OtherProductsMember_documentation_en-US" xlink:label="lab_cpix_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherProductsMember" xlink:href="cpix-20210630.xsd#cpix_OtherProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_OtherProductsMember" xlink:to="lab_cpix_OtherProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_32922523-19a8-4c84-91df-436018e5bf07_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_1a43fef7-512e-4d01-a648-d2e0e3104dbc_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_df07de94-13a2-4faa-88f3-ead2b39f7b32_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventories classified as current</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4622e3ef-ce0c-426d-a9f5-9fe3338edebb_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_258b959b-fea6-4be5-90cf-3313cd4e0f08_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryLineItems_92fca27e-c2e3-485c-bd37-f3386fe55e12_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems" xlink:to="lab_us-gaap_InventoryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_2f5d9b04-ef71-40fc-9d69-2da64adf6365_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_79bf47c0-46e7-4a4d-a30c-5ba360a8d7cd_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest, Total</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_4c23be43-d299-44f6-bea1-fb74daf88a53_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_VaprisolMember_a8ef1f86-254d-4af7-b7aa-e77581d6bae6_terseLabel_en-US" xlink:label="lab_cpix_VaprisolMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acetadote</link:label>
    <link:label id="lab_cpix_VaprisolMember_label_en-US" xlink:label="lab_cpix_VaprisolMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaprisol [Member]</link:label>
    <link:label id="lab_cpix_VaprisolMember_documentation_en-US" xlink:label="lab_cpix_VaprisolMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaprisol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VaprisolMember" xlink:href="cpix-20210630.xsd#cpix_VaprisolMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_VaprisolMember" xlink:to="lab_cpix_VaprisolMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_7edcfce2-51da-43d5-bd1c-7127ac467841_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to common shareholders - Discontinued operations - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_1769b8d4-5751-4cdc-b25f-bbcbbcc60794_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ShareholdersEquityTextualAbstract_19c27ada-5985-4c70-90c5-2490c17f0bc3_verboseLabel_en-US" xlink:label="lab_cpix_ShareholdersEquityTextualAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' Equity (Textual) [Abstract]</link:label>
    <link:label id="lab_cpix_ShareholdersEquityTextualAbstract_label_en-US" xlink:label="lab_cpix_ShareholdersEquityTextualAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders Equity (Textual) [Abstract]</link:label>
    <link:label id="lab_cpix_ShareholdersEquityTextualAbstract_documentation_en-US" xlink:label="lab_cpix_ShareholdersEquityTextualAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders Equity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareholdersEquityTextualAbstract" xlink:href="cpix-20210630.xsd#cpix_ShareholdersEquityTextualAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract" xlink:to="lab_cpix_ShareholdersEquityTextualAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_0b2c3eaa-0d02-4ff1-a56b-6e821661e546_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis" xlink:to="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_7968f735-ba62-4df7-8503-a5172dfbee22_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_b8a4283c-b7d8-4fac-a035-e44d7ea209f4_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested restricted shares (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_39fe03aa-734c-4d0a-bed2-cf3200693234_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_326a3b22-f7cb-4e21-9b1c-514e245e9693_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">- diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_786fcee9-43a1-4912-b0a3-bd3c1a74efb5_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding &#8211; diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_e87c90b1-acd4-4be3-a00f-35d14199d8e2_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario, Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_c694efbc-d53a-44b5-bdf9-e8f6f8208e94_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to common shareholders - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_7514dce3-efb3-4d17-b2d8-c91a012e839b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on forgiveness of debt</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_eb6c67f8-16e2-4656-84e9-7a6315d5875a_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_30fe7a14-83ef-4c05-bf2f-6f640a0163e9_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_619cdcd7-b5f3-4394-958d-2f9f6e0714ca_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_d12e35fb-0136-4e2c-9abc-5487ff6bbf02_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryCurrentTable_5cc4e6fc-435b-408b-8d60-026ccefedc27_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:label id="lab_us-gaap_InventoryCurrentTable_label_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryCurrentTable" xlink:to="lab_us-gaap_InventoryCurrentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_29c181d5-13c8-40be-91dd-a13a367ec753_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_9df602db-a861-4b4c-8eb4-2a1077db5447_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling and marketing</link:label>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_0ba5441d-b2c0-4113-8f54-37b7ecf6c8f6_terseLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, Marketing and other</link:label>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_label_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling and Marketing Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpense" xlink:to="lab_us-gaap_SellingAndMarketingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity_bc921790-43c7-4078-a97f-0f511fe9e0fd_terseLabel_en-US" xlink:label="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total capacity</link:label>
    <link:label id="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity_label_en-US" xlink:label="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity, Total Capacity</link:label>
    <link:label id="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity_documentation_en-US" xlink:label="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity, Total Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity" xlink:href="cpix-20210630.xsd#cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity" xlink:to="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_64e13063-1433-4ed3-bdd3-e36bb7aab05b_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_IncentiveStockOptionsMember_d2d5a555-95cf-4e58-992d-b2ea11d62338_terseLabel_en-US" xlink:label="lab_cpix_IncentiveStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Stock Options</link:label>
    <link:label id="lab_cpix_IncentiveStockOptionsMember_label_en-US" xlink:label="lab_cpix_IncentiveStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Stock Options [Member]</link:label>
    <link:label id="lab_cpix_IncentiveStockOptionsMember_documentation_en-US" xlink:label="lab_cpix_IncentiveStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Stock Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncentiveStockOptionsMember" xlink:href="cpix-20210630.xsd#cpix_IncentiveStockOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_IncentiveStockOptionsMember" xlink:to="lab_cpix_IncentiveStockOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockNoParValue_1bba9993-3098-42e2-be0d-ebf3950d381d_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNoParValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockNoParValue_label_en-US" xlink:label="lab_us-gaap_CommonStockNoParValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, No Par Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNoParValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockNoParValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNoParValue" xlink:to="lab_us-gaap_CommonStockNoParValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_a47356bd-b5b2-47bd-bf7e-b5b8e788d162_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_65f1e210-e0ea-4575-a9f9-5b1a1839061d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_962c4c74-87c3-434a-b03e-97e5212ecd5e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Dissolution Payments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:to="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_6300a225-1341-4521-895f-c83cba67ac71_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryValuationReserves_96b657c9-a045-4925-bdaa-cd13311138e2_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Obsolescence and discontinuance losses</link:label>
    <link:label id="lab_us-gaap_InventoryValuationReserves_label_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Valuation Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryValuationReserves" xlink:to="lab_us-gaap_InventoryValuationReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_OmeclamoxPakMember_b93a57d4-9a87-4a39-b7e8-8b98696de6f4_terseLabel_en-US" xlink:label="lab_cpix_OmeclamoxPakMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vibativ</link:label>
    <link:label id="lab_cpix_OmeclamoxPakMember_label_en-US" xlink:label="lab_cpix_OmeclamoxPakMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omeclamox-Pak [Member]</link:label>
    <link:label id="lab_cpix_OmeclamoxPakMember_documentation_en-US" xlink:label="lab_cpix_OmeclamoxPakMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omeclamox-Pak</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OmeclamoxPakMember" xlink:href="cpix-20210630.xsd#cpix_OmeclamoxPakMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_OmeclamoxPakMember" xlink:to="lab_cpix_OmeclamoxPakMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_fe8dbe0b-3759-4259-9df7-dfbfe79f006d_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_e3acb967-d5c2-49af-88bb-8690ec921903_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_5847d050-00b7-4433-8cfc-49154cb092d3_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock&#8212;no par value; 100,000,000 shares authorized; 15,555,865 and 15,723,075 shares issued and outstanding as of June 30, 2018 and December 31, 2017, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_5f1cb881-1fc7-4f88-a359-19dd9e592536_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_7a1a8807-beaf-4bc5-bb67-745b6f0a4f9f_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_71161361-c9cb-447c-a128-b5443bc6f938_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity of Lease Liabilities at June 30, 2021</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_faf27022-ca2b-4720-8b5e-5202e813d0fb_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_dd45b255-0639-4927-aa5e-ea2cc934c205_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_ce0e4f13-7198-48e4-97dc-e88f3411d4bc_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1100892e-53a4-4274-a627-22a7763c5b94_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of numerator and denominator</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRoyalties_8a4ca21a-b1db-4e8f-91cf-72c0ea5e46b1_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRoyalties" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payment of royalty during the period</link:label>
    <link:label id="lab_us-gaap_PaymentsForRoyalties_label_en-US" xlink:label="lab_us-gaap_PaymentsForRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRoyalties" xlink:to="lab_us-gaap_PaymentsForRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_b35f35d1-d1f1-472a-911b-2e30a02cab30_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d5a70072-7cde-466c-83dd-baf367a5f350_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_3738f353-af83-485a-af39-7cb52267b6cd_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_40145be6-03df-401f-8b14-6a2d2fd56507_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncome_6f046f75-ca59-455c-8447-fc498f3ca82d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_us-gaap_OtherIncome_label_en-US" xlink:label="lab_us-gaap_OtherIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncome" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncome" xlink:to="lab_us-gaap_OtherIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived_7bccee16-d42e-47c9-86c1-a99d0f89cd4d_terseLabel_en-US" xlink:label="lab_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate amount</link:label>
    <link:label id="lab_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived_label_en-US" xlink:label="lab_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Coronavirus Aid, Relief, and Economic Security Act, Loan Proceeds Received</link:label>
    <link:label id="lab_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived_documentation_en-US" xlink:label="lab_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Coronavirus Aid, Relief, and Economic Security Act, Loan Proceeds Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" xlink:href="cpix-20210630.xsd#cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" xlink:to="lab_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_6abc974f-0963-4a4d-9595-1f7a1b2b9844_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COLLABORATIVE AGREEMENTS</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9ea2d3a6-2525-46c0-9041-e96b1978e801_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_bf348b90-d2c3-4767-8b29-a6c70c56012f_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_e31f6038-4737-4af4-87d9-b942e792fa3f_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_RediTrexMember_7870726e-d9e8-414b-be74-21ace0240395_terseLabel_en-US" xlink:label="lab_cpix_RediTrexMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RediTrex</link:label>
    <link:label id="lab_cpix_RediTrexMember_label_en-US" xlink:label="lab_cpix_RediTrexMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RediTrex [Member]</link:label>
    <link:label id="lab_cpix_RediTrexMember_documentation_en-US" xlink:label="lab_cpix_RediTrexMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RediTrex</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RediTrexMember" xlink:href="cpix-20210630.xsd#cpix_RediTrexMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_RediTrexMember" xlink:to="lab_cpix_RediTrexMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_28a64eba-5464-4fb9-94ec-206467341926_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_06ea4e9b-9672-47be-9fdc-fcf1487e76b1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_b4d81365-3a36-47dd-ad8b-0e10f1d5f452_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_90cf9af3-77d6-4c45-a757-b9681c08f822_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_7fdbffa9-363d-47fe-a880-fa4568d0c0af_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_a2326c8c-05e6-4a83-a283-c11bb1b02f5c_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_TieredRoyaltyPaymentsPercentage_6630ffff-c01b-459d-a43e-422f97ea2e79_terseLabel_en-US" xlink:label="lab_cpix_TieredRoyaltyPaymentsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of tiered royalty payments (up to)</link:label>
    <link:label id="lab_cpix_TieredRoyaltyPaymentsPercentage_label_en-US" xlink:label="lab_cpix_TieredRoyaltyPaymentsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tiered Royalty Payments, Percentage</link:label>
    <link:label id="lab_cpix_TieredRoyaltyPaymentsPercentage_documentation_en-US" xlink:label="lab_cpix_TieredRoyaltyPaymentsPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tiered Royalty Payments, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TieredRoyaltyPaymentsPercentage" xlink:href="cpix-20210630.xsd#cpix_TieredRoyaltyPaymentsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_TieredRoyaltyPaymentsPercentage" xlink:to="lab_cpix_TieredRoyaltyPaymentsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_12fbf164-7e60-4a8a-b85d-f24dfa26c08c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_10b332ee-db9b-4d57-853c-b108fc4cb411_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_a0ab4b1f-ce4e-4759-be41-b4c8efac4d49_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_95af8cc9-b9e7-4af4-a501-26a3e7f8586f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_0b74ea5d-4d1f-4094-a5cb-0301374bc73c_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_8d07a930-2c91-4e71-b1be-b88ec1330770_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_178a4af4-7642-4059-bac8-46cf4b85412b_verboseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock available for purchase through restricted stock awards and options (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_e9857eb2-f407-449a-aa3c-531733dcaee8_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:to="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_PinnacleBankMember_3dab1a9f-6ed5-44a1-b2a9-d39b343cb514_terseLabel_en-US" xlink:label="lab_cpix_PinnacleBankMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Bank</link:label>
    <link:label id="lab_cpix_PinnacleBankMember_label_en-US" xlink:label="lab_cpix_PinnacleBankMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Bank [Member]</link:label>
    <link:label id="lab_cpix_PinnacleBankMember_documentation_en-US" xlink:label="lab_cpix_PinnacleBankMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Bank</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PinnacleBankMember" xlink:href="cpix-20210630.xsd#cpix_PinnacleBankMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_PinnacleBankMember" xlink:to="lab_cpix_PinnacleBankMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ba674aeb-ae8e-4f81-a980-1d8fe9c614b7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_07d63671-1f9a-49eb-accb-4b24d15b59b6_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive effect of other securities (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_137f7393-b080-4f6d-b9e3-108765f5ffce_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_6d4da88e-9e88-4997-b9a7-0c55f3cd892d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of net revenue</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_91f2cf31-32e8-4846-b971-1b2b4b45a252_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested common stock, value</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_5d1b2da7-1c2d-49e8-a59c-8fde011624fb_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion_b494681d-2d9c-45b1-8c6c-6af823929870_verboseLabel_en-US" xlink:label="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion_label_en-US" xlink:label="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long Term Obligations, Excluding Current Portion</link:label>
    <link:label id="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion_documentation_en-US" xlink:label="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long Term Obligations, Excluding Current Portion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion" xlink:href="cpix-20210630.xsd#cpix_OtherLongTermObligationsExcludingCurrentPortion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion" xlink:to="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c6996811-a0d1-4ac1-8c40-a3925ef4fead_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_KristaloseMember_debe9631-4e48-4118-a0a7-d6001dfa5314_terseLabel_en-US" xlink:label="lab_cpix_KristaloseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Caldolor</link:label>
    <link:label id="lab_cpix_KristaloseMember_label_en-US" xlink:label="lab_cpix_KristaloseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kristalose [Member]</link:label>
    <link:label id="lab_cpix_KristaloseMember_documentation_en-US" xlink:label="lab_cpix_KristaloseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kristalose</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_KristaloseMember" xlink:href="cpix-20210630.xsd#cpix_KristaloseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_KristaloseMember" xlink:to="lab_cpix_KristaloseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_90a6c59b-69be-4615-a71c-6e7dc4f80107_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_3726bcfa-08ff-4fe9-89dd-5620b92872fe_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_44ce066a-57a4-48d9-8901-40050452f6c2_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_c7914f8a-4730-4013-a7d4-cbb1883ffaa0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_3ea9bad5-0e31-4cff-8af1-5d995dc1634b_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_ca951a93-4f04-4641-882c-0cbf6e7556bb_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) attributable to common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_0a5a4f69-f8f6-4db2-950f-f6cb8412fb77_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) attributable to common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_f6436027-07cd-4cd4-9b0a-20096374185e_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable" xlink:to="lab_us-gaap_LineOfCreditFacilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a48876b8-2290-4f8b-939d-7c1ab2e3b03c_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net changes in assets and liabilities affecting operating activities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_69413006-baad-4538-b944-65b35304fe2a_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3130cdc9-955b-4d5e-946a-20773c951af7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_eedfca92-5140-4aea-a2fb-0264143a1dfb_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_65392d84-5f4e-4e11-8858-5283552cac70_terseLabel_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIBOR</link:label>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_label_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_8cf8d0ee-6174-4bf1-8bd3-20d21438a336_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVENTORIES</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_9ef8402e-8377-4733-be76-5d0a2cf2ead6_terseLabel_en-US" xlink:label="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Position</link:label>
    <link:label id="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities, Lessee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="cpix-20210630.xsd#cpix_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_3434c3a7-a88d-41ab-a897-15d4e67ebefd_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">REVENUES</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_56adaf11-deca-47f2-8150-13f4f4651af6_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_2db0f28a-4d22-4471-b23e-dab54f1ad8f7_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_8aa0f341-39bf-42e0-9165-df72c213afde_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_e74fb8cc-a573-463b-8d13-ebee971740bd_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consigned inventory</link:label>
    <link:label id="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_label_en-US" xlink:label="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Inventory, Materials, Supplies and Merchandise under Consignment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:to="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_bae75f05-1847-4663-8218-e0e68e9f9b62_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_a2bacefd-083d-46e0-ac7b-29a3aef06841_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_545d76e3-d060-408e-ae99-8c4cf673adbe_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_72f69bae-c712-43b0-9eb2-fec7975915ad_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to common shareholders</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_1dc29709-e86a-4356-b1cd-e668a203131c_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_cd246151-88b4-4cc2-8c55-ef1b60450f10_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations income</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:to="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_5e726e3a-73ab-4ace-9fa2-8215ead3cca7_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_a267d36e-53ad-4cb3-bf50-b1e211f3539a_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_458f1e33-f519-48d7-9aaa-37dee842ebe7_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_e848d702-cb65-4854-848f-71fbdfd6f30f_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_6ff334bf-d20f-49e8-8cb6-c6783ed552cd_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock_917ee746-a22c-498d-a2a5-6a0abc8efadb_terseLabel_en-US" xlink:label="lab_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Rent Expense and Sublease Income</link:label>
    <link:label id="lab_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock_label_en-US" xlink:label="lab_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Rent Expense and Sublease Income [Table Text Block]</link:label>
    <link:label id="lab_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock_documentation_en-US" xlink:label="lab_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Rent Expense and Sublease Income [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" xlink:href="cpix-20210630.xsd#cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" xlink:to="lab_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_54e3bca3-631a-4a06-b55c-0af05b15edd2_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_7276357b-4296-407b-b866-5035621325c6_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_bfa0590a-b983-4f86-86d6-7137f1421cbb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_d619bf49-bf93-447f-a6ab-d74e95b32d3f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c1fbb707-b036-4e42-92b9-8238939a3eda_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_d2ecdbcd-8506-4812-bd36-068d56314f5c_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_068126d0-cbfc-4afa-8042-24e6689f7d28_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_970d2ca7-27f6-4368-b831-d0314d90b715_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_d6fc2adb-8c5c-48ba-8965-d6ea07f71711_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest_c42ef46c-e1ae-4052-9155-a4ce0d9b72c5_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of subsidiary shares from noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Redeemable Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_3a372788-03f0-4700-8ef3-54b0501eed62_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:to="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_5d94c7cf-0724-4570-80cb-57f574c71ba6_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_900cbcf4-7bc9-4133-b18d-d6760938ab77_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_def2b8d8-b9aa-4665-b394-26f6a0ff54cf_negatedLabel_en-US" xlink:label="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in non-cash contingent consideration</link:label>
    <link:label id="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_label_en-US" xlink:label="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess Tax Benefit from Share-based Compensation, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:to="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_c12031e2-34aa-413e-8d0d-41582f991a51_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials and work in process</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_4a799db2-5737-4a35-bffb-8c07c09b247c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_6991ffe4-8d58-4ffe-a2a8-72523691d06b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate spread</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryGross_2b165781-6a20-42f1-9f6e-eca37d6e37e6_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventories</link:label>
    <link:label id="lab_us-gaap_InventoryGross_label_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross" xlink:to="lab_us-gaap_InventoryGross" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_FourthAmendmentMember_9fa1f6aa-9d52-44bc-89d8-5e8be0520fde_terseLabel_en-US" xlink:label="lab_cpix_FourthAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fourth Amendment</link:label>
    <link:label id="lab_cpix_FourthAmendmentMember_label_en-US" xlink:label="lab_cpix_FourthAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fourth Amendment [Member]</link:label>
    <link:label id="lab_cpix_FourthAmendmentMember_documentation_en-US" xlink:label="lab_cpix_FourthAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fourth Amendment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FourthAmendmentMember" xlink:href="cpix-20210630.xsd#cpix_FourthAmendmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_FourthAmendmentMember" xlink:to="lab_cpix_FourthAmendmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_75689bd3-54c1-4899-8c20-edf717107bb5_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income (loss) from continuing operations to net cash provided by (used in) operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_e021e5e5-1f41-4d59-ac35-f8e8e9b88428_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to common shareholders - Continuing operations - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0dc08107-de4f-4bec-8622-7c318075be2e_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_d37f5e7a-f06f-47ba-b037-24ffbf5e9c72_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ADDITIONS AND RETURN OF PRODUCT RIGHTS</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals_d59163c9-19be-4425-9983-cb3ce38c8787_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future minimum sublease income under noncancelable operating subleases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Future Minimum Sublease Rentals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_db1a3fd2-29ce-43ca-a61d-949547551aa7_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_0349fc5d-ce14-4afb-a3fb-7fd594eb3212_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, Beginning of Period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_2b6643b8-0de8-4ad0-8d9b-64e549e53988_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, End of Period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_6fbfb9a8-32eb-4570-8dd2-40fd9115f02d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturity of Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_17ffce08-64c1-4a2e-b5ab-e182b3ada450_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7496b016-06be-430c-93dd-1134bc97d461_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">- basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c8ac721c-48a4-4045-a9ff-71f8da4e1a1d_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding &#8211; basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_c36ab15f-b54d-4eef-b055-d15c9640f661_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_7cbe2d57-2df8-42ce-8657-9de665c6633a_verboseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_95351a82-3a38-4d3e-a34c-fab288a2953f_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial investment in joint ventures</link:label>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_label_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:to="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_c6fdbe7b-6748-4d75-971b-30980f1250bc_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_fc9dce5f-e9d4-40b9-baee-837065034f50_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_388e70c3-8d7d-4368-bcfc-bebad5741632_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_853a1fc6-1b02-4998-9204-b451420f9019_terseLabel_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration earned and accrued in operating expenses</link:label>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_label_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses</link:label>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_documentation_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:href="cpix-20210630.xsd#cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:to="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_MethotrexateMember_7f5fb9ae-04d8-47e0-9905-76b8c338362f_terseLabel_en-US" xlink:label="lab_cpix_MethotrexateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Methotrexate</link:label>
    <link:label id="lab_cpix_MethotrexateMember_label_en-US" xlink:label="lab_cpix_MethotrexateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Methotrexate [Member]</link:label>
    <link:label id="lab_cpix_MethotrexateMember_documentation_en-US" xlink:label="lab_cpix_MethotrexateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Methotrexate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_MethotrexateMember" xlink:href="cpix-20210630.xsd#cpix_MethotrexateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_MethotrexateMember" xlink:to="lab_cpix_MethotrexateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_81242cbb-f3e3-4088-b78a-f1be3134a636_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8c91ca26-3afb-40bf-8980-6aa3f829a549_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, Beginning of Period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0bb5f874-9261-4b41-b94c-c76d30562295_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, End of Period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_b7df7532-4150-4681-bdf6-a58dbbcea0b3_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ORGANIZATION AND BASIS OF PRESENTATION</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_beae8818-1221-47b7-9618-161129e38cba_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability recorded</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Liabilities Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_7b75acd3-f13a-4344-9908-138412fb20c2_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax (expense) benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3e263402-0bba-4b3e-8471-9ae4065653b6_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_13582548-f02c-4721-960c-1e78f5483d4e_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_9fcbb351-997e-42d6-8604-cc77cf79bf27_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_3c287eb7-8d3e-4532-8040-de23e264c219_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_cd479974-611f-4b83-bce9-b921eac8821c_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to common shareholders - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_d9be5e45-a8cf-42de-96cc-e4759cfebd22_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent expense</link:label>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_label_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Rent Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseAndRentalExpense" xlink:to="lab_us-gaap_LeaseAndRentalExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_a59f7681-478c-48db-b130-924438f692d3_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_fc0ca832-fbcf-40c5-988e-d71dcc9e5e6c_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_9d16fc9b-a184-4ddf-8037-e0429abbd145_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment to acquire business upon closing</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_47bc4ae0-7cf5-4386-bb21-9c40aae4a767_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided by (Used in) Operating Activities, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_c77f22db-bf0d-4cea-a7c4-708bee15efa7_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_4401834a-3a0b-4c9e-8c8d-6ef9d02c8a6b_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_86a9c357-832c-48fd-b1e8-6ecdda7bb864_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_015aa3a6-fd4d-4c45-bbe8-764b2a7be019_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_dae37341-f8ff-40a5-9902-551880ea62a5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_f4565e52-4f36-41ce-9f95-5d7a42c0262f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_988f210b-4be3-49b4-850a-fa4fc814c560_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_af7334f4-2798-4288-8833-31979d9eebc4_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_EquityAndDebtAbstract_label_en-US" xlink:label="lab_cpix_EquityAndDebtAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity and Debt [Abstract]</link:label>
    <link:label id="lab_cpix_EquityAndDebtAbstract_documentation_en-US" xlink:label="lab_cpix_EquityAndDebtAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity and Debt [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EquityAndDebtAbstract" xlink:href="cpix-20210630.xsd#cpix_EquityAndDebtAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_EquityAndDebtAbstract" xlink:to="lab_cpix_EquityAndDebtAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPaymentsToAcquireBusinesses_21ff85d1-9086-4e64-9e7a-bd857d1d4b01_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Payments to Acquire Businesses</link:label>
    <link:label id="lab_us-gaap_OtherPaymentsToAcquireBusinesses_label_en-US" xlink:label="lab_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Payments to Acquire Businesses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:to="lab_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermLineOfCredit_f753feb5-4118-40b8-9859-0e0db440d0d4_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermLineOfCredit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving line of credit</link:label>
    <link:label id="lab_us-gaap_LongTermLineOfCredit_label_en-US" xlink:label="lab_us-gaap_LongTermLineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Line of Credit, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermLineOfCredit" xlink:to="lab_us-gaap_LongTermLineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount_eea50c39-141a-4b5c-b12a-527322516848_terseLabel_en-US" xlink:label="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase amount (up to)</link:label>
    <link:label id="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount_label_en-US" xlink:label="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity, Increase Amount</link:label>
    <link:label id="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount_documentation_en-US" xlink:label="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity, Increase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount" xlink:href="cpix-20210630.xsd#cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount" xlink:to="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_e49f0031-fab1-4c39-84b0-2b12c3739c4a_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit, maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_8bf7ce01-2aa3-4b23-be6b-120f95a5eae9_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_a3607dc3-9217-4d6b-82d1-531cf6945048_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_e3c8870c-e11c-47be-a8b3-1eb32037004d_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_aeceaee1-b308-4e78-8fc2-828ea941abe2_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_6c852357-9dd8-4786-b543-172dc77435af_verboseLabel_en-US" xlink:label="lab_cpix_IncreaseDecreaseInCurrentOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and other current liabilities</link:label>
    <link:label id="lab_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_label_en-US" xlink:label="lab_cpix_IncreaseDecreaseInCurrentOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IncreaseDecreaseInCurrentOperatingLiabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities" xlink:href="cpix-20210630.xsd#cpix_IncreaseDecreaseInCurrentOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities" xlink:to="lab_cpix_IncreaseDecreaseInCurrentOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_5debeb15-9fdb-4364-af04-4f9b9996d935_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_38c4abdd-c7ca-4f6a-90ff-55c1bc6a83ba_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_43fea51e-d25f-4942-ac19-51eb04efd567_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash interest expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_61403650-9f7f-4210-b82f-ddcbc1f816d7_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_ff85f614-ca21-4676-be7b-f1cbefb6cccb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_c3b6fd8f-f4ba-4fc7-86d2-6a9ceca5bda8_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_820e1041-e293-4e81-914e-476ccf3bc199_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_133e8230-a1fb-46f1-915c-aa6dedf60fa8_periodStartLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_1b04cb6e-348b-40c0-bd2c-fbc3f3826ae9_periodEndLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_63d721c4-84ea-4b6f-b492-41220a689887_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_0ad9b9a5-2740-4172-9a6e-b4f1ef273265_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payment of contingent consideration</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Contingent Consideration Liability, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_7ad748a5-55e7-4d86-9746-32d4291b5ffb_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_8faeda40-9067-4eb3-b500-60a39bda7764_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note receivable investment funding</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_2de07b54-9a4f-49ce-b9b4-108df7c12bb6_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_c93add2d-ebbe-4e6c-aab6-1c865b60806b_verboseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase outstanding common shares</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_36b26506-6b76-4737-bb20-0cfbc158553c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_aa532a14-3275-41b5-b250-93810bff2f6b_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_0cd608fc-3bf0-44ce-adac-6d439fd9e149_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_36b5b35a-e7dc-482c-a959-5804e1907cf3_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bbab3019-8300-4aa5-9bab-c91b45db9a98_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_7de07939-3bff-49d4-ae13-b4d7efc803ed_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) from continuing operations before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_655713da-486d-4631-bc7b-8417a90ec1af_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_9b50b6e8-3003-400a-bf5f-08ac5d578c0f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_e07815a3-ccf8-4dae-902f-328f2a6d1051_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit, unused capacity, commitment fee percentage</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Unused Capacity, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_99b02563-9726-4ab4-9dfc-fbd157925060_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_11746010-58ae-434d-89e0-fc8087627061_negatedLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common shares</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_5f24acc2-39bf-4d88-888b-f2fc07a99397_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of shares, value</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_a653a15f-f3c2-4441-9bb5-58cca327c4ca_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CaldolorMember_5aa64530-05a9-4b5c-a36d-66d8746787b3_terseLabel_en-US" xlink:label="lab_cpix_CaldolorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omeclamox-Pak</link:label>
    <link:label id="lab_cpix_CaldolorMember_label_en-US" xlink:label="lab_cpix_CaldolorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Caldolor [Member]</link:label>
    <link:label id="lab_cpix_CaldolorMember_documentation_en-US" xlink:label="lab_cpix_CaldolorMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Caldolor</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CaldolorMember" xlink:href="cpix-20210630.xsd#cpix_CaldolorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CaldolorMember" xlink:to="lab_cpix_CaldolorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNoncurrent_a19c56c6-caf9-4459-aaec-fa1cc6ab8ec7_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_bff1ce7c-a508-4255-8ed7-93f3210f034d_negatedLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_label_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNoncurrent" xlink:to="lab_us-gaap_InventoryNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_WinHealthInvestmentSingaporeLtdDomain_207fd21b-02cd-431e-90c0-91189d8cfe8a_terseLabel_en-US" xlink:label="lab_cpix_WinHealthInvestmentSingaporeLtdDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WinHealth</link:label>
    <link:label id="lab_cpix_WinHealthInvestmentSingaporeLtdDomain_label_en-US" xlink:label="lab_cpix_WinHealthInvestmentSingaporeLtdDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WinHealth Investment (Singapore) Ltd [Domain]</link:label>
    <link:label id="lab_cpix_WinHealthInvestmentSingaporeLtdDomain_documentation_en-US" xlink:label="lab_cpix_WinHealthInvestmentSingaporeLtdDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WinHealth Investment (Singapore) Ltd</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_WinHealthInvestmentSingaporeLtdDomain" xlink:href="cpix-20210630.xsd#cpix_WinHealthInvestmentSingaporeLtdDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_WinHealthInvestmentSingaporeLtdDomain" xlink:to="lab_cpix_WinHealthInvestmentSingaporeLtdDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_d6676ec3-a4a1-4c3e-91b1-6400a5a75ce4_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EARNINGS (LOSS) PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_529b1c54-a1bd-4146-945d-499731165bcd_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net, Items Net of Reserve Alternative [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract" xlink:to="lab_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_dc3c8e71-729c-438e-a064-bcc247340366_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_7c70df27-298d-4525-b8f7-5d9cb9999ece_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_ff588980-a885-4d96-b220-c216dea05329_terseLabel_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Registration, sale of corporate securities (up to)</link:label>
    <link:label id="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_label_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:href="cpix-20210630.xsd#cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:to="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_c8eb4a7a-6a00-4ca6-8bb0-fcd727f1fd9c_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_9e79fc83-2f89-4535-9f93-9990ad38146a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable" xlink:to="lab_us-gaap_IncomeTaxContingencyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_eee3e8ab-482e-4eb8-91a0-830ca4c4d905_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Guidance</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>cpix-20210630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:976bbab0-2784-42fd-860c-1897d99c723d,g:5df55cfc-81cf-4a6f-b91d-2b22fdc37eaa-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CoverPage" xlink:type="simple" xlink:href="cpix-20210630.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_5da6984e-f744-42a8-b816-396c8421d20b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_e7c66834-f404-4973-91f4-e59eba5a3482" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5da6984e-f744-42a8-b816-396c8421d20b" xlink:to="loc_dei_DocumentType_e7c66834-f404-4973-91f4-e59eba5a3482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_e750d4d3-9929-4370-abee-d7a4929475ba" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5da6984e-f744-42a8-b816-396c8421d20b" xlink:to="loc_dei_DocumentQuarterlyReport_e750d4d3-9929-4370-abee-d7a4929475ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_2c961b07-2454-48b1-9a72-514eb7a4b500" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5da6984e-f744-42a8-b816-396c8421d20b" xlink:to="loc_dei_DocumentPeriodEndDate_2c961b07-2454-48b1-9a72-514eb7a4b500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_b69118f3-c449-46a7-af63-d67d071b7e66" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5da6984e-f744-42a8-b816-396c8421d20b" xlink:to="loc_dei_DocumentTransitionReport_b69118f3-c449-46a7-af63-d67d071b7e66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_1a8f55b5-e0b4-4032-babe-e23d6dcb5342" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5da6984e-f744-42a8-b816-396c8421d20b" xlink:to="loc_dei_EntityFileNumber_1a8f55b5-e0b4-4032-babe-e23d6dcb5342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_85390dea-9df4-46e2-bcdb-d91281ea6cec" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5da6984e-f744-42a8-b816-396c8421d20b" xlink:to="loc_dei_EntityRegistrantName_85390dea-9df4-46e2-bcdb-d91281ea6cec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_b61b8cf6-6082-4a51-9104-5eec4e126ea8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5da6984e-f744-42a8-b816-396c8421d20b" xlink:to="loc_dei_EntityIncorporationStateCountryCode_b61b8cf6-6082-4a51-9104-5eec4e126ea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_2502f9dd-92a3-4274-899e-f0890684e442" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5da6984e-f744-42a8-b816-396c8421d20b" xlink:to="loc_dei_EntityTaxIdentificationNumber_2502f9dd-92a3-4274-899e-f0890684e442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_ba6def9a-edc7-40e2-a810-6f49377a4db5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5da6984e-f744-42a8-b816-396c8421d20b" xlink:to="loc_dei_EntityAddressAddressLine1_ba6def9a-edc7-40e2-a810-6f49377a4db5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_619ce005-134a-4caf-9cf6-4c3c460caab1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5da6984e-f744-42a8-b816-396c8421d20b" xlink:to="loc_dei_EntityAddressAddressLine2_619ce005-134a-4caf-9cf6-4c3c460caab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_b55eedcf-00bb-438d-948b-a4e35176335f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5da6984e-f744-42a8-b816-396c8421d20b" xlink:to="loc_dei_EntityAddressCityOrTown_b55eedcf-00bb-438d-948b-a4e35176335f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_0a28f2bb-2687-42ee-a1fa-efd65d050213" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5da6984e-f744-42a8-b816-396c8421d20b" xlink:to="loc_dei_EntityAddressStateOrProvince_0a28f2bb-2687-42ee-a1fa-efd65d050213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_851441c6-0a73-4c10-9bc4-2b9179507d9c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5da6984e-f744-42a8-b816-396c8421d20b" xlink:to="loc_dei_EntityAddressPostalZipCode_851441c6-0a73-4c10-9bc4-2b9179507d9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_8e8d1833-820c-478e-90e2-fd4236b78706" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5da6984e-f744-42a8-b816-396c8421d20b" xlink:to="loc_dei_CityAreaCode_8e8d1833-820c-478e-90e2-fd4236b78706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_6d19189c-17f8-409b-81df-8fd614385fb8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5da6984e-f744-42a8-b816-396c8421d20b" xlink:to="loc_dei_LocalPhoneNumber_6d19189c-17f8-409b-81df-8fd614385fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_45d0e63a-ef00-470b-a3fc-b4d535544d82" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5da6984e-f744-42a8-b816-396c8421d20b" xlink:to="loc_dei_Security12bTitle_45d0e63a-ef00-470b-a3fc-b4d535544d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_de2b28ed-0b80-48ad-97ea-7c37d75df39d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5da6984e-f744-42a8-b816-396c8421d20b" xlink:to="loc_dei_TradingSymbol_de2b28ed-0b80-48ad-97ea-7c37d75df39d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_2824771a-6805-4752-af1f-da6f72fb33d6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5da6984e-f744-42a8-b816-396c8421d20b" xlink:to="loc_dei_SecurityExchangeName_2824771a-6805-4752-af1f-da6f72fb33d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_9d59dda6-6295-42a6-b997-b5cb0bde20c1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5da6984e-f744-42a8-b816-396c8421d20b" xlink:to="loc_dei_EntityCurrentReportingStatus_9d59dda6-6295-42a6-b997-b5cb0bde20c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_e291d300-d7e2-4612-9a1a-6ba0902e0ed7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5da6984e-f744-42a8-b816-396c8421d20b" xlink:to="loc_dei_EntityInteractiveDataCurrent_e291d300-d7e2-4612-9a1a-6ba0902e0ed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_2a2ee9fb-b201-4bb6-8b5e-43b235e5261b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5da6984e-f744-42a8-b816-396c8421d20b" xlink:to="loc_dei_EntityFilerCategory_2a2ee9fb-b201-4bb6-8b5e-43b235e5261b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_88e0a41c-5532-4454-a057-26ddf2ba09e7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5da6984e-f744-42a8-b816-396c8421d20b" xlink:to="loc_dei_EntitySmallBusiness_88e0a41c-5532-4454-a057-26ddf2ba09e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_aba191a1-1109-4763-9be4-9d260b0f7141" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5da6984e-f744-42a8-b816-396c8421d20b" xlink:to="loc_dei_EntityEmergingGrowthCompany_aba191a1-1109-4763-9be4-9d260b0f7141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_717f89cf-250d-4bce-8c56-c6d63b20843c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5da6984e-f744-42a8-b816-396c8421d20b" xlink:to="loc_dei_EntityShellCompany_717f89cf-250d-4bce-8c56-c6d63b20843c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_88ae06de-98e6-4c4f-af30-59efc549e724" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5da6984e-f744-42a8-b816-396c8421d20b" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_88ae06de-98e6-4c4f-af30-59efc549e724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_fcacbea7-ace7-41d9-b76d-ecf341ff2c01" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5da6984e-f744-42a8-b816-396c8421d20b" xlink:to="loc_dei_DocumentFiscalYearFocus_fcacbea7-ace7-41d9-b76d-ecf341ff2c01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_d97cd77e-5a03-4117-8985-2e8f1e3b8ea9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5da6984e-f744-42a8-b816-396c8421d20b" xlink:to="loc_dei_DocumentFiscalPeriodFocus_d97cd77e-5a03-4117-8985-2e8f1e3b8ea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_c10ef174-5a19-4cfb-a7d1-20ca3dd2ffb0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5da6984e-f744-42a8-b816-396c8421d20b" xlink:to="loc_dei_AmendmentFlag_c10ef174-5a19-4cfb-a7d1-20ca3dd2ffb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_9b25a330-52a6-4eee-95d6-ce550f85bb5e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5da6984e-f744-42a8-b816-396c8421d20b" xlink:to="loc_dei_EntityCentralIndexKey_9b25a330-52a6-4eee-95d6-ce550f85bb5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_4c74b642-3bc6-441d-b152-17a15cd52765" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5da6984e-f744-42a8-b816-396c8421d20b" xlink:to="loc_dei_CurrentFiscalYearEndDate_4c74b642-3bc6-441d-b152-17a15cd52765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cpix-20210630.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_6dd313ba-208b-4d8d-a327-960189f1b590" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_f5190ff1-fc39-446b-bbf6-c1196b6ee0dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6dd313ba-208b-4d8d-a327-960189f1b590" xlink:to="loc_us-gaap_AssetsAbstract_f5190ff1-fc39-446b-bbf6-c1196b6ee0dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_e7297137-cac0-4e41-b262-a090ca15176b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f5190ff1-fc39-446b-bbf6-c1196b6ee0dd" xlink:to="loc_us-gaap_AssetsCurrentAbstract_e7297137-cac0-4e41-b262-a090ca15176b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0fdc7287-2f1c-44db-ae38-4cdf1c803149" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e7297137-cac0-4e41-b262-a090ca15176b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0fdc7287-2f1c-44db-ae38-4cdf1c803149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_67e68b18-ae1e-4af1-8015-808b68007441" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e7297137-cac0-4e41-b262-a090ca15176b" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_67e68b18-ae1e-4af1-8015-808b68007441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_163392b8-d81c-419d-bcb3-583efdc8ed56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e7297137-cac0-4e41-b262-a090ca15176b" xlink:to="loc_us-gaap_InventoryNet_163392b8-d81c-419d-bcb3-583efdc8ed56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_ee6beb2c-ece9-47d1-9571-3de964232033" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e7297137-cac0-4e41-b262-a090ca15176b" xlink:to="loc_us-gaap_OtherAssetsCurrent_ee6beb2c-ece9-47d1-9571-3de964232033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_8d285d98-06d6-4c16-ace1-b1c6eaef9d9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e7297137-cac0-4e41-b262-a090ca15176b" xlink:to="loc_us-gaap_AssetsCurrent_8d285d98-06d6-4c16-ace1-b1c6eaef9d9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_f3fd9867-e51b-4a95-a387-4eec98e92e7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f5190ff1-fc39-446b-bbf6-c1196b6ee0dd" xlink:to="loc_us-gaap_InventoryNoncurrent_f3fd9867-e51b-4a95-a387-4eec98e92e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_08cd6d71-2e34-4512-805a-f05559055362" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f5190ff1-fc39-446b-bbf6-c1196b6ee0dd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_08cd6d71-2e34-4512-805a-f05559055362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_fe0cc249-aafb-4142-b4bd-c17693a4c70d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f5190ff1-fc39-446b-bbf6-c1196b6ee0dd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_fe0cc249-aafb-4142-b4bd-c17693a4c70d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_2804ec6e-1d54-4093-9fdc-80d3ceaa0a15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f5190ff1-fc39-446b-bbf6-c1196b6ee0dd" xlink:to="loc_us-gaap_Goodwill_2804ec6e-1d54-4093-9fdc-80d3ceaa0a15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_150e835e-bb80-4630-95c2-db89126f3ddb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f5190ff1-fc39-446b-bbf6-c1196b6ee0dd" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_150e835e-bb80-4630-95c2-db89126f3ddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_5ab0d86d-02e6-4274-9a38-93a700fa6d9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f5190ff1-fc39-446b-bbf6-c1196b6ee0dd" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_5ab0d86d-02e6-4274-9a38-93a700fa6d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_49608232-62d8-4a12-bb51-4e6219f06184" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f5190ff1-fc39-446b-bbf6-c1196b6ee0dd" xlink:to="loc_us-gaap_Assets_49608232-62d8-4a12-bb51-4e6219f06184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9f3980c2-3cde-4d5b-a638-b565c195423e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6dd313ba-208b-4d8d-a327-960189f1b590" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9f3980c2-3cde-4d5b-a638-b565c195423e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_16511e57-f8b8-42a8-8451-03ab5423d2b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9f3980c2-3cde-4d5b-a638-b565c195423e" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_16511e57-f8b8-42a8-8451-03ab5423d2b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_3009f1cc-1572-43c2-806b-53d796c3d1d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_16511e57-f8b8-42a8-8451-03ab5423d2b5" xlink:to="loc_us-gaap_AccountsPayableCurrent_3009f1cc-1572-43c2-806b-53d796c3d1d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_5040aa5b-141c-49f8-934f-bc3e8aaac4a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_16511e57-f8b8-42a8-8451-03ab5423d2b5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_5040aa5b-141c-49f8-934f-bc3e8aaac4a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_b2df0730-ad58-4eba-9bf8-36a1a0da5c24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_16511e57-f8b8-42a8-8451-03ab5423d2b5" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_b2df0730-ad58-4eba-9bf8-36a1a0da5c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_37bb7373-e6b1-4c6b-9bce-b52e71d60e0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_16511e57-f8b8-42a8-8451-03ab5423d2b5" xlink:to="loc_us-gaap_LiabilitiesCurrent_37bb7373-e6b1-4c6b-9bce-b52e71d60e0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_56344a3c-ae98-4b4e-be3f-cd82af38aefe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9f3980c2-3cde-4d5b-a638-b565c195423e" xlink:to="loc_us-gaap_LongTermLineOfCredit_56344a3c-ae98-4b4e-be3f-cd82af38aefe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e7aac33e-2135-49bf-b5c3-b21f58713711" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9f3980c2-3cde-4d5b-a638-b565c195423e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e7aac33e-2135-49bf-b5c3-b21f58713711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion_a6852fef-2206-4005-91b3-e1018bdc17e4" xlink:href="cpix-20210630.xsd#cpix_OtherLongTermObligationsExcludingCurrentPortion"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9f3980c2-3cde-4d5b-a638-b565c195423e" xlink:to="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion_a6852fef-2206-4005-91b3-e1018bdc17e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_cebad082-53e4-4dce-98ae-fcfda6f360d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9f3980c2-3cde-4d5b-a638-b565c195423e" xlink:to="loc_us-gaap_Liabilities_cebad082-53e4-4dce-98ae-fcfda6f360d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_02a275c7-73b0-4060-86ed-abb5a69021df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9f3980c2-3cde-4d5b-a638-b565c195423e" xlink:to="loc_us-gaap_CommitmentsAndContingencies_02a275c7-73b0-4060-86ed-abb5a69021df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_9534cbb5-90ce-476b-90ae-97ffa03d6b74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9f3980c2-3cde-4d5b-a638-b565c195423e" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_9534cbb5-90ce-476b-90ae-97ffa03d6b74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_666cc71b-e0e7-46b0-864e-a40413591398" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_9534cbb5-90ce-476b-90ae-97ffa03d6b74" xlink:to="loc_us-gaap_StockholdersEquityAbstract_666cc71b-e0e7-46b0-864e-a40413591398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_d2a7845d-eeae-4a7d-9403-d29b7133ff4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_666cc71b-e0e7-46b0-864e-a40413591398" xlink:to="loc_us-gaap_CommonStockValue_d2a7845d-eeae-4a7d-9403-d29b7133ff4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_eb239f54-6278-4f6a-be11-579e38ef5ff4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_666cc71b-e0e7-46b0-864e-a40413591398" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_eb239f54-6278-4f6a-be11-579e38ef5ff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_084c253b-4197-4d1a-a6b9-328b0a2d1d57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_666cc71b-e0e7-46b0-864e-a40413591398" xlink:to="loc_us-gaap_StockholdersEquity_084c253b-4197-4d1a-a6b9-328b0a2d1d57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_dbb0406a-c8e1-42dd-b07a-ea11edfcb79f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_9534cbb5-90ce-476b-90ae-97ffa03d6b74" xlink:to="loc_us-gaap_MinorityInterest_dbb0406a-c8e1-42dd-b07a-ea11edfcb79f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ea2a48a1-2ae4-4083-94f6-88c6a6d75589" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_9534cbb5-90ce-476b-90ae-97ffa03d6b74" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ea2a48a1-2ae4-4083-94f6-88c6a6d75589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_b37f8eac-e967-4dc0-aaa7-a5f3fc438b51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9f3980c2-3cde-4d5b-a638-b565c195423e" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_b37f8eac-e967-4dc0-aaa7-a5f3fc438b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="cpix-20210630.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_78d8a908-d7d7-49d1-a60a-9fa9520b68ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNoParValue_f76d0579-86d2-4088-9e68-4a9a94d25aae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockNoParValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_78d8a908-d7d7-49d1-a60a-9fa9520b68ab" xlink:to="loc_us-gaap_CommonStockNoParValue_f76d0579-86d2-4088-9e68-4a9a94d25aae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_a8b76e20-c629-4449-8585-e95fb8c5e9da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_78d8a908-d7d7-49d1-a60a-9fa9520b68ab" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_a8b76e20-c629-4449-8585-e95fb8c5e9da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_f4050d17-d43a-42c5-ab51-669038038891" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_78d8a908-d7d7-49d1-a60a-9fa9520b68ab" xlink:to="loc_us-gaap_CommonStockSharesIssued_f4050d17-d43a-42c5-ab51-669038038891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_85f1e0ef-452e-4bef-bf1b-d196b9ff3f8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_78d8a908-d7d7-49d1-a60a-9fa9520b68ab" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_85f1e0ef-452e-4bef-bf1b-d196b9ff3f8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="cpix-20210630.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_4d3183b8-3562-4a25-bcce-3cdc89c87f31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e7b0476d-70af-40b0-b069-b60bbef7f8e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4d3183b8-3562-4a25-bcce-3cdc89c87f31" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e7b0476d-70af-40b0-b069-b60bbef7f8e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_d646a0ac-3221-4e8f-9fc8-cbdca861d0c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4d3183b8-3562-4a25-bcce-3cdc89c87f31" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_d646a0ac-3221-4e8f-9fc8-cbdca861d0c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_311e8850-c927-49e9-a428-1090c1c81262" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d646a0ac-3221-4e8f-9fc8-cbdca861d0c4" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_311e8850-c927-49e9-a428-1090c1c81262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_2dca4478-4c6e-49a0-b17f-eca490fa3711" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d646a0ac-3221-4e8f-9fc8-cbdca861d0c4" xlink:to="loc_us-gaap_SellingAndMarketingExpense_2dca4478-4c6e-49a0-b17f-eca490fa3711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_fba8bc3c-a965-463d-a282-1eb9e5d1d75b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d646a0ac-3221-4e8f-9fc8-cbdca861d0c4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_fba8bc3c-a965-463d-a282-1eb9e5d1d75b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_392272ae-d39a-46fe-b3e0-3156934944e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d646a0ac-3221-4e8f-9fc8-cbdca861d0c4" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_392272ae-d39a-46fe-b3e0-3156934944e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_1295eeab-04b0-4f7b-beaf-5853cc647b65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d646a0ac-3221-4e8f-9fc8-cbdca861d0c4" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_1295eeab-04b0-4f7b-beaf-5853cc647b65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_3f0f1a03-8323-4144-9708-7180d09b4e37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d646a0ac-3221-4e8f-9fc8-cbdca861d0c4" xlink:to="loc_us-gaap_CostsAndExpenses_3f0f1a03-8323-4144-9708-7180d09b4e37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_3f40e7ec-33df-4bfa-8176-158bb13cb2ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d646a0ac-3221-4e8f-9fc8-cbdca861d0c4" xlink:to="loc_us-gaap_OperatingIncomeLoss_3f40e7ec-33df-4bfa-8176-158bb13cb2ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_2585570f-f398-4ab1-8591-dc19f2e52ea8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4d3183b8-3562-4a25-bcce-3cdc89c87f31" xlink:to="loc_us-gaap_InvestmentIncomeInterest_2585570f-f398-4ab1-8591-dc19f2e52ea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncome_0e4aec64-f450-4b36-9c2e-fd16a44d2490" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4d3183b8-3562-4a25-bcce-3cdc89c87f31" xlink:to="loc_us-gaap_OtherIncome_0e4aec64-f450-4b36-9c2e-fd16a44d2490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_98d816fa-fc45-405b-ab6b-f1fec33afc13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4d3183b8-3562-4a25-bcce-3cdc89c87f31" xlink:to="loc_us-gaap_InterestExpense_98d816fa-fc45-405b-ab6b-f1fec33afc13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_da7cc150-4018-416f-b9df-cac847278aed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4d3183b8-3562-4a25-bcce-3cdc89c87f31" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_da7cc150-4018-416f-b9df-cac847278aed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e301eb83-c562-4894-a363-4c0b8de4ae12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4d3183b8-3562-4a25-bcce-3cdc89c87f31" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_e301eb83-c562-4894-a363-4c0b8de4ae12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_333cd1de-ec09-45e1-ac4f-b4c67b289509" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4d3183b8-3562-4a25-bcce-3cdc89c87f31" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_333cd1de-ec09-45e1-ac4f-b4c67b289509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_a39ef442-5c96-4858-8acb-ad1c2f154a99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4d3183b8-3562-4a25-bcce-3cdc89c87f31" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_a39ef442-5c96-4858-8acb-ad1c2f154a99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_d63e1b13-ea61-40e7-9101-99c54a89866f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4d3183b8-3562-4a25-bcce-3cdc89c87f31" xlink:to="loc_us-gaap_ProfitLoss_d63e1b13-ea61-40e7-9101-99c54a89866f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_a1ed6aa7-5008-4639-a21c-7a1159e79ac3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4d3183b8-3562-4a25-bcce-3cdc89c87f31" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_a1ed6aa7-5008-4639-a21c-7a1159e79ac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a3889b1c-b2c7-44dd-bdb4-f7e1f97a6749" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4d3183b8-3562-4a25-bcce-3cdc89c87f31" xlink:to="loc_us-gaap_NetIncomeLoss_a3889b1c-b2c7-44dd-bdb4-f7e1f97a6749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_e94481fa-a137-4da5-bd16-2bf50dff48d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4d3183b8-3562-4a25-bcce-3cdc89c87f31" xlink:to="loc_us-gaap_EarningsPerShareAbstract_e94481fa-a137-4da5-bd16-2bf50dff48d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_ac969f8e-c7a4-4daa-b4ba-45cfaed91137" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e94481fa-a137-4da5-bd16-2bf50dff48d2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_ac969f8e-c7a4-4daa-b4ba-45cfaed91137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_c1ea9762-3746-452b-adcf-14087eb32b5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e94481fa-a137-4da5-bd16-2bf50dff48d2" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_c1ea9762-3746-452b-adcf-14087eb32b5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_821aa48b-72ad-4b9a-9181-d85825ea3b50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e94481fa-a137-4da5-bd16-2bf50dff48d2" xlink:to="loc_us-gaap_EarningsPerShareBasic_821aa48b-72ad-4b9a-9181-d85825ea3b50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_9eae850f-64c4-4233-9e71-981a37cb6903" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e94481fa-a137-4da5-bd16-2bf50dff48d2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_9eae850f-64c4-4233-9e71-981a37cb6903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_9ffe7acd-a344-42f7-96a6-ca7552a748c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e94481fa-a137-4da5-bd16-2bf50dff48d2" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_9ffe7acd-a344-42f7-96a6-ca7552a748c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_d6d44fed-f8d9-41ca-91e2-80ddbf392467" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e94481fa-a137-4da5-bd16-2bf50dff48d2" xlink:to="loc_us-gaap_EarningsPerShareDiluted_d6d44fed-f8d9-41ca-91e2-80ddbf392467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_e7677bf4-6d99-4458-a224-9c9fdbf9868d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4d3183b8-3562-4a25-bcce-3cdc89c87f31" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_e7677bf4-6d99-4458-a224-9c9fdbf9868d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c5e99158-1194-4c96-919e-e9f5960e8c01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_e7677bf4-6d99-4458-a224-9c9fdbf9868d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c5e99158-1194-4c96-919e-e9f5960e8c01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d3a628d6-003e-41b5-a367-b6e1cbba77c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_e7677bf4-6d99-4458-a224-9c9fdbf9868d" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d3a628d6-003e-41b5-a367-b6e1cbba77c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cpix-20210630.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_02a64641-048d-4eb0-b68a-eaeea8fb1acd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9745e53a-eb02-4a72-aaaa-3c32a8b8fc25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_02a64641-048d-4eb0-b68a-eaeea8fb1acd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9745e53a-eb02-4a72-aaaa-3c32a8b8fc25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_cd1770f5-d825-48e0-a138-008b69a6c341" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9745e53a-eb02-4a72-aaaa-3c32a8b8fc25" xlink:to="loc_us-gaap_ProfitLoss_cd1770f5-d825-48e0-a138-008b69a6c341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_ef40d83f-a810-4ee1-a1c2-0f573cd75a1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9745e53a-eb02-4a72-aaaa-3c32a8b8fc25" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_ef40d83f-a810-4ee1-a1c2-0f573cd75a1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_ae2796e0-04dc-4274-99a9-fc968e9af954" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9745e53a-eb02-4a72-aaaa-3c32a8b8fc25" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_ae2796e0-04dc-4274-99a9-fc968e9af954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f7adf10f-8431-4588-b64c-6f433c8f99be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9745e53a-eb02-4a72-aaaa-3c32a8b8fc25" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f7adf10f-8431-4588-b64c-6f433c8f99be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_67c515de-a8d0-42b2-9532-169d2e325f31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f7adf10f-8431-4588-b64c-6f433c8f99be" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_67c515de-a8d0-42b2-9532-169d2e325f31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_dd62b157-0fb5-48f4-bbd1-e78331dadd20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f7adf10f-8431-4588-b64c-6f433c8f99be" xlink:to="loc_us-gaap_ShareBasedCompensation_dd62b157-0fb5-48f4-bbd1-e78331dadd20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_5987cace-dfe2-417e-9a36-e22a2febb15d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f7adf10f-8431-4588-b64c-6f433c8f99be" xlink:to="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_5987cace-dfe2-417e-9a36-e22a2febb15d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy_b792c4b1-ffe9-4183-bbfa-920e430acd4e" xlink:href="cpix-20210630.xsd#cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f7adf10f-8431-4588-b64c-6f433c8f99be" xlink:to="loc_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy_b792c4b1-ffe9-4183-bbfa-920e430acd4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_b696e7f7-c2e5-4567-8b85-e2da5696f2a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f7adf10f-8431-4588-b64c-6f433c8f99be" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_b696e7f7-c2e5-4567-8b85-e2da5696f2a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_bef62c57-744d-48b1-8af3-cfb3260da6be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f7adf10f-8431-4588-b64c-6f433c8f99be" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_bef62c57-744d-48b1-8af3-cfb3260da6be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7b65a372-ad3f-4308-a4f3-0302a60c711e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f7adf10f-8431-4588-b64c-6f433c8f99be" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7b65a372-ad3f-4308-a4f3-0302a60c711e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ad9f4009-85de-4ac0-a186-7862141c3639" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7b65a372-ad3f-4308-a4f3-0302a60c711e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ad9f4009-85de-4ac0-a186-7862141c3639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_0f6e2157-ade0-43c7-8cb2-5378c8d93437" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7b65a372-ad3f-4308-a4f3-0302a60c711e" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_0f6e2157-ade0-43c7-8cb2-5378c8d93437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_31ceb255-5ff9-4516-baab-a4b69b989f96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7b65a372-ad3f-4308-a4f3-0302a60c711e" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_31ceb255-5ff9-4516-baab-a4b69b989f96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_8367833e-e20c-4b29-bca9-8a05dba39de3" xlink:href="cpix-20210630.xsd#cpix_IncreaseDecreaseInCurrentOperatingLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7b65a372-ad3f-4308-a4f3-0302a60c711e" xlink:to="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_8367833e-e20c-4b29-bca9-8a05dba39de3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_f1db7afd-5018-4894-87dc-13aa91c15597" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7b65a372-ad3f-4308-a4f3-0302a60c711e" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_f1db7afd-5018-4894-87dc-13aa91c15597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_207d8106-b6e1-48b4-a7c7-45206813a734" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9745e53a-eb02-4a72-aaaa-3c32a8b8fc25" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_207d8106-b6e1-48b4-a7c7-45206813a734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_6c75c3b1-d246-4156-bf90-56429f66d13a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9745e53a-eb02-4a72-aaaa-3c32a8b8fc25" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_6c75c3b1-d246-4156-bf90-56429f66d13a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce901d61-34b1-4506-a542-d8ea4745b664" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9745e53a-eb02-4a72-aaaa-3c32a8b8fc25" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce901d61-34b1-4506-a542-d8ea4745b664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5464fe95-1618-446c-876c-ef5776386219" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_02a64641-048d-4eb0-b68a-eaeea8fb1acd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5464fe95-1618-446c-876c-ef5776386219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8c8b1c84-c1e1-4eb2-8334-2f33dbadd55e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5464fe95-1618-446c-876c-ef5776386219" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8c8b1c84-c1e1-4eb2-8334-2f33dbadd55e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_5cd82264-434e-4762-b93e-df03cec93d00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5464fe95-1618-446c-876c-ef5776386219" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_5cd82264-434e-4762-b93e-df03cec93d00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_9f0b6f4a-68f6-43c4-abc1-167615483494" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5464fe95-1618-446c-876c-ef5776386219" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_9f0b6f4a-68f6-43c4-abc1-167615483494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_34c17734-1844-493c-b1a5-8e182ad9792c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5464fe95-1618-446c-876c-ef5776386219" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_34c17734-1844-493c-b1a5-8e182ad9792c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fd8a0ef2-400c-403d-a94b-66f005e6e641" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_02a64641-048d-4eb0-b68a-eaeea8fb1acd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fd8a0ef2-400c-403d-a94b-66f005e6e641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_cc1f9d30-7f90-4e36-ad55-ea5c7dbd5e92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fd8a0ef2-400c-403d-a94b-66f005e6e641" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_cc1f9d30-7f90-4e36-ad55-ea5c7dbd5e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_626b47b6-eb9c-40de-b4bd-8d289d4a4917" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fd8a0ef2-400c-403d-a94b-66f005e6e641" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_626b47b6-eb9c-40de-b4bd-8d289d4a4917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_1dca4280-3749-4f82-a1e9-9def5fcdaa2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fd8a0ef2-400c-403d-a94b-66f005e6e641" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_1dca4280-3749-4f82-a1e9-9def5fcdaa2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest_8f79878f-af2f-4fe5-9df2-b12f4fb9123d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fd8a0ef2-400c-403d-a94b-66f005e6e641" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest_8f79878f-af2f-4fe5-9df2-b12f4fb9123d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_6a846abc-8ec9-41b3-8f8f-84b5ce12e6ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fd8a0ef2-400c-403d-a94b-66f005e6e641" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_6a846abc-8ec9-41b3-8f8f-84b5ce12e6ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_dbecd8fe-ac39-4912-938e-b005270a5990" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fd8a0ef2-400c-403d-a94b-66f005e6e641" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_dbecd8fe-ac39-4912-938e-b005270a5990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_54fb3a62-0945-4bf0-8515-761bfcc567c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fd8a0ef2-400c-403d-a94b-66f005e6e641" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_54fb3a62-0945-4bf0-8515-761bfcc567c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e4d83847-db9b-4582-b83a-94439232f4bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fd8a0ef2-400c-403d-a94b-66f005e6e641" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e4d83847-db9b-4582-b83a-94439232f4bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_dab0e99c-41e9-48ee-b71a-cf3fe952b003" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fd8a0ef2-400c-403d-a94b-66f005e6e641" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_dab0e99c-41e9-48ee-b71a-cf3fe952b003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" xlink:type="simple" xlink:href="cpix-20210630.xsd#CondensedConsolidatedStatementofEquity"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_4188936e-ce84-43ca-ae17-063a6092a369" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_05b7dec8-5b91-47d5-979e-844c1fb95712" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_4188936e-ce84-43ca-ae17-063a6092a369" xlink:to="loc_us-gaap_StatementTable_05b7dec8-5b91-47d5-979e-844c1fb95712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_ab0a6e93-67e8-49f6-9e59-b8b917ff9a04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_05b7dec8-5b91-47d5-979e-844c1fb95712" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_ab0a6e93-67e8-49f6-9e59-b8b917ff9a04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a14d2e77-c7da-4561-880d-54ee0e45d7ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ab0a6e93-67e8-49f6-9e59-b8b917ff9a04" xlink:to="loc_us-gaap_EquityComponentDomain_a14d2e77-c7da-4561-880d-54ee0e45d7ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_07d9a040-b410-4e9b-84c8-dc70d5937e50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a14d2e77-c7da-4561-880d-54ee0e45d7ac" xlink:to="loc_us-gaap_CommonStockMember_07d9a040-b410-4e9b-84c8-dc70d5937e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_030ca2c0-db98-4d69-9309-e55c64498f9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a14d2e77-c7da-4561-880d-54ee0e45d7ac" xlink:to="loc_us-gaap_RetainedEarningsMember_030ca2c0-db98-4d69-9309-e55c64498f9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_9dda376b-9dcb-4617-b3d2-87a8067be63a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a14d2e77-c7da-4561-880d-54ee0e45d7ac" xlink:to="loc_us-gaap_NoncontrollingInterestMember_9dda376b-9dcb-4617-b3d2-87a8067be63a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f07d455b-2f6b-4a24-8027-0b27e69ead44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_05b7dec8-5b91-47d5-979e-844c1fb95712" xlink:to="loc_us-gaap_StatementLineItems_f07d455b-2f6b-4a24-8027-0b27e69ead44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5512c361-45f1-4506-b99e-f245bef4eb5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f07d455b-2f6b-4a24-8027-0b27e69ead44" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5512c361-45f1-4506-b99e-f245bef4eb5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c2840c25-d2a1-4094-85e1-fa32c924ad65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5512c361-45f1-4506-b99e-f245bef4eb5d" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c2840c25-d2a1-4094-85e1-fa32c924ad65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4f4656a6-730d-43b9-80c9-3e8ebda1e6e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5512c361-45f1-4506-b99e-f245bef4eb5d" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_4f4656a6-730d-43b9-80c9-3e8ebda1e6e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_01d9d7cd-72df-45b8-bb4b-a31d1018968e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5512c361-45f1-4506-b99e-f245bef4eb5d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_01d9d7cd-72df-45b8-bb4b-a31d1018968e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_1e685c27-6638-4fa6-9d7b-6b0223d2c451" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5512c361-45f1-4506-b99e-f245bef4eb5d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_1e685c27-6638-4fa6-9d7b-6b0223d2c451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_9ba6c5d7-9878-456f-ac30-646a9bc41ac5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5512c361-45f1-4506-b99e-f245bef4eb5d" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_9ba6c5d7-9878-456f-ac30-646a9bc41ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_48f5ee04-ecaf-492c-9976-c4d48533b3d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5512c361-45f1-4506-b99e-f245bef4eb5d" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_48f5ee04-ecaf-492c-9976-c4d48533b3d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_4b268c83-3417-4ca6-ab8a-b7ca676bbc96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5512c361-45f1-4506-b99e-f245bef4eb5d" xlink:to="loc_us-gaap_ProfitLoss_4b268c83-3417-4ca6-ab8a-b7ca676bbc96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_23d4dacf-46c0-4c4f-8849-e3e3faff0689" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5512c361-45f1-4506-b99e-f245bef4eb5d" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_23d4dacf-46c0-4c4f-8849-e3e3faff0689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_52801704-b2da-4ddc-a77b-5f150770b06a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5512c361-45f1-4506-b99e-f245bef4eb5d" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_52801704-b2da-4ddc-a77b-5f150770b06a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation" xlink:type="simple" xlink:href="cpix-20210630.xsd#OrganizationandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_11a39ca8-302f-4196-84f2-ec5044475546" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_d837af13-5f2e-4d62-99fc-ffecec609107" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_11a39ca8-302f-4196-84f2-ec5044475546" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_d837af13-5f2e-4d62-99fc-ffecec609107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies" xlink:type="simple" xlink:href="cpix-20210630.xsd#OrganizationandBasisofPresentationPolicies"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b864e8dd-f1aa-4d50-bbdf-3d60a3fcb8cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_d3a8641f-5c96-495c-9eea-d58df9c4f076" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b864e8dd-f1aa-4d50-bbdf-3d60a3fcb8cf" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_d3a8641f-5c96-495c-9eea-d58df9c4f076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_57b2876d-cc1f-4038-8253-4bf48f4b2540" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b864e8dd-f1aa-4d50-bbdf-3d60a3fcb8cf" xlink:to="loc_us-gaap_UseOfEstimates_57b2876d-cc1f-4038-8253-4bf48f4b2540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_282bb18f-b0b2-4c7d-a567-032cd09a5d9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b864e8dd-f1aa-4d50-bbdf-3d60a3fcb8cf" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_282bb18f-b0b2-4c7d-a567-032cd09a5d9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails" xlink:type="simple" xlink:href="cpix-20210630.xsd#OrganizationandBasisofPresentationOrganizationDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2c93176d-e862-488d-a3f7-430d377f1850" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_75f4b4e6-b1db-4c2e-b3a1-c5ab3dddbc6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2c93176d-e862-488d-a3f7-430d377f1850" xlink:to="loc_us-gaap_NumberOfOperatingSegments_75f4b4e6-b1db-4c2e-b3a1-c5ab3dddbc6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="simple" xlink:href="cpix-20210630.xsd#EarningsLossPerShare"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_5570ef68-0f0a-45d5-b792-b363ded9c61c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_7c99725f-a0c2-4dae-a98b-7936a555475c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5570ef68-0f0a-45d5-b792-b363ded9c61c" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_7c99725f-a0c2-4dae-a98b-7936a555475c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="simple" xlink:href="cpix-20210630.xsd#EarningsLossPerShareTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_14ee2341-381d-4ced-b35c-aeb1c7886f95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_b93d480b-c149-47eb-a142-e5c05fc5196c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_14ee2341-381d-4ced-b35c-aeb1c7886f95" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_b93d480b-c149-47eb-a142-e5c05fc5196c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" xlink:type="simple" xlink:href="cpix-20210630.xsd#EarningsLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_b26f4d36-5253-46b5-ba8b-5b95b49a5ded" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NumeratorAbstract_9881b7ab-9f3e-4cd1-96e6-149f67d6a3e0" xlink:href="cpix-20210630.xsd#cpix_NumeratorAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b26f4d36-5253-46b5-ba8b-5b95b49a5ded" xlink:to="loc_cpix_NumeratorAbstract_9881b7ab-9f3e-4cd1-96e6-149f67d6a3e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_f9010b24-e03d-4787-a0b3-baf6527a8c81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_NumeratorAbstract_9881b7ab-9f3e-4cd1-96e6-149f67d6a3e0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_f9010b24-e03d-4787-a0b3-baf6527a8c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_eb2d3129-96fe-4008-a968-a134a6e9ef99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_NumeratorAbstract_9881b7ab-9f3e-4cd1-96e6-149f67d6a3e0" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_eb2d3129-96fe-4008-a968-a134a6e9ef99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_926ab7b5-e8d0-4173-93fd-9314847e14c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_NumeratorAbstract_9881b7ab-9f3e-4cd1-96e6-149f67d6a3e0" xlink:to="loc_us-gaap_ProfitLoss_926ab7b5-e8d0-4173-93fd-9314847e14c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_4dbd2c86-b27e-46f9-8582-51bbf7519b3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_NumeratorAbstract_9881b7ab-9f3e-4cd1-96e6-149f67d6a3e0" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_4dbd2c86-b27e-46f9-8582-51bbf7519b3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_caced6b1-eb72-47a9-8ca2-6439fd4cd769" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_NumeratorAbstract_9881b7ab-9f3e-4cd1-96e6-149f67d6a3e0" xlink:to="loc_us-gaap_NetIncomeLoss_caced6b1-eb72-47a9-8ca2-6439fd4cd769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DenominatorAbstract_23594908-12d2-4466-af92-fb5155787349" xlink:href="cpix-20210630.xsd#cpix_DenominatorAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b26f4d36-5253-46b5-ba8b-5b95b49a5ded" xlink:to="loc_cpix_DenominatorAbstract_23594908-12d2-4466-af92-fb5155787349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b52e7e37-ec67-4cc8-8270-ad8104b9a0e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DenominatorAbstract_23594908-12d2-4466-af92-fb5155787349" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b52e7e37-ec67-4cc8-8270-ad8104b9a0e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_9627da7b-bd6e-4655-8abb-65288fd56b0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DenominatorAbstract_23594908-12d2-4466-af92-fb5155787349" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_9627da7b-bd6e-4655-8abb-65288fd56b0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0507e457-dcac-4cea-96f3-c050e105c618" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DenominatorAbstract_23594908-12d2-4466-af92-fb5155787349" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0507e457-dcac-4cea-96f3-c050e105c618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual" xlink:type="simple" xlink:href="cpix-20210630.xsd#EarningsLossPerShareDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_fbf6f984-1ba7-4299-b134-30090dc21cc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6118dbba-a10d-4714-91c5-3fe457cbd5f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fbf6f984-1ba7-4299-b134-30090dc21cc4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6118dbba-a10d-4714-91c5-3fe457cbd5f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Revenues" xlink:type="simple" xlink:href="cpix-20210630.xsd#Revenues"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/Revenues" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_3c3fe8b3-2a76-4117-b348-5271b6e65813" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_123d53f9-f901-4e83-9bdb-0589b1e18be1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_3c3fe8b3-2a76-4117-b348-5271b6e65813" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_123d53f9-f901-4e83-9bdb-0589b1e18be1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:type="simple" xlink:href="cpix-20210630.xsd#RevenuesTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_10dfe7a1-74a0-4472-95a7-87079f3551a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_0b44ee04-ca83-499d-b854-263490eb66b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_10dfe7a1-74a0-4472-95a7-87079f3551a8" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_0b44ee04-ca83-499d-b854-263490eb66b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesDetails" xlink:type="simple" xlink:href="cpix-20210630.xsd#RevenuesDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_b78f1206-f2ef-42a7-a1ab-339a28d5ddc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_0259c23d-598c-43e7-9ba4-3a129e913c8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_b78f1206-f2ef-42a7-a1ab-339a28d5ddc6" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_0259c23d-598c-43e7-9ba4-3a129e913c8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0d33a87d-6d76-4dd0-8b74-f0dac68fc6ad" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_0259c23d-598c-43e7-9ba4-3a129e913c8f" xlink:to="loc_srt_ProductOrServiceAxis_0d33a87d-6d76-4dd0-8b74-f0dac68fc6ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d3fbf0bb-6076-4957-8039-0d53b4c42a1f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_0d33a87d-6d76-4dd0-8b74-f0dac68fc6ad" xlink:to="loc_srt_ProductsAndServicesDomain_d3fbf0bb-6076-4957-8039-0d53b4c42a1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AcetadoteMember_ebeaf36f-cd30-470d-9243-acfbf6195604" xlink:href="cpix-20210630.xsd#cpix_AcetadoteMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d3fbf0bb-6076-4957-8039-0d53b4c42a1f" xlink:to="loc_cpix_AcetadoteMember_ebeaf36f-cd30-470d-9243-acfbf6195604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OmeclamoxPakMember_1fc274d6-7fc4-402e-8a72-96dbbdc2e6e3" xlink:href="cpix-20210630.xsd#cpix_OmeclamoxPakMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d3fbf0bb-6076-4957-8039-0d53b4c42a1f" xlink:to="loc_cpix_OmeclamoxPakMember_1fc274d6-7fc4-402e-8a72-96dbbdc2e6e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_KristaloseMember_5abdb4f0-906f-4058-b419-b5898af772e2" xlink:href="cpix-20210630.xsd#cpix_KristaloseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d3fbf0bb-6076-4957-8039-0d53b4c42a1f" xlink:to="loc_cpix_KristaloseMember_5abdb4f0-906f-4058-b419-b5898af772e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VaprisolMember_8848c34d-09e6-4f48-af08-f564bdb742f4" xlink:href="cpix-20210630.xsd#cpix_VaprisolMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d3fbf0bb-6076-4957-8039-0d53b4c42a1f" xlink:to="loc_cpix_VaprisolMember_8848c34d-09e6-4f48-af08-f564bdb742f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CaldolorMember_127d7581-551a-4d83-8992-065e639927ba" xlink:href="cpix-20210630.xsd#cpix_CaldolorMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d3fbf0bb-6076-4957-8039-0d53b4c42a1f" xlink:to="loc_cpix_CaldolorMember_127d7581-551a-4d83-8992-065e639927ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_075315ac-e440-4543-8030-347812e16f60" xlink:href="cpix-20210630.xsd#cpix_VIBATIVMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d3fbf0bb-6076-4957-8039-0d53b4c42a1f" xlink:to="loc_cpix_VIBATIVMember_075315ac-e440-4543-8030-347812e16f60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RediTrexMember_e4d61221-0bc5-4fe9-8caf-95ab2045d037" xlink:href="cpix-20210630.xsd#cpix_RediTrexMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d3fbf0bb-6076-4957-8039-0d53b4c42a1f" xlink:to="loc_cpix_RediTrexMember_e4d61221-0bc5-4fe9-8caf-95ab2045d037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherProductsMember_a5571674-4554-49c4-9435-878b974cf197" xlink:href="cpix-20210630.xsd#cpix_OtherProductsMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d3fbf0bb-6076-4957-8039-0d53b4c42a1f" xlink:to="loc_cpix_OtherProductsMember_a5571674-4554-49c4-9435-878b974cf197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_66bec454-c310-4222-9c25-addd8e1f2505" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d3fbf0bb-6076-4957-8039-0d53b4c42a1f" xlink:to="loc_us-gaap_GrantMember_66bec454-c310-4222-9c25-addd8e1f2505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_e7b164ff-3bd2-43e9-90f9-fec70855ec55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_0259c23d-598c-43e7-9ba4-3a129e913c8f" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_e7b164ff-3bd2-43e9-90f9-fec70855ec55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_a7caafe2-eb17-4071-8643-f9444e0695f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_e7b164ff-3bd2-43e9-90f9-fec70855ec55" xlink:to="loc_us-gaap_RevenuesAbstract_a7caafe2-eb17-4071-8643-f9444e0695f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductsAbstract_bdeed07f-8012-4ea3-aede-7e57c9194037" xlink:href="cpix-20210630.xsd#cpix_ProductsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_a7caafe2-eb17-4071-8643-f9444e0695f4" xlink:to="loc_cpix_ProductsAbstract_bdeed07f-8012-4ea3-aede-7e57c9194037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ee46d480-1747-47ea-b8d9-b47f05c257aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ProductsAbstract_bdeed07f-8012-4ea3-aede-7e57c9194037" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ee46d480-1747-47ea-b8d9-b47f05c257aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Inventories" xlink:type="simple" xlink:href="cpix-20210630.xsd#Inventories"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_fd63d211-48af-43b9-b169-c923e390a583" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_a45c2508-cad6-4374-b5bf-963282395b8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_fd63d211-48af-43b9-b169-c923e390a583" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_a45c2508-cad6-4374-b5bf-963282395b8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesTables" xlink:type="simple" xlink:href="cpix-20210630.xsd#InventoriesTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_d45cf506-913d-45c0-b731-6bbb8325eb49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_700d7750-d279-420d-af93-6e7345261860" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_d45cf506-913d-45c0-b731-6bbb8325eb49" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_700d7750-d279-420d-af93-6e7345261860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20210630.xsd#InventoriesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_26c8ae24-454e-4176-b2aa-24066c91e49b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_dbd78eff-28c5-4138-a565-f8c90ddbaab7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_26c8ae24-454e-4176-b2aa-24066c91e49b" xlink:to="loc_us-gaap_InventoryCurrentTable_dbd78eff-28c5-4138-a565-f8c90ddbaab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_daa3b86f-b626-44dc-98f4-d138caf278b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_dbd78eff-28c5-4138-a565-f8c90ddbaab7" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_daa3b86f-b626-44dc-98f4-d138caf278b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e55912b3-ea83-4776-a0cf-08b51cecfd35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_daa3b86f-b626-44dc-98f4-d138caf278b1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e55912b3-ea83-4776-a0cf-08b51cecfd35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IfetrobanClinicalMember_6cb53e50-f60a-4794-a0b8-6d4e337e9087" xlink:href="cpix-20210630.xsd#cpix_IfetrobanClinicalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e55912b3-ea83-4776-a0cf-08b51cecfd35" xlink:to="loc_cpix_IfetrobanClinicalMember_6cb53e50-f60a-4794-a0b8-6d4e337e9087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_bcdaa1f4-f38b-4cba-aa07-855bddfe517b" xlink:href="cpix-20210630.xsd#cpix_VIBATIVMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e55912b3-ea83-4776-a0cf-08b51cecfd35" xlink:to="loc_cpix_VIBATIVMember_bcdaa1f4-f38b-4cba-aa07-855bddfe517b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_ff4d8255-86f4-4bd4-ba4c-c641774bfa91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_dbd78eff-28c5-4138-a565-f8c90ddbaab7" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_ff4d8255-86f4-4bd4-ba4c-c641774bfa91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_837d2757-628d-4aa6-9676-5c367ea7fb42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_ff4d8255-86f4-4bd4-ba4c-c641774bfa91" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_837d2757-628d-4aa6-9676-5c367ea7fb42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IfetrobanClinicalMember_0cf60287-beaa-4f4e-a07f-4b8fb9a003c8" xlink:href="cpix-20210630.xsd#cpix_IfetrobanClinicalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_837d2757-628d-4aa6-9676-5c367ea7fb42" xlink:to="loc_cpix_IfetrobanClinicalMember_0cf60287-beaa-4f4e-a07f-4b8fb9a003c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_22456984-f261-4000-9dd6-ce85df139fef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_dbd78eff-28c5-4138-a565-f8c90ddbaab7" xlink:to="loc_us-gaap_InventoryLineItems_22456984-f261-4000-9dd6-ce85df139fef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_0891d467-b059-4382-a6a6-8897a28f158e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_22456984-f261-4000-9dd6-ce85df139fef" xlink:to="loc_us-gaap_InventoryValuationReserves_0891d467-b059-4382-a6a6-8897a28f158e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_0cd54360-0528-4077-beae-de0433fe9bb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_22456984-f261-4000-9dd6-ce85df139fef" xlink:to="loc_us-gaap_InventoryNoncurrent_0cd54360-0528-4077-beae-de0433fe9bb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_a8955473-4943-4664-b56c-7007516d70a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_22456984-f261-4000-9dd6-ce85df139fef" xlink:to="loc_us-gaap_InventoryFinishedGoods_a8955473-4943-4664-b56c-7007516d70a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="simple" xlink:href="cpix-20210630.xsd#InventoriesScheduleofInventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_2703d843-a515-4572-a351-795eb1b3d320" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_a1aea2f3-c571-438f-a4c1-cd50347e0002" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_2703d843-a515-4572-a351-795eb1b3d320" xlink:to="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_a1aea2f3-c571-438f-a4c1-cd50347e0002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_db7a3cae-9733-42a3-96e6-82910cf25bd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_a1aea2f3-c571-438f-a4c1-cd50347e0002" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_db7a3cae-9733-42a3-96e6-82910cf25bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_4bad9722-02e1-46ec-ab62-e1b57ee50d2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_a1aea2f3-c571-438f-a4c1-cd50347e0002" xlink:to="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_4bad9722-02e1-46ec-ab62-e1b57ee50d2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_b443e3de-b03c-4745-a2a6-e5d592a096ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_a1aea2f3-c571-438f-a4c1-cd50347e0002" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_b443e3de-b03c-4745-a2a6-e5d592a096ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_618c3250-8039-43be-8395-8fb533fcea29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_a1aea2f3-c571-438f-a4c1-cd50347e0002" xlink:to="loc_us-gaap_InventoryGross_618c3250-8039-43be-8395-8fb533fcea29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_3e732154-aa73-45ee-882c-be15a7f634d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_a1aea2f3-c571-438f-a4c1-cd50347e0002" xlink:to="loc_us-gaap_InventoryNoncurrent_3e732154-aa73-45ee-882c-be15a7f634d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_ee3900e7-dbb5-45a2-a714-d221c7f0fb1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_a1aea2f3-c571-438f-a4c1-cd50347e0002" xlink:to="loc_us-gaap_InventoryNet_ee3900e7-dbb5-45a2-a714-d221c7f0fb1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Leases" xlink:type="simple" xlink:href="cpix-20210630.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_a01f7481-0a70-4c9c-9512-3424a382e4f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_96b6fad6-a9d1-43be-8a57-2b14cef94d73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a01f7481-0a70-4c9c-9512-3424a382e4f0" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_96b6fad6-a9d1-43be-8a57-2b14cef94d73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesTables" xlink:type="simple" xlink:href="cpix-20210630.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_c37ad424-bb09-42b9-a985-4abefaae6667" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_b8541992-e05a-4823-bffd-111ba328fc52" xlink:href="cpix-20210630.xsd#cpix_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c37ad424-bb09-42b9-a985-4abefaae6667" xlink:to="loc_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_b8541992-e05a-4823-bffd-111ba328fc52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_31cbb38d-8725-4efa-bf77-701ff498bbd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c37ad424-bb09-42b9-a985-4abefaae6667" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_31cbb38d-8725-4efa-bf77-701ff498bbd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock_e9e405bc-50d5-4769-ba05-15344aa283e8" xlink:href="cpix-20210630.xsd#cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c37ad424-bb09-42b9-a985-4abefaae6667" xlink:to="loc_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock_e9e405bc-50d5-4769-ba05-15344aa283e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20210630.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_9c13ab27-c0c3-43b5-bd44-ae6523555858" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_d16a3b3b-d827-4486-9551-de184c47c7bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9c13ab27-c0c3-43b5-bd44-ae6523555858" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_d16a3b3b-d827-4486-9551-de184c47c7bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8d9cf30f-1ff9-434c-b5b5-bda89935756e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_d16a3b3b-d827-4486-9551-de184c47c7bc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8d9cf30f-1ff9-434c-b5b5-bda89935756e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_933500e1-33a8-4cab-b147-5965f477ae46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8d9cf30f-1ff9-434c-b5b5-bda89935756e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_933500e1-33a8-4cab-b147-5965f477ae46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_a0020784-9274-4675-8095-5b8078d925cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_933500e1-33a8-4cab-b147-5965f477ae46" xlink:to="loc_us-gaap_BuildingMember_a0020784-9274-4675-8095-5b8078d925cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OfficeBuildingMember_de9366d5-28ab-4846-bfe5-face0e9ec17c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OfficeBuildingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_933500e1-33a8-4cab-b147-5965f477ae46" xlink:to="loc_srt_OfficeBuildingMember_de9366d5-28ab-4846-bfe5-face0e9ec17c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_ff631491-a4ed-4652-91cf-ac5c5441f1db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_d16a3b3b-d827-4486-9551-de184c47c7bc" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_ff631491-a4ed-4652-91cf-ac5c5441f1db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_a5c45c58-c501-4341-80b5-267303f9166a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ff631491-a4ed-4652-91cf-ac5c5441f1db" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_a5c45c58-c501-4341-80b5-267303f9166a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_4bdaa34c-1bee-4637-8824-8f544452f298" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ff631491-a4ed-4652-91cf-ac5c5441f1db" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_4bdaa34c-1bee-4637-8824-8f544452f298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_20c4180c-a333-489e-a224-010e77ad7e99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ff631491-a4ed-4652-91cf-ac5c5441f1db" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_20c4180c-a333-489e-a224-010e77ad7e99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals_2e52eebf-74a9-4f32-971b-08d5e5b71ff4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ff631491-a4ed-4652-91cf-ac5c5441f1db" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals_2e52eebf-74a9-4f32-971b-08d5e5b71ff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" xlink:type="simple" xlink:href="cpix-20210630.xsd#LeasesLeasePositionDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_2c7ec552-6dd9-4ffd-93f4-5f5a59961ea6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_67b0d144-868f-4b2e-9db0-4a67bd6d856c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2c7ec552-6dd9-4ffd-93f4-5f5a59961ea6" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_67b0d144-868f-4b2e-9db0-4a67bd6d856c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_a898c06a-c374-4c4b-9f96-e22b69d2bd00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2c7ec552-6dd9-4ffd-93f4-5f5a59961ea6" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_a898c06a-c374-4c4b-9f96-e22b69d2bd00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a40669f8-e9dc-4507-bd1b-b52296684568" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2c7ec552-6dd9-4ffd-93f4-5f5a59961ea6" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a40669f8-e9dc-4507-bd1b-b52296684568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LeaseLiability_824d6f14-f5e8-4bb5-bb5b-cafebb541453" xlink:href="cpix-20210630.xsd#cpix_LeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2c7ec552-6dd9-4ffd-93f4-5f5a59961ea6" xlink:to="loc_cpix_LeaseLiability_824d6f14-f5e8-4bb5-bb5b-cafebb541453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" xlink:type="simple" xlink:href="cpix-20210630.xsd#LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_0910b0b9-362a-4239-b966-d75811e014c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_38945895-caf9-4bf0-ac37-3bdd161d4091" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0910b0b9-362a-4239-b966-d75811e014c1" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_38945895-caf9-4bf0-ac37-3bdd161d4091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6e6efb6b-dbd1-4bbb-9b80-d509af3f1a53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_38945895-caf9-4bf0-ac37-3bdd161d4091" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6e6efb6b-dbd1-4bbb-9b80-d509af3f1a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d0b9523d-80c1-4d28-85b3-80898a2c29f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_38945895-caf9-4bf0-ac37-3bdd161d4091" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d0b9523d-80c1-4d28-85b3-80898a2c29f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_56d07cfb-34d4-47be-a63e-d846adefa8d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_38945895-caf9-4bf0-ac37-3bdd161d4091" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_56d07cfb-34d4-47be-a63e-d846adefa8d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree_db8d9662-3e48-4eac-a4f0-dc948e23cc70" xlink:href="cpix-20210630.xsd#cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_38945895-caf9-4bf0-ac37-3bdd161d4091" xlink:to="loc_cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree_db8d9662-3e48-4eac-a4f0-dc948e23cc70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_bd8a0b93-62e9-4b4a-9a9a-0d843cbae495" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_38945895-caf9-4bf0-ac37-3bdd161d4091" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_bd8a0b93-62e9-4b4a-9a9a-0d843cbae495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d280673f-baf4-4f00-abc3-6be9b0147944" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_38945895-caf9-4bf0-ac37-3bdd161d4091" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d280673f-baf4-4f00-abc3-6be9b0147944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_e95a7e6c-05e9-4a21-a9d9-c8827bf7ff06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_38945895-caf9-4bf0-ac37-3bdd161d4091" xlink:to="loc_us-gaap_OperatingLeaseLiability_e95a7e6c-05e9-4a21-a9d9-c8827bf7ff06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1" xlink:type="simple" xlink:href="cpix-20210630.xsd#LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesRentExpenseDetails" xlink:type="simple" xlink:href="cpix-20210630.xsd#LeasesRentExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesRentExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_189e7d4c-ec7f-4f45-87e0-4d6fa1608efe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense_7e54b969-0a3d-4667-96a6-2e1cf43565a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_189e7d4c-ec7f-4f45-87e0-4d6fa1608efe" xlink:to="loc_us-gaap_LeaseAndRentalExpense_7e54b969-0a3d-4667-96a6-2e1cf43565a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_12268cfe-c65b-4ab3-b2bc-07c3b7a7c9e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesRentExpenseSubleaseRentals1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_189e7d4c-ec7f-4f45-87e0-4d6fa1608efe" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_12268cfe-c65b-4ab3-b2bc-07c3b7a7c9e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt" xlink:type="simple" xlink:href="cpix-20210630.xsd#ShareholdersEquityandDebt"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EquityAndDebtAbstract_248fa2c3-1aab-4027-a606-055237fe8c59" xlink:href="cpix-20210630.xsd#cpix_EquityAndDebtAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_fa7f695d-4000-411a-a3ba-b67c01c2ca82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_EquityAndDebtAbstract_248fa2c3-1aab-4027-a606-055237fe8c59" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_fa7f695d-4000-411a-a3ba-b67c01c2ca82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" xlink:type="simple" xlink:href="cpix-20210630.xsd#ShareholdersEquityandDebtShareholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EquityAndDebtAbstract_85085960-591a-4453-8db2-37c71e13a243" xlink:href="cpix-20210630.xsd#cpix_EquityAndDebtAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1f5e0319-6c10-477b-9481-808f90578979" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_EquityAndDebtAbstract_85085960-591a-4453-8db2-37c71e13a243" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1f5e0319-6c10-477b-9481-808f90578979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4a78742f-1bc2-4950-b3ff-1458e05e981c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1f5e0319-6c10-477b-9481-808f90578979" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4a78742f-1bc2-4950-b3ff-1458e05e981c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_88abdcab-9f4e-46ad-ab10-ba6b1e32f201" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4a78742f-1bc2-4950-b3ff-1458e05e981c" xlink:to="loc_us-gaap_EquityComponentDomain_88abdcab-9f4e-46ad-ab10-ba6b1e32f201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_fcf2d4cf-16df-4cf4-be1d-30deca29381e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_88abdcab-9f4e-46ad-ab10-ba6b1e32f201" xlink:to="loc_us-gaap_CommonStockMember_fcf2d4cf-16df-4cf4-be1d-30deca29381e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_e6dcf714-fa9d-43af-a974-51d7501632b8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1f5e0319-6c10-477b-9481-808f90578979" xlink:to="loc_srt_TitleOfIndividualAxis_e6dcf714-fa9d-43af-a974-51d7501632b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5db0969f-6c9e-4bbe-8913-9518e1628c3c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_e6dcf714-fa9d-43af-a974-51d7501632b8" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5db0969f-6c9e-4bbe-8913-9518e1628c3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_1450522c-d046-405e-9ab4-779ad39c3716" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5db0969f-6c9e-4bbe-8913-9518e1628c3c" xlink:to="loc_srt_DirectorMember_1450522c-d046-405e-9ab4-779ad39c3716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_59123591-880f-4ff6-ae12-c25d024f179e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1f5e0319-6c10-477b-9481-808f90578979" xlink:to="loc_us-gaap_AwardTypeAxis_59123591-880f-4ff6-ae12-c25d024f179e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3b96def8-580a-4b13-bff1-9ca719bf321c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_59123591-880f-4ff6-ae12-c25d024f179e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3b96def8-580a-4b13-bff1-9ca719bf321c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_43fb9620-87f7-43bb-b6cd-a30677cb68bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3b96def8-580a-4b13-bff1-9ca719bf321c" xlink:to="loc_us-gaap_RestrictedStockMember_43fb9620-87f7-43bb-b6cd-a30677cb68bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncentiveStockOptionsMember_96db1504-bbb8-46ab-b7eb-860f985ee5ed" xlink:href="cpix-20210630.xsd#cpix_IncentiveStockOptionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3b96def8-580a-4b13-bff1-9ca719bf321c" xlink:to="loc_cpix_IncentiveStockOptionsMember_96db1504-bbb8-46ab-b7eb-860f985ee5ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_b42b0f6c-457a-4baa-a6e6-b2a20d4ef7c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1f5e0319-6c10-477b-9481-808f90578979" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_b42b0f6c-457a-4baa-a6e6-b2a20d4ef7c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_c2e03cb6-0634-4f5f-b5dc-a9e868c516b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_b42b0f6c-457a-4baa-a6e6-b2a20d4ef7c7" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_c2e03cb6-0634-4f5f-b5dc-a9e868c516b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PinnacleBankMember_49aff30f-0a44-4380-9a56-847bfb0e6727" xlink:href="cpix-20210630.xsd#cpix_PinnacleBankMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_c2e03cb6-0634-4f5f-b5dc-a9e868c516b1" xlink:to="loc_cpix_PinnacleBankMember_49aff30f-0a44-4380-9a56-847bfb0e6727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3ed7d3ee-4ba1-43d0-8981-6b6bcc8821f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1f5e0319-6c10-477b-9481-808f90578979" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3ed7d3ee-4ba1-43d0-8981-6b6bcc8821f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareholdersEquityTextualAbstract_98b76d16-04da-47b4-b741-60979fdff07f" xlink:href="cpix-20210630.xsd#cpix_ShareholdersEquityTextualAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3ed7d3ee-4ba1-43d0-8981-6b6bcc8821f3" xlink:to="loc_cpix_ShareholdersEquityTextualAbstract_98b76d16-04da-47b4-b741-60979fdff07f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_31807f65-dec2-4764-af93-0e301b8e194a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_98b76d16-04da-47b4-b741-60979fdff07f" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_31807f65-dec2-4764-af93-0e301b8e194a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_a314613a-1dcd-4f3b-a50e-ecca3c07d952" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_98b76d16-04da-47b4-b741-60979fdff07f" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_a314613a-1dcd-4f3b-a50e-ecca3c07d952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_af6a4b6b-2bd8-4d08-9866-b4966faf1b2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_98b76d16-04da-47b4-b741-60979fdff07f" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_af6a4b6b-2bd8-4d08-9866-b4966faf1b2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_9a24b73a-8b5c-43a2-8c04-4d5a8779316f" xlink:href="cpix-20210630.xsd#cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_98b76d16-04da-47b4-b741-60979fdff07f" xlink:to="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_9a24b73a-8b5c-43a2-8c04-4d5a8779316f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_958b9336-8d0a-4706-9144-f8bbc452b0be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_98b76d16-04da-47b4-b741-60979fdff07f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_958b9336-8d0a-4706-9144-f8bbc452b0be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b1602609-74c5-42de-b0ba-1692f4dbdbc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_98b76d16-04da-47b4-b741-60979fdff07f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b1602609-74c5-42de-b0ba-1692f4dbdbc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" xlink:type="simple" xlink:href="cpix-20210630.xsd#ShareholdersEquityandDebtDebtDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EquityAndDebtAbstract_30441a7e-560b-45e2-a7bf-3b3e5912d491" xlink:href="cpix-20210630.xsd#cpix_EquityAndDebtAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_dd279bb3-7b50-4cbb-b4a2-8fb267b48e43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_EquityAndDebtAbstract_30441a7e-560b-45e2-a7bf-3b3e5912d491" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_dd279bb3-7b50-4cbb-b4a2-8fb267b48e43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_c5873076-010d-4bd4-bb5f-d53ed67bb2ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_dd279bb3-7b50-4cbb-b4a2-8fb267b48e43" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_c5873076-010d-4bd4-bb5f-d53ed67bb2ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_5572dfa7-9789-4161-b01d-37ea2f1a28b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_c5873076-010d-4bd4-bb5f-d53ed67bb2ac" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_5572dfa7-9789-4161-b01d-37ea2f1a28b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PinnacleBankMember_87edd50f-39f3-4ebb-9330-a881dcda3653" xlink:href="cpix-20210630.xsd#cpix_PinnacleBankMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_5572dfa7-9789-4161-b01d-37ea2f1a28b3" xlink:to="loc_cpix_PinnacleBankMember_87edd50f-39f3-4ebb-9330-a881dcda3653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d94143d1-8e3e-4741-9786-2eeb76993c69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_dd279bb3-7b50-4cbb-b4a2-8fb267b48e43" xlink:to="loc_us-gaap_DebtInstrumentAxis_d94143d1-8e3e-4741-9786-2eeb76993c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_86f0a42e-ea7e-45c9-bdc7-7f25712bf2c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_d94143d1-8e3e-4741-9786-2eeb76993c69" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_86f0a42e-ea7e-45c9-bdc7-7f25712bf2c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FourthAmendmentMember_b4870271-a3a5-4a5e-88da-9d3327c1aa3c" xlink:href="cpix-20210630.xsd#cpix_FourthAmendmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_86f0a42e-ea7e-45c9-bdc7-7f25712bf2c9" xlink:to="loc_cpix_FourthAmendmentMember_b4870271-a3a5-4a5e-88da-9d3327c1aa3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_96a69636-29b6-4213-8caf-2dee4a93fab5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_86f0a42e-ea7e-45c9-bdc7-7f25712bf2c9" xlink:to="loc_us-gaap_LineOfCreditMember_96a69636-29b6-4213-8caf-2dee4a93fab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_4debb1a4-1c2b-430c-840d-c9db9d15e967" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_dd279bb3-7b50-4cbb-b4a2-8fb267b48e43" xlink:to="loc_us-gaap_CreditFacilityAxis_4debb1a4-1c2b-430c-840d-c9db9d15e967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_1e30a2af-813d-4176-93fb-990619aa2cb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_4debb1a4-1c2b-430c-840d-c9db9d15e967" xlink:to="loc_us-gaap_CreditFacilityDomain_1e30a2af-813d-4176-93fb-990619aa2cb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_1979b08a-f314-46fd-bc49-126b799d13ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_1e30a2af-813d-4176-93fb-990619aa2cb4" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_1979b08a-f314-46fd-bc49-126b799d13ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8f8c12e1-cc6d-4b87-a50f-97f6bdd07dcb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_dd279bb3-7b50-4cbb-b4a2-8fb267b48e43" xlink:to="loc_srt_RangeAxis_8f8c12e1-cc6d-4b87-a50f-97f6bdd07dcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_38a255cd-067a-43fa-b13f-709f1aa43e30" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_8f8c12e1-cc6d-4b87-a50f-97f6bdd07dcb" xlink:to="loc_srt_RangeMember_38a255cd-067a-43fa-b13f-709f1aa43e30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_59041581-8a17-4bb4-b95a-057499034192" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_38a255cd-067a-43fa-b13f-709f1aa43e30" xlink:to="loc_srt_MinimumMember_59041581-8a17-4bb4-b95a-057499034192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7d4339fb-0e03-49a9-b724-1ef7499db133" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_38a255cd-067a-43fa-b13f-709f1aa43e30" xlink:to="loc_srt_MaximumMember_7d4339fb-0e03-49a9-b724-1ef7499db133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_df3223fd-8180-4342-99d0-8aa18c20f34a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_dd279bb3-7b50-4cbb-b4a2-8fb267b48e43" xlink:to="loc_us-gaap_VariableRateAxis_df3223fd-8180-4342-99d0-8aa18c20f34a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_69ba2bc0-d471-430f-be65-328878fb3eb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_df3223fd-8180-4342-99d0-8aa18c20f34a" xlink:to="loc_us-gaap_VariableRateDomain_69ba2bc0-d471-430f-be65-328878fb3eb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_991c8031-ae78-48d7-9228-040c772273be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_69ba2bc0-d471-430f-be65-328878fb3eb7" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_991c8031-ae78-48d7-9228-040c772273be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1e162a2f-8152-4086-921b-c40dec12568d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_dd279bb3-7b50-4cbb-b4a2-8fb267b48e43" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1e162a2f-8152-4086-921b-c40dec12568d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2ef9735f-120e-463e-a005-973045d24732" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1e162a2f-8152-4086-921b-c40dec12568d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2ef9735f-120e-463e-a005-973045d24732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_6147715c-55df-4191-b4ac-e7fe6f83f708" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2ef9735f-120e-463e-a005-973045d24732" xlink:to="loc_us-gaap_ConvertibleDebtMember_6147715c-55df-4191-b4ac-e7fe6f83f708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c3e30c75-091c-489c-86d6-dc4564514887" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_dd279bb3-7b50-4cbb-b4a2-8fb267b48e43" xlink:to="loc_srt_CounterpartyNameAxis_c3e30c75-091c-489c-86d6-dc4564514887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_311704f5-39ba-4a50-af4c-9db11ff866d8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_c3e30c75-091c-489c-86d6-dc4564514887" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_311704f5-39ba-4a50-af4c-9db11ff866d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_WinHealthInvestmentSingaporeLtdDomain_dd32eac0-475c-4a6e-b4b4-e116102aeefa" xlink:href="cpix-20210630.xsd#cpix_WinHealthInvestmentSingaporeLtdDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_311704f5-39ba-4a50-af4c-9db11ff866d8" xlink:to="loc_cpix_WinHealthInvestmentSingaporeLtdDomain_dd32eac0-475c-4a6e-b4b4-e116102aeefa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_214e5821-564c-4f2d-a0fd-cd7f63008c53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_dd279bb3-7b50-4cbb-b4a2-8fb267b48e43" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_214e5821-564c-4f2d-a0fd-cd7f63008c53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_e3ee3d97-8b78-42ed-93f4-dacdb4142bcb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_214e5821-564c-4f2d-a0fd-cd7f63008c53" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_e3ee3d97-8b78-42ed-93f4-dacdb4142bcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount_8f3b8422-e6ae-4e56-89c9-438580665a54" xlink:href="cpix-20210630.xsd#cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_214e5821-564c-4f2d-a0fd-cd7f63008c53" xlink:to="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount_8f3b8422-e6ae-4e56-89c9-438580665a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity_acd5d256-e168-403d-a22b-95e1d79fb249" xlink:href="cpix-20210630.xsd#cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_214e5821-564c-4f2d-a0fd-cd7f63008c53" xlink:to="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity_acd5d256-e168-403d-a22b-95e1d79fb249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_3f90f5d0-baa5-49ff-8476-314a3d07f5de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_214e5821-564c-4f2d-a0fd-cd7f63008c53" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_3f90f5d0-baa5-49ff-8476-314a3d07f5de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_d2f08cdb-6163-4f1b-aa11-9194df3934a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_214e5821-564c-4f2d-a0fd-cd7f63008c53" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_d2f08cdb-6163-4f1b-aa11-9194df3934a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_9af08c69-dcf1-4a75-b6cc-b17784dd5af0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_214e5821-564c-4f2d-a0fd-cd7f63008c53" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_9af08c69-dcf1-4a75-b6cc-b17784dd5af0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived_df101c15-132a-43d0-b1b0-58637448bcde" xlink:href="cpix-20210630.xsd#cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_214e5821-564c-4f2d-a0fd-cd7f63008c53" xlink:to="loc_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived_df101c15-132a-43d0-b1b0-58637448bcde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_febe9688-690f-49fc-9c8f-98fdaf8d2c76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_214e5821-564c-4f2d-a0fd-cd7f63008c53" xlink:to="loc_us-gaap_LongTermLineOfCredit_febe9688-690f-49fc-9c8f-98fdaf8d2c76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_63bd9ff0-8259-45eb-816f-f1c6640bda95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_214e5821-564c-4f2d-a0fd-cd7f63008c53" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_63bd9ff0-8259-45eb-816f-f1c6640bda95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_abac43a1-972f-4bc3-929d-4486522439c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_214e5821-564c-4f2d-a0fd-cd7f63008c53" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_abac43a1-972f-4bc3-929d-4486522439c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:type="simple" xlink:href="cpix-20210630.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_e94ef998-22a5-4912-89c0-de494a1be59a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_b58c6d77-67a0-44d3-8496-be37951c0909" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e94ef998-22a5-4912-89c0-de494a1be59a" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_b58c6d77-67a0-44d3-8496-be37951c0909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual" xlink:type="simple" xlink:href="cpix-20210630.xsd#IncomeTaxesDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_4ecad284-747d-4930-a43e-aebd5838f6df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_dd763eb3-96c2-4863-96ec-17d14ef66619" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4ecad284-747d-4930-a43e-aebd5838f6df" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_dd763eb3-96c2-4863-96ec-17d14ef66619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_5ed1f2b2-2a2f-44f7-99dd-5fc977c903ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_dd763eb3-96c2-4863-96ec-17d14ef66619" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_5ed1f2b2-2a2f-44f7-99dd-5fc977c903ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_f174c5aa-fa0d-4b6d-9f98-d3cc753727d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_5ed1f2b2-2a2f-44f7-99dd-5fc977c903ed" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_f174c5aa-fa0d-4b6d-9f98-d3cc753727d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_29015967-7582-45a5-a506-d1769e49456b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_f174c5aa-fa0d-4b6d-9f98-d3cc753727d2" xlink:to="loc_us-gaap_DomesticCountryMember_29015967-7582-45a5-a506-d1769e49456b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_ff26ccfc-3bb6-4e79-95bd-5b51b49805b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_dd763eb3-96c2-4863-96ec-17d14ef66619" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_ff26ccfc-3bb6-4e79-95bd-5b51b49805b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_6fcdc13e-b89c-41a7-a618-969504327e04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_ff26ccfc-3bb6-4e79-95bd-5b51b49805b7" xlink:to="loc_us-gaap_OperatingLossCarryforwards_6fcdc13e-b89c-41a7-a618-969504327e04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CollaborativeAgreements" xlink:type="simple" xlink:href="cpix-20210630.xsd#CollaborativeAgreements"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CollaborativeAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a6f019ca-afb9-4f81-a035-fe9605a22473" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_7a108eb3-43f2-408a-88b4-e39982e16a4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a6f019ca-afb9-4f81-a035-fe9605a22473" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_7a108eb3-43f2-408a-88b4-e39982e16a4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights" xlink:type="simple" xlink:href="cpix-20210630.xsd#AdditionsandReturnsofProductRights"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_8dba60de-7247-479c-a33a-b955c7726e14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_1bd56d2b-88d3-4cee-8b94-d0eaaca8669f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_8dba60de-7247-479c-a33a-b955c7726e14" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_1bd56d2b-88d3-4cee-8b94-d0eaaca8669f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables" xlink:type="simple" xlink:href="cpix-20210630.xsd#AdditionsandReturnsofProductRightsTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_cf37029b-9123-4ebb-b00b-ac313b62f047" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_d6903aa6-d2c0-4f99-9240-6a6666d01551" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_cf37029b-9123-4ebb-b00b-ac313b62f047" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_d6903aa6-d2c0-4f99-9240-6a6666d01551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_48790e28-69de-48a1-9b1c-cc9c168fbeee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_cf37029b-9123-4ebb-b00b-ac313b62f047" xlink:to="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_48790e28-69de-48a1-9b1c-cc9c168fbeee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" xlink:type="simple" xlink:href="cpix-20210630.xsd#AdditionsandReturnsofProductRightsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_896d7dbd-cac0-4c8a-bf7f-8ba8a7d5256e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1fb820d6-5c8e-481a-a913-e91e60d80994" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_896d7dbd-cac0-4c8a-bf7f-8ba8a7d5256e" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1fb820d6-5c8e-481a-a913-e91e60d80994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_592c068f-b9e7-402b-9339-a159c5f7f92b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1fb820d6-5c8e-481a-a913-e91e60d80994" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_592c068f-b9e7-402b-9339-a159c5f7f92b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bb8ecac6-da71-4143-b930-f2c4683c4428" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_592c068f-b9e7-402b-9339-a159c5f7f92b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bb8ecac6-da71-4143-b930-f2c4683c4428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_d7c68325-a5b7-4888-be3f-67b7ad96eb36" xlink:href="cpix-20210630.xsd#cpix_VIBATIVMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bb8ecac6-da71-4143-b930-f2c4683c4428" xlink:to="loc_cpix_VIBATIVMember_d7c68325-a5b7-4888-be3f-67b7ad96eb36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_MethotrexateMember_dd3a0af9-ca29-4ece-94dc-7b64934b0d89" xlink:href="cpix-20210630.xsd#cpix_MethotrexateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bb8ecac6-da71-4143-b930-f2c4683c4428" xlink:to="loc_cpix_MethotrexateMember_dd3a0af9-ca29-4ece-94dc-7b64934b0d89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ece6feb5-d75c-42e3-a978-0075ad96706d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1fb820d6-5c8e-481a-a913-e91e60d80994" xlink:to="loc_srt_CounterpartyNameAxis_ece6feb5-d75c-42e3-a978-0075ad96706d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3e98799b-d677-43f3-82d1-371ce91bb145" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_ece6feb5-d75c-42e3-a978-0075ad96706d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3e98799b-d677-43f3-82d1-371ce91bb145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ClinigenHealthcareLimitedMember_5d5e46ce-d8ec-4c08-9f7f-7e5a4e4f4a94" xlink:href="cpix-20210630.xsd#cpix_ClinigenHealthcareLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3e98799b-d677-43f3-82d1-371ce91bb145" xlink:to="loc_cpix_ClinigenHealthcareLimitedMember_5d5e46ce-d8ec-4c08-9f7f-7e5a4e4f4a94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_d2842b8c-1a64-4c9c-a505-dc3769a8e9e9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1fb820d6-5c8e-481a-a913-e91e60d80994" xlink:to="loc_srt_StatementScenarioAxis_d2842b8c-1a64-4c9c-a505-dc3769a8e9e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_b0d2740b-4caf-4b44-a49f-9fa0dc117d0e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_d2842b8c-1a64-4c9c-a505-dc3769a8e9e9" xlink:to="loc_srt_ScenarioUnspecifiedDomain_b0d2740b-4caf-4b44-a49f-9fa0dc117d0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_110cdbda-60b0-41fd-9334-4b29612111a8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_b0d2740b-4caf-4b44-a49f-9fa0dc117d0e" xlink:to="loc_srt_ScenarioForecastMember_110cdbda-60b0-41fd-9334-4b29612111a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d2b0deda-c858-4cca-b3e0-83d89b573ab4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1fb820d6-5c8e-481a-a913-e91e60d80994" xlink:to="loc_us-gaap_AwardTypeAxis_d2b0deda-c858-4cca-b3e0-83d89b573ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_067f0aa3-4c90-4e78-9fa8-ac303aa70335" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_d2b0deda-c858-4cca-b3e0-83d89b573ab4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_067f0aa3-4c90-4e78-9fa8-ac303aa70335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_55ad34fe-576f-46d9-abac-487764329abb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_067f0aa3-4c90-4e78-9fa8-ac303aa70335" xlink:to="loc_us-gaap_RestrictedStockMember_55ad34fe-576f-46d9-abac-487764329abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_9e0959d1-485d-4985-897b-644c6180e4c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1fb820d6-5c8e-481a-a913-e91e60d80994" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_9e0959d1-485d-4985-897b-644c6180e4c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_9aba2864-127f-4fee-a168-8a72eaf3bcce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_9e0959d1-485d-4985-897b-644c6180e4c6" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_9aba2864-127f-4fee-a168-8a72eaf3bcce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_d9a1707f-6b61-462c-b1bb-cda6e80b5717" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_9aba2864-127f-4fee-a168-8a72eaf3bcce" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_d9a1707f-6b61-462c-b1bb-cda6e80b5717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_2318bf6a-0ae5-4cca-821b-d19343528a17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_9aba2864-127f-4fee-a168-8a72eaf3bcce" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_2318bf6a-0ae5-4cca-821b-d19343528a17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_3c2b281c-232a-4fb4-b79e-bc53f48c5a03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1fb820d6-5c8e-481a-a913-e91e60d80994" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_3c2b281c-232a-4fb4-b79e-bc53f48c5a03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_e89b1186-4874-4e2c-9acc-01a22c84739f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3c2b281c-232a-4fb4-b79e-bc53f48c5a03" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_e89b1186-4874-4e2c-9acc-01a22c84739f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_980a172d-b2f0-4850-af09-83ba91aa75d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3c2b281c-232a-4fb4-b79e-bc53f48c5a03" xlink:to="loc_us-gaap_OtherPaymentsToAcquireBusinesses_980a172d-b2f0-4850-af09-83ba91aa75d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TieredRoyaltyPaymentsPercentage_37bbc9c4-3291-4ad5-8fc8-5b0a9282ddde" xlink:href="cpix-20210630.xsd#cpix_TieredRoyaltyPaymentsPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3c2b281c-232a-4fb4-b79e-bc53f48c5a03" xlink:to="loc_cpix_TieredRoyaltyPaymentsPercentage_37bbc9c4-3291-4ad5-8fc8-5b0a9282ddde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_10ab573e-47c3-4d42-a7ca-8d40d187b616" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3c2b281c-232a-4fb4-b79e-bc53f48c5a03" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_10ab573e-47c3-4d42-a7ca-8d40d187b616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_ec7fbd3c-51ea-4c35-ac72-e83648835e40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3c2b281c-232a-4fb4-b79e-bc53f48c5a03" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_ec7fbd3c-51ea-4c35-ac72-e83648835e40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_98ac7a2f-fab0-467a-9345-7e97c7abe221" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3c2b281c-232a-4fb4-b79e-bc53f48c5a03" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_98ac7a2f-fab0-467a-9345-7e97c7abe221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_28097e33-db2e-45e2-bc1f-ec6cb7e593d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3c2b281c-232a-4fb4-b79e-bc53f48c5a03" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_28097e33-db2e-45e2-bc1f-ec6cb7e593d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_539cbe87-09d5-42e8-b09b-8f6ce0e3f176" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3c2b281c-232a-4fb4-b79e-bc53f48c5a03" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_539cbe87-09d5-42e8-b09b-8f6ce0e3f176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_0ad62a25-ae16-4682-8550-4cc5e5e2b452" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3c2b281c-232a-4fb4-b79e-bc53f48c5a03" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_0ad62a25-ae16-4682-8550-4cc5e5e2b452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment_10af34ef-16ae-4fdd-8ed6-9e92b835fb98" xlink:href="cpix-20210630.xsd#cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3c2b281c-232a-4fb4-b79e-bc53f48c5a03" xlink:to="loc_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment_10af34ef-16ae-4fdd-8ed6-9e92b835fb98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_88922ef2-de6b-47d8-b6c5-4b36a235acb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3c2b281c-232a-4fb4-b79e-bc53f48c5a03" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_88922ef2-de6b-47d8-b6c5-4b36a235acb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails" xlink:type="simple" xlink:href="cpix-20210630.xsd#AdditionsandReturnsofProductRightsChangeinConsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_890b6474-fb80-411e-83a4-77ab94f86ad1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_dc4efe6b-2b49-4a51-8db3-c4bc759f3db6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_890b6474-fb80-411e-83a4-77ab94f86ad1" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_dc4efe6b-2b49-4a51-8db3-c4bc759f3db6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_48232c98-1090-47a0-a64d-40407f83fb18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_dc4efe6b-2b49-4a51-8db3-c4bc759f3db6" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_48232c98-1090-47a0-a64d-40407f83fb18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1c54ff7d-29cd-4312-b13a-c8f396c39052" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_48232c98-1090-47a0-a64d-40407f83fb18" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1c54ff7d-29cd-4312-b13a-c8f396c39052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_980dedfc-7d32-4ddd-99e1-54a5294ebcc7" xlink:href="cpix-20210630.xsd#cpix_VIBATIVMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1c54ff7d-29cd-4312-b13a-c8f396c39052" xlink:to="loc_cpix_VIBATIVMember_980dedfc-7d32-4ddd-99e1-54a5294ebcc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_f8ca68ff-1616-45dc-8419-6d3e2a5c634a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_dc4efe6b-2b49-4a51-8db3-c4bc759f3db6" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_f8ca68ff-1616-45dc-8419-6d3e2a5c634a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualRollForward_03559210-8578-4bf5-aab3-1090efda1370" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8ca68ff-1616-45dc-8419-6d3e2a5c634a" xlink:to="loc_us-gaap_LossContingencyAccrualRollForward_03559210-8578-4bf5-aab3-1090efda1370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_5a2f77e2-517e-42dc-9439-184bef21a6bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_03559210-8578-4bf5-aab3-1090efda1370" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_5a2f77e2-517e-42dc-9439-184bef21a6bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties_0c097a2c-3763-46ea-bb7a-2cf621dff67b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_03559210-8578-4bf5-aab3-1090efda1370" xlink:to="loc_us-gaap_PaymentsForRoyalties_0c097a2c-3763-46ea-bb7a-2cf621dff67b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_063ced27-322f-4b75-9a95-8ec1d311b961" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_03559210-8578-4bf5-aab3-1090efda1370" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_063ced27-322f-4b75-9a95-8ec1d311b961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_7c13dd3d-8625-4d41-9e48-e42da816ec2e" xlink:href="cpix-20210630.xsd#cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_03559210-8578-4bf5-aab3-1090efda1370" xlink:to="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_7c13dd3d-8625-4d41-9e48-e42da816ec2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_2601148a-e8eb-4bc5-9d82-f9151b48161a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_03559210-8578-4bf5-aab3-1090efda1370" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_2601148a-e8eb-4bc5-9d82-f9151b48161a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails" xlink:type="simple" xlink:href="cpix-20210630.xsd#AdditionsandReturnsofProductRightsDissolutionPaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_13fc13d1-a1e0-4e4d-879d-645341cdeeb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2562284e-a27d-4235-9903-488e3c7c0c18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_13fc13d1-a1e0-4e4d-879d-645341cdeeb2" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2562284e-a27d-4235-9903-488e3c7c0c18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_97be0449-83a0-4ee2-b467-db7c79fdaf66" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2562284e-a27d-4235-9903-488e3c7c0c18" xlink:to="loc_srt_CounterpartyNameAxis_97be0449-83a0-4ee2-b467-db7c79fdaf66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9ebf09a3-41c7-4f4f-878d-8e83f51154e3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_97be0449-83a0-4ee2-b467-db7c79fdaf66" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9ebf09a3-41c7-4f4f-878d-8e83f51154e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ClinigenHealthcareLimitedMember_4582fa3f-e27e-4c1c-833a-4c90bd167d15" xlink:href="cpix-20210630.xsd#cpix_ClinigenHealthcareLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9ebf09a3-41c7-4f4f-878d-8e83f51154e3" xlink:to="loc_cpix_ClinigenHealthcareLimitedMember_4582fa3f-e27e-4c1c-833a-4c90bd167d15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_b52d5fd7-3659-456f-9e74-e6316c02c9f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2562284e-a27d-4235-9903-488e3c7c0c18" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_b52d5fd7-3659-456f-9e74-e6316c02c9f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_68a78744-bbd2-438a-9b57-350e8d977876" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b52d5fd7-3659-456f-9e74-e6316c02c9f3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_68a78744-bbd2-438a-9b57-350e8d977876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_64290789-4d75-4dc1-892e-f3dbd9747752" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b52d5fd7-3659-456f-9e74-e6316c02c9f3" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_64290789-4d75-4dc1-892e-f3dbd9747752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_88cc9708-5630-4fe2-a3bf-836bd7b0702e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b52d5fd7-3659-456f-9e74-e6316c02c9f3" xlink:to="loc_us-gaap_SellingAndMarketingExpense_88cc9708-5630-4fe2-a3bf-836bd7b0702e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_9d5c9c62-bd6a-41f4-8648-595435bfafc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b52d5fd7-3659-456f-9e74-e6316c02c9f3" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_9d5c9c62-bd6a-41f4-8648-595435bfafc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>cpix-20210630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cpix="http://www.cumberlandpharma.com/20210630"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cpix-20210630.xsd" xlink:type="simple"/>
    <context id="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i85957d50b58d4241a665bd7848aa809d_I20210809">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2021-08-09</instant>
        </period>
    </context>
    <context id="iba716d2d6c004c9c85738b68d83bc0b7_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ie36ac2d370b44b7b850f453251764d25_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i0932967c9c90454494cbf245d9fa585d_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iffc2a4291a32445fb79072f7fe43a870_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i53d85ca5dcbd44ba870830f97461a800_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i166678b245754127b39f5e9c73e8cf2d_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ie98ab83b91d54ad0aa13294fe0c3bdb6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4860200ab8134ae18446101822694027_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i3d6d3147bec94616bcf72690b2be296a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i83e7ecfbf2a84991a8389944813821f5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i114a57733d5043469e08faf40e0cd3f8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i466ef04c404e4ac6a59e26ee7fd0c3cf_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="iab72c368dd2d4ce9a791ab677393c6a5_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="if884adb91afc4270896a5966ea47d7aa_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="iba53f6b880994dffa4c65f2e2602560a_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ifcedca0bf3ff4536974d961a488fc053_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i1e77b9f22c1042519f6f27f64401d843_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ifb9ba2c0e442481695058478aea8e7d6_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ic49b798ae420415688228a42789077ba_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i8a150324b9d0427e89459a576fa87284_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i4067952523e04c2eb44fce178eac9c45_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i58fc83ab5ccd43ce857e2367d7e167ac_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i757638cd1ac54400a7212a39551700fa_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ic2543a120857490e9cdf7ff91a0a636a_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i1721669d68794a37916477190e8866d2_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i851f7a722da048d59591d314f36aabc7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia9f59f7e0e644c3e9406612323559f4b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4a6e35b8c49547efba40d6119ccf44be_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id451c947a6d945de824fde928e9539b8_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8613f3fef30a4cf99a52244890006824_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6b5aa580bb2d4a5f8f2914acb615a1e1_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i46f84339676244a68c635efc3276aab8_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic2444510ac2f491e93494d3efc1d3f10_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6bfadd4b687f465caceadefb291b8a5a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i236298ea92174d4481784e6bae4c0605_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i759d312796b74964bece38516542bb38_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i9737d5fe1a1a4b64a348bd61bcd44e8b_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i625473b616364e838b15588a276d254c_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if4378e699a13493b8e84114b0815eeb1_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie2772008cf324e93b9ddec0ec4490b6e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i8b884d549e1f475999a61e98b2694ba2_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i9809a8bcb7eb490aa76cb00858c80e7c_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia5edd42c5f134552b215b0303905dc64_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="idf76e1a947e34b99bf20371f1394bc94_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i6b7593836c514ab7ae6235e51053a4d3_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i165e5c5a2d664922aea782b5ec2beaa1_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ifad013eb9e344ea389599dff33e69ac5_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="icb72b6c62fb3497caec435b11f56df5b_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ie99d1326bbe74354aa379ee065b7c800_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if75eedbbeb5a4ee7b41a92f8a8b0fb07_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib9e93a7211e0479a81c8bd344131c4e7_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i76b0812334e5493ba0a8152f3015bf4a_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iabe2fb0732864cfb86e1ccecbb610f34_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i857d42211e8846b8ae37d954dc44d6a5_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib8bb9cad97f943fca7a044ed530e9867_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib2de112b4b874426a53bf6ed84e287a5_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i54cb558d5ce44437ad69a746dc9c0d82_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if2dc8e2802e642b5b94cadd517394321_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i8e418762fd0d400aa38934d9baef2d1f_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ief1b47cbad4647fdb4c761fccef2aa59_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ie9fecc8c7c5546288fd7851d2d94e26c_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic88623cc09cd42dfa613a0b3710040a3_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ibaa9e52c4cd5496c898ae44c5f71a2f6_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if58606b340b94db39d3ecaa02a4573ed_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i16a80924d1204bd0b90b95ff2356a104_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic02c2f75924e441689c5ffc79ba729b8_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ifca6a00e3fc6401ab98a098751461284_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:RediTrexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia2c40ebe0b7f44769ff470354a3fe426_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:RediTrexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="idb0eee768e294f599281385f4a3835f6_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:RediTrexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6095f924cf50491b815b0dfba23349fd_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:RediTrexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ifb0ee00056ff487ca51af9d696aa113b_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5c43803cc80549529c2ba24144989e73_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic93c6aab3bcf4cda8e32399f9d56970e_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ice06f3366d2249119a9109b31bb8f7d2_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i6172287cab0745339de538f8ae5b507b_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i15931d26dd6041dfa28287b72ffd540a_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i6742997b2ea4497a8b57f546e21e37aa_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifaa5fd674df1464290cfa2809fea1eaf_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i339d4531f62d4de7929176842fce1307_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">cpix:IfetrobanClinicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic8de84d46a4b4f1288caecd9e279f91c_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">cpix:IfetrobanClinicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i5d1ec29c3e7d45128f2daec3011f8ff5_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="idfffd86898e74da5b26d2c9090d7aef5_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">srt:OfficeBuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iea5110fd579441d385d9a44cd82a7b57_I20100513">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2010-05-13</instant>
        </period>
    </context>
    <context id="i1e44f0e8ba3a437db0695f10422fa49b_I20160131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2016-01-31</instant>
        </period>
    </context>
    <context id="i569ae37ae6bd451aba5271c09e866dd6_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i51df30cfe8df40d49c632283258bef9d_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i84950ce31a9648138dca94d14b435ecc_D20171101-20171130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2017-11-30</endDate>
        </period>
    </context>
    <context id="i6837db1dd6864c6f9523c35e88733824_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7809f262685d483280e68e02e89f4262_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i6eaa74b46ec44f199aa9dfd669c1664f_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4f5feacbf7384a1087c1db7cf1ec114c_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cpix:IncentiveStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ifadcff6052794ad7afbe6463edf069fc_I20201007">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cpix:FourthAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-07</instant>
        </period>
    </context>
    <context id="i7949c2029147408c82a03b03371c2934_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="id63b8386c6dd4a9096c2f08b1caa166d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iec72b3e70c5e4d5b9f0a256af0a2e6eb_D20200814-20200814">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-14</startDate>
            <endDate>2020-08-14</endDate>
        </period>
    </context>
    <context id="i42c0403c56e842038637f32dfa213083_D20200814-20200814">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-14</startDate>
            <endDate>2020-08-14</endDate>
        </period>
    </context>
    <context id="i4487ea5e24834d4bb26ece0c7fc05f81_D20200814-20200814">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-14</startDate>
            <endDate>2020-08-14</endDate>
        </period>
    </context>
    <context id="ic1ff553c5d964f12b7361c40d75ba752_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i22d029b9f8fc4612bd2da5c75672b40a_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3ea7837abdfa48999669b93f02fe29d4_D20200420-20200420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-20</startDate>
            <endDate>2020-04-20</endDate>
        </period>
    </context>
    <context id="i3738112144924be8b7ed4df49c530139_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:WinHealthInvestmentSingaporeLtdDomain</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="i5161e91b97f647a1a447fe4ae410abff_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:WinHealthInvestmentSingaporeLtdDomain</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="i93503f9d933448f182c19f672ad05ba9_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="idfbdaba777624b8b96b3800f1e5753bf_D20181101-20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="i666e3ad219a249f69a70f9d7525a1f8b_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ieca5d4731d90438e81ee926eb9a44d99_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i543d802ba6254fea92215d118fe3fb4e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i1f48945eef8d4b2d820f10f38c6f7a00_D20161101-20161130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-11-01</startDate>
            <endDate>2016-11-30</endDate>
        </period>
    </context>
    <context id="ib90d441c6774404295b76ceae446e40d_D20161101-20161130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-11-01</startDate>
            <endDate>2016-11-30</endDate>
        </period>
    </context>
    <context id="i537c330f50e745f197afdd484a2730ec_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0b8a1a744ec04c1d913f27f1efc5efa2_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="i9e8de0e06633438faeea349c72c801a5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i452c4da6ebcf4c4ebc44e66aaa120e9b_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i8f2247edd8fd4841affbe5d013f55977_D20191001-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>cpix:Segment</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <dei:DocumentFiscalYearFocus
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180L2ZyYWc6M2FmZWJiOGVkZDVlNDNiY2I5NmJjZDFlNGJlZmMxNWQvdGFibGU6MmYzOWM4ZmJiNGU0NGEyMTkxN2IyMTA1MTllY2Q2ZWMvdGFibGVyYW5nZToyZjM5YzhmYmI0ZTQ0YTIxOTE3YjIxMDUxOWVjZDZlY181LTEtMS0xLTA_9690d087-941b-4e11-bfea-bdf2c2cb1e08">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180L2ZyYWc6M2FmZWJiOGVkZDVlNDNiY2I5NmJjZDFlNGJlZmMxNWQvdGFibGU6MmYzOWM4ZmJiNGU0NGEyMTkxN2IyMTA1MTllY2Q2ZWMvdGFibGVyYW5nZToyZjM5YzhmYmI0ZTQ0YTIxOTE3YjIxMDUxOWVjZDZlY182LTEtMS0xLTA_3fbfee24-977e-4338-ab9c-e5fb07a88f8a">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180L2ZyYWc6M2FmZWJiOGVkZDVlNDNiY2I5NmJjZDFlNGJlZmMxNWQvdGFibGU6MmYzOWM4ZmJiNGU0NGEyMTkxN2IyMTA1MTllY2Q2ZWMvdGFibGVyYW5nZToyZjM5YzhmYmI0ZTQ0YTIxOTE3YjIxMDUxOWVjZDZlY183LTEtMS0xLTA_872613f0-2a3d-4e7e-8bef-db14770f3422">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180L2ZyYWc6M2FmZWJiOGVkZDVlNDNiY2I5NmJjZDFlNGJlZmMxNWQvdGV4dHJlZ2lvbjozYWZlYmI4ZWRkNWU0M2JjYjk2YmNkMWU0YmVmYzE1ZF83OA_127e60e9-9aaf-4b96-b550-192db0c28852">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCentralIndexKey
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180L2ZyYWc6M2FmZWJiOGVkZDVlNDNiY2I5NmJjZDFlNGJlZmMxNWQvdGV4dHJlZ2lvbjozYWZlYmI4ZWRkNWU0M2JjYjk2YmNkMWU0YmVmYzE1ZF83OQ_ad8098cc-3a36-4468-8378-74add67f5dae">0001087294</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xL2ZyYWc6ZjI4NWRkNTBmZGMxNDMyNmJmNDRjNDgyNWZhOTBhNGIvdGV4dHJlZ2lvbjpmMjg1ZGQ1MGZkYzE0MzI2YmY0NGM0ODI1ZmE5MGE0Yl8yMDMy_ba758f3c-4572-46c3-b15e-ebd69ddabe6e">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xL2ZyYWc6ZjI4NWRkNTBmZGMxNDMyNmJmNDRjNDgyNWZhOTBhNGIvdGFibGU6Yzc0MWQ5YjA3MjBmNDc5YmIyM2M2M2YxNGVhNWMyODMvdGFibGVyYW5nZTpjNzQxZDliMDcyMGY0NzliYjIzYzYzZjE0ZWE1YzI4M18wLTAtMS0xLTA_01b2f31a-db6e-473d-a006-afc0f5b25af7">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xL2ZyYWc6ZjI4NWRkNTBmZGMxNDMyNmJmNDRjNDgyNWZhOTBhNGIvdGV4dHJlZ2lvbjpmMjg1ZGQ1MGZkYzE0MzI2YmY0NGM0ODI1ZmE5MGE0Yl8yNzQ4Nzc5MDcxNzA5_100568a1-3de8-46ac-90dd-6cd65c7edfb1">2021-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xL2ZyYWc6ZjI4NWRkNTBmZGMxNDMyNmJmNDRjNDgyNWZhOTBhNGIvdGFibGU6YWJiNjNmODcxYWI0NGYxN2E0OTljYzNhZjMxNDMxNmEvdGFibGVyYW5nZTphYmI2M2Y4NzFhYjQ0ZjE3YTQ5OWNjM2FmMzE0MzE2YV8wLTAtMS0xLTA_7d56cb17-5d2e-4642-8a0d-808a2c989e69">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xL2ZyYWc6ZjI4NWRkNTBmZGMxNDMyNmJmNDRjNDgyNWZhOTBhNGIvdGV4dHJlZ2lvbjpmMjg1ZGQ1MGZkYzE0MzI2YmY0NGM0ODI1ZmE5MGE0Yl8yMDI5_12a6b018-42d4-4c7b-a93d-dfcda3380c56">001-33637</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xL2ZyYWc6ZjI4NWRkNTBmZGMxNDMyNmJmNDRjNDgyNWZhOTBhNGIvdGV4dHJlZ2lvbjpmMjg1ZGQ1MGZkYzE0MzI2YmY0NGM0ODI1ZmE5MGE0Yl8yMDMw_ab5ea1c5-a891-47cd-aba1-76a0d77e8441">Cumberland Pharmaceuticals Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xL2ZyYWc6ZjI4NWRkNTBmZGMxNDMyNmJmNDRjNDgyNWZhOTBhNGIvdGFibGU6YzE5ZWQ4MWU2ZDQxNDljYjgwZmZmNDYyODJhYWZkZDUvdGFibGVyYW5nZTpjMTllZDgxZTZkNDE0OWNiODBmZmY0NjI4MmFhZmRkNV8wLTAtMS0xLTA_5fee8bb7-3375-4fd3-a440-c35ecb1f5c26">TN</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xL2ZyYWc6ZjI4NWRkNTBmZGMxNDMyNmJmNDRjNDgyNWZhOTBhNGIvdGFibGU6YzE5ZWQ4MWU2ZDQxNDljYjgwZmZmNDYyODJhYWZkZDUvdGFibGVyYW5nZTpjMTllZDgxZTZkNDE0OWNiODBmZmY0NjI4MmFhZmRkNV8wLTItMS0xLTA_163e9beb-b80c-4c2e-9620-b63c6ef47429">62-1765329</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xL2ZyYWc6ZjI4NWRkNTBmZGMxNDMyNmJmNDRjNDgyNWZhOTBhNGIvdGFibGU6YzE5ZWQ4MWU2ZDQxNDljYjgwZmZmNDYyODJhYWZkZDUvdGFibGVyYW5nZTpjMTllZDgxZTZkNDE0OWNiODBmZmY0NjI4MmFhZmRkNV8zLTAtMS0xLTAvdGV4dHJlZ2lvbjpjOTFkYzI3ZGU1Zjg0NTIwOTVkZjQzNTMxY2NmNTAyYV81_65758720-a630-4ea5-83b9-1e7e89eb3e1f">2525 West End Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xL2ZyYWc6ZjI4NWRkNTBmZGMxNDMyNmJmNDRjNDgyNWZhOTBhNGIvdGFibGU6YzE5ZWQ4MWU2ZDQxNDljYjgwZmZmNDYyODJhYWZkZDUvdGFibGVyYW5nZTpjMTllZDgxZTZkNDE0OWNiODBmZmY0NjI4MmFhZmRkNV8zLTAtMS0xLTAvdGV4dHJlZ2lvbjpjOTFkYzI3ZGU1Zjg0NTIwOTVkZjQzNTMxY2NmNTAyYV85_345b656a-d49e-4b0a-9044-52651df55d9e">Suite 950</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xL2ZyYWc6ZjI4NWRkNTBmZGMxNDMyNmJmNDRjNDgyNWZhOTBhNGIvdGFibGU6YzE5ZWQ4MWU2ZDQxNDljYjgwZmZmNDYyODJhYWZkZDUvdGFibGVyYW5nZTpjMTllZDgxZTZkNDE0OWNiODBmZmY0NjI4MmFhZmRkNV8zLTAtMS0xLTAvdGV4dHJlZ2lvbjpjOTFkYzI3ZGU1Zjg0NTIwOTVkZjQzNTMxY2NmNTAyYV8xMw_f7dfc5b3-9566-4466-8972-56894ce0bec0">Nashville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xL2ZyYWc6ZjI4NWRkNTBmZGMxNDMyNmJmNDRjNDgyNWZhOTBhNGIvdGFibGU6YzE5ZWQ4MWU2ZDQxNDljYjgwZmZmNDYyODJhYWZkZDUvdGFibGVyYW5nZTpjMTllZDgxZTZkNDE0OWNiODBmZmY0NjI4MmFhZmRkNV8zLTAtMS0xLTAvdGV4dHJlZ2lvbjpjOTFkYzI3ZGU1Zjg0NTIwOTVkZjQzNTMxY2NmNTAyYV8xNw_682a491b-2dc3-41b6-9079-1b7e2f8c3d92">TN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xL2ZyYWc6ZjI4NWRkNTBmZGMxNDMyNmJmNDRjNDgyNWZhOTBhNGIvdGFibGU6YzE5ZWQ4MWU2ZDQxNDljYjgwZmZmNDYyODJhYWZkZDUvdGFibGVyYW5nZTpjMTllZDgxZTZkNDE0OWNiODBmZmY0NjI4MmFhZmRkNV8zLTItMS0xLTA_4799f669-1e4a-4b4e-b610-d03bf98fcd1e">37203</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xL2ZyYWc6ZjI4NWRkNTBmZGMxNDMyNmJmNDRjNDgyNWZhOTBhNGIvdGV4dHJlZ2lvbjpmMjg1ZGQ1MGZkYzE0MzI2YmY0NGM0ODI1ZmE5MGE0Yl8yMDMx_3aed4f37-f13c-411c-a7d8-dc704e4171f6">615</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xL2ZyYWc6ZjI4NWRkNTBmZGMxNDMyNmJmNDRjNDgyNWZhOTBhNGIvdGV4dHJlZ2lvbjpmMjg1ZGQ1MGZkYzE0MzI2YmY0NGM0ODI1ZmE5MGE0Yl8yMDM0_f67a3d00-3cbe-4252-9c88-36d1089becf4">255-0068</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xL2ZyYWc6ZjI4NWRkNTBmZGMxNDMyNmJmNDRjNDgyNWZhOTBhNGIvdGFibGU6MDg2YmZlODJmMDZkNDVlYzg5YWU0NTQzYjE4M2NkYWEvdGFibGVyYW5nZTowODZiZmU4MmYwNmQ0NWVjODlhZTQ1NDNiMTgzY2RhYV8yLTAtMS0xLTE5NTg_7a9a191e-6fe3-42bc-9557-6fe939d42390">Common stock, no par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xL2ZyYWc6ZjI4NWRkNTBmZGMxNDMyNmJmNDRjNDgyNWZhOTBhNGIvdGFibGU6MDg2YmZlODJmMDZkNDVlYzg5YWU0NTQzYjE4M2NkYWEvdGFibGVyYW5nZTowODZiZmU4MmYwNmQ0NWVjODlhZTQ1NDNiMTgzY2RhYV8yLTItMS0xLTE5NTg_19eb3b67-722c-43ce-953b-bec798a6248c">CPIX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xL2ZyYWc6ZjI4NWRkNTBmZGMxNDMyNmJmNDRjNDgyNWZhOTBhNGIvdGFibGU6MDg2YmZlODJmMDZkNDVlYzg5YWU0NTQzYjE4M2NkYWEvdGFibGVyYW5nZTowODZiZmU4MmYwNmQ0NWVjODlhZTQ1NDNiMTgzY2RhYV8yLTQtMS0xLTE5NTg_3773c0c9-9f73-4320-b350-d5147d3918b8">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xL2ZyYWc6ZjI4NWRkNTBmZGMxNDMyNmJmNDRjNDgyNWZhOTBhNGIvdGV4dHJlZ2lvbjpmMjg1ZGQ1MGZkYzE0MzI2YmY0NGM0ODI1ZmE5MGE0Yl8yMDM1_0af5933d-63dd-4e8a-aecf-ae3678a38c99">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xL2ZyYWc6ZjI4NWRkNTBmZGMxNDMyNmJmNDRjNDgyNWZhOTBhNGIvdGV4dHJlZ2lvbjpmMjg1ZGQ1MGZkYzE0MzI2YmY0NGM0ODI1ZmE5MGE0Yl8yMDM2_edd9457f-f8ff-47d5-8e74-49c024fa7caf">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xL2ZyYWc6ZjI4NWRkNTBmZGMxNDMyNmJmNDRjNDgyNWZhOTBhNGIvdGFibGU6ZWVhNDQxOGE2Yzc0NDI2ZmJlYjQ5OThhYjQ0MDQ2NjMvdGFibGVyYW5nZTplZWE0NDE4YTZjNzQ0MjZmYmViNDk5OGFiNDQwNDY2M18xLTAtMS0xLTA_87f13264-a45c-4672-905c-f43f70e446e7">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xL2ZyYWc6ZjI4NWRkNTBmZGMxNDMyNmJmNDRjNDgyNWZhOTBhNGIvdGFibGU6ZWVhNDQxOGE2Yzc0NDI2ZmJlYjQ5OThhYjQ0MDQ2NjMvdGFibGVyYW5nZTplZWE0NDE4YTZjNzQ0MjZmYmViNDk5OGFiNDQwNDY2M18xLTUtMS0xLTA_a31549c1-fb5e-4fa0-b7af-112099a9f36e">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xL2ZyYWc6ZjI4NWRkNTBmZGMxNDMyNmJmNDRjNDgyNWZhOTBhNGIvdGFibGU6ZWVhNDQxOGE2Yzc0NDI2ZmJlYjQ5OThhYjQ0MDQ2NjMvdGFibGVyYW5nZTplZWE0NDE4YTZjNzQ0MjZmYmViNDk5OGFiNDQwNDY2M18yLTItMS0xLTA_1b206b25-3db5-4d1d-8887-bfccfc06a50f">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xL2ZyYWc6ZjI4NWRkNTBmZGMxNDMyNmJmNDRjNDgyNWZhOTBhNGIvdGV4dHJlZ2lvbjpmMjg1ZGQ1MGZkYzE0MzI2YmY0NGM0ODI1ZmE5MGE0Yl8yMDM3_160b35b9-b1f3-4c0c-9cf1-7e29c464289f">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i85957d50b58d4241a665bd7848aa809d_I20210809"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xL2ZyYWc6ZjI4NWRkNTBmZGMxNDMyNmJmNDRjNDgyNWZhOTBhNGIvdGV4dHJlZ2lvbjpmMjg1ZGQ1MGZkYzE0MzI2YmY0NGM0ODI1ZmE5MGE0Yl8xOTMx_3ff28572-e5c8-451f-9958-9f56ff9c8784"
      unitRef="shares">14879599</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMy0xLTEtMS0w_8d2f314e-a4aa-45e5-adda-da0c4cae2777"
      unitRef="usd">25670462</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMy0zLTEtMS0w_c8612fbd-00f3-4846-8890-139f721c2ec7"
      unitRef="usd">24753796</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfNS0xLTEtMS0w_5e60e14f-4c02-427f-ad17-0b9fbd14dcd5"
      unitRef="usd">9147493</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfNS0zLTEtMS0w_afcb5590-3f89-45e5-9e71-6aba8800dd5a"
      unitRef="usd">12377713</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfNi0xLTEtMS0w_46622e68-e6a2-4f5b-80b8-4b60db3e88b8"
      unitRef="usd">10104219</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfNi0zLTEtMS0w_43a04b71-55fa-4efc-8df7-921018bb7631"
      unitRef="usd">10638157</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent
      contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfNy0xLTEtMS0w_c2b994a8-f681-4cd1-8880-a8e9dc658d03"
      unitRef="usd">1758332</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfNy0zLTEtMS0w_8363468a-5e76-4ef3-99ee-0e6353d96351"
      unitRef="usd">2199926</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfOC0xLTEtMS0w_0bf186fb-ed07-43a5-92b0-e05c225f4569"
      unitRef="usd">46680506</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfOC0zLTEtMS0w_683e235a-4de9-435b-b711-7adb67654606"
      unitRef="usd">49969592</us-gaap:AssetsCurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfOS0xLTEtMS0w_bbaf57d8-e010-4045-b3eb-b148d7e3cd62"
      unitRef="usd">9880766</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfOS0zLTEtMS0w_2489393c-0446-4f13-9ec0-d14bf0fca410"
      unitRef="usd">11656742</us-gaap:InventoryNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMTAtMS0xLTEtMA_ae62976f-9667-4a20-b962-3f8e484327f9"
      unitRef="usd">493256</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMTAtMy0xLTEtMA_8d7fe9b0-7158-428d-ac59-b285f02ad94a"
      unitRef="usd">574169</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMTEtMS0xLTEtMA_cc8e0661-7664-40b6-a5a8-9111a0023948"
      unitRef="usd">25888622</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMTEtMy0xLTEtMA_f9660c5b-ebe4-43d4-917e-2b959543f346"
      unitRef="usd">28118316</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:Goodwill
      contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMTItMS0xLTEtMA_667dff7a-79f1-4a16-8354-23b7828ba06d"
      unitRef="usd">882000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMTItMy0xLTEtMA_9dc389b6-5966-471a-855a-4923b1fae01a"
      unitRef="usd">882000</us-gaap:Goodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMTMtMS0xLTEtMA_2e05e7f0-60a9-432f-b689-714e14aa54d6"
      unitRef="usd">1535556</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMTMtMy0xLTEtMA_53309c83-57d8-4782-995c-5783f3665269"
      unitRef="usd">2028148</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMTQtMS0xLTEtMA_2d3f8d8d-e206-4e0c-8d32-2f326123287f"
      unitRef="usd">3490768</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMTQtMy0xLTEtMA_eb1d6912-a35b-4b52-868b-c3c5bf19d145"
      unitRef="usd">3234338</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMTUtMS0xLTEtMA_4c1163de-4522-4992-9d97-d0f46c4424fb"
      unitRef="usd">88851474</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMTUtMy0xLTEtMA_261bf230-c8bd-4e2d-839a-a0e26e6fd5e8"
      unitRef="usd">96463305</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMTgtMS0xLTEtMA_6f916c4b-28f8-4767-923c-14dc047bd503"
      unitRef="usd">8962916</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMTgtMy0xLTEtMA_cac2316e-4d09-4993-adea-8835e3bd500c"
      unitRef="usd">13396286</us-gaap:AccountsPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMTktMS0xLTEtMA_76cf164b-f512-47ff-9598-0ce24a62b161"
      unitRef="usd">1067880</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMTktMy0xLTEtMA_9cf1e8d6-554c-40d5-8761-2fc00629e997"
      unitRef="usd">1016779</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMjAtMS0xLTEtMA_3bbd1746-681f-4ee9-8507-50b3b2dd6b2f"
      unitRef="usd">8615995</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMjAtMy0xLTEtMA_1aca0fcc-b8f1-4107-9c7e-5343ceba81f4"
      unitRef="usd">11254381</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMjEtMS0xLTEtMA_769e13d2-4180-457d-975c-dae98ebb5b64"
      unitRef="usd">18646791</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMjEtMy0xLTEtMA_c2664694-ee79-4c56-b755-30fc0bed1943"
      unitRef="usd">25667446</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermLineOfCredit
      contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMjItMS0xLTEtMA_104889ae-44ad-4962-b63b-9ae24450108d"
      unitRef="usd">14000000</us-gaap:LongTermLineOfCredit>
    <us-gaap:LongTermLineOfCredit
      contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMjItMy0xLTEtMA_1e22ec19-a5e4-4d6f-ad7f-8d26e266f7ac"
      unitRef="usd">15000000</us-gaap:LongTermLineOfCredit>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMjMtMS0xLTEtMA_27314676-eaef-4b08-b629-1bd57f9cb72d"
      unitRef="usd">512324</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMjMtMy0xLTEtMA_2365ee51-2da6-4722-864a-e0100f76ed91"
      unitRef="usd">1059693</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <cpix:OtherLongTermObligationsExcludingCurrentPortion
      contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMjQtMS0xLTEtMA_b7bcc86c-7659-40e4-a1fe-5c641aa1571f"
      unitRef="usd">7883952</cpix:OtherLongTermObligationsExcludingCurrentPortion>
    <cpix:OtherLongTermObligationsExcludingCurrentPortion
      contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMjQtMy0xLTEtMA_fc3a1203-88a2-427f-ab6d-9eaee68bbc66"
      unitRef="usd">7862772</cpix:OtherLongTermObligationsExcludingCurrentPortion>
    <us-gaap:Liabilities
      contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMjUtMS0xLTEtMA_d8bad717-c04f-41d6-84ca-dc8fd49c642b"
      unitRef="usd">41043067</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMjUtMy0xLTEtMA_7c10d1de-63ba-4f3d-acfe-7a2824714570"
      unitRef="usd">49589911</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMjYtMS0xLTEtMA_0943f11b-8206-433f-b37e-9577c92e2868"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMjYtMy0xLTEtMA_55aaae7b-a5a9-4d07-b9bf-56652eead23a"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockNoParValue
      contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmFhYThiODQ3Y2Q2MTQ2MzA4MDRlZWJkZWFkZjM4YWNlXzE3_9e77537b-c588-40ff-a2a6-400cec234149"
      unitRef="usdPerShare">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockNoParValue
      contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmFhYThiODQ3Y2Q2MTQ2MzA4MDRlZWJkZWFkZjM4YWNlXzE3_ba8fef5e-002f-48c7-b490-b93943b548c2"
      unitRef="usdPerShare">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmFhYThiODQ3Y2Q2MTQ2MzA4MDRlZWJkZWFkZjM4YWNlXzMx_1f1229f8-81f3-4cb0-8b7a-9c8eba94b67e"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmFhYThiODQ3Y2Q2MTQ2MzA4MDRlZWJkZWFkZjM4YWNlXzMx_c19e2d18-900c-4d57-88d8-28d1d8976efd"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmFhYThiODQ3Y2Q2MTQ2MzA4MDRlZWJkZWFkZjM4YWNlXzUz_088ac56d-aca6-4940-970c-a94af63c3c48"
      unitRef="shares">14926059</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmFhYThiODQ3Y2Q2MTQ2MzA4MDRlZWJkZWFkZjM4YWNlXzUz_5c8f8f95-d951-4ec4-8adf-8b7158ff57f0"
      unitRef="shares">14926059</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmFhYThiODQ3Y2Q2MTQ2MzA4MDRlZWJkZWFkZjM4YWNlXzYw_8aff7bee-6fe0-4718-81c9-8aaed874e0d7"
      unitRef="shares">14988429</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmFhYThiODQ3Y2Q2MTQ2MzA4MDRlZWJkZWFkZjM4YWNlXzYw_aadd4dd1-57d2-4b72-9bb7-8618d0f93709"
      unitRef="shares">14988429</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMjktMS0xLTEtMA_b45a4686-a266-45e9-bbf4-1d23225cfe23"
      unitRef="usd">48688384</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMjktMy0xLTEtMA_109ee336-1067-4371-ae21-46895568bcd2"
      unitRef="usd">49121523</us-gaap:CommonStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMzAtMS0xLTEtMA_d6b208f2-f575-4ad5-88b2-8f3a5e1dd90e"
      unitRef="usd">-735625</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMzAtMy0xLTEtMA_f45a004a-831a-4b14-936f-8ecd0bd3c406"
      unitRef="usd">-2131013</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMzEtMS0xLTEtMA_8d7d2a57-c1fa-45ec-81bf-83c12a24f6fe"
      unitRef="usd">47952759</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMzEtMy0xLTEtMA_2fb44e57-1612-41a5-a841-7bbbc11ced18"
      unitRef="usd">46990510</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMzItMS0xLTEtMA_198da7c9-35ca-44b0-836e-339bd55088db"
      unitRef="usd">-144352</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMzItMy0xLTEtMA_f720cadb-1c86-4274-9ebd-8c9bd95a235a"
      unitRef="usd">-117116</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMzMtMS0xLTEtMA_d761dd63-9c17-4b2f-8948-42064e559ab0"
      unitRef="usd">47808407</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMzMtMy0xLTEtMA_7c79ca6f-ebc9-4589-86d3-84ee837f4c9b"
      unitRef="usd">46873394</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMzQtMS0xLTEtMA_2b5b19f0-24bd-44b2-bf93-12785dfef94b"
      unitRef="usd">88851474</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xNi9mcmFnOjRlMWE5YWQ2ZGMzNTQ5MDE5ZjE3ZjEyZjk2YWNlMjdhL3RhYmxlOmUxYTQzYjk0Y2YxNTQ4MDdhMmJhNGRmZjY4OGEyOWJlL3RhYmxlcmFuZ2U6ZTFhNDNiOTRjZjE1NDgwN2EyYmE0ZGZmNjg4YTI5YmVfMzQtMy0xLTEtMA_406594fa-bea6-452a-8930-e7c7af80ddd3"
      unitRef="usd">96463305</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMi0xLTEtMS0w_43c14d3c-5e73-420c-8691-da04c351d460"
      unitRef="usd">9055483</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMi0zLTEtMS0w_f926022a-c432-40ae-91ff-49f270f64eb5"
      unitRef="usd">9598177</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMi01LTEtMS0w_98fb81f8-ba3f-4c21-92c9-c8cef7867be5"
      unitRef="usd">19592642</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMi03LTEtMS0w_7866b9b9-31f9-4dc8-883e-3ec2193a9625"
      unitRef="usd">17928911</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfNC0xLTEtMS0w_30bf56db-8819-4131-8c81-f5ad73b048ee"
      unitRef="usd">1740649</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfNC0zLTEtMS0w_7b3b5bcd-d334-4d5a-80ce-410e08e71c67"
      unitRef="usd">2609982</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfNC01LTEtMS0w_400faead-c1e1-4315-91e9-0a8e8d51f5db"
      unitRef="usd">4157978</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfNC03LTEtMS0w_43bd455d-74d0-421d-901a-adfd18b6198f"
      unitRef="usd">4244163</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingAndMarketingExpense
      contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfNS0xLTEtMS0w_06d9718d-93d2-442a-b46c-97fcf09565ce"
      unitRef="usd">4121817</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfNS0zLTEtMS0w_b3c62998-7ed4-4258-8d2d-e428f55cfcb9"
      unitRef="usd">3865406</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfNS01LTEtMS0w_b1e38330-db68-4bce-a66c-750c396e59c2"
      unitRef="usd">7909157</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfNS03LTEtMS0w_245fdf4a-c89b-49bc-a0e5-cf6dd63e6e3b"
      unitRef="usd">7573082</us-gaap:SellingAndMarketingExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfNi0xLTEtMS0w_a68220ec-d5a7-481c-8b0e-06cc3233f9a9"
      unitRef="usd">1360398</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfNi0zLTEtMS0w_df6a19c7-6ab7-4c24-89f9-715ab89839c3"
      unitRef="usd">1421502</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfNi01LTEtMS0w_b611ffe6-37f2-458f-9b32-55425b54c477"
      unitRef="usd">2617765</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfNi03LTEtMS0w_00607ed0-835c-4897-a315-d74ad5ef4e07"
      unitRef="usd">3144057</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfNy0xLTEtMS0w_0af888b3-5ad6-4232-81ac-8af03fac5baa"
      unitRef="usd">2097130</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfNy0zLTEtMS0w_851ed82c-5e31-4a64-8de4-05018f4a6144"
      unitRef="usd">2190764</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfNy01LTEtMS0w_e7bf2be7-579f-4ae0-8469-dc6f4d00b6f7"
      unitRef="usd">4327639</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfNy03LTEtMS0w_6a56f486-2a34-4d46-8d61-54788f739be3"
      unitRef="usd">4227048</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfOC0xLTEtMS0w_add048c2-1343-453f-99eb-a0f67b1d9521"
      unitRef="usd">1171218</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfOC0zLTEtMS0w_ab50613a-dad2-4459-b36e-3f4dfb003e6e"
      unitRef="usd">1091485</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfOC01LTEtMS0w_3c2f9590-0412-497a-96ec-2f791f14597c"
      unitRef="usd">2340132</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfOC03LTEtMS0w_bfb6de10-c4a9-4a52-9bd2-4b98f56a1153"
      unitRef="usd">2167524</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:CostsAndExpenses
      contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfOS0xLTEtMS0w_7b02229c-6b19-4d99-9a50-e3ca8bcd1d6f"
      unitRef="usd">10491212</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfOS0zLTEtMS0w_8c5e592b-ce59-491a-b4e3-959eb6ba0e8c"
      unitRef="usd">11179139</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfOS01LTEtMS0w_12482a8b-d44d-4f56-b899-13decf3317b1"
      unitRef="usd">21352671</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfOS03LTEtMS0w_ac3eb413-efc4-48b8-a547-bfcf0f3f5783"
      unitRef="usd">21355874</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTAtMS0xLTEtMA_1387e406-65fb-45ae-9d1f-4e562f72aa89"
      unitRef="usd">-1435729</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTAtMy0xLTEtMA_0ae2d962-c7c9-4109-aa07-94778977c56f"
      unitRef="usd">-1580962</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTAtNS0xLTEtMA_21b694aa-c8ca-4ccc-86d9-db2a5c9aedba"
      unitRef="usd">-1760029</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTAtNy0xLTEtMA_6c61448c-e459-4928-aaf7-f3649334888e"
      unitRef="usd">-3426963</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTEtMS0xLTEtMA_3bbcedc4-38ef-4f2b-b843-6efbcd7ebb34"
      unitRef="usd">6591</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTEtMy0xLTEtMA_008dd6c6-905d-4a83-9a47-05dc6fae93ef"
      unitRef="usd">28661</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTEtNS0xLTEtMA_23a82b58-ed6a-4d12-9667-ea5e8c3d34b9"
      unitRef="usd">12017</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTEtNy0xLTEtMA_437cdcda-7875-46a8-bef5-5d71f5a311a5"
      unitRef="usd">58549</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherIncome
      contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTItMS0xLTEtMTY_1ac8f5cc-7397-4f6b-99be-b2e27b619bab"
      unitRef="usd">2187140</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTItMy0xLTEtMTY_a616ae82-8c26-4bbb-bcd9-854fb787ff1d"
      unitRef="usd">0</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTItNS0xLTEtNDQ_33b7d1ef-4672-4af2-babe-a9f8152703dc"
      unitRef="usd">2187140</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTItNy0xLTEtNDA_62f26054-b64b-45e1-a627-1fc78eeee253"
      unitRef="usd">0</us-gaap:OtherIncome>
    <us-gaap:InterestExpense
      contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTItMS0xLTEtMA_805e04bd-ab99-44a5-baf6-5e70fcb57464"
      unitRef="usd">25859</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTItMy0xLTEtMA_5538e440-f580-4aca-83f8-a49fdba3765d"
      unitRef="usd">119455</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTItNS0xLTEtMA_d09862a4-0c84-4cd6-8362-e1a634552a14"
      unitRef="usd">50276</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTItNy0xLTEtMA_030a05d3-8a2b-4c61-80d4-86abca5ec29f"
      unitRef="usd">152520</us-gaap:InterestExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTMtMS0xLTEtMA_300fc29f-1399-4e26-9d74-0cc63ca58793"
      unitRef="usd">732143</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTMtMy0xLTEtMA_217ad10d-4d0f-4b3a-931b-572e476382d5"
      unitRef="usd">-1671756</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTMtNS0xLTEtMA_d44cf48a-fa1b-43fe-be6b-971f02eef115"
      unitRef="usd">388852</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTMtNy0xLTEtMA_31067390-fa60-4be1-a047-ac5aedc5c5cb"
      unitRef="usd">-3520934</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTQtMS0xLTEtMA_d8fd549a-1d72-4cb7-b89a-7d2ea0ff1ae4"
      unitRef="usd">7459</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTQtMy0xLTEtMA_5ed24682-4f39-4a7b-82c8-f5be96d317a8"
      unitRef="usd">7455</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTQtNS0xLTEtMA_a01ba25a-005d-46ad-ac30-471ad8081705"
      unitRef="usd">14917</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTQtNy0xLTEtMA_028be3e3-26bc-4faf-bc47-e6c6b6361845"
      unitRef="usd">41695</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTUtMS0xLTEtMA_761328f0-deef-47f7-9f51-604c18a2e233"
      unitRef="usd">724684</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTUtMy0xLTEtMA_d81f4724-54a3-4bf0-afb3-205bc093c40b"
      unitRef="usd">-1679211</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTUtNS0xLTEtMA_a63db8bb-8ef8-4664-9c16-a1c90b7c2460"
      unitRef="usd">373935</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTUtNy0xLTEtMA_edf48b93-5a80-48fd-b726-5a6b729875c2"
      unitRef="usd">-3562629</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0932967c9c90454494cbf245d9fa585d_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTYtMS0xLTEtMA_33139f42-0425-4d08-841a-9ae006c66914"
      unitRef="usd">498807</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iffc2a4291a32445fb79072f7fe43a870_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTYtMy0xLTEtMA_cf0ce557-4fdd-47c1-9191-c917bd799f4a"
      unitRef="usd">738622</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i53d85ca5dcbd44ba870830f97461a800_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTYtNS0xLTEtMA_1bcf2509-7467-4c5c-b800-3d442a6bcef9"
      unitRef="usd">994217</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i166678b245754127b39f5e9c73e8cf2d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTYtNy0xLTEtMA_72de53a1-48b1-4c79-aa3d-faa22b8da99b"
      unitRef="usd">1556895</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ProfitLoss
      contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTctMS0xLTEtMA_38da6285-7070-402f-b837-0f3086a49f75"
      unitRef="usd">1223491</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTctMy0xLTEtMA_dcb401ca-38e5-45c6-95be-49953c1e7e9e"
      unitRef="usd">-940589</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTctNS0xLTEtMA_38cb88e6-86a6-4d02-81c9-6ac76b42e377"
      unitRef="usd">1368152</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTctNy0xLTEtMA_7826b7b4-b91b-4335-a18c-a35cbf70f406"
      unitRef="usd">-2005734</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTgtMS0xLTEtMA_ad9cdbb0-35e4-4783-875f-a33b803b750c"
      unitRef="usd">-5069</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTgtMy0xLTEtMA_47af32b2-36dc-48d1-ae83-7216b2cc2889"
      unitRef="usd">-22314</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTgtNS0xLTEtMA_3132eb79-3ac2-46ef-b108-4ed939312a07"
      unitRef="usd">-27236</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTgtNy0xLTEtMA_16452e5d-8d67-4eab-b11e-724dc4efa96b"
      unitRef="usd">-31839</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTktMS0xLTEtMA_b8dfc5cf-c6a5-4f7c-9c61-6a80b153a842"
      unitRef="usd">1228560</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTktMy0xLTEtMA_334f259a-7999-4f1a-857c-595692c065d0"
      unitRef="usd">-918275</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTktNS0xLTEtMA_c4f19629-5882-4929-89aa-d989770a2c78"
      unitRef="usd">1395388</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMTktNy0xLTEtMA_461cc6b8-bca3-4299-be42-5d55162be78f"
      unitRef="usd">-1973895</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMjEtMS0xLTEtMA_2a8ede92-0da7-4fc4-bccb-641e06e375c9"
      unitRef="usdPerShare">0.05</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMjEtMy0xLTEtMA_f113112f-72e5-4fee-8d1d-72109c1935c3"
      unitRef="usdPerShare">-0.11</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMjEtNS0xLTEtMA_3ed3949f-e6e1-4fdf-a405-900344e298d5"
      unitRef="usdPerShare">0.02</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMjEtNy0xLTEtMA_54e90f0a-4fff-4305-8614-3c6bc6cd1698"
      unitRef="usdPerShare">-0.23</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMjItMS0xLTEtMA_bf0076e8-2ef4-4178-8412-323e5c33171d"
      unitRef="usdPerShare">0.03</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMjItMy0xLTEtMA_38fb56c4-5d5f-40ca-803e-1175fad896af"
      unitRef="usdPerShare">0.05</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMjItNS0xLTEtMA_e2ad922a-cef8-4623-91a0-4986b6daf631"
      unitRef="usdPerShare">0.07</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMjItNy0xLTEtMA_46a02ac7-e916-484e-b0b1-e01c4d6fa6ff"
      unitRef="usdPerShare">0.10</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMjMtMS0xLTEtMA_83c569a8-15d9-42eb-9285-667fb502455a"
      unitRef="usdPerShare">0.08</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMjMtMy0xLTEtMA_d98ecdea-22dc-4e7b-93e0-d279e57d5694"
      unitRef="usdPerShare">-0.06</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMjMtNS0xLTEtMA_148c7eab-edab-49e7-9555-4e09a44ae4c3"
      unitRef="usdPerShare">0.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMjMtNy0xLTEtMA_5d98fc53-f6cf-4236-9386-49c02fdb3649"
      unitRef="usdPerShare">-0.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMjUtMS0xLTEtMA_0f500a0c-8d4d-44f1-ba73-0e451c8e451f"
      unitRef="usdPerShare">0.05</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMjUtMy0xLTEtMA_df2301ab-921f-4113-94e1-1c7d25285dc6"
      unitRef="usdPerShare">-0.11</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMjUtNS0xLTEtMA_8ca9685c-2555-4e95-ad9e-260beaecc625"
      unitRef="usdPerShare">0.02</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMjUtNy0xLTEtMA_e78f0b20-3cf0-4ed3-8c5a-f0afabd2aad2"
      unitRef="usdPerShare">-0.23</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMjYtMS0xLTEtMA_66cfa766-1e1c-44b4-b330-7d514228ec5c"
      unitRef="usdPerShare">0.03</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMjYtMy0xLTEtMA_ad2e8087-31c8-4b9c-926d-01fa1db330eb"
      unitRef="usdPerShare">0.05</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMjYtNS0xLTEtMA_57d43691-d252-4a15-9b9d-ca0d93f74203"
      unitRef="usdPerShare">0.07</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMjYtNy0xLTEtMA_8e97a492-d312-4906-ae51-bf6ef8acad7a"
      unitRef="usdPerShare">0.10</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMjctMS0xLTEtMA_532a0445-d941-4f4a-9574-95b69bf182bc"
      unitRef="usdPerShare">0.08</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMjctMy0xLTEtMA_b7027d9d-7985-497f-9d48-74f9e75ddcd8"
      unitRef="usdPerShare">-0.06</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMjctNS0xLTEtMA_2bca3d5c-cf8d-4c0b-a351-7036fb54be79"
      unitRef="usdPerShare">0.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMjctNy0xLTEtMA_16cc53be-5f87-4ea6-930b-c0dfad689b07"
      unitRef="usdPerShare">-0.13</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMjktMS0xLTEtMA_c2df2a85-063d-4e72-8cc0-f113580e1ac4"
      unitRef="shares">14976034</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMjktMy0xLTEtMA_3df73b08-d9bc-4067-b6c3-56fa9ffd698a"
      unitRef="shares">15241463</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMjktNS0xLTEtMA_90bf369c-59f5-475e-bb5e-dc29a315c526"
      unitRef="shares">14970241</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMjktNy0xLTEtMA_34d5a1e5-220b-41a6-8215-a9b0c1b42040"
      unitRef="shares">15241020</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMzAtMS0xLTEtMA_2cc9f5cb-2fc2-45a0-a213-fabe436ff549"
      unitRef="shares">15109246</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMzAtMy0xLTEtMA_64d8a77f-6e7d-4077-8194-074fafdb8a68"
      unitRef="shares">15241463</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMzAtNS0xLTEtMA_c14f7212-bbfa-4857-84b0-5aa8c727c9ef"
      unitRef="shares">15171589</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18xOS9mcmFnOjY4MzVmMGFjZmQyNzRhNjE5MDdiZjNiM2U3N2UxN2Q0L3RhYmxlOmM0ODE2ZWQ2NTlhMTQxM2VhZTRmMzVmMGM1NDU3OTkyL3RhYmxlcmFuZ2U6YzQ4MTZlZDY1OWExNDEzZWFlNGYzNWYwYzU0NTc5OTJfMzAtNy0xLTEtMA_65f2f002-432e-4d27-b6d3-2268b01e4d04"
      unitRef="shares">15241020</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMy0xLTEtMS0w_642afdcd-46f9-4c19-a167-43040be50bf0"
      unitRef="usd">1368152</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMy0zLTEtMS0w_b1e7ec1d-6fd5-4ce1-9c97-4417accf6f1b"
      unitRef="usd">-2005734</us-gaap:ProfitLoss>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfNC0xLTEtMS0w_53b31483-cda3-4cc1-a8e4-e06397e34e25"
      unitRef="usd">994217</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfNC0zLTEtMS0w_7d8306ad-1422-4f4f-97fe-1a8c9686fd61"
      unitRef="usd">1556895</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfNS0xLTEtMS0w_24eea12d-4d46-462c-94c6-604ce1e3cde1"
      unitRef="usd">373935</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfNS0zLTEtMS0w_6d888c8a-c33b-4042-82b3-2ed8d2b3e292"
      unitRef="usd">-3562629</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfNy0xLTEtMS0w_93ac9757-3fec-4344-9d27-e05f57e0532d"
      unitRef="usd">2455576</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfNy0zLTEtMS0w_b7edd077-5d16-4ffa-96fc-086471a27be2"
      unitRef="usd">2334669</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfOC0xLTEtMS0w_ecf88537-947d-4c24-8567-b4a73fbfc8f0"
      unitRef="usd">354914</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfOC0zLTEtMS0w_c055897d-2037-43e2-b0c9-bf5b72584e99"
      unitRef="usd">542923</us-gaap:ShareBasedCompensation>
    <us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfOS0xLTEtMS0w_f2f5ce0c-975c-46ee-bcc9-3fcec763e72d"
      unitRef="usd">180110</us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities>
    <us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
      contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfOS0zLTEtMS0w_4d9e291e-2f0f-4555-8ad3-a6586353e561"
      unitRef="usd">645571</us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities>
    <cpix:IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMTAtMS0xLTEtMA_ed642114-bf1e-4c19-9d7c-22332f8a8ca4"
      unitRef="usd">226897</cpix:IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy>
    <cpix:IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy
      contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMTAtMy0xLTEtMA_d8735c7e-34de-43e8-bcd9-e7f9773958a2"
      unitRef="usd">-215116</cpix:IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMTEtMS0xLTEtMA_85c3751f-c19a-4700-b5b4-0e0ae5454c33"
      unitRef="usd">27666</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMTEtMy0xLTEtMA_e8a67e53-6157-4328-ae6c-32b90c1f1062"
      unitRef="usd">22973</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMTItMS0xLTEtNTM_4f111ca0-7e8c-4350-890c-f6e183e4b29f"
      unitRef="usd">2187140</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMTItMy0xLTEtNTM_b9b8e0db-1857-46f0-bb4c-599c14e59895"
      unitRef="usd">0</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMTMtMS0xLTEtMA_41edc7d0-d2de-4eb5-85b8-bb5f40559cb3"
      unitRef="usd">-3230220</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMTMtMy0xLTEtMA_1c4b7547-7ef4-4c0f-bd17-5fcf24b51ae4"
      unitRef="usd">80421</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMTQtMS0xLTEtMA_cbfd967f-f119-4ebb-a2d8-416b981ae72a"
      unitRef="usd">-2309914</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMTQtMy0xLTEtMA_ea0e8766-0762-4c01-b277-c8bcc7852f43"
      unitRef="usd">-1158916</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMTUtMS0xLTEtMA_e56bd93a-dfc7-40a4-9729-5e10e7db7007"
      unitRef="usd">-866987</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMTUtMy0xLTEtMA_cfd5120e-0fda-4a06-91b3-12f31c7b5c12"
      unitRef="usd">-802534</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <cpix:IncreaseDecreaseInCurrentOperatingLiabilities
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMTYtMS0xLTEtMA_98bab84a-96ab-4f88-8ba0-0161943d4bc7"
      unitRef="usd">-3008323</cpix:IncreaseDecreaseInCurrentOperatingLiabilities>
    <cpix:IncreaseDecreaseInCurrentOperatingLiabilities
      contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMTYtMy0xLTEtMA_1b6eff17-dd79-48ca-8ce6-278c583ebb8d"
      unitRef="usd">2413768</cpix:IncreaseDecreaseInCurrentOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMTctMS0xLTEtMA_493ba5e9-7b25-411f-b6d6-fab9b822524f"
      unitRef="usd">-526189</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMTctMy0xLTEtMA_21f251e4-64ee-4217-b467-d43f629a96ff"
      unitRef="usd">-869644</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMTgtMS0xLTEtMA_2fc44eac-7dda-4b19-adf7-c87e4a011e1d"
      unitRef="usd">3490553</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMTgtMy0xLTEtMA_ff0dc61c-038e-4f40-a1ac-8075480d9292"
      unitRef="usd">2332634</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMTktMS0xLTEtMA_aa0eea8a-b57b-4f52-8a91-57d1d16460cd"
      unitRef="usd">994217</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMTktMy0xLTEtMA_4ba1577a-2dae-4279-9849-c7888d7aab06"
      unitRef="usd">1371437</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMjAtMS0xLTEtMA_821d029f-ef00-4828-bf0e-9b14acc7e271"
      unitRef="usd">4484770</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMjAtMy0xLTEtMA_fa5d3d03-3121-4a64-8938-ae84f1c4ecf5"
      unitRef="usd">3704071</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMjItMS0xLTEtMA_f44b2557-10f9-4e93-bac3-783b69b1ed0d"
      unitRef="usd">34531</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMjItMy0xLTEtMA_c7963437-e83f-46f1-bd48-501e85ed46ff"
      unitRef="usd">50883</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMjMtMS0xLTEtMA_133669a0-0727-4fc3-8b92-2de7885ee88e"
      unitRef="usd">200000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMjMtMy0xLTEtMA_f21a799c-844c-462a-99f7-66e5145948dd"
      unitRef="usd">0</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMjQtMS0xLTEtMA_48e93d70-128b-445d-bbb6-85e62235d484"
      unitRef="usd">132323</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMjQtMy0xLTEtMA_f259694b-bd37-420b-9696-d864956f2235"
      unitRef="usd">722131</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMjUtMS0xLTEtMA_b32a99f2-7f55-4d1b-8f49-2c1a3e2f97f2"
      unitRef="usd">-366854</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMjUtMy0xLTEtMA_bfd6274d-9913-441a-8903-3c8113ba5699"
      unitRef="usd">-773014</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromRepaymentsOfLinesOfCredit
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMjgtMS0xLTEtMA_83608c38-ca81-4b64-a7dc-de88210236bf"
      unitRef="usd">29000000</us-gaap:ProceedsFromRepaymentsOfLinesOfCredit>
    <us-gaap:ProceedsFromRepaymentsOfLinesOfCredit
      contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMjgtMy0xLTEtMA_5afd82af-82aa-48f0-93ae-1b655f747c12"
      unitRef="usd">35500000</us-gaap:ProceedsFromRepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMjktMS0xLTEtMA_3cff173c-ebd9-4271-b6d5-9eaf7599eea9"
      unitRef="usd">30000000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMjktMy0xLTEtMA_a3ce262c-d7fc-447e-85e9-292e3e2e6aba"
      unitRef="usd">37000000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMzAtMS0xLTEtMA_b3507769-327f-406a-976d-60b478c2d7d8"
      unitRef="usd">1423586</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMzAtMy0xLTEtMA_70177a1d-0cde-40a7-a23c-1a46cbe03f70"
      unitRef="usd">260735</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentsForRepurchaseOfRedeemableNoncontrollingInterest
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMzEtMS0xLTEtMA_a3fa1ec6-0388-4197-b886-75fb22bf5016"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfRedeemableNoncontrollingInterest>
    <us-gaap:PaymentsForRepurchaseOfRedeemableNoncontrollingInterest
      contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMzEtMy0xLTEtMA_f4db0bf7-868e-4600-8f45-f8d714eabf70"
      unitRef="usd">800000</us-gaap:PaymentsForRepurchaseOfRedeemableNoncontrollingInterest>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMzItMS0xLTEtMA_a884db7a-954f-45fb-a57f-d18076f910f3"
      unitRef="usd">777664</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMzItMy0xLTEtMA_3238029f-9388-4a11-82c9-8a17b430dc0d"
      unitRef="usd">1209220</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMzMtMS0xLTEtMA_03f034f9-d3f2-459a-b5c5-f0b58214ed2a"
      unitRef="usd">-3201250</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMzMtMy0xLTEtMA_eb27c94c-fe43-4551-91c3-c505de79525d"
      unitRef="usd">-3769955</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMzQtMS0xLTEtMA_f10bd4aa-c83c-4207-8cdf-35f7d64dd2d9"
      unitRef="usd">916666</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMzQtMy0xLTEtMA_53935b95-ac64-48b8-bad0-5dc9078bc8ac"
      unitRef="usd">-838898</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMzUtMS0xLTEtMA_893d9c8f-6d2f-4717-a91e-06076e566dd2"
      unitRef="usd">24753796</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie98ab83b91d54ad0aa13294fe0c3bdb6_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMzUtMy0xLTEtMA_e08c36f3-9326-4bae-a41e-5f218cf3ce38"
      unitRef="usd">28212635</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMzYtMS0xLTEtMA_8f192b10-1f32-41d3-b1a5-64fe3c151f85"
      unitRef="usd">25670462</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4860200ab8134ae18446101822694027_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yMi9mcmFnOmNkMGU0MjRlYzA3ZjQyYjdhMDFkMWM4YjFmMmVmYzIxL3RhYmxlOjc0Y2VmOGUzMTVhODRjMGRhYjdmMWEzNmU3MDYyMjYyL3RhYmxlcmFuZ2U6NzRjZWY4ZTMxNWE4NGMwZGFiN2YxYTM2ZTcwNjIyNjJfMzYtMy0xLTEtMA_42bb130f-4249-481b-886c-44d8f14d847d"
      unitRef="usd">27373737</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i3d6d3147bec94616bcf72690b2be296a_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjk4M2M0NGFhMTU2YjRhMDg4NDg3YjMyMDJmZTM1YmU5L3RhYmxlcmFuZ2U6OTgzYzQ0YWExNTZiNGEwODg0ODdiMzIwMmZlMzViZTlfMi0xLTEtMS0w_f6f3df32-0091-4d14-8522-cc47eff6bb4b"
      unitRef="shares">15263555</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3d6d3147bec94616bcf72690b2be296a_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjk4M2M0NGFhMTU2YjRhMDg4NDg3YjMyMDJmZTM1YmU5L3RhYmxlcmFuZ2U6OTgzYzQ0YWExNTZiNGEwODg0ODdiMzIwMmZlMzViZTlfMi0zLTEtMS0w_acef6610-95d6-402c-8afb-4e189b122b68"
      unitRef="usd">49914478</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i83e7ecfbf2a84991a8389944813821f5_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjk4M2M0NGFhMTU2YjRhMDg4NDg3YjMyMDJmZTM1YmU5L3RhYmxlcmFuZ2U6OTgzYzQ0YWExNTZiNGEwODg0ODdiMzIwMmZlMzViZTlfMi01LTEtMS0w_b1e7fcdc-c912-4b2f-ac85-45fe72454eec"
      unitRef="usd">1208395</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i114a57733d5043469e08faf40e0cd3f8_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjk4M2M0NGFhMTU2YjRhMDg4NDg3YjMyMDJmZTM1YmU5L3RhYmxlcmFuZ2U6OTgzYzQ0YWExNTZiNGEwODg0ODdiMzIwMmZlMzViZTlfMi03LTEtMS0w_d88f8c60-2f47-417d-b2d2-ae81330e62db"
      unitRef="usd">-37620</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie98ab83b91d54ad0aa13294fe0c3bdb6_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjk4M2M0NGFhMTU2YjRhMDg4NDg3YjMyMDJmZTM1YmU5L3RhYmxlcmFuZ2U6OTgzYzQ0YWExNTZiNGEwODg0ODdiMzIwMmZlMzViZTlfMi05LTEtMS0w_c8ea0ce2-dc9b-42f0-bca5-3c8cf77a2533"
      unitRef="usd">51085253</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i466ef04c404e4ac6a59e26ee7fd0c3cf_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjk4M2M0NGFhMTU2YjRhMDg4NDg3YjMyMDJmZTM1YmU5L3RhYmxlcmFuZ2U6OTgzYzQ0YWExNTZiNGEwODg0ODdiMzIwMmZlMzViZTlfMy0xLTEtMS0w_827c0712-d898-4e40-bd25-234ee4400bed"
      unitRef="shares">219850</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i466ef04c404e4ac6a59e26ee7fd0c3cf_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjk4M2M0NGFhMTU2YjRhMDg4NDg3YjMyMDJmZTM1YmU5L3RhYmxlcmFuZ2U6OTgzYzQ0YWExNTZiNGEwODg0ODdiMzIwMmZlMzViZTlfMy0zLTEtMS0w_0b907adb-9c1f-4c82-80ef-b00f6f80f36b"
      unitRef="usd">264574</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="iab72c368dd2d4ce9a791ab677393c6a5_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjk4M2M0NGFhMTU2YjRhMDg4NDg3YjMyMDJmZTM1YmU5L3RhYmxlcmFuZ2U6OTgzYzQ0YWExNTZiNGEwODg0ODdiMzIwMmZlMzViZTlfMy05LTEtMS0w_b5f3e386-b298-4839-b7ad-853bc8f0768c"
      unitRef="usd">264574</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i466ef04c404e4ac6a59e26ee7fd0c3cf_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjk4M2M0NGFhMTU2YjRhMDg4NDg3YjMyMDJmZTM1YmU5L3RhYmxlcmFuZ2U6OTgzYzQ0YWExNTZiNGEwODg0ODdiMzIwMmZlMzViZTlfNC0xLTEtMS0w_74482229-ae44-4c9f-90a8-b9768c47de10"
      unitRef="shares">164866</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i466ef04c404e4ac6a59e26ee7fd0c3cf_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjk4M2M0NGFhMTU2YjRhMDg4NDg3YjMyMDJmZTM1YmU5L3RhYmxlcmFuZ2U6OTgzYzQ0YWExNTZiNGEwODg0ODdiMzIwMmZlMzViZTlfNC0zLTEtMS0w_521bb0a2-fa17-4ec1-a900-1fd01b086225"
      unitRef="usd">441624</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="iab72c368dd2d4ce9a791ab677393c6a5_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjk4M2M0NGFhMTU2YjRhMDg4NDg3YjMyMDJmZTM1YmU5L3RhYmxlcmFuZ2U6OTgzYzQ0YWExNTZiNGEwODg0ODdiMzIwMmZlMzViZTlfNC05LTEtMS0w_b6e85ecf-32d5-4d7f-88dd-7ef4cafb9ab3"
      unitRef="usd">441624</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:ProfitLoss
      contextRef="if884adb91afc4270896a5966ea47d7aa_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjk4M2M0NGFhMTU2YjRhMDg4NDg3YjMyMDJmZTM1YmU5L3RhYmxlcmFuZ2U6OTgzYzQ0YWExNTZiNGEwODg0ODdiMzIwMmZlMzViZTlfNS01LTEtMS0w_826b5d16-43a0-4c51-bade-b304659278ed"
      unitRef="usd">-1055620</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="iba53f6b880994dffa4c65f2e2602560a_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjk4M2M0NGFhMTU2YjRhMDg4NDg3YjMyMDJmZTM1YmU5L3RhYmxlcmFuZ2U6OTgzYzQ0YWExNTZiNGEwODg0ODdiMzIwMmZlMzViZTlfNS03LTEtMS0w_8b6e0df7-cc20-498b-975a-f5eed4a4df5c"
      unitRef="usd">-9525</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="iab72c368dd2d4ce9a791ab677393c6a5_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjk4M2M0NGFhMTU2YjRhMDg4NDg3YjMyMDJmZTM1YmU5L3RhYmxlcmFuZ2U6OTgzYzQ0YWExNTZiNGEwODg0ODdiMzIwMmZlMzViZTlfNS05LTEtMS0w_bc5dc888-2b66-4c59-915e-ae20b2925f81"
      unitRef="usd">-1065145</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ifcedca0bf3ff4536974d961a488fc053_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjk4M2M0NGFhMTU2YjRhMDg4NDg3YjMyMDJmZTM1YmU5L3RhYmxlcmFuZ2U6OTgzYzQ0YWExNTZiNGEwODg0ODdiMzIwMmZlMzViZTlfNi0xLTEtMS0w_abd03d34-1937-4945-abe0-709dee247ed1"
      unitRef="shares">15318539</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifcedca0bf3ff4536974d961a488fc053_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjk4M2M0NGFhMTU2YjRhMDg4NDg3YjMyMDJmZTM1YmU5L3RhYmxlcmFuZ2U6OTgzYzQ0YWExNTZiNGEwODg0ODdiMzIwMmZlMzViZTlfNi0zLTEtMS0w_f65a66ed-74d9-48ab-a465-4ae4befd97a0"
      unitRef="usd">49737428</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1e77b9f22c1042519f6f27f64401d843_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjk4M2M0NGFhMTU2YjRhMDg4NDg3YjMyMDJmZTM1YmU5L3RhYmxlcmFuZ2U6OTgzYzQ0YWExNTZiNGEwODg0ODdiMzIwMmZlMzViZTlfNi01LTEtMS0w_a5a5d4fd-2c95-41a7-bef0-6149239fb8b7"
      unitRef="usd">152775</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifb9ba2c0e442481695058478aea8e7d6_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjk4M2M0NGFhMTU2YjRhMDg4NDg3YjMyMDJmZTM1YmU5L3RhYmxlcmFuZ2U6OTgzYzQ0YWExNTZiNGEwODg0ODdiMzIwMmZlMzViZTlfNi03LTEtMS0w_c80360b2-64f8-41ce-b571-f3a91fb2b38b"
      unitRef="usd">-47145</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic49b798ae420415688228a42789077ba_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjk4M2M0NGFhMTU2YjRhMDg4NDg3YjMyMDJmZTM1YmU5L3RhYmxlcmFuZ2U6OTgzYzQ0YWExNTZiNGEwODg0ODdiMzIwMmZlMzViZTlfNi05LTEtMS0w_625fd4e3-ff6a-4d3a-ba6d-267b907b6dbc"
      unitRef="usd">49843058</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ifcedca0bf3ff4536974d961a488fc053_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjc2YmIwODkwZjljMzQyNmZiNTNhZDRiMDM2MWU3ZjljL3RhYmxlcmFuZ2U6NzZiYjA4OTBmOWMzNDI2ZmI1M2FkNGIwMzYxZTdmOWNfMS0xLTEtMS0w_66cb66b5-ef64-4341-90cf-1a4c722e6e7b"
      unitRef="shares">15318539</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifcedca0bf3ff4536974d961a488fc053_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjc2YmIwODkwZjljMzQyNmZiNTNhZDRiMDM2MWU3ZjljL3RhYmxlcmFuZ2U6NzZiYjA4OTBmOWMzNDI2ZmI1M2FkNGIwMzYxZTdmOWNfMS0zLTEtMS0w_12db626e-c3f0-4b99-a4ac-8a029ecc2a8e"
      unitRef="usd">49737428</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1e77b9f22c1042519f6f27f64401d843_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjc2YmIwODkwZjljMzQyNmZiNTNhZDRiMDM2MWU3ZjljL3RhYmxlcmFuZ2U6NzZiYjA4OTBmOWMzNDI2ZmI1M2FkNGIwMzYxZTdmOWNfMS01LTEtMS0w_e2b75297-7af8-4f25-8674-aa970ee9911d"
      unitRef="usd">152775</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifb9ba2c0e442481695058478aea8e7d6_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjc2YmIwODkwZjljMzQyNmZiNTNhZDRiMDM2MWU3ZjljL3RhYmxlcmFuZ2U6NzZiYjA4OTBmOWMzNDI2ZmI1M2FkNGIwMzYxZTdmOWNfMS03LTEtMS0w_121cbf8b-3f23-4ca2-8405-340d3dac9eb9"
      unitRef="usd">-47145</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic49b798ae420415688228a42789077ba_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjc2YmIwODkwZjljMzQyNmZiNTNhZDRiMDM2MWU3ZjljL3RhYmxlcmFuZ2U6NzZiYjA4OTBmOWMzNDI2ZmI1M2FkNGIwMzYxZTdmOWNfMS05LTEtMS0w_f0938152-59b4-474c-90ae-ce59b21a4fa5"
      unitRef="usd">49843058</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i8a150324b9d0427e89459a576fa87284_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjc2YmIwODkwZjljMzQyNmZiNTNhZDRiMDM2MWU3ZjljL3RhYmxlcmFuZ2U6NzZiYjA4OTBmOWMzNDI2ZmI1M2FkNGIwMzYxZTdmOWNfMi0xLTEtMS0w_7170b2f8-c5c6-49f4-b9b5-d823978aaa6d"
      unitRef="shares">4200</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i8a150324b9d0427e89459a576fa87284_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjc2YmIwODkwZjljMzQyNmZiNTNhZDRiMDM2MWU3ZjljL3RhYmxlcmFuZ2U6NzZiYjA4OTBmOWMzNDI2ZmI1M2FkNGIwMzYxZTdmOWNfMi0zLTEtMS0w_f3602cbb-05c5-4594-8808-18b9044921f5"
      unitRef="usd">278349</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjc2YmIwODkwZjljMzQyNmZiNTNhZDRiMDM2MWU3ZjljL3RhYmxlcmFuZ2U6NzZiYjA4OTBmOWMzNDI2ZmI1M2FkNGIwMzYxZTdmOWNfMi05LTEtMS0w_9ee71383-af42-4753-a1ab-f3030cefbdd4"
      unitRef="usd">278349</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i8a150324b9d0427e89459a576fa87284_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjc2YmIwODkwZjljMzQyNmZiNTNhZDRiMDM2MWU3ZjljL3RhYmxlcmFuZ2U6NzZiYjA4OTBmOWMzNDI2ZmI1M2FkNGIwMzYxZTdmOWNfNC0xLTEtMS0w_442fb05c-6e76-4c58-a86d-61829041b538"
      unitRef="shares">141463</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i8a150324b9d0427e89459a576fa87284_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjc2YmIwODkwZjljMzQyNmZiNTNhZDRiMDM2MWU3ZjljL3RhYmxlcmFuZ2U6NzZiYjA4OTBmOWMzNDI2ZmI1M2FkNGIwMzYxZTdmOWNfNC0zLTEtMS0w_f5e8212d-a078-4f53-8c5c-08a568b57b13"
      unitRef="usd">769648</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjc2YmIwODkwZjljMzQyNmZiNTNhZDRiMDM2MWU3ZjljL3RhYmxlcmFuZ2U6NzZiYjA4OTBmOWMzNDI2ZmI1M2FkNGIwMzYxZTdmOWNfNC05LTEtMS0w_6cdf6310-57ea-4a6f-a9c7-b03e68ca8290"
      unitRef="usd">769648</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:ProfitLoss
      contextRef="i4067952523e04c2eb44fce178eac9c45_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjc2YmIwODkwZjljMzQyNmZiNTNhZDRiMDM2MWU3ZjljL3RhYmxlcmFuZ2U6NzZiYjA4OTBmOWMzNDI2ZmI1M2FkNGIwMzYxZTdmOWNfNS01LTEtMS0w_023fd88b-feca-442b-b200-f7b22871aa84"
      unitRef="usd">-918275</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i58fc83ab5ccd43ce857e2367d7e167ac_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjc2YmIwODkwZjljMzQyNmZiNTNhZDRiMDM2MWU3ZjljL3RhYmxlcmFuZ2U6NzZiYjA4OTBmOWMzNDI2ZmI1M2FkNGIwMzYxZTdmOWNfNS03LTEtMS0w_5abf9643-4af2-48dc-a619-f36e56eb1bf1"
      unitRef="usd">-22314</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjc2YmIwODkwZjljMzQyNmZiNTNhZDRiMDM2MWU3ZjljL3RhYmxlcmFuZ2U6NzZiYjA4OTBmOWMzNDI2ZmI1M2FkNGIwMzYxZTdmOWNfNS05LTEtMS0w_73c2a219-2836-401d-9cf4-47d000a77b58"
      unitRef="usd">-940589</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i757638cd1ac54400a7212a39551700fa_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjc2YmIwODkwZjljMzQyNmZiNTNhZDRiMDM2MWU3ZjljL3RhYmxlcmFuZ2U6NzZiYjA4OTBmOWMzNDI2ZmI1M2FkNGIwMzYxZTdmOWNfNi0xLTEtMS0w_f3ab345e-5f40-4444-83c2-d8b57db302bf"
      unitRef="shares">15181276</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i757638cd1ac54400a7212a39551700fa_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjc2YmIwODkwZjljMzQyNmZiNTNhZDRiMDM2MWU3ZjljL3RhYmxlcmFuZ2U6NzZiYjA4OTBmOWMzNDI2ZmI1M2FkNGIwMzYxZTdmOWNfNi0zLTEtMS0w_c0923a71-b604-4100-b6b6-9d2aaa93efa4"
      unitRef="usd">49246129</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic2543a120857490e9cdf7ff91a0a636a_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjc2YmIwODkwZjljMzQyNmZiNTNhZDRiMDM2MWU3ZjljL3RhYmxlcmFuZ2U6NzZiYjA4OTBmOWMzNDI2ZmI1M2FkNGIwMzYxZTdmOWNfNi01LTEtMS0w_758c169e-56e7-4677-b4db-b97a3fda4851"
      unitRef="usd">-765500</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1721669d68794a37916477190e8866d2_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjc2YmIwODkwZjljMzQyNmZiNTNhZDRiMDM2MWU3ZjljL3RhYmxlcmFuZ2U6NzZiYjA4OTBmOWMzNDI2ZmI1M2FkNGIwMzYxZTdmOWNfNi03LTEtMS0w_b9c659a8-22bd-47f5-aa3c-e7fed5df9373"
      unitRef="usd">-69459</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4860200ab8134ae18446101822694027_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjc2YmIwODkwZjljMzQyNmZiNTNhZDRiMDM2MWU3ZjljL3RhYmxlcmFuZ2U6NzZiYjA4OTBmOWMzNDI2ZmI1M2FkNGIwMzYxZTdmOWNfNi05LTEtMS0w_956f9628-ea97-4656-a0a5-c418e9071a40"
      unitRef="usd">48411170</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i851f7a722da048d59591d314f36aabc7_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjMwMmY0NmFlODQ2YzQ5MjFhYTQ1Y2JmMGRkY2E1YWU1L3RhYmxlcmFuZ2U6MzAyZjQ2YWU4NDZjNDkyMWFhNDVjYmYwZGRjYTVhZTVfMi0xLTEtMS0w_d3f27e6d-fb00-4d5e-ab87-1bd63e59f113"
      unitRef="shares">14988429</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i851f7a722da048d59591d314f36aabc7_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjMwMmY0NmFlODQ2YzQ5MjFhYTQ1Y2JmMGRkY2E1YWU1L3RhYmxlcmFuZ2U6MzAyZjQ2YWU4NDZjNDkyMWFhNDVjYmYwZGRjYTVhZTVfMi0zLTEtMS0w_2ed1e463-c97b-4820-984f-9cfef0433fdc"
      unitRef="usd">49121523</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia9f59f7e0e644c3e9406612323559f4b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjMwMmY0NmFlODQ2YzQ5MjFhYTQ1Y2JmMGRkY2E1YWU1L3RhYmxlcmFuZ2U6MzAyZjQ2YWU4NDZjNDkyMWFhNDVjYmYwZGRjYTVhZTVfMi01LTEtMS0w_2a697983-f4e2-4de3-ad3f-3cc704a99831"
      unitRef="usd">-2131013</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4a6e35b8c49547efba40d6119ccf44be_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjMwMmY0NmFlODQ2YzQ5MjFhYTQ1Y2JmMGRkY2E1YWU1L3RhYmxlcmFuZ2U6MzAyZjQ2YWU4NDZjNDkyMWFhNDVjYmYwZGRjYTVhZTVfMi03LTEtMS0w_36d7c36a-bf88-4232-847c-f683065e2e54"
      unitRef="usd">-117116</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjMwMmY0NmFlODQ2YzQ5MjFhYTQ1Y2JmMGRkY2E1YWU1L3RhYmxlcmFuZ2U6MzAyZjQ2YWU4NDZjNDkyMWFhNDVjYmYwZGRjYTVhZTVfMi05LTEtMS0w_36ce383f-ba95-462c-a37e-11bb80fd6675"
      unitRef="usd">46873394</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="id451c947a6d945de824fde928e9539b8_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjMwMmY0NmFlODQ2YzQ5MjFhYTQ1Y2JmMGRkY2E1YWU1L3RhYmxlcmFuZ2U6MzAyZjQ2YWU4NDZjNDkyMWFhNDVjYmYwZGRjYTVhZTVfMy0xLTEtMS0w_294b783b-962a-4f2a-b5eb-6c2a6b491511"
      unitRef="shares">187759</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="id451c947a6d945de824fde928e9539b8_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjMwMmY0NmFlODQ2YzQ5MjFhYTQ1Y2JmMGRkY2E1YWU1L3RhYmxlcmFuZ2U6MzAyZjQ2YWU4NDZjNDkyMWFhNDVjYmYwZGRjYTVhZTVfMy0zLTEtMS0w_bb58027f-a3aa-46bb-a471-8d21146d271d"
      unitRef="usd">162960</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i8613f3fef30a4cf99a52244890006824_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjMwMmY0NmFlODQ2YzQ5MjFhYTQ1Y2JmMGRkY2E1YWU1L3RhYmxlcmFuZ2U6MzAyZjQ2YWU4NDZjNDkyMWFhNDVjYmYwZGRjYTVhZTVfMy05LTEtMS0w_f3d3d0ed-9ba5-4139-a2a2-a058530c29bc"
      unitRef="usd">162960</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="id451c947a6d945de824fde928e9539b8_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjMwMmY0NmFlODQ2YzQ5MjFhYTQ1Y2JmMGRkY2E1YWU1L3RhYmxlcmFuZ2U6MzAyZjQ2YWU4NDZjNDkyMWFhNDVjYmYwZGRjYTVhZTVfNC0xLTEtMS0w_846ea41b-34ee-4ece-a81c-ac6b4eb5d70f"
      unitRef="shares">91724</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="id451c947a6d945de824fde928e9539b8_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjMwMmY0NmFlODQ2YzQ5MjFhYTQ1Y2JmMGRkY2E1YWU1L3RhYmxlcmFuZ2U6MzAyZjQ2YWU4NDZjNDkyMWFhNDVjYmYwZGRjYTVhZTVfNC0zLTEtMS0w_3cf49f0a-7e96-4d9b-94cb-eb85b0761db7"
      unitRef="usd">303088</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i8613f3fef30a4cf99a52244890006824_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjMwMmY0NmFlODQ2YzQ5MjFhYTQ1Y2JmMGRkY2E1YWU1L3RhYmxlcmFuZ2U6MzAyZjQ2YWU4NDZjNDkyMWFhNDVjYmYwZGRjYTVhZTVfNC05LTEtMS0w_3d8670d2-a7c4-4062-b2a1-5f7f5daabb55"
      unitRef="usd">303088</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:ProfitLoss
      contextRef="i6b5aa580bb2d4a5f8f2914acb615a1e1_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjMwMmY0NmFlODQ2YzQ5MjFhYTQ1Y2JmMGRkY2E1YWU1L3RhYmxlcmFuZ2U6MzAyZjQ2YWU4NDZjNDkyMWFhNDVjYmYwZGRjYTVhZTVfNS01LTEtMS0w_b2fa6259-c128-4817-9bb8-3c1106904c9b"
      unitRef="usd">166828</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i46f84339676244a68c635efc3276aab8_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjMwMmY0NmFlODQ2YzQ5MjFhYTQ1Y2JmMGRkY2E1YWU1L3RhYmxlcmFuZ2U6MzAyZjQ2YWU4NDZjNDkyMWFhNDVjYmYwZGRjYTVhZTVfNS03LTEtMS0w_14bcb590-1b8b-4277-aacc-26fc485bff58"
      unitRef="usd">-22167</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i8613f3fef30a4cf99a52244890006824_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjMwMmY0NmFlODQ2YzQ5MjFhYTQ1Y2JmMGRkY2E1YWU1L3RhYmxlcmFuZ2U6MzAyZjQ2YWU4NDZjNDkyMWFhNDVjYmYwZGRjYTVhZTVfNS05LTEtMS0w_c399b7fe-50fa-48e4-b52b-58736b55aa86"
      unitRef="usd">144661</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic2444510ac2f491e93494d3efc1d3f10_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjMwMmY0NmFlODQ2YzQ5MjFhYTQ1Y2JmMGRkY2E1YWU1L3RhYmxlcmFuZ2U6MzAyZjQ2YWU4NDZjNDkyMWFhNDVjYmYwZGRjYTVhZTVfNi0xLTEtMS0w_d79ca5b2-82e2-49e6-bb28-4f43b8c65899"
      unitRef="shares">15084464</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic2444510ac2f491e93494d3efc1d3f10_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjMwMmY0NmFlODQ2YzQ5MjFhYTQ1Y2JmMGRkY2E1YWU1L3RhYmxlcmFuZ2U6MzAyZjQ2YWU4NDZjNDkyMWFhNDVjYmYwZGRjYTVhZTVfNi0zLTEtMS0w_89e1f86c-a5f3-4439-827e-de11e4d28ac6"
      unitRef="usd">48981395</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6bfadd4b687f465caceadefb291b8a5a_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjMwMmY0NmFlODQ2YzQ5MjFhYTQ1Y2JmMGRkY2E1YWU1L3RhYmxlcmFuZ2U6MzAyZjQ2YWU4NDZjNDkyMWFhNDVjYmYwZGRjYTVhZTVfNi01LTEtMS0w_702e9a7c-0adf-49e3-a03e-e0bfc69451eb"
      unitRef="usd">-1964185</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i236298ea92174d4481784e6bae4c0605_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjMwMmY0NmFlODQ2YzQ5MjFhYTQ1Y2JmMGRkY2E1YWU1L3RhYmxlcmFuZ2U6MzAyZjQ2YWU4NDZjNDkyMWFhNDVjYmYwZGRjYTVhZTVfNi03LTEtMS0w_d337694f-5c8e-4a86-aefe-2ab839583084"
      unitRef="usd">-139283</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i759d312796b74964bece38516542bb38_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjMwMmY0NmFlODQ2YzQ5MjFhYTQ1Y2JmMGRkY2E1YWU1L3RhYmxlcmFuZ2U6MzAyZjQ2YWU4NDZjNDkyMWFhNDVjYmYwZGRjYTVhZTVfNi05LTEtMS0w_af12deae-840d-4f63-a7ed-b0510a72b054"
      unitRef="usd">46877927</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic2444510ac2f491e93494d3efc1d3f10_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjI1ZWZiZDVhOWQ4ZDRjNmE4YjNhNjhkOTI5YjViNWYzL3RhYmxlcmFuZ2U6MjVlZmJkNWE5ZDhkNGM2YThiM2E2OGQ5MjliNWI1ZjNfMS0xLTEtMS0w_d79ca5b2-82e2-49e6-bb28-4f43b8c65899"
      unitRef="shares">15084464</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic2444510ac2f491e93494d3efc1d3f10_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjI1ZWZiZDVhOWQ4ZDRjNmE4YjNhNjhkOTI5YjViNWYzL3RhYmxlcmFuZ2U6MjVlZmJkNWE5ZDhkNGM2YThiM2E2OGQ5MjliNWI1ZjNfMS0zLTEtMS0w_89e1f86c-a5f3-4439-827e-de11e4d28ac6"
      unitRef="usd">48981395</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6bfadd4b687f465caceadefb291b8a5a_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjI1ZWZiZDVhOWQ4ZDRjNmE4YjNhNjhkOTI5YjViNWYzL3RhYmxlcmFuZ2U6MjVlZmJkNWE5ZDhkNGM2YThiM2E2OGQ5MjliNWI1ZjNfMS01LTEtMS0w_702e9a7c-0adf-49e3-a03e-e0bfc69451eb"
      unitRef="usd">-1964185</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i236298ea92174d4481784e6bae4c0605_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjI1ZWZiZDVhOWQ4ZDRjNmE4YjNhNjhkOTI5YjViNWYzL3RhYmxlcmFuZ2U6MjVlZmJkNWE5ZDhkNGM2YThiM2E2OGQ5MjliNWI1ZjNfMS03LTEtMS0w_d337694f-5c8e-4a86-aefe-2ab839583084"
      unitRef="usd">-139283</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i759d312796b74964bece38516542bb38_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjI1ZWZiZDVhOWQ4ZDRjNmE4YjNhNjhkOTI5YjViNWYzL3RhYmxlcmFuZ2U6MjVlZmJkNWE5ZDhkNGM2YThiM2E2OGQ5MjliNWI1ZjNfMS05LTEtMS0w_af12deae-840d-4f63-a7ed-b0510a72b054"
      unitRef="usd">46877927</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i9737d5fe1a1a4b64a348bd61bcd44e8b_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjI1ZWZiZDVhOWQ4ZDRjNmE4YjNhNjhkOTI5YjViNWYzL3RhYmxlcmFuZ2U6MjVlZmJkNWE5ZDhkNGM2YThiM2E2OGQ5MjliNWI1ZjNfMi0zLTEtMS0w_efccb2d6-b872-4cb6-a15b-a562ff5809b6"
      unitRef="usd">191954</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjI1ZWZiZDVhOWQ4ZDRjNmE4YjNhNjhkOTI5YjViNWYzL3RhYmxlcmFuZ2U6MjVlZmJkNWE5ZDhkNGM2YThiM2E2OGQ5MjliNWI1ZjNfMi05LTEtMS0w_a2fb7dc2-4286-475c-9652-e87bb150d831"
      unitRef="usd">191954</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i9737d5fe1a1a4b64a348bd61bcd44e8b_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjI1ZWZiZDVhOWQ4ZDRjNmE4YjNhNjhkOTI5YjViNWYzL3RhYmxlcmFuZ2U6MjVlZmJkNWE5ZDhkNGM2YThiM2E2OGQ5MjliNWI1ZjNfMy0xLTEtMS0w_c7669d4c-e0b5-48fe-b2ae-84925cd1cbe5"
      unitRef="shares">158405</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i9737d5fe1a1a4b64a348bd61bcd44e8b_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjI1ZWZiZDVhOWQ4ZDRjNmE4YjNhNjhkOTI5YjViNWYzL3RhYmxlcmFuZ2U6MjVlZmJkNWE5ZDhkNGM2YThiM2E2OGQ5MjliNWI1ZjNfMy0zLTEtMS0w_f15af3c3-c051-4948-9785-3ec1b56f9889"
      unitRef="usd">484965</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjI1ZWZiZDVhOWQ4ZDRjNmE4YjNhNjhkOTI5YjViNWYzL3RhYmxlcmFuZ2U6MjVlZmJkNWE5ZDhkNGM2YThiM2E2OGQ5MjliNWI1ZjNfMy05LTEtMS0w_202d18a3-594f-485c-9759-a34bd8b0dc0b"
      unitRef="usd">484965</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:ProfitLoss
      contextRef="i625473b616364e838b15588a276d254c_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjI1ZWZiZDVhOWQ4ZDRjNmE4YjNhNjhkOTI5YjViNWYzL3RhYmxlcmFuZ2U6MjVlZmJkNWE5ZDhkNGM2YThiM2E2OGQ5MjliNWI1ZjNfNC01LTEtMS0w_6ce42412-e3fe-46e8-885f-ca9f524e15de"
      unitRef="usd">1228560</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="if4378e699a13493b8e84114b0815eeb1_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjI1ZWZiZDVhOWQ4ZDRjNmE4YjNhNjhkOTI5YjViNWYzL3RhYmxlcmFuZ2U6MjVlZmJkNWE5ZDhkNGM2YThiM2E2OGQ5MjliNWI1ZjNfNC03LTEtMS0w_d3034095-4741-4f18-8158-0ab8f17ef52d"
      unitRef="usd">-5069</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjI1ZWZiZDVhOWQ4ZDRjNmE4YjNhNjhkOTI5YjViNWYzL3RhYmxlcmFuZ2U6MjVlZmJkNWE5ZDhkNGM2YThiM2E2OGQ5MjliNWI1ZjNfNC05LTEtMS0w_1ee195d7-afa7-4d9b-8c99-6376ac4d999d"
      unitRef="usd">1223491</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ie2772008cf324e93b9ddec0ec4490b6e_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjI1ZWZiZDVhOWQ4ZDRjNmE4YjNhNjhkOTI5YjViNWYzL3RhYmxlcmFuZ2U6MjVlZmJkNWE5ZDhkNGM2YThiM2E2OGQ5MjliNWI1ZjNfNS0xLTEtMS0w_b4d14566-8c4b-4bed-930d-3dcf8562bae2"
      unitRef="shares">14926059</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie2772008cf324e93b9ddec0ec4490b6e_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjI1ZWZiZDVhOWQ4ZDRjNmE4YjNhNjhkOTI5YjViNWYzL3RhYmxlcmFuZ2U6MjVlZmJkNWE5ZDhkNGM2YThiM2E2OGQ5MjliNWI1ZjNfNS0zLTEtMS0w_41be566a-3f40-4262-8ca2-60c6b2c7ec41"
      unitRef="usd">48688384</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8b884d549e1f475999a61e98b2694ba2_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjI1ZWZiZDVhOWQ4ZDRjNmE4YjNhNjhkOTI5YjViNWYzL3RhYmxlcmFuZ2U6MjVlZmJkNWE5ZDhkNGM2YThiM2E2OGQ5MjliNWI1ZjNfNS01LTEtMS0w_32760054-18bc-41e5-8d47-3276db4df161"
      unitRef="usd">-735625</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9809a8bcb7eb490aa76cb00858c80e7c_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjI1ZWZiZDVhOWQ4ZDRjNmE4YjNhNjhkOTI5YjViNWYzL3RhYmxlcmFuZ2U6MjVlZmJkNWE5ZDhkNGM2YThiM2E2OGQ5MjliNWI1ZjNfNS03LTEtMS0w_e672b0f0-8f27-4af0-9e4a-414224e492ac"
      unitRef="usd">-144352</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18yNS9mcmFnOmYxNDNlOTFjN2ZiYjQ1ZDVhYzVkYmU0ZTlkNzJhN2ExL3RhYmxlOjI1ZWZiZDVhOWQ4ZDRjNmE4YjNhNjhkOTI5YjViNWYzL3RhYmxlcmFuZ2U6MjVlZmJkNWE5ZDhkNGM2YThiM2E2OGQ5MjliNWI1ZjNfNS05LTEtMS0w_a364857c-93f4-408c-b2b8-522b1f6c34a3"
      unitRef="usd">47808407</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zMS9mcmFnOjY1MWQ4MjUzMDhmMzRiNGY4Njc2N2U0MjYxMTM1N2YwL3RleHRyZWdpb246NjUxZDgyNTMwOGYzNGI0Zjg2NzY3ZTQyNjExMzU3ZjBfMTAwMjk_f997184d-8ed0-4952-9708-e57b9702b26d">ORGANIZATION AND BASIS OF PRESENTATION&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland Pharmaceuticals Inc. (&#x201c;Cumberland,&#x201d; the &#x201c;Company,&#x201d; or as used in the context of &#x201c;we,&#x201d; &#x201c;us,&#x201d; or &#x201c;our&#x201d;) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products.  The Company's primary target markets are hospital acute care, gastroenterology and rheumatology. These medical specialties are characterized by relatively concentrated prescriber bases that the Company believes can be penetrated effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve quality of care for patients and address unmet or poorly met medical needs.  The Company promotes its approved products through its hospital and field sales forces in the United States and is establishing a network of international partners to bring its medicines to patients in their countries.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland focuses its resources on maximizing the commercial potential of its products, as well as developing new product candidates, and has both internal development and commercial capabilities. The Company&#x2019;s products are manufactured by third parties, which are overseen by Cumberland&#x2019;s quality control and manufacturing professionals. The Company works closely with its third-party distribution partners to make its products available in the United States.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the opinion of management, the accompanying unaudited condensed consolidated financial statements of the Company have been prepared on a basis consistent with the December 31, 2020, audited consolidated financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly present the information set forth herein. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements have been prepared in accordance with the regulations of the Securities and Exchange Commission (the &#x201c;SEC&#x201d;), and certain information and disclosures have been condensed or omitted as permitted by the SEC for interim period presentation. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December 31, 2020 (the &#x201c;2020 Annual Report on Form 10-K&#x201d;). The results of operations for the three and six months ended June 30, 2021, are not necessarily indicative of the results to be expected for the entire fiscal year or any future period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Discontinued Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed further in Note 9, during May 2019, Cumberland entered into a Dissolution Agreement  ("Dissolution Agreement") with Clinigen Healthcare Limited ("Clinigen") in which the Company returned the exclusive rights to commercialize Ethyol&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and Totect&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the United States to Clinigen. Under the terms of the Dissolution Agreement, Cumberland is no longer involved directly or indirectly with the distribution, marketing and promotion of either Ethyol or Totect or any competing products following December 31, 2019. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's exit from Ethyol and Totect meets the accounting criteria to be reported as discontinued operations and the discontinued operating results have been presented in the financial statements and footnotes to reflect the discontinued status of Ethyol and Totect. Refer to Note 9, for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revision of prior period condensed consolidated statement of cash flows presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has made a revision to prior period amounts to conform to the current year presentation of the cash surrender value of life insurance policies over premiums paid on the condensed consolidated statement of cash flows.  The revised amounts were previously included as net changes in assets affecting operating activities.  These revisions have no net effect on the reported net cash provided by operating activities nor any impact on the reported operating results or balance sheet for the 2020 period presented.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;COVID-19 Pandemic &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the U.S. declared a health care emergency following the outbreak of the SARS-CoV-2, a novel strain of coronavirus that causes COVID-19, a respiratory illness.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland has remained open for business, as the Company is considered to be essential by the United States Department of Homeland Security. The Company has implemented measures to address the impact of the novel coronavirus on the business and taken appropriate action to protect its employees, secure the supply chain, and support the patients who can benefit from its medicines.  All of the Company's employees have been given the opportunity to work remotely, and those that wish to work from Cumberland's office and laboratories are encouraged to practice the behaviors outlined by the Centers for Disease Control.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Throughout the pandemic, Cumberland has faced the same headwinds affecting other companies that rely on hospital admissions and patient visits to drive revenue.  Our business and our clinical studies were impacted as less patients sought elective surgeries and our access to medical facilities was substantially limited.  During 2020 and 2021, we carefully monitored our supply chain during the pandemic including the flow of raw materials into the plants that manufacture our products as well as the batches of finished product emerging from those facilities. Several of our brands were negatively impacted by the lockdowns and postponement of physician office visits and elective procedures. However, we are fortunate to have a diversified product portfolio, with other brands delivering a strong performance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland relies on third-party organizations around the world to supply components, manufacture and distribute its products. The Company is aware that it may experience revenue loss, supply interruptions, time delays and incur unplanned expenses as a result of the impact of the ongoing COVID-19 pandemic.   The Company continues to monitor the COVID-19 pandemic situation both in the U.S. and internationally in order to maintain its employees&#x2019; safety and well-being, while also keeping its business operating.  Given the uncertainty, magnitude and impact of such changes, the Company is unable to quantify the impact on the future results as of the date of this filing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Guidance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements - Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board ("FASB") issued ASU No. 2016-13, &#x201c;Financial Instruments-Credit Losses,&#x201d; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#x201c;expected loss&#x201d; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose additional information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the ASU&#x2019;s provisions as a cumulative-effect adjustment, if any, to retained earnings as of the beginning of the first reporting period in which the guidance is adopted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Related to ASU No. 2016-13 discussed above, in May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably elect the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met and the election must be applied on an instrument-by-instrument basis. The election is not available for either available-for-sale or held-to-maturity debt securities. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company will adopt both ASU 2016-13 and ASU 2019-05 on January 1, 2023. The adoption of ASU 2016-13 and ASU 2019-05 are not expected to have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting Policies:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates under different assumptions and conditions.  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns, (2) the allowances for obsolescent or unmarketable inventory and (3) valuation of a contingent consideration liability associated with a business combination.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Operating Segments&lt;/span&gt;&lt;/div&gt;The Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#x2019;s assets are located in the United States and total revenues are primarily attributable to U.S.&#160;customers.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zMS9mcmFnOjY1MWQ4MjUzMDhmMzRiNGY4Njc2N2U0MjYxMTM1N2YwL3RleHRyZWdpb246NjUxZDgyNTMwOGYzNGI0Zjg2NzY3ZTQyNjExMzU3ZjBfMTAwMzI_1d494f0f-a948-4e60-b352-faa6463f2879">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Guidance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements - Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board ("FASB") issued ASU No. 2016-13, &#x201c;Financial Instruments-Credit Losses,&#x201d; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#x201c;expected loss&#x201d; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose additional information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the ASU&#x2019;s provisions as a cumulative-effect adjustment, if any, to retained earnings as of the beginning of the first reporting period in which the guidance is adopted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Related to ASU No. 2016-13 discussed above, in May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably elect the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met and the election must be applied on an instrument-by-instrument basis. The election is not available for either available-for-sale or held-to-maturity debt securities. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company will adopt both ASU 2016-13 and ASU 2019-05 on January 1, 2023. The adoption of ASU 2016-13 and ASU 2019-05 are not expected to have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zMS9mcmFnOjY1MWQ4MjUzMDhmMzRiNGY4Njc2N2U0MjYxMTM1N2YwL3RleHRyZWdpb246NjUxZDgyNTMwOGYzNGI0Zjg2NzY3ZTQyNjExMzU3ZjBfMTAwMjU_2a30d72e-1f6b-4ae1-b899-96926ec8aca0">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates under different assumptions and conditions.  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns, (2) the allowances for obsolescent or unmarketable inventory and (3) valuation of a contingent consideration liability associated with a business combination.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zMS9mcmFnOjY1MWQ4MjUzMDhmMzRiNGY4Njc2N2U0MjYxMTM1N2YwL3RleHRyZWdpb246NjUxZDgyNTMwOGYzNGI0Zjg2NzY3ZTQyNjExMzU3ZjBfMTAwMjg_e7d7cf66-94c8-4929-af5c-2534db8c10fc">Operating SegmentsThe Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#x2019;s assets are located in the United States and total revenues are primarily attributable to U.S.&#160;customers.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zMS9mcmFnOjY1MWQ4MjUzMDhmMzRiNGY4Njc2N2U0MjYxMTM1N2YwL3RleHRyZWdpb246NjUxZDgyNTMwOGYzNGI0Zjg2NzY3ZTQyNjExMzU3ZjBfOTIxOQ_1cfac7b6-9dc8-4721-b576-99c71896f153"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RleHRyZWdpb246Yzg3MDM5YjJjZDE2NGFhMDhhNDYxMjg1MDI2YjIyMDZfNDE1_b0e1a26a-86b0-4a53-9bc6-12f8b07b95ac">EARNINGS (LOSS) PER SHARE&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles the numerator and denominator used to calculate diluted earnings (loss) per share for the three and six months ended June 30, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;724,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,679,211)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;738,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,223,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(940,589)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (income) loss at subsidiary attributable to noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,228,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(918,275)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,976,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,241,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,109,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,241,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,562,629)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;994,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,556,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,368,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,005,734)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) at subsidiary attributable to noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,395,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,973,895)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,970,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,241,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,171,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,241,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June 30, 2021 and 2020, restricted stock awards and options to purchase 198,300 and 13,500 shares of common stock, respectively, were outstanding but were not included in the computation of diluted earnings per share because the effect would be antidilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RleHRyZWdpb246Yzg3MDM5YjJjZDE2NGFhMDhhNDYxMjg1MDI2YjIyMDZfNDE4_ce674444-875f-4353-bd10-25290019cffc">The following table reconciles the numerator and denominator used to calculate diluted earnings (loss) per share for the three and six months ended June 30, 2021 and 2020:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;724,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,679,211)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;738,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,223,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(940,589)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (income) loss at subsidiary attributable to noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,228,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(918,275)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,976,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,241,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,109,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,241,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,562,629)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;994,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,556,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,368,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,005,734)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) at subsidiary attributable to noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,395,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,973,895)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,970,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,241,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,171,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,241,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RhYmxlOjM5Y2E3ZWIwOTM4YTQ1ZjFhNjkxNzgzYWQyOTI0YzFiL3RhYmxlcmFuZ2U6MzljYTdlYjA5MzhhNDVmMWE2OTE3ODNhZDI5MjRjMWJfMy0xLTEtMS0w_761328f0-deef-47f7-9f51-604c18a2e233"
      unitRef="usd">724684</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RhYmxlOjM5Y2E3ZWIwOTM4YTQ1ZjFhNjkxNzgzYWQyOTI0YzFiL3RhYmxlcmFuZ2U6MzljYTdlYjA5MzhhNDVmMWE2OTE3ODNhZDI5MjRjMWJfMy0zLTEtMS0w_d81f4724-54a3-4bf0-afb3-205bc093c40b"
      unitRef="usd">-1679211</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0932967c9c90454494cbf245d9fa585d_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RhYmxlOjM5Y2E3ZWIwOTM4YTQ1ZjFhNjkxNzgzYWQyOTI0YzFiL3RhYmxlcmFuZ2U6MzljYTdlYjA5MzhhNDVmMWE2OTE3ODNhZDI5MjRjMWJfNC0xLTEtMS0w_33139f42-0425-4d08-841a-9ae006c66914"
      unitRef="usd">498807</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iffc2a4291a32445fb79072f7fe43a870_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RhYmxlOjM5Y2E3ZWIwOTM4YTQ1ZjFhNjkxNzgzYWQyOTI0YzFiL3RhYmxlcmFuZ2U6MzljYTdlYjA5MzhhNDVmMWE2OTE3ODNhZDI5MjRjMWJfNC0zLTEtMS0w_cf0ce557-4fdd-47c1-9191-c917bd799f4a"
      unitRef="usd">738622</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ProfitLoss
      contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RhYmxlOjM5Y2E3ZWIwOTM4YTQ1ZjFhNjkxNzgzYWQyOTI0YzFiL3RhYmxlcmFuZ2U6MzljYTdlYjA5MzhhNDVmMWE2OTE3ODNhZDI5MjRjMWJfNS0xLTEtMS0w_1cf241d4-6bf5-4bad-bea5-208a40f95dc7"
      unitRef="usd">1223491</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RhYmxlOjM5Y2E3ZWIwOTM4YTQ1ZjFhNjkxNzgzYWQyOTI0YzFiL3RhYmxlcmFuZ2U6MzljYTdlYjA5MzhhNDVmMWE2OTE3ODNhZDI5MjRjMWJfNS0zLTEtMS0w_f7a6eeb6-48b4-480a-b905-3cdff1cdd39b"
      unitRef="usd">-940589</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RhYmxlOjM5Y2E3ZWIwOTM4YTQ1ZjFhNjkxNzgzYWQyOTI0YzFiL3RhYmxlcmFuZ2U6MzljYTdlYjA5MzhhNDVmMWE2OTE3ODNhZDI5MjRjMWJfNi0xLTEtMS0w_ad9cdbb0-35e4-4783-875f-a33b803b750c"
      unitRef="usd">-5069</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RhYmxlOjM5Y2E3ZWIwOTM4YTQ1ZjFhNjkxNzgzYWQyOTI0YzFiL3RhYmxlcmFuZ2U6MzljYTdlYjA5MzhhNDVmMWE2OTE3ODNhZDI5MjRjMWJfNi0zLTEtMS0w_47af32b2-36dc-48d1-ae83-7216b2cc2889"
      unitRef="usd">-22314</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RhYmxlOjM5Y2E3ZWIwOTM4YTQ1ZjFhNjkxNzgzYWQyOTI0YzFiL3RhYmxlcmFuZ2U6MzljYTdlYjA5MzhhNDVmMWE2OTE3ODNhZDI5MjRjMWJfNy0xLTEtMS0w_b8dfc5cf-c6a5-4f7c-9c61-6a80b153a842"
      unitRef="usd">1228560</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RhYmxlOjM5Y2E3ZWIwOTM4YTQ1ZjFhNjkxNzgzYWQyOTI0YzFiL3RhYmxlcmFuZ2U6MzljYTdlYjA5MzhhNDVmMWE2OTE3ODNhZDI5MjRjMWJfNy0zLTEtMS0w_334f259a-7999-4f1a-857c-595692c065d0"
      unitRef="usd">-918275</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RhYmxlOjM5Y2E3ZWIwOTM4YTQ1ZjFhNjkxNzgzYWQyOTI0YzFiL3RhYmxlcmFuZ2U6MzljYTdlYjA5MzhhNDVmMWE2OTE3ODNhZDI5MjRjMWJfOS0xLTEtMS0w_c2df2a85-063d-4e72-8cc0-f113580e1ac4"
      unitRef="shares">14976034</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RhYmxlOjM5Y2E3ZWIwOTM4YTQ1ZjFhNjkxNzgzYWQyOTI0YzFiL3RhYmxlcmFuZ2U6MzljYTdlYjA5MzhhNDVmMWE2OTE3ODNhZDI5MjRjMWJfOS0zLTEtMS0w_3df73b08-d9bc-4067-b6c3-56fa9ffd698a"
      unitRef="shares">15241463</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RhYmxlOjM5Y2E3ZWIwOTM4YTQ1ZjFhNjkxNzgzYWQyOTI0YzFiL3RhYmxlcmFuZ2U6MzljYTdlYjA5MzhhNDVmMWE2OTE3ODNhZDI5MjRjMWJfMTAtMS0xLTEtMA_7cff8ac9-0ed5-4b11-8e7a-cea2ff1c999d"
      unitRef="shares">133212</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RhYmxlOjM5Y2E3ZWIwOTM4YTQ1ZjFhNjkxNzgzYWQyOTI0YzFiL3RhYmxlcmFuZ2U6MzljYTdlYjA5MzhhNDVmMWE2OTE3ODNhZDI5MjRjMWJfMTAtMy0xLTEtMA_9446fe7b-8c2e-4b10-932d-d37ebd418003"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RhYmxlOjM5Y2E3ZWIwOTM4YTQ1ZjFhNjkxNzgzYWQyOTI0YzFiL3RhYmxlcmFuZ2U6MzljYTdlYjA5MzhhNDVmMWE2OTE3ODNhZDI5MjRjMWJfMTEtMS0xLTEtMA_2cc9f5cb-2fc2-45a0-a213-fabe436ff549"
      unitRef="shares">15109246</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RhYmxlOjM5Y2E3ZWIwOTM4YTQ1ZjFhNjkxNzgzYWQyOTI0YzFiL3RhYmxlcmFuZ2U6MzljYTdlYjA5MzhhNDVmMWE2OTE3ODNhZDI5MjRjMWJfMTEtMy0xLTEtMA_64d8a77f-6e7d-4077-8194-074fafdb8a68"
      unitRef="shares">15241463</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RhYmxlOmMyMzhjNTkyMThkMzQ4NTQ5M2ZlOTU5ZDY2MWNiNjg1L3RhYmxlcmFuZ2U6YzIzOGM1OTIxOGQzNDg1NDkzZmU5NTlkNjYxY2I2ODVfNC0xLTEtMS0w_a63db8bb-8ef8-4664-9c16-a1c90b7c2460"
      unitRef="usd">373935</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RhYmxlOmMyMzhjNTkyMThkMzQ4NTQ5M2ZlOTU5ZDY2MWNiNjg1L3RhYmxlcmFuZ2U6YzIzOGM1OTIxOGQzNDg1NDkzZmU5NTlkNjYxY2I2ODVfNC0zLTEtMS0w_edf48b93-5a80-48fd-b726-5a6b729875c2"
      unitRef="usd">-3562629</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i53d85ca5dcbd44ba870830f97461a800_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RhYmxlOmMyMzhjNTkyMThkMzQ4NTQ5M2ZlOTU5ZDY2MWNiNjg1L3RhYmxlcmFuZ2U6YzIzOGM1OTIxOGQzNDg1NDkzZmU5NTlkNjYxY2I2ODVfNS0xLTEtMS0w_1bcf2509-7467-4c5c-b800-3d442a6bcef9"
      unitRef="usd">994217</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i166678b245754127b39f5e9c73e8cf2d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RhYmxlOmMyMzhjNTkyMThkMzQ4NTQ5M2ZlOTU5ZDY2MWNiNjg1L3RhYmxlcmFuZ2U6YzIzOGM1OTIxOGQzNDg1NDkzZmU5NTlkNjYxY2I2ODVfNS0zLTEtMS0w_72de53a1-48b1-4c79-aa3d-faa22b8da99b"
      unitRef="usd">1556895</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ProfitLoss
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RhYmxlOmMyMzhjNTkyMThkMzQ4NTQ5M2ZlOTU5ZDY2MWNiNjg1L3RhYmxlcmFuZ2U6YzIzOGM1OTIxOGQzNDg1NDkzZmU5NTlkNjYxY2I2ODVfNi0xLTEtMS0xOTEw_6aa1b4ee-aaf7-4bfd-bd7a-dcff090035e3"
      unitRef="usd">1368152</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RhYmxlOmMyMzhjNTkyMThkMzQ4NTQ5M2ZlOTU5ZDY2MWNiNjg1L3RhYmxlcmFuZ2U6YzIzOGM1OTIxOGQzNDg1NDkzZmU5NTlkNjYxY2I2ODVfNi0zLTEtMS0xOTEw_86ca889e-63e3-4465-be34-caf967ed5d0e"
      unitRef="usd">-2005734</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RhYmxlOmMyMzhjNTkyMThkMzQ4NTQ5M2ZlOTU5ZDY2MWNiNjg1L3RhYmxlcmFuZ2U6YzIzOGM1OTIxOGQzNDg1NDkzZmU5NTlkNjYxY2I2ODVfNi0xLTEtMS0w_3132eb79-3ac2-46ef-b108-4ed939312a07"
      unitRef="usd">-27236</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RhYmxlOmMyMzhjNTkyMThkMzQ4NTQ5M2ZlOTU5ZDY2MWNiNjg1L3RhYmxlcmFuZ2U6YzIzOGM1OTIxOGQzNDg1NDkzZmU5NTlkNjYxY2I2ODVfNi0zLTEtMS0w_16452e5d-8d67-4eab-b11e-724dc4efa96b"
      unitRef="usd">-31839</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RhYmxlOmMyMzhjNTkyMThkMzQ4NTQ5M2ZlOTU5ZDY2MWNiNjg1L3RhYmxlcmFuZ2U6YzIzOGM1OTIxOGQzNDg1NDkzZmU5NTlkNjYxY2I2ODVfNy0xLTEtMS0w_c4f19629-5882-4929-89aa-d989770a2c78"
      unitRef="usd">1395388</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RhYmxlOmMyMzhjNTkyMThkMzQ4NTQ5M2ZlOTU5ZDY2MWNiNjg1L3RhYmxlcmFuZ2U6YzIzOGM1OTIxOGQzNDg1NDkzZmU5NTlkNjYxY2I2ODVfNy0zLTEtMS0w_461cc6b8-bca3-4299-be42-5d55162be78f"
      unitRef="usd">-1973895</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RhYmxlOmMyMzhjNTkyMThkMzQ4NTQ5M2ZlOTU5ZDY2MWNiNjg1L3RhYmxlcmFuZ2U6YzIzOGM1OTIxOGQzNDg1NDkzZmU5NTlkNjYxY2I2ODVfOS0xLTEtMS0w_90bf369c-59f5-475e-bb5e-dc29a315c526"
      unitRef="shares">14970241</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RhYmxlOmMyMzhjNTkyMThkMzQ4NTQ5M2ZlOTU5ZDY2MWNiNjg1L3RhYmxlcmFuZ2U6YzIzOGM1OTIxOGQzNDg1NDkzZmU5NTlkNjYxY2I2ODVfOS0zLTEtMS0w_34d5a1e5-220b-41a6-8215-a9b0c1b42040"
      unitRef="shares">15241020</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RhYmxlOmMyMzhjNTkyMThkMzQ4NTQ5M2ZlOTU5ZDY2MWNiNjg1L3RhYmxlcmFuZ2U6YzIzOGM1OTIxOGQzNDg1NDkzZmU5NTlkNjYxY2I2ODVfMTAtMS0xLTEtMA_0166a493-6c22-41f5-a106-006b3518215a"
      unitRef="shares">201348</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RhYmxlOmMyMzhjNTkyMThkMzQ4NTQ5M2ZlOTU5ZDY2MWNiNjg1L3RhYmxlcmFuZ2U6YzIzOGM1OTIxOGQzNDg1NDkzZmU5NTlkNjYxY2I2ODVfMTAtMy0xLTEtMA_678521a4-269b-4b08-b750-3d06bd336ba4"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RhYmxlOmMyMzhjNTkyMThkMzQ4NTQ5M2ZlOTU5ZDY2MWNiNjg1L3RhYmxlcmFuZ2U6YzIzOGM1OTIxOGQzNDg1NDkzZmU5NTlkNjYxY2I2ODVfMTEtMS0xLTEtMA_c14f7212-bbfa-4857-84b0-5aa8c727c9ef"
      unitRef="shares">15171589</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RhYmxlOmMyMzhjNTkyMThkMzQ4NTQ5M2ZlOTU5ZDY2MWNiNjg1L3RhYmxlcmFuZ2U6YzIzOGM1OTIxOGQzNDg1NDkzZmU5NTlkNjYxY2I2ODVfMTEtMy0xLTEtMA_65f2f002-432e-4d27-b6d3-2268b01e4d04"
      unitRef="shares">15241020</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RleHRyZWdpb246Yzg3MDM5YjJjZDE2NGFhMDhhNDYxMjg1MDI2YjIyMDZfMjM4_ca9751be-b0ee-4ce2-9cf0-0899b1802915"
      unitRef="shares">198300</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNC9mcmFnOmM4NzAzOWIyY2QxNjRhYTA4YTQ2MTI4NTAyNmIyMjA2L3RleHRyZWdpb246Yzg3MDM5YjJjZDE2NGFhMDhhNDYxMjg1MDI2YjIyMDZfMjQ1_9c9feaa0-7ef4-48ab-b20a-df0c15335590"
      unitRef="shares">13500</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RleHRyZWdpb246NTEwNDc5MDRkNjM5NDZkMDhhNjJmMTU5OTUyNmVhMTBfMjU2NQ_0f07d3cc-6496-41eb-8b5d-e4b28ad9a2dd">REVENUES&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for revenues from contracts with customers under ASC 606, which became effective January 1, 2018. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s net revenues consisted of the following for the three and six months ended June 30, 2021 and 2020:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Products:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Kristalose&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,275,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,477,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,269,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,771,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vibativ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,844,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,299,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,897,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,721,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Caldolor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;938,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,166,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,477,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,261,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vaprisol&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;399,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,534,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;382,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acetadote&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;595,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,308,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Omeclamox-Pak&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,109)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(474,371)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RediTrex&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,870)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;461,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;874,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;643,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,359,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,055,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,598,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,592,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,928,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Omeclamox-Pak revenue for the first and second quarter of 2021 was the result of Cumberland currently being out of commercial inventory of this product.  The packager for our Omeclamox-Pak product encountered financial difficulties due to the impact of COVID-19.  They are under new management and are in the process of a reorganization. Discussions with the packager are ongoing.  Net revenue was also negatively impacted by product returns during the periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has agreements with international partners for commercialization of the Company's products with associated payments included in other revenues. Those agreements provide that each of the partners are responsible for seeking regulatory approvals for the product, and following approval, each partner will be responsible for the ongoing distribution and sales in the respective international territories. The Company provides a dossier for product registration and maintains responsibility for the relevant intellectual property. Cumberland is typically entitled to receive a non-refundable, up-front payment at the time each agreement is executed as consideration for the product dossier and for the rights to the distinct intellectual property rights in the respective international territory. These agreements also typically provide for additional payments upon a partner&#x2019;s achievement of a defined regulatory approval and sales milestones. The Company may also be entitled to receive royalties on future sales of the products and a transfer price on supplies.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contractual payments associated with the partner&#x2019;s achievement of regulatory approvals, sales milestones and royalties on future sales are recognized as revenue upon occurrence, or at such time that the Company has a high degree of confidence that the revenue would not be reversed in a subsequent period.&lt;/span&gt;&lt;/div&gt;Other revenues also include funding from federal grant programs including those secured by CET through the Small Business Administration as well as lease income generated by CET&#x2019;s Life Sciences Center. The Life Sciences Center is a research center that provides scientists with access to flexible lab space and other resources to develop biomedical products. Grant revenue from these programs totaled approximately $0.2&#160;million and $0.5 million for the three months ended June 30, 2021 and 2020</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RleHRyZWdpb246NTEwNDc5MDRkNjM5NDZkMDhhNjJmMTU5OTUyNmVhMTBfMjU2Ng_da483623-8a1f-47d8-ab43-e6644e364301">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s net revenues consisted of the following for the three and six months ended June 30, 2021 and 2020:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Products:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Kristalose&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,275,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,477,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,269,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,771,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vibativ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,844,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,299,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,897,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,721,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Caldolor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;938,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,166,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,477,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,261,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vaprisol&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;399,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,534,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;382,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acetadote&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;595,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,308,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Omeclamox-Pak&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,109)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(474,371)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RediTrex&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,870)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;461,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;874,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;643,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,359,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,055,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,598,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,592,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,928,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia5edd42c5f134552b215b0303905dc64_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfMy0xLTEtMS0w_0edb5017-f321-40d0-ab64-886ee654563b"
      unitRef="usd">5275065</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idf76e1a947e34b99bf20371f1394bc94_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfMy0zLTEtMS0w_ea09c2ad-ac24-4841-a454-e342c765fcea"
      unitRef="usd">3477471</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6b7593836c514ab7ae6235e51053a4d3_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfMy01LTEtMS0w_67d7ff69-71cc-42c4-a565-308d376ee726"
      unitRef="usd">8269443</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i165e5c5a2d664922aea782b5ec2beaa1_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfMy03LTEtMS0w_d7da85d3-2eaf-4da3-b76b-5002a9cdde5d"
      unitRef="usd">6771433</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifad013eb9e344ea389599dff33e69ac5_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfNC0xLTEtMS0w_63ff5608-d229-4f94-ba7f-c1cfed41d2a0"
      unitRef="usd">1844936</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icb72b6c62fb3497caec435b11f56df5b_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfNC0zLTEtMS0w_022d405d-1685-4a94-a749-a335c7fe209a"
      unitRef="usd">3299507</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie99d1326bbe74354aa379ee065b7c800_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfNC01LTEtMS0w_5e729359-cf7c-44fa-bc9c-353f131687ac"
      unitRef="usd">6897179</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if75eedbbeb5a4ee7b41a92f8a8b0fb07_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfNC03LTEtMS0w_d6be61cd-17aa-499c-ad48-852288e7bde5"
      unitRef="usd">5721708</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib9e93a7211e0479a81c8bd344131c4e7_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfNS0xLTEtMS0w_6bad5f86-2c6c-42f4-a92e-a03e77b21888"
      unitRef="usd">938328</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i76b0812334e5493ba0a8152f3015bf4a_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfNS0zLTEtMS0w_e3d3c205-690e-4462-88ba-c5a4370ef53c"
      unitRef="usd">1166569</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iabe2fb0732864cfb86e1ccecbb610f34_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfNS01LTEtMS0w_b6111921-6cfc-4576-88c1-9892cbdd3d84"
      unitRef="usd">2477824</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i857d42211e8846b8ae37d954dc44d6a5_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfNS03LTEtMS0w_c5fd03ca-36d6-46aa-8819-a445d6cb40e5"
      unitRef="usd">2261286</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib8bb9cad97f943fca7a044ed530e9867_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfNi0xLTEtMS0xNjI5_ec1e972a-4ca3-4bad-a00b-c3154e0a998d"
      unitRef="usd">399952</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib2de112b4b874426a53bf6ed84e287a5_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfNi0zLTEtMS0xNjI5_092f5490-34c4-4ded-bb2f-cacec2dac859"
      unitRef="usd">174159</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i54cb558d5ce44437ad69a746dc9c0d82_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfNi01LTEtMS0xNjI5_f29d3cf5-d215-46cc-943c-9dab0d997aeb"
      unitRef="usd">1534216</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if2dc8e2802e642b5b94cadd517394321_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfNi03LTEtMS0xNjI5_d4b1e529-87b8-4394-8823-69ac9d8a34f1"
      unitRef="usd">382016</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8e418762fd0d400aa38934d9baef2d1f_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfNi0xLTEtMS0w_eb2e6dc7-5485-4f3c-91e4-310483a913f5"
      unitRef="usd">152781</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ief1b47cbad4647fdb4c761fccef2aa59_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfNi0zLTEtMS0w_576280e5-6943-4343-8c9f-2734feca9c59"
      unitRef="usd">595310</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie9fecc8c7c5546288fd7851d2d94e26c_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfNi01LTEtMS0w_9c40ec14-05ae-4ac4-9a92-cf70ad5df573"
      unitRef="usd">269972</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic88623cc09cd42dfa613a0b3710040a3_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfNi03LTEtMS0w_d05304ab-654a-4c3b-ad9c-0a359768c1ce"
      unitRef="usd">1308711</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibaa9e52c4cd5496c898ae44c5f71a2f6_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfNy0xLTEtMS0w_e5d867ad-489f-45bc-ae33-6e8fce793b17"
      unitRef="usd">-24109</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if58606b340b94db39d3ecaa02a4573ed_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfNy0zLTEtMS0w_c44228fd-e1a8-431e-b015-7ff9fd4e2a51"
      unitRef="usd">10948</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i16a80924d1204bd0b90b95ff2356a104_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfNy01LTEtMS0w_cd2ff1c6-9fe5-4e90-81c2-85dcfc7361a2"
      unitRef="usd">-474371</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic02c2f75924e441689c5ffc79ba729b8_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfNy03LTEtMS0w_7c8c2cc3-b0a3-4351-bd81-ac3e33a2af95"
      unitRef="usd">124371</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifca6a00e3fc6401ab98a098751461284_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfOS0xLTEtMS0w_e0f19739-1e72-4e9e-8127-041ecee527d5"
      unitRef="usd">7382</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia2c40ebe0b7f44769ff470354a3fe426_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfOS0zLTEtMS0w_815d6a56-f553-4c47-91a2-578243e5fc0f"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idb0eee768e294f599281385f4a3835f6_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfOS01LTEtMS00MDM_ecaf8c8e-b5ef-42f6-9cb8-6dccc1a20c67"
      unitRef="usd">-24870</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6095f924cf50491b815b0dfba23349fd_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfOS03LTEtMS00MDk_2828e277-3674-45e9-9f20-45200e60e9bc"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifb0ee00056ff487ca51af9d696aa113b_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfMTAtMS0xLTEtMA_4edf9b34-5201-4759-bf5d-9a43aa793f78"
      unitRef="usd">461148</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5c43803cc80549529c2ba24144989e73_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfMTAtMy0xLTEtMA_dc972368-5ea2-4f21-97d8-fdab556fd21f"
      unitRef="usd">874213</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic93c6aab3bcf4cda8e32399f9d56970e_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfMTAtNS0xLTEtMA_e316daa1-74d0-4e15-ac5a-3b48acd7ddb3"
      unitRef="usd">643249</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ice06f3366d2249119a9109b31bb8f7d2_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfMTAtNy0xLTEtMA_9ded4987-d4c4-4878-b8de-6a956de9c3fa"
      unitRef="usd">1359386</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfMTEtMS0xLTEtMA_9bf99773-3e3e-4aa9-b4c5-26ed00af32f2"
      unitRef="usd">9055483</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i042fd2dea7024b67baac743b1839c02a_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfMTEtMy0xLTEtMA_7fd6bd5e-76a9-40c1-8ee0-574e20ed2c43"
      unitRef="usd">9598177</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfMTEtNS0xLTEtMA_3497de80-568a-4545-b64f-6fa67ca9cfe8"
      unitRef="usd">19592642</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RhYmxlOjU4ZTk2ODIxMjM5MTRkMWQ4OTE1ZDQ2ZTUzZjc0YzNlL3RhYmxlcmFuZ2U6NThlOTY4MjEyMzkxNGQxZDg5MTVkNDZlNTNmNzRjM2VfMTEtNy0xLTEtMA_a3de6319-3953-49e8-9cb8-174973c31f68"
      unitRef="usd">17928911</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6172287cab0745339de538f8ae5b507b_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RleHRyZWdpb246NTEwNDc5MDRkNjM5NDZkMDhhNjJmMTU5OTUyNmVhMTBfMjUwMw_8e1501bc-ba94-497c-bc51-ea3af6d8ecbd"
      unitRef="usd">200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i15931d26dd6041dfa28287b72ffd540a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM18zNy9mcmFnOjUxMDQ3OTA0ZDYzOTQ2ZDA4YTYyZjE1OTk1MjZlYTEwL3RleHRyZWdpb246NTEwNDc5MDRkNjM5NDZkMDhhNjJmMTU5OTUyNmVhMTBfMjUxMA_d1acc996-5fb5-4ff3-b49f-d409563cf8cd"
      unitRef="usd">500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180MC9mcmFnOjk4M2EzMDk1MjI5ZTQwYzQ4M2Q4MjUyMjMwMDdlNzA5L3RleHRyZWdpb246OTgzYTMwOTUyMjllNDBjNDgzZDgyNTIyMzAwN2U3MDlfMjI0Mw_f0af525f-b17f-4290-a0f0-64c2413b6708">INVENTORIES&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company works closely with third parties to manufacture and package finished goods for sale.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on the arrangements with the manufacturer or packager, the Company will either take title to the finished goods at the time of shipment or at the time of arrival at the Company&#x2019;s warehouses.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company then holds such goods in inventory until distribution and sale. These finished goods inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continually evaluates inventory for potential losses due to excess, obsolete or slow-moving goods by comparing sales history and projections to the inventory on hand. When evidence indicates that the carrying value may not be recoverable, a charge is taken to reduce the inventory to its current net realizable value.  At June 30, 2021 and December 31, 2020, the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company had recognized and maintained cumulative net realizable value charges for potential obsolescence and discontinuance losses of approximately $0.3 million and $0.2 million, respectively.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is responsible for the purchase of the active pharmaceutical ingredient (&#x201c;API&#x201d;) for Kristalose and maintains the inventory at third-party packagers. As that API is consumed in production, the value of the API is transferred from raw materials to finished goods.  API for the Company's Vaprisol brand is also included in the raw materials inventory at June 30, 2021 and December 31, 2020.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consigned inventory represents Authorized Generic inventory stored with Perrigo until shipment.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the Vibativ acquisition, Cumberland acquired API and work in process inventories of $15.6 million that were all initially classified as non-current inventories at the date of acquisition.  At June 30, 2021 and December 31, 2020, total non-current inventory, including Vibativ and ifetroban, was $9.9&#160;million and $11.7&#160;million, respectively. The Company had $0.3 million and $2.1 million of Vibativ finished goods included in non-current inventory at June 30, 2021 and December 31, 2020, respectively.  The Company also has obtained $0.4&#160;million of finished goods in non-current inventory for API related to its ifetroban clinical initiatives at June 30, 2021 and December 31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At June 30, 2021 and December 31, 2020 the Company's net inventories consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.681%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials and work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,156,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,223,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consigned inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,639,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,943,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,984,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,294,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;less non-current inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,880,766)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,656,742)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories classified as current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,104,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,638,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:InventoryValuationReserves
      contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180MC9mcmFnOjk4M2EzMDk1MjI5ZTQwYzQ4M2Q4MjUyMjMwMDdlNzA5L3RleHRyZWdpb246OTgzYTMwOTUyMjllNDBjNDgzZDgyNTIyMzAwN2U3MDlfMTAzOA_f4c7b9ae-163b-4cbc-8c0c-ee24275cdc57"
      unitRef="usd">300000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves
      contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180MC9mcmFnOjk4M2EzMDk1MjI5ZTQwYzQ4M2Q4MjUyMjMwMDdlNzA5L3RleHRyZWdpb246OTgzYTMwOTUyMjllNDBjNDgzZDgyNTIyMzAwN2U3MDlfMTA0NQ_a7b05c43-fa7a-4473-8072-de3f04e667e7"
      unitRef="usd">200000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryNoncurrent
      contextRef="i6742997b2ea4497a8b57f546e21e37aa_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180MC9mcmFnOjk4M2EzMDk1MjI5ZTQwYzQ4M2Q4MjUyMjMwMDdlNzA5L3RleHRyZWdpb246OTgzYTMwOTUyMjllNDBjNDgzZDgyNTIyMzAwN2U3MDlfMTcyOA_d44273dd-74ad-48bc-b686-287d752fe32a"
      unitRef="usd">15600000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180MC9mcmFnOjk4M2EzMDk1MjI5ZTQwYzQ4M2Q4MjUyMjMwMDdlNzA5L3RleHRyZWdpb246OTgzYTMwOTUyMjllNDBjNDgzZDgyNTIyMzAwN2U3MDlfMTkwMg_12b171a1-ae21-4162-8668-207fde0d6c92"
      unitRef="usd">9900000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180MC9mcmFnOjk4M2EzMDk1MjI5ZTQwYzQ4M2Q4MjUyMjMwMDdlNzA5L3RleHRyZWdpb246OTgzYTMwOTUyMjllNDBjNDgzZDgyNTIyMzAwN2U3MDlfMTkwOQ_8ff38ed3-53f7-40a5-aced-0e8dc95a9c4b"
      unitRef="usd">11700000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryFinishedGoods
      contextRef="ifaa5fd674df1464290cfa2809fea1eaf_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180MC9mcmFnOjk4M2EzMDk1MjI5ZTQwYzQ4M2Q4MjUyMjMwMDdlNzA5L3RleHRyZWdpb246OTgzYTMwOTUyMjllNDBjNDgzZDgyNTIyMzAwN2U3MDlfMTk0Mw_4875a249-9c02-42ff-8cf6-d5bbcd598ba8"
      unitRef="usd">300000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="i6742997b2ea4497a8b57f546e21e37aa_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180MC9mcmFnOjk4M2EzMDk1MjI5ZTQwYzQ4M2Q4MjUyMjMwMDdlNzA5L3RleHRyZWdpb246OTgzYTMwOTUyMjllNDBjNDgzZDgyNTIyMzAwN2U3MDlfMTk1MA_9871b433-1a29-4abd-ab43-4c8c11147484"
      unitRef="usd">2100000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNoncurrent
      contextRef="i339d4531f62d4de7929176842fce1307_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180MC9mcmFnOjk4M2EzMDk1MjI5ZTQwYzQ4M2Q4MjUyMjMwMDdlNzA5L3RleHRyZWdpb246OTgzYTMwOTUyMjllNDBjNDgzZDgyNTIyMzAwN2U3MDlfMjA1OA_3e8e1c70-40c3-4cec-8037-1079a3621250"
      unitRef="usd">400000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="ic8de84d46a4b4f1288caecd9e279f91c_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180MC9mcmFnOjk4M2EzMDk1MjI5ZTQwYzQ4M2Q4MjUyMjMwMDdlNzA5L3RleHRyZWdpb246OTgzYTMwOTUyMjllNDBjNDgzZDgyNTIyMzAwN2U3MDlfMjA1OA_89f3981c-2f7d-48ce-ba1e-49e91b94f38a"
      unitRef="usd">400000</us-gaap:InventoryNoncurrent>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180MC9mcmFnOjk4M2EzMDk1MjI5ZTQwYzQ4M2Q4MjUyMjMwMDdlNzA5L3RleHRyZWdpb246OTgzYTMwOTUyMjllNDBjNDgzZDgyNTIyMzAwN2U3MDlfMjI0Ng_f2edaa20-b3bf-407e-a5b4-b01fa55e4a97">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At June 30, 2021 and December 31, 2020 the Company's net inventories consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.681%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials and work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,156,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,223,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consigned inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,639,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,943,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,984,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,294,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;less non-current inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,880,766)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,656,742)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories classified as current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,104,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,638,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180MC9mcmFnOjk4M2EzMDk1MjI5ZTQwYzQ4M2Q4MjUyMjMwMDdlNzA5L3RhYmxlOmNiYjI2M2FjMjIwYzRkMGI5ZmNlZDc0ODQ1YTA0OTc1L3RhYmxlcmFuZ2U6Y2JiMjYzYWMyMjBjNGQwYjlmY2VkNzQ4NDVhMDQ5NzVfMi0yLTEtMS0w_e599f474-e5c9-41ab-84a0-5c689d88ae6c"
      unitRef="usd">14156248</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180MC9mcmFnOjk4M2EzMDk1MjI5ZTQwYzQ4M2Q4MjUyMjMwMDdlNzA5L3RhYmxlOmNiYjI2M2FjMjIwYzRkMGI5ZmNlZDc0ODQ1YTA0OTc1L3RhYmxlcmFuZ2U6Y2JiMjYzYWMyMjBjNGQwYjlmY2VkNzQ4NDVhMDQ5NzVfMi00LTEtMS0w_21ecfeaa-7eca-4ddc-93c1-f1a23a13e93d"
      unitRef="usd">16223162</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180MC9mcmFnOjk4M2EzMDk1MjI5ZTQwYzQ4M2Q4MjUyMjMwMDdlNzA5L3RhYmxlOmNiYjI2M2FjMjIwYzRkMGI5ZmNlZDc0ODQ1YTA0OTc1L3RhYmxlcmFuZ2U6Y2JiMjYzYWMyMjBjNGQwYjlmY2VkNzQ4NDVhMDQ5NzVfMi00LTEtMS0w_7fa538f3-b811-4ab9-a876-03f910965528"
      unitRef="usd">16223162</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment
      contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180MC9mcmFnOjk4M2EzMDk1MjI5ZTQwYzQ4M2Q4MjUyMjMwMDdlNzA5L3RhYmxlOmNiYjI2M2FjMjIwYzRkMGI5ZmNlZDc0ODQ1YTA0OTc1L3RhYmxlcmFuZ2U6Y2JiMjYzYWMyMjBjNGQwYjlmY2VkNzQ4NDVhMDQ5NzVfMy0yLTEtMS0w_5734324b-528f-4597-a664-5249f3f7631e"
      unitRef="usd">189141</us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment>
    <us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment
      contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180MC9mcmFnOjk4M2EzMDk1MjI5ZTQwYzQ4M2Q4MjUyMjMwMDdlNzA5L3RhYmxlOmNiYjI2M2FjMjIwYzRkMGI5ZmNlZDc0ODQ1YTA0OTc1L3RhYmxlcmFuZ2U6Y2JiMjYzYWMyMjBjNGQwYjlmY2VkNzQ4NDVhMDQ5NzVfMy00LTEtMS0w_1d022e68-1567-4fe8-8b21-fcf571a5d758"
      unitRef="usd">128005</us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment>
    <us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment
      contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180MC9mcmFnOjk4M2EzMDk1MjI5ZTQwYzQ4M2Q4MjUyMjMwMDdlNzA5L3RhYmxlOmNiYjI2M2FjMjIwYzRkMGI5ZmNlZDc0ODQ1YTA0OTc1L3RhYmxlcmFuZ2U6Y2JiMjYzYWMyMjBjNGQwYjlmY2VkNzQ4NDVhMDQ5NzVfMy00LTEtMS0w_58b0239d-21fd-416a-ac22-1becaa71e82b"
      unitRef="usd">128005</us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180MC9mcmFnOjk4M2EzMDk1MjI5ZTQwYzQ4M2Q4MjUyMjMwMDdlNzA5L3RhYmxlOmNiYjI2M2FjMjIwYzRkMGI5ZmNlZDc0ODQ1YTA0OTc1L3RhYmxlcmFuZ2U6Y2JiMjYzYWMyMjBjNGQwYjlmY2VkNzQ4NDVhMDQ5NzVfNC0yLTEtMS0w_22d93e61-9b5f-4829-901e-1719afd053de"
      unitRef="usd">5639596</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180MC9mcmFnOjk4M2EzMDk1MjI5ZTQwYzQ4M2Q4MjUyMjMwMDdlNzA5L3RhYmxlOmNiYjI2M2FjMjIwYzRkMGI5ZmNlZDc0ODQ1YTA0OTc1L3RhYmxlcmFuZ2U6Y2JiMjYzYWMyMjBjNGQwYjlmY2VkNzQ4NDVhMDQ5NzVfNC00LTEtMS0w_04b35f85-4703-4559-a801-e64470646b4e"
      unitRef="usd">5943732</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180MC9mcmFnOjk4M2EzMDk1MjI5ZTQwYzQ4M2Q4MjUyMjMwMDdlNzA5L3RhYmxlOmNiYjI2M2FjMjIwYzRkMGI5ZmNlZDc0ODQ1YTA0OTc1L3RhYmxlcmFuZ2U6Y2JiMjYzYWMyMjBjNGQwYjlmY2VkNzQ4NDVhMDQ5NzVfNC00LTEtMS0w_bc034471-fa1b-4442-ab51-0150f419b078"
      unitRef="usd">5943732</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryGross
      contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180MC9mcmFnOjk4M2EzMDk1MjI5ZTQwYzQ4M2Q4MjUyMjMwMDdlNzA5L3RhYmxlOmNiYjI2M2FjMjIwYzRkMGI5ZmNlZDc0ODQ1YTA0OTc1L3RhYmxlcmFuZ2U6Y2JiMjYzYWMyMjBjNGQwYjlmY2VkNzQ4NDVhMDQ5NzVfNS0yLTEtMS0w_af0b302a-3ee1-4705-84ce-e102922e4790"
      unitRef="usd">19984985</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180MC9mcmFnOjk4M2EzMDk1MjI5ZTQwYzQ4M2Q4MjUyMjMwMDdlNzA5L3RhYmxlOmNiYjI2M2FjMjIwYzRkMGI5ZmNlZDc0ODQ1YTA0OTc1L3RhYmxlcmFuZ2U6Y2JiMjYzYWMyMjBjNGQwYjlmY2VkNzQ4NDVhMDQ5NzVfNS00LTEtMS0w_6cc7177a-af26-4188-ab49-4beb937aef7f"
      unitRef="usd">22294899</us-gaap:InventoryGross>
    <us-gaap:InventoryNoncurrent
      contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180MC9mcmFnOjk4M2EzMDk1MjI5ZTQwYzQ4M2Q4MjUyMjMwMDdlNzA5L3RhYmxlOmNiYjI2M2FjMjIwYzRkMGI5ZmNlZDc0ODQ1YTA0OTc1L3RhYmxlcmFuZ2U6Y2JiMjYzYWMyMjBjNGQwYjlmY2VkNzQ4NDVhMDQ5NzVfNi0yLTEtMS0w_89509102-cb6f-48fd-abc2-82a2ed2ae841"
      unitRef="usd">9880766</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180MC9mcmFnOjk4M2EzMDk1MjI5ZTQwYzQ4M2Q4MjUyMjMwMDdlNzA5L3RhYmxlOmNiYjI2M2FjMjIwYzRkMGI5ZmNlZDc0ODQ1YTA0OTc1L3RhYmxlcmFuZ2U6Y2JiMjYzYWMyMjBjNGQwYjlmY2VkNzQ4NDVhMDQ5NzVfNi00LTEtMS0w_d5cde96e-f801-4bb8-b627-2140833d82b4"
      unitRef="usd">11656742</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNet
      contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180MC9mcmFnOjk4M2EzMDk1MjI5ZTQwYzQ4M2Q4MjUyMjMwMDdlNzA5L3RhYmxlOmNiYjI2M2FjMjIwYzRkMGI5ZmNlZDc0ODQ1YTA0OTc1L3RhYmxlcmFuZ2U6Y2JiMjYzYWMyMjBjNGQwYjlmY2VkNzQ4NDVhMDQ5NzVfNy0yLTEtMS0w_a61f8262-9943-47bc-a6b1-804b212190aa"
      unitRef="usd">10104219</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180MC9mcmFnOjk4M2EzMDk1MjI5ZTQwYzQ4M2Q4MjUyMjMwMDdlNzA5L3RhYmxlOmNiYjI2M2FjMjIwYzRkMGI5ZmNlZDc0ODQ1YTA0OTc1L3RhYmxlcmFuZ2U6Y2JiMjYzYWMyMjBjNGQwYjlmY2VkNzQ4NDVhMDQ5NzVfNy00LTEtMS0w_0b3821d5-b799-4d72-a5eb-c513ec38fb5a"
      unitRef="usd">10638157</us-gaap:InventoryNet>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180My9mcmFnOmU1ZmQ2MDUyZGJjZjQwNDdhMTFiNGE2NThiZGY0NTIyL3RleHRyZWdpb246ZTVmZDYwNTJkYmNmNDA0N2ExMWI0YTY1OGJkZjQ1MjJfMTk3Nw_253eff07-8abd-4c94-a9f0-5cbc3862b4c0">LEASES&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland&#x2019;s significant operating leases include the lease of approximately 25,500 square feet of office space in Nashville, Tennessee for its corporate headquarters.  This lease currently expires in October 2022.  The Company's operating leases also include the lease of approximately 14,200 square feet of wet laboratory and office space in Nashville, Tennessee by CET, our majority-owned subsidiary, where it operates the CET Life Sciences Center.  This lease currently expires in April 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities are recorded as the present value of remaining lease payments not yet paid for the lease term discounted using the incremental borrowing rate associated with each lease. Operating lease right-of-use assets represent operating lease liabilities adjusted for lease incentives and initial direct costs. As Cumberland&#x2019;s leases do not contain implicit borrowing rates, the incremental borrowing rates were calculated based on information available at January 1, 2019. Incremental borrowing rates reflect the Company&#x2019;s estimated interest rates for collateralized borrowings over similar lease terms.  The weighted-average incremental borrowing rate used to discount the present value of the remaining lease payments is 7.42%. The weighted-average remaining lease term at June 30, 2021 is 1.5 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Lease Position&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At June 30, 2021 and December 31, 2020 , the Company's lease assets and liabilities were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Right-of-Use Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,535,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,028,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Lease Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,067,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,016,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;512,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,059,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,580,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,076,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumulative future minimum sublease income under non-cancelable operating subleases totals approximately $0.2 million and will be paid through the leases ending in October 2022 and April 2023. Future minimum lease payments under non-cancelable operating leases (with initial or remaining lease terms in excess of one year) are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Maturity of Lease Liabilities at June 30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;579,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,019,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,690,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(110,770)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,580,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rent expense is recognized over the expected term of the lease, including renewal option periods, if applicable, on a straight-line basis as a component of general and administrative expense. Rent expense and sublease income were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rent expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;605,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;571,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i5d1ec29c3e7d45128f2daec3011f8ff5_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180My9mcmFnOmU1ZmQ2MDUyZGJjZjQwNDdhMTFiNGE2NThiZGY0NTIyL3RleHRyZWdpb246ZTVmZDYwNTJkYmNmNDA0N2ExMWI0YTY1OGJkZjQ1MjJfMjc0ODc3OTA3MTQ3MA_a8375541-6385-4184-875a-38aa36db9874"
      unitRef="sqft">25500</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="idfffd86898e74da5b26d2c9090d7aef5_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180My9mcmFnOmU1ZmQ2MDUyZGJjZjQwNDdhMTFiNGE2NThiZGY0NTIyL3RleHRyZWdpb246ZTVmZDYwNTJkYmNmNDA0N2ExMWI0YTY1OGJkZjQ1MjJfMjc0ODc3OTA3MTQ2Mg_c7827861-55c5-4d39-84ee-f6dab6073913"
      unitRef="sqft">14200</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180My9mcmFnOmU1ZmQ2MDUyZGJjZjQwNDdhMTFiNGE2NThiZGY0NTIyL3RleHRyZWdpb246ZTVmZDYwNTJkYmNmNDA0N2ExMWI0YTY1OGJkZjQ1MjJfMTI0Ng_cf18bda7-b6b7-4e6a-9100-e57a48752131"
      unitRef="number">0.0742</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180My9mcmFnOmU1ZmQ2MDUyZGJjZjQwNDdhMTFiNGE2NThiZGY0NTIyL3RleHRyZWdpb246ZTVmZDYwNTJkYmNmNDA0N2ExMWI0YTY1OGJkZjQ1MjJfMTMwMQ_fd997387-c7dd-42a8-b0a5-6cbf62e36614">P1Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <cpix:AssetsAndLiabilitiesLesseeTableTextBlock
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180My9mcmFnOmU1ZmQ2MDUyZGJjZjQwNDdhMTFiNGE2NThiZGY0NTIyL3RleHRyZWdpb246ZTVmZDYwNTJkYmNmNDA0N2ExMWI0YTY1OGJkZjQ1MjJfMTk3OA_2c08834d-f8ef-42de-8368-82cb041bfefd">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At June 30, 2021 and December 31, 2020 , the Company's lease assets and liabilities were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Right-of-Use Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,535,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,028,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Lease Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,067,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,016,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;512,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,059,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,580,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,076,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumulative future minimum sublease income under non-cancelable operating subleases totals approximately $0.2 million and will be paid through the leases ending in October 2022 and April 2023. Future minimum lease payments under non-cancelable operating leases (with initial or remaining lease terms in excess of one year) are as follows:&lt;/span&gt;&lt;/div&gt;</cpix:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180My9mcmFnOmU1ZmQ2MDUyZGJjZjQwNDdhMTFiNGE2NThiZGY0NTIyL3RhYmxlOmMzYTAwNGJhZjZlNDQyNjQ5NTQ4ZWMzZWUzMzE1NWE1L3RhYmxlcmFuZ2U6YzNhMDA0YmFmNmU0NDI2NDk1NDhlYzNlZTMzMTU1YTVfMS0yLTEtMS0w_2e05e7f0-60a9-432f-b689-714e14aa54d6"
      unitRef="usd">1535556</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180My9mcmFnOmU1ZmQ2MDUyZGJjZjQwNDdhMTFiNGE2NThiZGY0NTIyL3RhYmxlOmMzYTAwNGJhZjZlNDQyNjQ5NTQ4ZWMzZWUzMzE1NWE1L3RhYmxlcmFuZ2U6YzNhMDA0YmFmNmU0NDI2NDk1NDhlYzNlZTMzMTU1YTVfMS00LTEtMS0w_87914a4b-997d-48db-bfce-a1cf0934844f"
      unitRef="usd">2028148</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180My9mcmFnOmU1ZmQ2MDUyZGJjZjQwNDdhMTFiNGE2NThiZGY0NTIyL3RhYmxlOjdiMWZiYjFhODVkMjRiYWNhZTY5NmRhNDg3MTNlMTU3L3RhYmxlcmFuZ2U6N2IxZmJiMWE4NWQyNGJhY2FlNjk2ZGE0ODcxM2UxNTdfMS0yLTEtMS0w_76cf164b-f512-47ff-9598-0ce24a62b161"
      unitRef="usd">1067880</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180My9mcmFnOmU1ZmQ2MDUyZGJjZjQwNDdhMTFiNGE2NThiZGY0NTIyL3RhYmxlOjdiMWZiYjFhODVkMjRiYWNhZTY5NmRhNDg3MTNlMTU3L3RhYmxlcmFuZ2U6N2IxZmJiMWE4NWQyNGJhY2FlNjk2ZGE0ODcxM2UxNTdfMS00LTEtMS0w_a32dda76-901f-4c26-817a-d2e6ddfe2cc3"
      unitRef="usd">1016779</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180My9mcmFnOmU1ZmQ2MDUyZGJjZjQwNDdhMTFiNGE2NThiZGY0NTIyL3RhYmxlOjdiMWZiYjFhODVkMjRiYWNhZTY5NmRhNDg3MTNlMTU3L3RhYmxlcmFuZ2U6N2IxZmJiMWE4NWQyNGJhY2FlNjk2ZGE0ODcxM2UxNTdfMy0yLTEtMS0w_27314676-eaef-4b08-b629-1bd57f9cb72d"
      unitRef="usd">512324</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180My9mcmFnOmU1ZmQ2MDUyZGJjZjQwNDdhMTFiNGE2NThiZGY0NTIyL3RhYmxlOjdiMWZiYjFhODVkMjRiYWNhZTY5NmRhNDg3MTNlMTU3L3RhYmxlcmFuZ2U6N2IxZmJiMWE4NWQyNGJhY2FlNjk2ZGE0ODcxM2UxNTdfMy00LTEtMS0w_6799f033-aab7-4267-8e75-e285b68d2ef6"
      unitRef="usd">1059693</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <cpix:LeaseLiability
      contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180My9mcmFnOmU1ZmQ2MDUyZGJjZjQwNDdhMTFiNGE2NThiZGY0NTIyL3RhYmxlOjdiMWZiYjFhODVkMjRiYWNhZTY5NmRhNDg3MTNlMTU3L3RhYmxlcmFuZ2U6N2IxZmJiMWE4NWQyNGJhY2FlNjk2ZGE0ODcxM2UxNTdfNC0yLTEtMS0w_68131312-3580-4549-8bff-c24271148b4f"
      unitRef="usd">1580204</cpix:LeaseLiability>
    <cpix:LeaseLiability
      contextRef="ie36ac2d370b44b7b850f453251764d25_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180My9mcmFnOmU1ZmQ2MDUyZGJjZjQwNDdhMTFiNGE2NThiZGY0NTIyL3RhYmxlOjdiMWZiYjFhODVkMjRiYWNhZTY5NmRhNDg3MTNlMTU3L3RhYmxlcmFuZ2U6N2IxZmJiMWE4NWQyNGJhY2FlNjk2ZGE0ODcxM2UxNTdfNC00LTEtMS0w_6745505a-b30c-444c-9c49-09283de29782"
      unitRef="usd">2076472</cpix:LeaseLiability>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals
      contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180My9mcmFnOmU1ZmQ2MDUyZGJjZjQwNDdhMTFiNGE2NThiZGY0NTIyL3RleHRyZWdpb246ZTVmZDYwNTJkYmNmNDA0N2ExMWI0YTY1OGJkZjQ1MjJfMTUwOA_5b000c8b-7668-43d5-bc82-f35d78f90d1b"
      unitRef="usd">200000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180My9mcmFnOmU1ZmQ2MDUyZGJjZjQwNDdhMTFiNGE2NThiZGY0NTIyL3RleHRyZWdpb246ZTVmZDYwNTJkYmNmNDA0N2ExMWI0YTY1OGJkZjQ1MjJfMTk3OQ_ccd504fe-9d7a-4ba6-b8d5-5273ca24c343">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Maturity of Lease Liabilities at June 30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;579,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,019,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,690,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(110,770)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,580,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180My9mcmFnOmU1ZmQ2MDUyZGJjZjQwNDdhMTFiNGE2NThiZGY0NTIyL3RhYmxlOjQxNTA0MGFhYzQ0YTRjOGNhMGYwNzk2MWVlMTljN2NmL3RhYmxlcmFuZ2U6NDE1MDQwYWFjNDRhNGM4Y2EwZjA3OTYxZWUxOWM3Y2ZfMS0yLTEtMS0w_7b57d960-891f-4c2e-b842-87f92178d907"
      unitRef="usd">579183</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180My9mcmFnOmU1ZmQ2MDUyZGJjZjQwNDdhMTFiNGE2NThiZGY0NTIyL3RhYmxlOjQxNTA0MGFhYzQ0YTRjOGNhMGYwNzk2MWVlMTljN2NmL3RhYmxlcmFuZ2U6NDE1MDQwYWFjNDRhNGM4Y2EwZjA3OTYxZWUxOWM3Y2ZfMi0yLTEtMS0w_3a154e76-5901-4f17-a896-774d8fff8905"
      unitRef="usd">1019313</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180My9mcmFnOmU1ZmQ2MDUyZGJjZjQwNDdhMTFiNGE2NThiZGY0NTIyL3RhYmxlOjQxNTA0MGFhYzQ0YTRjOGNhMGYwNzk2MWVlMTljN2NmL3RhYmxlcmFuZ2U6NDE1MDQwYWFjNDRhNGM4Y2EwZjA3OTYxZWUxOWM3Y2ZfMy0yLTEtMS0w_56dbd299-8c56-442f-ab12-fff1f30e8f75"
      unitRef="usd">92478</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <cpix:LesseeOperatingLeaseLiabilityToBePaidAfterYearThree
      contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180My9mcmFnOmU1ZmQ2MDUyZGJjZjQwNDdhMTFiNGE2NThiZGY0NTIyL3RhYmxlOjQxNTA0MGFhYzQ0YTRjOGNhMGYwNzk2MWVlMTljN2NmL3RhYmxlcmFuZ2U6NDE1MDQwYWFjNDRhNGM4Y2EwZjA3OTYxZWUxOWM3Y2ZfNC0yLTEtMS0w_91952288-a75e-44bd-b82c-20405d4d4406"
      unitRef="usd">0</cpix:LesseeOperatingLeaseLiabilityToBePaidAfterYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180My9mcmFnOmU1ZmQ2MDUyZGJjZjQwNDdhMTFiNGE2NThiZGY0NTIyL3RhYmxlOjQxNTA0MGFhYzQ0YTRjOGNhMGYwNzk2MWVlMTljN2NmL3RhYmxlcmFuZ2U6NDE1MDQwYWFjNDRhNGM4Y2EwZjA3OTYxZWUxOWM3Y2ZfNS0yLTEtMS0w_b45b66d3-118d-414f-8bd1-894ea5e2dd91"
      unitRef="usd">1690974</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180My9mcmFnOmU1ZmQ2MDUyZGJjZjQwNDdhMTFiNGE2NThiZGY0NTIyL3RhYmxlOjQxNTA0MGFhYzQ0YTRjOGNhMGYwNzk2MWVlMTljN2NmL3RhYmxlcmFuZ2U6NDE1MDQwYWFjNDRhNGM4Y2EwZjA3OTYxZWUxOWM3Y2ZfNi0yLTEtMS0w_a78c679b-a921-44ad-a9ca-a638d4e9b4f4"
      unitRef="usd">110770</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180My9mcmFnOmU1ZmQ2MDUyZGJjZjQwNDdhMTFiNGE2NThiZGY0NTIyL3RhYmxlOjQxNTA0MGFhYzQ0YTRjOGNhMGYwNzk2MWVlMTljN2NmL3RhYmxlcmFuZ2U6NDE1MDQwYWFjNDRhNGM4Y2EwZjA3OTYxZWUxOWM3Y2ZfNy0yLTEtMS0w_e897ea14-fd16-4e13-9409-5a0787da5322"
      unitRef="usd">1580204</us-gaap:OperatingLeaseLiability>
    <cpix:ScheduleofRentExpenseandSubleaseIncomeTableTextBlock
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180My9mcmFnOmU1ZmQ2MDUyZGJjZjQwNDdhMTFiNGE2NThiZGY0NTIyL3RleHRyZWdpb246ZTVmZDYwNTJkYmNmNDA0N2ExMWI0YTY1OGJkZjQ1MjJfMTk3Ng_05073709-a3a8-4c91-8b95-de1c6fa0670b">Rent expense and sublease income were as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rent expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;605,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;571,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</cpix:ScheduleofRentExpenseandSubleaseIncomeTableTextBlock>
    <us-gaap:LeaseAndRentalExpense
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180My9mcmFnOmU1ZmQ2MDUyZGJjZjQwNDdhMTFiNGE2NThiZGY0NTIyL3RhYmxlOmYxNTc2YjFlZmMxOTQ4NGFiYTg3NGU2ODg0OWI1ZjBkL3RhYmxlcmFuZ2U6ZjE1NzZiMWVmYzE5NDg0YWJhODc0ZTY4ODQ5YjVmMGRfMy0yLTEtMS0w_5a35dd65-e535-4026-b334-809328906ac7"
      unitRef="usd">605130</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180My9mcmFnOmU1ZmQ2MDUyZGJjZjQwNDdhMTFiNGE2NThiZGY0NTIyL3RhYmxlOmYxNTc2YjFlZmMxOTQ4NGFiYTg3NGU2ODg0OWI1ZjBkL3RhYmxlcmFuZ2U6ZjE1NzZiMWVmYzE5NDg0YWJhODc0ZTY4ODQ5YjVmMGRfMy00LTEtMS0w_e5ece971-1cab-4df6-993c-c6265166be4b"
      unitRef="usd">571399</us-gaap:LeaseAndRentalExpense>
    <us-gaap:OperatingLeasesRentExpenseSubleaseRentals1
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180My9mcmFnOmU1ZmQ2MDUyZGJjZjQwNDdhMTFiNGE2NThiZGY0NTIyL3RhYmxlOmYxNTc2YjFlZmMxOTQ4NGFiYTg3NGU2ODg0OWI1ZjBkL3RhYmxlcmFuZ2U6ZjE1NzZiMWVmYzE5NDg0YWJhODc0ZTY4ODQ5YjVmMGRfNS0yLTEtMS0w_bcac05d7-b051-44b9-9b40-7da60efa6fcd"
      unitRef="usd">348411</us-gaap:OperatingLeasesRentExpenseSubleaseRentals1>
    <us-gaap:OperatingLeasesRentExpenseSubleaseRentals1
      contextRef="i872eef21e3d04e8db8cde16038ae6139_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180My9mcmFnOmU1ZmQ2MDUyZGJjZjQwNDdhMTFiNGE2NThiZGY0NTIyL3RhYmxlOmYxNTc2YjFlZmMxOTQ4NGFiYTg3NGU2ODg0OWI1ZjBkL3RhYmxlcmFuZ2U6ZjE1NzZiMWVmYzE5NDg0YWJhODc0ZTY4ODQ5YjVmMGRfNS00LTEtMS0w_2d64c735-50bc-4a23-9d7e-52ed5444cd72"
      unitRef="usd">323489</us-gaap:OperatingLeasesRentExpenseSubleaseRentals1>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180Ni9mcmFnOjc2MjExMDY0NDEzNTRjODE4YmMzOTA3MTA3MTQ3MDk5L3RleHRyZWdpb246NzYyMTEwNjQ0MTM1NGM4MThiYzM5MDcxMDcxNDcwOTlfODIxOQ_eaaf3461-646b-4e8c-bbbc-7e628ac06925">SHAREHOLDERS&#x2019; EQUITY AND DEBT&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Share repurchases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland currently has a share repurchase program to repurchase up to $10 million of its common stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934. In January 2019, the Company's Board of Directors established the current $10 million repurchase program to replace the prior authorizations.  During the six months ended June 30, 2021 and June 30, 2020, the Company repurchased 250,129 shares and 306,329 shares, respectively, of common stock for approximately $0.8 million and $1.2 million, respectively.  At June 30, 2021, approximately $5.4 million of common shares was left to repurchase under this program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Share purchases and sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the Company's March 2021 trading window, several members of Cumberland's Board of Directors entered into share purchase agreements of the Company's stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934. These purchases are designed to increase ownership in the Company by the members of the Board.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Share Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2017, Cumberland filed a Shelf Registration on Form S-3 with the SEC associated with the sale of up to $100 million in corporate securities. The Shelf Registration was declared effective in January 2018. It also included an At the Market ("ATM") feature that allowed the Company to sell common shares at market prices, along with an agreement with B. Riley FBR Inc. to support such a placement of shares. The Company filed an updated Form S-3 with the SEC in December 2020, which was declared effective in January 2021. The Company does not currently have an ATM feature in place.  Cumberland plans to continue to evaluate the market for its common shares, and if favorable, will further evaluate whether or not to enter into an ATM feature through B. Riley FBR, Inc. that would allow the Company to issue shares of its common stock.  The Company did not issue any shares under an ATM during the six months ended June 30, 2021 or June 30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Share Grants and Incentive Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the six months ended June 30, 2021 and June 30, 2020, the Company issued 36,850 shares and 229,141 shares of restricted stock to employees and directors, respectively. Restricted stock issued to employees generally cliff-vests on the fourth anniversary of the date of grant and for directors on the one-year anniversary of the date of grant.  During the six months ended June 30, 2021, the Company also issued 173,350 incentive stock options to employees that cliff-vest on the fourth anniversary of the date of grant, that are set to expire in March and May 2031. Stock compensation expense is presented as a component of general and administrative expense in the condensed consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 7, 2020, the Company entered into a Third Amendment to the Revolving Credit Note and Fourth Amendment (&#x201c;Fourth Amendment&#x201d;) to the Revolving Credit Loan Agreement with Pinnacle Bank (the &#x201c;Pinnacle Agreement&#x201d;). The original Pinnacle Agreement was dated July 2017. The Fourth Amendment provides for a principal available for borrowing of up to $15&#160;million and Cumberland has the ability to request an increase of up to an additional $5&#160;million, upon the satisfaction of certain conditions and approval by Pinnacle Bank. If fully expanded, the Fourth Amendment would provide a maximum principal available for borrowing of up to $20&#160;million.  The Fourth Amendment extended the maturity date of the Pinnacle Agreement through October 1, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 10, 2019, the Company entered into a third amendment ("Third Amendment") to the Pinnacle Agreement, which extended the term of the Pinnacle Agreement through July 31, 2021 as well as modified certain definitions and terms of the existing financial covenants, including the definition of the Funded Debt Ratio and the compliance target of the Tangible Capital Ratio. Both Third Amendment modifications were related to the Vibativ transaction.  Under the Pinnacle Agreement, Cumberland was initially subject to one financial covenant, the maintenance of a Funded Debt Ratio, as such term is defined in the agreement and determined on a quarterly basis.  On August 14, 2018, the Company amended the Pinnacle Agreement ("First Amendment") to replace the single financial covenant with the maintenance of either the Funded Debt Ratio or a Tangible Capital Ratio, as defined in the First Amendment.  The Company was in compliance with the Tangible Capital Ratio financial covenant as of June 30, 2021.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June 30, 2021 and December 31, 2020, the Company had $14.0 million and $15.0 million in borrowings outstanding under its revolving credit facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The interest rate on the Pinnacle Agreement is based on LIBOR plus an interest rate spread. The pricing under the Fourth Amendment provides for an interest rate spread of 1.75% to 2.75% above LIBOR with a minimum LIBOR of 0.90%. The applicable interest rate under the Pinnacle Agreement was 3.65% at June 30, 2021.  In addition, a fee of 0.25% per year is charged on the unused line of credit.  Interest and the unused line fee are payable quarterly.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings under the line of credit are collateralized by substantially all of the Company's assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Paycheck Protection Program Loan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 20, 2020, Cumberland received the funding of a loan from Pinnacle Bank in the amount of $2,187,140 pursuant to the Paycheck Protection Program (the &#x201c;PPP&#x201d;) under the Federal Coronavirus Aid, Relief, and Economic Security Act ("CARES Act"), which was enacted March 27, 2020.  The PPP is administered by the U.S. Small Business Administration ("SBA").&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the PPP requirements, loan funds were used to maintain payroll, continue group health care benefits, and pay for rent and utilities during the pandemic. We applied for this loan after carefully considering, with our bank, the eligibility criteria to participate in this program, and determining that Cumberland met those criteria. We evaluated and provided information on our payroll and other qualifying expenses to determine the amount of PPP funds to apply for. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the PPP, certain amounts of the loan may be forgiven if they are used for qualifying expenses as described in the CARES Act. Cumberland used the PPP loan funds for such qualifying expenses. Due to assistance from our PPP loan, the Company did not lay off or furlough any employees as a result of the COVID-19 pandemic.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland elected to account for the proceeds of the loan as a government grant under &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;International Accounting Standard 20 ("IAS 20"), Accounting for Government Grants and Disclosure of Government Assistance. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The permitted analogous use of  IAS 20 outlines a model for the accounting for government assistance, including forgivable loans. As a result, the Company recorded the $2,187,140 as a deferred income liability, which was included as a component of other current liabilities on the condensed consolidated balance sheet at December 31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2020, Cumberland submitted a request for the loan&#x2019;s forgiveness. On June 11, 2021, the Company received a formal notice from the SBA that the full amount of the loan was forgiven. The Company accounted for the forgiveness of the PPP loan under IAS 20 and recorded the $2,187,140 as other income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Joint Venture Agreement&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, Cumberland entered into an agreement with WinHealth Investment (Singapore) Ltd creating &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;WHC Biopharmaceuticals, Pte. Ltd&lt;/span&gt;. The joint venture, as a limited liability company, will focus on acquiring, developing, registering, and commercializing development stage and commercial stage biopharmaceuticals for China, Hong Kong and other Asian markets.  The agreement provides for initial investment from WinHealth in the form of a $0.2&#160;million equity contribution and an initial investment from Cumberland in the form of a $0.2&#160;million convertible note, which was funded during the first quarter 2021. The joint venture will seek additional future capital from additional investors and has entered into exclusive option agreements to license intellectual property from both Cumberland Pharmaceuticals Inc. and Cumberland Emerging Technologies.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="iea5110fd579441d385d9a44cd82a7b57_I20100513"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180Ni9mcmFnOjc2MjExMDY0NDEzNTRjODE4YmMzOTA3MTA3MTQ3MDk5L3RleHRyZWdpb246NzYyMTEwNjQ0MTM1NGM4MThiYzM5MDcxMDcxNDcwOTlfMTMz_8d20ba3d-dc13-4a46-ba8e-8a65a4837578"
      unitRef="usd">10000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i1e44f0e8ba3a437db0695f10422fa49b_I20160131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180Ni9mcmFnOjc2MjExMDY0NDEzNTRjODE4YmMzOTA3MTA3MTQ3MDk5L3RleHRyZWdpb246NzYyMTEwNjQ0MTM1NGM4MThiYzM5MDcxMDcxNDcwOTlfMjk0_07fb81db-30b5-460d-9044-f851b8fde08e"
      unitRef="usd">10000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i569ae37ae6bd451aba5271c09e866dd6_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180Ni9mcmFnOjc2MjExMDY0NDEzNTRjODE4YmMzOTA3MTA3MTQ3MDk5L3RleHRyZWdpb246NzYyMTEwNjQ0MTM1NGM4MThiYzM5MDcxMDcxNDcwOTlfNDAw_ec7726eb-0eab-45f6-8d7b-f3380c2e3c03"
      unitRef="shares">250129</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i51df30cfe8df40d49c632283258bef9d_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180Ni9mcmFnOjc2MjExMDY0NDEzNTRjODE4YmMzOTA3MTA3MTQ3MDk5L3RleHRyZWdpb246NzYyMTEwNjQ0MTM1NGM4MThiYzM5MDcxMDcxNDcwOTlfNDE0_0645e95f-f610-4aff-9995-24fe9235b1e5"
      unitRef="shares">306329</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i569ae37ae6bd451aba5271c09e866dd6_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180Ni9mcmFnOjc2MjExMDY0NDEzNTRjODE4YmMzOTA3MTA3MTQ3MDk5L3RleHRyZWdpb246NzYyMTEwNjQ0MTM1NGM4MThiYzM5MDcxMDcxNDcwOTlfNDcz_eb0318c0-5d56-4ade-b57c-19946e3a7f06"
      unitRef="usd">800000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i51df30cfe8df40d49c632283258bef9d_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180Ni9mcmFnOjc2MjExMDY0NDEzNTRjODE4YmMzOTA3MTA3MTQ3MDk5L3RleHRyZWdpb246NzYyMTEwNjQ0MTM1NGM4MThiYzM5MDcxMDcxNDcwOTlfNDgw_848face6-4fc4-459d-a069-7f1557baeb49"
      unitRef="usd">1200000</us-gaap:StockRepurchasedDuringPeriodValue>
    <cpix:StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities
      contextRef="i84950ce31a9648138dca94d14b435ecc_D20171101-20171130"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180Ni9mcmFnOjc2MjExMDY0NDEzNTRjODE4YmMzOTA3MTA3MTQ3MDk5L3RleHRyZWdpb246NzYyMTEwNjQ0MTM1NGM4MThiYzM5MDcxMDcxNDcwOTlfOTcz_5cb765e1-b9ab-4819-9e76-1f8887ef6821"
      unitRef="usd">100000000</cpix:StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i6837db1dd6864c6f9523c35e88733824_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180Ni9mcmFnOjc2MjExMDY0NDEzNTRjODE4YmMzOTA3MTA3MTQ3MDk5L3RleHRyZWdpb246NzYyMTEwNjQ0MTM1NGM4MThiYzM5MDcxMDcxNDcwOTlfMTg1OA_9b194600-ee1e-46a0-8109-4e5c0c09f812"
      unitRef="shares">36850</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i7809f262685d483280e68e02e89f4262_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180Ni9mcmFnOjc2MjExMDY0NDEzNTRjODE4YmMzOTA3MTA3MTQ3MDk5L3RleHRyZWdpb246NzYyMTEwNjQ0MTM1NGM4MThiYzM5MDcxMDcxNDcwOTlfMTg3Mg_811e1773-0fdd-4c35-aa54-f9d7e1debe63"
      unitRef="shares">229141</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i6eaa74b46ec44f199aa9dfd669c1664f_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180Ni9mcmFnOjc2MjExMDY0NDEzNTRjODE4YmMzOTA3MTA3MTQ3MDk5L3RleHRyZWdpb246NzYyMTEwNjQ0MTM1NGM4MThiYzM5MDcxMDcxNDcwOTlfODIyMQ_6771156a-0489-4b37-9f0b-fd0b46bfbfa8">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i4f5feacbf7384a1087c1db7cf1ec114c_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180Ni9mcmFnOjc2MjExMDY0NDEzNTRjODE4YmMzOTA3MTA3MTQ3MDk5L3RleHRyZWdpb246NzYyMTEwNjQ0MTM1NGM4MThiYzM5MDcxMDcxNDcwOTlfMjE1Nw_9a336b6f-b61f-4cb4-b43f-646f851f08e7"
      unitRef="shares">173350</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ifadcff6052794ad7afbe6463edf069fc_I20201007"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180Ni9mcmFnOjc2MjExMDY0NDEzNTRjODE4YmMzOTA3MTA3MTQ3MDk5L3RleHRyZWdpb246NzYyMTEwNjQ0MTM1NGM4MThiYzM5MDcxMDcxNDcwOTlfMjgxNQ_822a9130-9034-4aab-a51c-3afb2f7391b4"
      unitRef="usd">15000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <cpix:LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount
      contextRef="ifadcff6052794ad7afbe6463edf069fc_I20201007"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180Ni9mcmFnOjc2MjExMDY0NDEzNTRjODE4YmMzOTA3MTA3MTQ3MDk5L3RleHRyZWdpb246NzYyMTEwNjQ0MTM1NGM4MThiYzM5MDcxMDcxNDcwOTlfMjg5NQ_b0c7eda1-00b7-4bdc-84b0-be49f02f1eef"
      unitRef="usd">5000000</cpix:LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount>
    <cpix:LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity
      contextRef="ifadcff6052794ad7afbe6463edf069fc_I20201007"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180Ni9mcmFnOjc2MjExMDY0NDEzNTRjODE4YmMzOTA3MTA3MTQ3MDk5L3RleHRyZWdpb246NzYyMTEwNjQ0MTM1NGM4MThiYzM5MDcxMDcxNDcwOTlfMzA4MQ_85055d96-acf2-49ef-840b-a454bc31c501"
      unitRef="usd">20000000</cpix:LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity>
    <us-gaap:LongTermLineOfCredit
      contextRef="i7949c2029147408c82a03b03371c2934_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180Ni9mcmFnOjc2MjExMDY0NDEzNTRjODE4YmMzOTA3MTA3MTQ3MDk5L3RleHRyZWdpb246NzYyMTEwNjQ0MTM1NGM4MThiYzM5MDcxMDcxNDcwOTlfNDIxMg_da91aace-079d-477e-b7c4-97ca4fd58910"
      unitRef="usd">14000000.0</us-gaap:LongTermLineOfCredit>
    <us-gaap:LongTermLineOfCredit
      contextRef="id63b8386c6dd4a9096c2f08b1caa166d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180Ni9mcmFnOjc2MjExMDY0NDEzNTRjODE4YmMzOTA3MTA3MTQ3MDk5L3RleHRyZWdpb246NzYyMTEwNjQ0MTM1NGM4MThiYzM5MDcxMDcxNDcwOTlfMTA5OTUxMTYzNjAxMQ_969c1ec4-1f66-4a99-944f-303b3a195a79"
      unitRef="usd">15000000.0</us-gaap:LongTermLineOfCredit>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="iec72b3e70c5e4d5b9f0a256af0a2e6eb_D20200814-20200814"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180Ni9mcmFnOjc2MjExMDY0NDEzNTRjODE4YmMzOTA3MTA3MTQ3MDk5L3RleHRyZWdpb246NzYyMTEwNjQ0MTM1NGM4MThiYzM5MDcxMDcxNDcwOTlfNDQ0OQ_e0c77484-8a00-44bd-bdf7-73cd9bec44e3"
      unitRef="number">0.0175</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i42c0403c56e842038637f32dfa213083_D20200814-20200814"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180Ni9mcmFnOjc2MjExMDY0NDEzNTRjODE4YmMzOTA3MTA3MTQ3MDk5L3RleHRyZWdpb246NzYyMTEwNjQ0MTM1NGM4MThiYzM5MDcxMDcxNDcwOTlfNDQ1NQ_ebad8dd5-c833-4ed5-bd00-fc8b001af034"
      unitRef="number">0.0275</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i4487ea5e24834d4bb26ece0c7fc05f81_D20200814-20200814"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180Ni9mcmFnOjc2MjExMDY0NDEzNTRjODE4YmMzOTA3MTA3MTQ3MDk5L3RleHRyZWdpb246NzYyMTEwNjQ0MTM1NGM4MThiYzM5MDcxMDcxNDcwOTlfNDQ5NA_1fa55020-43e2-4daa-b374-194e9d37a2cc"
      unitRef="number">0.0090</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic1ff553c5d964f12b7361c40d75ba752_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180Ni9mcmFnOjc2MjExMDY0NDEzNTRjODE4YmMzOTA3MTA3MTQ3MDk5L3RleHRyZWdpb246NzYyMTEwNjQ0MTM1NGM4MThiYzM5MDcxMDcxNDcwOTlfNDU2MA_cc2ff146-3f97-45c3-8071-bf45f2acad89"
      unitRef="number">0.0365</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="i22d029b9f8fc4612bd2da5c75672b40a_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180Ni9mcmFnOjc2MjExMDY0NDEzNTRjODE4YmMzOTA3MTA3MTQ3MDk5L3RleHRyZWdpb246NzYyMTEwNjQ0MTM1NGM4MThiYzM5MDcxMDcxNDcwOTlfNDU5Mw_23fd2a7e-b13d-4a96-a729-795ae48b89e4"
      unitRef="number">0.0025</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <cpix:TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived
      contextRef="i3ea7837abdfa48999669b93f02fe29d4_D20200420-20200420"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180Ni9mcmFnOjc2MjExMDY0NDEzNTRjODE4YmMzOTA3MTA3MTQ3MDk5L3RleHRyZWdpb246NzYyMTEwNjQ0MTM1NGM4MThiYzM5MDcxMDcxNDcwOTlfNDkyNw_f573256b-2007-4b99-8426-1baedc046de1"
      unitRef="usd">2187140</cpix:TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived>
    <cpix:TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived
      contextRef="i3ea7837abdfa48999669b93f02fe29d4_D20200420-20200420"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180Ni9mcmFnOjc2MjExMDY0NDEzNTRjODE4YmMzOTA3MTA3MTQ3MDk5L3RleHRyZWdpb246NzYyMTEwNjQ0MTM1NGM4MThiYzM5MDcxMDcxNDcwOTlfNjE4OA_c5a60c6b-d7ae-4370-be14-81bf410cfa98"
      unitRef="usd">2187140</cpix:TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived>
    <cpix:TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived
      contextRef="i3ea7837abdfa48999669b93f02fe29d4_D20200420-20200420"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180Ni9mcmFnOjc2MjExMDY0NDEzNTRjODE4YmMzOTA3MTA3MTQ3MDk5L3RleHRyZWdpb246NzYyMTEwNjQ0MTM1NGM4MThiYzM5MDcxMDcxNDcwOTlfMTA5OTUxMTYzOTkwMw_c5a60c6b-d7ae-4370-be14-81bf410cfa98"
      unitRef="usd">2187140</cpix:TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i3738112144924be8b7ed4df49c530139_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180Ni9mcmFnOjc2MjExMDY0NDEzNTRjODE4YmMzOTA3MTA3MTQ3MDk5L3RleHRyZWdpb246NzYyMTEwNjQ0MTM1NGM4MThiYzM5MDcxMDcxNDcwOTlfNzgwOA_6804d17c-515c-4b03-bca9-488fca64b373"
      unitRef="usd">200000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i5161e91b97f647a1a447fe4ae410abff_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180Ni9mcmFnOjc2MjExMDY0NDEzNTRjODE4YmMzOTA3MTA3MTQ3MDk5L3RleHRyZWdpb246NzYyMTEwNjQ0MTM1NGM4MThiYzM5MDcxMDcxNDcwOTlfNzg5MA_c8634ac8-9926-4544-a554-060fc670655d"
      unitRef="usd">200000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180OS9mcmFnOjQyYjc2MDI0M2I4OTRjOTBhZjUxODJmNWUyY2M3YmVlL3RleHRyZWdpb246NDJiNzYwMjQzYjg5NGM5MGFmNTE4MmY1ZTJjYzdiZWVfNjM1_233052a4-666a-40b6-9d50-487746ca1fa7">INCOME TAXESAs of June 30, 2021, the Company has approximately $56.5 million in federal net operating loss carryforwards including approximately $44.1 million of net operating loss carryforwards resulting from the exercise of nonqualified stock options. These have historically been used to significantly offset income tax obligations. The Company expects it will continue to pay minimal income taxes during 2021 and beyond, through the continued utilization of these net operating loss carryforwards, on any taxable income generated from our operations. The Company does not allocate any portion of its income tax expense (benefit) to discontinued operations.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i93503f9d933448f182c19f672ad05ba9_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180OS9mcmFnOjQyYjc2MDI0M2I4OTRjOTBhZjUxODJmNWUyY2M3YmVlL3RleHRyZWdpb246NDJiNzYwMjQzYjg5NGM5MGFmNTE4MmY1ZTJjYzdiZWVfNjI_6f83c77d-1126-4646-94ab-666940c0b9d0"
      unitRef="usd">56500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="iba716d2d6c004c9c85738b68d83bc0b7_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM180OS9mcmFnOjQyYjc2MDI0M2I4OTRjOTBhZjUxODJmNWUyY2M3YmVlL3RleHRyZWdpb246NDJiNzYwMjQzYjg5NGM5MGFmNTE4MmY1ZTJjYzdiZWVfMTMz_f0fa9450-52b5-460b-8899-8aec8f26c58f"
      unitRef="usd">44100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181Mi9mcmFnOjcyZmEyMTJmMzU2YTQyZWY5NmEwMzRhNTRiODNiZWYxL3RleHRyZWdpb246NzJmYTIxMmYzNTZhNDJlZjk2YTAzNGE1NGI4M2JlZjFfMTAyNw_9880cefd-cdf8-4622-9c12-a8f8252b1655">COLLABORATIVE AGREEMENTS&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland is a party to several collaborative arrangements with research institutions to identify and pursue promising pharmaceutical product candidates. The funding for these programs is primarily provided through Federal Small Business Administration (SBIR/STTR) and other grant awards. The Company has determined that these collaborative agreements, with the exception of the collaborative payment received related to RediTrex, do not meet the criteria for accounting under ASC Topic 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Agreements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The agreements do not specifically designate each party&#x2019;s rights and obligations to each other under the collaborative arrangements. Except for patent defense costs, expenses incurred by one party are not required to be reimbursed by the other party.  Expenses incurred under these collaborative agreements are included in research and development expenses and funding received from grants are recorded as net revenues in the condensed consolidated statements of operations.&lt;/span&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RleHRyZWdpb246MGZlYjk3NjIxNmQ3NGJiNzlhYmM0YjZhZjNhZGRiMWRfNTg0MQ_0b247c2d-cbd5-4fb2-b689-32ecb9b56b21">ADDITIONS AND RETURN OF PRODUCT RIGHTS&lt;div style="margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Vibativ&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During November 2018, the Company closed on an agreement with Theravance Biopharma ("Theravance") to acquire the global responsibility for Vibativ including the marketing, distribution, manufacturing and regulatory activities associated with the brand.  Vibativ is a patented, Food and Drug Administration ("FDA") approved injectable anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland has accounted for the transaction as a business combination in accordance with ASC 805 and the product sales are included in the results of operations subsequent to the acquisition date. The Company made an upfront payment of $20.0&#160;million at the closing of the transaction and a $5.0&#160;million milestone payment in early April 2019. In addition, Cumberland has agreed to pay a royalty of up to 20% of on-going net sales of the product.  The future royalty payments were required to be recognized at their acquisition-date fair value as a contingent consideration liability, as part of the contingent consideration transferred in the business combination. Cumberland prepared the valuations of the contingent consideration liability utilizing significant unobservable inputs.  As a result, the valuation is classified as Level 3 fair value measurement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis.  The contingent consideration earned and accrued in operating expenses is paid to Theravance quarterly.&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.345%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,200,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payment of royalty during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,423,586)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration included in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(180,110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration earned and accrued in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;760,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,357,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contingent consideration liability of $7.4&#160;million was classified as other current liabilities of $2.9&#160;million and other long-term liabilities of $4.5&#160;million on the condensed consolidated balance sheet as of June 30, 2021.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;RediTrex&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2016, the Company announced an agreement with the Nordic Group B.V. ("Nordic") to acquire the exclusive U.S. rights to Nordic&#x2019;s injectable methotrexate product line designed for the treatment of active rheumatoid arthritis, juvenile idiopathic arthritis, severe psoriatic arthritis, and severe disabling psoriasis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As consideration for the license Cumberland paid a deposit of $100,000 at closing.  The Company provided $0.9&#160;million in consideration through a grant of 180,000 restricted shares of Cumberland common stock to be vested upon the FDA approval of the first Nordic product. Cumberland also agreed to provide Nordic a series of payments tied to the products&#x2019; FDA approval, launch and achievement of certain sales milestones. Under the terms of the agreement, Cumberland is responsible for the product registration and commercialization in the U.S. Nordic is responsible for product manufacturing and supply.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 27, 2019, Cumberland received FDA approval for the first Nordic injectable product and authorization to market them under the RediTrex brand name.  The 180,000 shares of restricted Cumberland common stock previously provided to Nordic vested upon approval and were valued at $0.9&#160;million on the vesting date. The FDA approval also resulted in a $1.0&#160;million milestone payment due to Nordic.  During December 2020, Cumberland introduced RediTrex and the launch that will take place in late 2021 will result in a $1.0&#160;million milestone payment due to Nordic.  This milestone payment will be paid during 2022 and is being reported as a current liability at June 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland has approximately $2.7&#160;million in net intangible assets related to RediTrex at June 30, 2021.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Ethyol and Totect &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2016, Cumberland entered into an agreement with Clinigen for the rights and responsibilities associated with the commercialization of Ethyol in the United States.  In 2017, the Company entered into another agreement with Clinigen for the rights and responsibilities associated with the commercialization of Totect in the United States.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Early in 2019, Cumberland announced a strategic review of the Company's brands, capabilities, and international partners. This review followed an accelerated business development initiative, which resulted in a series of transactions. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During May 2019, Cumberland entered into the Dissolution Agreement with Clinigen in which the Company returned the exclusive rights to commercialize Ethyol and Totect&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in the United States to Clinigen. Under the final terms of the Dissolution Agreement, Cumberland was no longer responsible for the distribution, marketing and promotion of either Ethyol or Totect or any competing products after December 31, 2019.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In exchange for the return of these product license rights and the non-compete provisions of the Dissolution Agreement, Cumberland is receiving $5&#160;million in financial consideration paid in quarterly installments over the two-years following the transition date. Cumberland recorded the first four quarterly installments totaling $3.0 million during 2020 and the next two installments totaling $1.0 million during the six months ended June 30, 2021, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;as discontinued operations.  The Company will record the remaining two quarterly installments during the balance of 2021.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The exit from Ethyol and Totect meets the accounting criteria to be reported as discontinued operations. December 31, 2019, as the transition date, was the final day Cumberland was responsible for the products. Cumberland was responsible for the products through December 31, 2019 and beginning on January 1, 2020, the products' rights transitioned back to Clinigen. As a result, January 1, 2020, was the first day of discontinued operations for the Ethyol and Totect products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The dissolution payments from Clinigen are reflected as revenue from discontinued operations.  The Company does not &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;incur expenses associated with these payments from Clinigen. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.590%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.499%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Six months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;738,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;994,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,556,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Costs of products sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, Marketing and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;738,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;994,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,556,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="idfbdaba777624b8b96b3800f1e5753bf_D20181101-20181130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RleHRyZWdpb246MGZlYjk3NjIxNmQ3NGJiNzlhYmM0YjZhZjNhZGRiMWRfOTY3_6f80e612-e4b8-44f2-96aa-9489c8ab84c7"
      unitRef="usd">20000000.0</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:OtherPaymentsToAcquireBusinesses
      contextRef="idfbdaba777624b8b96b3800f1e5753bf_D20181101-20181130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RleHRyZWdpb246MGZlYjk3NjIxNmQ3NGJiNzlhYmM0YjZhZjNhZGRiMWRfMTAxMA_fd23de30-4d82-481f-9279-146703059160"
      unitRef="usd">5000000.0</us-gaap:OtherPaymentsToAcquireBusinesses>
    <cpix:TieredRoyaltyPaymentsPercentage
      contextRef="idfbdaba777624b8b96b3800f1e5753bf_D20181101-20181130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RleHRyZWdpb246MGZlYjk3NjIxNmQ3NGJiNzlhYmM0YjZhZjNhZGRiMWRfMTExMw_9763332d-33f5-4424-b95c-a5658171c968"
      unitRef="number">0.20</cpix:TieredRoyaltyPaymentsPercentage>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RleHRyZWdpb246MGZlYjk3NjIxNmQ3NGJiNzlhYmM0YjZhZjNhZGRiMWRfNTg0Mw_e38e2e17-30e8-4370-903f-d63d88f56734">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis.  The contingent consideration earned and accrued in operating expenses is paid to Theravance quarterly.&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.345%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,200,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payment of royalty during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,423,586)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration included in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(180,110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration earned and accrued in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;760,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,357,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i6742997b2ea4497a8b57f546e21e37aa_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RhYmxlOmZlNTllYmZmOTk4OTQ2ZDY5YmUyYzk0MDliOWUwZjZiL3RhYmxlcmFuZ2U6ZmU1OWViZmY5OTg5NDZkNjliZTJjOTQwOWI5ZTBmNmJfOS0xLTEtMS0w_4e2164eb-eddb-4017-b250-361e039a32e7"
      unitRef="usd">8200552</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:PaymentsForRoyalties
      contextRef="i666e3ad219a249f69a70f9d7525a1f8b_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RhYmxlOmZlNTllYmZmOTk4OTQ2ZDY5YmUyYzk0MDliOWUwZjZiL3RhYmxlcmFuZ2U6ZmU1OWViZmY5OTg5NDZkNjliZTJjOTQwOWI5ZTBmNmJfMTAtMS0xLTEtMA_322a0500-f232-4d8d-8ece-894c02e0f2b3"
      unitRef="usd">1423586</us-gaap:PaymentsForRoyalties>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i666e3ad219a249f69a70f9d7525a1f8b_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RhYmxlOmZlNTllYmZmOTk4OTQ2ZDY5YmUyYzk0MDliOWUwZjZiL3RhYmxlcmFuZ2U6ZmU1OWViZmY5OTg5NDZkNjliZTJjOTQwOWI5ZTBmNmJfMTEtMS0xLTEtMA_6968bc16-09fe-4b20-8fc1-d4297de74fc7"
      unitRef="usd">-180110</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses
      contextRef="i666e3ad219a249f69a70f9d7525a1f8b_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RhYmxlOmZlNTllYmZmOTk4OTQ2ZDY5YmUyYzk0MDliOWUwZjZiL3RhYmxlcmFuZ2U6ZmU1OWViZmY5OTg5NDZkNjliZTJjOTQwOWI5ZTBmNmJfMTItMS0xLTEtMA_a2fa170d-1a86-4b9e-bafd-ebaed3183a0d"
      unitRef="usd">760225</cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ifaa5fd674df1464290cfa2809fea1eaf_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RhYmxlOmZlNTllYmZmOTk4OTQ2ZDY5YmUyYzk0MDliOWUwZjZiL3RhYmxlcmFuZ2U6ZmU1OWViZmY5OTg5NDZkNjliZTJjOTQwOWI5ZTBmNmJfMTMtMS0xLTEtMA_f2799e1d-4ec4-4e05-8098-196351808896"
      unitRef="usd">7357081</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ifaa5fd674df1464290cfa2809fea1eaf_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RleHRyZWdpb246MGZlYjk3NjIxNmQ3NGJiNzlhYmM0YjZhZjNhZGRiMWRfMTg1OA_01dc136d-39ec-417b-849f-2c8efa3add9d"
      unitRef="usd">7400000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ieca5d4731d90438e81ee926eb9a44d99_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RleHRyZWdpb246MGZlYjk3NjIxNmQ3NGJiNzlhYmM0YjZhZjNhZGRiMWRfMTkwOA_fbd7acaf-f43e-47b1-9367-0a28d48b0c21"
      unitRef="usd">2900000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i543d802ba6254fea92215d118fe3fb4e_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RleHRyZWdpb246MGZlYjk3NjIxNmQ3NGJiNzlhYmM0YjZhZjNhZGRiMWRfMTk0Ng_4d13ca46-540e-4391-9291-6bc5c38955de"
      unitRef="usd">4500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i1f48945eef8d4b2d820f10f38c6f7a00_D20161101-20161130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RleHRyZWdpb246MGZlYjk3NjIxNmQ3NGJiNzlhYmM0YjZhZjNhZGRiMWRfMjQwNA_73e67b2a-30a5-40c5-a3a4-47a7f1742857"
      unitRef="usd">100000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred
      contextRef="i1f48945eef8d4b2d820f10f38c6f7a00_D20161101-20161130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RleHRyZWdpb246MGZlYjk3NjIxNmQ3NGJiNzlhYmM0YjZhZjNhZGRiMWRfMjQ0MQ_2069b6c9-e3b5-4c25-8370-81ee33a0c2c6"
      unitRef="usd">900000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="ib90d441c6774404295b76ceae446e40d_D20161101-20161130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RleHRyZWdpb246MGZlYjk3NjIxNmQ3NGJiNzlhYmM0YjZhZjNhZGRiMWRfMjQ4MA_1cfe0deb-3154-498d-9f70-c6567b7fd2b8"
      unitRef="shares">180000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="ib90d441c6774404295b76ceae446e40d_D20161101-20161130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RleHRyZWdpb246MGZlYjk3NjIxNmQ3NGJiNzlhYmM0YjZhZjNhZGRiMWRfMzA5MQ_4e8ae41f-37d0-4ddc-bc84-a96197380fb3"
      unitRef="shares">180000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i537c330f50e745f197afdd484a2730ec_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RleHRyZWdpb246MGZlYjk3NjIxNmQ3NGJiNzlhYmM0YjZhZjNhZGRiMWRfMzIwOQ_31a509b7-41db-4a46-96e3-047b0af5b99c"
      unitRef="usd">900000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i0b8a1a744ec04c1d913f27f1efc5efa2_I20200731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RleHRyZWdpb246MGZlYjk3NjIxNmQ3NGJiNzlhYmM0YjZhZjNhZGRiMWRfMzI2OQ_7e973f0a-fe66-42bd-a3fe-d5f2ed709b02"
      unitRef="usd">1000000.0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i9e8de0e06633438faeea349c72c801a5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RleHRyZWdpb246MGZlYjk3NjIxNmQ3NGJiNzlhYmM0YjZhZjNhZGRiMWRfMjc0ODc3OTA3NTYwNQ_ce0078b9-0b87-4071-b828-a377b958d239"
      unitRef="usd">1000000.0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i452c4da6ebcf4c4ebc44e66aaa120e9b_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RleHRyZWdpb246MGZlYjk3NjIxNmQ3NGJiNzlhYmM0YjZhZjNhZGRiMWRfMzU4NA_47f96630-1062-49a1-a2e4-c438f6b17154"
      unitRef="usd">2700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:ProceedsFromSaleOfIntangibleAssets
      contextRef="i8f2247edd8fd4841affbe5d013f55977_D20191001-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RleHRyZWdpb246MGZlYjk3NjIxNmQ3NGJiNzlhYmM0YjZhZjNhZGRiMWRfNDc5Ng_f54f9166-1fff-4242-8cc6-c6bc3d120bca"
      unitRef="usd">5000000</us-gaap:ProceedsFromSaleOfIntangibleAssets>
    <cpix:ProceedsFromSaleOfIntangibleAssetsInstallmentPayment
      contextRef="i8613f3fef30a4cf99a52244890006824_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RleHRyZWdpb246MGZlYjk3NjIxNmQ3NGJiNzlhYmM0YjZhZjNhZGRiMWRfNDk3NA_ec0d0e86-6808-4cac-b2b3-7cd453fb8aa9"
      unitRef="usd">3000000.0</cpix:ProceedsFromSaleOfIntangibleAssetsInstallmentPayment>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="i53d85ca5dcbd44ba870830f97461a800_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RleHRyZWdpb246MGZlYjk3NjIxNmQ3NGJiNzlhYmM0YjZhZjNhZGRiMWRfMTA5OTUxMTYzMzY2Ng_38c2c8f4-0913-4445-a238-2d1934f0c714"
      unitRef="usd">1000000.0</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock
      contextRef="i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RleHRyZWdpb246MGZlYjk3NjIxNmQ3NGJiNzlhYmM0YjZhZjNhZGRiMWRfNTg0NA_a50756f2-8640-467c-af56-6a46cf244a29">&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The dissolution payments from Clinigen are reflected as revenue from discontinued operations.  The Company does not &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;incur expenses associated with these payments from Clinigen. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.590%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.499%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Six months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;738,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;994,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,556,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Costs of products sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, Marketing and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;738,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;994,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,556,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0932967c9c90454494cbf245d9fa585d_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RhYmxlOmI0ZDgzZDVmYmQ0ZjQzYWI5YWIxMjFiZmMyNjAxZDQxL3RhYmxlcmFuZ2U6YjRkODNkNWZiZDRmNDNhYjlhYjEyMWJmYzI2MDFkNDFfMy0yLTEtMS02Nzc_33139f42-0425-4d08-841a-9ae006c66914"
      unitRef="usd">498807</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iffc2a4291a32445fb79072f7fe43a870_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RhYmxlOmI0ZDgzZDVmYmQ0ZjQzYWI5YWIxMjFiZmMyNjAxZDQxL3RhYmxlcmFuZ2U6YjRkODNkNWZiZDRmNDNhYjlhYjEyMWJmYzI2MDFkNDFfMy00LTEtMS02ODA_cf0ce557-4fdd-47c1-9191-c917bd799f4a"
      unitRef="usd">738622</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i53d85ca5dcbd44ba870830f97461a800_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RhYmxlOmI0ZDgzZDVmYmQ0ZjQzYWI5YWIxMjFiZmMyNjAxZDQxL3RhYmxlcmFuZ2U6YjRkODNkNWZiZDRmNDNhYjlhYjEyMWJmYzI2MDFkNDFfMi0yLTEtMS0w_1bcf2509-7467-4c5c-b800-3d442a6bcef9"
      unitRef="usd">994217</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i166678b245754127b39f5e9c73e8cf2d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RhYmxlOmI0ZDgzZDVmYmQ0ZjQzYWI5YWIxMjFiZmMyNjAxZDQxL3RhYmxlcmFuZ2U6YjRkODNkNWZiZDRmNDNhYjlhYjEyMWJmYzI2MDFkNDFfMi00LTEtMS0w_72de53a1-48b1-4c79-aa3d-faa22b8da99b"
      unitRef="usd">1556895</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i0932967c9c90454494cbf245d9fa585d_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RhYmxlOmI0ZDgzZDVmYmQ0ZjQzYWI5YWIxMjFiZmMyNjAxZDQxL3RhYmxlcmFuZ2U6YjRkODNkNWZiZDRmNDNhYjlhYjEyMWJmYzI2MDFkNDFfNC0yLTEtMS0xOTMy_73e3971e-9ede-43ec-a884-d62e3d3ee54d"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="iffc2a4291a32445fb79072f7fe43a870_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RhYmxlOmI0ZDgzZDVmYmQ0ZjQzYWI5YWIxMjFiZmMyNjAxZDQxL3RhYmxlcmFuZ2U6YjRkODNkNWZiZDRmNDNhYjlhYjEyMWJmYzI2MDFkNDFfNC00LTEtMS0xOTMy_1586e2f5-0081-4c1c-9682-66cbd4db029d"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i53d85ca5dcbd44ba870830f97461a800_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RhYmxlOmI0ZDgzZDVmYmQ0ZjQzYWI5YWIxMjFiZmMyNjAxZDQxL3RhYmxlcmFuZ2U6YjRkODNkNWZiZDRmNDNhYjlhYjEyMWJmYzI2MDFkNDFfMy0yLTEtMS0w_c6231f1b-81ff-41ca-87cd-8167c4dfb7c1"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i166678b245754127b39f5e9c73e8cf2d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RhYmxlOmI0ZDgzZDVmYmQ0ZjQzYWI5YWIxMjFiZmMyNjAxZDQxL3RhYmxlcmFuZ2U6YjRkODNkNWZiZDRmNDNhYjlhYjEyMWJmYzI2MDFkNDFfMy00LTEtMS0w_cf7336e0-920d-409c-b057-e4f14bfcab55"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingAndMarketingExpense
      contextRef="i0932967c9c90454494cbf245d9fa585d_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RhYmxlOmI0ZDgzZDVmYmQ0ZjQzYWI5YWIxMjFiZmMyNjAxZDQxL3RhYmxlcmFuZ2U6YjRkODNkNWZiZDRmNDNhYjlhYjEyMWJmYzI2MDFkNDFfNS0yLTEtMS0xOTMy_0ded215b-1970-4e65-82ee-aab2661aaa70"
      unitRef="usd">0</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="iffc2a4291a32445fb79072f7fe43a870_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RhYmxlOmI0ZDgzZDVmYmQ0ZjQzYWI5YWIxMjFiZmMyNjAxZDQxL3RhYmxlcmFuZ2U6YjRkODNkNWZiZDRmNDNhYjlhYjEyMWJmYzI2MDFkNDFfNS00LTEtMS0xOTMy_f002396c-2013-481d-8d86-1381b0958c78"
      unitRef="usd">0</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="i53d85ca5dcbd44ba870830f97461a800_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RhYmxlOmI0ZDgzZDVmYmQ0ZjQzYWI5YWIxMjFiZmMyNjAxZDQxL3RhYmxlcmFuZ2U6YjRkODNkNWZiZDRmNDNhYjlhYjEyMWJmYzI2MDFkNDFfNC0yLTEtMS0w_da98a761-aded-447e-bea5-e45be2b6c435"
      unitRef="usd">0</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="i166678b245754127b39f5e9c73e8cf2d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RhYmxlOmI0ZDgzZDVmYmQ0ZjQzYWI5YWIxMjFiZmMyNjAxZDQxL3RhYmxlcmFuZ2U6YjRkODNkNWZiZDRmNDNhYjlhYjEyMWJmYzI2MDFkNDFfNC00LTEtMS0w_08b0d6a7-6055-4baa-a480-0f544d9b0569"
      unitRef="usd">0</us-gaap:SellingAndMarketingExpense>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i0932967c9c90454494cbf245d9fa585d_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RhYmxlOmI0ZDgzZDVmYmQ0ZjQzYWI5YWIxMjFiZmMyNjAxZDQxL3RhYmxlcmFuZ2U6YjRkODNkNWZiZDRmNDNhYjlhYjEyMWJmYzI2MDFkNDFfNi0yLTEtMS0xOTMy_9c49a1ee-6ffb-4239-938f-58eb8cd99fd1"
      unitRef="usd">498807</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="iffc2a4291a32445fb79072f7fe43a870_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RhYmxlOmI0ZDgzZDVmYmQ0ZjQzYWI5YWIxMjFiZmMyNjAxZDQxL3RhYmxlcmFuZ2U6YjRkODNkNWZiZDRmNDNhYjlhYjEyMWJmYzI2MDFkNDFfNi00LTEtMS0xOTMy_8a8d90d1-b209-4db6-83bd-e6da9e3763cb"
      unitRef="usd">738622</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i53d85ca5dcbd44ba870830f97461a800_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RhYmxlOmI0ZDgzZDVmYmQ0ZjQzYWI5YWIxMjFiZmMyNjAxZDQxL3RhYmxlcmFuZ2U6YjRkODNkNWZiZDRmNDNhYjlhYjEyMWJmYzI2MDFkNDFfNS0yLTEtMS0w_73a58345-6061-4cea-815c-c24f309a2f82"
      unitRef="usd">994217</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i166678b245754127b39f5e9c73e8cf2d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwZmFhMDZhODkwOTQ0NmZhMjM5NGY1OWMxNDkwYTAzL3NlYzpkMGZhYTA2YTg5MDk0NDZmYTIzOTRmNTljMTQ5MGEwM181NS9mcmFnOjBmZWI5NzYyMTZkNzRiYjc5YWJjNGI2YWYzYWRkYjFkL3RhYmxlOmI0ZDgzZDVmYmQ0ZjQzYWI5YWIxMjFiZmMyNjAxZDQxL3RhYmxlcmFuZ2U6YjRkODNkNWZiZDRmNDNhYjlhYjEyMWJmYzI2MDFkNDFfNS00LTEtMS0w_6439f0f5-4367-45f6-bc88-8c80fbf93e63"
      unitRef="usd">1556895</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140141276959832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Aug. 09, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Cumberland Pharmaceuticals Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">TN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">62-1765329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2525 West End Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Nashville<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">37203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">255-0068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, no par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CPIX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,879,599<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001087294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140141275923512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 25,670,462<span></span>
</td>
<td class="nump">$ 24,753,796<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">9,147,493<span></span>
</td>
<td class="nump">12,377,713<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">10,104,219<span></span>
</td>
<td class="nump">10,638,157<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">1,758,332<span></span>
</td>
<td class="nump">2,199,926<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">46,680,506<span></span>
</td>
<td class="nump">49,969,592<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Non-current inventories</a></td>
<td class="nump">9,880,766<span></span>
</td>
<td class="nump">11,656,742<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">493,256<span></span>
</td>
<td class="nump">574,169<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">25,888,622<span></span>
</td>
<td class="nump">28,118,316<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">882,000<span></span>
</td>
<td class="nump">882,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">1,535,556<span></span>
</td>
<td class="nump">2,028,148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">3,490,768<span></span>
</td>
<td class="nump">3,234,338<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">88,851,474<span></span>
</td>
<td class="nump">96,463,305<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">8,962,916<span></span>
</td>
<td class="nump">13,396,286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease current liabilities</a></td>
<td class="nump">1,067,880<span></span>
</td>
<td class="nump">1,016,779<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">8,615,995<span></span>
</td>
<td class="nump">11,254,381<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">18,646,791<span></span>
</td>
<td class="nump">25,667,446<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLineOfCredit', window );">Revolving line of credit</a></td>
<td class="nump">14,000,000<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease noncurrent liabilities</a></td>
<td class="nump">512,324<span></span>
</td>
<td class="nump">1,059,693<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_OtherLongTermObligationsExcludingCurrentPortion', window );">Other long-term liabilities</a></td>
<td class="nump">7,883,952<span></span>
</td>
<td class="nump">7,862,772<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">41,043,067<span></span>
</td>
<td class="nump">49,589,911<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock&#8212;no par value; 100,000,000 shares authorized; 15,555,865 and 15,723,075 shares issued and outstanding as of June 30, 2018 and December 31, 2017, respectively</a></td>
<td class="nump">48,688,384<span></span>
</td>
<td class="nump">49,121,523<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings (deficit)</a></td>
<td class="num">(735,625)<span></span>
</td>
<td class="num">(2,131,013)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">47,952,759<span></span>
</td>
<td class="nump">46,990,510<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="num">(144,352)<span></span>
</td>
<td class="num">(117,116)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">47,808,407<span></span>
</td>
<td class="nump">46,873,394<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 88,851,474<span></span>
</td>
<td class="nump">$ 96,463,305<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_OtherLongTermObligationsExcludingCurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Long Term Obligations, Excluding Current Portion</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_OtherLongTermObligationsExcludingCurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1336-112600<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1314-112600<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140141270654200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">14,926,059<span></span>
</td>
<td class="nump">14,988,429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">14,926,059<span></span>
</td>
<td class="nump">14,988,429<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140141275280600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">$ 9,055,483<span></span>
</td>
<td class="nump">$ 9,598,177<span></span>
</td>
<td class="nump">$ 19,592,642<span></span>
</td>
<td class="nump">$ 17,928,911<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of products sold</a></td>
<td class="nump">1,740,649<span></span>
</td>
<td class="nump">2,609,982<span></span>
</td>
<td class="nump">4,157,978<span></span>
</td>
<td class="nump">4,244,163<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Selling and marketing</a></td>
<td class="nump">4,121,817<span></span>
</td>
<td class="nump">3,865,406<span></span>
</td>
<td class="nump">7,909,157<span></span>
</td>
<td class="nump">7,573,082<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">1,360,398<span></span>
</td>
<td class="nump">1,421,502<span></span>
</td>
<td class="nump">2,617,765<span></span>
</td>
<td class="nump">3,144,057<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">2,097,130<span></span>
</td>
<td class="nump">2,190,764<span></span>
</td>
<td class="nump">4,327,639<span></span>
</td>
<td class="nump">4,227,048<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization</a></td>
<td class="nump">1,171,218<span></span>
</td>
<td class="nump">1,091,485<span></span>
</td>
<td class="nump">2,340,132<span></span>
</td>
<td class="nump">2,167,524<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">10,491,212<span></span>
</td>
<td class="nump">11,179,139<span></span>
</td>
<td class="nump">21,352,671<span></span>
</td>
<td class="nump">21,355,874<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="num">(1,435,729)<span></span>
</td>
<td class="num">(1,580,962)<span></span>
</td>
<td class="num">(1,760,029)<span></span>
</td>
<td class="num">(3,426,963)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">6,591<span></span>
</td>
<td class="nump">28,661<span></span>
</td>
<td class="nump">12,017<span></span>
</td>
<td class="nump">58,549<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other income</a></td>
<td class="nump">2,187,140<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,187,140<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(25,859)<span></span>
</td>
<td class="num">(119,455)<span></span>
</td>
<td class="num">(50,276)<span></span>
</td>
<td class="num">(152,520)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income (loss) from continuing operations before income taxes</a></td>
<td class="nump">732,143<span></span>
</td>
<td class="num">(1,671,756)<span></span>
</td>
<td class="nump">388,852<span></span>
</td>
<td class="num">(3,520,934)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (expense) benefit</a></td>
<td class="num">(7,459)<span></span>
</td>
<td class="num">(7,455)<span></span>
</td>
<td class="num">(14,917)<span></span>
</td>
<td class="num">(41,695)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest, Total</a></td>
<td class="nump">724,684<span></span>
</td>
<td class="num">(1,679,211)<span></span>
</td>
<td class="nump">373,935<span></span>
</td>
<td class="num">(3,562,629)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">994,217<span></span>
</td>
<td class="nump">1,556,895<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">1,223,491<span></span>
</td>
<td class="num">(940,589)<span></span>
</td>
<td class="nump">1,368,152<span></span>
</td>
<td class="num">(2,005,734)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net (income) loss at subsidiary attributable to noncontrolling interests</a></td>
<td class="nump">5,069<span></span>
</td>
<td class="nump">22,314<span></span>
</td>
<td class="nump">27,236<span></span>
</td>
<td class="nump">31,839<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to common shareholders</a></td>
<td class="nump">$ 1,228,560<span></span>
</td>
<td class="num">$ (918,275)<span></span>
</td>
<td class="nump">$ 1,395,388<span></span>
</td>
<td class="num">$ (1,973,895)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings (loss) per share attributable to common shareholders</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Earnings (loss) per share attributable to common shareholders - Continuing operations - basic (in dollars per share)</a></td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="nump">$ 0.02<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Earnings (loss) per share attributable to common shareholders - Discontinued operations - basic (in dollars per share)</a></td>
<td class="nump">0.03<span></span>
</td>
<td class="nump">0.05<span></span>
</td>
<td class="nump">0.07<span></span>
</td>
<td class="nump">0.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings (loss) per share attributable to common shareholders - basic (in dollars per share)</a></td>
<td class="nump">0.08<span></span>
</td>
<td class="num">(0.06)<span></span>
</td>
<td class="nump">0.09<span></span>
</td>
<td class="num">(0.13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Earnings (loss) per share attributable to common shareholders - Continuing operations - diluted (in dollars per share)</a></td>
<td class="nump">0.05<span></span>
</td>
<td class="num">(0.11)<span></span>
</td>
<td class="nump">0.02<span></span>
</td>
<td class="num">(0.23)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Earnings (loss) per share attributable to common shareholders - Discontinued operations - diluted (in dollars per share)</a></td>
<td class="nump">0.03<span></span>
</td>
<td class="nump">0.05<span></span>
</td>
<td class="nump">0.07<span></span>
</td>
<td class="nump">0.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings (loss) per share attributable to common shareholders - diluted (in dollars per share)</a></td>
<td class="nump">$ 0.08<span></span>
</td>
<td class="num">$ (0.06)<span></span>
</td>
<td class="nump">$ 0.09<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">- basic (in shares)</a></td>
<td class="nump">14,976,034<span></span>
</td>
<td class="nump">15,241,463<span></span>
</td>
<td class="nump">14,970,241<span></span>
</td>
<td class="nump">15,241,020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">- diluted (in shares)</a></td>
<td class="nump">15,109,246<span></span>
</td>
<td class="nump">15,241,463<span></span>
</td>
<td class="nump">15,171,589<span></span>
</td>
<td class="nump">15,241,020<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868656-224227<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868656-224227<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398118&amp;loc=d3e355146-122828<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140141275951736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 1,368,152<span></span>
</td>
<td class="num">$ (2,005,734)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Discontinued operations</a></td>
<td class="nump">994,217<span></span>
</td>
<td class="nump">1,556,895<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net income (loss) from continuing operations</a></td>
<td class="nump">373,935<span></span>
</td>
<td class="num">(3,562,629)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) from continuing operations to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">2,455,576<span></span>
</td>
<td class="nump">2,334,669<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">354,914<span></span>
</td>
<td class="nump">542,923<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities', window );">Decrease in non-cash contingent consideration</a></td>
<td class="num">(180,110)<span></span>
</td>
<td class="num">(645,571)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy', window );">Increase (Decrease) In Cash Surrender Value Of Life Insurance Policy</a></td>
<td class="num">(226,897)<span></span>
</td>
<td class="nump">215,116<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Noncash interest expense</a></td>
<td class="nump">27,666<span></span>
</td>
<td class="nump">22,973<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Gain on forgiveness of debt</a></td>
<td class="num">(2,187,140)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Net changes in assets and liabilities affecting operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">3,230,220<span></span>
</td>
<td class="num">(80,421)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="nump">2,309,914<span></span>
</td>
<td class="nump">1,158,916<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other current assets and other assets</a></td>
<td class="nump">866,987<span></span>
</td>
<td class="nump">802,534<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_IncreaseDecreaseInCurrentOperatingLiabilities', window );">Accounts payable and other current liabilities</a></td>
<td class="num">(3,008,323)<span></span>
</td>
<td class="nump">2,413,768<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long-term liabilities</a></td>
<td class="num">(526,189)<span></span>
</td>
<td class="num">(869,644)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash provided by (used in) operating activities from continuing operations</a></td>
<td class="nump">3,490,553<span></span>
</td>
<td class="nump">2,332,634<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations', window );">Discontinued operations</a></td>
<td class="nump">994,217<span></span>
</td>
<td class="nump">1,371,437<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">4,484,770<span></span>
</td>
<td class="nump">3,704,071<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Additions to property and equipment</a></td>
<td class="num">(34,531)<span></span>
</td>
<td class="num">(50,883)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Note receivable investment funding</a></td>
<td class="num">(200,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Additions to intangible assets</a></td>
<td class="num">(132,323)<span></span>
</td>
<td class="num">(722,131)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(366,854)<span></span>
</td>
<td class="num">(773,014)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit', window );">Borrowings on line of credit</a></td>
<td class="nump">29,000,000<span></span>
</td>
<td class="nump">35,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments on line of credit</a></td>
<td class="num">(30,000,000)<span></span>
</td>
<td class="num">(37,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Cash payment of contingent consideration</a></td>
<td class="num">(1,423,586)<span></span>
</td>
<td class="num">(260,735)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest', window );">Repurchase of subsidiary shares from noncontrolling interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(800,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common shares</a></td>
<td class="num">(777,664)<span></span>
</td>
<td class="num">(1,209,220)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(3,201,250)<span></span>
</td>
<td class="num">(3,769,955)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">916,666<span></span>
</td>
<td class="num">(838,898)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">24,753,796<span></span>
</td>
<td class="nump">28,212,635<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">$ 25,670,462<span></span>
</td>
<td class="nump">$ 27,373,737<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Cash Surrender Value Of Life Insurance Policy</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_IncreaseDecreaseInCurrentOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_IncreaseDecreaseInCurrentOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11374-113907<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period for redemption of redeemable noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140141268869576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Retained earnings</div></th>
<th class="th"><div>Noncontrolling interests</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Beginning of Period at Dec. 31, 2019</a></td>
<td class="nump">$ 51,085,253<span></span>
</td>
<td class="nump">$ 49,914,478<span></span>
</td>
<td class="nump">$ 1,208,395<span></span>
</td>
<td class="num">$ (37,620)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, Beginning of Period (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,263,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">264,574<span></span>
</td>
<td class="nump">$ 264,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">219,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common shares</a></td>
<td class="num">(441,624)<span></span>
</td>
<td class="num">$ (441,624)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(164,866)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(1,065,145)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,055,620)<span></span>
</td>
<td class="num">(9,525)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, End of Period at Mar. 31, 2020</a></td>
<td class="nump">49,843,058<span></span>
</td>
<td class="nump">$ 49,737,428<span></span>
</td>
<td class="nump">152,775<span></span>
</td>
<td class="num">(47,145)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, End of Period (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,318,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Beginning of Period at Dec. 31, 2019</a></td>
<td class="nump">51,085,253<span></span>
</td>
<td class="nump">$ 49,914,478<span></span>
</td>
<td class="nump">1,208,395<span></span>
</td>
<td class="num">(37,620)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, Beginning of Period (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,263,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(306,329)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(2,005,734)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, End of Period at Jun. 30, 2020</a></td>
<td class="nump">48,411,170<span></span>
</td>
<td class="nump">$ 49,246,129<span></span>
</td>
<td class="num">(765,500)<span></span>
</td>
<td class="num">(69,459)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, End of Period (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,181,276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Beginning of Period at Mar. 31, 2020</a></td>
<td class="nump">49,843,058<span></span>
</td>
<td class="nump">$ 49,737,428<span></span>
</td>
<td class="nump">152,775<span></span>
</td>
<td class="num">(47,145)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, Beginning of Period (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,318,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">278,349<span></span>
</td>
<td class="nump">$ 278,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common shares</a></td>
<td class="num">(769,648)<span></span>
</td>
<td class="num">$ (769,648)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(141,463)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(940,589)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(918,275)<span></span>
</td>
<td class="num">(22,314)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, End of Period at Jun. 30, 2020</a></td>
<td class="nump">48,411,170<span></span>
</td>
<td class="nump">$ 49,246,129<span></span>
</td>
<td class="num">(765,500)<span></span>
</td>
<td class="num">(69,459)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, End of Period (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,181,276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Beginning of Period at Dec. 31, 2020</a></td>
<td class="nump">$ 46,873,394<span></span>
</td>
<td class="nump">$ 49,121,523<span></span>
</td>
<td class="num">(2,131,013)<span></span>
</td>
<td class="num">(117,116)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, Beginning of Period (in shares) at Dec. 31, 2020</a></td>
<td class="nump">14,988,429<span></span>
</td>
<td class="nump">14,988,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">$ 162,960<span></span>
</td>
<td class="nump">$ 162,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common shares</a></td>
<td class="num">(303,088)<span></span>
</td>
<td class="num">$ (303,088)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(91,724)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">144,661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,828<span></span>
</td>
<td class="num">(22,167)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, End of Period at Mar. 31, 2021</a></td>
<td class="nump">46,877,927<span></span>
</td>
<td class="nump">$ 48,981,395<span></span>
</td>
<td class="num">(1,964,185)<span></span>
</td>
<td class="num">(139,283)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, End of Period (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,084,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Beginning of Period at Dec. 31, 2020</a></td>
<td class="nump">$ 46,873,394<span></span>
</td>
<td class="nump">$ 49,121,523<span></span>
</td>
<td class="num">(2,131,013)<span></span>
</td>
<td class="num">(117,116)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, Beginning of Period (in shares) at Dec. 31, 2020</a></td>
<td class="nump">14,988,429<span></span>
</td>
<td class="nump">14,988,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(250,129)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 1,368,152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, End of Period at Jun. 30, 2021</a></td>
<td class="nump">$ 47,808,407<span></span>
</td>
<td class="nump">$ 48,688,384<span></span>
</td>
<td class="num">(735,625)<span></span>
</td>
<td class="num">(144,352)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, End of Period (in shares) at Jun. 30, 2021</a></td>
<td class="nump">14,926,059<span></span>
</td>
<td class="nump">14,926,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Beginning of Period at Mar. 31, 2021</a></td>
<td class="nump">$ 46,877,927<span></span>
</td>
<td class="nump">$ 48,981,395<span></span>
</td>
<td class="num">(1,964,185)<span></span>
</td>
<td class="num">(139,283)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, Beginning of Period (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,084,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">191,954<span></span>
</td>
<td class="nump">$ 191,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common shares</a></td>
<td class="num">(484,965)<span></span>
</td>
<td class="num">$ (484,965)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(158,405)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">1,223,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,228,560<span></span>
</td>
<td class="num">(5,069)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, End of Period at Jun. 30, 2021</a></td>
<td class="nump">$ 47,808,407<span></span>
</td>
<td class="nump">$ 48,688,384<span></span>
</td>
<td class="num">$ (735,625)<span></span>
</td>
<td class="num">$ (144,352)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, End of Period (in shares) at Jun. 30, 2021</a></td>
<td class="nump">14,926,059<span></span>
</td>
<td class="nump">14,926,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140141270742152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">ORGANIZATION AND BASIS OF PRESENTATION</a></td>
<td class="text">ORGANIZATION AND BASIS OF PRESENTATION<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland Pharmaceuticals Inc. (&#8220;Cumberland,&#8221; the &#8220;Company,&#8221; or as used in the context of &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products.  The Company's primary target markets are hospital acute care, gastroenterology and rheumatology. These medical specialties are characterized by relatively concentrated prescriber bases that the Company believes can be penetrated effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve quality of care for patients and address unmet or poorly met medical needs.  The Company promotes its approved products through its hospital and field sales forces in the United States and is establishing a network of international partners to bring its medicines to patients in their countries.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland focuses its resources on maximizing the commercial potential of its products, as well as developing new product candidates, and has both internal development and commercial capabilities. The Company&#8217;s products are manufactured by third parties, which are overseen by Cumberland&#8217;s quality control and manufacturing professionals. The Company works closely with its third-party distribution partners to make its products available in the United States.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, the accompanying unaudited condensed consolidated financial statements of the Company have been prepared on a basis consistent with the December 31, 2020, audited consolidated financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly present the information set forth herein. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements have been prepared in accordance with the regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;), and certain information and disclosures have been condensed or omitted as permitted by the SEC for interim period presentation. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December 31, 2020 (the &#8220;2020 Annual Report on Form 10-K&#8221;). The results of operations for the three and six months ended June 30, 2021, are not necessarily indicative of the results to be expected for the entire fiscal year or any future period.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Discontinued Operations</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed further in Note 9, during May 2019, Cumberland entered into a Dissolution Agreement  ("Dissolution Agreement") with Clinigen Healthcare Limited ("Clinigen") in which the Company returned the exclusive rights to commercialize Ethyol</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Totect</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States to Clinigen. Under the terms of the Dissolution Agreement, Cumberland is no longer involved directly or indirectly with the distribution, marketing and promotion of either Ethyol or Totect or any competing products following December 31, 2019. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's exit from Ethyol and Totect meets the accounting criteria to be reported as discontinued operations and the discontinued operating results have been presented in the financial statements and footnotes to reflect the discontinued status of Ethyol and Totect. Refer to Note 9, for additional information.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revision of prior period condensed consolidated statement of cash flows presentation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has made a revision to prior period amounts to conform to the current year presentation of the cash surrender value of life insurance policies over premiums paid on the condensed consolidated statement of cash flows.  The revised amounts were previously included as net changes in assets affecting operating activities.  These revisions have no net effect on the reported net cash provided by operating activities nor any impact on the reported operating results or balance sheet for the 2020 period presented.  </span></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Pandemic </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the U.S. declared a health care emergency following the outbreak of the SARS-CoV-2, a novel strain of coronavirus that causes COVID-19, a respiratory illness.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has remained open for business, as the Company is considered to be essential by the United States Department of Homeland Security. The Company has implemented measures to address the impact of the novel coronavirus on the business and taken appropriate action to protect its employees, secure the supply chain, and support the patients who can benefit from its medicines.  All of the Company's employees have been given the opportunity to work remotely, and those that wish to work from Cumberland's office and laboratories are encouraged to practice the behaviors outlined by the Centers for Disease Control.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout the pandemic, Cumberland has faced the same headwinds affecting other companies that rely on hospital admissions and patient visits to drive revenue.  Our business and our clinical studies were impacted as less patients sought elective surgeries and our access to medical facilities was substantially limited.  During 2020 and 2021, we carefully monitored our supply chain during the pandemic including the flow of raw materials into the plants that manufacture our products as well as the batches of finished product emerging from those facilities. Several of our brands were negatively impacted by the lockdowns and postponement of physician office visits and elective procedures. However, we are fortunate to have a diversified product portfolio, with other brands delivering a strong performance.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland relies on third-party organizations around the world to supply components, manufacture and distribute its products. The Company is aware that it may experience revenue loss, supply interruptions, time delays and incur unplanned expenses as a result of the impact of the ongoing COVID-19 pandemic.   The Company continues to monitor the COVID-19 pandemic situation both in the U.S. and internationally in order to maintain its employees&#8217; safety and well-being, while also keeping its business operating.  Given the uncertainty, magnitude and impact of such changes, the Company is unable to quantify the impact on the future results as of the date of this filing.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Guidance</span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements - Not Yet Adopted</span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board ("FASB") issued ASU No. 2016-13, &#8220;Financial Instruments-Credit Losses,&#8221; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#8220;expected loss&#8221; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose additional information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the ASU&#8217;s provisions as a cumulative-effect adjustment, if any, to retained earnings as of the beginning of the first reporting period in which the guidance is adopted.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related to ASU No. 2016-13 discussed above, in May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably elect the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met and the election must be applied on an instrument-by-instrument basis. The election is not available for either available-for-sale or held-to-maturity debt securities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will adopt both ASU 2016-13 and ASU 2019-05 on January 1, 2023. The adoption of ASU 2016-13 and ASU 2019-05 are not expected to have a material impact on the Company&#8217;s consolidated financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Policies:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Use of Estimates</span></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates under different assumptions and conditions.  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns, (2) the allowances for obsolescent or unmarketable inventory and (3) valuation of a contingent consideration liability associated with a business combination.</span></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Operating Segments</span></div>The Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#8217;s assets are located in the United States and total revenues are primarily attributable to U.S.&#160;customers.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140141270811784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">EARNINGS (LOSS) PER SHARE</a></td>
<td class="text">EARNINGS (LOSS) PER SHARE<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the numerator and denominator used to calculate diluted earnings (loss) per share for the three and six months ended June 30, 2021 and 2020:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.987%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">724,684&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,679,211)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498,807&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">738,622&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,223,491&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(940,589)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (income) loss at subsidiary attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,069&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,314&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,228,560&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(918,275)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; basic</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,976,034&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,241,463&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of other securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,212&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; diluted</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,109,246&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,241,463&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:58.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.518%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.987%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373,935&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,562,629)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">994,217&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,556,895&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,368,152&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,005,734)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) at subsidiary attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,839&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,395,388&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,973,895)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; basic</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,970,241&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,241,020&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of other securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,348&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; diluted</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,171,589&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,241,020&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021 and 2020, restricted stock awards and options to purchase 198,300 and 13,500 shares of common stock, respectively, were outstanding but were not included in the computation of diluted earnings per share because the effect would be antidilutive.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140141270743832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">REVENUES</a></td>
<td class="text">REVENUES<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Revenues</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for revenues from contracts with customers under ASC 606, which became effective January 1, 2018. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s net revenues consisted of the following for the three and six months ended June 30, 2021 and 2020:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristalose</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,275,065&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,477,471&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,269,443&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,771,433&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,844,936&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,299,507&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,897,179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,721,708&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938,328&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,166,569&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,477,824&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,261,286&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaprisol</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399,952&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,534,216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382,016&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acetadote</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,781&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">595,310&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269,972&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,308,711&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Omeclamox-Pak</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,109)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,948&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(474,371)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,371&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RediTrex</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,382&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,870)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">461,148&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">874,213&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">643,249&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,359,386&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,055,483&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,598,177&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,592,642&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,928,911&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Omeclamox-Pak revenue for the first and second quarter of 2021 was the result of Cumberland currently being out of commercial inventory of this product.  The packager for our Omeclamox-Pak product encountered financial difficulties due to the impact of COVID-19.  They are under new management and are in the process of a reorganization. Discussions with the packager are ongoing.  Net revenue was also negatively impacted by product returns during the periods. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Revenues</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has agreements with international partners for commercialization of the Company's products with associated payments included in other revenues. Those agreements provide that each of the partners are responsible for seeking regulatory approvals for the product, and following approval, each partner will be responsible for the ongoing distribution and sales in the respective international territories. The Company provides a dossier for product registration and maintains responsibility for the relevant intellectual property. Cumberland is typically entitled to receive a non-refundable, up-front payment at the time each agreement is executed as consideration for the product dossier and for the rights to the distinct intellectual property rights in the respective international territory. These agreements also typically provide for additional payments upon a partner&#8217;s achievement of a defined regulatory approval and sales milestones. The Company may also be entitled to receive royalties on future sales of the products and a transfer price on supplies.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual payments associated with the partner&#8217;s achievement of regulatory approvals, sales milestones and royalties on future sales are recognized as revenue upon occurrence, or at such time that the Company has a high degree of confidence that the revenue would not be reversed in a subsequent period.</span></div>Other revenues also include funding from federal grant programs including those secured by CET through the Small Business Administration as well as lease income generated by CET&#8217;s Life Sciences Center. The Life Sciences Center is a research center that provides scientists with access to flexible lab space and other resources to develop biomedical products. Grant revenue from these programs totaled approximately $0.2&#160;million and $0.5 million for the three months ended June 30, 2021 and 2020<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140141272060936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text">INVENTORIES<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company works closely with third parties to manufacture and package finished goods for sale.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the arrangements with the manufacturer or packager, the Company will either take title to the finished goods at the time of shipment or at the time of arrival at the Company&#8217;s warehouses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company then holds such goods in inventory until distribution and sale. These finished goods inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually evaluates inventory for potential losses due to excess, obsolete or slow-moving goods by comparing sales history and projections to the inventory on hand. When evidence indicates that the carrying value may not be recoverable, a charge is taken to reduce the inventory to its current net realizable value.  At June 30, 2021 and December 31, 2020, the </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company had recognized and maintained cumulative net realizable value charges for potential obsolescence and discontinuance losses of approximately $0.3 million and $0.2 million, respectively.  </span></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is responsible for the purchase of the active pharmaceutical ingredient (&#8220;API&#8221;) for Kristalose and maintains the inventory at third-party packagers. As that API is consumed in production, the value of the API is transferred from raw materials to finished goods.  API for the Company's Vaprisol brand is also included in the raw materials inventory at June 30, 2021 and December 31, 2020.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consigned inventory represents Authorized Generic inventory stored with Perrigo until shipment.   </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Vibativ acquisition, Cumberland acquired API and work in process inventories of $15.6 million that were all initially classified as non-current inventories at the date of acquisition.  At June 30, 2021 and December 31, 2020, total non-current inventory, including Vibativ and ifetroban, was $9.9&#160;million and $11.7&#160;million, respectively. The Company had $0.3 million and $2.1 million of Vibativ finished goods included in non-current inventory at June 30, 2021 and December 31, 2020, respectively.  The Company also has obtained $0.4&#160;million of finished goods in non-current inventory for API related to its ifetroban clinical initiatives at June 30, 2021 and December 31, 2020. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June 30, 2021 and December 31, 2020 the Company's net inventories consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:57.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.121%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.430%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.681%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and work in process</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,156,248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,223,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consigned inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,005&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,639,596&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,943,732&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,984,985&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,294,899&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">less non-current inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,880,766)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,656,742)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories classified as current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,104,219&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,638,157&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140141270753576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text">LEASES<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland&#8217;s significant operating leases include the lease of approximately 25,500 square feet of office space in Nashville, Tennessee for its corporate headquarters.  This lease currently expires in October 2022.  The Company's operating leases also include the lease of approximately 14,200 square feet of wet laboratory and office space in Nashville, Tennessee by CET, our majority-owned subsidiary, where it operates the CET Life Sciences Center.  This lease currently expires in April 2023. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities are recorded as the present value of remaining lease payments not yet paid for the lease term discounted using the incremental borrowing rate associated with each lease. Operating lease right-of-use assets represent operating lease liabilities adjusted for lease incentives and initial direct costs. As Cumberland&#8217;s leases do not contain implicit borrowing rates, the incremental borrowing rates were calculated based on information available at January 1, 2019. Incremental borrowing rates reflect the Company&#8217;s estimated interest rates for collateralized borrowings over similar lease terms.  The weighted-average incremental borrowing rate used to discount the present value of the remaining lease payments is 7.42%. The weighted-average remaining lease term at June 30, 2021 is 1.5 years.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lease Position</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June 30, 2021 and December 31, 2020 , the Company's lease assets and liabilities were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Right-of-Use Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,535,556&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,028,148&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067,880&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,016,779&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease noncurrent liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">512,324&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,059,693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,580,204&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,076,472&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumulative future minimum sublease income under non-cancelable operating subleases totals approximately $0.2 million and will be paid through the leases ending in October 2022 and April 2023. Future minimum lease payments under non-cancelable operating leases (with initial or remaining lease terms in excess of one year) are as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.554%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity of Lease Liabilities at June 30, 2021</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">579,183&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,019,313&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,690,974&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110,770)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,580,204&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense is recognized over the expected term of the lease, including renewal option periods, if applicable, on a straight-line basis as a component of general and administrative expense. Rent expense and sublease income were as follows:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rent expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">605,130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">571,399&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348,411&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323,489&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140141272060936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity and Debt<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_EquityAndDebtAbstract', window );"><strong>Equity and Debt [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">SHAREHOLDERS' EQUITY AND DEBT</a></td>
<td class="text">SHAREHOLDERS&#8217; EQUITY AND DEBT<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share repurchases</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland currently has a share repurchase program to repurchase up to $10 million of its common stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934. In January 2019, the Company's Board of Directors established the current $10 million repurchase program to replace the prior authorizations.  During the six months ended June 30, 2021 and June 30, 2020, the Company repurchased 250,129 shares and 306,329 shares, respectively, of common stock for approximately $0.8 million and $1.2 million, respectively.  At June 30, 2021, approximately $5.4 million of common shares was left to repurchase under this program.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share purchases and sales</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the Company's March 2021 trading window, several members of Cumberland's Board of Directors entered into share purchase agreements of the Company's stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934. These purchases are designed to increase ownership in the Company by the members of the Board.  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share Sales</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, Cumberland filed a Shelf Registration on Form S-3 with the SEC associated with the sale of up to $100 million in corporate securities. The Shelf Registration was declared effective in January 2018. It also included an At the Market ("ATM") feature that allowed the Company to sell common shares at market prices, along with an agreement with B. Riley FBR Inc. to support such a placement of shares. The Company filed an updated Form S-3 with the SEC in December 2020, which was declared effective in January 2021. The Company does not currently have an ATM feature in place.  Cumberland plans to continue to evaluate the market for its common shares, and if favorable, will further evaluate whether or not to enter into an ATM feature through B. Riley FBR, Inc. that would allow the Company to issue shares of its common stock.  The Company did not issue any shares under an ATM during the six months ended June 30, 2021 or June 30, 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Share Grants and Incentive Stock Options</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June 30, 2021 and June 30, 2020, the Company issued 36,850 shares and 229,141 shares of restricted stock to employees and directors, respectively. Restricted stock issued to employees generally cliff-vests on the fourth anniversary of the date of grant and for directors on the one-year anniversary of the date of grant.  During the six months ended June 30, 2021, the Company also issued 173,350 incentive stock options to employees that cliff-vest on the fourth anniversary of the date of grant, that are set to expire in March and May 2031. Stock compensation expense is presented as a component of general and administrative expense in the condensed consolidated statements of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 7, 2020, the Company entered into a Third Amendment to the Revolving Credit Note and Fourth Amendment (&#8220;Fourth Amendment&#8221;) to the Revolving Credit Loan Agreement with Pinnacle Bank (the &#8220;Pinnacle Agreement&#8221;). The original Pinnacle Agreement was dated July 2017. The Fourth Amendment provides for a principal available for borrowing of up to $15&#160;million and Cumberland has the ability to request an increase of up to an additional $5&#160;million, upon the satisfaction of certain conditions and approval by Pinnacle Bank. If fully expanded, the Fourth Amendment would provide a maximum principal available for borrowing of up to $20&#160;million.  The Fourth Amendment extended the maturity date of the Pinnacle Agreement through October 1, 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 10, 2019, the Company entered into a third amendment ("Third Amendment") to the Pinnacle Agreement, which extended the term of the Pinnacle Agreement through July 31, 2021 as well as modified certain definitions and terms of the existing financial covenants, including the definition of the Funded Debt Ratio and the compliance target of the Tangible Capital Ratio. Both Third Amendment modifications were related to the Vibativ transaction.  Under the Pinnacle Agreement, Cumberland was initially subject to one financial covenant, the maintenance of a Funded Debt Ratio, as such term is defined in the agreement and determined on a quarterly basis.  On August 14, 2018, the Company amended the Pinnacle Agreement ("First Amendment") to replace the single financial covenant with the maintenance of either the Funded Debt Ratio or a Tangible Capital Ratio, as defined in the First Amendment.  The Company was in compliance with the Tangible Capital Ratio financial covenant as of June 30, 2021.  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021 and December 31, 2020, the Company had $14.0 million and $15.0 million in borrowings outstanding under its revolving credit facility.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate on the Pinnacle Agreement is based on LIBOR plus an interest rate spread. The pricing under the Fourth Amendment provides for an interest rate spread of 1.75% to 2.75% above LIBOR with a minimum LIBOR of 0.90%. The applicable interest rate under the Pinnacle Agreement was 3.65% at June 30, 2021.  In addition, a fee of 0.25% per year is charged on the unused line of credit.  Interest and the unused line fee are payable quarterly.  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the line of credit are collateralized by substantially all of the Company's assets. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Paycheck Protection Program Loan</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 20, 2020, Cumberland received the funding of a loan from Pinnacle Bank in the amount of $2,187,140 pursuant to the Paycheck Protection Program (the &#8220;PPP&#8221;) under the Federal Coronavirus Aid, Relief, and Economic Security Act ("CARES Act"), which was enacted March 27, 2020.  The PPP is administered by the U.S. Small Business Administration ("SBA").</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the PPP requirements, loan funds were used to maintain payroll, continue group health care benefits, and pay for rent and utilities during the pandemic. We applied for this loan after carefully considering, with our bank, the eligibility criteria to participate in this program, and determining that Cumberland met those criteria. We evaluated and provided information on our payroll and other qualifying expenses to determine the amount of PPP funds to apply for. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the PPP, certain amounts of the loan may be forgiven if they are used for qualifying expenses as described in the CARES Act. Cumberland used the PPP loan funds for such qualifying expenses. Due to assistance from our PPP loan, the Company did not lay off or furlough any employees as a result of the COVID-19 pandemic.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland elected to account for the proceeds of the loan as a government grant under </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">International Accounting Standard 20 ("IAS 20"), Accounting for Government Grants and Disclosure of Government Assistance. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The permitted analogous use of  IAS 20 outlines a model for the accounting for government assistance, including forgivable loans. As a result, the Company recorded the $2,187,140 as a deferred income liability, which was included as a component of other current liabilities on the condensed consolidated balance sheet at December 31, 2020. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, Cumberland submitted a request for the loan&#8217;s forgiveness. On June 11, 2021, the Company received a formal notice from the SBA that the full amount of the loan was forgiven. The Company accounted for the forgiveness of the PPP loan under IAS 20 and recorded the $2,187,140 as other income.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Joint Venture Agreement</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, Cumberland entered into an agreement with WinHealth Investment (Singapore) Ltd creating </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">WHC Biopharmaceuticals, Pte. Ltd</span>. The joint venture, as a limited liability company, will focus on acquiring, developing, registering, and commercializing development stage and commercial stage biopharmaceuticals for China, Hong Kong and other Asian markets.  The agreement provides for initial investment from WinHealth in the form of a $0.2&#160;million equity contribution and an initial investment from Cumberland in the form of a $0.2&#160;million convertible note, which was funded during the first quarter 2021. The joint venture will seek additional future capital from additional investors and has entered into exclusive option agreements to license intellectual property from both Cumberland Pharmaceuticals Inc. and Cumberland Emerging Technologies.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_EquityAndDebtAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity and Debt [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_EquityAndDebtAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140141275597400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">INCOME TAXESAs of June 30, 2021, the Company has approximately $56.5 million in federal net operating loss carryforwards including approximately $44.1 million of net operating loss carryforwards resulting from the exercise of nonqualified stock options. These have historically been used to significantly offset income tax obligations. The Company expects it will continue to pay minimal income taxes during 2021 and beyond, through the continued utilization of these net operating loss carryforwards, on any taxable income generated from our operations. The Company does not allocate any portion of its income tax expense (benefit) to discontinued operations.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140141272156120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Agreements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">COLLABORATIVE AGREEMENTS</a></td>
<td class="text">COLLABORATIVE AGREEMENTS<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland is a party to several collaborative arrangements with research institutions to identify and pursue promising pharmaceutical product candidates. The funding for these programs is primarily provided through Federal Small Business Administration (SBIR/STTR) and other grant awards. The Company has determined that these collaborative agreements, with the exception of the collaborative payment received related to RediTrex, do not meet the criteria for accounting under ASC Topic 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The agreements do not specifically designate each party&#8217;s rights and obligations to each other under the collaborative arrangements. Except for patent defense costs, expenses incurred by one party are not required to be reimbursed by the other party.  Expenses incurred under these collaborative agreements are included in research and development expenses and funding received from grants are recorded as net revenues in the condensed consolidated statements of operations.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140141270763960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additions and Returns of Product Rights<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">ADDITIONS AND RETURN OF PRODUCT RIGHTS</a></td>
<td class="text">ADDITIONS AND RETURN OF PRODUCT RIGHTS<div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vibativ</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During November 2018, the Company closed on an agreement with Theravance Biopharma ("Theravance") to acquire the global responsibility for Vibativ including the marketing, distribution, manufacturing and regulatory activities associated with the brand.  Vibativ is a patented, Food and Drug Administration ("FDA") approved injectable anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has accounted for the transaction as a business combination in accordance with ASC 805 and the product sales are included in the results of operations subsequent to the acquisition date. The Company made an upfront payment of $20.0&#160;million at the closing of the transaction and a $5.0&#160;million milestone payment in early April 2019. In addition, Cumberland has agreed to pay a royalty of up to 20% of on-going net sales of the product.  The future royalty payments were required to be recognized at their acquisition-date fair value as a contingent consideration liability, as part of the contingent consideration transferred in the business combination. Cumberland prepared the valuations of the contingent consideration liability utilizing significant unobservable inputs.  As a result, the valuation is classified as Level 3 fair value measurement. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis.  The contingent consideration earned and accrued in operating expenses is paid to Theravance quarterly.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.345%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,200,552&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment of royalty during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,423,586)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration included in operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(180,110)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration earned and accrued in operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">760,225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,357,081&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration liability of $7.4&#160;million was classified as other current liabilities of $2.9&#160;million and other long-term liabilities of $4.5&#160;million on the condensed consolidated balance sheet as of June 30, 2021.  </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RediTrex</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2016, the Company announced an agreement with the Nordic Group B.V. ("Nordic") to acquire the exclusive U.S. rights to Nordic&#8217;s injectable methotrexate product line designed for the treatment of active rheumatoid arthritis, juvenile idiopathic arthritis, severe psoriatic arthritis, and severe disabling psoriasis. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As consideration for the license Cumberland paid a deposit of $100,000 at closing.  The Company provided $0.9&#160;million in consideration through a grant of 180,000 restricted shares of Cumberland common stock to be vested upon the FDA approval of the first Nordic product. Cumberland also agreed to provide Nordic a series of payments tied to the products&#8217; FDA approval, launch and achievement of certain sales milestones. Under the terms of the agreement, Cumberland is responsible for the product registration and commercialization in the U.S. Nordic is responsible for product manufacturing and supply.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 27, 2019, Cumberland received FDA approval for the first Nordic injectable product and authorization to market them under the RediTrex brand name.  The 180,000 shares of restricted Cumberland common stock previously provided to Nordic vested upon approval and were valued at $0.9&#160;million on the vesting date. The FDA approval also resulted in a $1.0&#160;million milestone payment due to Nordic.  During December 2020, Cumberland introduced RediTrex and the launch that will take place in late 2021 will result in a $1.0&#160;million milestone payment due to Nordic.  This milestone payment will be paid during 2022 and is being reported as a current liability at June 30, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has approximately $2.7&#160;million in net intangible assets related to RediTrex at June 30, 2021.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ethyol and Totect </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, Cumberland entered into an agreement with Clinigen for the rights and responsibilities associated with the commercialization of Ethyol in the United States.  In 2017, the Company entered into another agreement with Clinigen for the rights and responsibilities associated with the commercialization of Totect in the United States.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Early in 2019, Cumberland announced a strategic review of the Company's brands, capabilities, and international partners. This review followed an accelerated business development initiative, which resulted in a series of transactions. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During May 2019, Cumberland entered into the Dissolution Agreement with Clinigen in which the Company returned the exclusive rights to commercialize Ethyol and Totect</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the United States to Clinigen. Under the final terms of the Dissolution Agreement, Cumberland was no longer responsible for the distribution, marketing and promotion of either Ethyol or Totect or any competing products after December 31, 2019.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In exchange for the return of these product license rights and the non-compete provisions of the Dissolution Agreement, Cumberland is receiving $5&#160;million in financial consideration paid in quarterly installments over the two-years following the transition date. Cumberland recorded the first four quarterly installments totaling $3.0 million during 2020 and the next two installments totaling $1.0 million during the six months ended June 30, 2021, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as discontinued operations.  The Company will record the remaining two quarterly installments during the balance of 2021.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exit from Ethyol and Totect meets the accounting criteria to be reported as discontinued operations. December 31, 2019, as the transition date, was the final day Cumberland was responsible for the products. Cumberland was responsible for the products through December 31, 2019 and beginning on January 1, 2020, the products' rights transitioned back to Clinigen. As a result, January 1, 2020, was the first day of discontinued operations for the Ethyol and Totect products.</span></div><div style="margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The dissolution payments from Clinigen are reflected as revenue from discontinued operations.  The Company does not </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">incur expenses associated with these payments from Clinigen. </span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.499%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three months ended June 30,</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498,807&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">738,622&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">994,217&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,556,895&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs of products sold</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, Marketing and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498,807&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">738,622&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">994,217&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,556,895&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140141272192248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Guidance</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Guidance</span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements - Not Yet Adopted</span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board ("FASB") issued ASU No. 2016-13, &#8220;Financial Instruments-Credit Losses,&#8221; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#8220;expected loss&#8221; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose additional information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the ASU&#8217;s provisions as a cumulative-effect adjustment, if any, to retained earnings as of the beginning of the first reporting period in which the guidance is adopted.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related to ASU No. 2016-13 discussed above, in May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably elect the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met and the election must be applied on an instrument-by-instrument basis. The election is not available for either available-for-sale or held-to-maturity debt securities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will adopt both ASU 2016-13 and ASU 2019-05 on January 1, 2023. The adoption of ASU 2016-13 and ASU 2019-05 are not expected to have a material impact on the Company&#8217;s consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Use of Estimates</span></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates under different assumptions and conditions.  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns, (2) the allowances for obsolescent or unmarketable inventory and (3) valuation of a contingent consideration liability associated with a business combination.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Operating Segments</a></td>
<td class="text">Operating SegmentsThe Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#8217;s assets are located in the United States and total revenues are primarily attributable to U.S.&#160;customers.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140141358099944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Reconciliation of numerator and denominator</a></td>
<td class="text">The following table reconciles the numerator and denominator used to calculate diluted earnings (loss) per share for the three and six months ended June 30, 2021 and 2020:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.987%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">724,684&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,679,211)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498,807&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">738,622&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,223,491&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(940,589)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (income) loss at subsidiary attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,069&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,314&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,228,560&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(918,275)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; basic</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,976,034&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,241,463&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of other securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,212&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; diluted</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,109,246&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,241,463&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:58.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.518%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.987%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373,935&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,562,629)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">994,217&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,556,895&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,368,152&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,005,734)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) at subsidiary attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,839&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,395,388&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,973,895)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; basic</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,970,241&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,241,020&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of other securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,348&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; diluted</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,171,589&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,241,020&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140141270782984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Summary of net revenue</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s net revenues consisted of the following for the three and six months ended June 30, 2021 and 2020:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristalose</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,275,065&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,477,471&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,269,443&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,771,433&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,844,936&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,299,507&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,897,179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,721,708&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938,328&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,166,569&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,477,824&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,261,286&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaprisol</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399,952&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,534,216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382,016&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acetadote</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,781&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">595,310&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269,972&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,308,711&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Omeclamox-Pak</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,109)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,948&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(474,371)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,371&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RediTrex</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,382&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,870)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">461,148&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">874,213&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">643,249&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,359,386&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,055,483&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,598,177&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,592,642&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,928,911&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140141275672632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Inventory</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June 30, 2021 and December 31, 2020 the Company's net inventories consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:57.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.121%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.430%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.681%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and work in process</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,156,248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,223,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consigned inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,005&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,639,596&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,943,732&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,984,985&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,294,899&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">less non-current inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,880,766)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,656,742)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories classified as current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,104,219&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,638,157&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140141270780168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Lease Position</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June 30, 2021 and December 31, 2020 , the Company's lease assets and liabilities were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Right-of-Use Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,535,556&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,028,148&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067,880&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,016,779&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease noncurrent liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">512,324&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,059,693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,580,204&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,076,472&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumulative future minimum sublease income under non-cancelable operating subleases totals approximately $0.2 million and will be paid through the leases ending in October 2022 and April 2023. Future minimum lease payments under non-cancelable operating leases (with initial or remaining lease terms in excess of one year) are as follows:</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturity of Lease Liabilities</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.554%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity of Lease Liabilities at June 30, 2021</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">579,183&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,019,313&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,690,974&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110,770)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,580,204&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock', window );">Schedule of Rent Expense and Sublease Income</a></td>
<td class="text">Rent expense and sublease income were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rent expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">605,130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">571,399&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348,411&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323,489&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assets and Liabilities, Lessee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Rent Expense and Sublease Income [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140141269628184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additions and Returns of Product Rights (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock', window );">Schedule of Business Acquisitions by Acquisition, Contingent Consideration</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis.  The contingent consideration earned and accrued in operating expenses is paid to Theravance quarterly.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.345%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,200,552&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment of royalty during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,423,586)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration included in operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(180,110)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration earned and accrued in operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">760,225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,357,081&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Schedule of Dissolution Payments</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The dissolution payments from Clinigen are reflected as revenue from discontinued operations.  The Company does not </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">incur expenses associated with these payments from Clinigen. </span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.499%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three months ended June 30,</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498,807&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">738,622&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">994,217&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,556,895&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs of products sold</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, Marketing and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498,807&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">738,622&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">994,217&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,556,895&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=SL51724579-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1474-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5D<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721677-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721659-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721665-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721671-107760<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721663-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140141270767880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation Organization (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2021 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140141275658680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_NumeratorAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net income (loss) from continuing operations</a></td>
<td class="nump">$ 724,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,679,211)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 373,935<span></span>
</td>
<td class="num">$ (3,562,629)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">994,217<span></span>
</td>
<td class="nump">1,556,895<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">1,223,491<span></span>
</td>
<td class="nump">$ 144,661<span></span>
</td>
<td class="num">(940,589)<span></span>
</td>
<td class="num">$ (1,065,145)<span></span>
</td>
<td class="nump">1,368,152<span></span>
</td>
<td class="num">(2,005,734)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net (income) loss at subsidiary attributable to noncontrolling interests</a></td>
<td class="nump">5,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,236<span></span>
</td>
<td class="nump">31,839<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to common shareholders</a></td>
<td class="nump">$ 1,228,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (918,275)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,395,388<span></span>
</td>
<td class="num">$ (1,973,895)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_DenominatorAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding &#8211; basic (in shares)</a></td>
<td class="nump">14,976,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,241,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,970,241<span></span>
</td>
<td class="nump">15,241,020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive effect of other securities (in shares)</a></td>
<td class="nump">133,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">201,348<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding &#8211; diluted (in shares)</a></td>
<td class="nump">15,109,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,241,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,171,589<span></span>
</td>
<td class="nump">15,241,020<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_DenominatorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Denominator.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_DenominatorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_NumeratorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Numerator.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_NumeratorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140141270510680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share (Details Textual) - shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock available for purchase through restricted stock awards and options (in shares)</a></td>
<td class="nump">198,300<span></span>
</td>
<td class="nump">13,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140141265721640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 9,055,483<span></span>
</td>
<td class="nump">$ 9,598,177<span></span>
</td>
<td class="nump">$ 19,592,642<span></span>
</td>
<td class="nump">$ 17,928,911<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_AcetadoteMember', window );">Kristalose</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">5,275,065<span></span>
</td>
<td class="nump">3,477,471<span></span>
</td>
<td class="nump">269,972<span></span>
</td>
<td class="nump">1,308,711<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_OmeclamoxPakMember', window );">Vibativ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,844,936<span></span>
</td>
<td class="nump">3,299,507<span></span>
</td>
<td class="num">(474,371)<span></span>
</td>
<td class="nump">124,371<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_KristaloseMember', window );">Caldolor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">938,328<span></span>
</td>
<td class="nump">1,166,569<span></span>
</td>
<td class="nump">8,269,443<span></span>
</td>
<td class="nump">6,771,433<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_VaprisolMember', window );">Acetadote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">152,781<span></span>
</td>
<td class="nump">595,310<span></span>
</td>
<td class="nump">1,534,216<span></span>
</td>
<td class="nump">382,016<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_CaldolorMember', window );">Omeclamox-Pak</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="num">(24,109)<span></span>
</td>
<td class="nump">10,948<span></span>
</td>
<td class="nump">2,477,824<span></span>
</td>
<td class="nump">2,261,286<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_VIBATIVMember', window );">Vaprisol</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">399,952<span></span>
</td>
<td class="nump">174,159<span></span>
</td>
<td class="nump">6,897,179<span></span>
</td>
<td class="nump">5,721,708<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_RediTrexMember', window );">RediTrex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">7,382<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(24,870)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_OtherProductsMember', window );">Other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">461,148<span></span>
</td>
<td class="nump">874,213<span></span>
</td>
<td class="nump">$ 643,249<span></span>
</td>
<td class="nump">$ 1,359,386<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ProductsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Products.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ProductsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_AcetadoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_AcetadoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_OmeclamoxPakMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_OmeclamoxPakMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_KristaloseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_KristaloseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_VaprisolMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_VaprisolMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_CaldolorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_CaldolorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_VIBATIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_VIBATIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_RediTrexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_RediTrexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_OtherProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_OtherProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140141351707288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Obsolescence and discontinuance losses</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Non-current inventories</a></td>
<td class="nump">9,880,766<span></span>
</td>
<td class="nump">11,656,742<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=cpix_IfetrobanClinicalMember', window );">Ifetroban Clinical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Non-current inventories</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember', window );">Vaprisol</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Non-current inventories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=cpix_IfetrobanClinicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=cpix_IfetrobanClinicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140141270925464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Schedule of Inventories) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract', window );"><strong>Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials and work in process</a></td>
<td class="nump">$ 14,156,248<span></span>
</td>
<td class="nump">$ 16,223,162<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment', window );">Consigned inventory</a></td>
<td class="nump">189,141<span></span>
</td>
<td class="nump">128,005<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">5,639,596<span></span>
</td>
<td class="nump">5,943,732<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total inventories</a></td>
<td class="nump">19,984,985<span></span>
</td>
<td class="nump">22,294,899<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventory, Noncurrent</a></td>
<td class="num">(9,880,766)<span></span>
</td>
<td class="num">(11,656,742)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories classified as current</a></td>
<td class="nump">$ 10,104,219<span></span>
</td>
<td class="nump">$ 10,638,157<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount of inventory owned by the entity but in the hands of a customer, typically a reseller.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140141358470440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Narrative) (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Present value of remaining lease payments, percent</a></td>
<td class="nump">7.42%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">1 year 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals', window );">Future minimum sublease income under noncancelable operating subleases | $</a></td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Office Space</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Square feet of office space</a></td>
<td class="nump">25,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=srt_OfficeBuildingMember', window );">Wet Laboratory and Office Space</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Square feet of office space</a></td>
<td class="nump">14,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractually required future rental payments receivable on noncancelable subleasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=srt_OfficeBuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=srt_OfficeBuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140141270681304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Lease Position) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 1,535,556<span></span>
</td>
<td class="nump">$ 2,028,148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease current liabilities</a></td>
<td class="nump">1,067,880<span></span>
</td>
<td class="nump">1,016,779<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease noncurrent liabilities</a></td>
<td class="nump">512,324<span></span>
</td>
<td class="nump">1,059,693<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_LeaseLiability', window );">Total</a></td>
<td class="nump">$ 1,580,204<span></span>
</td>
<td class="nump">$ 2,076,472<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_LeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease, Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_LeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140141351506872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Maturity of Lease Liabilities at June 30, 2021</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 579,183<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">1,019,313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">92,478<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree', window );">After 2023</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">1,690,974<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Interest</a></td>
<td class="num">(110,770)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 1,580,204<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, to be Paid, after Year Three</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140141270552008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Rent Expense (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rent expense</a></td>
<td class="nump">$ 605,130<span></span>
</td>
<td class="nump">$ 571,399<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1', window );">Sublease income</a></td>
<td class="nump">$ 348,411<span></span>
</td>
<td class="nump">$ 323,489<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of sublease rental income recognized during the period that reduces the entity's rent expense incurred under operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseSubleaseRentals1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140141265550312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity and Debt (Shareholders' Equity) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jan. 31, 2016</div></th>
<th class="th"><div>May 13, 2010</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ShareholdersEquityTextualAbstract', window );"><strong>Shareholders' Equity (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Repurchase outstanding common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of shares, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (484,965)<span></span>
</td>
<td class="num">$ (303,088)<span></span>
</td>
<td class="num">$ (769,648)<span></span>
</td>
<td class="num">$ (441,624)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities', window );">Shelf Registration, sale of corporate securities (up to)</a></td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ShareholdersEquityTextualAbstract', window );"><strong>Shareholders' Equity (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock granted in period, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,850<span></span>
</td>
<td class="nump">229,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cpix_IncentiveStockOptionsMember', window );">Incentive Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ShareholdersEquityTextualAbstract', window );"><strong>Shareholders' Equity (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock granted in period, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">173,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director | Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ShareholdersEquityTextualAbstract', window );"><strong>Shareholders' Equity (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Restricted stock awards, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ShareholdersEquityTextualAbstract', window );"><strong>Shareholders' Equity (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">158,405<span></span>
</td>
<td class="nump">91,724<span></span>
</td>
<td class="nump">141,463<span></span>
</td>
<td class="nump">164,866<span></span>
</td>
<td class="nump">250,129<span></span>
</td>
<td class="nump">306,329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of shares, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (484,965)<span></span>
</td>
<td class="num">$ (303,088)<span></span>
</td>
<td class="num">$ (769,648)<span></span>
</td>
<td class="num">$ (441,624)<span></span>
</td>
<td class="num">$ (800,000)<span></span>
</td>
<td class="num">$ (1,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ShareholdersEquityTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shareholders Equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ShareholdersEquityTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cpix_IncentiveStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cpix_IncentiveStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140141269240568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity and Debt (Debt) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 14, 2020</div></th>
<th class="th"><div>Apr. 20, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Oct. 07, 2020</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLineOfCredit', window );">Revolving line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,000,000<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_WinHealthInvestmentSingaporeLtdDomain', window );">WinHealth</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Initial investment in joint ventures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | WinHealth</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Convertible note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember', window );">LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate</a></td>
<td class="nump">0.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLineOfCredit', window );">Revolving line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,000,000.0<span></span>
</td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember', window );">Pinnacle Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived', window );">Aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,187,140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember', window );">Pinnacle Bank | Fourth Amendment | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount', window );">Increase amount (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity', window );">Total capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember', window );">Pinnacle Bank | Line of Credit | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate spread</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Line of credit, unused capacity, commitment fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember', window );">Pinnacle Bank | Line of Credit | Revolving Credit Facility | Minimum | LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate</a></td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember', window );">Pinnacle Bank | Line of Credit | Revolving Credit Facility | Maximum | LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate</a></td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Maximum Borrowing Capacity, Increase Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Maximum Borrowing Capacity, Total Capacity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Coronavirus Aid, Relief, and Economic Security Act, Loan Proceeds Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1336-112600<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1314-112600<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_WinHealthInvestmentSingaporeLtdDomain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_WinHealthInvestmentSingaporeLtdDomain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cpix_FourthAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cpix_FourthAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140141275972632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details Textual)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 44,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 56,500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140141269248808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additions and Returns of Product Rights - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">24 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2018</div></th>
<th class="th"><div>Nov. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment', window );">Financial consideration received in exchange for product license rights, installment payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_ClinigenHealthcareLimitedMember', window );">Clinigen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax', window );">Discontinued operations income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_ClinigenHealthcareLimitedMember', window );">Clinigen | Scenario, Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfIntangibleAssets', window );">Financial consideration received in exchange for product license rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember', window );">Vaprisol</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payment to acquire business upon closing</a></td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPaymentsToAcquireBusinesses', window );">Other Payments to Acquire Businesses</a></td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_TieredRoyaltyPaymentsPercentage', window );">Percentage of tiered royalty payments (up to)</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Additional liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,357,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,200,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember', window );">Vaprisol | Other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Additional liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember', window );">Vaprisol | Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Additional liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_MethotrexateMember', window );">Methotrexate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payment to acquire business upon closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Additional liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Liability recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Vested common stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Net intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_MethotrexateMember', window );">Methotrexate | Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Unvested restricted shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Sale of Intangible Assets, Installment Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_TieredRoyaltyPaymentsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tiered Royalty Payments, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_TieredRoyaltyPaymentsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6405-128476<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPaymentsToAcquireBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with other payments to acquire businesses including deposit on pending acquisitions and preacquisition costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPaymentsToAcquireBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_ClinigenHealthcareLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_ClinigenHealthcareLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_MethotrexateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_MethotrexateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140141276261960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additions and Returns of Product Rights - Change in Consideration (Details) - Vaprisol<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualRollForward', window );"><strong>Loss Contingency Accrual [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Beginning balance</a></td>
<td class="nump">$ 8,200,552<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Cash payment of royalty during the period</a></td>
<td class="num">(1,423,586)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration included in operating expenses</a></td>
<td class="num">(180,110)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses', window );">Contingent consideration earned and accrued in operating expenses</a></td>
<td class="nump">760,225<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Ending balance</a></td>
<td class="nump">$ 7,357,081<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140141369998024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additions and Returns of Product Rights - Dissolution Payments (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 9,055,483<span></span>
</td>
<td class="nump">$ 9,598,177<span></span>
</td>
<td class="nump">$ 19,592,642<span></span>
</td>
<td class="nump">$ 17,928,911<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Costs of products sold</a></td>
<td class="nump">1,740,649<span></span>
</td>
<td class="nump">2,609,982<span></span>
</td>
<td class="nump">4,157,978<span></span>
</td>
<td class="nump">4,244,163<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Selling, Marketing and other</a></td>
<td class="nump">4,121,817<span></span>
</td>
<td class="nump">3,865,406<span></span>
</td>
<td class="nump">7,909,157<span></span>
</td>
<td class="nump">7,573,082<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_ClinigenHealthcareLimitedMember', window );">Clinigen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">498,807<span></span>
</td>
<td class="nump">738,622<span></span>
</td>
<td class="nump">994,217<span></span>
</td>
<td class="nump">1,556,895<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Costs of products sold</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Selling, Marketing and other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Income from discontinued operations</a></td>
<td class="nump">$ 498,807<span></span>
</td>
<td class="nump">$ 738,622<span></span>
</td>
<td class="nump">$ 994,217<span></span>
</td>
<td class="nump">$ 1,556,895<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_ClinigenHealthcareLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_ClinigenHealthcareLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>48
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MI(!(M@;P?JF4>;FQQ[3]L?SB/U!+ P04    "  $B0U3V-Q(,X,"  #0!@
M&    'AL+W=O<FMS:&5E=',O<VAE970S+GAM;)5576_:,!3]*U?1'EJI:T*
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M,_&]@9/)*)[V:T\Z[<G[M5-#-I;)G,OM:P:2MQKH#>PS$![T&]?KOS*]Y=*
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M"O60[RKS13__4^T)"1MOI:NV^S]ZWF/))%KM6J,W^\%P!9NR[O_F+WLAC@9
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M# @9'*?..LX1(.,QH=QMF1B0)E*P>(3TD1>A0=(_:P,KOO):)RH 17C%&2C
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M:G.Y8SDD9RT [S<"*KC^1B\P?%2\^A]02P,$%     @ !(D-4]"*'_%H!P
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M]=7-29G=K=_/_)B59;9:'RY-A'Y8"?#[FRPK'T^J5SYW+Q&?_0]02P,$%
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M\0)XO]+:[3?>P#B+SO\$4$L#!!0    (  2)#5->L-6#F08  )<.   8
M>&PO=V]R:W-H965T<R]S:&5E=#DN>&ULC5=K;^.V$OTKA%O<MH#6UM.2MDF
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MK1S0Z-VJ&C7?#9KQ"YIK]KM6;F_9!U6+^JG^"E[,KL23*^_B5P%_[=62)6'
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MVU$6E/6]*PR(NY6**X]=R^U65O!*(CDU@G+:NRK1>=7@ZL?;7]Z_B4IO#"/
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M4'Q,KGV:7/>;@8(>/FVT <<$%F3@CP7PB\X% :BW#QF2NYK8!G&S'U-=NZ5
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M4C=#,4R7.R$)C8HB]_!!:((J 9?9+!EWX?T+ZFD*\8AJX-4TRR84=#XT 2>
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M#CH-Z:U?O*G"761J/-ULPB,?,-'R!OH^,\:O7]C YG)Z]A]02P,$%     @
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MK)H&A0E_^\MB-CW[WO5)1:'02M$F'PG\FBY%5!"[#L*+03/L$8VPT1%V RH
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MY49) #X-P/N508+&&UJ@_;K\]C]02P,$%     @ !(D-4ZO8KM-""   )A0
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M\=::L/'B)U-2>;A_!K@]YF6'^6KYI,%?6S,5)_.Q6,Z7BR?LG?0<G$1[)]_
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M5_>0TU$#0^RL TF<%+O)_HKG+(U<_C T@00Q:$:]%B7?=2SK1P0*#[^FT>F
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M)M_H%K!HK=&'T[CG;>M42EZU?TUEM?$^#UH1&O+ZH-K&V:N6J_X+2G+@E0$
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M,TVC>D9OVLL!['7MOF1BVVK<Z1FDH[$?9G$3)YNX8S\.W3:&<439EL%L:9I
MQO#S3UD41K^VZ?DJ;B%E;N"/1PE1:"KM.T%RJ V\"\. RB$XAP>K/B7_,RMJ
MYZD&XG4I[7.^)RS#+BS#_QR61TO]84M/!=LG*">?]M5RYZKE5&1ZT4]'QM'@
M <WKHGS3!)_X%LIF0*$=4*]BY]K0$>H9#(/4#^/ 13#TX_'XQ9B6Y0SB)/.3
MT$8YCF(_R<8G'3HXF,LEJI5[?6C(92U,,Z*[T^Z!,VOF^LOUYG5TS]2*"SL"
MEB0:7(XHKU7SXF@V1E9NRL^EH3>#6Z[ID8;*7J#O2RG-?F,)NF??]!]02P,$
M%     @ !(D-4_@4 3_K P  9@D  !D   !X;"]W;W)K<VAE971S+W-H965T
M,C$N>&ULG59;;^LV#/XKA#<,+6#4EUSJ=DF )MVP,^  1=MM#\,>%)N)A<I2
M*LE)\^]'RJF; S39Y271C1\_?J1$3W;&OK@:T<-;H[2;1K7WF]LD<66-C7!7
M9H.:=E;&-L+3U*X3M[$HJF#4J"1/TW'2"*FCV22L/=C9Q+1>28T/%ES;-,+N
MYZC,;AIET?O"HUS7GA>2V60CUOB$_K?-@Z59TJ-4LD'MI-%@<36-[K+;^8C/
MAP._2]RYHS%P)$MC7GCRI9I&*1-"A:5G!$%_6UR@4@Q$-%X/F%'OD@V/Q^_H
M/X?8*9:E<+@PZ@]9^7H:%1%4N!*M\H]F]PL>X@D$2Z-<^(5==_9Z%$'9.F^:
M@S$Q:*3N_L7;08<C@R(]89 ?#/+ NW,46-X++V83:W9@^32A\2"$&JR)G-2<
ME"=O:5>2G9_=595D>1P(7<$C^M;2V*S@P9JJ+3V$-#FX>!9+A>YRDGCRRK9)
M>? P[SSD)SR,X:O1OG;PDZZP^M8^(;8]Y?R=\CP_"_AKJZ]@D,:0IWEV!F_0
M2S (>(,3>//6T8ISL##-4FK1R?'GW=)Y2T7SUQD7P][%,+@8GG#Q1'>I:A6R
ML+V[N_*UE>Z@_G)_/(^)B_92KU%['CI9H0W$/M/_K&^^U;=N(TJ<1G1M'=HM
M1K/G&F%E%%U)<@*><PMA5U.N/6V6M2#O#J0.TY60%K9"M2&$<."#8'E,$)04
M2ZFDW],QX4$ZNKL-"M=:K(#O(<W+UEIV3/=)NBMX/H>'PFJRY/(496E;&A,I
M>I5XGS#PC1XHQU0=;(2LP!L&M&(K=(GPV@KKT:K]%<R%"DO$ZAY+;)9H89"%
M.DKA>RAB>LGBT2B'A7 U8>T;9D/Q6K,7B@*JVL":PR?WTE1PD<7#?!"/BO$E
M+()D3.Y;M4Y&)G6IVNID/!=9D<99EEX>%\/_U.9ZG,9Y/CJ6@*X1]M>(PK^.
M!Z/K."TR.%/PH[[@1_^ZX.^E<T:U@?!#)ZK[K(S/(IXNX^H(_I S!RMK&E@0
MAB350%CD!L*=@-7BBMRBINR$8P30I8CE.VA'*G=E26_"1FA*O2$5M?&<M-9^
M""O(>2D%X^ZDK[DV')[@P8@6$9KN/41^#S_2\"3?3NR$!(4B_1@]=A$X2MSP
MIHB+])I3."CB<9[3Z.9F&.<9KV54T>.XN!E1*,Z'IWW3/>T.2+<*?OBNR+/\
MQY/_3]0QJ99B^"KL"X:RXGHS%*G]1^,ONC3->9W_0P2?%69RU/L:M.O0X1W=
MDU;[K@WVJ_U'Q%W7.S^.=U\@%.!:$B&%*S)-K[AGVZZK=Q-O-J&3+HVGOAR&
M-7T(H>4#M+\RQK]/V$'_:37[&U!+ P04    "  $B0U3;()W.2<"  "@!
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M]5"U6LO46=K-MIV&<9BD.,['_K9?EX' %.,('EW@!^JXHX[/4L\D;,:5H!6
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MEW8VHW(&]CZ3TNPV;EQ4TW[T"U!+ P04    "  $B0U3^5J!'FT"  !H!@
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MN\%/ 2B;@/<K*<US8*=-_W$I_@-02P,$%     @ !(D-4SQ":,>* @  T08
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M5K@L!-\A8;QU-C.P4FVT+HXTYE 62NA5HN-4^0!:DD1G"WW:54<!\1K9.?1
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M1'=V'U;[8!*WL4CBC.VT(,V/7SM)T\NX:= ('FALG^_<?'S.L4=KREYY@K$
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M,\%(GDA%(-<7E(K-0 EHGXW&_P-02P,$%     @ !(D-4\A?P'1K!   9A0
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MH.3>\S'P#8WZESU.'ITG[51Y/@9V/&J*@7MT@:)OX-YCL:$L!3%9*T&>@CE
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M#0=OL0*ZG;_6L*KR/;]1%B?(+PN\LD [!SS?*F5/AANC_A),?P%02P,$%
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MRN+ ],L2OU"@G0$^7RME#QL7H/OF37\!4$L#!!0    (  2)#5.)IO<WI ,
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MV%,214GB1@!S*X@B#(&G$4<P!: !0Z*H.P</SJ-@<TX%V]]'9K\ 4$L#!!0
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MF@&S71I4%9%=47\Y&RTY&/N!7/\LO>'K3W\"2Q="8JI(([MBJG)= +EGS]W
M869(HZM!2K;4AE63$G*U-E 9P77X,"FDD:UPQ;FH"^O>O -7&O4GE6E>YB$F
MIH4TLA?0E-N15XJ)(8ULAG\F77+D)Z0RQ,34D$9V0YM\&RJPQR$8)H4TLA6"
M/+R7#5-$&MD134+>AT4Q3]#(GD '<&=D4$P@-+) \ $<3NPHNMJ(K!!D $_
ML1 3LPJ-;!44L]OIF%QH9+F\YIDJ>$)V1PWF$QK9)YU$<\-,X^?C%C3$Q'Q"
M(_ND@[GP#?)20C5HFHH0$_,)C>R3-C6^#62WQS&UT,AJ:1GK(YEK6V?-O3V.
M68:^DV7"SFZ09X(M1;C?@5DG>Y?5"?GHA:,<N7[>5HOVO9V>8=;)#KEL(4<A
M)F:=++)U4,SN)A>ZRQ79.N'ZZF]?DWMX=B63G3['I),=<D73F6EDF(&RR ;"
M,0<A)F:@++*!<,QAB(D9**L-U&LWV3FLA )^XQ]A?7G.9#XWI#HTFPB#8375
M7Y52?O%EMVJF&6_W[-O_&RY_ U!+ P04    "  $B0U3F3ZBA'P!  "6%@
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M79-:E<W!GW7_P&=?4$L! A0#%     @ !(D-4P=!36*!    L0   !
M         ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  $B0U3
M4D!K".\    K @  $0              @ &O    9&]C4')O<',O8V]R92YX
M;6Q02P$"% ,4    "  $B0U3F5R<(Q &  "<)P  $P              @ '-
M 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    (  2)#5/,[LVV2@4
M  $6   8              " @0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX
M;6Q02P$"% ,4    "  $B0U3 :!K02P&  "B%P  &               @(&.
M#0  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ !(D-4]C<
M2#.# @  T 8  !@              ("!\!,  'AL+W=O<FMS:&5E=',O<VAE
M970S+GAM;%!+ 0(4 Q0    (  2)#5.W_DGKJ@<  -\B   8
M  " @:D6  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    "  $
MB0U3?KQ)Y2,'  !@'   &               @(&)'@  >&PO=V]R:W-H965T
M<R]S:&5E=#4N>&UL4$L! A0#%     @ !(D-4]"*'_%H!P  4"P  !@
M         ("!XB4  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0
M   (  2)#5-+$W %11   $ I   8              " @8 M  !X;"]W;W)K
M<VAE971S+W-H965T-RYX;6Q02P$"% ,4    "  $B0U3Z GLA5 $  "7"@
M&               @('[/0  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L!
M A0#%     @ !(D-4UZPU8.9!@  EPX  !@              ("!@4(  'AL
M+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    (  2)#5.OT[*E.P8
M .P.   9              " @5!)  !X;"]W;W)K<VAE971S+W-H965T,3 N
M>&UL4$L! A0#%     @ !(D-4W/P:YX?!@  J X  !D              ("!
MPD\  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    "  $B0U3
M@$A70M ,  "=(0  &0              @($85@  >&PO=V]R:W-H965T<R]S
M:&5E=#$R+GAM;%!+ 0(4 Q0    (  2)#5,A9WEM%P,  ,T&   9
M      " @1]C  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%
M  @ !(D-4P._MK+P P  @ @  !D              ("!;68  'AL+W=O<FMS
M:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    "  $B0U32-ZL5#P+  !I'@
M&0              @(&4:@  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+
M 0(4 Q0    (  2)#5.KV*[30@@  "84   9              " @0=V  !X
M;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ !(D-4_GEHN+E
M P  I0D  !D              ("!@'X  'AL+W=O<FMS:&5E=',O<VAE970Q
M-RYX;6Q02P$"% ,4    "  $B0U3)W?STG #  #B!@  &0
M@(&<@@  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    (  2)
M#5, -OQ^VP(  /8%   9              " @4.&  !X;"]W;W)K<VAE971S
M+W-H965T,3DN>&UL4$L! A0#%     @ !(D-4^&:94L>!    @H  !D
M         ("!58D  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4
M    "  $B0U3^!0!/^L#  !F"0  &0              @(&JC0  >&PO=V]R
M:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    (  2)#5-L@G<Y)P(  * $
M   9              " @<R1  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL
M4$L! A0#%     @ !(D-4_*V+"Y0!   2P\  !D              ("!*I0
M 'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    "  $B0U3%QR_
M%ED"  !0!0  &0              @(&QF   >&PO=V]R:W-H965T<R]S:&5E
M=#(T+GAM;%!+ 0(4 Q0    (  2)#5.X?T.Y<P0  -03   9
M  " @4&;  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @
M!(D-4UYL@O.E @  . @  !D              ("!ZY\  'AL+W=O<FMS:&5E
M=',O<VAE970R-BYX;6Q02P$"% ,4    "  $B0U3*,$4,,("  "Z!P  &0
M            @(''H@  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4
M Q0    (  2)#5/T4/0SW (  /D'   9              " @<"E  !X;"]W
M;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ !(D-4_E:@1YM @
M: 8  !D              ("!TZ@  'AL+W=O<FMS:&5E=',O<VAE970R.2YX
M;6Q02P$"% ,4    "  $B0U3/$)HQXH"  #1!@  &0              @(%W
MJP  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    (  2)#5/9
MY$9V1 (  (L%   9              " @3BN  !X;"]W;W)K<VAE971S+W-H
M965T,S$N>&UL4$L! A0#%     @ !(D-4][;" QE!   0A(  !D
M     ("!L[   'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  2)#5.)IO<WI ,  !D-   9              "
M@9[$  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ !(D-
M4W?J?=(1 P  +!$   T              ( !><@  'AL+W-T>6QE<RYX;6Q0
M2P$"% ,4    "  $B0U3EXJ[',     3 @  "P              @ &URP
M7W)E;',O+G)E;'-02P$"% ,4    "  $B0U3]T< AV@#  #S&   #P
M        @ &>S   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ !(D-4YD^
MHH1\ 0  EA8  !H              ( !,]   'AL+U]R96QS+W=O<FMB;V]K
M+GAM;"YR96QS4$L! A0#%     @ !(D-4ZIG%&&8 0  "Q<  !,
M     ( !Y]$  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     "T +0 R#
&L-,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>119</ContextCount>
  <ElementCount>255</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>34</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="cpix-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cpix-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cpix-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cpix-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cpix-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cpix-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statement of Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity</Role>
      <ShortName>Condensed Consolidated Statement of Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cpix-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation</Role>
      <ShortName>Organization and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cpix-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2104102 - Disclosure - Earnings (Loss) Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EarningsLossPerShare</Role>
      <ShortName>Earnings (Loss) Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cpix-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2108103 - Disclosure - Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/Revenues</Role>
      <ShortName>Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cpix-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2111104 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cpix-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2115105 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cpix-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2121106 - Disclosure - Shareholders' Equity and Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt</Role>
      <ShortName>Shareholders' Equity and Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cpix-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2124107 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cpix-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2126108 - Disclosure - Collaborative Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CollaborativeAgreements</Role>
      <ShortName>Collaborative Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cpix-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2127109 - Disclosure - Additions and Returns of Product Rights</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights</Role>
      <ShortName>Additions and Returns of Product Rights</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cpix-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Organization and Basis of Presentation (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies</Role>
      <ShortName>Organization and Basis of Presentation (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cpix-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Earnings (Loss) Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EarningsLossPerShareTables</Role>
      <ShortName>Earnings (Loss) Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/EarningsLossPerShare</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="cpix-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2309302 - Disclosure - Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/RevenuesTables</Role>
      <ShortName>Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/Revenues</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="cpix-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2312303 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/Inventories</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="cpix-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2316304 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/Leases</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="cpix-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2328305 - Disclosure - Additions and Returns of Product Rights (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables</Role>
      <ShortName>Additions and Returns of Product Rights (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="cpix-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2403401 - Disclosure - Organization and Basis of Presentation Organization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails</Role>
      <ShortName>Organization and Basis of Presentation Organization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="cpix-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Earnings (Loss) Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails</Role>
      <ShortName>Earnings (Loss) Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/EarningsLossPerShareTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="cpix-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Earnings (Loss) Per Share (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual</Role>
      <ShortName>Earnings (Loss) Per Share (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/EarningsLossPerShareTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="cpix-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/RevenuesDetails</Role>
      <ShortName>Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/RevenuesTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="cpix-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2413405 - Disclosure - Inventories (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails</Role>
      <ShortName>Inventories (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/InventoriesTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="cpix-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2414406 - Disclosure - Inventories (Schedule of Inventories) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails</Role>
      <ShortName>Inventories (Schedule of Inventories) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/InventoriesTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="cpix-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2417407 - Disclosure - Leases (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/LeasesTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="cpix-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2418408 - Disclosure - Leases (Lease Position) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails</Role>
      <ShortName>Leases (Lease Position) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/LeasesTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="cpix-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2419409 - Disclosure - Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails</Role>
      <ShortName>Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/LeasesTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="cpix-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2420410 - Disclosure - Leases - Rent Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LeasesRentExpenseDetails</Role>
      <ShortName>Leases - Rent Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="cpix-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2422411 - Disclosure - Shareholders' Equity and Debt (Shareholders' Equity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails</Role>
      <ShortName>Shareholders' Equity and Debt (Shareholders' Equity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="cpix-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2423412 - Disclosure - Shareholders' Equity and Debt (Debt) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails</Role>
      <ShortName>Shareholders' Equity and Debt (Debt) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="cpix-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2425413 - Disclosure - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual</Role>
      <ShortName>Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/IncomeTaxes</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="cpix-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2429414 - Disclosure - Additions and Returns of Product Rights - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails</Role>
      <ShortName>Additions and Returns of Product Rights - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="cpix-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2430415 - Disclosure - Additions and Returns of Product Rights - Change in Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails</Role>
      <ShortName>Additions and Returns of Product Rights - Change in Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="cpix-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2431416 - Disclosure - Additions and Returns of Product Rights - Dissolution Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails</Role>
      <ShortName>Additions and Returns of Product Rights - Dissolution Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="cpix-20210630.htm">cpix-20210630.htm</File>
    <File>a2021q2-exhibit311.htm</File>
    <File>a2021q2-exhibit312.htm</File>
    <File>a2021q2-exhibit321.htm</File>
    <File>cpix-20210630.xsd</File>
    <File>cpix-20210630_cal.xml</File>
    <File>cpix-20210630_def.xml</File>
    <File>cpix-20210630_lab.xml</File>
    <File>cpix-20210630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>53
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "cpix-20210630.htm": {
   "axisCustom": 0,
   "axisStandard": 17,
   "contextCount": 119,
   "dts": {
    "calculationLink": {
     "local": [
      "cpix-20210630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cpix-20210630_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "cpix-20210630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cpix-20210630_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cpix-20210630_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "cpix-20210630.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 307,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 5,
    "total": 5
   },
   "keyCustom": 14,
   "keyStandard": 241,
   "memberCustom": 15,
   "memberStandard": 18,
   "nsprefix": "cpix",
   "nsuri": "http://www.cumberlandpharma.com/20210630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.cumberlandpharma.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111104 - Disclosure - Inventories",
     "role": "http://www.cumberlandpharma.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115105 - Disclosure - Leases",
     "role": "http://www.cumberlandpharma.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121106 - Disclosure - Shareholders' Equity and Debt",
     "role": "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt",
     "shortName": "Shareholders' Equity and Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124107 - Disclosure - Income Taxes",
     "role": "http://www.cumberlandpharma.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126108 - Disclosure - Collaborative Agreements",
     "role": "http://www.cumberlandpharma.com/role/CollaborativeAgreements",
     "shortName": "Collaborative Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2127109 - Disclosure - Additions and Returns of Product Rights",
     "role": "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights",
     "shortName": "Additions and Returns of Product Rights",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Organization and Basis of Presentation (Policies)",
     "role": "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies",
     "shortName": "Organization and Basis of Presentation (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Earnings (Loss) Per Share (Tables)",
     "role": "http://www.cumberlandpharma.com/role/EarningsLossPerShareTables",
     "shortName": "Earnings (Loss) Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2309302 - Disclosure - Revenues (Tables)",
     "role": "http://www.cumberlandpharma.com/role/RevenuesTables",
     "shortName": "Revenues (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312303 - Disclosure - Inventories (Tables)",
     "role": "http://www.cumberlandpharma.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "iba716d2d6c004c9c85738b68d83bc0b7_I20210630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "iba716d2d6c004c9c85738b68d83bc0b7_I20210630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cpix:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2316304 - Disclosure - Leases (Tables)",
     "role": "http://www.cumberlandpharma.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cpix:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2328305 - Disclosure - Additions and Returns of Product Rights (Tables)",
     "role": "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables",
     "shortName": "Additions and Returns of Product Rights (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403401 - Disclosure - Organization and Basis of Presentation Organization (Details)",
     "role": "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails",
     "shortName": "Organization and Basis of Presentation Organization (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Earnings (Loss) Per Share (Details)",
     "role": "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails",
     "shortName": "Earnings (Loss) Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Earnings (Loss) Per Share (Details Textual)",
     "role": "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual",
     "shortName": "Earnings (Loss) Per Share (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - Revenues (Details)",
     "role": "http://www.cumberlandpharma.com/role/RevenuesDetails",
     "shortName": "Revenues (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "ia5edd42c5f134552b215b0303905dc64_D20210401-20210630",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "iba716d2d6c004c9c85738b68d83bc0b7_I20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryValuationReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413405 - Disclosure - Inventories (Narrative) (Details)",
     "role": "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails",
     "shortName": "Inventories (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "iba716d2d6c004c9c85738b68d83bc0b7_I20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryValuationReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "iba716d2d6c004c9c85738b68d83bc0b7_I20210630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414406 - Disclosure - Inventories (Schedule of Inventories) (Details)",
     "role": "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails",
     "shortName": "Inventories (Schedule of Inventories) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "iba716d2d6c004c9c85738b68d83bc0b7_I20210630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "iba716d2d6c004c9c85738b68d83bc0b7_I20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417407 - Disclosure - Leases (Narrative) (Details)",
     "role": "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails",
     "shortName": "Leases (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "iba716d2d6c004c9c85738b68d83bc0b7_I20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "iba716d2d6c004c9c85738b68d83bc0b7_I20210630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418408 - Disclosure - Leases (Lease Position) (Details)",
     "role": "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails",
     "shortName": "Leases (Lease Position) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cpix:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "iba716d2d6c004c9c85738b68d83bc0b7_I20210630",
      "decimals": "0",
      "lang": "en-US",
      "name": "cpix:LeaseLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "iba716d2d6c004c9c85738b68d83bc0b7_I20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockNoParValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "iba716d2d6c004c9c85738b68d83bc0b7_I20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockNoParValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "iba716d2d6c004c9c85738b68d83bc0b7_I20210630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419409 - Disclosure - Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)",
     "role": "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails",
     "shortName": "Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "iba716d2d6c004c9c85738b68d83bc0b7_I20210630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseAndRentalExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420410 - Disclosure - Leases - Rent Expense (Details)",
     "role": "http://www.cumberlandpharma.com/role/LeasesRentExpenseDetails",
     "shortName": "Leases - Rent Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseAndRentalExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "i1e44f0e8ba3a437db0695f10422fa49b_I20160131",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422411 - Disclosure - Shareholders' Equity and Debt (Shareholders' Equity) (Details)",
     "role": "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails",
     "shortName": "Shareholders' Equity and Debt (Shareholders' Equity) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "i1e44f0e8ba3a437db0695f10422fa49b_I20160131",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "iba716d2d6c004c9c85738b68d83bc0b7_I20210630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermLineOfCredit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423412 - Disclosure - Shareholders' Equity and Debt (Debt) (Details)",
     "role": "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails",
     "shortName": "Shareholders' Equity and Debt (Debt) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "i3738112144924be8b7ed4df49c530139_I20200831",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "iba716d2d6c004c9c85738b68d83bc0b7_I20210630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425413 - Disclosure - Income Taxes (Details Textual)",
     "role": "http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual",
     "shortName": "Income Taxes (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "iba716d2d6c004c9c85738b68d83bc0b7_I20210630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "i8613f3fef30a4cf99a52244890006824_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "cpix:ProceedsFromSaleOfIntangibleAssetsInstallmentPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429414 - Disclosure - Additions and Returns of Product Rights - Narrative (Details)",
     "role": "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
     "shortName": "Additions and Returns of Product Rights - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "i8613f3fef30a4cf99a52244890006824_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "cpix:ProceedsFromSaleOfIntangibleAssetsInstallmentPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "i6742997b2ea4497a8b57f546e21e37aa_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430415 - Disclosure - Additions and Returns of Product Rights - Change in Consideration (Details)",
     "role": "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails",
     "shortName": "Additions and Returns of Product Rights - Change in Consideration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "i666e3ad219a249f69a70f9d7525a1f8b_D20210101-20210630",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:PaymentsForRoyalties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431416 - Disclosure - Additions and Returns of Product Rights - Dissolution Payments (Details)",
     "role": "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails",
     "shortName": "Additions and Returns of Product Rights - Dissolution Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "i0932967c9c90454494cbf245d9fa585d_D20210401-20210630",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations",
     "role": "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations",
     "shortName": "Condensed Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "i1d02e5c5b36b42faa519c6a441665489_D20210401-20210630",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "ie98ab83b91d54ad0aa13294fe0c3bdb6_I20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statement of Equity",
     "role": "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
     "shortName": "Condensed Consolidated Statement of Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "iab72c368dd2d4ce9a791ab677393c6a5_D20200101-20200331",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Basis of Presentation",
     "role": "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation",
     "shortName": "Organization and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104102 - Disclosure - Earnings (Loss) Per Share",
     "role": "http://www.cumberlandpharma.com/role/EarningsLossPerShare",
     "shortName": "Earnings (Loss) Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108103 - Disclosure - Revenues",
     "role": "http://www.cumberlandpharma.com/role/Revenues",
     "shortName": "Revenues",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210630.htm",
      "contextRef": "i7ef00c4903504e60b3239efcf51b7d98_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 34,
   "tag": {
    "cpix_AcetadoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acetadote",
        "label": "Acetadote [Member]",
        "terseLabel": "Kristalose"
       }
      }
     },
     "localname": "AcetadoteMember",
     "nsuri": "http://www.cumberlandpharma.com/20210630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets and Liabilities, Lessee",
        "label": "Assets and Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Lease Position"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://www.cumberlandpharma.com/20210630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses",
        "label": "Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses",
        "terseLabel": "Contingent consideration earned and accrued in operating expenses"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses",
     "nsuri": "http://www.cumberlandpharma.com/20210630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_CaldolorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Caldolor",
        "label": "Caldolor [Member]",
        "terseLabel": "Omeclamox-Pak"
       }
      }
     },
     "localname": "CaldolorMember",
     "nsuri": "http://www.cumberlandpharma.com/20210630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_ClinigenHealthcareLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinigen Healthcare Limited",
        "label": "Clinigen Healthcare Limited [Member]",
        "terseLabel": "Clinigen"
       }
      }
     },
     "localname": "ClinigenHealthcareLimitedMember",
     "nsuri": "http://www.cumberlandpharma.com/20210630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_DenominatorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Denominator.",
        "label": "Denominator [Abstract]",
        "verboseLabel": "Denominator:"
       }
      }
     },
     "localname": "DenominatorAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20210630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_EquityAndDebtAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity and Debt [Abstract]",
        "label": "Equity and Debt [Abstract]"
       }
      }
     },
     "localname": "EquityAndDebtAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20210630",
     "xbrltype": "stringItemType"
    },
    "cpix_FourthAmendmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fourth Amendment",
        "label": "Fourth Amendment [Member]",
        "terseLabel": "Fourth Amendment"
       }
      }
     },
     "localname": "FourthAmendmentMember",
     "nsuri": "http://www.cumberlandpharma.com/20210630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_IfetrobanClinicalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ifetroban Clinical",
        "label": "Ifetroban Clinical [Member]",
        "terseLabel": "Ifetroban Clinical"
       }
      }
     },
     "localname": "IfetrobanClinicalMember",
     "nsuri": "http://www.cumberlandpharma.com/20210630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_IncentiveStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incentive Stock Options",
        "label": "Incentive Stock Options [Member]",
        "terseLabel": "Incentive Stock Options"
       }
      }
     },
     "localname": "IncentiveStockOptionsMember",
     "nsuri": "http://www.cumberlandpharma.com/20210630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Cash Surrender Value Of Life Insurance Policy",
        "label": "Increase (Decrease) In Cash Surrender Value Of Life Insurance Policy",
        "negatedTerseLabel": "Increase (Decrease) In Cash Surrender Value Of Life Insurance Policy"
       }
      }
     },
     "localname": "IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy",
     "nsuri": "http://www.cumberlandpharma.com/20210630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_IncreaseDecreaseInCurrentOperatingLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "IncreaseDecreaseInCurrentOperatingLiabilities",
        "verboseLabel": "Accounts payable and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInCurrentOperatingLiabilities",
     "nsuri": "http://www.cumberlandpharma.com/20210630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_KristaloseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Kristalose",
        "label": "Kristalose [Member]",
        "terseLabel": "Caldolor"
       }
      }
     },
     "localname": "KristaloseMember",
     "nsuri": "http://www.cumberlandpharma.com/20210630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_LeaseLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease, Liability",
        "label": "Lease, Liability",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "LeaseLiability",
     "nsuri": "http://www.cumberlandpharma.com/20210630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, to be Paid, after Year Three",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Three",
        "terseLabel": "After 2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearThree",
     "nsuri": "http://www.cumberlandpharma.com/20210630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of Credit Facility, Maximum Borrowing Capacity, Increase Amount",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity, Increase Amount",
        "terseLabel": "Increase amount (up to)"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount",
     "nsuri": "http://www.cumberlandpharma.com/20210630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of Credit Facility, Maximum Borrowing Capacity, Total Capacity",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity, Total Capacity",
        "terseLabel": "Total capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity",
     "nsuri": "http://www.cumberlandpharma.com/20210630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_MethotrexateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Methotrexate [Member]",
        "label": "Methotrexate [Member]",
        "terseLabel": "Methotrexate"
       }
      }
     },
     "localname": "MethotrexateMember",
     "nsuri": "http://www.cumberlandpharma.com/20210630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_NumeratorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Numerator.",
        "label": "Numerator [Abstract]",
        "verboseLabel": "Numerator:"
       }
      }
     },
     "localname": "NumeratorAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20210630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_OmeclamoxPakMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Omeclamox-Pak",
        "label": "Omeclamox-Pak [Member]",
        "terseLabel": "Vibativ"
       }
      }
     },
     "localname": "OmeclamoxPakMember",
     "nsuri": "http://www.cumberlandpharma.com/20210630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_OtherLongTermObligationsExcludingCurrentPortion": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Long Term Obligations, Excluding Current Portion",
        "label": "Other Long Term Obligations, Excluding Current Portion",
        "verboseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLongTermObligationsExcludingCurrentPortion",
     "nsuri": "http://www.cumberlandpharma.com/20210630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_OtherProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Products",
        "label": "Other Products [Member]",
        "terseLabel": "Other revenue"
       }
      }
     },
     "localname": "OtherProductsMember",
     "nsuri": "http://www.cumberlandpharma.com/20210630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_PinnacleBankMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pinnacle Bank",
        "label": "Pinnacle Bank [Member]",
        "terseLabel": "Pinnacle Bank"
       }
      }
     },
     "localname": "PinnacleBankMember",
     "nsuri": "http://www.cumberlandpharma.com/20210630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Sale of Intangible Assets, Installment Payment",
        "label": "Proceeds from Sale of Intangible Assets, Installment Payment",
        "terseLabel": "Financial consideration received in exchange for product license rights, installment payments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfIntangibleAssetsInstallmentPayment",
     "nsuri": "http://www.cumberlandpharma.com/20210630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_ProductsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Products.",
        "label": "Products [Abstract]",
        "verboseLabel": "Products:"
       }
      }
     },
     "localname": "ProductsAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20210630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_RediTrexMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RediTrex",
        "label": "RediTrex [Member]",
        "terseLabel": "RediTrex"
       }
      }
     },
     "localname": "RediTrexMember",
     "nsuri": "http://www.cumberlandpharma.com/20210630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Rent Expense and Sublease Income [Table Text Block]",
        "label": "Schedule of Rent Expense and Sublease Income [Table Text Block]",
        "terseLabel": "Schedule of Rent Expense and Sublease Income"
       }
      }
     },
     "localname": "ScheduleofRentExpenseandSubleaseIncomeTableTextBlock",
     "nsuri": "http://www.cumberlandpharma.com/20210630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cpix_ShareholdersEquityTextualAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shareholders Equity.",
        "label": "Shareholders Equity (Textual) [Abstract]",
        "verboseLabel": "Shareholders' Equity (Textual) [Abstract]"
       }
      }
     },
     "localname": "ShareholdersEquityTextualAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20210630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities",
        "terseLabel": "Shelf Registration, sale of corporate securities (up to)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities",
     "nsuri": "http://www.cumberlandpharma.com/20210630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Coronavirus Aid, Relief, and Economic Security Act, Loan Proceeds Received",
        "label": "The Coronavirus Aid, Relief, and Economic Security Act, Loan Proceeds Received",
        "terseLabel": "Aggregate amount"
       }
      }
     },
     "localname": "TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived",
     "nsuri": "http://www.cumberlandpharma.com/20210630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_TieredRoyaltyPaymentsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tiered Royalty Payments, Percentage",
        "label": "Tiered Royalty Payments, Percentage",
        "terseLabel": "Percentage of tiered royalty payments (up to)"
       }
      }
     },
     "localname": "TieredRoyaltyPaymentsPercentage",
     "nsuri": "http://www.cumberlandpharma.com/20210630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cpix_VIBATIVMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "VIBATIV",
        "label": "VIBATIV [Member]",
        "terseLabel": "Vaprisol"
       }
      }
     },
     "localname": "VIBATIVMember",
     "nsuri": "http://www.cumberlandpharma.com/20210630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_VaprisolMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vaprisol",
        "label": "Vaprisol [Member]",
        "terseLabel": "Acetadote"
       }
      }
     },
     "localname": "VaprisolMember",
     "nsuri": "http://www.cumberlandpharma.com/20210630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_WinHealthInvestmentSingaporeLtdDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "WinHealth Investment (Singapore) Ltd",
        "label": "WinHealth Investment (Singapore) Ltd [Domain]",
        "terseLabel": "WinHealth"
       }
      }
     },
     "localname": "WinHealthInvestmentSingaporeLtdDomain",
     "nsuri": "http://www.cumberlandpharma.com/20210630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r64",
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Director"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r204",
      "r207",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r337",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r204",
      "r207",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r337",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OfficeBuildingMember": {
     "auth_ref": [
      "r345",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office Building [Member]",
        "terseLabel": "Wet Laboratory and Office Space"
       }
      }
     },
     "localname": "OfficeBuildingMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r167",
      "r200",
      "r201",
      "r307",
      "r336",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r167",
      "r200",
      "r201",
      "r307",
      "r336",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r202",
      "r204",
      "r207",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r337",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r202",
      "r204",
      "r207",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r337",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Scenario, Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario, Unspecified [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r191",
      "r205",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r172",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Relationship to Entity [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r22",
      "r35",
      "r173",
      "r174"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "verboseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net income (loss) from continuing operations to net cash provided by (used in) operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r72",
      "r89",
      "r286"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "verboseLabel": "Noncash interest expense"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r89",
      "r183",
      "r185"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "verboseLabel": "Amortization"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "verboseLabel": "Common stock available for purchase through restricted stock awards and options (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of a real estate property.",
        "label": "Area of Real Estate Property",
        "terseLabel": "Square feet of office space"
       }
      }
     },
     "localname": "AreaOfRealEstateProperty",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r95",
      "r147",
      "r157",
      "r163",
      "r176",
      "r262",
      "r267",
      "r276",
      "r310",
      "r323"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r23",
      "r24",
      "r63",
      "r95",
      "r176",
      "r262",
      "r267",
      "r276"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r210",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r274",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BuildingMember": {
     "auth_ref": [
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Building [Member]",
        "terseLabel": "Office Space"
       }
      }
     },
     "localname": "BuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r203",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r203",
      "r206",
      "r242",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]",
        "verboseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": {
     "auth_ref": [
      "r246",
      "r248",
      "r249",
      "r252"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.",
        "label": "Business Combination, Consideration Transferred, Liabilities Incurred",
        "terseLabel": "Liability recorded"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r88",
      "r254"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Change in fair value of contingent consideration included in operating expenses"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r247",
      "r250",
      "r253"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Additional liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "ADDITIONS AND RETURN OF PRODUCT RIGHTS"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r244",
      "r245"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "verboseLabel": "Net intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r20",
      "r45",
      "r91"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r85",
      "r91",
      "r92"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r85",
      "r277"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r13",
      "r85"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations",
        "terseLabel": "Discontinued operations"
       }
      }
     },
     "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r256",
      "r257",
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "COLLABORATIVE AGREEMENTS"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CollaborativeAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r56",
      "r190",
      "r315",
      "r328"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r102",
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "verboseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNoParValue": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount per share of no-par value common stock.",
        "label": "Common Stock, No Par Value",
        "verboseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockNoParValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "verboseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "verboseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r34",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Balance, End of Period (in shares)",
        "periodStartLabel": "Balance, Beginning of Period (in shares)",
        "verboseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock\u2014no par value; 100,000,000 shares authorized; 15,555,865 and 15,723,075 shares issued and outstanding as of June 30, 2018 and December 31, 2017, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt [Member]",
        "terseLabel": "Convertible Debt"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r74",
      "r307"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Costs of products sold",
        "verboseLabel": "Cost of products sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total costs and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "verboseLabel": "Costs and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r30",
      "r31",
      "r32",
      "r311",
      "r312",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r285",
      "r287"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Convertible note"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate spread"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r89",
      "r145"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "verboseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax": {
     "auth_ref": [
      "r1",
      "r2",
      "r3",
      "r4",
      "r5",
      "r12",
      "r69",
      "r330"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax",
        "terseLabel": "Discontinued operations income"
       }
      }
     },
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "verboseLabel": "Earnings (loss) per share attributable to common shareholders"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r71",
      "r107",
      "r108",
      "r109",
      "r110",
      "r111",
      "r115",
      "r117",
      "r120",
      "r121",
      "r122",
      "r126",
      "r127",
      "r319",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Earnings (loss) per share attributable to common shareholders - basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r71",
      "r107",
      "r108",
      "r109",
      "r110",
      "r111",
      "r117",
      "r120",
      "r121",
      "r122",
      "r126",
      "r127",
      "r319",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Earnings (loss) per share attributable to common shareholders - diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r123",
      "r124",
      "r125",
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "EARNINGS (LOSS) PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue from External Customer [Line Items]",
        "terseLabel": "Revenue from External Customer [Line Items]"
       }
      }
     },
     "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r106",
      "r112",
      "r114",
      "r129",
      "r177",
      "r196",
      "r197",
      "r216",
      "r217",
      "r218",
      "r232",
      "r233",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r340",
      "r341",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities": {
     "auth_ref": [
      "r220"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.",
        "label": "Excess Tax Benefit from Share-based Compensation, Operating Activities",
        "negatedLabel": "Decrease in non-cash contingent consideration"
       }
      }
     },
     "localname": "ExcessTaxBenefitFromShareBasedCompensationOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r184",
      "r308"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "verboseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "verboseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r181",
      "r182",
      "r309"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrantMember": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award of money not required to be repaid.",
        "label": "Grant [Member]",
        "terseLabel": "Grant"
       }
      }
     },
     "localname": "GrantMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r99",
      "r147",
      "r156",
      "r159",
      "r162",
      "r165"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income (loss) from continuing operations before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r95",
      "r105",
      "r147",
      "r156",
      "r159",
      "r162",
      "r165",
      "r176",
      "r261",
      "r276"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      },
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income (loss) from continuing operations",
        "totalLabel": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest, Total"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "auth_ref": [
      "r67",
      "r71",
      "r105",
      "r107",
      "r108",
      "r109",
      "r110",
      "r117",
      "r120",
      "r121",
      "r316",
      "r317",
      "r319",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "terseLabel": "Earnings (loss) per share attributable to common shareholders - Continuing operations - basic (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "auth_ref": [
      "r67",
      "r71",
      "r105",
      "r107",
      "r108",
      "r109",
      "r110",
      "r117",
      "r120",
      "r121",
      "r122",
      "r319",
      "r329",
      "r332",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "terseLabel": "Earnings (loss) per share attributable to common shareholders - Continuing operations - diluted (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": {
     "auth_ref": [
      "r1",
      "r2",
      "r3",
      "r4",
      "r5",
      "r15",
      "r18",
      "r238",
      "r330"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Discontinued operations"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": {
     "auth_ref": [
      "r1",
      "r2",
      "r3",
      "r4",
      "r5",
      "r12",
      "r15",
      "r261"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent",
        "terseLabel": "Income from discontinued operations"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": {
     "auth_ref": [
      "r69",
      "r71",
      "r118",
      "r120",
      "r121",
      "r319",
      "r330",
      "r332",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share",
        "terseLabel": "Earnings (loss) per share attributable to common shareholders - Discontinued operations - basic (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": {
     "auth_ref": [
      "r118",
      "r120",
      "r121",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share",
        "terseLabel": "Earnings (loss) per share attributable to common shareholders - Discontinued operations - diluted (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Contingency [Line Items]",
        "terseLabel": "Income Tax Contingency [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxContingencyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "auth_ref": [
      "r225",
      "r226",
      "r228",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Income Tax Contingency [Table]",
        "terseLabel": "Income Tax Contingency [Table]"
       }
      }
     },
     "localname": "IncomeTaxContingencyTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r223",
      "r227",
      "r229",
      "r234",
      "r236",
      "r239",
      "r240",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r96",
      "r113",
      "r114",
      "r146",
      "r222",
      "r235",
      "r237",
      "r334"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax (expense) benefit"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Net changes in assets and liabilities affecting operating activities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other current assets and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r68",
      "r144",
      "r284",
      "r286",
      "r320"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryCurrentTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Current [Table]",
        "terseLabel": "Inventory, Current [Table]"
       }
      }
     },
     "localname": "InventoryCurrentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "INVENTORIES"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r59"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r40",
      "r179"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "verboseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, Gross",
        "totalLabel": "Total inventories"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Inventory [Line Items]",
        "terseLabel": "Inventory [Line Items]"
       }
      }
     },
     "localname": "InventoryLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r21",
      "r60"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Total inventories classified as current",
        "verboseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Net, Items Net of Reserve Alternative [Abstract]",
        "verboseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNetItemsNetOfReserveAlternativeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNoncurrent": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.",
        "label": "Inventory, Noncurrent",
        "negatedLabel": "Inventory, Noncurrent",
        "terseLabel": "Non-current inventories"
       }
      }
     },
     "localname": "InventoryNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r41",
      "r179"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "verboseLabel": "Raw materials and work in process"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryValuationReserves": {
     "auth_ref": [
      "r60",
      "r101",
      "r178"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation reserve for inventory.",
        "label": "Inventory Valuation Reserves",
        "terseLabel": "Obsolescence and discontinuance losses"
       }
      }
     },
     "localname": "InventoryValuationReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r76",
      "r143"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "verboseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": {
     "auth_ref": [
      "r46"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate.",
        "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures",
        "terseLabel": "Initial investment in joint ventures"
       }
      }
     },
     "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseAndRentalExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "Operating Leases, Rent Expense",
        "terseLabel": "Rent expense"
       }
      }
     },
     "localname": "LeaseAndRentalExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesRentExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Maturity of Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r295"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r295"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r295"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r295"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r295"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: Interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "LEASES"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r51",
      "r95",
      "r158",
      "r176",
      "r263",
      "r267",
      "r268",
      "r276"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r39",
      "r95",
      "r176",
      "r276",
      "r314",
      "r326"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r53",
      "r95",
      "r176",
      "r263",
      "r267",
      "r268",
      "r276"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r50",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]",
        "terseLabel": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]",
        "terseLabel": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Line of Credit Facility [Line Items]",
        "terseLabel": "Line of Credit Facility [Line Items]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r50"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Line of credit, maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "auth_ref": [
      "r50",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Line of Credit Facility [Table]",
        "terseLabel": "Line of Credit Facility [Table]"
       }
      }
     },
     "localname": "LineOfCreditFacilityTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.",
        "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage",
        "terseLabel": "Line of credit, unused capacity, commitment fee percentage"
       }
      }
     },
     "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "London Interbank Offered Rate (LIBOR) [Member]",
        "terseLabel": "LIBOR"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermLineOfCredit": {
     "auth_ref": [
      "r55",
      "r192",
      "r193"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-term Line of Credit, Noncurrent",
        "verboseLabel": "Revolving line of credit"
       }
      }
     },
     "localname": "LongTermLineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r55",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyAccrualRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Loss Contingency Accrual [Roll Forward]",
        "terseLabel": "Loss Contingency Accrual [Roll Forward]"
       }
      }
     },
     "localname": "LossContingencyAccrualRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r58",
      "r95",
      "r176",
      "r276",
      "r313",
      "r325"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r85",
      "r87",
      "r90"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": {
     "auth_ref": [
      "r85",
      "r87",
      "r90"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations",
        "totalLabel": "Net cash provided by (used in) operating activities from continuing operations"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r18",
      "r65",
      "r66",
      "r70",
      "r90",
      "r95",
      "r105",
      "r107",
      "r108",
      "r109",
      "r110",
      "r113",
      "r114",
      "r119",
      "r147",
      "r156",
      "r159",
      "r162",
      "r165",
      "r176",
      "r276",
      "r318",
      "r331"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income (loss) attributable to common shareholders",
        "totalLabel": "Net income (loss) attributable to common shareholders"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r65",
      "r66",
      "r113",
      "r114",
      "r265",
      "r270"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedLabel": "Net (income) loss at subsidiary attributable to noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Guidance"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r197",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "verboseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r147",
      "r156",
      "r159",
      "r162",
      "r165"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating income (loss)"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Maturity of Lease Liabilities at June 30, 2021"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r291"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r291"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease current liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r291"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease noncurrent liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r290"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r294",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Present value of remaining lease payments, percent"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r293",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals": {
     "auth_ref": [
      "r289"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractually required future rental payments receivable on noncancelable subleasing arrangements.",
        "label": "Operating Leases, Future Minimum Payments Due, Future Minimum Sublease Rentals",
        "terseLabel": "Future minimum sublease income under noncancelable operating subleases"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesRentExpenseSubleaseRentals1": {
     "auth_ref": [
      "r288"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of sublease rental income recognized during the period that reduces the entity's rent expense incurred under operating leases.",
        "label": "Operating Leases, Rent Expense, Sublease Rentals",
        "terseLabel": "Sublease income"
       }
      }
     },
     "localname": "OperatingLeasesRentExpenseSubleaseRentals1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesRentExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r230"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r19",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "ORGANIZATION AND BASIS OF PRESENTATION"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "verboseLabel": "Prepaid and other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "verboseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current liabilities.",
        "label": "Other Current Liabilities [Member]",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherIncome": {
     "auth_ref": [
      "r335"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue and income classified as other.",
        "label": "Other Income",
        "terseLabel": "Other income"
       }
      }
     },
     "localname": "OtherIncome",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount of inventory owned by the entity but in the hands of a customer, typically a reseller.",
        "label": "Other Inventory, Materials, Supplies and Merchandise under Consignment, Gross",
        "terseLabel": "Consigned inventory"
       }
      }
     },
     "localname": "OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r25",
      "r26",
      "r52"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "verboseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherPaymentsToAcquireBusinesses": {
     "auth_ref": [
      "r78"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with other payments to acquire businesses including deposit on pending acquisitions and preacquisition costs.",
        "label": "Other Payments to Acquire Businesses",
        "terseLabel": "Other Payments to Acquire Businesses"
       }
      }
     },
     "localname": "OtherPaymentsToAcquireBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "negatedLabel": "Cash payment of contingent consideration"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Repurchase of common shares"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period for redemption of redeemable noncontrolling interests.",
        "label": "Payments for Repurchase of Redeemable Noncontrolling Interest",
        "negatedLabel": "Repurchase of subsidiary shares from noncontrolling interest"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfRedeemableNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRoyalties": {
     "auth_ref": [
      "r86"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for royalties during the current period.",
        "label": "Payments for Royalties",
        "negatedLabel": "Cash payment of royalty during the period"
       }
      }
     },
     "localname": "PaymentsForRoyalties",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r78",
      "r251"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Payment to acquire business upon closing"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedLabel": "Additions to intangible assets"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedTerseLabel": "Note receivable investment funding"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Additions to property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRepaymentsOfLinesOfCredit": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).",
        "label": "Proceeds from (Repayments of) Lines of Credit",
        "terseLabel": "Borrowings on line of credit"
       }
      }
     },
     "localname": "ProceedsFromRepaymentsOfLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfIntangibleAssets": {
     "auth_ref": [
      "r77"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Proceeds from Sale of Intangible Assets",
        "terseLabel": "Financial consideration received in exchange for product license rights"
       }
      }
     },
     "localname": "ProceedsFromSaleOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r18",
      "r65",
      "r66",
      "r84",
      "r95",
      "r105",
      "r113",
      "r114",
      "r147",
      "r156",
      "r159",
      "r162",
      "r165",
      "r176",
      "r261",
      "r264",
      "r266",
      "r270",
      "r271",
      "r276",
      "r321"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income (loss)",
        "totalLabel": "Net income (loss)",
        "verboseLabel": "Net income (loss)"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r47",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r28",
      "r29",
      "r187",
      "r327"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "verboseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r28",
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PublicUtilitiesInventoryAxis": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of inventory held.",
        "label": "Inventory [Axis]",
        "terseLabel": "Inventory [Axis]"
       }
      }
     },
     "localname": "PublicUtilitiesInventoryAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PublicUtilitiesInventoryTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale.",
        "label": "Inventory [Domain]",
        "terseLabel": "Inventory [Domain]"
       }
      }
     },
     "localname": "PublicUtilitiesInventoryTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayments of Notes Payable",
        "negatedTerseLabel": "Repayments on line of credit"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r221",
      "r347"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r36",
      "r197",
      "r219",
      "r324",
      "r343",
      "r344"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "verboseLabel": "Retained earnings (deficit)"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r106",
      "r112",
      "r114",
      "r177",
      "r216",
      "r217",
      "r218",
      "r232",
      "r233",
      "r340",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "verboseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r141",
      "r142",
      "r155",
      "r160",
      "r161",
      "r167",
      "r168",
      "r170",
      "r199",
      "r200",
      "r307"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenues",
        "verboseLabel": "Net revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "verboseLabel": "Net Revenues"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.",
        "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]",
        "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r242",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": {
     "auth_ref": [
      "r0",
      "r6",
      "r7",
      "r8",
      "r9",
      "r10",
      "r11",
      "r14",
      "r16",
      "r17",
      "r18",
      "r188",
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]",
        "terseLabel": "Schedule of Dissolution Payments"
       }
      }
     },
     "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Reconciliation of numerator and denominator"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table]",
        "terseLabel": "Revenue from External Customers by Products and Services [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "terseLabel": "Summary of net revenue"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r27",
      "r42",
      "r43",
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r210",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r137",
      "r139",
      "r140",
      "r147",
      "r148",
      "r159",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r169",
      "r170",
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "REVENUES"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/Revenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r93",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "verboseLabel": "Operating Segments"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingAndMarketingExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.",
        "label": "Selling and Marketing Expense",
        "terseLabel": "Selling, Marketing and other",
        "verboseLabel": "Selling and marketing"
       }
      }
     },
     "localname": "SellingAndMarketingExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Restricted stock awards, vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Restricted stock granted in period, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r208",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r57",
      "r102",
      "r103",
      "r104",
      "r106",
      "r112",
      "r114",
      "r129",
      "r177",
      "r196",
      "r197",
      "r216",
      "r217",
      "r218",
      "r232",
      "r233",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r340",
      "r341",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r129",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r33",
      "r34",
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "terseLabel": "Unvested restricted shares (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r33",
      "r34",
      "r196",
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Share-based compensation (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "auth_ref": [
      "r57",
      "r196",
      "r197"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued pursuant to acquisitions during the period.",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "terseLabel": "Vested common stock, value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r33",
      "r34",
      "r197",
      "r209",
      "r214"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "verboseLabel": "Repurchase outstanding common shares"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r33",
      "r34",
      "r196",
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Shares",
        "negatedLabel": "Repurchase of shares (in shares)",
        "terseLabel": "Repurchase of shares (in shares)"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r33",
      "r34",
      "r196",
      "r197"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Value",
        "negatedLabel": "Repurchase of common shares",
        "negatedTerseLabel": "Repurchase of shares, value"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r34",
      "r37",
      "r38",
      "r95",
      "r175",
      "r176",
      "r276"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Shareholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r95",
      "r102",
      "r103",
      "r104",
      "r106",
      "r112",
      "r176",
      "r177",
      "r197",
      "r216",
      "r217",
      "r218",
      "r232",
      "r233",
      "r259",
      "r260",
      "r269",
      "r276",
      "r278",
      "r279",
      "r283",
      "r341",
      "r342"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Balance, End of Period",
        "periodStartLabel": "Balance, Beginning of Period",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "verboseLabel": "Equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r94",
      "r197",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "SHAREHOLDERS' EQUITY AND DEBT"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment.",
        "label": "Unrealized Gain (Loss) on Investments",
        "negatedTerseLabel": "Gain on forgiveness of debt"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r122"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "terseLabel": "Dilutive effect of other securities (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r116",
      "r122"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Weighted-average shares outstanding \u2013 diluted (in shares)",
        "verboseLabel": "- diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "verboseLabel": "Weighted-average shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r115",
      "r122"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average shares outstanding \u2013 basic (in shares)",
        "verboseLabel": "- basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1314-112600"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1336-112600"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109126253&loc=d3e4852-112606"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11374-113907"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121610041&loc=d3e36027-109320"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109227538&loc=d3e44648-109337"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121600890&loc=d3e2207-128464"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6904-107765"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.E)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120398118&loc=d3e355146-122828"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(Note 3)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121580752&loc=d3e38371-112697"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(20))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.4)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r348": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r349": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r351": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r352": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r353": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(d))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(13))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868656-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(14))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>54
<FILENAME>0001628280-21-017022-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-21-017022-xbrl.zip
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M^-$C&I*(3AF1;,K9#-*NCK@B[X5,B.?6_DU$2/IY,F8RIFE /D54)M1GN1F
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M)T+]A 9$UJ,[IR375,X;2?U:A"R1SYFX*_*)@Y7RMSCCR4^;COX%4$L#!!0
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MRNLD8L+8 S0P@8$/8)?[90)S3H(X%8R^*PJJM&WV,"$VUK8ZOBCSR#'KRA"
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MWN\!<^6"R/T7==5(6C5/+RB>OYQ[B49+BD;3V\2B1*.GH=%U9.=!8HS(B'C
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M"4=,PHAR"'+!SU/DDF&(4*5%2#$9#@Y ZZH6I,K5DQW Q UIQ@FO$E)+2%U
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MHE !((]7J':^ $W'*D\60"N MBFNG@)CZX"Q]ME97'N5*_3$ #^XB0H9(00
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M8_&50SOY,!A5Z3>F^LX=@Q?-X/4FQI[U?GP([S[.98+WQC-X^FS<>SNR\S
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M\4"XD!+ B3O$73[7G.& 6/!)"TF=C337EN\;*OM8G&<$FU<;I!1@NN]DWE*
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M_>QZ!N7**\DD>QFJ4T@G@/2?!Y-YXW+WMO+*+L:S7V'"]&@ <VP\@4DX'([
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MPT\9/EDIDC*;?#-/2W(;K]SB,:<:'W7;P AORL+Y!7]J93;,;_F.SP9]'S$
M- .Z%: N JC3"3=.A^2%3PB622">E$>P8@1)J[$C@EG-:1D#TG4A\8*8ND2A
MG@IU5@MUECU"5>'/+^#/Q=2.-T]4&(N4,0;PAUBD!8"0,$(:ZK$4 :^],D37
MJ1*W#U)5L:A?RL>9'#&KDNB?8Q+]E^(?,2";^V4<QI*O%VV-BJ*>X\K(A/Q9
ME-OTMP@K/J>X0CD=3T=NQ^NS42[/N$).<4JWOS-9I.+$;F5\%C ^.],;H)Z&
M1*T6"-8J(!X51=I[C!(A3.A\VMUS(+^\;I2L8[;T"><O42M_G?M56KD,6CE%
M"4-2S&&-@G$><2P5<M(S)&2R)J4@C;:@E:)..:ESR1Y?*Y\_ <Q5!'*U\7'#
MVC3JN3"IC_WX&XU/-QVKQ1-&Y3NNP-+&90>""IL6.2:RNY%QJ60-&P?*IZ2M
M-PC'D).F"$$Z*HM\M#2G58 ;&P"=&*M3\K09G*6^K-8VXZKH^/VRCHO8ZP;;
M/ZK4^XG4^_Q2O8LJ;E$Y< 1HS.J-D6$TH,!4=($3C3%;>U7XQO3/95'OEQB6
M&!4ZN@T-*6,\HRI #"8X=(=YN[*(\SRKM,[5(BH[Z28LJQ!L(03;FB8HU'N3
MA'>()D\1%Q8C2PD#@7.1,YF2X*9PGP@VX$+).VWI_9(R/5UN=X4$RQI$J9#@
MOI!@PF4D#]HJE9",*B".E4*:&(ZPXLFFX+25^NZ!E*=$@H+P_*M(.GKL H'&
MK!-*[UH?D)J'*+DGR.U*[BWV.\$>I)BA('J1^H#C+XS0C148_\LE\1[QJS\A
MYV.Y!+V+/[[[==]\T)M7 ZX&7 VX&G UX*<=<#4;U8"K 5<#?HX#?AHGKJKR
M_LA5WI^[%_=LJ]5_O*DWQ&/7JK\F=+3D4_>KY>H7S9-^5C-7%:V_SVSVE4BY
M?_99]U7I^IO>9$7WTJZ>1/O%SKE5Z?K[V6\[:9PW+HZ.F[M?SQN[1U\;%^_A
M>W!ONM_>V?TD]C?W:.-+L]4\/B3S^VU[%S">=PU2].!]]_ZBN7E(X#TN]D\^
M"1CCU^;QWO<]NDUW-C_/UFZUD@6GG4,Z)HVXE!P93R2RQ!OLE*=<XK573+&Z
M85=/LBW928(*;E;CY*M6%(PJ)9$%P!N=F[*'")+$M(V2,#/:N"=5Z?KG!CR3
M\Q(Q)*Z=84A8C1'7*2"GJ(1_2OC;:"4\!>"I"TGKDMZ^TEMU4J(J77__#$FP
MH(6W(G@7.'>YF+5F.!G%)0'YQ??(D%YL9>O'0J&98K+.)RJP0;"0"G$O/'*P
MG(C!*E- (A^367ME#*]34I6N?\8*3J242CO*A1*<4.6822(:KUC4("+AYY2D
M4O#E4? )S5 T1,$LR>5DX0^O#+*6!9 W2ZG3P1I3=,@10M:U6=##J8K75\7K
M7T[HYKE5MWXL.)K4>_V^L[MU=B"M)8['"$"45&[:!9Y/4!8%GQ(V&%8RL@Q)
M3.HZ$;]\&O,)"]C_%*.JRO8K$CVI=/^NNG\QH_M:>JNUB4BRR!#G4B 7&4?>
M)B-5#"+@N/:*UC$6=75-Z9:JOOU3;WY5]>V7C+]4E:^7#O.F6@,21J,#IXO9
M?*Q3QH0<P1KQ& PSC%"+%>"=JE.VZ)'.*KRR0FK^%)RE4O-'HC9G!T1R0:,(
M2(<<1HW6@9J3B!3EP?.8K)%N[14C=<V6J8_%\TW1J0K</_M2T\L9)'J&!:8?
M"U"G"]Q[GHB1U""A-? F S]I8RV"Q3)*84N]TD6,R(@ZT[HJ<+]$BOFL46?9
M U45_OP"_DQU+)+$>^DT<MXRQ*DQR$5.D0A"$$E=5#IE_#&*7;MM5I6X7\T2
M]U7*_3(L<U7H_@[5H!Z1Y+[ DMJ/9(1F"MT;[!*3)K=5R9V^E8C(.?@C>&HL
M(\(+*D>%[G&N!K7LZ>DO42M_G0-66KD,6CE5Z)X'84D4B%+L$"=6(K!$ EGC
ML">.4\SQ97VVXDAD5>B^*G2_/(CTU#SAI53"?B1LFBMTCXF4EAN&I*<4T F(
M@X4U1&!9'!,D(Y7-1[5)G?%%PV95H?M5T?'[91U5H?LG5N^IXK!*"THL1U0:
M(!^YWXY3(I_7 /T.C$EG>57H?@G"$@L7NO]Y!9!GZ1\]-1MY[C6L'PVF9JK9
M>\*3 @A"SB6+N!8*:0 K)*S57E'E88G+:O:*U(5>-"=B@9HY3UJR_H7J]-/'
M/"J=OB^=GJ(>(E' :G J6.ZQ$VAN\!<8HE1JATGDL-AWCWL\N$Y?7]*.B/NI
M:3<U_+F:^@ON*#WL,V>*-^;U&9V"+XZ_/SJTT PM&_T<OAG7IZME(U\#9<T_
MP#]S6F*OY4&785Q=_[5FSVPO](MO=$^+0_LYO>MTV/-'MA]KCTH^MIMO%X"J
M#9CI, I<?;R,4Y6G76,H3\.>G X'Q5KLI"W;Z\#Z]?^)O0+&-DZ FJ^\[]2.
M__YPOO\EG#K* 8P.66.S(?:._SK>W]RBS7=YO+E9QM[W!H!78W.;[AW#M9O[
M"<;-#[PU"I8F(H<C0)"/%!F?,,+:&$<TIH8(@""CZPQ?Q9]":![5DE4"\I@"
M\IX<&&]2M!8CT&P.O#/GX5)L44C8$\&8$";'YEE=7"<?8W<N7::+9L@I0.@T
M^KPL[?-Z[2SVXHS+YX:#\L-.MTA#+98+?J@-CF*^TWC)\HU';F$MCA:O=IJC
MUOFY-1>]'0*$Y:M&<>VS[K =X!<@N1/16+^TH*'U[3H4AX]'2X\3S(6TVN"B
M09X%=.-)&&#G!EO,#IA:&]\F7S1"_MG*O!)0?/1)MC2R,";E %SO7Z]F!S-U
MEQ'(\US9][3;;^6Q_=&+;9O?85+0-Y/+J:M&#\632ZP#+@!S=N,E8'@\ HW-
MR_A'?W@"@SV_6BGS\8ES8=W4W&)-_7G4F]C\0X"T7K1?D4TPUC]L^\R>]]?^
M-;LLL *C>PL.#[]I/GZX?(3^</VNK.*UDWM+ 7G$^J/%7/_&?A_#>U&8L^7O
MP=K/0O3'>)@CF!_B:2Z1U3G,=83:W?ZP%W?A,:_; !=/#;OG(]@]_O2]L?F>
M[>QN8' (X+OOZ?YFAMV]\_WC+7  OI+&\7Y[;W?K;!YVF_!9<]/#LSZ 0P#C
MVMS_6L#N\5\G#7 PP,D R/Y\U-A]#;#[B3;?'^"$56#>(\F-1)Q$A[03 47N
MJ+;!6!I&V9%%S:6-; \3)S)ZKY(5D6.A+(9O&R^#)R& 5[%6BV#+3F'Z![UA
M7'OU8>OS5O/3UL<Q<(\6>4Z$Y^"P7(V?/VIV:"IA8RV1(A#''8O&*D,2<]@;
MZ62B"VC<@^I#<<<_6@- .G\+-/JGUPU#L"NC"BS]&\%[:OQZ-C:1@_BM=/Y$
M<+H+MC&3(-LYKUGO,^'I9X(%)KI\HTEMUHQ8_=I9:W!4\Z/*,GU@>^ QU38^
MOJE)+,&4'[7\46%X3\8V-^\J_V5!>'KG-9+=$:+7:[\T3P^,2/XHAF$[ A\$
M 1Z<?VF%N-TI.2>(_U2MG:WO8%HZMCVNL]-_?3Z2A_Y&)WR,O6\M'_LO&L<.
M#X+EFDG*D+8D(:Z"1M9QAJ*4G$<F.<-D'I>>6A.*+0?U9[_6B8.)(H"@]5O]
MS#6!=F9.F;KM=O<L$]:L,/F3P5$OQL(KZM]4+W[6'[_,N5V9O@_,K#/S 'T?
MV#K6=^WM\.A]'ZK!%GT1;W[H+PWV=NT_7FHGBMT"8W[>B^*%34O5H*-JT/'T
M#3HJL:K$JNK[LOAV^-AOJLZ@58-<EM-\92*)66:U^=\>.*2VW>W'JD_.\KS"
M @?:K8@A<.I%(HP+01TEPF&&F<$B>,E'\2K^TJO WRUV52;W''_B^[M?Z<[F
M]O<\GL;NAZ^-+^_YSNX6V=^$ZW<_7>P?>[QWT6S/)_<T=X_:.[M[O'&\==ZX
M^/J]^>[]]_U-&._NYZ\PWG9SMWG2O/APW*"?4V.ZV@:.P0E,%$J,$L1QP,@Z
MR9'6,D8IN)#,K;T2=:I$'<NJ#4Z%)O>!)B$I&8DU7$7&G3$N4<P4 6PQW'G#
M1\D5_*67G%\--)GJ;&.Q\=0&9#W-21B<(,L%1[#*U"LIDH\V=[;A2L%_2W]J
MN4*3E4 3Z90P3#/I!>'6*1LE92(*@@6S/+"J0\TJH0FY1!.I@DI)&J2(]P@0
MA",KI$ ,Z\# @$25BR#H.I6FSCFKT*1"DWMIAP/0X86E04IN*+71*DV=B)ZZ
M:"VIVN&L$IJP2S0)*E@M\JF%:!/BP3+DE'1(8$RM\2%$$=9>R;I2I,[9$Z#)
M/<5.5R :]+GE<BYH51K^)@Q*-F#"HC- G'FT3!MA3$B)L2B-]:**MJP,!LVT
M')8L)2&Q1H%2@W@R'#FK$O+$IQ@X"=3F)/6ZYKQNJK+PSUG%O5/422]I<HP;
MY6WTG E'" A(2,)5(9!54O%)" 13&C@6 1&I!>(65-PJ;I!E3'B5(L6F"(%0
M8^H"5XTUG[&*1[#9A%'I7%2@V]Q:IDR,6 JG?-4Y=\54?!*7$%%1PX1!/BF/
M.$\6.6\\8H(EPD#OE?79D]!&U8E:IJX/E8K?-U%7(L8 "NZ$Y3$JQXDU-&FK
M'4X.JRI8L$HJ/A4LD"Y*XL&**VL1-Z#=-G"-M*!4:UCG$$7>%E64U!5^VFIJ
MO]+8906"!6]L.^1'O;!"SU>QQIEHF 6)(Q%S9:PF7KO . >;XWE455!@=;!F
MNM:S=#:(I"6B7N9MC@0>@Z$16<RB4HX2K?7:*\-TG=$%D68I*B(];ZU4TF%-
M*&,\"FZ8LQ@44]#$,!$N<5OY\:NDE5.I#"PP3[% TN"8V]52I+6SR /18PK'
M))C/H3HB95W(!4E^I9</G[#H(LT,'#!3<I^<EI$ S?+.28(3XY7SO4IZ.7&^
M8?D(,90@Z1-82Z$DZ*4GR&A#O0N!!<US&^F<8J3IU3;2E5X^<3M4H0*GF<1J
MS:73-C(5C,C-,GF05E0>\RKIY<1C]B(%S+Q%3 :)N 2W66MBD.5<!.D=Q]EC
MIG4J21T@N=I>?\#M=7O::_6[[6I__4976CMGO U&)<-9\E99S'D,@N%HM*Q<
MZ14"H4G/]>_-XVUQ$#V)1E&+>-&_S^5L9(P=\HP('K$U1H>U5\R8NA%TB0)W
M56S^OI6<AD@(==QIQ3D%;L%<DA'X8:1:73*-RC-?"26_F%%R;&@2W&#$N.>(
MAQB0<S0A;\'%H\%Z+0QXYXK7B:@VX)ZQD@ONG1 Z"!\YYTS9((U57 9O/ Z:
M5F[^*BDYF5'R1$U@/@D4<I,U+KU'P-;@CV =#L8H&UT.P0G&ZY14V7+/6,T3
M#5Z#V<8T2DZ=< ;870B"* 8B0:ND_)52<S:CYH$[$@4U2"NG$8<%15I3AG*F
MLPG:,IX($'9-ZWBIE/S9[;1O^#BPH!A7:C2\O"!EY$0K25/  6YF<P8^X\$X
M&P&)2*KB ZL$-Y.M]NC ?@2OD. Y.3=E,D$B1PS64C-K"$NYBX"@=:67_G3R
MB]/*F(CCRCL;N.0J!<>]DB0!I"=JK3"50[]*6CG9:A> M!K'O-7.&1  ^$-[
MDQ!58/JCM\9G9UX840<]K;1RV;32P!IY[947@L-"ZA24%B308'BDTE<>^"II
MY62CW7B.HR<<86$CXM9S9*RA.>D=VR!"$HJMO<IG[XU:,(Y>:>7#'R_36E+F
M/38^<!J2E819[)@BV4!:5CG,JZ254XGI6##,K4-2\+S%Q1RRP7@$2RJ,DMH3
M'W-,C&%=5^0)..RS\XIW3J)OVY/N=_2/_?H\/>/?%ME5L]9$03WW07 CO3;:
M1LZ]2(I8FN3/7>,^O.__74,5PBP/PDQ7!(PB:*EL0%P#!^?">60C8TA&G7Q4
MACFBP.[S.L%7=]9^KRS^DX7(A998.L:Q,SPX9@(#W\EB:CDPM1@J[WB5]''B
M'7O.*06G"D5B<WB<Y!Z81""5DDD!7"PK"%A\7#>\.AVR=.:22*NQH3P0BKD+
MH)OP/Y$294):,),_]XXK<[F$ZCEQDWV@*1$OD4E1(!X-1IIXBK0(/GG%)+"B
MM5=<\3J[IN!E92^?SD/&U-.D!"@G\%<BM0$."RMFG%74.%UYR*NDD!,/67GM
MJ?<,K&3._V2"(!<T0=8SH+&6VF3R'@^]7B&?VC]^1FGH'V)H[?;B]RH-_4;*
M[JVT&$>6O 1>;AWXTMAH)0B7A.JJJ/[J0-#.](GNB!,QBAE$HJ*9$T3@!%0A
MS$D$N194!8 @56>Z2D!_QNIM:=Y"<1$[E3A7TJ3$%<Z%H%B*G,K%//*+V.L&
MVS^J-/O1-7OBC&LB\B%%B9(00"X\5\@ P4=":<I9%,GCM/:J:,M*_ZQT>\5T
M>Q''/C@<8U121VIX$L9039@6"91;,W$9!Z\<^]52];%CCQN;C8/H;=)>1^1$
M3+DR"WCYWFDD@_<>U!Y[68;"M;J:EW*3:U_I^9/K^2*]); 1R5#ND\#<$*=S
MVZN0G,T57TP*BT4)*AO^9(K-)HK]]8!J"KBM%&)2<<1%-,@DBN$G6,(H<33.
M+Z,97VQS?7E# SN#H]@;-ZQ_GGOJBX0!,I6 T0@)#H)6W@IBDPG22&L)8:X*
M ZP,T#1V-XJ#+078;!SP&))QC"/ %8*X$@:Y) (REC-KE6%)Z;577)(ZJ3;O
MEDXOA>=,8^:]QH(;08VG8/<YX=QH$Q6K=M172R_/+_4R>*,HDQJ)",X[3Y0@
MHX)&*5@G (8#)>#&:Y7/E2Y]7ZD7IY?>, ^FT3'G$_?!ZL@H,P9,II!&X5AE
MG*^47C8G]C(R(@.0'J1X #8>B4#6"XN8X]KZH$)P;.V5Y*Q.>55R<>GT,F*9
M&),R4%@>0HPU! /](<[II *M=M172R\G]M*$&(#T*!2*<BM::>1TB$A:(V2(
MQK-DBZQS8>ILA8N[+:_'O-L=V':M$P=CK[F_:/S!=7LA]E Y;W\PF.C0';IV
MK(T'/_H"O.,?>1GZW78K%+_\>8AO95I6/OCL/!LP)P'3W ?3,>DX3=8*8H!U
MY4PI*;@V55!BA<!\:SHH85PR1BF&6&3Y8)\UR'$O$)4Q8&P3HXFNO3)U+$2=
MZP7=GX=6L"?>&'FXMZQP=M$)>C90BP%? PW1*DRYD\I9ZQ5GCFAF/*95"X$5
M@]H);U8I2!=$1 J8,N+8$Z1CQ$@H'BF.@7K.,M0*H^M$W5<SP/O3L0IMEPI3
M*K2]CX8M,6'LN<%,8!XE=CEX&)-/@C@5C*ZBARN%ME/1P]Q'-T0-\"JU15QP
M@9SD"<EDI<IE9%+4:Z](AEM:E_R^<F\KN*W@MH+;&TOI*0IS0TED >!6!Z=]
MB*!F3-LH"3-54'BUX'9";BT+43)B$#,Y%]I$769'$@4XS#PC26:X575#==TL
M6HMDB>&V"#;_:V#AH:_&+]4<@H2U//P[M+Z]^A_X8_PB4_<^!DELI?.1TK[Z
M']?[UZO+U[_U=8^H[+0(/1_%VDP1E'$(.FMF;0"_3:U>?U"S'5B\",H?:O\9
MVMX@]FK=5,L<JG9F^\47>[$_; _RQV^&)R[VVOD:/^SU8F?0/J^Y"$M3ZPZ+
M;_CN"4RI;]EVK=6!YPVZO?/\^>"HU:^=]KIAZ ?KM5H>W2G(BCV$Y^4!=8>]
MN>&.OER+'0_R!..* 8;<L9WBYJ&54LO#L%HP90'>:M MQMHZ@=N68]WYO+V)
MB"F?=EZSO0B(!S)6Z\ ,P_S"LT]@@,4,Y%^V.L4=X+D>@";?PL*K=WN'MM.Z
ML%GVUVN;K;X?]OOP<[]V!BA57C%^D7R7;N>P"_,!3VU.PO[%5 (R=N'9AW"K
M;Q'FK1PJO)4[OWS97AP,>YW\1KT\J<7=8?V[H;]>6USFEDA6BSO^T1K X_PM
MI+=,-?PPOVDR_P8GMG?8ZA2@(6=IR=,KWYLNK&_GO':4E_ZP%PMA&TE-*\MS
MIY ID.534+M.[/4+19@HT$CH2NVYO-]_7ZK1Z%ZVW^_"U[,@G=KS\B&M3C::
M\ G(='<Z:Q/$:/>HVX_3(X+;?6L%T* C"]IF_='XB9?CRG(-(' *4M_*F)W'
MV8_Q:Q;17CP<MFVAYO8TWPK$_!)B1B.M%SJ6NNUV]RQ?,_YBO7S<Z#GP.NTV
MH,F51^4[C=0*]+X_Z+7<L)B9 KN "/3'NINOC#[KU]P4P\^]%@RR5<[ 9'5&
M+P_O" 8)%'L$1Q-]/,P/M)>/.[%P8_BO/QEEJ]T:G%\.M!?;\9L%6,D#:+=A
M-,.\Q+TNZ/'@?'T:0@$1!^>GV6 !&L!2M 9M6#( LE[T,;^#K8&-0KV8 +>R
MW:K7AJ<H]4#\QDM=@R7+3QV ]):3>;FP^?;Q>_3#+!D@@SX/%N"O?)>Y%;I\
M^7*A1J^2);H_1M8\\R!7-[S8^,NW78CS8AEF!;$ R,F,C.4R#R?;_TMM&0GY
M\#2OR5AZBK1O]2?<Q1^U0-B+*2@P/$0P&S 'UTCJE 0!"D1@G)UY 3FQY^7
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M)P+&#W,S*-I6EMUYKC'K(R@,W6(V,I39W&[SY+3=\B"3LV_8K_]D"OIELPK
M(3\L2[2Z<8?65J=$N*)B^#?;:A=%*G-M5@L$"O2J*"E'S'IM^P>W[\74SN]T
M73?5"%)Z4CRTE34%_CFZ*$]44?82/LVMY/*PQO<%LP N++ ;D%S;FUK]_LA^
ME+(9 [*Y*>3A#P5@V"^+THX%YWIY+'H/W223H-HWFIM.L7SW$BG?;KY=Y"SF
MC/_Q930C&^6$;(Y>]D.V1;'GI[=4$7UIMFBW*$GK$]$N6(6<= J![V>1 8\8
M1:%LKKA/"2-KK]3Z-7NB_[5^O=C-2TR!4%=*&T_$YUJ/=!%AF9*.W/7SCS#L
MG4?;6T@V/HP'7?QR%X9,7IQ -,X:[P]2, :F6B&O OBLU&KD<N,-Z5V2-#(I
M2=XJ7Q?S+F<MSWG_[EV$'\YH%W?\HP4PV/*W,..%!-3^&47*KGC2#Q!#\:=P
MWXW"M&YTPM\3$UH&59:K=/83A%)V-@ZHQUHS'E#2,8%8AH@TDQIIZAWFQ*68
MPI72V4LA??=1:+L^5VJ[!-81&<N73-.NL@M7?U1NN_]$Q;;!B*SC,K2Z<+5M
MN:X,?X!JVQSKARA@S?A*#5;>9[7MU2@'_6'LPWP"M2F!]B57QZ[*A"]2)GSA
M_-E;;U4N;V;>+8( 3U$5>W:+>&YR7V:FR3W.S+-)-'F$^G\SOF1A7G82&)?"
MMJQZ?'N4>=*X@.><-=_]=;1_O-]N;KX_;QZ_%\W=]WS_2^-B_\NGB\;%%FE^
MV;J:>7+1A'?:P'LG;X'=?X(Q;E-X#]+</()W:+;W=QL7C=U/9&_W<VI,GQRE
M$8NH$D826X,XHREWHC5($1X)MU;P(,'YK LFZD+<5_F3>]"=)2_:7>%FA9M+
MD:!7X>8]XN8D8T\K _#('3*F:'D7''+)1V2)3]@PKCG/)W#KF.HZN;>N!4^(
MF[/Y>G<(-5;!D"H8\D*#(65\>RK*_)(C %4H9#E"(8454*L4$AF72F@OI$@/
M1>U?-'M_,03]L0,;8R,Q;N+[/!CZ<6@UONRW]H[?PM@^?VT<?VCM?6D>[>_N
MB>;)AZ/FYB%K[#;;P+39/$-OTNWO^R=_P?5;O/D%F#VP_#WZMMT\_DKWWVWE
M[+[O#?KI>W,WS$8VE/2)2&#H21"*N$H)&6$TPCY2;B5U1)(<V<!2Y=H1]\O0
MGT7PHD*XEX!PCQV"J!#NUQ!N$H.PC(9@E<P%JQ/BGDJDB;(HT"A#2)%ZSPJ$
M([*NU"^?KWX4A+N^4;!\]$;!C_C5^RQZME)\OG-99^>A*?TSKZ.T"GQV&8LJ
MK0+@3U?4H(H1+@'PH\TI>0X7194,(BX(E8QWBH:U5T!WZXSR)2I?76GQ<^%L
ME1;?58NGBK<J8Q)F#%F;#P!0J9".2J!(M<A(3&,JMMRQ,'5IV!+I\=V#\LM%
M1(HJ:+\0>I[=Q'K)97BJ:CN/PJV*XPJS2%SA[P+X.]/Q26K"X/\I8D)CQ 4W
M2+N4D*><*D*X=GGKGM3AMW6*%^512U=]K *Q"L26@EI6(/;+(#9-(KD06%CD
M&/:YN9%'Q@.284,U"Y$:I6F1?Z1DG:NK1TF7%L1^+<]H>4H3O!F>#,L:8;4T
M' Q[L7;2ZK1.AB>YP,/ET?SN201EA.DL>P'8CH_EX??)*?_QU_NU0::M_;D"
M)/_GP0D*$G?V&_MOBU=OE&_^S^@@^^8PSGS^<?2&'XJ#\Y.V('(U0>$7#EY^
M.MO9.! .)--KAY24&G&6RP)Z35%B(BB=# [$K;W"ZU>5&D2LW2Z**'1RF8EV
MN^9B6<%B< 0^X>'1I(I%OQ8[65?G*^,4ETY7"7D[*[QS)0E^(KNC1_U6E+P8
MEY[H]JX]L%[4)XG??6Z,D8L"=6)QOOGWHI#'-8<K)S4"IZMP_0@KUA[J-/&/
M*K)=VKJ&A8F$OZNSQ>\/O \PR2DB$Y1%W%F)G 8Y%U0Q;RGWC+,K9XM7)H%4
MJ74A'B(G4^&;'[K4.9DWAW^>M/[E]7EY8T7-*'0E<_-*68TY.'J:/,;'"*5=
M/UF3/;W2X%?'.<MYN65R:Y6Z4Z7N+&/ \5:,9HK/-V%,NV>Q_2TV8(!'2]3:
M[Y<<^_?@>&_@QKNW1WL7[X',?#C>>=<\:KP#LG/QE3:^? :GOGW<I,V3*X[]
MYA9I;+X_V_OR]KBY^>&H^:[!]^C6V?[Q!MO9W?N^_^73=W@WMD?WY](6G0"V
M*3'2IDSJB4"-.$5:)4.)TL%@M?9**%,G^K[VAAXEI6?E=XVR>W0?YQ7HM:_^
M_#:IEP>=]L"/W#WK5J"T""A-]^!CE@@>E43"Y&Y>B2ADM9%(*1YT2DD;+,I,
M0U-G9$%86J+&H4L-/JS*C'M!<'74B[$"K$4 :SI33LC@ C4&:2\DXIPF9!VA
M"+"*)(:C3@H R] Z5_=U-KNB2A.UV\@M06JWQ*R*,-TG EW$7C?8_M'<KNL/
MD&>W^SK^8UNA6+0I[*D0YR>(,Y-58H@1E.9&[$I$0!P7P&^C'E',L0@\<([E
MVJNB(#7]LR)(#]39='9[ZJD)TR\$XRH@NQ<J53&H1?!L.@[EN'!2!H8(T0%Q
MPA/2+A"D#8]61!J"*8[/2H/K1MW7:8,J$G4;5<S2_T=M>]3)X,53K$7:R#\Q
M-'WJ3!J';!6Y#ALG^5\53BV"4].A*:NTE\HX9 TEP+ML@)^\158R'7@TCJ>B
MT3RN*W7UD/]-7>8KRG4+O?MGOGO)E88T3U^Q]D4F-#_HU"RW+5@J4W"#$:C
M?A&PGP[K16U4M(2C%(A$/!*&#,<&"8N55L$*1NG=CVX\I-H\8)ODVZ9'ZV5*
MC\ZYOKDQ7>SD1.A^T:GML%/TWRJ:;N5$U?QKGWMV%?V,1MVQ"AM3'[5F++IK
MQ4X\RVFEIX7"@\JUNJ$/WRA:-;9A9EWNO9>S8N$E>[:HJYX'E/N/P9,M_ ^
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M?K62T4Q!^(56_]?0HEK]>UK]P[,#S74"C@$+GSP'@V$"LL CD4I$".5L=-P
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M24@NU[.('L;\M>+W197K_PQM#SZ!$145KN&%0"0WAH>@%37""ZG4<]&8DXD
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M"CF<^G4IHKE"S_B,\HQYC]_!!>WG:A%E%8SI0KOP:["JHQ(2@]C.8;8AW!+
M]A1>[;Q\ELMGJ:8$_Y\Y7"_J!LX=E=X":W"8WWTW^J,.6-/#7-#RJM6M77=F
MYI;]_\QU_?]6JD&:>O &:=N%0[!KOR]?3[2=CV/U?W^^ER%@<QLWZ#;?R>J_
M^_IH__C3]YW-OTZ:7SZ=[]$&VSOYW+ZB_IM_M0 "SAK'[R_V\OGL=Z#V[]["
ML[9XXV2/[._^=;QW$5K[7SZGYG&#'% @48):CJ24%G'L)#)!8# =2G'I+4E6
MS?-[1A-.V"7EK.<>S(MS0D28_QA3")3,=T3;;K[9:6S5=C?^W];''[<^6\EL
MDNLYZ\\G:792 R,D<*NM2)@G)HRPB6!#(O8AMWF[]B#:_)&S_B\TM#"@5"R9
M8!CC7">BJ2<F245MP,)9<P\'T";]<[O]_AO;ZYW#I;D:U/(PN,=7PNT#F33S
M2@4$'!L,L.2@@]RZK)*&8X^="7CM_[/WY<UM&TG?7P7E-_NL4P5R<1_QLZE2
M9#M1GEAR)"4NYQ_7$!B(L$F  4 =^?1O=\\, %X2=9*4L+5);!(<S-'3=__Z
M1]?K+^8.MHN1$ID7D&$UL-II#7A<B6'@9J];88"[4\N ^:876[$7&883A5'@
M@HTP\((XL <P8W\YM=RMV7)'+))8J($<L!46.L"B74OTZAKT@@!34AB/@L3R
M(C=(7OWH./TEF(NMGA4W4HF(!5&P2/F ^26:M"(D!>.*L&Y:8R]*5#'56( @
MH8<IJF*H%V&Y->=9G22!?0:H^ISPH_,D0=@P&3NHV*66#X"WLV;$!B+@$@$@
M@8PKH1ZV<:0Q?8)J.D@/5&,UR1-U]>Z 7^49 8.(>G\98! ,621=_,-:M?BP
MGIMV3"<O J)"LTM9.D 3$'AEY/I6 >X6YIBVK!?TH@-IL7=U0O][LUDI=[/4
M6HH;CDC:$:L$ #:BG;?Z&K9(0,&YO98Y,E15'X/B5A_4#'C;@BY]5TW:M79>
MDPX>79/>Q^3802Z0]UJ(CUNG6)L?&KOZZJ_Q.["/?P5+^@_X[>_ AC^[AV-X
M[I_C(=C9Z=';0V"UGR\7[>I?<?Q+8,E@C_\U!+8]^NOK-POG=/CS.["S#YP/
M%G[V'B,:F#88!H$1@;+7B^(D $9M63T@,:O'@B2P@'F;8%@O:=OK@3WN#,R!
MZUB&'[B&&1J@E7'7"V,_FE>M]X]^^VWOIZ/CO=.#/]]I>S\?OWOWX=WAZ6.K
MV:NRRZ^?^\;39C")D1+:9/\&T:\G:A.RQAI*+H7W'Z$H*2TRS6#]U;2&SDQC
M!-5,KD06&V8+4OK-.$6P#VW6VXM?Q-.H I&1Q12YEE)-Y1G+L&C3/[,4.)@@
MR@K8E"9+3DDLE09Z0_;ER4\'Q_\Y.3T]_K[E6I:0QB2V9H7KD-*^:KP4%?$M
M^?PVU4X3O4$+X9<1G[0!;&9_,Q'XKTVPN04V<\SC]+3@ESH("1(18\Y%K+E.
M1J02[R;/1<2(]T[VM=-\ OPM, )]RV(O,RRRB=F5F\PTZL_&$4JUWXBJ3>H8
M*FJB"Q0*:,Z \.G*U&D%!8XFG&LM'8T07_%A06%-NO+JZ]7'OE1 ,'2RF& *
MM(%9)!E16XFD56<C@E8P+63B,8('B5N,28PX>9F62Y0T0!"C=#R ^]CD*8M)
MT8_Z&KQV?M1ZNM<0.KVM3F!)LX8QB#38)@S4Y% B:+B\X#75DQ9X)I/3"'))
MYC; U4,=LX"10""4]T:Q7=0K;ZL'N<OTH#55GF6U25LZRI,5NFU-39NUBS5M
M6]$@\7JU.WQTM5L)>A#8@U0DRFZ?QGU8.T9^&O_UZ< 54:F_OAW^<YQ^_AJY
MGS_]^A4T9NOSI\__?/YT_.WSU_??YC5N>-_H\]=O]N'7@\O#\>_VX<_H*!D-
M/X\_&)^__C7\Z^OA\*^?C],/GXZ3P],SX\/O7PSXG1]9H'$/8K?G) .K-_""
ML&=;/!J$ ]<;+/I=73L('--AEF>%CF4YS/=-RXO@9'C,XCB<U[CWWKX].#TX
M.CS1]@[?:L?O3O\X/M2.WFL?CX_>_K%_JAT?_/S+3?KW4O7YYHG,3MSA5A![
M9A#;#'YE.*'+61QR#A9YXKD16WK[\'KXVYWH)"$'=RYE4S9Z:+=3G$,1Q$LJ
M,0@74HQ *2O8.26RUMDZA':I/A:0@B))112YG(WR >C_V! %:WMD=@OJ4@JU
M<19?4F22B 07-!!DA%^'+[(I NZ*!8ATR[,I2+^\P,1-&$GDX2[K[3@ /09[
M?=:O%"961>#]NO8^ST61S]MB>K98&?;^[1ZL2T#YDDZ%^)#D.\,:VUZ:J79T
M*FFTPB0KU0U/E;W@@6&R_ !KV J1I9"(LKJVLWN8EQ0P[LE-%!/#2'-*:^VU
MUM<,-<GX=)QG8'_(M!Y"!B$%[%LJTB/H#YA7$,FV=^KEHN-@',,1D3:HD>Y+
M)0A@X/6$W@"K:[V-5</\#+2]67!0K*"JVRNH2BZ,IZ<)J.S34077H4=[0Q,:
MH^,VAAWOP9LI^[]: XMQZV[4'-+X8@IQ"Y54)'L-E!4<-=(1U6C\:1$WT)9H
M-0:&6X,G*..<6A<OZ/GXA/"&SZG:5 Z.&=A-D2#1EE '">)WUKH>LYB+5HU@
M!& 2E[2(;UDY'">#F U 0/B>Y0R"0>@-[, P$I.[OFL/J*T02&'9%C58:(MZ
MFYB=;-I2GN9[XMHH!827/Q=YN37!F"?7.8Y./]L8NC.X9UH]#N?0<YS$ZH4>
M8[W0"<(H8(/ B7Q$CEZ"(SB'K"^='2 B9-7Y H%C(M;6D@FU[[F&5EXLF7PX
MW;O\L/<EB2T[YK;1<^+ PJZX22^T_+!G.IYOV(8; C&\^G$9WN0LG<!_,;DI
M:[QIP* X0S!CA6Q@AOU9Y*%Y/HJ:1ZRB92"4\BLVJJX:4/O; 13=D\JLV3**
M%.7:L9B1(J<MA!G: !F]N_QP\27T/=NVP<*Q[00L',=R>H/0C7K,]=S ],TH
M](*E2/7_(LF5]<YR9"_H9A*R3C(:*0!EEK%,L%.$(2FM1@B?\[5%^5E&^"B"
MAZ5%6PCV".<^8? I%GUS5?A%/EPD7Z7-"%G=*AJ#!]%?U[B25_R$>&1=>B:4
MTB5JP$S%\J3@$VIXC$^+8G22YS>]JTDB%Q%BW,M6'!MN2@X*07$NP[^3*25N
M+Y16UF\DP*<1EFA2&!V6_!NZ$36[O6-CSM"V%\#=]ZID>5S/Q$DTY/%TQ(\2
MQ?;W&CHH?[IJ_6V_WN#]]OZ^:/?%Q1=N!]SBIM^S#1Z(LB<XCZ07>W8<!(GK
M^;8S[X[86+5RDF,W;#)/B-IEQS;1$"@:HJ%3>[!;Q+S^#2-[)\4\%'D!)'I_
M@75T9*DJ]/[3ZP8$V9A)4P^L@&(JN$23Q]%$&)#?I,366L9X YVF;IY8;NT#
M+N!-/0H93$K^@_K#&["P)R-V]4.:T?;1C^:2!=#;3 G3$=JD=%7IUHJO&S]J
MWQ"^U*J ?V+U9OEUG[[Z3Q4O?N>'?<=U5WYM],V5WUTWK!GT;6>]8?]#4R[F
MW.RF0_Y9+)G*1[BG_WUEOVI\SC':O#\8FDE/J7>L^ZA\Y:K?J&,!-LBO'WW9
MD]W@W>"[,?ABNE@4<9XD;]2EL2:7>&W:>L*()XL,*9\(/_*3"QKB>3_)VOYE
M5?US$:)97K36^@UMS5T0'/GIA2WMP7?U0N^RQ/;2*'"_56N[A3/#\QTK#/V!
MQ9GCA#X+!JZ?N(['+9/;/F/+FV;<)N%X261MA9[ZFU)2MJ5H_ZX:*VBCEZ.C
M\5\C&&_T>?S7^.CTFP-SL_YZ^]G]//[CZO,_WXP/;T?IT:<_+O[Z^E>J?@/O
MFOYE_>']-?X#YOYG"C-SCV">,,=OAU]'*68MPS@71S"7OTY_&A^.?TV.3HS+
MWT[?51].C(LO#IR;Y_!!C\?QH.<8H/4.+-?HV9[)#3MDMH4-C0/=,@S==5>5
MGMWG:L"]UVYY1>[&>66B[ITX[R8NY3XKAVW/M'(#M/'GJ"GW_.[7NV'=;C>6
M\N'M8U:O;\.M/(_;++;,D%E.F'@A\S$3TG<MEYE),+@!M?LV;$MYR=[GA?";
MI2UO:\>7;N9+'T[WD"<)WK3WQ;8L9KC84\*RL7M $/<"T#UZ0>A$AL6-Q!I@
MFQ'=L6S=#;P%SO3]VDQI.6-X&J9T'W5P(TR)/ I4YC3C3%AI][<#>(O6_IU8
MU[HJY$MG7>@1_>^KWJ.H7JU"@U+0Q$$FROB/DINT-;-CB[=BB^_:;-$+O6 0
MF5[/"!/><P:6T0N2R.S%H);[,?>=!".=9F#HIKD8?EB?*7::VBV8XGV=GB],
M@]LN!8X"GNMSOG=TIGM9O"=.]""K*V15/GO'WV[%WP[:_(U9"3-](^Z9+/ 0
MY)WW!BR)>QQ!WFTSL)D1O_K1]PS=6M+#Y9;FZ*YJ?MO@")P!0+B;$U!&;2CQ
M'+:=:BHT7,1+< ^NN?AGP\D3QMPD]GPGQM9>H*T@?J05H!K#3,Z2^R,5=([#
MQ^;4']J<.K'\,.1FW'.P@:_##;<'IQGTS-"S75! @P [$_FZ[?JZ$2RB(-S-
M=;C>M;DG%Y^+E+K7!$IO%"IK1%!7CM%:K TKBO,IQKQG5KL8=?T/!;E_7"Q]
MV)5\XVOS")K$A%LFZ]Z-_]PJ^?(^#.CEY6.>F4=[7PPSCDS;BWMVR*.>8_J#
M7@!Z?L^* IXP&PMN4-WK.S?D8R*XW6P&US4XYK<C'!XQ-W9\VXQ#P[$#'IB<
MAY;'!R%SG#A\"$"FCG!N0SC?$&LS&<0^BUC22QR;]QQ_8/9"V_-[!MSIV D&
M1F1A,ZA^>%/"=UV,/\JSLQY6W-^'6%S'C@/#&C#/<AW@+*%EF6YLFD'"[63@
M\(Y8GII8C,.S+TYLVA%SO)[K& AD'@*Q6/ O;Q"YD1V$KAOS5S\Z2X"]9HGE
M5AT0%F'BUB_^V9HJ0(4'L8W([3>AC+=+ +W9$D"69:!N1>2;FR\!Q.<.0?%*
M(^UGZA+V4__/OO;ZE?ALL?ZO 3*E+FP2E@$>$C^H\1I:575C7@WS"K85D[)5
MT1,UOA2(#S.U5:U*.R:J\(HAGP*OR$'S944U+(!3E;KV=7K.LQ03GN,TQP(V
M6$#K:X)9@;>5>9$"=YCYCJKGQ/=Q6L(4"3B%GJ34SIT[_;UR3FVL&W-(6-EV
M$CIFFV+?%*H#O"W#-Q,G"!T7;!,0.P,K#BPC,8W$#B(O\9EA4-F%I\HNO/FR
MB[M$F&\L =M18_;N7/[K[Q>'>U]\FWO^P&(]VV!NSS$BMP<:))BF/O,3TW>L
MP,70B&'H0'Q+FE54JNQ+YC(K9E%#_CPA73R 1M#*YV]*,WYK5)L#";KR<I4#
MQ.;^_8ME>.' B\(>MQ'(,;+<7H Y_ZCGVS8#13+R$'?[)DTRS>8K8B1"%),X
M3]?UG"^'C #T9\$]0R-V'#/R?-]Q##!9W8'O19QQQ_&X8\0WT-#M>LZ?(';D
M05E.>2Q*Z#]2<M$)3:Q=0?*2V8SS8>^+&27<B/F@9YLN,)<PB'MA O02>2ZP
M'S^)K4$@(K!+V0QVBR]2:ALH#AWIHB6.L&-%GDDH3U';A3CJ"(XTD?KG^[=[
MLEB?U8VO!8Z[U%OJ,K+6N$ 2>;OF4# U]0M&U?MB,G6=696*9UN5::549V;F
MH&LC!MK44 8ZARFH$@O@ %3F5I=-@E*QHI-FK8W-%$Q2 8H$6!@U. 1*=Q+=
M0>2]F^\.4I>?UYURY:*7#*H&7,1B**?8M71-%7ZKE*&CMBI,+87-<'G#[1G"
MJAN$M2FKI<2JK:)#GX)"6ZBMIM:["'*!OQ^W,,B4-2'@*H@!25G;,<9=9HS_
M[+D@2!T>8)^0I&?[,198QU%O$ 5.CX6>&?IV8"24L;>*,3;<L,4B5S'&2<'/
M$6QD!I%1F5PS#+.F9QR#*F<I:8W*9&_EV;']R+:-Q#6X[[@)K(@E<>P$#K-\
MV^#1#9D(MU+H5I#<GSCQI13WXE2W?PXNCG[_8IO,-<*!WW-,S%Y'#T_H<;MG
M./[ 8(D[",-H'=5-RE4D&VHE50.&S#!$DJ"B?E@D\MP.!L(8!,QDP+!X9#B1
M&8>FG5A@F/ D<GG"+-E:Q[]':YW.-7@K$K* A'P.K"DQ6"_AGM=SK$$,1F/"
M>[&;6#SV@;H,"YC6'0 A8@&%+E@2B#D)3%474"UTOTNSBD0J$%<M*!4RCE2P
MJ!B7T-8K]@U>-6(1)>,B?JL 5:<O9<_M6Y-HR(.8&]SP/-MV["!AG#/;"2/?
MB@(#[MKRXIZ.1!_-X(B,H[>1C<VF#D\_7QS^_B7BP"&"0=@#;@)LS_#-WB"P
M J!9WQ^$;A!;=O@PY'HZ3,LECQ%]#;CPFC5H_I8FM?0!%R"KB"9?]Q>>"\)=
M+>0/;65GT%N!8MVY@X?C6I$3,X\/HL2)'/@/2 C/8XS!BW@X>)R(T7$-%W(@
MT+-3U.GWRI)7I?0N8HYCRUT$WTW'F.Y8L>P,[:67K'W\X1SN?7'\) 1.:?3@
M=*R>$S*SQRSN]")DG=[ ]$W7P1"D?[/C**.>&VIG$>$/SF$9+O?BS9DW2._=
M>[8#ZET"U&OO(E#O4GS3.^.5;GECYG?5\"H75MYI7O&HVCV@Q8-,ABK7;XF\
M#Z.DH#K5WIH6*OP,(NDJX-!%1QD8X'(OE<LLH\Z])Y7HEJ"):?JS$=6Y>8J4
MBB>9K#SM%9/=.2)X1R!R:;;HIFL%K35R=O*S-$*8^A3>++VG\CC^70H76ZEC
M>\Y:AHM(+[;4+(0:0%"G197Q@OI/D$.4AA.P0C(^'D5\)%LGU9!>;9Q]T906
M>;_J-3IK)3>NY1:08BNLO%4-EJ29]H%=+9[ #)'C=K]-2Y)@2(I[*X@=MD!L
M2ONZ%+R:%IE$/FLR")KD@3:I<VV!N6VR=<5VGMNR^X\;J<ZA'7!(4J3\F;##
MTI.<.7Q,,<QR2A.#899%(^;AG"7.L^A+4^3C7+$LGA)[E*<*OY8\##NK9*(S
MNOBEBKIHI$_,@Z^887^C=+"=A #B"2Z4J%.N!0U=MZ:'7)-S(])!6H(('P==
MO2<.@0OW<MF&);R95(B/8DP%S_ VQF"06);C\S@.$G0MFRQ)!MR-#=-.7#?T
M?0ILA* K2B=S.&<5>K=))RGRB/.X? ^4><(0+["Q[80A^&(-O,.WD7MX]B5Q
MG20T/:]G OWV',NQ>D$4>;W(&T1V#-0V0'7YIJ1!K)4'?I,A+Y_+$" G"GQ?
MH]M1;RLV&LE^,N<J0'J1]ZXX*\HVW)_")6Z#7,\&]40[FR:&EV#/PQ7OJG)4
MM&]+KAX0IIWPQ#:8$R5AR%R@7R<(X89[@>7,QT3L.S@.J3SS9EH]:!8C\Z1>
M,/7"<WM?>&3$!@^\GA<80<^)6-0;6 .[YT>QX]K)(& L?/6CO<156/<G;?Q[
M1L,;X?21(!^ ?%P[#ES,KH\&L>,,6. ;@6TDH>]X)@M$CM1#A=3>MMI5'BGD
M>-&%'!O;(F$M?>0G#J_@=;OR%TM4'T[WW*/3/RX_G'[^Y\,_GRU@CW8065&0
M.#TC-.V>XSANCUEVT+-B,[2=Q(A\TUGNBYXG,*2K,KW4QK#]PQ+4;.1;<QVV
M-ZGI8#.^%>U.9U,%9?0%.:_4.\8,U$]<(MR8%:RWM0DJA1PTC1FW^%8I6+MG
M4Y^2D956HN?;HJ<(FQR6LF]$W=BP;GBH +:;D,9*8EA0T D_>XFHULF<:&R1
M&,S-.5OCFGRGLG^;A^M$Q(79R1;,<&9$HS"W7UD&1'JE27!'?6:@?]?V:;T8
MT:/EVZRA-0.TO3!BLW#427#A0.TK=K1>R^*9U5NQT-/I2;"U05A,\I*-J$0
M<VE%DYBE,J04XN-$=0J45?0G6">"0!*R0P ;-1W$RI>,P0W*"W,-W_424+@]
MQ^@YGA_U6.*"+L,<+TI QV360DNP^W"BC3/54^$_J W+.@F36%;M3!*-*I,1
MCR0KDETJQ6/K":FZ_?<F12JU_&QUZ%ST]I9\Q2:L5X^R\MAW!CC<,?MNN/KK
MZX##K_\NL.R'AR.W^D[H/?_);F0//-]_G,F&M\&/?RRL^/:CX<*C2\!?1"CX
M:8!0PIL:CAJ">Q><+S=?5F)[[>A23U;9:3,+?4*267QT)_9Q!C;I12[?N,7R
M=V5-W9$N,H&YK*'P$=N.K,#7N1$S: O?MW*0#<S[>L"AYXQW?"S,J]4(G;=8
M[/P)=#TRGBG4G1':5NCY41B%AN,Z3NA$@\1RW#A,F!NXL70T.0^ .B_I$\,7
MF$:/D_L$]O,^6+OYF!?O+J5?"H-D\/^80AB[Z%"22'<'QE]OS_[YZ^V?X\_C
MWXV_OOX.SQS ;PXN/WQ]G_XU_G!U^'7O\J^WOU_.(]U]_GK\[>CMX;?#3W^E
M?[V%>;T]''[^.H)_WEU]^/3K^/,_!]:'M^^_';Y]GWRX,JYDBPSK\)_HBVV;
M=I@X5L]P++?GQ$;0P^!\+V3<,+S(\T*,=#AAH ?&JFS?32 O=XRJ8U378N(E
MD<4<*S29;3F.FPS\T/"MQ$^X8V,TEAB5H1B5T3&J+614AF)41V_WOD2)$7'7
M]7M.$L<]QX_,7FB&9B\*37\0^R$P,?;J1]\.=,_:IF8^'9-YODSFGED>'9/9
M.)-):VWHXHLYB!++-<(>'!^PF<B->@,XQ)X-9VLQ;Q#Q)'SU8Q@ZNF5VJE#'
MI7:%2YF>Y_G! *PTWW5,RQ^ PN_R,/)M'@#%QU(5,C>E"NTVM,A3\RNCYE>^
M%7/79F;/"0;PK\@/>XS9,= ;LZQ!$+,P'& ;,=?U]""\=T>)IVN;LS,NM/V\
MK 2NE,I'*O/1ZJ:%M_!<6DLWX_DUP7E8?](_',Z!E<-YMH3G=)3\G.=QN9?%
M)[PX3R->GL!9==SG%MSG<+_6EBZ/3C]<(2RE'?HF[X4\1O!A'O58$#B]V+.X
M'=N<NT[\ZD?"5;/>W([_/)YBU-V]1W&1='?OL>^>,7/W3#?PN)6X/<,(4/J;
M42_T JOG>6B,Q@/#"K?E[KV4"_6P[H#N0CU5(.3B2^19MIF8@UY@8CF<&;%>
MX$<Q_!5T$R<&UAB96W*9.D'VR 9N=^^>RJ\/]R[Q;=OC1B^TC+CG&&'4&QBN
MW^-.8CJ#)&(#U]W@O7OV.2 G?(2EC;KV8::BGR!.'B,OY)DWP=XZPU>>+_"K
M^H!E)]>.9]U&^3Z9,WR-F,>6Z0YZ9N@;/8=[;B^P..\Q-K \4/88\XT[\JU=
M"!5TU_AI;>CN&C_4-9ZUH1/#L.S0BQ!*W>XY@0D:?QQX/=,.S($1ND'D!]M^
MC5_\%7P:J[N[@@_M0K[X$K,P8+YG]AB(TY[C^+PWX,P%[=\=<&O@18Y]5^V_
MDZ*[=(6?QH#OKO!#>Z(OOAC!P(@]YO<\PW5[P'U9CSF!T3,2%SO(@C'OA=MX
MA9]+!%K +UQ;(G^/</1L\8RL#9]OU[U>V_(=SQAZB!UX-NSZ"8M UH"Q*@]Y
M=92<LLN]2D!4(I[!:7Y,H#;(X^$'K4X+'8M?@\6G<_Z.,$(,>,Y[7I(,>@X8
M3;W0#I*>&_!!$,5AF,3F7:M$'N!J/4U<I>.&'3?<;*5)QPTWQ UGW48!"^+0
MB,W>P#+"GA,/O%Y@#^(>]\"BY;;OV='@KJ4HF^6&'8OK6-QFZUPZ%K?A -?%
M%]\&+=YV7+#I/<PLXZP7F&[4BRPGL8V064E@W;4.IE/V.DZXRYSP"6MI.DZX
MX1CAQ1?/@>,U$K?GV%@1Z"8>MOT->D&$'7^3T.:>??<*FPWR0G)__H?(I=U<
MK8&7O:'9VLOKDN:L[I*&TQ7WRD@8,SP6A$;H.%["+#MT$C>,3"<TF&%_<8-7
MV]]:K348[%;4@Q- >OZAG(YAJ*LWU[[!JU_P>">T -$E>J-4?"SNF]77/K ,
M=A4!5BGTX+\IL;5)-"VQVPFEN.UE;'15IE2]];[N8;&?9P*PF)XY)IQG>N1H
MT9V^ J!UY;YL<X>Y!IU9*_@9*Y#!H*2Z@#_V1GG^#?]>*I#G&_=@ZUJ:(D9P
MTU\D;D@!.1Q+LU*+@%VR-+MFT77_+X(HUL:+)*::P6*;,:*:9%KAEF)1K&S!
MTT8N/B4@X-8+TNP\'YWS>BY%6GX3/\/>:/19T^H,KN24J7[()4SG"M:5)+S0
ML%-K =0\NA)QH6K(QWWM_>J%(?+RF,5<FTR+<LI@!;('6,D2K@U9 <)H2;.@
MCT5ZCLV93S@L7'2V^PW^<R8:P!QC=XFQMH>]GQ+-#$.WCW]9,><2:"1-0%YE
M56O:]9/RQ$37-0&@O/J@^MH)QL32,6I!N)H$]BHOU 'B6R,V+9O18;5R&O1B
M1&Z.*HG2GA+\.?]!8^<L':DFO[ B5D.;@WXWJ.A,^-]3_#9B$[QY;V2?+"0R
M\6R)/4X),A^(NSV"_(7HKB1:U+[1L*6->B&U31/J'_Z9B3ZVHA,>C^OZTS=U
M^Z<2-+[R38M*<<XXXEF17U3#NEO>65%W&Z3WX<"EFBP^,YXP+&S%1^#[NDD>
M@^WDHQ'^M^ZWM]B!3VR &(G# O(Q4HG8=V(QZJ#WC_X\>-LS0VV""QICF^9/
MPW1TW3'7-Y'FQ4<I3TJ)^E]6VM=I?$;+'C DF^D$+[N\GVDFE'#J909OOZ(;
M@+#A9U,&.UIQWKZ^<&7I>;B#?>V(VILMTA:U+V](:^YV-A0V?SFO61].:I[P
M-9#(XG"PM7$U@B^0_5C&FV-@%MI[,1OZR'Q#NR&_/@&:1@EWF,.-/:YYO.(*
MO\G7UT#^]1B2,/:R#!<D3 NDAO=XNTVC]W]U(P-LXR2!<^?:,6!O!.)^,)!H
MGYFDF(I1-OTO3][M/U+'-^L>'=^>2CY]@I/.B0*GV,FO8M_HFD_ 'D@C()7I
M!#MK8!,];&*)])5=J9-934$Z21Y%.22%!)TBARM23NU8"D7FHJ\<<KP8^#"\
MC1ZESB% :E$Z(0A[1='4#@8G3/U#J)5C3"*M)6<G\#"\LV8P2T1F/*N5L996
M-M-9K*65%8U6UNJF40[SZ2B6LZ'; K_Z"G*3?D=DAILUS=@TIC:*."CF_M"?
MR+RB]35O;=]$>JWH6 UKYK58D->2V/;\Q?A]L?/[=G6@7JK=;XW!Y>YB6^H;
MSW@].]$S7]W2&I-M(39D>QW]^>[XSX-WG]9L7K&I6<+]_TGJ+SO7YZG5%.DC
M:.1C%O$I^7=*[2 #;>FUE//-<[J2X,C"U;>B3TK]%79E+;5I2[^0WD[DKO(W
M%[Q^7'XR+=L#R ^!N\H/O]=1CV5:*50.T%XG,S.F)K HP)(\HE?GF6Q05>N>
M^DP39ESTTO[8C?K+RZA()Z*]3-U("J0JZ5!<"+281"J:,:3ZI%F6GQ-3;;>3
M I$'RAT\Q&E.?X/2(Q7^",="70<$85J+!5#B"]2')WF.W<_&'%MNQ;3,#-LZ
MWK.CRR9(#>_)I$B1O6@5S!&7I/1XV()A7@ICA44@76A;=.V,E561D\" 69Y=
M"9$YY%/0=^D#9>ZJS5'$0?W0A?:!? UF_ \VWKK2E,0;8=/@#&61:-,MSQJ5
M2U3MY9E=<&$"H/4,.S9 1;DXA\<Y:-V1' =&+<>@>NMR6? UF4EXJA$7!".:
M&7-A#$V($.+%=F/X;;,/&:H-?#0[VM*N[8)DT"50HO,U+8=4<@FD4EWDQ3<D
ML^4MS)%T"WZ6EM@K639=!CH6\Z0]1;9&!*ZH4[P_+31J^X9MRA<5DKN2XL9[
M2A&-@L(%RF::DP_O[5YS7J)!?&V[W\UEAQLA?>T]C-;]X%M+MT9\E*(V6?W0
M,Y]"OBW?$V*_WIME=LP3GM<RV3N[CZ;3=W&3]B)>L1@NV]/.V,.WKS'E!=4;
MB:)G]Y?TQD)&A /@&9B^L^DC6&'AOM[4M&[IC 9% 7X070&O@^^V<B^_!Z7K
MJ_#$Z+7_HP([I%*N-EP$O#G+)T,PP2=Y6N;8B/+-C>I QXPVPHSVV2C&UW>\
MJ.-%K8FF@RGH% G/MG(;;V9#$XPCD8(*JG'QIF,^6\E\_J](L6EV7G:J4,=^
MVA,=81SIZ>EB;?:#/.>H #OU1#;WU<&8G?'&C-@ED<P*_A2!09VED8QHDS\A
MSX"93,@ [OC5=O*KHS&/1FR<7W;LZBD<U[V/[-M6,@!]9QAI/N:3@OV3CX 1
M >D6*7KRQE=1FLEL&B#F-$H1(& K=_K[Y>SS%R#>*!^0XU2;7,%<TITYDE_Z
M<L9;NN%IE@C5>B;\&T]S$!<@\::C"/8\3DL.+&33@FKCVW6-!-NDH#KF<7I:
M\)<AIS:K/6^.D8QY-<R!+8*BN51/WH0UOM%4IDUNP@IG*(5953PPC77MZ_2<
M9YC@E\9I#MK^4!H!)?HIN#8I03# I8 /"Q#5<$\P[;7).02^B_$S3#*B)\NT
M?$$\>+F:N&M6Q)]L4J1E/GH1S'GC$GIG],(HS])S-JG8MFKB+9\K1N49YF/"
M8-.Q5N9Q"O\98>X*!>!5C@ E-=21><I&Y--SL$;&DNT-KR:\4!_ 7_*, 0<=
MIXR2>#LWR'8RL'2 K*'C7QW_:DVT@@T_QQSB'>!?RWVRLOP(7Y!/2TVX%S E
MNC:)56X-*F"*Q_5D44I,# V3S5.@O+SHL;+,HY2LYV:H20:Z('!Z-J/686;@
M2";KE=]DZ(K^4%;%-*(\]682#Y?/]%2;?Y#553^RQJKDK=1&F;BD8SK;D('&
M_'$(5U,[.- B&(ORYB9%?E:P<2D*!2[8E<;/V0A+=.$H,!DL37A5Y -6)T)B
M0EQ,V>UPE!P?HZ3+P=6<0(JP)"0?7Y$V?J6U3HV^?CN-ACS+N/9A6D;3$2NT
MMU>8\S>!9U7RZ=L/;YL<4*;%_(QGE*%_SI6G1-=.,+$#Q=Q)-.)%CMG^ZO<G
M)]'L[UD\@IE,P608CZ<9;RH!A-=N#RBO@'-^=\F : <TV6..'R+A76'-)[ZS
M'G_OW?',!*6Q085J:*:4U7#,=H^J6KG!0"_:8)J.L.BL(-*:\(H#,Q()B: H
MB'*;M=)KY])V9Q)KB3SK+$;,K<7D8381!6OX.DQ_%3FWDC'42;T+;VP5LLWE
M-JLDROY)7]9VB23/"Y'GB9I6P<ZXJ,'@EVE9B=3>I& -QX IE-.)J,^ &R+J
M^^!EHA2NKV$R8:M0KN)L3&&H5'5WG-T'T)3@N(&\SF%K8=YEJYZ&\JCK(KG6
M+NOU=9SYL.!G4^*25SI.88KE9-."6G)0,JDN4V]59PY1GL)W-*MXV<:([4Y1
M^4P3JFZ5#$T5NF;\+*]28E]J"V<RQ4%><#@KN4%1WA,IO.2X/2NXJ@D56<T+
M1R!/&^6?> '8I+S"U&?U,'('/".4.+JDDY((J6;*906B$.<[*?B$%9CG.QJU
MSA;(;S!.R[*NJH1[DR1ED[Q+):#P$U%R(R:K4L_Q^1G2T"@CA4;#*Y+#%2BY
M2%>?(R'0_8C_T2N'Z:1=!]K<9D'^;2H3><SB8*A<<X*W82#*,<72&YE%SIVT
M*4R&JTFYS%A0CEG7=>T52 "!4D)9^JW$9C@^O*8S%;8X4@R7'19WM3#EK52L
MUKV2UQ01/>/?=%5M5-7F[6A5VU85<OTL2MA/J"+D[&KG1&&CK_V[5/7XI5R,
M H% =(3+=)S^@SP96?LDKU!$ L.5W+#6=F2UPP75RTN4 /I53JI@C"DY[5()
M48E.@U6MXA92ZV2)/%:G@T1$KEQ2#3&65]15,'6=!4H#E!5+:UU><#GW::M,
M:'D]#YEX6 B$HE(=5J%LN+4+>JC$;53F&A9_"^%,>BXBF*7BYZ";JM+[^@!A
M3GD;?D*^ LADHC2=NM2I5G(JM-MAXAGL4;NRNZQ+^Y62363!$9M!1W(&*P%!
M0?*BE^*TA'$O-":Q %6?1? C?'$)"NVB-6.AK[2H=\:-@*'Z'NA89[.&SA*#
M.!6P%JK,;;$X3:A'S29(G4@.*ZJW)NF$_&=XN<3N++QGA"\8$8['C16#.\?/
M9)TE'O^(U&W)LTK>4@X;J ?."C#B4-K1 173LUESM-):!NT[4#//<+Q3'@TS
M+"7$L>IJUW>GC3U/-X=]S0O0'WOY189D-AV4:9R""M#7X-E&ZZ3)L(@1U@AJ
MN#"I: CD /M83>4-R)59(M111=[$C=$-@Z>(YB'8&RD9(,L/7Y? ,W-F.@[3
MD#J11C(M"!UCI9V\>[1!N",([#,:7=5,#\P58GJC/#OK 7L<P]Z6Z'-$0#HE
M$0=7-Q;N;7"URS63$T$BRHX2O%=)<,2%D;)[@7UM5%SU-I>VL^%LA4]\!E9)
M>1YFI64#:"+$;U-JB@(AA]N*)(S\/YV!A:J%!G !AD)[I"A"#B3AH0C@J^0D
M"PE6969*EY,1>O)FA2)*6#"5^4@,6$I_<J-!-!7+N>!*BQ*^K^VAYXJ-)^1G
M4B[G$M&\D#)!)C&0^5&]5GV.GFD"$BA.>!8)*$A5==*Z5%F55%*WVF^UXDJ3
M(B,4%!$$%%$*$G3H)Y+J=V^CA#P76,A7.+O:OAK)BTE]5 RYI6S5%$2DMJX^
MU<8I(^-#:DAM^V/9]A'Q$QZ$1@"\B'TJ2_%C'6]<KS8Z4&$HU]?V)$# S3@-
MRVZ?U N7^!UG%DTOJ-WMJ:2663M+%]>+.,R 3*8*YL\%3ACZ'7F!.!,*( L^
MJ03=*4M,X?XA,P)^@=.KW=\S]N"L]ULHL.V9PQ'(R#7A=&2*"0A</_A(V:+;
MK&TLOZP?I5JFV& 3-E,JNL"HBZ8#$3%3$&_R@&>Y+&JBH#0^D7A<8<A^:I M
MT@H/K,&>:QOX+1.D!6S25DAGUJ:#Q@4J*=TB 9*2"[;>,ESK0&(=A9R[7A2(
MK&%6!".9L0'F$ 5I\U?<UGE# 8V$J]XJ$Z%Y6)S1,NT>5HJ><?F8ZFK>Z/IY
M<<8R&>T2"'U2ZZ[U>7UF%H^KV.^>8/Q-,)\Z[CP7<U/N@W8\1AW0,)UL6F"V
MKA6Q[[F@QMQJ,-8XY*,)D*+ "VI5N)WGH^F8*U"6!GR3+D;MEY$\%=2I)O*!
M[\61&X$HIM&.HI(9D0T98?4MZ( $?2D%Z/N\4)Q<E\M9OO7B>GS,043-04GI
M DL*W_D^OUP&-B6?0#(G0830FFTW4]L%U%2UPH4M\K+<.A^AINW>M?NIUJJR
MI6"KFQ=7"ZD!!/MYD;7O5YO&]58R4761R^@C'(6 &]:%4@G,IDD%D$M55V !
M\HMD44O_;.$K"<?D.C!+,W:4B,)^HS#K6(4J1WP=!^V"5MF6 BWW[,T@4,+%
M7S9.!IJB_%9B:LKY2UC?Y;D=/(&=:T\80[Q2VX07%VF5B]F?SL*RM55' <,I
M$AXHCX8TZ8M54Q?[1Z<VP\9V3\<D;'FU^2T$4N*J#7PH(INF$]+)-GXC51\'
M1!TF$@,B%(D,=4),5@IO.$VX#MD7&/R92C\Y-J00Y$MA>4W$9 EQK825HUE"
MD,9MC/-/B,<ZQFQ"3.9#*9BCUEWODHKKZG+[V'E>*"=@B3$PI $)FZ9^/6 C
M$H? 6WBUU8K32M7C@E,B8Y07<!68O$5F&(8B&1P9Z(!SU#E8_/<4[A OQ#.'
ML-7GP$] Q)]B-EZ)F1^@JT8T'">-I*^]%7DBEF&$9.<+!:.BU$Q-!&%&$EP8
MKC08J43.2:T$P4TOAR*/!35V:5=*F$:80LS^ADW+HV] .@(V6%B9%WP Q\EK
M8QNLE8N+BWY4Z\<BDZH/[]C-<R,)T&+^+7-)K7T!++N<0<O6M=_%><)57/+]
M[SI8$P*E?/[;H/=_R@%0HXB3)EJJ/)]9,T?\&A2U,D=!@$^Q,D<7.^8VH0D5
MT2(HQ4#* 0'+W81J2-BV\/TI(B./7-L'2A%)37J3P?EN7P5D%.*C@OJNY?*,
M\*1@BJ!$T(9O8)1)\HC'BY1:\JA_EB_-Z'\J*MN2L/F=;V67![1.'I#_//*
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M5=I<\2#.\464"#_0)FSWQ0K!HG-U)[B! S[,7CQITNK=Y]S1\8I]V'92=L-
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M?D&M>."M&9T.6-VK[I.NCI6DM5:E8SB_U3=);H6#2#&3O$QQ]!\*/L*J)MX
MQ" J2.M74@@;S4_8 ,A^6JW^"1Q/U(,S+X!\?A P.5>+H ,;H@'+FMV@]K^'
M1:-1G_'>  [I6X\E,-D?V.B"796O_C-+YT#D"EG*@;>OVI ;]1FY%S_^[Z"
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MC+5.,Q_ YC)9U(RYCGB\HER]G?4X85<:)LN-*<^Q(?1&[LCLT &_RK,8*XK
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MAF^1JO?,#\IW;3@J?U= .+>7A:BT>@S843@=](9[N/AF?2K+:Z!>1IGV0^S
M=M]!FRJQ#?>&2NP'V(BG4:\ZVGU)M&LZON[?A,FR0=J=*>+<QJ"MV[?6B-JN
M,D:M?K"F,?J@DP[6*Q+%2+.2C$T]@<P6KU-B1%).8_H+RW\A]BZROZ._IRDF
M"8DDFU2D1F(!4%/8 (]A;ID*;--/Q.:ICT0NNGR#99C!\TP=VQMC6I2LE=AH
MM7![)G46BJK^8B(]8"HRORF-B$UHD?\0D50L.TNIGK<L.:54(?U0*9@D&#Q-
MV!(:E7A"J6,&%B8SZ)@E&'/,NBQ59A:FL<0\H<>)^# -I3W#]6L@XQL27.#U
MB->#!#N!V5ZF8WC]Z ISXYH$&AP&/JCS9S#QIIQ@&1L6F.Q*SLDMB?,@B_(Q
M5FI?-B;V9C*FFIG4I/E:I@!]?YO:*H:,"L.9[(S+8D8<]_4H+\OO16*,S.=#
MVFUEV PXO(6KYVE'=.)VK^U^\/V_9C(C7YM]"SY:LSC^Z4H@KZ^/3./_ODIC
M(V',\%@0&J'C> FS[-!)W# RG=!@AOW%-U[=8:KKE69VHVS_*$]6/@N\(NH!
M@1<LJGXHIV.8[-5B3L*F:FK=':^I7;J[:U+($Z9ZT&;_=O#['P=O#TX_:WN'
M;[7]O8\'IWN_:<?O3H[^.-Y_=W)?@G_JY7S*BV\H7/:% K4;BL/U9<^8OT[%
M*E=@%TQ!OI*I,$I!J8\I.1TD)R7V<OCD'%0M4OKHDV247ZBZTD;:4N4(V@5C
MK$P&Z9L717XA30IVSM*14$>I"AFU44J=Q^)H$,%I17GY ["O^#G(ZB&KZ)D4
M&49&U2QGE'^-"?C-)'30+-*2P@H7\HBDCEM7Q,Z^1;L 51!>HX'N^O<4RU>Q
M H#2"7G],NT,)EX-]?J+P;2$4<IRILJ@51T@-%8J)%"O)XT'7C@M6H7DJ(Z4
MG-,^)%/\[AY*Z :SG)OT9)F!3,P(!BGEEM=$!#NR<#!$:#-J'CWWED><RD1L
M4VA9FTIS#ON.Z=XIS3GH^^YZR;BWS/%UW. 1$I(#*WR4R7KK3>CA$U%W(PUR
MAO0?(E]Y5S=BX<8O2PZ=4V)]VH*GR4?>0 KTS#C//D%@'P4YX93,*1KW"9GN
M>'!CK25N=_3"<G7/-W3GA@RE7<A3Z AOIPC/T3'SP@\WV,M@N=@R[4>66T\M
MM%ZHQ/HT9\R\E@A;*H8R0BM1?39*V2 =I8C&=:^>#1UCV?3:K$ W;& LYNYG
MWG6$MU.$Y^BV8>FFLWF)MO.YA/N2+9/#4GL]1D"-R4@X!V>Y."(:K\'#GT?"
MN]5__%3W%UE(T+^^7&]#RN;=4[5W?8R=!$!8U?P5T8]0$9T+;\@X"W*LJ[MD
M#2[D2>ZV!G"KI6XY.]%A?/SG[BFA\RO>GKSECNRVE>S6ZN;[%$1WCX1CT]SF
M:"DB-4=#EIT)2*YHE4]\S90Y^NU,MEH71^WBJ!W<48=AU+;Y-H)A)+G'XE#/
M:V?7"6-[]PD'A%U,>;7"@I!+)#JQKU$:B_X1KZ<"G/[[']:A^LZZW>#Y'=5
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M/'.GRSN<7S%V>99"]@]V":OT_*/2+RC$I!E%H$NQA?L6XJ(<)I;";_,1%XV
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MVF87=MVZ[<+37I?/T[,^=)G5L9G]\<)N-.P&^ZO9NPK'B!8DY]O9?)UC6\;
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M"UF:" CEM> @]BF4]2C'="BI)>NN6K1VJJSF3]="O$D83]+_G:Q6FB91R!S
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MD^TW="P?/L/T$[R>SY:'BXF*6=L0RB7-."LD]:7KEA(D!D:ET2"#;'+,=UO
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MGR^__N76]_\4BV\SY]R+Q:>77^W&Z[Z(EV4O_OOGM^_C&9Q[,IYV,S^-WVZ
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M=L*#$>^^'%T(_B1TL];'V<B;Z'T&3B"4*!PU^)QI*4AV4DJ@VJE<Q4>]">0
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M:HZFM4R1.)LE23@J]%PY^CU5EH4-> Z50#" HIOA!5YAG5@'J[QL 5;.5@^
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M:/\11HEG''(*1#,M4!PL$.\9(XXYF;(HQ6BJ^./](1XO@093S)Z"?_^<SDN
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M2.<="8:C60BY($DXMCY;F_TT>/7.3U"##Q9<!7OWZG&:BZ!L%IP+-+$LL[C
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MG6WN@[]OLM^7WQ@ _U[<]'+S\)0M[[YN Q0B>/ZOV5_2).:<\1"@A!) D):
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MRJ RLQ&KC3BQ9V4CADUV#L1&. -Q,A(+$#3+>>'%K@F#" I_4JMM7OT&V-^
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MG;6.*-5LK75MJ8<*WTF&JU4AL,5\5QM[EN&0=QA!'">IH("$,;-G?27@+*&
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MN*N#BFD<DB1!(*'$3&)XK #'J0**TT03&D,NA _?778Q-T:K+"Q&3\?"LC5
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MT"*_KGU/6_K7$Y&+@L"^]W?88GREUIM[>R!FD^T5(9)$AI$)4@P;A0P0Q2/
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M]BS%<1UW1_8;$LVQ::XGD/ZLY@K.H/1UM=-I><H5@PM"<KZQAQ[,2<WKMX7
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M/ERH?@V((8/VQKXF#=^O>7P>R%^]OH. R.GQT862.HIIK &2,+4%G.P$7$"
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M$0(2JP001LQT%)N):<09CD-&96(5]=R+18YCIA<'35!:TEW+Y?@08&>9X9O
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M-.00,"&)E2/ 9M8<:H C"8EY2R553HMES5W,+0RMK+P)*CO="P$T@-A.1L-
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MOM?6#;IZ4T<:J2*&H@K9V?[')V4WWZM_-#/Z>[B0$"D<:6YPQK'=&Q<@95R
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M!RQ:HYVV^Z>+9QR\.(E87*[O*#Q2G'(JFGV_^<BR7]GJ42T@YRQ-4PQPF%)
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M:\WA\FUSN@2OCMZ>9']U;:-C<KS*<Z4::@U5YSU?/:K_5BS[\L=F(>+4UM&
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M*B-W[SHEY7&OKI-7NMC?=0SK0:F2QZT^!-T+]:8LM^2;F&7*F)!20&5?I A
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MR]VO5V]S+OC''[]M#KKZ7+/M_*U0=+K*IV@*]"IX]>?5<C.#.660B!#D3*9
MG4DS0*G.MV(P)$1 DF=&<7\GW$Q-536YK%O>*3;M\ZGZKX^9VAH-=<\ZK4B,
MJ@4)Z(_@@Y9%'1!^:G0RV\MS%1RLT-WY%>J54#486=<)5?T9&CVA:C!V;0E5
MPQ_:3]4J:G?R=K.=/^O1"S.6YS*.M4M/AAQ )@@@.8,@#Q$5(DJ%)+G=L?^0
MP/1.ZXH_G<.SX]!.$[Z#STRU]8?$LZYZC\55<+]:S-F/X(_J7R\UV^UPN%0P
M[RB,JC':I7NO DY<U6]/EX?#FS*38%<F V$8H002D)"0JJV-!4 ,<9 )B7D8
M,T0R:K>U6^E,;X=7#%:..,LI=.U8FNWSP?AXWNXE?U=!#9"/>J-.#%SN\79"
MHV[U3EG?[_CNBX<.G"OKF/8-XC*"69+F "6Z^@1)#F@DD-K[C'.24XHR:+?W
M3Y&:WO:O.5,FMV:T[U2X=XB::0 7*'E6 GL6@Y+'*P]-N<[AX&?6VCM:%QJC
MUB[QZ0EI)ZX?6$N_&TI3)>:'44I(0C(@N9Z4S6 **%4:(<\@C95&$(9C!,X1
MFIK_HU$?WIC38U4'<19;4]TP'#'ONJ$/6/VKZ4\@X:6<_CVMR]33GY#X9$']
MJ>OM\WK**H=KSM4+LZG^^66^%-&,$Y'D"8R 1%*'_DFJ^VS$($TCA$)!LI@8
M17,ZJ4Q-+U05416+5_4/@68VN%L:F@W=P';K!6=P>58*O9&RR@LZB\2 !*'3
MSQXM4^BL>,V4H?,7N]O^\4S"-$M%&@,HDPS B F )4Y!RG,"8Q;&AN,-.JG\
ME]K^3W^NAF__>,#VMX+KDMN_"RDGVS_VN/WCRV__V&;[QSVW?\.H6.MDX4^B
M_/?+\F[[7:SWD8?"0S'#",DXTBY#JF< 8 H!2D,")(&2H0BR- NMVVX9$#9Z
MYT?MPE5P&; #=V*1#+8J_M GT<]P#8Q/%*YP'>U\43 :?*A9_JF8\%3 V8B.
M=@/;Y[QA@9/CTX<)Y;'/(A9HM)Q,;.[N:ZC</HOU-_6XG]>K/[??;U;/+V3Y
M8T9DGB100A#G& $8(P002A*%.LXQQT)0!NU,E58Z$S56:EZ#DMF@XM;65&F'
MUM18&0S8..:*+58]C)5.) :;*^U/']E@Z13QV&3IOKS',+9R1D QW)V:!N-.
MWSBEM[3@K[ E-(<FD3A3="PFC U&::0A8SW0LILTU@E$Y["Q]CO'FS?6R?G!
MR+'N*WNV.]&?_H[<T%D<28E2'@$<H@Q D4& 14X Y2C-><0A#2.K;B=G"$[M
MRUU:MMUISI:M3LY!;G9T< FD9UTY"$/[-B>&P#CM<G*.YKA-3@P1..IQ8GI?
MSTX$J^6W)[%^UIZ0.WFS%GR^G>FY.U+0%, H0GH0'@(8I1B$(N04PI"'W#+/
MH8W,]'(<'L3;:O%6-%'2;KB5#%C!J65?@C9(S?3'4)@\ZPS-'E *_KET4RI\
M2A;]M$;J L-I:X(V.N-V)NB0]*@Q0=>U/0X#S>=\)JQHH/0K^6O^_/K\<;56
M1PZU'6Z(>B'*L6*%=^+Z>?6ZW,Z$(&G($@PB&.F.RBD#-(H)2.,\B>,TRA!$
MQA.<^_,Q->MDYXXC!7O!AU?=+-*PM]'0-3$XQ8V#M&]5=*" @EJ.JZ"2)-B)
M$M2R%',5RY4IQ1EG12Q.CN.LS$C'2Z\K9'<0'8YKYVEUP./'.](.Q^#@W.O@
M<3T-5@O",P&Q5$!%0!(: :B_54@=CD&LOE,LR1/,H-6\,!OB4_LL_7)@TEX%
MS]4VI+MMR"K.+<U=FP4Q-(,]P3R];Y)#:[D'9DZM:!OZXUK7/9 YLKK[/*-G
MV=&?9,V?U+W7?\TW,T1ESH2".R8D439VG  J,@JB.)0X):D@PBK!^.#I4U-1
M!7.!YB[X0_-GF4E\B)R9JNF-AV==8@Z%?2U1F\A.:X@."(Q;.]0FVU'-4.M%
M]I,4'IE8DO5\]=MR\R+87,X%KU+729*%.6<)P'&4 \C5AD4QCT":1$QF&*:A
MV<FXD\K4=F_-Z%708+7'<(33L'9O:6=@>=[:-8^.IQR<%7WH/(/3!$:;7'!6
MQN:,@O,7VV_Y!_&B7H/O^C#S;2V*X68W^E CUB]DO?WQ52U[]:Z*A"&4APR(
M*-*3JJ@ !-$$1((F<9CD80BYJ0HPICHUE=#D,M!L]E 'YI"?5P]>@/2L+GI@
M:*4WK#$9JD?,"8ZF5ZPQ:.H9^YL=]8^[7^O.0]L?]^I]V5XON<Y%>-&7S(A@
MZF @(D"3$ $H<@209+$R0I @&$;J^98S?LV)&VV=41..K[DZM>DF+SK*_5+Q
M7>2]B)KI@2WE3J^$V2G$,;J7:S-7\WT5%)Q?%2C?GD5Y>,^YLX!Y[3YWFOIE
M^]"=1>5L1[KS3^@1<SS.=JX:..P'NNS[<,XRAM)8=UW G"/=+CT#-(7*DLIC
MSO(<)BF19MD(]L2GEZ-PS9C^N&R"%_*C:*N[KYSH/?"IQZ(8Q!F] >U9KUGQ
M[2A"U0NKSJ"4W1/'BT/UDO0@]-3O"?8E$S<ZL5-1N%EQ,4NYH()&*<"24P"3
M# (B0PB@Q!1CG'&<&%=S-Q\\N1-;496HF LT=^9%$ =@=2N'(1#X/FN926]5
MUM FZH ZAH/'C5:XT"9$LU*A]>_V[I4JI/*K*"9])(A!0CD'+&=$[;2, !Q*
M"=*4191E!"74*'I[].2I;;J*.7.?R"%.Y_T>O:7WO-_JP.@?)6>./!JMT@[U
M6AP^=#3/1*LL3>]#^P4]0X_/J_5V_G>1&'0G/\^79,ET8'.UV6YF,)&"I)$
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M8$!WY&X)YD@<-TRPN/?4MF@NZB_JIW__M_HWZO_INO=__[?_#U!+ P04
M"  $B0U331 _N)=3  #DG0, %0   &-P:7@M,C R,3 V,S!?<')E+GAM;.2]
M67=;29(F^%Z_(B;[=:S"]Z5.5?6A%!$YFE:&-)(RLWM><'PQ%]$) 2H 5$CU
MZ\<<W$F0PG(=UU5S3H1$D>"]MGQN;N9NR[_^]Z^?9C]]P>5JNIC_VY_X/[,_
M_83SM,C3^<=_^]-?/_P&[D___=__Z9_^]?\ ^)\OWKW^Z9=%NOB$\_5/+Y<8
MUIA_^F.Z/O_I[QE7__BI+!>??OK[8OF/Z9< \.^;7WJY^/QM.?UXOOY),,$?
M_G3Y+]Z:&$-D(*Q3H$3)X Q+P)VWV?MDA<S_Y\=_T;EHG4H"QU,!%4R!Z'D&
M$07]2I(6P^5#9]/Y/_ZE_A'#"G\BYN:KS3__[4_GZ_7G?_GYYS_^^..?O\;E
M[)\7RX\_"\;DS]>?_M/5Q[\^^OP?<O-I[KW_>?/3FX^NIML^2(_E/__/O[Q^
MG\[Q4X#I?+4.\U1?L)K^RVKSS=>+%-8;F7^7KI^>_$3]%UQ_#.JW@ N0_)^_
MKO*?_OV??OKI4AS+Q0S?8?FI_OW7=Z_NO9*T&7$Y"_/\^3PL/X5_3HM//]</
M_OQR0;!X&SY6LC>/67_[C/_VI]7TT^?9S??.EUC^[4_I\_0K5/TR(UE]^7^[
M_>6?;^GXO,0506?#]VOZQM4SZMN.HPF_KG&>\9+GZ[?-%NG>AV95XHOE]6_.
M0L39YKN3C-/)YLEG<;5>AK2>Z!R,=PJA6%51&1Q$QPU(;Y)3@F?!XGT15/)7
M1/]&02M,__QQ\>5G>C I2K#Z194/ \:OU//?'KWT4E*'47^]*C_09R=HDS%.
M*BB*$?'>2O"\*$#M,08=I')B .+OOO,^[7?U?+9,/RV6&9=D7*Y?&I;ID<[O
M _OJ$S]_#DMZ$*3SZ2Q?_W:U,D/H;;T80'Z7RB%R__03<5UPN<3\^E(W3S*W
MX6Q-)A<WGQQ"[__/15C2$V??WN'GQ7)-+&B652;"O?"@I&5 OXB0;5#T'65U
M# -"X,'K=T*#Z!\-QTBU$V"\Q>5TD7^=YU]HLYZ(Y V/S()0F@3B(@<?K #-
M%49B(FK&!H3%O9?O! K9/R@.EV@GD/BP#//5M K^"M;1>,Y=D9"4(EB;8"$4
M(R$;FYGET:(Q0^X7#]Z_$S!4_\ X2JXC8^/7^7JZ_O;;=(:_;WRO"0^.'.ZH
M 5DD83 I@+QT!"1WW.04M51#^! /W[L3%G2_6#A*CEU@X!U^G%8AS->_AT\X
M<5IZEC& S^0!*8-$?\H1LN?"<0PF81H,!_??O1,63.]8.$*>7>#AU3PMEF3.
M-H)_3_+'EXN+^7KY[>4B(YDX'ETJ!@QS@L)R3=L?)Z=9(R:%7!@,;C!X/$O*
M3FBQO:-E.&EW 9X/X>NK3.*;ENGE:<>5512:B>)S!B^")"%9!<Y[DAESGAF2
MGAIP=WF"B)T XWH'S! 2[@(J9SF3"E97?[V>SI%/8C 9BP^ .5G:/,E8!L<9
MF**\M.1=YZ@'@\D6 G:"B.\=(L=*ME-XB(GA/B%C&KA4 50*!7RUCBK)I Q+
M(43>$!YBMT,O]N/A8S_1]H2/E_3EF^6'Q1_S2=2T+>94@+$804E'MI#B<P@*
MI>;62*G+T.BX??UNV.CX1'0(L?:$C(TS]6;Y=KGX,ITGG+ @7!'$@C".+*!
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M<62/B]H3IWJ<4,,==++:D=7M.8\3DZQ.,G+(HC80X9K8+IZ!-DKX8DPF?EO
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MDVG2NN$Q*2-WLVJR,QTI\.X@<R</U9G"@A((6'T_I9.'F),%6X2V7,0BT@F
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M<CU\II^LOTU0(LKL+;A8CR<$YGI5KR"'E*/B2L2=[J8'@=A31'98/' 8-G9
MW2"*&GMOW(>Q5_.TW$P1WS1XFK@BHU-" )I 00W6UHP^^=JI43MFC Y:[;1A
M'DY#?T4'Q\'ME"KYD9#W8;$.LYOU1<N(8F;B#;FA]<4D25:("%XCS];3)J)V
MFR%], G]Y9">&'>'*Z2#7?=^UO:+L)JNWA,M(;^9W[UWX!-9/"LZUWET-5'?
MEU*;SQK:(%60F5GZ69,+FET)["]Q;)C=MHF"N@/>YCJ*PJ/*RF:L9GZ+R]KD
M/WPD%UD4$E&.8+B1)#X>(03.P7.O<I%>JM"D^<KN)/:7H= "?(,IJ0/X;9/9
M7^<7M8?,E26O,S6GFWC]-\0[C/I0&34><BJ<0G6KZ]"2!)%;ZU3.FGY^JM!C
M)XK[NWIL%X<,K\*Q7<,/Y_ARL5S,PY?I\F)U-LWO<#;%<C;/OZ;%?/%IFJZ:
MVWT[2^O7BW#3!N\=)IQ^P3S)A3.>N 8N1;CLIQQY9*"=D58I%]/#G?L)%_%H
M4OJ[:!C 53RM@GHPG8OYQP^X_'17GI."$;UQ#HRO(\U\2>"3*^!=R:&X+)+=
M9=KE01?F#XGI[ZAO((-WK."[Z"Q]>PZ^>C4_*X4$1*[$ZOU%7$WSE%Q:7)VM
M5HNT^2ZMHO][,9VO_T8?OZCMC8V,F5Q;!DYH7ULT17#<%"@\&:-8S,$WJ;8]
MBNJ= .E_/$">3I4=F+W[OC )\OJ@*<20E RU)X*@%1B3!"_J4&3EC!9"2=]F
M4M=3!.UV[LQ^/+@-HH'>>S:^FM.7^"%\Q8-:,][]]4$[,#Y)UY&-%F]MR=7S
M?YFNTFRQ(A-QTY</O<+BO0,A-D<;7-2C7 89E:>P,J+V30H1GJ'I^%WPT:-K
M2]07])E_3**FZ"1;"\8&1BC.$ISR!B)*ZS5/S+,F#6F>(VK<VZRAT/%X!QM(
M#3^06;EJEWK5@?=((_/@8:U,SG,TG\  *4PA"Z? *DO;BJ]]T51-7,28M9.N
MF-QD!L4I#-#+Q;SV/\9YNLE(L$9BI#W4U%DU%(325YB VTR;=S'&\+;6YR%%
M_9J>?7#QI.DY2@$=.,8WC%R-/;KJR:$Q\R*B@$V:N%+%UJJG#+HD;VWR3#X<
MBCPPC.Z1TPF&CM/U4P@Z7/!=PN<J)Z[PVH(]!"AAT_/49/"%MODL4[):6F%S
MDQJ,IPCJ!$)'*/N[^#E \AT@B*BN/?S3)G5S>=US17C&M3<6+,6;H#3YAD$S
M YE;XZMKJ$V3%+&MU/2&G4,4_3 :/UKJ'4!GFV&^/:PH19B42@(9:ZLYM!Z\
MCK2XHN91><=TFXKF9ZD:-\^K\4YVM!HZP-2;SU@'4LT_OEZL5B_#<OFM+)9U
MTLAJ8DK*B9.#&&L90ITU ,%P1X+RFBDI++(F3=R>)JD3PW2\WA=-E-![6/]R
M,2,$UAEGTR^W-0P'G1P^]:A!0_J=Z!THH'^S_!CFT__<4$OX6BUFTWR)['E^
M>X>3-^6WZ3S,TS3,-EDM&XIN0KQ@"N,^!0@E>E#%<0A,:BCH#=-!U'K%)DMV
M".J/KW&]JZ[;@4K;3LMLX,Q5^Z]DV50$!W"NEK!([YU ;D*;;C%[T#BNL3L]
M'A^7S[919^]6\BSGZ6:B'?WL':XOEB3\\G:YR!=I_6[Z\?PP@[G#4P>UG?MR
M,9 9?7&QHAV9-M'%ITBXW%!P@T:78S L(UC"'2A+&VJ0,M0N9[KV"3'(FS@T
MSQ%UK-';\NQM"X3'K$T6L?8KIU62$,%%KR S#"$%9XQO<B:\&WGCFKK!,//0
M@C70S8]OO#;Q5R,3=O7L$QNR;1R=PIRE(BT3/H+GXFH(3F0L0DB2RVA$8:I)
MP-_2G+U/YY@O9OBF7+_E+/W'Q71UJ8(7W^[\ZR8*6U?_9)KQ<K#R[;K*QC,9
M@H$L:JUR\121"<7 ! KO369<ZS9C4(?CH6/#N _Z'LU '4G+'9RWW+).6\'G
MQ2K,_KQ<7'Q>O9JGV44F3NL.L>'Y O/5N0 Q?GGV<.-AOPADJA*^/T=<DT-^
M;:/"['9_6=V*2#GK&8J:=4D;F7(U]RCR!"GYQ(TK$;'-M.S3\SKN>>,)%DR?
MJ/GQW9+?P_(RTCQBTO !;SFQJ_(\ER>)P;S)-L<,*51SG2A2C\46\GB#"S9K
MH4T36]2)TW)Y^\!+=()E SJYNK1X@."Y!/0<*=APS/LF@>B^A';L?NR#HR/<
MC_WUU8&/L86KR^MW3RX266X*7I%B628V4S,]!*Y]TB0]+YI<,C]!S[CH:@N"
M)TX"CM%(I\"J7R[QNO-4C YI19(W'FJO7ZXDL289%)&4<3(I)9ITE/PN97V8
MLJ/TOP.F#E?&V)6C?WOUXNS#J[]=)69DFXA 4=,Q(LG%.5?SF L8&VW(WF"4
MYGO>V./']H>!(_2U&$1X8ZO]+[@^7ZR7^)5"E&ORLPPL%$\[N_ 4)R4$KW("
M&XWR4D4RM;LUB7G\[#ZBPP8 .%*,/?:9)8)-P:@A;YH,"I2TW5H'C%E=46R9
MV24CMVV?V698.8EW,HCL?YSVL^B=]3Y"-M;6BV()3F3"@>6)I!0C5[L4X_Z7
M;C^[E^(/:S^[AQ;&WIQ>TG>G'_&J)6HBD;Z>?IJN,5\/S,H:E2'#FLEL4PS*
M'/@:@UK40:$J*CP,XY_8J;[SHA^BY>P^>ETT$O+(MNCFH/5]PGE83A>7 W6$
M4R*Z!#P810S4&V3-:(DE:8T/#CWN4J&TD]W92L&X/>].MI,=+_VQX7-%]U_G
MJ\^8IF6*UPV7R5D35K%(](=:,JX4!.4++83 <N+<9K;+H>EN$'J*BO&LT ":
M70PMYDZP\MMB21'#ZGJX!.<LY9@#&!89!1"E-K"5))THO.&"<QX&:[&_G801
M43*,7K<@Y0@A=W!H=U83R6]&X61!TD B/CGM2" I0)3(P$F*!Z.V,K29S'Z/
MBG';7Y[TY/=PZ7< G??G)- 7H3:I6WSZC//5E8YN<G%)6K>?>1N^U>]M.+YE
M>Y[?SL+\CJ?(C"TLA)KIYEDME*@.77#U'KPF<E@F99.F2"V8&?=$\0AL/;P1
M&UO1'8#]':[6RVFBR./]>I'^<1U^4-PK54'0UM#>8;*'VL"'K("U1DGA0VQR
M9[:5FI%OS$8'R6)HC74 N[M).:_KIZ_OACPRKSV%T,KIVJ[!:7#>1C!*)<,=
M0_JKR57:$P2-VS;XM->U0^BD4VQ=K3M:!4$X"IRXL+1*"B*$V@/>!2LP%!E3
M:I.'\R1)(]_.#:+R'7!T@/P[0-*;]3DN7UXLJRA?3T.LC?*FN+J^:_*!6T9\
MF&A(4$;4[L0Q0LK!H&/D?/ FF>C/4M4?G@Y1_<-*X<'TT NH?E_,TU/\",E=
M+"8 "Z@O75I7Y[9F[J626KC0$%?/$#;R/7)#: VEC0[0M<5/>'U3K2^3B,+Q
M!&+3Q;I$!=%ZA)BT+,HE'5B30NGGB!JW]?W8^7"'Z::+)M%7H<[JP^(JG^.:
M/5S]>;E8K29( 3CGSM081%&00W;9AY0('T&(Y)25;:HOOT=8=PE1!X)@T5 ?
M'5BRC65^AJF)=XQLK\@016'54:WS/ID')R,M28JB=6[3]N$[A'67;S4,O@;5
MQ]A)#A^F2&]\M_@69NMOUTS=&3\B;8S))P52^#I^)%/\4Y(#'5GPPHF<=QW(
M\?R+QKVE'APK@\NV SNTI2#CB?+,:^?QVX2S4,^>R4&P28+*2D"PU7/,BF7N
M+ 4J;4ZQ]J=UW%NI9M:JM=:Z!>:=:N%EF*^N*+L-:UY=ACIY@LF6F&4"S9&D
MFZ2&D*P =-(HYZ1&U61(UG%DCWL>>V*X-M%E!\C=7%R\6JTN,/]RL:0U2;O#
M=)$WURCW C#R*8B/VC:UA)IU8&P "KLU6/26?A!1B#;=#':E<-SPM1D>VVBH
M7^C]+<PN\!Y?@D)YBU)"C@+KZ!M!@N,%,)D4+6HO<YL+^QT)''=0VZF!=YQ^
M.L#=%@/_#M/BXWSZGYA?91+YM&PFQ9Y1++5>7457^6Q^U][3SRX^T<=)T?./
MT]I_9Z*E3Q&=!>;)CU8"'43F(WG4)B%#6?C_U]V5]+9U ^%[_\L CSMY*>"Z
M3M%#&R NT*/ 9=@(5?0*20[2?U^.Y<9+K$A/>M2C#!B^6(8X"X>S?E-GJ5LE
M>J;="W?.Y_WLTF\C:?BP6/%=X?VMI[SK(SE;VF>=3YI[&N1#ILN#8CE8I6C:
M/2HLUSQ(5053?O_1IMT15R]Q.*Y,ID[M[">'%I3YQ8+R$@_I"0K]LI"8@6E?
M7I.<$EA,&APZ'HK_G(-[T4*\(]]SS+=/O VN3A:HNA@:>-1?Q1_:P@\1IC61
M_NI'?L+<K_ KLO;,6L<Y9@X)=0!IDJ5EQ\6@!Z$]%\K'4&6=STCG/TQ_+Z^B
M,H5X+Q]3ZOHC=4;.G^<OJN)+??<;SXPU=3CUY\&=ZH*61D(.EH8V&((57H(I
M@;F3V6J?JJ1/FL*=2K&\*'3SBIOB0'K%P*8@(,H0C7)9I% E1'I3N%.'Z]')
MN%-#Y-6 $[ +Y4;:\N1$9X%UU.--^RF]E@ED)SN3K<B!G0T4Z/)PIP8IP8&X
M4T,DTJAB/4=.85')G$T"[F(A0S .@0F:A<G"Z2A<5R=4OE#<J4'R'XP[-408
M4\?(SZ&3G*41JAS!),%!IA)U.8<,5+EVW$D,\>5V]+> .S5(7KMQIX8PKTVC
M\A@L91N]MIG";TKSJ!3!2N9 )X'<JZA%G?TP)_>'MH-(-/*[=9QLFDCUWF_U
M>MP9=A7CZLXO/O2+Q;OMFJ]9)Y1RQ8: 5<:6:#@K\+[PBLPSYN29,%4Z$/:>
MK#G3=:0:]#4ETI Q&]+DHSS/QB 'Q0R"Y(6!3@H'S,J F3.O0[RDUJQJ:CBR
MMHS0GS5$=$=KYS_;1H>-7VU&;9,O3-NV1,YQ/>MBYXSG$831 J1&#R$8#SQF
MS5G*69LJ\]6O'6;:![:NEIW,_.%JY+9JM,2__.;AL^<S<T_'TK>9R%^75Y\(
MN^Q]WG>]V*PX\Q$3-R X+:H.1H'S3H'%R))@+#A]KFQA#?JF[;5NQ9R>3T6F
M#G(/Y\F-7RWONRWNI4(M%E]WT]Y\(<R'8C5,9"(ED<!JKJ@YF(%#:0'+.^0M
MTQCY81,!HQYKVN[M.CH]L? NU*_ENF-,6@]H,11.QW(SD^60':-5S(5(5C5V
M']NOK=;#W8HA/DYT)_JU-\NG+LED->*?Y^MUO[BC#_WOHE6M$'_G^\Y<'SZ4
M\G-4AYG(9!<9>(:$0B2+?30N@99*2!838JA:/FBB.LR5YMQ*!,]-*D&E*)?/
M=8(V"*"()G:Q3IGN#56'A^C1R=7A(?)J$>'?F8"=E#06ZXE9U+<NM8$43#2N
MO"Y9']*-4!?AOYTZ\"!Q[T/X'\+[BT'X=QARYPA+CD4#,LM<;I^EQDDKLF),
M23QD#/Y-(_P/$OQ1"/]#I#!U8+P/?%XJR[,7&9!3GC6R6/@F_#U884A,F\34
M/I_LK2#\#Y+K$(3_(4QN*"1]M2@5%$\J)P-"*P=2Z5S":R,!M6 Z=CRZW":N
M4#MUXV/>N=%ETX">?<#/N+Q#ZJVFN)G\RS_GFX_7=^M-_PE7-U\>5O_2"$'Y
M2=1?K:TWUD@)(20.4I1(FJ!_0:@.;7*F_+%*@^<19VW#BS]=4;[!I*TKM084
M\[I?;][G7_H^K:^6Z197G^<1U[?](LVTY*XSMC M&<HN1@;6<01J]BB$2&/J
MM.'M/E+#$$2GJ-E(,FA FVYQL:#[L$R_^=7?^"19/;,V1F<Z"ZKX4H1FR,&+
M4-P.H4,RH3/=RT+#2 F)G4=J&*3H%&T:208-:-,!,TGKW[%<G6)WKS:;U3S<
M;<CK^*,OCG"_NJ>\_,/FWYE+*KJH2WB4M*<M'Q*LEH4/3DFA0O:Y#OSV:!0T
M#&=TBJY.(^'ZPV@/?Z!?H41C/_[P'U!+ 0(4 Q0    (  2)#5,AGLH1@P@
M .XP   6              "  0    !A,C R,7$R+65X:&EB:70S,3$N:'1M
M4$L! A0#%     @ !(D-4S0)'OM["   Z#   !8              ( !MP@
M &$R,#(Q<3(M97AH:6)I=#,Q,BYH=&U02P$"% ,4    "  $B0U338KTB#H%
M  #(&@  %@              @ %F$0  83(P,C%Q,BUE>&AI8FET,S(Q+FAT
M;5!+ 0(4 Q0    (  2)#5,)'H!*LV$! &8H#P 1              "  =06
M  !C<&EX+3(P,C$P-C,P+FAT;5!+ 0(4 Q0    (  2)#5.O]F=Z#PL  &AJ
M   1              "  ;9X 0!C<&EX+3(P,C$P-C,P+GAS9%!+ 0(4 Q0
M   (  2)#5-N),MUFA8  (G5   5              "  ?2# 0!C<&EX+3(P
M,C$P-C,P7V-A;"YX;6Q02P$"% ,4    "  $B0U3NB%LU>0H   3H@$ %0
M            @ '!F@$ 8W!I>"TR,#(Q,#8S,%]D968N>&UL4$L! A0#%
M  @ !(D-4QF;2'UCAP  .Y(% !4              ( !V,,! &-P:7@M,C R
M,3 V,S!?;&%B+GAM;%!+ 0(4 Q0    (  2)#5--$#^XEU,  .2= P 5
M          "  6Y+ @!C<&EX+3(P,C$P-C,P7W!R92YX;6Q02P4&      D
,"0!6 @  .)\"

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
